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Abstract 
 
Depression is twice as prevalent among people with long-term physical conditions 
(LTPCs), and it confers an increased risk of additional morbidity and early mortality. 
Psychological interventions such as those based on cognitive behavioural therapy 
(CBT), can improve outcomes but widespread provision is problematic. Written 
emotional disclosure (WED) is a brief, inexpensive intervention that may offer a 
pragmatic solution. Its effects, however, are unclear, since reviews have drawn 
different conclusions and used inadequate methodology.  
 
A methodologically robust systematic review of RCTs, evaluating WEDs effects on 
psychological health and quality of life (QoL) in adults with LTPCs, concluded that 
WED may be effective for reducing negative affect including depression, and some 
associated outcomes. However, future endeavours must improve methodological 
rigor and explore WED for LTPCs impacted by negative affect. Type 2 diabetes is 
consistent with this specification yet understudied in WED. 
 
An exploratory RCT investigating WED for improving depressive symptom severity, 
and some secondary outcomes, in adults with Type 2 diabetes was undertaken. A 
test of WEDs anticipated effect, further exploration of this and an investigation of 
feasibility was initially intended. However, ethical and recruitment issues 
necessitated that the objectives be narrowed down to a focus on feasibility and a 
very much exploratory analysis of the effectiveness of WED. Recruitment was via 
primary care supplemented with online support groups, albeit secondary care was 
also attempted. The study identified that WED may be acceptably and feasibly 
implemented as part of general practice in the UK and for use with LTPCs in this 
context, specifically Type 2 diabetes. However, ethical and recruitment also issues 
necessitated delivery of WED to patients with none or very low-level depressive 
symptoms, for whom it may cause iatrogenic harm. However, a number of 
methodological issues substantially undermined these findings. Further research 
addressing the pitfalls associated with previous endeavours is required before 
consideration of WED in primary care for LTPCs including Type 2 diabetes.  
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Chapter 1 Long-term physical conditions and psychological morbidity 
 
Overview of chapter 
The present thesis was born out of an interest in and previous study on the 
psychological impact of LTPCs, and a desire to identify feasible and effective means 
of ameliorating this impact which could reasonably be implemented as part of 
routine clinical care. Consequently, the initial chapter presents an overview of 
psychological morbidity in LTPCs. LTPCs are described briefly, after which the 
notable consequences for psychological health are considered, with an emphasis 
on depression and its prevalence, pathophysiology and prognosis in LTPCs. The 
expressed need, and policy imperatives, for emotional and psychological (E&P) 
support in LTPCs are then described, as are recent changes in clinical practice 
intended to achieve this and persisting barriers to E&P support in LTPCs. 
 
LTPCs 
LTPCs such as heart disease, diabetes, cancer, asthma and arthritis, are conditions 
that cannot, at present, be cured but can be controlled by medication and other 
therapies (Department of Health (DoH), 2008). The global prevalence of LTPCs is 
increasing (World Health Organisation (WHO), 2002). In 2002, LTPCs accounted for 
60% of the global burden of disease (WHO, 2002), and in developed countries they 
account for 80% of the disease burden (WHO, 2003). In England, 33% of the 
population report having a LTPC (DoH, 2008). The increased and rising prevalence 
of LTPCs is a consequence of an aging population, which is owing to advances in 
medicine and public health and is problematic because the risk of LTPCs increases 
with age. It is also due to a rise in preventable, modifiable risk factors, for example 
poor diet and physical inactivity, which adversely affect physiological parameters 
that are implicated in LTPCs (DoH, 2009; DoH, 2008; WHO, 2002; WHO, 2003). 
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LTPCs are associated with reduced QoL (Sprangers, de Regt, Andries, van Agt, 
Bijl, de Boer, Foets, Hoeymans, Jacobs, Kempen, Miedema, Tijhuis & de Haes, 
2000), early mortality (e.g. deaths before the age of 65) (British Heart Foundation 
(BHF), 2006 & 2008; Cancer Research UK (CRUK), 2009) and increased and 
increasing health care use (HCU) and costs (Bagust, Hopkinson, Maslove & Currie, 
2002; BHF, 2008; Wolff, Starfield & Anderson, 2002). They are also associated with 
additional morbidity that exacerbates this impact (Fillenbaum, Pieper, Cohen, 
Coroni-Huntley & Guralnik, 2000; Heyworth, Hazell, Linehan & Frank, 2009; Wolff et 
al, 2002). In the UK, numerous policy imperatives directing the management of 
LTPCs have therefore recently emerged (discussed later), with some impact upon 
incidence, morbidity and mortality rates (BHF, 2008; CRUK, 2010a; 2010b; WHO, 
2003; DoH, 2009). Indeed, it is only now that people survive longer post-diagnosis 
that cancer is considered a LTPC rather than an acute condition. However, there is 
still much to be done, and as described below targeting the psychological impact of 
LTPCs may offer some additional means of ameliorating this impact.  
 
Globally, and in the UK, cardiovascular disease (CVD), cancer and diabetes are 
flagged as priorities given their prevalence and burden, and because they are 
particularly amenable to intervention in that much of the morbidity and mortality is 
preventable (DoH, 2008). For ease, these LTPCs will be discussed herein. 
 
LTPCs and psychological morbidity 
LTPCs can have a significant, negative impact upon the lives of sufferers with 
important implications for psychological health (Dobbie & Mellor, 2008; Silverman, 
Nutini, Musa, Schoenberg & Albert, 2009). 
 
22 
 
Psychological morbidity can be conceptualised as a non-specific term encapsulating 
mild, moderate and severe forms of both transient and persistent mood states 
ranging from normal emotional responses to adversity such as illness, for example 
sadness and frustration, to psychological distress and symptoms of disorders such 
as anxiety and depression (i.e. negative affect) (Carney & Freedland, 2002). 
Adjustment reactions are common in approximately one quarter of individuals with a 
LTPC (MacHale, 2002). However, the evidence suggests that negative affect, 
particularly depression, is especially relevant.  
 
Epidemiology  
Prevalence of depression in LTPCs 
The prevalence of depression in LTPCs has been reported in a number of large 
population-based, randomly sampled and nationally representative epidemiological 
studies from a number of countries including the UK. Prevalence rates have also 
been identified for primary and secondary care patients (i.e. more selectively 
sampled health seeking populations with variable disease severity), albeit these 
may be underestimated as they reflect patients willing and able to attend regular 
medical appointments. The prevalence rates in each of these sampling contexts are 
presented in Table 1. In endeavouring to explain the variation in estimates a 
distinction is made for the operationalisation of depression. This has varied greatly 
between studies such that the estimates reflect different aggregations of 
psychological conditions and vary in the range of severity of disorder included. 
These studies are also heterogeneous on a number of characteristics that may 
further explain the variation in estimates. For example, the estimates reflect different 
aggregations of LTPCs with some additionally including acute physical conditions, 
and they differ in the method of psychological assessment; most have employed 
diagnostic clinical interviews, yet there is variation in the diagnostic criteria 
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employed1 and these are generally not administered by appropriately qualified 
clinicians (i.e. a psychiatrist; the gold standard). This raises concerns about inter-
rater reliability and the inclusion of LTPCs symptoms in depression diagnoses (i.e. 
false positives).  
 
Table 1 Prevalence of depression in LTPCs 
Sampling context Operationalisation of depression Prevalence 
Community  
 
Major depressive disorder (MDD) 8.8%2 
Depression episode  9.3-23%3 
Non-psychotic psychiatric morbidity 
(including depression) 
19.5%4 
Primary care  
 
Common mental disorders (including 
affective disorders ranging from sub-
threshold diagnoses and minor disorders 
to major disorders) 
56.8%5 
Secondary care  Depression (unspecified) 28.2% (minor (15%), 
major (10%) & severe 
depression (4%)6 
 
Importantly, though, these studies suggest that across sampling contexts, having an 
LTPC significantly elevates the risk of having depression, ranging from sub-
threshold diagnoses and minor disorders to major disorders, for example MDD 
(Egede, 2007; Filipčić et al, 2007; Gili et al, 2010; Moussavi et al, 2007). These 
studies have also provided strong and consistent evidence that the prevalence of 
depression increases as the additional co-morbidity conferred by LTPCs increases 
(i.e. the number of LTPCs increases) (Cooke et al, 2007; Egede, 2007; Gili et al, 
2010; Moussavi et al, 2007). Studies have been variable, however, in the extent to 
which analyses have been adjusted for potentially confounding factors, especially 
clinical factors (e.g. medical co-morbidity and past/family history of depression). 
                                                             
1 Whether the International Classification of Diseases and Related Health Problems,10th Revision 
(ICD-10) or Diagnostic and Statistical Manual of Mental Disorders, 4th Edition DSM-IV) criteria was 
applied. 
2 Egede (2007). 
3 Moussavi, Chatterji, Verdes, Tandon, Patel & Ustun (2007); WHO World Health Survey administered 
in 60 countries. 
4 Cooke, Newman, Sacker, DeVellis, Bebbington & Meltzer (2007). 
5 Gili, Comas, García-García, Monzón, Antoni & Roca (2010). 
6 Filipčić, Popović-Grle, Marčinko, Bašić, Hotujac, Pavičić, Hanjšnek & Aganović (2007). 
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Indeed, the increased prevalence of depression for diabetes is apparently largely 
related to the presence of medical co-morbidity (Cooke et al, 2007), which other 
studies and systematic reviews have supported (Ali, Stone, Davies & Khunti, 2006; 
Egede, 2005; Engum, Mykletun, Midthjell, Holen & Dahl, 2005). 
 
Incidence of depression in LTPCs 
The aforementioned prevalence data has been derived in cross-sectional studies. 
Consequently, they do not speak about the direction of the association and whether 
LTPCs are associated with the onset of depression (i.e. incidence). Prevalence 
rates are additionally potentially confounded as they reflect the incidence but also 
the duration of depression; should LTPCs prolong depression rates are inflated in 
the absence of an increase in incidence (Patten, 2001). Prospective data is 
therefore more informative to this end.  
 
However, population based, randomly sampled and nationally representative cohort 
studies and systematic reviews including longitudinal studies with unselected 
samples from countries including the UK, have generally supported this prospective 
relationship. In a Canadian study of people with no MDD at baseline, those with a 
LTPC experienced double the risk of incident depression (4%) compared to those 
without a LTPC two years later (Patten, 2001). It is notable, however, that in this 
study depression may have emerged and resolved within the follow up, diluting the 
effect had this occurred equally across groups or deriving a positive bias again 
should LTPCs prolong depression. Moreover, a past history of MDD was apparently 
not ruled out or controlled for (only demographic factors were controlled). The 
systematic review evidence reports that the incidence of depression is inflated in 
cardiac disease (OR 1.37), but not hypertension (OR 2.15), diabetes (OR 1.50) and 
cancer survivorship (OR .87), albeit only older samples were included (Chang-
Quan, Bi-Rong, Zhen-Chan, Ji-Rong & Qing-Xiu, 2010). Importantly though, effect 
25 
 
heterogeneity and an absence of adequately powered studies were noted for 
diabetes and hypertension, and the search employed was lacking in 
comprehensiveness; a seemingly eligible study reporting an increased risk of 
incident depression in diabetes was not included (de Jonge, Roy, Saz, Marcos & 
Lobo, 2006).   
 
Trajectory of depression in LTPCs 
The aforementioned incidence evidence does not then, however, speak about how 
LTPCs might be implicated in the course of depression (i.e. recurrence and 
chronicity). Some longitudinal evidence has however indicated that the course of 
depression, even at lower-levels, is persistent in LTPCs; over 40% remain 
depressed at follow up (Di Benedetto, Linder, Hare & Kent, 2007; McKenzie, Clarke, 
McKenzie & Smith, 2010). 
 
Bidirectional relationship between LTPCs and depression 
The evidence presented thus far therefore suggests that depression is prevalent in 
LTPCs and that LTPCs are a risk factor for both the development and course of 
depression. However, it must be noted that depression may also occur prior to and 
thus be implicated in the development of LTPCs. Indeed some population-based, 
prospective research typically controlling for important prognostic variables supports 
such a bidirectional relationship. In fact, contrary to expectations depression is 
apparently a more notable risk factor for LTPCs than the reverse association. 
 
For example, metabolic syndrome (MS) is a cluster of factors that increase the risk 
for morbidity and mortality from CVD and Type 2 diabetes, for example impaired 
glucose and lipid metabolism, obesity and hypertension.   Evidence suggests that 
MDD is consistently associated with an increased risk for the onset of MS (OR 1.21-
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1.82) (Goldbacher, Bromberger & Matthews, 2009; Räikkönen, Matthews & Kuller, 
2007). In diabetes, a recent systematic review of prospective studies indicated that 
depression is associated with a 60% increase in the risk of onset Type 2 diabetes 
(OR 1.60) whilst Type 2 diabetes is modestly associated with incident depression 
(OR 1.15) (Mezuk, Eaton, Albrecht & Golden, 2008). Indeed, these bidirectional 
effects were confirmed within one large, multiethnic and landmark longitudinal study 
by Golden, Lazo, Carnethon, Bertoni, Schreiner, Diez Roux, Lee & Lyketsos (2008). 
Research in cancer is more limited but longitudinal studies have suggested that 
negative affect is associated with an increased risk of cancer onset over nine years, 
although this was restricted to only a few cancers and associations were weak 
(White, English, Coates, Lagerlund, Borland & Giles, 2007). Apparently stress may 
play a more important role in cancer onset (Chen, David, Nunnerley, Michell, 
Dawson, Berry, Dobbs & Fahy, 1995). 
  
Pathophysiology of the bidirectional relationship between LTPCs and 
depression 
There is a dearth of literature explicitly delineating the mechanisms of the bi-
directional relationship between LTPCs and depression. However, a number of 
pathways have been suggested. Depression may cause LTPCs directly, for 
example CHD via disturbances in blood clotting mechanisms and alterations in 
inflammatory processes (Goldsten & Baillie, 2008) and Type 2 diabetes via 
increased counter-regulatory hormone release (e.g. glucocorticoids) and alterations 
in glucose utilisation and inflammatory processes, which are posited to raise blood 
glucose levels and or increase insulin resistance (Mussleman, Betan, Larsen & 
Phillips, 2003; Williams, Clouse & Lustman, 2006). Indeed, cross-sectional studies 
support an association between depression and disturbed glucose metabolism 
(Adriaanse, Dekker, Heine, Snoek, Beekman, Stehouwer, Bouter, Nijpels & Pouwer, 
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2008; Eriksson, Ekbom, Granath, Hilding, Efendic & Östenson, 2008; Gale, 
Kivimaki, Lawlor, Carroll, Philips & Batty, 2010) and insulin resistance (Timonen, 
Salmenkaita, Jokelainen, Laakso, Härkönen, Koskela, Meyer-Rochow, Pietso & 
Kienänen-Kiukaanniemi, 2007), albeit causality cannot be inferred here. It is posited 
that alterations in inflammatory processes in CHD and diabetes may also produce 
depression (Goldsten & Baillie, 2008; Mussleman et al, 2003). 
 
Importantly, the aforementioned and additional prospective evidence has suggested 
some indirect mechanisms underpinning the incidence of depression/LTPCs. 
Depression may cause incident LTPCs via use of antidepressants (Andersohn, 
Schade, Suissa & Garbe, 2009; Delaney, Oddson, Kramer, Shea, Psaty & 
McClelland, 2010), negative lifestyle factors (Golden et al, 2008; Goldbacher et al, 
2009) and central adiposity in diabetes, which may operate indirectly via an 
exacerbation of insulin resistance (Everson-Rose, Meyer, Powell, Pandey, Torréns, 
Kravitz, Bromberger & Matthews, 2004). Some research suggests that diabetes 
may cause incident depression via the burden of a LTPC and its management 
(Golden et al, 2008), with which various other prospective and cross-sectional 
studies concur (Knol, Heerdink, Egberts, Geerlings, Gorter, Numans, Grobbee, 
Klungel & Burger, 2007; Knol, Geerlings, Grobbee, Egberts & Heerdink, 2009). 
Clinicians additionally speculate that side effects of LTPC medication may be 
implicated in the development of depression (House & Stark, 2002; MacHale, 2002). 
However, in most of these studies mediation cannot be presumed as formal 
mediation models were not performed and or causal models were not established 
(formal mediation analysis is discussed in chapter five). Typically, mediators were 
identified having attenuated the prospective relationship observed, yet it cannot be 
presumed that the baseline condition caused the mediator where these were 
measured at the same time. 
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It is clear, however, that psycho-social factors and illness-related stressors, 
apparently experienced at any point in a LTPCs trajectory, play an important role in 
depression in LTPCs. 
 
Psycho-social factors  
Prospective studies have indicated that trait anxiety in cancer (De Vries, Van der 
Steeg & Roukema, 2009) and illness beliefs, for example that the condition has 
severe consequences, in coronary artery disease (CAD) (Stafford, Berk & Jackson, 
2009), predict depression at follow up and changes in depression over time 
respectively. Cross-sectional evidence suggests that illness beliefs predict 
depression only when these are experienced in combination with general stress, 
albeit here depression may have preceded these beliefs (Traeger, Penedo, 
Gonzalez, Dahn, Lechner, Schneiderman & Antoni, 2009).  
 
Prospective studies in cancer have indicated that perceived emotional support is 
associated with improvement in depressive symptoms over time (Manne, Rini, 
Rubin, Rosenbaum, Bergman, Edelson, Hernandez, Carlson & Rocereto, 2008; 
Talley, Molix, Schlegel & Bettencourt, 2010). Cross-sectional studies have also 
supported this association in diabetes (Koopmans, Pouwer, de Bie, Leusink, 
Denollet & Pop, 2009) and heart failure (Trivedi, Blumenthal, O’Connor, Adams, 
Hinderliter, Dupree, Johnson & Sherwood, 2009), although here depression may 
have caused people to withdraw (Mind, 2011).  Nonetheless, emotional support 
apparently buffers the negative emotional impact of a LTPC. Some prospective 
mediation analyses have also demonstrated that perceived emotional support with 
illness-related issues produces improvements in negative affect via improvements in 
cognitive processing (i.e. fewer intrusive thoughts). However, that the change in 
intrusive thoughts produced the change in negative affect cannot be presumed as 
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these occurred concurrently (Christie, Meyerowitz, Giedzinska-Simons, Gross & 
Agus, 2009). 
 
It is also worth pointing out that prospective studies eliciting the psycho-social 
determinants of depression in LTPCs have identified predictors of depression at 
follow up or changes in depression (i.e. the course of depression), rather than 
depression onset (i.e. aetiology). Most have controlled for baseline depression, 
amongst other potential confounders, yet this merely removes the confounding 
effect of this prognostic variable and does not offer causal information.  
Disappointingly few studies, besides those described earlier, have examined 
precursors of incident depression in LTPCs.   Moreover, the precise mechanisms by 
which these factors may influence depression have infrequently been empirically 
examined.  
 
Illness-related stressors 
Research has identified an array of demographic and clinical predictors of 
depression in LTPCs, which are largely the same as those in non-LTPC samples 
(Egede, 2007; Engum et al, 2005). Examples are included in Table 2, albeit this is 
not an exhaustive list. It is noteworthy that some studies have produced somewhat 
inconsistent results, for example for HbA1c (Connell, Storandt & Lichty, 1990); 
whilst speculative it could be that the associations are less evident for certain sub-
groups (Pouwer & Snoek, 2000). Typically studies have been cross-sectional, and 
indeed some of the factors described, for example BMI, treatment burden and 
medical co-morbidity could also result from depression (discussed later). However, 
some prospective evidence has reported that such clinical factors, for example 
physical symptoms, are associated with increases in depression over time, for 
example in diabetes (Vileikyte, Peyrot, Gonzalez, Rubin, Garrow, Stickings, 
Waterman, Ulbrecht, Cavanagh & Boulton, 2009). 
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Importantly, however, it is plausible that some of these clinical factors may be 
experienced as stressful (i.e. as illness-related stressors) and related to depression. 
Indeed, the evidence indicates the same factors are also associated with general 
emotional/illness-related distress. Again, a non exhaustive list of examples is 
included in Table 2, yet the aforementioned causality issue again applies to these 
cross-sectional studies. In further support of this assertion, it is well established that 
stressful life events are associated with depression (Kessler, 1997); depression can 
result when people do not have the opportunity or ability to deal effectively with the 
negative emotions evoked by stressful events (Diabetes UK (DUK), 2008c; Mind, 
2011). A positive association between general emotional and or illness-related 
distress and depression has also been supported in cancer (Graves et al, 2007), 
post acute coronary syndrome (Di Benedetto et al, 2007) and diabetes (Adriaanse, 
Pouwer, Dekker, Nijpels, Stehouwer, Heine & Snoek, 2008; Koopmans et al, 2009).  
 
These studies are again cross-sectional, thus while they indicate that distress may 
cause depression, depression may also cause people to experience LTPCs as 
stressful; a bi-directional relationship is again probable. Indeed, in diabetes 
longitudinal data suggests a history of MDD is predictive of developing diabetes-
specific emotional distress (DSED) (Fisher, Mullan, Skaff, Glasgow, Arean & 
Hessler, 2009) and that higher baseline DSED is associated with persistence of 
significant depressive symptoms 12 months later, albeit this finding does not 
indicate causality (Pibernik-Okanovic, Begic, Peros, Szabo & Metelko, 2008). 
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Table 2 Socio-demographic and or clinical predictors of depression and general emotional/illness-related distress in LTPCs7  
 
  
                                                             
7 The references supporting these predictors are: 1.Adriaanse & Bosman (2010); 2.Bell, Smith, Arcury, Snively, Stafford & Quandt (2005);  3.Chen & Chang (2004); 4.Chouhan 
& Shalini (2006); 5.Delahanty, Grant, Wittenberg, Bosch, Wexler, Cagliero & Meigs (2007); 6.Dunlop, Lyons, Manheim, Song & Chang (2004); 7.Egede & Zheng (2003); 
8.Engum et al (2005); 9.Graves, Arnold, Love, Kirsh, Moore & Passik (2007); 10. Hänninen, Takala, Keinänen-Kiukaanniemi (1999); 11.Henselman, Helgeson, Seltman, de 
Vries, Sanderman & Ranchor (2010); 12.McKenzie, Simpson & Stewart (2010); 13.Norton, Manne, Rubin, Carlson, Hernadez, Edelson, Rosenblum, Warshal & Bergman 
(2004); 14. Shehatah, Rabie & Al-Shahry (2010); 15.Strong, Waters, Hibberd, Rush, Cargill, Storey, Walker, Wall, Fallon & Sharpe (2007); 16.Tellez-Zenteno & Cardiel (2002); 
17.Weijman, Ros, Rutten, Schaufeli, Schabracq & Winnubst (2005); 18.West & McDowell (2002). 
LTPC Depression Distress 
Demographic Clinical Clinical 
Cancer Younger age (13, 15). 
 
Being female (15). 
 
Symptom burden (3). 
 
Greater disease severity/burden (13, 15). 
Treatment burden (11)  
 
Poorer physical functioning (9). 
CVD Being female (12). 
 
Functional limitations (6)  
Diabetes Being female (2, 7, 16). 
 
Lower level of education (2, 7, 8). 
 
Being widowed or divorced (10; 
16). 
Higher BMI (2). 
 
Multiple medications (2, 10). 
 
Self-management burden (17). 
 
Poor HbA1c (10, 16). 
 
Poorer physical functioning (2). 
 
Medical co-morbidities (1, 2, 8, 14, 16)  
Poor HbA1c (4). 
 
Greater disease severity/burden (5, 
18). 
 
More invasive treatment (i.e. insulin) 
(5, 18). 
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Nonetheless, it is apparent that targeting illness-related stressors and 
general/illness-related distress in addition to depression in LTPCs may optimise 
improvement in depression. Such intervention trials are therefore indicated. There is 
some promising evidence that interventions aimed at reducing general emotional 
distress can improve both this and depressive symptoms, for example stress-
management interventions in cancer (Bohlmeijer, Prenger, Taal & Cuijpers, 2010) 
and CHD (Olivo, Dodson-Lavelle, Wren, Fang & Oz, 2009).  The interdependence 
of improvements in distress and depression is yet to be established however.  
 
Prognosis of depression in LTPCs 
Just as depression is seemingly implicated in the aetiology of LTPCs, research 
suggests that it can additionally influence their course.  
 
Self-management behaviours (SMBs) and clinical outcomes 
A vast amount of cross-sectional and systematic review evidence suggests that 
depression in LTPCs has a universal and adverse effect on SMBs, for example poor 
adherence to patient-initiated SMBs that are difficult to maintain (e.g. exercise and 
diet) yet not preventative services (e.g. retinopathy screening) in diabetes  (Lin, 
Katon, Von Korff, Rutter, Simon, Oliver, Ciechanowski, Ludman, Bush & Young, 
2004), adverse health behaviours, for example smoking in diabetes (Katon, Simon, 
Von Korff, Ludman, Ciechanowski, Walker, Russo, Bush, Lin & Young, 2004a), and 
non-compliance with medication (DiMatteo, Lepper, Croghan, 2000). The latter is 
true even for mild to moderate depressive symptoms in CHD, albeit to a less 
significant extent (Gehi, Haas, Pipkin, & Wooley, 2005).  Depression also has an 
adverse effect on important clinical outcomes in LTPCs conferring additional 
morbidity and worsening prognosis, for example cardiac risk factors in CVD (Kop, 
Kuhl, Barasch, Jenny, Gottleib & Gottdiener, 2010), and hyperglycemia (Lustman, 
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Anderson, Freedland, DeGroot, Carney & Clouse, 2000), other aspects of metabolic 
control (e.g. increased blood pressure, cholesterol and triglyceride levels) (Gary, 
Crum, Cooper-Patrick, Ford, Brancati, 2000) and long-term medical complications 
(DeGroot, Anderson, Freedland, Clouse & Lustman, 2001) in diabetes.  
 
Emerging prospective evidence  
However, these cross-sectional studies are of limited utility because, as described 
above, these outcomes are additionally likely implicated in the aetiology and course 
of depression in LTPCs. Importantly, then, prospective evidence has recently 
demonstrated that in LTPCs, baseline depression predicts these outcomes at long-
term follow up or better yet a change in them over time. In diabetes, both mild and 
major depression predict non-compliance with and discontinuation of medication 
over a follow up period (Kalsekar, Madhavan, Amonkar, Douglas, Makela, Elswick & 
Scott, 2006; Kalsekar, Madhavan, Amonkar, Makela, Scott, Douglas & Elswick, 
2006), and in fact a systematic review suggests that longitudinal designs report 
larger effects on SMBs, for example for diet SMBs (Gonzalez, Peyrot, McCarl, 
Collins, Serpa, Mimiaga & Safren, 2008b). In diabetes, depression is associated 
with poorer glycaemic control (Chiu, Wray, Beverly & Dominic, 2010; McKellar, 
Humphreys & Piette, 2004) and the onset of CHD (Clouse, Lustman, Freedland, 
Griffith, McGill & Carney, 2003) over time. In CHD, depression is  associated with 
increased risk of future cardiac events (e.g. heart failure, MI, stroke, transient 
ischemic attack or death) over time (Whooley, de Jonge, Vittinghoff, Otte, Moos, 
Carney, Ali, Dowray, Na, Feldman, Schiller & Browner, 2008), and again a 
systematic review suggests that prospective studies report more consistent effects 
(Frasure-Smith & Lesperance, 2005). There is additionally some evidence that this 
is true for even for mild depression in coronary artery bypass graft patients 
(Rafanelli, Roncuzzi & Milaneschi, 2006). 
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Exactly how depression influences these parameters is unclear. It is likely the 
processes implicated in the development of LTPCs in depression may also explain 
how depression influences their course. Indeed, the aforementioned prospective 
studies of the effect of depression on LTPC course have indicated that controlling 
for inflammatory markers attenuates the relationship between depression and future 
cardiac events (Whooley et al, 2008). Again, it is posited that depression may cause 
the onset of LTPCs via lifestyle factors, and indeed some prospective evidence 
suggests that poorer SMBs may explain the effect of depression on clinical 
outcomes in CHD (Whooley et al, 2008) and diabetes (McKellar et al, 2004). 
Importantly, a study in diabetes actually confirmed this indirect effect, in addition to 
a direct effect of depression on HbA1c, in a structural equation model with variables 
measured such that causality can be established (Chiu et al, 2010). Interestingly, 
cross-sectional studies suggest that lower self-efficacy (i.e. the belief that one is 
capable of performing certain behaviours to attain certain goals) may explain the 
effect of depression on SMBs (Wagner, Tennen & Osborn, 2010) and clinical 
outcomes (Cherrington, Wallston & Rothman, 2010) in diabetes.     
 
QoL 
Depression in LTPCs has been demonstrated to be associated with an increased 
risk of functional disability (Schmitz, Wang, Malla & Lesage, 2007) and impairments 
in role functioning (Lee, Guo, Tsang, He, Huang, Liu, Zhang, Shen & Kessler, 2009) 
in cross-sectional studies, increased medial symptom burden in prospective studies 
(Katon, Lin & Kroenke, 2007), and therefore unsurprisingly reduced QoL in 
systematic reviews (Ali, Stone, Skinner, Robertson, Davies & Khunti, 2010; Stafford, 
Berk, Roddy & Jackson, 2007) and prospective studies (Howren, Christensen, 
Karnell & Funk, 2010; Schram, Baan & Pouwer, 2009).  
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HCU and costs  
Patients with CHD and depressive symptoms are substantially more likely to report 
doctor-patient communication deficits (Schenker, Stewart, Na & Whooley, 2009). 
Research in the USA has also indicated that in LTPCs having depression, even 
lower-levels, is associated with double the odds of using secondary care services 
(Himelhoch, Weller, Wu, Anderson & Cooper, 2004) and twice the odds of incurring 
paid sick and health and disability costs (Druss, Rosenheck & Sledge, 2000). 
Studies in diabetes suggest productivity losses are inflated (i.e. prolonged bed days 
and lost work days) (Subramaniam, Sum, Pek, Stahl, Verma, Liow, Chua, Abdin & 
Chong, 2009; Vamos, Mucsi, Keszei, Kopp & Novak, 2009) and medical costs are 
inflated five-fold (Egede, Zheng & Simpson, 2002), which is not accounted for by 
increased mental health care costs (Finkelstein, Bray, Chen, Larson, Miller, 
Tompkins, Keme & Maderscheid, 2003; Simon, Katon, Lin, Ludman, Von Korff, 
Ciechanowski & Young, 2005). Although the precise magnitude of this impact 
cannot be generalized to the UK owing to differences in health service delivery and 
costs, the observed associations undoubtedly apply.  
 
Early mortality  
Research has additionally indicated that having depression is associated with a 
greater mortality risk in acute coronary syndrome (Kronish, Reickmann, Schwartz, 
Schwartz & Davidson, 2009) and diabetes (Egede, Nietert & Zheng, 2005). In fact, 
even mild depression may inflate mortality rates in diabetes, but perhaps only for 
those people with more severe medical illness (Zhang, Norris, Gregg, Cheng, 
Beckles & Kahn, 2005). It is also interesting that new onset depression apparently 
confers a greater mortality risk than previous/recurrent depression, for example in 
post-myocardial infarction (MI) patients (Dickens, McGowan, Percival, Tomenson, 
Cotter, Heagerty & Creed, 2008; Carney, Freedland, Steinmeyer, Blumenthal, de 
Jonge, Davidson, Czajkowski & Jaffe, 2009). 
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Depression in LTPCs is therefore associated with a clear worsening of their course 
and an adverse effect on other important outcomes, typically even after controlling 
for important prognostic and potentially confounding clinical variables. As such, 
depression in LTPCs furthers the aforementioned impact of LTPCs upon QoL, early 
mortality, and HCU and costs. The identification and treatment of depression in 
individuals with LTPCs is therefore important as it is prevalent in this population, 
and because as mentioned earlier this may offer an additional means of 
ameliorating the impact of LTPCs. This is again important given the limited scope 
for directly improving these outcomes in LTPCs. 
 
Current provision of E&P support in LTPCs 
Over recent years, evidence of inadequate provision of E&P support in LTPCs has 
been commonplace. Individuals with LTPCs have stated that they want and need 
yet lack E&P support. In the USA, between 21 and 33% of LTPC patients (i.e. 
diabetes, hypertension and CHD) reporting some psychological distress in primary 
care have expressed a need for E&P support, and of these 63% to 72% have 
reported that this need is unmet (Sherbourne, Jackson, Meredith, Camp & Wells, 
1996). Similar research in cancer has additionally suggested that despite the high 
prevalence of psychological morbidity, only a small proportion of individuals receive 
treatment or access to mental health services (Norton et al, 2004). Such issues are 
anticipated in the UK. Indeed, the white paper our health, our care, our say (DoH, 
2006b) recognised in 2006 that it was not possible to meet the complex 
psychological needs of patients within existing primary care services, nor could they 
all be referred to secondary care which is focussed on those with severe enduring 
mental illness. 
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Policy imperatives for improving provision of E&P support in LTPCs 
E&P support should be a fundamental component of the care individuals with 
LTPCs receive. Indeed, a number of recent UK policy documents, mentioned 
earlier, have responded to the unmet need, highlighting the importance of E&P need 
and support in LTPCs. 
 
White papers 
Choosing health (DoH, 2004) underpins the approach to LTPCs. It outlines the 
public and governments shared priority for a healthier future, which includes 
improving the known risk factors for LTPCs (e.g. obesity, exercise and smoking), 
and improving mental health. Mental health is recognised as a precursor to making 
healthy lifestyle choices, physical health and employment. The next steps in 
achieving this objective are reported, which includes a shift in focus from treatment 
to prevention and health promotion with better provision of support to people with 
mental health conditions, for example new approaches to helping them manage 
their own care and health, and return to work. 
 
Our health, our care, our say (DoH, 2006b) set a new direction for the health and 
social care system. Amongst its main objectives was more support for people with 
LTPCs, for instance empowering self-management in line with patients’ preferences 
for care delivery, and again a shift of resources to prevention services with earlier 
intervention including support to maintain mental health and emotional well-being. 
The latter was identified as a top priority amongst patients. Mental health is 
considered as important as physical health. It is also advocated that people must 
receive help in managing depressive disorder, but also the ‘widespread misery that 
does not reach the threshold for clinical diagnosis yet nevertheless reduces QoL of 
thousands of people’. Talking therapies are posited to offer a real alternative to 
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medication for lower-level E&P need. New technology, such as computerised CBT 
(cCBT), is also highlighted a means of increasing treatment options in mental health 
care, disseminating E&P support into the community and facilitating self-
management of mental health. Finally, primary care is specified as an opportunity 
for provision of psychological therapies for mild to moderate mental health 
problems. 
 
LTPC-specific imperatives  
Supporting people with long-term conditions to self-care – an NHS and social care 
model to support local innovation and integration (DoH, 2005) provided a model for 
supporting local NHS and social care organisations in improving services for people 
with LTPCs, advocating a shift from care in secondary care to primary care, the 
community or home, personalised care, and the provision of self-care support to 
assist people in making healthier lifestyle choices. Specifically for vulnerable 
patients with complex conditions case management is advocated, which entails a 
comprehensive needs assessment including psychological needs and wishes.  
 
Supporting people with long-term conditions to self-care – a guide to developing 
local strategies and best practice (DoH, 2006c) outlines how health and social care 
services can support people with LTPCs to self-care, recognising that this 
necessitates assuming responsibility for staying both physically and mentally 
healthy, and dealing with the emotional changes produced by a LTPC and its impact 
on daily life. This is anticipated to improve mental health and reduce depression. 
 
Generic choice model for long-term conditions (DoH, 2007) highlights how the care 
planning process, in which the full range of patients’ needs, goals and preferences 
are identified, can and should inform commissioning of more personalised services 
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in which patients with LTPCs have more control over and choice in the care they 
receive. It specifies that commissioners should provide a genuine menu of options 
that are attractive to patients and offer real alternatives, informed by the content of 
care plans. E&P needs, goals and preferences should be elicited via discussion and 
routine screening during the course of living with a LTPC. Health care providers 
(HCPs) and patients should then be able to identify tailored services from the range 
of treatment options derived from patients’ choices and commissioned thereafter. 
Examples of treatment options include psychological therapies such as CBT, 
counselling and emotional support groups. In 2007 the implementation of this 
approach was explored in diabetes ‘year of care’ pilot sites. 
 
Common core principles to support self care – a guide to support implementation 
(Skills for Health & Skills for Social Care, 2008) describes the behaviours required 
by HCPs to effectively support people with LTPCs to self-manage, conceptualised 
as making the most of life, coping with difficulties and taking actions to meet 
psychological needs and maintain health and well-being. Examples include 
supporting and enabling development of self-care skills and use of technology to 
support self-care. 
 
Supporting people with long-term conditions: commissioning personalised care 
planning - a guide for commissioners (DoH, 2009) provides commissioners with 
information and support with respect to how personalised care planning can be 
embedded into their localities, which again involves discussion of E&P needs and 
patients preferences for meeting these. It is recognised that this will derive demand 
for psychological therapies such as CBT, which could be used as an adjunct or 
alternative to medication. The anticipated result of this holistic approach, which 
extends beyond medical needs, is improved mental health and well-being. 
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Your health your way – a guide to long-term conditions and self-care (DoH, 2009) 
advocates supported self-care in LTPCs and the need to embed this into clinical 
care. This approach, for example encouraging use of self-help and internet 
resources, is anticipated to enable people to manage the impact of their condition 
on emotional life and meet their psychological needs. Support networks are 
identified as key to empowering and supporting people with LTPCs, underscoring 
the importance of both practical and emotional support. 
 
Improving the health and well-being of people with long-term conditions: world class 
services for people with long-term conditions – information tool for commissioners 
(Department of Heath, 2010) describes a common vision of good services in LTPCs 
and offers practical suggestions for commissioners to achieve this. Personalised 
care planning, self-care support and provision of care in more appropriate settings 
for example primary care and at home is advocated. The importance of moving 
beyond the medical model and addressing the full range of patients’ needs, 
including E&P needs, by offering a broad range of services required to meet these 
holistic needs, for example access to psychological therapies, is additionally 
emphasised 
 
The importance of proving ‘talking therapies’ as a form of E&P support in health 
care is now being campaigned by five leading mental health charities (Mental Health 
Foundation, Mind, Rethink, The Sainsbury Centre for Mental Health, Young Minds, 
2006).     
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Recent changes in UK clinical practice with respect to E&P support in 
LTPCs 
These imperatives have spurred endeavours to improve service delivery, the most 
notable of which are described below. 
  
National Service Frameworks (NSFs) for LTPCs 
The NSFs for specific LTPCs are intended to improve the quality of care and health, 
and reduce inequalities. The NSFs for CHD and diabetes each outline 12 standards, 
rationales, key interventions, service models and performance indicators for 
achieving this. The areas in which E&P needs and support are acknowledged are 
highlighted below. 
 
CHD 
The CHD NSF advocates that psychological support is offered to people with 
uncontrollable symptoms or those at the end of life. Specifically, standard 12 
identifies that psychological needs should be assessed before discharge from 
hospital and early in the post-discharge phase to facilitate cardiac rehabilitation, with 
psychological interventions then received according to an agreed plan. Referral to 
psychological services is advocated for long-term maintenance of change as 
clinically indicated (DoH 2000a; 2000b). 
 
Diabetes  
Standard 3 in the diabetes NSF recognises that diabetes and its diagnosis can have 
an adverse effect on psychological adjustment, which then adversely impacts self-
care. Provision of psychological support in diabetes is therefore crucial. Standard 12 
also emphasises that for people with diabetes that develop complications and 
require complex care, QoL can be improved with psychological support. 
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Psychological support is conceptualised as empowering people to self-manage and 
develop strategies to deal with the psychological consequences of diabetes, which 
will assist them in identifying any emotional or behavioural barriers to effective self-
management. The development of a comprehensive evidence base of appropriate 
psychological interventions and their effect upon self-management is specified as a 
future research priority (DoH, 2001; 2003). 
 
GPs Quality and Outcomes Framework (QoF)  
In the UK, detection of depression in some LTPCs recently became a general 
practice performance indicator, underscoring the importance of detection and 
management of depression in primary care. Specifically, as part of the General 
Medical Services (GMS) QoF for primary care in the UK, participating general 
practices now receive points and thus financial reward in accordance with their 
achievement of national, evidence-based quality standards. In 2006, three 
indicators relating to the identification and assessment of depression in high risk 
groups of adults, namely those with significant physical conditions causing disability 
(i.e. CHD and diabetes), were introduced (BMA & NHS Employers, 2009). These 
are described below. 
 
Indicator 1: Patients are to be asked two case finding questions every 15 months.8 
Individuals responding positively to either or both are identified as potentially 
experiencing depression that should be investigated further. The evidence relating 
to the diagnostic accuracy of these questions for identifying depression in primary 
care is reported in chapter four. The specificity of diagnoses (i.e. rate of false 
positives) is modestly improved by additionally asking those responding positively 
                                                             
8 These questions are: During the last month, have you often been bothered by feeling down, 
depressed or hopeless? & During the last month, have you often been bothered by having little interest 
or pleasure in doing things? 
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whether this is something with which they would like help (Arroll, Goodyear-Smith, 
Kerse, Fishman & Gunn, 2005).   
 
Indicator 2: For individuals responding positively, subsequent assessment of 
severity using a tool validated for use in primary care is advocated to inform 
appropriate intervention. Self-report depressive symptom measures are employed,9 
for which cut-points that indicate whether depressive symptoms warranting 
intervention are present have been agreed upon. Higher scores indicate greater 
severity requiring different types of treatment, for example antidepressants can be 
targeted to only moderate to severe depression (discussed below).  Additional 
factors must also be considered, however, for example degree of functional 
impairment and family/previous history of depression.  
 
Indicator 3: If the initial severity assessment indicates potential problems, a further 
assessment is advocated 5-12 weeks later, to identify whether very mild symptoms 
not immediately requiring intervention have worsened (i.e. watchful waiting) and 
treatment has sufficiently resolved more substantial symptoms, which as described 
earlier are typically chronic in LTPCs. 
 
National Institute for Clinical Excellence (NICE) guidance for the 
treatment of depression in adults with LTPCs  
HCPs are expected to take NICE clinical guidelines into account when exercising 
clinical judgement. These are recommendations about the treatment of people with 
specific conditions in the NHS in England and Wales, informed by careful review of 
the evidence base (NICE, 2009). The NICE guidelines for the treatment of 
depression in adults have recently been adapted to LTPCs. Both diagnosable 
                                                             
9 The self-reported depression measures employed include the Patient Health Questionnaire–9 (PHQ-
9), the Hospital Anxiety and Depression Scale (HADS) and the Beck Depression Inventory (BDI). 
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depression and sub-threshold symptoms are considered problematic and warranting 
intervention, yet intervention should be tailored and a stepped model of care is 
advocated.  
 
At step one patients’ are assessed on the severity of their condition, degree of 
functional impairment, duration of the depressive episode and other factors that 
influence the course of depression (i.e. past/family history and interpersonal/social 
difficulties). Vigilance for depression in LTPCs, especially in the presence of 
functional impairment, is advocated, hence as are the QoF indicators described 
above. Patients are then matched with the most appropriate service depending on 
their level of need, with the least intrusive and most effective intervention provided 
first. Should efficacy be insufficient, an appropriate intervention from the next step 
up is offered, each step up representing increasingly complex intervention to meet 
increasingly complex need. The treatment options at each step and thus level of 
need defined by diagnostic criteria (i.e. DSM-IV) are outlined below. 
 
 Step 1: General support, psycho-education and active monitoring (i.e. watchful 
waiting) where symptoms do not meet the criteria for the next steps. 
 
 Step 2: Low-intensity psychosocial intervention for patients presenting with 
persistent sub-threshold symptoms (i.e. present for several months and despite 
active monitoring), mild to moderate depression or sub-threshold depressive 
symptoms that complicate LTPC care. Examples include structured group physical 
activity, group-based peer support (self-help), individual guided self-help based on 
CBT principles and cCBT. Treatment choice is guided by patient preference. 
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 Step 3: High-intensity psychological intervention is offered to patients with persistent 
sub-threshold symptoms or mild to moderate depression with an inadequate 
response to initial intervention (i.e. low-intensity) or patients presenting with 
moderate to severe depression. Examples include group-based CBT, individual 
CBT (where group format is declined, not appropriate or unavailable) and 
behavioural couple’s therapy as appropriate. Collaborative care10 should be 
considered only for moderate to severe depression in LTPCs that are associated 
with functional impairment, which has not responded to high-intensity psychological 
interventions, antidepressants or both. 
 
 Step 4: Practitioners provide treatment in specialist mental health services for 
patients with complex and severe depression associated with a risk of self-neglect 
and harm. 
 
Antidepressants are not advocated for sub-threshold symptoms and mild 
depression owing to a poor risk-benefit ratio, unless there is a past history of 
moderate to severe depression, mild depression that complicates LTPC care, sub-
threshold symptoms that have persisted for more than two years (i.e. dysthymia), or 
sub-threshold symptoms or mild depression that has persisted after other 
interventions. They are, however, to be considered at step three after trying high-
intensity psychological intervention, or in combination with this where patients 
present with more severe depression.  
 
                                                             
10 Collaborative care involves case-management supervised by a senior mental health professional, 
and collaboration between primary and secondary physical health services and specialist mental 
health services to deliver a range of the aforementioned interventions and pharmacological 
treatment/medication management. 
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Improving access to psychological therapies (IAPT) 
In 2005, the labour parties’ general election manifesto specified intentions to 
improve access to therapies for mental health problems in primary and secondary 
care. IAPT is a government funded NHS initiative launched in 2007 aimed at 
supporting PCTs in implementing the aforementioned NICE guidelines, by 
improving access to evidence-based talking therapies in the NHS (i.e. via expansion 
of services and workforce). LTPCs are considered a priority group, and a four year 
plan of action has recently been specified which states that models of care 
specifically for people with LTPCs will be developed by 2015 (IAPT, 2011). 
 
The IAPT service model entails a team of therapists taking referrals predominantly 
from primary care but also self-referrals. Consistent with NICE, needs assessment, 
step allocation and then delivery of step-appropriate NICE-compliant therapies (i.e. 
watchful waiting or low- or high-intensity interventions)11 is executed, again with 
stepping up following insufficient response. Concurrent use of antidepressants is 
similarly not advocated for milder symptoms. Owing to greater prevalence of mild to 
moderate psychological problems, the model requires significant investment in low-
intensity interventions. Consistent with the policy imperatives described earlier, 
commissioners are also required to make a range of the evidence-based, NICE-
approved psychological treatments available to facilitate patient choice. This is 
posited to be critical for obtaining positive outcomes given the variation between 
patients in tolerance for different treatments (IAPT, 2008a). 
 
Routine outcome assessment has demonstrated effectiveness and clinical 
excellence (IAPT, 2008a). Two pilot sites (PCTs) established to inform the national 
                                                             
11 Low intensity psychological interventions for mild to moderate anxiety and depression at step 2 
include cCBT, pure self-help (i.e. un-facilitated e.g. books on prescription), guided self-help (i.e. 
facilitated and based on CBT principles), behavioural activation, structured exercise and other 
therapies, and high-intensity treatment for more severe disorder at step 3 includes CBT (i.e. cognitive 
therapy, problem solving and behavioural activation), interpersonal therapy and couples’ therapy. 
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role out saw up to 4, 000 patients in their first year, thus access was improved, and 
reported recovery of symptoms for 50% of patients receiving at least one treatment 
session and long-term maintenance of treatment gain. The authors note, however, 
that in the absence of a waitlist control condition it is unclear whether this 
improvement exceeds the natural trajectory of symptoms. An emphasis on low-
intensity interventions achieved a high throughput of patients, underscoring the 
importance of offering this level of service to appropriate patients (Clark, Layard, 
Smithies, Richards, Suckling & Wright, 2009). 
 
Problems associated with current provision of E&P support 
There are, however, problems associated with current provision of E&P support in 
LTPCs. 
 
HCP-level 
HCP-level barriers to the identification of E&P need and provision of E&P support in 
LTPCs include the dismissal of somatic features of depression (e.g. fatigue, loss of 
appetite and insomnia) that can result from an LTPC and its treatment, which can 
also prohibit patients recognition of depression (Haddad, 2009; MacHale, 2002), 
judgements that medical problems are a more immediate concern (IAPT, 2008b; 
Nutting, Rost, Dickinson, Werner, Dickinson, Smith & Gallovic, 2002), attribution of 
mental health problems to the LTPC (IAPT, 2008b), lack of recognition that 
psychological symptoms can be treated (IAPT, 2008b) and reluctance to prescribe 
owing to problematic side effects and drug interactions (discussed below) (Haddad, 
2009; MacHale, 2002).   
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Patient-level 
Patient-level barriers include distraction from depression owing to the LTPC 
(Haddad, 2009; IAPT, 2008b), prohibited treatment seeking behaviour due to 
embarrassment, stigma or denial (IAPT, 2008b; Kaltenthaler, Brazier, De Nigris, 
Tumur, Ferriter, Beverley, Parry, Rooney & Sutcliffe, 2006; Whooley & Simon, 
2000), an expectation that no support options are available (DUK, 2007b), that 
HCPs are too busy (DUK, 2008c), that the consultation is for physical problems and 
that emotional problems are not relevant to the LTPC (Pouwer, Beekman, Lubach & 
Snoek, 2006), prohibited travel owing to illness (i.e. to therapy sessions) (IAPT, 
2008b; MacHale, 2002) and treatment burden, namely adverse drug reactions and 
long therapy sessions (discussed below). Indeed, premature discontinuation of both 
physical and psychological intervention is commonplace (Whooley & Simon, 2000), 
albeit there is some evidence that people with a LTPC prefer talking therapies to 
antidepressants (Hodges, Butcher, Kleiboer, McHugh, Murray, Walker, Wilson & 
Sharpe, 2009). 
 
Problems associated with current treatment options 
Intervention currently advocated for psychological co-morbidity in LTPCs is also 
problematic. 
 
Pharmacological intervention 
Effectiveness 
Antidepressants have demonstrated efficacy for improving psychological and clinical 
markers in LTPCs. An early Cochrane systematic review of randomised controlled 
trials (RCTs) testing selective serotonin re-uptake inhibitors (SSRIs), tricyclic 
antidepressants (TCAs) and atypical antidepressants reported consistent 
improvements in depressive symptoms (Gill & Hatcher, 1999). More recent RCTs 
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testing TCAs in diabetes (i.e. Nortriptyline) (Lustman, Griffith, Clouse, Freedland, 
Eisen, Rubin, Carney, McGill, 1997a) and SSRIs in CVD (Lespérance, Frasure-
Smith, Koszycki, Lalibérte, van Zyl, Baker, Swenson, Ghatavi, Abramson, Dorian & 
Guertin, 2007; Thombs, de Jonge, Coyne, Whooley, Frasure-Smith, Mitchell, 
Zuidersma, Eze-Nliam, Lima, Smith, Soderlund & Ziegelstein, 2008) and diabetes 
(i.e. Fluoxetine, Sertraline & Paroxetine) (Goodnick, Kumar, Henry, Buki & 
Goldberg, 1997; Gülseren, Gülseren, Hekimsoy & Mete, 2004; Lustman, Freedland, 
Griffith, Clouse, 2000; Lustman, Clouse, Nix, Freedland,  Rubin, McGill, Williams, 
Gelenberg, Ciechanowski & Hirsch, 2006) concur. The improvement incurred is 
apparently indistinguishable to that derived for people without LTPCs (Simon, Von 
Korff & Lin, 2005).  
 
In LTPCs antidepressants apparently also produce concurrent improvements in 
SMBs, such as diet and exercise (Goodnick et al, 1997; Lustman, Williams, Sayux, 
Nix & Clouse, 2007), QoL (Gülseren et al, 2004) and HbA1c (Gülseren et al, 2004; 
Lustman et al, 2006; Lustman et al, 2000; Lustman et al, 2007) in diabetes, but not 
cardiac event free survival in CVD, albeit this finding is based on very few studies 
(Thombs et al, 2008). Concurrent improvements in HbA1c have been attributed to 
improvement in depression in some (Lustman et al, 2007) but not other trials, where 
it is more likely that the antidepressant directly altered HbA1c (Gülseren et al, 2004; 
Lustman, et al, 2000). 
 
Limitations 
However, in LTPCs, antidepressants confer a risk of drug interactions, metabolic 
complications, complication of self-care and or increased sensitivity to medication 
side effects (MacHale, 2002), which must be considered in treatment decisions 
(NICE, 2009). TCAs are not well tolerated (Gill & Hatcher, 1999), and they can 
produce carbohydrate cravings, weight gain and have an adverse impact upon 
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clinical outcomes (Goodnick, Henry & Buki, 1995; Goodnick, 2001; Lustman et al, 
1997; MacHale, 2002; Simon, 2002; Whooley & Simon, 2000). SSRIs are the least 
problematic and thus the first line pharmacological treatment for depression in 
LTPCs (Goodnick et al, 1995; NICE, 2009; Simon, 2002). However, they can still 
incur intolerable side effects (Gülseren et al, 2004; Lespérance et al, 2007) and 
discontinuation symptoms (NICE, 2009), they are contraindicated with a number of 
LTPC medications (NICE, 2009) and they can produce sedation, weight gain and  
have an adverse impact upon clinical outcomes (Goodnick et al, 1995; MacHale, 
2002). Indeed, it is recognised that antidepressant trials reporting negative effects 
are often unpublished (Pouwer, 2009). Furthermore, in LTPCs SSRIs do not always 
produce depression remission (Lustman et al, 2006; Lustman et al, 2007), and 
relapse is often rapid and associated with a decline in clinical markers, for example 
HbA1c in diabetes (Lustman, Griffith, Freedland & Clouse, 1997b). Maintenance 
treatment lengthens the time until depression recurrence in LTPCs (Lustman et al, 
2006; Lustman et al, 2007), yet this incurs substantial health care costs (Jacobson 
& Weinger, 1998) and does not always prevent recurrence (Lustman et al, 2006). 
Psychological and collaborative interventions are therefore indicated. 
 
Psychological intervention 
Effectiveness 
RCTs of NICE concordant psychological interventions, and collaborative care, have 
demonstrated comparable efficacy for improving psychological and clinical markers 
in LTPCs. CBT has produced improvement in depression in cancer (Tatrow & 
Montgomery, 2006) and sustained remission of MDD in Type 2 diabetes 
(Georgiades, Zucker, Friedman, Mosunic, Applegate, Lane, Feinglos & Surwit, 
2007; Lustman, Griffith, Freedland, Kissel & Clouse, 1998; Simon et al, 2004), with 
concurrent improvements in HbA1c in diabetes (Lustman et al, 1998) and pain in 
cancer (Tatrow & Montgomery, 2006). Some CBT studies have, however, 
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demonstrated no concurrent change in HbA1c and or no association between 
changes in depression and HbA1c/pain (Georgiades et al, 2007; Lustman et al, 
1998; Tatrow & Montgomery, 2006). Interpersonal therapy has produced 
improvements in depressive symptoms in diabetes (Simson, Nawarotzky, Friese, 
Porck, Schottenfeld-Naor, Hahn, Scherbaum & Kruse, 2008) and a trend for 
improvement in CAD (Lespérance et al 2007), albeit the latter effect was likely 
diluted as many participants in each group, and thus controls, also received 
antidepressant therapy.  In fact, a comprehensive systematic review of RCTs in 
diabetes has indicated that psychological interventions including CBT and 
psychodynamic therapy can produce reductions in HbA1c large enough to influence 
the development and progression of micro vascular complications, where transitory 
fluctuations are averaged out. Equivocal effects are achieved when interventions 
are delivered by generalist rather than specialist clinicians, yet more intensive 
therapy derives greater improvement (Alam, Sturt, Lall & Winkley, 2009; Ismail, 
Winkley & Rabe-Hesketh, 2004). 
 
Limitations 
Psychological interventions such as CBT are expensive, the treatment period spans 
several weeks and they require involvement of highly skilled professionals12 
(Kaltenthaler et al, 2006; Mayor, 2006; MacHale, 2002; NICE, 2009). This prohibits 
widespread availability (the impact of the recent changes in UK clinical practice, 
including the IAPT programme, is discussed below). 
 
 
 
                                                             
12 Groups based CBT entails groups of six to eight participants with a common LTPC and lasts for 
about six to eight weeks, individual CBT is delivered until symptoms have remitted, which for moderate 
depression typically takes six to eight weeks with two follow up sessions within six months from the 
end of treatment and for severe depression can take 16-18 weeks with twice weekly sessions required 
initially and again two to three follow up sessions within 12 months post treatment (NICE, 2009). 
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Collaborative care 
Effectiveness 
Collaborative care interventions in the USA, for example the Improving Mood-
Promoting Access to Collaborative Treatment (IMPACT) programme and the 
Pathways study programme delivered to primary care patients with current MDD or 
dysthymia and a LTPC have evidenced improvements in depressive symptoms, 
some SMBs (i.e. only exercise in some instances) and cardiac events but not 
HbA1c (Davidson, Reickmann, Clemow, Schwartz, Shimbo, Medina, Albanese 
Kronish, Hegel & Burg, 2010; Harpole, Williams, Olsen, Stechuchak, Oddone, 
Callahan, Katon, Lin, Grympa & Unützer, 2005; Katon, Von Korff, Lin, Simon, 
Ludman, Russo, Ciechanowski, Walker, & Bush, 2004b; Lin, Katon, Rutter, Simon, 
Ludman, Von Korff, Young, Oliver, Ciechanowski, Kinder & Walker, 2006; Williams, 
Katon, Lin, Nöel, Worchel, Cornell, Harpole, Fultz, Hunkeler, Mika & Unützer, 2004). 
The null effect on HbA1c was, however, potentially due to a floor effect and dilution 
of the effect on depression again owing to antidepressant treatment in usual care 
controls.  
 
It is additionally noteworthy that there is evidence from these collaborative care 
trials that treating depression, including mild to moderate symptoms, may improve 
HCU and produce cost-savings. Studies have demonstrated acceptable incremental 
medical costs for additional benefits (i.e. depression free days) conferred over usual 
care (Katon, Unützer, Fan, Williams, Schoenbaum, Lin & Hunkeler, 2006), and 
additional benefit (i.e. depression free days) yet also reduced medical costs relative 
to usual care (Katon, Russo, Von Korff, Lin, Ludman & Ciechanowski, 2008; Simon, 
Katon, Lin, Rutter, Manning, Von Korff, Ciechanowski, Ludman and Young, 2007). 
Thus, an initial investment in services to improve depression will be offset by long-
term savings in medical costs (Katon, et al, 2008), not to mention the potential for 
wider cost reductions from societal and patient perspectives. 
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Limitations 
Collaborative care does not always produce depression remission (Katon et al, 
2004b; Koike, Unutzer & Wells, 2002).  
 
Lower level E&P need and low-intensity psychological intervention 
Provision of E&P support is also hampered by the complexity of E&P need amongst 
people with LTPCs, the different levels of which require different types of support 
consistent with NICE guidelines. Again, low-intensity psychological intervention is 
advocated for lower-level need. For these patients, high-intensity psychological 
intervention and collaborative care represent over investment of valuable resources. 
Antidepressants are not advocated, and consistent with the poor risk to benefit ratio 
reported by NICE there is evidence that they have limited effectiveness for milder 
symptoms, for example in Type 2 diabetes (Pailie-Hyvarian, Wahlbeck & Erikkson, 
2007).  
 
Effectiveness 
Low-intensity interventions have demonstrated clinical and cost-effectiveness, for 
example some cCBT packages, which are now advocated by NICE (Mayor, 2006; 
Kaltenthaler et al, 2006). Whilst evidence supporting their use in LTPCs is still to 
surface, psycho-education has demonstrated significant improvements in 
depressive symptoms and HbA1c in patients with diabetes and mild to moderate 
depressive symptoms (Pibernik-Okanovic, Begic, Ajdukovic, Andrijasevic & Metelko, 
2009). This improvement did not differ from that observed in controls, yet the control 
group received non-specific psychological support and qualitatively reported 
benefiting from this. Facilitated self-help interventions are also popular amongst 
patients with LTPCs and lower-level E&P need (Lyons, Nixon & Coren, 2006).   
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Limitations 
However, low-intensity interventions vary in the extent of professional contact, which 
ranges from monitoring to facilitation by trained practitioners13 and treatment is also 
still relatively intensive and burdensome14 (NICE, 2009). Some cCBT packages are 
also expensive, which is an important disadvantage in a group already incurring 
substantial health care costs (Kaltenthaler et al, 2006). These issues prohibit 
widespread availability (again, the impact of the recent changes in UK clinical 
practice, including the IAPT programme, is discussed below). cCBT also 
necessitates a certain degree of computer literacy to enable efficient use. 
 
Impact of the QoF, NICE guidelines and IAPT programme 
The evidence suggests that the QoF standards, and NICE guidelines, have 
improved screening and influenced treatment provision. Many practices now report 
administering the QoF questions to around 90% of patients with diabetes and/or 
CHD within the previous 15 months and then administering a severity assessment 
to the majority of those attaining a new diagnosis of depression (NHS The 
Information Centre for Health and Social Care, 2011). An audit of UK general 
practice medical records has additionally suggested that depression treatment is 
positively related to severity scores (Kendrick, Dowrick, McBride, Howe, Clarke, 
Maisey, Moore & Smith, 2009). However, in this study treatment rates were lower 
for patients with LTPCs, which it was posited may reflect HCPs concerns about drug 
side effects (as described above), HCPs not wanting to medicalise distress or label 
patients not complaining of depression, or patient’s unwillingness to accept 
treatment having been routinely screened rather than self-referred. Access to 
psychological intervention, especially low-level intervention, was also seemingly 
                                                             
13 Group based peer support necessitates facilitation by a practitioner with knowledge of the LTPC and 
its association with depression, individual guided self-help based on CBT involves support from a 
trained practitioner who facilitates the programme and computerised CBT is a stand-alone computer or 
web-based programme but with limited facilitation by a trained practitioner (NICE, 2009). 
14 These interventions typically take place over eight to 12 weeks, with weekly or only slightly fewer 
sessions, and are additionally usually face to face, with the exception of cCBT (NICE, 2009). 
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restricted; inconsistent with NICE guidelines, patients with minimal to moderate 
depression were prescribed antidepressants more often than referral to mental 
health specialists occurred (Kendrick et al, 2009). In fact, it is speculated that HCPs 
are more likely to prescribe antidepressants where specialist psychological 
treatment is less readily available (Kendrick et al, 2009). Since its national role out 
in recent years, the IAPT programme has undoubtedly improved access to low- and 
high-intensity psychological therapies. To date, 97% of the PCTs in England have a 
service from this programme in at least part of their area; 60% of the adult 
population has access (IAPT, 2011). Evidently, though, there is room for 
improvement in service provision, and indeed eight to 12 week waiting lists are still 
reported locally for referring patients with diabetes (JS15, 2011).  
 
Conclusions 
In sum, depression is prevalent in LTPCs, particularly lower-level need. The 
aetiological evidence is confused and suggests a bidirectional relationship with 
unclear mechanisms, yet some indication that targeting illness-related stressors and 
general/illness-related distress may optimise improvement in depression. Whether 
intervention derived improvements in distress are related to improvement in 
depression is yet to be established though. Intervention for depression is warranted 
as it has a clear and substantial adverse impact on important outcomes in LTPCs, 
which is evident even for lower-level need. This suggests that while the NICE 
guidelines direct treatment according to distinctions in depression severity defined 
by diagnostic criteria (e.g. DSM-IV) (i.e. level of need), these distinctions are 
apparently more quantitative than qualitative. The conceptualisation of depression 
as a continuum may hence be more appropriate. In LTPCs, both high- and low- 
intensity psychological intervention improves depression and has produced 
                                                             
15 PhD supervisor Dr Jackie Sturt. 
56 
 
concurrent improvements in other important outcomes, albeit evidence for the latter 
is equivocal and whether changes in these outcomes are related to improvements in 
depression is unclear (i.e. this has either not been investigated or is supported in 
some but not other instances). There is also some evidence that depression 
treatment, even for lower-level need, can produce cost savings. Unmet E&P need in 
LTPCs is identified as a national priority, particularly lower-level need owing to its 
prevalence and somewhat equivocal impact. Whilst access to E&P support has 
improved with recent changes in UK clinical practice, barriers persist across the 
continuum of depression/E&P need. Investigation of alternatives that overcome 
these barriers is therefore warranted. 
 
Overview of thesis 
This thesis considers a theoretically appropriate low-intensity psychological 
intervention, which is consistent with the current policy context for improving 
depression in adults with LTPCs and offers pragmatic advantages over existing 
alternatives; written emotional disclosure (WED). The author’s initial interest in WED 
emerged when it was encountered in previous study on the psychological impact of 
LTPCs. The aforementioned properties of WED, described fully in the next chapter, 
made it an attractive and apparently viable means of ameliorating the psychological 
impact of LTPCs that could reasonably be implemented as part of routine clinical 
care. 
 
The intervention, its theoretical grounding and the existing evidence base is 
reviewed, with relevant effectiveness RCTs considered systematically and attention 
paid to WEDs effects for negative affect, including depression, in LTPCs. The 
development, implementation and findings of an exploratory trial, informed by the 
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systematic review, testing WED for improving depressive symptom severity for 
individuals Type 2 diabetes is then described and evaluated.  
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Chapter 2 WED for adults with a LTPC 
 
Chapter overview 
This chapter describes WED and its theoretical and pragmatic appropriateness for 
improving depression for adults with a LTPC, in addition to its consistency with the 
policy context outlined in chapter one and its acceptability to patients and clinicians. 
The existing evidence base is then discussed in a preliminary sense, with attention 
to the evidence that suggests WED is selectively effective and which delineates 
some fairly consistently supported moderating influences. The evidence for 
hypothesised mechanisms of effect and similarities in the mechanisms of effect 
underpinning WED and other effective psychotherapies are considered, which 
suggest some possible critical processes in WED and provide some support for its 
anticipated effectiveness. The chapter concludes with a critical discussion of 
previous systematic reviews of WED and their informative potential and clinical 
utility for determining the effect of WED on negative affect, including depression, in 
LTPCs.  
 
WED description 
WED is a technique developed by Pennebaker and Beall (1986), which targets 
emotional aspects of stressors. It involves writing about a stressful event, exploring 
in detail thoughts and feelings surrounding this, for approximately 15-20 minutes a 
day for three to four days within a short time period, usually consecutive days. 
Where effectiveness is demonstrated, an initial mild increase in negative affect is 
typically yet quickly subsides, producing salutary health effects compared to control 
participants who write about emotionally neutral topics, such as their plans for the 
day, or receive usual care.  
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The appropriateness of WED for LTPCs 
Theoretical appropriateness 
Chapter one identified that illness-related stressors and general/illness-related 
distress are associated with depression in LTPCs, thus targeting this may optimise 
improvement in depression. WED targets emotional aspects of stressors and 
presumably distress, consequently improvement in depression may be optimised. 
Stressors are self-selected ensuring universal coverage of the wide range of 
stressors associated with depression in LTPCs (described in chapter one). By 
improving depression, even lower-levels, WED may additionally improve the 
outcomes adversely impacted by this, for example QoL, SMBs, clinical outcomes 
and HCU and costs. Again, concurrent improvements in these outcomes have been 
demonstrated in trials of low- and high-intensity depression treatment, albeit as 
described in chapter one the evidence is equivocal and it is unclear whether these 
changes are related to improvement in depression. 
 
Policy context 
Chapter one identified that supported self-management, prevention/early 
intervention, and management of mental health in the home, community and 
primary care are a priority in LTPCs. WED is self-administered at home, engaging 
people with an LTPC in their treatment.  Moreover, in chapter one lower-level 
depression was demonstrated to be particularly prevalent, impactful and a national 
priority in LTPCs, with some existing barriers to lower-level E&P support. Consistent 
with NICE WED is a low-intensity intervention that would serve the large proportion 
of people with a LTPC and lower-level need. Specifically, WED may protect 
individuals at risk of developing depression (i.e. delaying the onset of symptoms) 
and act as a remedial intervention for lower-level depression (i.e. delaying the 
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progression of significant symptoms), yet also provide a useful adjunct for more 
severe depression (i.e. supervised implementation of WED).  
 
Pragmatic advantages over existing low-intensity E&P support in 
LTPCs  
WED additionally overcomes some existing barriers to provision of low-intensity 
intervention in LTPCs. It is easily accessible, not labour intensive, inexpensive and 
does not exacerbate patient burden in that it is brief, portable, available 24 hours a 
day and seven days a week, and entirely self-administered with no requirement for 
computer literacy or access. Completed in anonymity, WED additionally provides a 
safe disclosure context that is not impeded by the social constraints reported by 
people with LTPCs with respect to E&P issues (see chapter one); it can access 
patients that are difficult to reach, for example those for whom interpersonal 
disclosure is unacceptable (Smyth & Helm, 2003).  
 
Acceptability to patients and clinicians  
WED is consistent with LTPC patients’ expressed need to talk. Indeed, people 
report WED to be a valuable experience (Pennebaker, 1997; Francis & Pennebaker, 
1992; Pennebaker & Seagal, 1999), including LTPC patients (Gellaitry, Peters, 
Bloomfield & Horne, 2010; Morgan, Graves, Poggi & Cheson, 2008). WED has also 
demonstrated a lower attrition rate than other therapist-lead and self-help 
interventions (Stice, Burton, Bearman & Rhode, 2006).  That negative effects post-
writing are not prolonged is confirmed by LTPC patients, and typically none report 
being upset or request additional support as a result of participation (Broderick, 
Stone, Smyth & Kaell, 2004; Gellaitry et al, 2010). WED is additionally advocated by 
clinicians (Baikie & Wilheim, 2005).  
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It is noteworthy that written disclosure may be considered to be more appropriate 
than verbal disclosure in LTPCs.  Therapeutic gain (Murray & Seagal, 1994) and 
long-term health effects (Pennebaker, 1997; Frattaroli, 2006) are equivocal, yet  
LTPC patients report a preference for writing as this is less restrictive in that one 
cannot hear themselves saying things they are reluctant to disclose to others 
(Byrne-Davis, Wetherell, Dieppe, Weinman, Byron, Donovan, Horne, Brooks & 
Vedhara, 2006). 
 
Preliminary overview of the evidence base for WED 
A large evidence base of RCTs suggests that WED can derive notable 
improvements in physiological and psychological health, and HCU, in healthy 
samples, typically students tested in a laboratory (Pennebaker, Kiecolt-Glaser & 
Glaser, 1988; Pennebaker & Beall, 1986). However, this does not indicate whether 
WED is effective for those with clinical need; WED may interact with unique 
characteristics of clinical samples and the treatment they receive (Smyth, 1998), or 
whether it has ecological validity; WED may be less effective in more naturalistic 
settings with less experimental control. These questions must be answered before 
WED can be applied in practice (Baikie & Wilheim, 2005; Smyth & Helm, 2003), and 
indeed such research has recently begun to emerge. For samples with greater 
clinical need more modest yet still potentially notable effects are reported  (Baikie & 
Wilheim, 2005), for example  on physical and psychological health, and HCU, in 
adults with current or past experience of a stressful event, for example caregivers 
(Campbell, 2003), with LTPCs ranging from those with a lower mortality risk for 
example arthritis (Smyth, Stone, Hurewitz & Kaell, 1999) to terminal illnesses such 
as cancer (Stanton, Danoff-Burg, Sworowski, Collins, Branstetter, Rodriguez-
Hanley, Kirk & Austenfeld, 2002), and with psychiatric/psychological problems for 
example psychiatric prison inmates (Richards, Beal, Seagal & Pennebaker, 2000) 
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and individuals with lower- and higher-levels of depression (Gortner, Rude & 
Pennebaker, 2006; Stice et al, 2006; Sloan & Marx, 2006). However, effects upon 
psychological health are generally not as consistent or notable as those on physical 
health (Baikie & Wilheim, 2005; Frisina, Borod & Lepore, 2004).  
 
Results have, however, been mixed with evidence of null effects on physical and 
psychological health, and HCU, amongst healthy participants (Swanbon, Boyce & 
Greenberg, 2008), and patients with traumatic injuries (Bugg, Turpin, Mason & 
Scholes, 2008), asthma (Harris, Thoresen, Humphreys & Faul, 2005), HIV (Rivkin, 
Gustafson, Weingarten & Chin, 2006) and eating disorders (Frayne & Wade, 2006). 
This inconsistency likely reflects heterogeneity in risk of bias and other study-
specific artefacts; study parameters have been unsystematically manipulated in 
search of the most effective design. Indeed, WED studies are highly variable with 
respect to a) participants (i.e. selection criteria and recruitment approach), b) the 
intervention (i.e. the number, length and spacing of writing sessions, whether the 
disclosure topic is self-selected (e.g. any stressor) or prescribed (e.g. a LTPC), 
whether past versus current and  traumatic versus stressful events are disclosed, 
whether the disclosure structure is participant-generated or guidance is received, 
whether topic switching across writing sessions is allowed, and whether the 
standard WED paradigm (e.g. genuine stressors) is implemented as opposed to 
variants of this (e.g. imagined stressors or positive events), c) the outcomes 
assessed and the measures employed, and d) the comparison exposure (i.e. 
alternative treatment, neutral writing or usual care). Interpretation of the evidence 
base is therefore extremely difficult.  
 
It should additionally be noted that a small number of studies have identified a 
negative effect of WED. Most have included samples defined by significant distress 
or individuals experiencing highly stressful situations, for example studies have 
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evidenced increased HCU in patients with apparent PTSD (Gidron, Peri, Connolly & 
Shalev, 1996), more fatigue in students with trauma history (Greenberg, Wortman & 
Stone, 1996) and high risk surgical patients (Solano, Pepe, Donati, Persichetti, 
Laudani & Colaci, 2007) and reduced satisfaction with prostheses in lower limb 
amputees (Gallagher & MacLachlan, 2002). WED apparently increases avoidance 
in these samples (Cohen, Sander, Slavin & Lumley, 2008; Gidron et al, 1996; 
Greenberg et al, 1996), which may be taken to reflect early but incomplete 
processing of evoked stressors.  It is posited that in this context WED may merely 
activate distress, which is too upsetting to confront or for which more disclosure 
sessions and/or additional assistance are required to achieve resolution (Cohen et 
al, 2008; Gallagher & MacLachlan, 2002; Gidron et al, 1996; Solano et al, 2007). 
These studies are limited, however, as in some instances effects were partially 
explained by improvement in controls (Cohen et al, 2008; Gidron et al, 1996) and 
the intervention deviated from the standard WED paradigm, for example additional 
use of mood induction procedures (Greenberg et al, 1996) and verbal elaboration 
(Gidron et al, 1996). Nonetheless, it is widespread clinical opinion that WED is not 
appropriate with very distressed patients (i.e. unsupervised) (Baikie & Wilheim, 
2005; Esterling, L’Abate, Murray, & Pennebaker, 1999; Honos-Webb, Harrick, Stiles 
& Park, 2000; Murray & Seagal, 1994; Pennebaker, 2004; Sloan & Marx, 2006; 
Smyth & Helm, 2003). WED has demonstrated some negative effects in unselected 
student samples, yet this was again apparently due to avoidance and an absence of 
proper resolution of evoked stressors (Honos-Webb et al, 2000; Rogers, Wilson, 
Gohm & Merwin, 2007). To date no negative effects have been reported in LTPCs 
(Baikie & Wilheim, 2005).  
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Moderators of WEDs effects: Interpersonal determinants of whether 
and to what extent WED is effective 
Research suggests that WED may be selectively effective for individuals possessing 
particular traits. This may explain the heterogeneity between apparently similar trials 
in that traits which maximise WEDs effects may be differently represented across 
samples. No moderator has consistently discriminated those that do and do not 
benefit from WED (Lumley, 2004); some studies demonstrate a particular 
moderating effect (i.e. WED is more effective for sub-group A than B) whilst others 
report no moderating effect for the same variable or an effect in the opposite 
direction (i.e. WED is more effective for sub-group B than A) (Smyth & Pennebaker, 
2008). However, this is again likely due to heterogeneity between studies. 
Nonetheless, two traits for which the evidence is fairly consistent are described 
below. 
 
Alexithymia 
Unsurprisingly, some evidence suggests that WED may be less effective for people 
that experience difficulty identifying and describing emotions and instead focus on 
more external processes, a trait termed alexithymia (Lumley, 2004). Perhaps the 
stronger effects of WED observed in students is a function of lower alexithymia. In 
fact, it is posited that WED may merely make alexithymic individuals acutely aware 
of distress resulting in increased perception of symptoms (Lumley, 2004). Indeed, 
for individuals with high alexithymia WED has derived worse physical and 
psychological health outcomes, including negative affect, compared to controls in 
chronic pain (Norman, Lumley, Dooley & Diamond, 2004; cited in Lumley, 2004) 
and migraine (Kraft, Lumley, D’Souza, Robertson, Stanislawski & Ramos et al, 
2003; cited in Lumley, 2004) samples. Other studies including LTPC samples have 
reported worse outcomes only for WED participants with particular facets of 
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alexithymia rather than the overall trait, namely more difficulty identifying emotions 
(Lumley & Provenzano, 2003; cited in Lumley, 2004; Norman et al, 2004; cited in 
Lumley, 2004) and externally oriented feelings (Baikie Mcllwian, 2008; Lumley & 
Provenzano, 2003; cited in Lumley, 2004; O’Connor & Ashley, 2008). Consistent 
with the evidence described above, it seems that for alexithymic individuals WED 
may increase intrusive thoughts and avoidance, which again may be taken to reflect 
early but incomplete processing of evoked stressors (Baikie & Mcllwain, 2008). 
Similar to those reporting significant distress, alexithymic individuals may 
additionally require more disclosure sessions or additional assistance (Baikie & 
Mcllwain, 2008; Lumley, 2004; Lumley & Provenzano, 2003; cited in Lumley, 2004).  
 
Some studies have reported no moderating effect of alexithymia (Van Middendorp & 
Geenen, 2008), however this study adapted WED to explicitly instruct emotional and 
cognitive processing (E&CP), which perhaps facilitated disclosure for alexithymics. 
Others report more benefit to be associated with higher alexithymia (Baikie & 
McIlwain, 2008; Paez, Velasco & Gonzalez, 1999; Solano, Donati, Pecci, Persichetti 
& Colaci, 2003). However, these analyses and or studies examined only the 
difficulty describing feelings facet of alexithymia. This is only marginally related to 
the other facets (Lumley, 2004) and confounded by inhibition (Paez et al, 1999), 
which is typically associated with more benefit from WED (discussed below).   
 
Optimism 
Evidence suggests that WED may be effective for optimists, who have a 
generalised disposition toward positive expectations/outcomes and therefore may 
cope well with evoked stress using the opportunity to resolves issues and derive 
insight. Conversely, for pessimists, with negative expectations about outcomes, it 
may promote rumination on the negative aspects of an issue with less success 
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achieving resolution (Cameron & Nicholls, 1998). Indeed, an increase in word use 
reflecting optimism across writing sessions has been found to predict improvement 
in psychological health including negative affect specifically for WED participants 
(Mackenzie, Wiprzycka, Hasher & Goldstein, 2008). There is also preliminary 
evidence of this moderating effect in LTPCs, for example HIV patients, although this 
refers to cognitive adaptability including optimism (Wagner, Hilker, Hepworth & 
Wallston, 2008). Research also suggests that WED typically evokes positive 
expectancies that it will reduce the emotional impact of an event and that benefits 
are restricted to these participants, whereas for those with negative expectancies 
negative effects are more likely (Langens & Schüler, 2007). Although speculative, 
the benefits apparently derived by optimists may be explained by concomitant 
positive expectancies about WED. Some studies have reported no moderating 
effect of optimism (Harrist, Carlozzi, McGovern & Harrist, 2007) or more benefit 
associated with less optimism (Mann, 2001). However these studies explored 
writing about life goals and a positive future with HIV respectively, rather than 
stressful issues, which may be contraindicated for optimists should reality not match 
their expectations (Mann, 2001). 
 
Why WED might be effective for treating psychological morbidity and 
improving health 
WED is seemingly associated with empirically supported influencing 
mechanisms  
WED was not derived from an established theoretical framework. However a 
number of mechanisms have been proposed and somewhat supported empirically, 
suggesting that WED may be considered to have a sound theoretical grounding for 
achieving improvements in health. This support is, however, variable such that no 
one theory has fully explained the observed effects (Sloan & Marx, 2004a; 
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Pennebaker, 2004), albeit these theories have yet to be adequately tested (Sloan & 
Marx, 2004a). It is possible that a number of these mechanisms, which are not 
mutually exclusive, operate simultaneously. The proposed mechanisms and the 
empirical support associated with each are presented below. 
 
Inhibition-confrontation approach 
It is posited that inhibition of a traumatic event necessitates cognitive monitoring and 
is a physiological drain (Baikie & Wilheim, 2005; Pennebaker, 1985; Pennebaker, 
1997; Sloan & Marx, 2004a). Autonomic nervous system activity is increased with 
physiological discharge along hidden channels, for instance increased 
electrodermal activity and thus increased skin conductance levels (i.e. greater hand 
perspiration) (Baikie & Wilheim, 2005; Pennebaker, 1985; Pennebaker & Susman, 
1988; Petrie, Booth & Pennebaker, 1998). People switch to lower-level processing 
with a narrower, superficial focus on the event and attention directed to other 
superficial topics, yet rumination and intrusive thoughts result which are 
physiologically arousing and psychologically harmful (Baikie & Wilheim, 2005; 
Pennebaker, 1985; Petrie et al, 1998). This prolonged autonomic arousal and 
psychological stress functions as a chronic, low-level, cumulative stressor, which 
adversely affects stress-related immune parameters (i.e. circulating lymphocytes) 
and the immune influencing parameters of the nervous system. Immune mediated 
disease processes are impacted and the associated risk of illness is thus enhanced 
(Pennebaker, 1985; Pennebaker & Susman, 1988; Pennebaker, 1997; Petrie et al, 
1998). WED was thus originally posited to permit suppressed traumatic experiences 
and the associated emotion to be relived, releasing inhibited thoughts and emotion 
and reducing the associated physiological, cognitive and psychological problems 
(Baikie & Wilheim, 2005; Pennebaker, 1997; Sloan & Marx, 2004a).  
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Evidence for the inhibition-confrontation approach 
It has long been asserted that emotional inhibition is associated with poor health 
and disease and that releasing this can derive benefit (i.e. catharsis). Evidence in 
LTPCs concurs (Gross, 1989; Nyklíček, Vingerhoets & Denollet, 2002; 
Panagopoulou, Kersbergen & Maes, 2002; Stanton, Danoff-Burg, Cameron, Bishop, 
Collins, Kirk, Sworowski & Twillman, 2000). There is also evidence that release of 
inhibition may underpin the health effects of WED. Thought suppression during 
WED has a detrimental effect upon outcomes (Petrie et al, 1998) and WED is more 
effective for individuals exhibiting more inhibition (McGuire, Greenberg & Gevirtz, 
2005; Gortner et al, 2006; Porter, Keefe, Baucom, Hurwitz, Moser, Patterson & Kim, 
2009). WED also improves physiological markers of inhibition, for instance skin 
conductance levels (Pennebaker, Hughes & O’Heeron, 1987; Pennebaker & 
Susman, 1988; Petrie, Booth, Pennebaker, Davison & Thomas, 1995), with some 
evidence of greater benefit for individuals exhibiting more verbal disclosure and a 
corresponding drop in skin conductance levels (Pennebaker, Barger & Tiebout, 
1989). Patient feedback about WED in LTPCs also supports inhibition as a 
mechanism (Byrne-Davis et al, 2006; Gellaitry et al, 2010). 
 
Evidence against the inhibition-confrontation approach 
Inconsistent with this model, however, WED reportedly derives benefit where 
trauma has previously been disclosed (Greenberg & Stone, 1992), although full 
disclosure may not have been achieved interpersonally (Sloan & Marx, 2004). 
Studies have also reported no moderating effect of inhibition (Smyth, Anderson, 
Hockemeyer & Stone, 2002; Esterling, Antoni, Kumar & Schneiderman, 1990; 
Esterling, Antoni, Fletcher, Margulies & Schneiderman, 1994) and more benefit for 
individuals exhibiting less inhibition (Francis & Pennebaker, 1992), although this 
may be because inhibitors avoid or do not engage in disclosure (Lumley, 2004). 
Health benefits are additionally not consistently related to post-writing negative 
69 
 
affect (i.e. taken as a proxy for emotional release) (Smyth, 1998), and in fact a 
short-term increase in negative affect rather than emotional relief post-writing is 
counterintuitive to this model (Baikie & Wilheim, 2005). Moreover, there is some 
evidence that evocation of stressors without resolution in WED produces adverse 
effects (discussed earlier). Finally, other forms of emotional expression, for example 
dance therapy (Krantz & Pennebaker, 1996, as cited in Pennebaker 1997) and 
drawing (Pantchenko, Lawson & Joyce, 2003) have not replicated WEDs effects. 
This suggests that while release of inhibition may play a role other processes are 
also seemingly implicated in WEDs effects. 
 
Cognitive processing approach  
It is posited that memories of traumas are fragmented, disorganised and 
inconsistent with other memory structures, and thus associated with persistent, 
distressing and intrusive thoughts, rumination, hyperactivity and avoidance. WED 
purportedly derives benefit by submitting these memories (i.e. the associated 
thoughts and feelings) to a linguistic format, forcing the labelling, re-structuring and 
re-organisation of the memory. This, it is proposed, promotes understanding of the 
event and the emotional responses to it (i.e. insight is derived, the cause and 
meaning of the event are ascertained and a coherent narrative is constructed), and 
reduces the associated emotion (Pennebaker, 1997; Pennebaker, 2000; 
Pennebaker & Francis, 1996; Pennebaker, Mayne & Francis, 1997; Smyth & Helm, 
2003) (i.e. there is emotional and cognitive processing (E&CP) of the event). The 
narrative is then supposedly simplified such that only information consistent with the 
story is recalled, and becomes biased as information is added in an unconscious 
effort promote cohesiveness (Pennebaker, 2000; Pennebaker & Seagal, 1999). The 
memory can then be stored and forgotten more efficiently, enabling a reduction in 
the associated symptoms. 
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The experiential model specifically posits that traumas are inconsistent with mental 
representations of the world (e.g. the belief that the world is a safe place), and are 
therefore associated with cognitive, affective and autonomic tension. WED is 
posited to resolve this incongruency by integrating the new information into existing 
schemas or altering them such that understanding of the event, or the world, is 
changed and the problematic symptoms are reduced (Baikie & Wilheim, 2005; 
Byrne-Davis et al, 2006; Sloan & Marx, 2004a).  
 
Evidence for the cognitive processing approach 
Defining and measuring E&CP, to identify whether this mediates WEDs effects, is 
difficult. Studies have therefore investigated whether linguistic features of WED 
presumed to reflect, or influence, the anticipated E&CP predict health improvement. 
Review of WED essay content has demonstrated more self-reflection, 
thoughtfulness, emotional openness (Graham, Lobel, Glass & Lokshina, 2008; 
Pennebaker, 2000) and the construction of a coherent narrative (Pennebaker, 1993) 
to be related to improvement. Objective language analysis of WED essays has also 
demonstrated no association between average use of words reflecting insight and 
causal thinking (Pennebaker, 1993), yet an association between increases in use of 
words reflecting insight and causal thinking (i.e. reflecting cognitive processing) 
across writing sessions and improvement in predominantly physical but also 
psychological health (Pennebaker, 1993; Pennebaker et al, 1997; Pennebaker & 
Francis, 1996). This association has also been demonstrated in LTPCs, although 
the improvements in health have not consistently been significant (Rivkin et al, 
2006; van Middendorp & Geenen, 2008) and the evidence is equivocal (Hamilton-
West & Quine, 2007; Walker, Nail & Croyle, 1999). 
 
In contrast, research investigating whether word use reflecting emotional processing 
is associated with health improvements is highly ambiguous. Initially, whether 
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average use of emotional words across writing sessions is related to WEDs effects 
was examined, as it was anticipated that the mere expression and labelling of 
emotions facilitates integration of emotional responses into ones understanding of 
the event and reduces the associated emotion (Pennebaker & Francis, 1996; 
Pennebaker et al, 1997). Improvement in WED has been linked to use of more 
negative and less positive emotion words overall (i.e. akin to cathartic expression of 
negative emotion) (Pennebaker, 1993), but more consistently and in more 
sophisticated analyses to use of more positive relative to less negative emotion 
words overall, with a moderate reference to negative emotion apparently being 
optimal (i.e. perhaps suggesting adaptive emotional processing wherein one has 
come to terms with the experience and achieved a positive emotional balance) 
(Baikie, Wilheim, Johnson, Boskovic, Wedgwood, Finch & Huon, 2006; O’Connor & 
Ashley, 2008; Pennebaker & Francis, 1996; Pennebaker et al, 1997; van 
Middendorp & Geenen, 2008). However, the evidence has not consistently indicated 
a prognostic effect of a higher average use of positive emotion words (Rivkin et al, 
2006; Walker et al, 1999).  
 
In view of the equivocal evidence relating to average use of emotional words, some 
albeit few studies including those with LTPC samples have additionally examined 
whether a change in use of positive and negative emotion words across writing 
sessions is associated with WEDs benefits. An increase in positive emotion words  
has been demonstrated to be associated with improvement in physical and 
psychological health, including depressive symptoms, specifically for WED 
participants (i.e. perhaps suggesting the temporal achievement of a positive 
emotional balance), albeit the improvements in health have not always been 
significant (Hamilton-West & Quine, 2007; Mackenzie et al, 2008). One study 
identified significant improvements in psychological health for WED participants with 
a concurrent increase in expression of affect-related words across writing sessions, 
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yet did not report on trends for changes in positive and negative emotion words 
separately nor examined the association between changes in word use and health.  
(Mankad & Gordon, 2010).  A decrease in negative emotion words across writing 
sessions has been found to be associated with significant improvements in physical 
health for WED participants (i.e. perhaps suggesting successful temporal emotional 
processing of and habituation to the associated emotion) (Hamilton-West & Quine, 
2007). 
 
Few studies have, however, examined whether emotional word use mediates WEDs 
effects in formal mediation analyses (again formal mediation analysis is described in 
chapter five). One study in cancer identified a decrease in negative emotion words 
across writing sessions that was exclusive to WED participants and was associated 
with improvement in health, yet did not mediate WEDs effects in a formal mediation 
analysis. None of the positive emotion word variables tested emerged as likely 
mediators of WEDs effects (Low, Stanton & Danoff-Burg, 2006).  However, the 
authors acknowledge limited power to detect significant  mediators of effects, and in 
this study no change in cognitive processing word use was observed across writing 
sessions. Indeed, while tentative another study has suggested that reduction in 
negative emotion words for WED participants may be prognostic only where 
successful cognitive processing has also occurred (Schwartz & Drotar, 2004).  
 
It is also problematic that it is unclear whether the linguistic changes observed to 
predict health improvements in these studies actually reflect the anticipated real 
world E&CP;  they could reflect other processes. Interestingly, however, WED has 
also improved proxy measures of cognitive change, for instance working memory 
suggesting pre-occupation with the event is reduced (Kellogg, Mertz & Morgan, 
2010; Klein & Boals, 2001; Yogo & Fujihara, 2008). In fact, the original WED study 
suggested that writing with only emotional expression or cognitive processing alone 
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is insufficient, rather both are required for benefit (Pennebaker & Beall, 1986), and 
enhancing aspects of cognitive processing, for instance cognitive re-structuring 
(Broderick et al, 2004; Gellaitry et al, 2010) and narrative structure (Smyth, True & 
Souto, 2001) has also demonstrated improvement/more improvement in WED, 
although this evidence is inconsistent (Danoff-Burg, Mosher, Seawell & Agee, 2010; 
Graybeal, Sexton & Pennebaker, 2002; Lichtenthal & Cruess, 2010). Patient 
feedback about WED in LTPCs additionally supports E&CP as a mechanism 
(Byrne-Davis et al, 2006; Gellaitry et al, 2010; Pennebaker, Colder & Sharp, 1990; 
Theadom, Smith, Horne, Bowskill, Apfelbacher & Frew, 2010).  
 
In sum, emotional and cognitive processing of stressors is seemingly required in 
WED. However, should this be the case, exactly which real world processes occur 
and the specific stages of change involved have yet to be delineated. The precise 
nature of the emotional processing component is particularly unclear as the 
evidence base is particularly under-developed, inconsistent and ambiguous, yet 
suggests that successful temporal emotional processing of and habituation to 
negative emotion and temporal attainment of a positive emotional balance may be 
required. 
 
Exposure approach 
Consistent with social learning theory, it is posited that the memory of an unresolved 
trauma is a faulty cognitive structure of erroneous information. Specifically, a 
traumatic event presents as an unconditioned stimulus (UCS), which evokes an 
unconditioned response (UCR) (i.e. fear and arousal). The memory of the event, 
initially a neutral stimulus (NS), becomes paired with the UCS (i.e. becomes a 
conditioned stimulus; CS) and elicits the negative emotional response (i.e. a 
conditioned response; CR) on its own. This CR is then reinforced by avoidance of 
the CS; that the CS might not produce the CR is never realised (Baikie & Wilheim, 
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2005; Sloan & Marx, 2004a).  Emotional processing of this fear structure, posited to 
underpin WED, is supposedly achieved via three stages; a) activation of the 
memory structure, the CS, b) modification of this via repeated exposure to and the 
provision of corrective information about the CS, c) gradual extinction of the 
UCS/CS association such that the CS no longer elicits the CR and associated 
symptoms such as intrusive thoughts and avoidance (Foa & Kozac, 1986). This is 
reflected by initial negative emotional arousal (i.e. emotional activation; EA), which 
then dissipates across exposure sessions (i.e. habituation; H).  
 
Evidence for the exposure approach 
There is some evidence that EA&H is observed in WED and that it may account for 
its effects. In samples defined by trauma, significantly more physiological activation 
(i.e. salivary cortisol reactivity) and subjective EA to the initial WED session and a 
reduction in this across writing sessions has been demonstrated relative to no such 
change in controls (Petrie et al, 1995; Smyth, Hockemeyer & Tulloch, 2008; Sloan & 
Marx, 2004b; Sloan, Marx & Epstein, 2005; Sloan & Marx, 2006; Sloan, Marx, 
Epstein, Lexington, 2007; Smyth et al, 2008). This pattern of activation has then 
been shown to be associated with clinically meaningful improvements in PTSD 
symptoms, depressive symptoms and physical health for disclosure participants 
(Sloan & Marx, 2004b; Sloan et al, 2005; Sloan & Marx, 2006), even in formal 
meditation analyses  (again formal mediation analysis is discussed in chapter five) 
(Sloan et al, 2007). In LTPCs larger increases in current negative mood post-writing 
have been observed for the first session compared to successive sessions (Smyth, 
Stone, Hurewitz & Kaell, 1999, cited in Lepore, Greenberg, Bruno & Smyth, 2002), 
and WEDs effects are reportedly explained by within-session heart rate habituation 
reflecting preliminary EA&H again in formal mediation analyses (Low et al, 2006). 
Indeed, EA&H would explain the initial increase in negative mood that is typical in 
WED studies, yet dissipates quickly. 
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Some WED studies have additionally demonstrated superior effects of emotional 
expression alone compared to writing facilitating cognitive processing when 
sufficient sessions are provided to achieve proper processing via exposure 
principles (Sloan et al, 2007). This suggests that while cognitive processing may be 
important, other process are also likely implicated in WEDs effects. Finally, WED is 
consistent with exposure principles in that repeated exposure to the same stimuli is 
apparently required to achieve EA&H and thus an improvement in symptoms (Sloan 
et al, 2005; Sloan & Marx, 2006). In WED topic switching is typically allowed and is 
variably implemented by participants, which may explain the mixed evidence base 
(Baikie & Wilheim, 2005; Sloan & Marx, 2004a). 
 
Evidence against the exposure approach 
However, WED is also inconsistent with exposure principles in some respects. 
Improvement is demonstrated irrespective of topic switching (Baikie & Wilheim, 
2005), which is not consistently related to effects (Pachankis & Goldfried, 2010), 
and even though the number, length and spacing of sessions is less than that 
typically required to facilitate emotional habituation16 (Baikie & Wilheim, 2005; 
Greenberg et al, 1996; Sloan & Marx, 2004a). Moreover, some WED studies with 
non-trauma samples have failed to confirm a pattern of E&AH, which is apparently 
not attributable to topic switching (Kloss & Lisman, 2002). However, in the absence 
of an overall effect WED may have failed to successfully produce E&AH in this 
study, which may still be attributable to topic switching given that this finding was 
unconvincing; the pattern of change was compared for individuals exhibiting more 
and less topic switching whereas topic switching versus no topic switching may 
have identified a difference. However, studies with LTPC samples have also failed 
to demonstrate EA&H (D’Souza, Lumley, Kraft & Dooley, 2008; Gillis, Lumley, 
                                                             
16 Exposure therapies typically involve six sessions of 90 minute duration. 
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Mosley-Williams,  Leisen & Roehrs, 2006; Norman, Lumley, Dooley & Diamond, 
2004), some of which have reported a positive effect of WED (Gillis et al, 2006; 
Norman et al, 2004). The explanatory power of the exposure approach in WED is 
therefore uncertain, at least in non-traumatised samples. It seems that while 
exposure may be important other processes are also likely implicated in WEDs 
effects.  
 
It is noteworthy that the three aforementioned theories are also supported in that 
WED seemingly produces health improvements by buffering the negative effect of 
and/or reducing intrusive thoughts (Lepore, 1997; Lepore & Greenberg, 2002) and 
avoidance (Zakowski, Ramati, Morton, Johnson & Flanigan, 2004) (i.e. this effect is 
integral to each approach). 
 
There are additionally some alternative theories and mediating processes that hold 
some explanatory potential for WED effects (Sloan & Marx, 2004a).    
 
Behaviour change approaches 
Some research has posited that WED positively influences aspects of behaviour, 
which in turn results in improved health. 
 
Health behaviour change approach 
It is posited that WED increases awareness of health threats which people 
endeavour to rectify, namely by increasing positive and reducing negative health 
behaviours (Byrne-Davis et al, 2006; Pennebaker & Seagal, 1999; Pennebaker, 
2000). Systematic reviews have reported no effect of WED on health behaviours, 
with one exception that reviewed predominantly healthy samples yet included HCU 
(Mogk, Otte, Reinhold-Hurley & Kroner-Herwig, 2006), improvements in which are 
consistently reported for healthy samples (Harris, 2006). While speculative, 
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improvements are apparently restricted to substance use for psychologically 
stressed/problematic populations (Pennebaker, 1997; Pennebaker & Seagal, 1999; 
Pennebaker, 2000; Pennebaker & Graybeal, 2001), for example cocaine 
use/cravings in intensive treatment for dependence (Grasing, Mathur & Desouza, 
2010), abstinence from smoking for those attending a smoking cessation 
intervention (Ames, Patten, Offord, Pennebaker, Croghan, Tri, Stevens & Hurt, 
2005; Ames, Patten, Werch, Schroeder, Stevens, Fredrickson, Echols, Pennebaker 
& Hurt, 2007) and alcohol use amongst recently unemployed professionals (Spera, 
Morin, Buhrfeind & Pennebaker, 1994). Indeed, null effects are reported for 
exercise, smoking and substance use in healthy students (Pennebaker & Beall, 
1986; Pennebaker, Colder & Sharp, 1990; Pennebaker et al, 1988; Greenberg & 
Stone, 1992) and exercise for people experiencing stressful situations (Spera et al, 
1994).  Evidence in LTPCs is underdeveloped yet mixed with no effect on diet, 
medication and substance use (Bodor, 2002; Stone, Smyth, Kaell & Hurewitz, 2000) 
but effects on exercise, diet, smoking and other unspecified positive changes 
(Bodor, 2002; McLaughlin, 2000; Rivkin et al, 2006). 
 
Social behaviour change approach 
It is posited that inhibition and rumination about a traumatic event can impede social 
functioning and create a distance from social networks (Pennebaker, 2000; 2004). 
WED purportedly improves seeking of and thus satisfaction with social support; 
people are less afraid to talk about the event (Brown & Heimberg, 2001) and they 
seek guidance owing to changes in the way they think and feel about the event 
(Andersson & Conley, 2008; Pennebaker, 2004). In doing this others are alerted to 
the person’s psychological state and the person feels socially tied (Pennebaker, 
2000; Pennebaker & Graybeal, 2001). This is beneficial to health. Indeed, studies 
have shown that following WED people disclose to others more (Pennebaker, 2004; 
Pennebaker & Graybeal, 2001; Pennebaker, Barger, Tiebout, 1989; Range, Kovac 
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& Marion, 2000; Sloan & Marx, 2006) and spend more time with them interacting in 
a more positive and socially integrated manner (Kim, 2009; Pennebaker, 2002; 
Pennebaker, 2004; Slatcher & Pennebaker, 2006).  
 
Some research additionally suggests that WED may derive benefit by improving 
perceptions of emotional support; in LTPCs WED is more effective for people with 
lower perceived emotional support suggesting that it may facilitate improvement in 
this (Low, Stanton, Bower & Gyllenhammer, 2010) and maintenance of satisfaction 
with perceived emotional support has been reported for WED participants (Gellaitry 
et al, 2010). This evidence is somewhat inconsistent, though, with some studies 
reporting no effect of WED on perceptions of practical support (Gellaitry et al, 2010) 
and illness-related support (Cohen, Lumley, Macklem, Leisen & Mosley-Williams, in 
preparation; Gillis et al, 2006). Importantly, there is also evidence that social 
changes in WED (i.e. an increase in social-theme words) are linked to health, albeit 
this finding is of limited informative potential because the effect on health was not 
significant (Rivkin et al, 2006). Moreover, this change may not reflect real world 
social changes and if it does it is unclear which changes it reflects. Encouragingly 
though, an unpublished dissertation has suggested that in chronic pain patients, 
where WED produces improvements in physical and psychological health, including 
depression, this is accompanied by concurrent improvements in social functioning. 
However, this was a case study with six participants thus this finding requires 
replication (Lee, 2002). It is notable, though, that some argue that this theory is too 
vast to explain WED effects (Andersson & Conley, 2008). 
 
Recent comprehensive approaches 
Recently some variants of the original WED paradigm have demonstrated equivocal 
and even superior effects, for example writing about stressful topics (Gortner et al, 
2006; Hamilton-West & Quine, 2007; Stice et al, 2006; Lu & Stanton, 2010), 
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imaginary trauma (Greenberg et al, 1996), positive events (Burton & King, 2004; 
2009; Marlo & Wagner, 1999) including one’s best possible self (King, 2001; 2002), 
a positive future (Mann, 2001), life goals (Austenfeld & Stanton, 2008; Harrist et al, 
2007) or positive aspects of stressors (i.e. benefit finding) (Danoff-Burg, Agee, 
Romanoff, Kremer & Strosberg, 2006; King & Miner, 2000; Lichtenthal & Cruess, 
2010; Lu & Stanton, 2010; Segal, Tucker & Coolidge, 2009; Stanton et al, 2002).  
Consequently, additional theories have been offered that would explain benefits 
derived from all variants of WED. 
 
Self-regulatory approach  
It is posited that under-regulation (i.e. control) of emotions is associated with chronic 
activation of the nervous and endocrine systems with an adverse effect on 
associated disease processes, and over-regulation of emotion produces the 
adverse health effects of inhibition (Lepore, Greenberg, Bruno & Smyth, 2002). 
WED purportedly facilitates optimal emotional-regulation by promoting skills, 
strategies and self-efficacy for emotion-regulation (i.e. WED is a mastery experience 
wherein people observe themselves controlling emotion) (Greenberg et al, 1996; 
Lepore et al, 2002). As such simply confronting any emotions and exercising control 
over them should improve outcomes via improved emotion-regulation capabilities 
(i.e. not just genuine trauma) (Greenberg et al, 1996; King, 2002; Lepore et al, 
2002). From a wider self-regulatory perspective, the original paradigm and the 
additional variants of WED are also purported to promote awareness and 
clarification of one’s goals and priorities and thus attainment of these (King, 2002).  
 
This model is somewhat supported in that WED is apparently more effective for 
people with greater emotion-regulation capabilities as they are able to engage with it 
(i.e. consistent with low alexithymia) (O’Connor, Allen & Kaszniak, 2005; Sloan & 
Epstein, 2005), and enhancing this aspect of WED has derived improvement in self-
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efficacy for emotional processing (Kirk, Schutte & Hine, 2011) and equivocal or 
superior health benefits including improved mood (Cameron & Nicholls, 1998; Lu & 
Stanton, 2010). Patient feedback about WED in LTPCs also supports improved 
emotion-regulation capabilities as a mechanism (Byrne-Davis et al, 2006), and WED 
adapted for eating disorders has evidenced symptom reduction that is associated 
with improvements in perceived mood-regulation abilities, although this was 
additionally observed from controls and the symptom reduction was not clinically 
significant in this study (Johnston, Startup, Lavender, Godfrey & Schmidt, 2010). 
However, some have questioned the validity of the evidence supporting this model 
as self-regulation is too difficult a concept to operationalise (Andersson & Conley, 
2008). 
 
It should be noted that this model overlaps with the cognitive processing and 
exposure models in proposing that key emotion-regulation processes in WED are 
habituation (i.e. initial affective immersion then increased ability to modulate evoked 
emotion) and cognitive adaptation (i.e. an understanding of emotion that evolves 
across writing sessions) (Lepore et al, 2002). Thus the evidence supporting these 
earlier approaches may, to some extent, additionally support this model (Lepore et 
al, 2002).  
 
Perceived control approach  
Again, it is posited that stress and trauma disrupt beliefs about a predictable and 
controllable world, which reduces perceived control over experiences, for example 
self-efficacy, with an adverse effect upon both physical and psychological health. 
WED purportedly restores perceived control specifically via the acquisition of 
meaning and formation of a coherent narrative. As such, writing about any 
emotional event may engender positive control expectations (i.e. not just genuine 
trauma) (Andersson & Conley, 2008). Indeed, WED has evidenced some 
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improvements in hopelessness (Segal, Bogaards, Becker & Chapman, 1999; Segal, 
Chatman, Bogaards & Becker, 2001) and ‘control-compromised populations’, for 
example patients with a LTPC apparently benefit from WED (Andersson & Conley, 
2008). In fact, in migraine sufferers WED has been demonstrated to be more 
effective for physical and psychological health including negative affect for those 
reporting lower self-efficacy for managing headaches, suggesting that WED may 
facilitate improvement in this. However, in this study self-efficacy also moderated 
the effect of other interventions suggesting that it may simply predict intervention 
success in general (Kraft, Lumley, D’Souza & Dooley, 2008). Encouragingly, the 
aforementioned unpublished dissertation reported that WED produced a trend for 
improvement in self-efficacy for managing pain in chronic pain patients post-
intervention, which was not observed for controls and was accompanied by 
subsequent improvements in physical and psychological health including 
depression. However, again this was a case study with six participants thus this 
finding requires replication (Lee, 2002). 
 
It is important to point out, however, that the aforementioned additional approaches 
have yet to be properly tested, namely in formal meditation analyses with causal 
models established (i.e. variables measured such that causality can be inferred); 
variables should be measured such that they demonstrate WED produces a change 
in behaviour, self-regulation or perceived control which is then related to health 
(again formal mediation analysis is discussed in chapter five). 
 
There is similarity in the mechanisms of effect proposed to underpin 
WED and other effective psychotherapies  
The processes proposed to underpin WED mirror basic processes involved in face-
to-face psychotherapies, and facilitated self-help interventions based on these, with 
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established efficacy (described in chapter one). Emotional disclosure (ED) is 
present yet the nature of this differs across modalities (Gidron et al, 1996; 
Pennebaker, 1997; Smyth & Helm, 2003). E&CP is also mandatory across 
modalities (Whelton, 2004; Murry & Seagal, 1994; Pennebaker, 1985; Pennebaker 
& Graybeal, 2001), which is similarly achieved by submitting problems to a linguistic 
format (Pennebaker & Graybeal, 2001) and constructing a coherent narrative 
(Pennebaker, 1997; Pennebaker & Segal, 1999; Pennebaker, 2000). CBT entails 
identifying, challenging and modifying maladaptive thought processes (Kaltenthaler 
et al, 2006; Mayor, 2006), while WED is similarly proposed to involve identifying, 
labelling and discussing the causes and consequences of the event (Pennebaker, 
1997). Behavioural approaches such as flooding and implosive therapy are 
underpinned by the three stages of emotional processing of fear that are apparently 
present in WED (Foa & Kozac, 1986). Both WED and humanistic/experiential 
therapies advocate introspection, expansion of awareness of experience and the 
discovery of meaning from this awareness (Whelton, 2004). Finally, NICE 
advocated group-based peer support similarly entails sharing experiences and 
feelings associated with having an LTPC (NICE, 2009). 
 
While therapist-led and group-based interventions offer interpersonal and supportive 
factors, the additional benefit may extend no further than an absence of the initial 
upsurge in negative mood observed in WED (Murray & Seagal, 1994). WED has 
evidenced equivocal outcomes to some face to face therapies and other facilitated 
self-help strategies (Donnelly & Murray, 1991; Largo-March & Spates, 2002; 
Murray, Lamnin & Carver, 1989; Smyth, 1998; Stice et al, 2006). It is cautioned, 
however, that further research is required before it can be asserted that WED is 
capable of producing effects comparable to traditional, therapist-led psychotherapy 
(Esterling et al, 1999).  
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Previous WED systematic reviews  
In view of the equivocal evidence yet potential for WED improving psychological 
health outcomes, including depression, in LTPCs, it is important to systematically 
review the evidence base to obtain a more accurate picture, and guide research 
endeavours. Systematic reviews are important as they review evidence on a clearly 
formulated question, and employ systematic, explicit and scientifically rigorous 
methods to identify, evaluate, and synthesise primary research. As such, the risk of 
bias is reduced. They also identify weaknesses and gaps in the evidence base, 
improving the quality of and promoting meaningful future research. Existing 
systematic reviews of WEDs effects on health were therefore initially identified and 
critically appraised according to established criteria (Bridle, 2003; Greenhalgh, 
1997). Particular attention was paid to their utility for delineating WED effects for 
psychological health outcomes, especially negative affect including depression, in 
LTPCs. To date, more than 100 RCTs have evaluated WED and this evidence base 
has been synthesised in six systematic reviews.  
 
Overall findings and conclusions 
Smyth (1998) meta-analysed 13 RCTs and reported WED significantly improves 
physical health, psychological well-being, physiological functioning, yet not health 
behaviours in health samples with an overall positive, medium-sized effect size 
(d=.47) representing a 23% improvement in overall health (Smyth, 1998).  The 
effect size varied significantly across outcome categories and was particularly large 
for psychological heath.  
  
Frisina, Borod & Lepore (2004) meta-analysed nine RCTs examining WED for 
improving physical and psychological health in physical and psychiatric disorders 
and reported a more modest yet positive and significant overall effect size of d=.19. 
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Effects were significantly larger for physical compared to psychological health, 
which was not significant. However, certain aspects of psychological health were 
influenced for example depressive symptoms and mood. WED was less effective for 
psychiatric than physically ill samples. 
 
Meads, Lyons & Carroll (2003)17 reviewed 61 trials examining ED for physical and 
psychological health, and HCU, in healthy volunteers, pre-existing physical 
conditions and those screened for stress/a psychological diagnosis. In contrast to 
the previous reviews, the pattern of results portrayed a mixed picture; positive 
effects, for example for depressive symptoms, were offset by null or unreported 
effects (a third of all outcomes measured were unreported). There was a slight trend 
for more negative mood for people with pre-existing physical conditions. The 
authors concluded that based on the available evidence there was no clear 
indication of effectiveness for any outcomes assessed, however re-assessment in 
light of further high quality, better reported research was advocated (Meads et al, 
2003; Meads & Nouwen, 2005). 
 
Mogk et al (2006) meta-analysed 30 RCTs investigating WED for psychological and 
physical health, and health behaviours, for healthy students, high risk individuals 
with experience of an adverse event, and clinical samples (i.e. physical and 
psychological conditions). It was concluded that WED has no significant overall 
effect (g=.04) with no evidence of different effects for different outcome categories, 
although there was a significant positive effect for health behaviours. 
 
Harris (2006) reviewed 30 RCTs, all examining the impact of WED upon HCU for 
healthy samples, samples with pre-existing medical conditions and samples 
                                                             
17 This was a Health Technology Assessment (HTA) review that was later additionally published in a 
peer reviewed journal; Meads & Nouwen (2005). 
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meeting psychological criteria.  He concluded that WED reduces HCU in healthy 
samples only, with an effect size of g=.16.   
 
Frattaroli (2006) meta-analysed 146 RCTs investigating ED for healthy samples or 
those defined by a history of stress or poor physical or psychological health, and the 
outcomes examined by Smyth (1998). She concluded that ED has a positive and 
significant overall effect size of d=.75. Consistent with Smyth (1998), effects were 
significant for all of the main outcome categories except health behaviours. WED 
was also selectively effective for subcategories within these outcome types, for 
instance within psychological health; distress and depressive symptoms yet not 
stress were improved. Having a physical illness or a history of trauma or stress, yet 
not having a psychological illness, was associated with a larger effect for some of 
the main outcome categories (i.e. having a physical illness was associated with 
larger effects for reported but not psychological health). 
 
Existing reviews thus report a mixed picture; three report positive overall effects, 
one reports a positive effect on HCU for the healthy population only, and two report 
no overall effect or an inability to draw conclusions. They all suggest that WED may 
be differentially effective for unique outcomes and populations. The heterogeneous 
conclusions are likely explained by differences in review conduct. Each imposed 
slightly different selection criteria and thus reviewed slightly different studies; some 
are more focussed in terms of populations, intervention implementation, 
comparisons and outcomes, and they vary in the potential for bias in review 
processes. The approach to data synthesis and exploration of heterogeneity has 
also been variable, as has the handling of poor reporting of outcome data. The 
characteristics of each review, and the observed effects, are reported in the 
appendix.  Importantly, each has been limited in some way that reduces their 
informative potential for determining the effects of WED for unique psychological 
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health outcomes, for example negative affect including depression, in distinct 
LTPCs.  
 
Variability in selection criteria 
Existing reviews have explored effects for a variable range of clinical and healthy 
samples, and again while Smyth (1998) reviewed only healthy samples this cannot 
be generalised to clinical populations. Most included only the original WED 
paradigm, however some included other variants of WED; written or verbal ED and 
any variant of written18 (Meads et al, 2003), or any variation of ED for example 
writing or talking, and writing about an imagined rather than genuine  stressful event 
and a positive rather than negative event (Frattaroli, 2006). Moreover, while Mogk et 
al (2006) reviewed only the original paradigm, where more than one disclosure 
group was reported effects were combined and thus cannot be attributed specifically 
to WED. Harris (2006) reviewed one relatively homogeneous outcome, HCU, yet 
the other reviews examined a variable range of health outcomes. The averaged 
effect sizes are thus usually confounded by notable clinical and methodological 
heterogeneity, which may be accompanied by heterogeneity in effects, with variable 
examination of this source of effect heterogeneity (discussed below). 
 
That differences in review conduct may have influenced the findings and 
conclusions drawn is demonstrated in that Mogk et al (2006) acknowledge that 
owing to different selection criteria they reviewed only one of the studies considered 
by Frisina et al (2004), which prohibits comparison. Indeed, different conclusions 
were derived in these reviews. Moreover, Smyth (1998) and Mogk et al (2006) 
included only trials with a neutral writing control group, whilst the others included 
any neutral comparison. Mogk et al (2006) concluded, in contrast to the other 
                                                             
18 However, it should be noted that in this review only two included studies described a verbal or 
combined written and verbal disclosure and there was only limited evidence or writing about positive 
rather than negative issues. 
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reviews, that WED is not effective. However, it cannot be assured that controls did 
not emotionally disclose in the included studies, which would underestimate effects. 
Finally, most of the reviews included outcomes measured at least one month post-
intervention, whereas Meads et al (2003) and Frattaroli (2006) included outcomes 
measured at least one week and one day post-intervention respectively. Frattaroli 
(2006) reported larger effects for studies with follow ups less than one month 
compared to longer. The other reviews may have provided a restricted 
representation of the effectiveness of WED, which may explain the heterogeneity in 
conclusions.  
 
Variation in the potential for bias in review processes 
Searching 
Smyth (1998) and Frisina et al (2004) employed narrow searches, in which key 
databases and search terms were omitted, search terms were limited and there was 
an inadequate attempt to identify unpublished literature (Meads & Sheffield, 2005). 
Indeed, attempts to replicate these searches identified some potentially relevant yet 
omitted studies available at that time, one of which reported a negative effect of 
WED (Meads et al, 2003). Interestingly, though, the number of excluded studies 
reporting null effects required to reduce the observed effects to non-significance in 
these reviews (i.e. fail safe N) was relatively large. Nonetheless, this may explain 
the more modest effects derived in reviews that achieved more comprehensive 
searches; unpublished studies are less likely to report positive and significant 
effects thus reducing the impact of publication bias (Frattaroli, 2006; Harris, 2006; 
Meads et al, 2003). It is also notable, however, that despite more adequate search 
strategies, in Meads et al’s (2003) and Frattaroli’s (2006) reviews a substantial 
number of potentially relevant studies, predominantly theses, were excluded as full 
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details could not be obtained (i.e. 15 and 20 studies respectively). A review 
including these studies is required. 
 
Risk of bias assessment 
Some of the existing reviews have not drawn inferences about the effectiveness of 
WED in light of the risk of bias associated with the evidence (Frisina et al, 2004; 
Mogk et al, 2006; Smyth, 1998). In fact, both Mogk et al (2006) and Meads et al 
(2003) concluded there was no evidence to suggest WED is effective, yet Meads et 
al (2003) identified that this may be due the vast limitations of the evidence base at 
that time; a very different and arguably more accurate conclusion. 
 
Duplication in review processes 
Existing reviews have reported variable but generally insufficient duplication in 
review processes, namely inclusion decisions, data interpretation/extraction and risk 
of bias assessment. Duplication is reported for data extraction only. This has varied 
from all (Smyth, 1998) to only a subset (Frattaroli, 2006; Meads et al, 2003; Mogk et 
al, 2006) of included studies, and has occasionally been limited to certain variables 
(Frattaroli, 2006; Meads et al, 2003) and even undertaken by the same reviewer at 
a later date rather than independent reviewers (Meads et al, 2003). Review 
processes may therefore have been influenced by reviewer’s sub-conscious 
expectations about whether WED is effective.  
 
Variability in the approach to data synthesis and exploration of 
heterogeneity 
Again, a number of the reviews combined conceptually distinct (i.e. clinically 
heterogeneous) outcomes and populations in averaged effect sizes, for which WED 
may be differentially effective, with variable exploration of this as a source of effect 
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heterogeneity (Frattaroli, 2006; Frisina et al, 2004; Mogk et al, 2006; Smyth, 1998). 
The approach to synthesis in each review and the degree to which effect sizes were 
reported for unique outcomes and populations is highlighted where the observed 
effects are reported in the appendix. 
 
Indeed, as described earlier where sources of effect heterogeneity were explored, 
WED was apparently differentially effective for the main outcome and population 
categories reviewed. It follows that for the distinct outcomes and populations within 
these main categories WEDs effects may additionally be heterogeneous. Indeed, 
Frattaroli (2006), and Mogk et al (2006) to some degree, examined effects for such 
outcome subcategories and supported this (as described earlier). Frisina et al 
(2004) discussed effects within distinct outcome sub-categories, for example 
depressive symptoms, and identified a trend for positive effects in some but not 
other sub-categories (as also described earlier). Effects for the population sub-
groups may also be statistically heterogeneous (Meads & Sheffield, 2005), and may 
reflect condition-specific differences, yet this has not been examined.  
 
Frattaroli (2006) went a step further than the aforementioned reviews in examining 
the moderating effect of the three main population categories on the overall effects 
and some of the main outcome categories. However, no reviews examined the 
effect of WED for each distinct outcome sub-category (i.e. distinct psychological 
health outcomes) for each distinct population sub-category (i.e. different LTPCs). 
Consequently, they are of limited informative potential and clinical utility; they do not 
represent WEDs effect in any specific context. The purpose of systematic reviews of 
effectiveness is to inform HCPs who make decisions about health care policy and 
influence practice, about whether an intervention effects the specific outcomes of 
interest in certain populations of interest/concern, for example negative affect 
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including depression in cancer. It is therefore crucial to delineate exactly which 
outcomes in which populations WED is effective for. 
 
With this in mind, two of the reviews did not inappropriately combine heterogeneous 
outcomes and populations. Harris (2006) reviewed one relatively homogeneous 
outcome and reported effects separately for populations reviewed, albeit these 
populations still contained some distinct subcategories. However, HCU cannot be 
presumed to be synonymous with health, thus this reviews is also of limited clinical 
utility. Meads et al (2003) included a range of heterogeneous outcomes and 
populations, yet presented effects separately for each distinct outcome and there 
was discussion for distinct populations within these albeit this was variable; 
synthesis was predominantly narrative with meta-analysis performed only where 
more than two RCTs reported the same outcome and had relatively homogeneous 
populations. However, this review was differently limited in that in the absence of 
sufficient data for meta-analysis effects were considered in terms of their 
significance (i.e. vote counting). As such, the magnitude and direction (i.e. effect 
size), and precision (i.e. confidence intervals) of effects could not be considered 
(Meads et al, 2003). Trials were identified as likely underpowered, thus 
consideration of small but potentially clinically important effects regardless of 
significance was important. 
 
In fact, the other reviews additionally demonstrated a tendency to interpret average 
effects in terms of significance. Whilst meta-analysis facilitates larger sample sizes 
and thus greater statistical power, given the small number of studies often available 
there is still a risk that some effects of a potentially important magnitude were 
omitted owing to insufficient power. Indeed, Mogk et al (2006) identified no 
significant effect of WED on clinical samples, yet this included a very small number 
of studies (n=4) to detect a very small but potentially meaningful effect (i.e. g=.08).  
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Inadequate exploration of heterogeneity relating to intervention implementation 
posed a further and substantial limitation in Frattaroli’s (2006) review. Again, any 
variant of ED was reviewed, which served to enhance the applied relevance of the 
review, statistical power and the precision of effects. However, this was at the cost 
of substantial interpretative problems. Implementation was examined as a 
moderator of effects, namely verbal versus written disclosure and whether the 
disclosure topic was positive or negative. However, these comparisons apparently 
still included heterogeneous interventions within each sub-group, for example 
writing about genuine and imagined negative events and then positive events or 
positive aspects of negative events were apparently considered together. Moreover, 
in such analyses there is a loss of randomisation thus a third variable may explain 
the observed effect, and the small number of studies within each sub-group 
compared introduces a loss of statistical power and thus a risk of Type 2 errors. 
Consequently, these analyses should be considered exploratory and require further 
support. In sum, the effect of each unique variant of WED, including the original 
paradigm, cannot be inferred in this review. In systematic reviews of effectiveness it 
is crucial that specific interventions are reviewed so that HCPs can determine 
exactly what was effective and how it should be implemented. 
 
One final note about investigation of heterogeneity is that it is important for 
systematic reviews to explore a range of sources of effect heterogeneity, even in the 
absence of significant effect heterogeneity, to determine the extent to which the 
averaged effects and patterns of results may have been influenced by this. This is 
especially important for WED studies as again they have typically been 
heterogeneous on study-specific artefacts, and this is likely related to heterogeneity 
in effects; some studies have seemingly implemented WED under more optimal 
conditions than others. Indeed, this may explain the less modest effects observed in 
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reviews that contained slightly less heterogeneous studies (Smyth, 1998). Some of 
the existing reviews examined additional moderators of WEDs effects for example 
gender (Frattaroli, 2006; Harris, 2006; Smyth, 1998), whilst others did not (Frisina et 
al, 2004; Meads et al 2003), in one instance owing to a non-significant intervention 
effect and test of heterogeneity (Mogk et al, 2006). However, this may be explained 
by an absence of sufficient statistical power in analyses. Meads et al (2003) noted 
substantial heterogeneity to be present, which may explain the very mixed pattern of 
results that was observed. 
 
Variation in the handling of poor reporting of outcome data 
The existing reviews have also varied in their approach to poor reporting of outcome 
data within studies, namely outcomes that are described as measured in the 
methods section but for which no data is reported or data is reported yet not that 
required for meta-analysis. Such reporting prohibits inference about the true trend of 
results. As it is unlikely that unreported outcomes were positive and significant, 
where this is not accounted for review conclusions are potentially influenced by 
reporting bias such that WEDs effects may have been overestimated. An effort to 
obtain missing data was reported in some reviews (Frattaroli, 2006; Harris, 2006; 
Mogk et al, 2006) or this was attempted for studies identified early on (Meads et al, 
2003). Otherwise, no attempts were apparent. Only Meads et al (2003) then 
adequately reported on all outcomes whether they were reported or not, counting 
them as unreported where no results were reported at all or again vote counting 
where adequate summary data were not provided. Their conclusions were therefore 
less likely to be influenced by reporting bias, which may explain the mixed pattern of 
results and the reduced confidence in WEDs effectiveness compared to most of the 
other reviews. 
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Study-level limitations 
Existing reviews have also served to identify study-level limitations (Frattaroli, 2006; 
Meads et al, 2003), which cast further doubt over their conclusions and must be 
addressed in future endeavours. Studies have generally been pilot RCTs employing 
small samples (n<50); effects may be imprecise and again analyses underpowered 
to identify potentially clinically important effects as significant. Risk of bias 
assessment indicated that a range of biases may have additionally influenced trial 
results. In Meads et al’s (2003) review the average Jadad Scale score was 0 (i.e. 
scores range from 0 to five); typically the method of randomisation was not 
described, allocation concealment and blinding were rarely mentioned, attrition and 
the proportion of participants receiving the intervention as intended was unreported, 
attrition was significant (>20%) and or imbalanced across groups where this was 
reported, and an intention to treat (ITT) analysis was infrequent; the participants 
available at follow up rather than those randomised were analysed. Consequently, 
effects may have been overestimated (discussed further in chapter three). However, 
Frisina et al (2004) acknowledged that studies that were adequately controlled and 
thus associated with a lesser risk of bias reported more positive and significant 
effects, suggesting WED may be effective for clinical samples.  Again, poor 
reporting of outcome data and heterogeneity amongst studies also presented a 
substantial problem.  
 
Conclusions 
In sum, WED is an acceptable, theoretically appropriate and pragmatically 
advantageous low-intensity psychological intervention that is consistent with current 
policy for improving depression in LTPCs. WED has may be considered to have a 
sound theoretical grounding for improving health in that it is seemingly underpinned 
by empirically supported influencing mechanisms, which are similar to those 
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underpinning other effective psychotherapies. There is evidence that suggests WED 
may improve negative affect including depression in LTPCs, yet the plethora of 
RCTs and systematic reviews in the area are associated with various limitations 
such that there is still uncertainty about this. The existing WED systematic reviews 
are additionally now outdated given that the latest searches were undertaken in 
2004 (Frattaroli, 2006; Harris, 2006; Mogk et al, 2006). An updated systematic 
review addressing the inadequacies of and updating previous endeavours was 
therefore required. It was anticipated that consistent with the recommendations of 
previous reviews more large scale, carefully conducted and better reported RCTs 
testing WED with clinical samples including LTPCs had since been conducted and 
completed. Indeed, Harris (2006) noted that since Smyth’s (1998) review 74 
additional WED trials had been undertaken. 
 
The evidence base does, however, suggest some possible critical processes in 
WED. WED may operate by facilitating E&CP and EA&H and promoting emotion-
regulation capabilities, perceived control over LTPCs and seeking of and thus 
satisfaction with emotional support. Consequently, WEDs effects may be optimised 
by targeting these mechanisms of change and mediating processes. Furthermore, 
targeting WED to individuals with lower alexithymia and higher optimism, or 
manipulating these traits before applying WED, may optimise improvement in 
outcomes. However, this evidence base is under-developed, inconsistent, 
ambiguous and yet to be adequately tested.  
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Chapter 3 Systematic review of WED for psychological health in adults 
with LTPCs 
 
Chapter overview 
This chapter presents a systematic review of WED for psychological health, and 
QoL, in adults with LTPCs. Psychological health outcomes and QoL were 
considered, rather than negative affect including depression alone, to provide a 
somewhat more comprehensive consideration of WEDs effects. Moreover, as 
described in chapter one, QoL is adversely impacted by depression in LTPCs, and it 
is asserted that by resolving depression, even at lower-levels, WED may improve 
the outcomes adversely impacted by this. Again, concurrent improvements in these 
outcomes have been demonstrated in trials of low- and high-intensity depression 
treatment, yet the evidence is inconsistent and it is unclear whether these changes 
are related to improvement in depression. It is therefore of interest to identify 
whether WED may additionally influence QoL.19 Importantly, the review extends 
previous endeavours by adopting a more focussed question with respect to the 
participants, intervention and outcomes (i.e. minimising clinical and methodological 
heterogeneity), exercising more duplication in review processes and employing a 
more appropriate approach to data synthesis, which acknowledges deficiencies in 
statistical power and includes an adequate exploration of clinical (i.e. outcomes and 
population) and the influence of methodological (i.e. trial methodology) sources of 
effect heterogeneity. This approach was intended to highlight exactly which 
psychological health and QoL outcomes, and specific LTPCs within these, that 
WED is likely effective for thus informing future research endeavours.  
                                                             
19 Investigation of WEDs effect upon secondary outcomes, namely physical health outcomes, SMBs 
and HCU, was also considered initially given that these outcomes are adversely impacted by 
depression in LTPCs and potentially improved with depression treatment. However, SMBs were 
infrequently measured and the identified trials otherwise presented a range of heterogeneous 
outcomes that could not be meaningfully combined and interpreted. These outcomes were therefore 
not included.  
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Review objectives 
The aim of the present review was therefore to synthesise relevant evidence of the 
effects of WED for improving psychological health and QoL among people with 
LTPCs, focussing on a) effectiveness and b) effect heterogeneity by outcome and 
condition. 
 
Method 
The review adhered to the NHS Centre for Reviews and Dissemination (CRD) 
guidelines on undertaking systematic reviews of research on effectiveness (NHS 
CRD, 2009) and is reported in accordance with the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISM) statement (Moher, Liberati, 
Tetzlaff, Altman & The PRISM Group, 2009). 
 
Review evidence 
Inclusion criteria 
Published or unpublished primary studies were eligible for inclusion if they were 
RCTs that included adults (i.e. ≥18 years) with a LTPC and evaluated the effects of 
WED on psychological health and or QoL measured at least one week post 
intervention. A trial was accepted as a RCT if the allocation of participants to 
treatment and comparison groups was reported as randomised. Only RCTs were 
included, consistent with the previous WED systematic reviews, as the initial scope 
of the WED literature suggested that most trials employed this design, to reduce 
heterogeneity in study design and risk of bias between included trials, and because 
this is considered to provide the most robust investigation of effectiveness to inform 
evidence-based practice (discussed further in chapter four). 
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One week was appropriate as WED effects can be seen as early as two weeks after 
completing writing (Frattaroli, 2006; Hamilton-West & Bridle, in preparation; 
Pennebaker, 2000), even in LTPC samples albeit this refers to objective 
physiological outcomes (Smyth et al, 1999). Consistent with the National Centre for 
Disease Control and Prevention (CDC) (2008), LTPCs were defined as conditions 
that are prolonged, do not resolve spontaneously and are rarely cured completely. 
 
Studies were accepted as evaluating WED if they required participants to disclose in 
writing a genuine, as opposed to imagined, stressful event during at least three 15 
minute sessions, consistent with the original WED paradigm and subsequent 
evidence base. Any control comparison was included. WED was to be delivered 
alone and not in combination with any other intervention, unless both groups 
received exactly the same treatment other than WED.  
 
Search strategy 
The search was initially conducted in December 2007 and then updated in May 
2009. Research databases were searched, without language restrictions and from 
1986 where possible corresponding with the date of the first WED trial (Pennebaker 
& Beall, 1986). This included the following: PsychINFO and PsychARTICLES (1986-
2009) (OVID, updated in CSA), CINAHL (1986-2009) (OVID, updated in EBSCO 
Host), Medline and Embase (1986-2009) (OVID), Cochrane Central Register of 
Controlled Trials (1986-2009) (2007, Issue 2, updated in 2009, Issue 3), Science 
Citation Index, Social Science Citation Index and ISI Proceedings (updated in 
Conference Papers Citation Index) (1986-2009) (Web of Science), Sociological 
Abstracts (earliest-2009) (CSA), Conference Papers Index (1986-2009) (CSA), 
FRANCIS and ERIC (1986-2009) (OCLC), and Proceedings First and Papers First 
(earliest-2009) (OCLC). Ongoing research databases were also searched to identify 
trials yet to be completed; UK National Research Register (updated with the 
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National Institute for Health Research (NIHR) portal from December 2007-May 
2009), Medical Research Council (MRC) research register, metaRegister of 
Controlled Trials (including the International Standardized Randomised Controlled 
Trial Number (ISRCTN) register), Health Services Research Projects in Progress 
and Computer Retrieval of Information on Scientific Projects database.20 21 
 
In consultation with library information specialists, search strategies were adapted to 
each database, and based on intervention index terms informed by the previous 
WED systematic reviews and wider evidence base; written emotional disclosure, 
written emotional expression, emotional disclosure, emotional expression, written 
disclosure, written expression, disclose/disclosure/disclosing, self 
disclosing/disclosure, expressive writing, therapeutic writing, affective writing, 
emotive writing, writing therapy, emotional disclosure/expression and/in writing, 
disclosure/expression and/in writing, expression, Pennebaker, creative writing, 
catharsis, journal, stressful/critical life events and writing, written communication, 
rehearsal, writing, and emotion/emotions.   
 
The internet was additionally utilised to search via search engine Google,22 The 
British Library’s Document Supply Grey Literature Collection of theses, proceedings 
and reports and Professor J.W. Pennebaker’s website, conduct a significant author 
citation search (performed via Science Citation Index and Social Science Citation 
                                                             
20 Databases that were intended to be searched but for which access could not be obtained included 
Sociofile, Chronic Disease Prevention, Combined Health Information Database, and System for 
Information on Grey Literature in Europe. 
21 The following reference databases were originally searched for dissertations and theses: UMI 
ProQuest Digital Dissertations, Index to Theses, WorldCat Dissertations and the Networked Digital 
Library of Theses and Dissertations (Scirus ETD search).  Eight hundred and seventy-six additional 
references were retrieved (plus an additional three retrieved via search alerts for these databases after 
completion of searching), of which 35 full copies were sought for detailed examination yet 18 (51%) 
were not obtainable. Therefore all were excluded and are not reported. The 18 unobtainable 
dissertations and the obtainable and eligible yet excluded dissertations are presented in the appendix. 
22 The first 100 references of searches for key terms were screened. 
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Index databases)23 and contact key researchers.24 The full search strategies are 
provided in the appendix. 
 
Current and recent editions of relevant journals were additionally searched 
retrospectively from the 12 months prior to the original search: Psychosomatic 
Medicine (January 2007-May 2009), Journal of Psychosomatic Research 
(December 2006-May 2009), Health Psychology (January 2007-May 2009), 
Psychology and Health (Issue 1 2007-Issue 5 2009), British Journal of Health 
Psychology (February 2007-May 2009), Journal of Health Psychology (January 
2007-May 2009), Journal of Consulting and Clinical Psychology (December 2006-
June 2009), Journal of Health Communication (Issue 1 2007-Issue 4 2009), 
Behavior Therapy (March 2007-June 2009), Behaviour, Research and Therapy 
(January 2007-May 2009), and Journal of the American Medical Association 
(January 2007-may 2009). 
 
As available, current and recent editions of relevant conference proceedings were 
additionally searched retrospectively from the 24 months prior to the original search: 
The British Psychological Society (2006, 2007, 2008 & 2009 Annual Conferences), 
Division of Health Psychology (2006, 2007 & 2008 Annual Conferences), The 
American Psychosomatic Society (2006 and 2007 Annual Conferences), The 
International Congress of Behavioural Medicine (2004 and 2006 Biannual 
Conferences), and The Association for Psychological Science25 (2006, 2007 & 2008 
Annual Conventions).  
 
                                                             
23 Performed for Professor J.W. Pennebaker, Professor M.A. Lumley, Dr J.M. Smyth and Dr S.J. 
Lepore. 
24 Contacted Professor J.W. Pennebaker, Professor M.A. Lumley, Dr J.M. Smyth, Dr A.H. Harris and 
Dr J. Frattaroli with the list of included studies. 
25 For The Association for Psychological Science conference proceedings key index terms were used 
to search the vast poster collection. 
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Finally, bibliographies of previous systematic reviews as well as primary studies 
selected for inclusion were then scanned for potentially relevant references. 
 
Journal and database search email alerts were established wherever possible 
following the updated search and any relevant papers identified were also included 
up until October 2010. 
 
Data collection and assessment 
Study selection 
Search results were recorded to bibliographic software where possible. One 
reviewer (KD) screened the search results (i.e. titles and, where available, 
abstracts) against the inclusion criteria, excluding those that were clearly not 
relevant and ordering full-text copies of the remainder. A sub-set of titles and 
abstracts for which no clear decision could be made (N=254, 3%) and all full-text 
copies were screened against the inclusion criteria by two reviewers independently 
(KD and CB26), achieving a good level of inter-rater agreement (Kappa=.82). 
Differences were resolved by discussion and consensus. The screening decision 
checks are presented in the appendix. Foreign papers were translated. Where a trial 
was reported in more than one record only one was included, preferably peer 
reviewed publications. Authors were contacted once to obtain studies where these 
were otherwise unobtainable. 
 
Data extraction and risk of bias assessment 
Data extraction and risk of bias assessment templates were developed and piloted 
on a small number of papers by each reviewer to ensure sufficiency and accuracy of 
data capture. Overall, data extraction and risk of bias assessment was duplicated or 
at least checked for accuracy by a second reviewer (CB or JS). Again differences 
                                                             
26 PhD supervisor Dr Christopher Bridle. 
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were resolved by discussion and consensus. Predefined data fields included details 
of the study design (i.e. sample size and final follow up), participants (e.g. 
demographics and LTPC), intervention and comparison exposure, process (i.e. 
intervention fidelity and compliance), outcomes (i.e. self-report measures) and 
results (i.e. final endpoint data).  
 
Study-level assessment of risk of bias was undertaken, and then heterogeneity in 
the risk of bias at the outcome-level was considered. Trials were assessed on 
criteria derived from the Cochrane risk of bias tool (i.e. randomisation, concealment 
of allocation, blinding of participants and outcome assessment, and completeness 
of outcome data; whether there was less than 20% overall attrition) (Cochrane, 
2009). The Cochrane risk of bias tool was selected as in contrast to many other 
tools, this assesses only the dimensions of trial methodology that have been 
empirically proven to be related to intervention effects/bias (Jüni, Altman & Egger, 
2001; Schultz, Chalmers, Hayes & Altman, 1995). 
 
Criteria were assessed in terms of whether these were met (Y), were not met (N) or 
it was unclear whether they were met (?). This provided an overall indication of the 
risk of bias at the study-level as low if all criteria were scored as Y (i.e. unlikely to 
seriously alter results), uncertain if one or more criteria were scored as ? (i.e. raising 
some doubts about results), or high if one or more criteria were scored as N (i.e. 
seriously weakening confidence in results). 
 
Data analysis 
Outcome specification 
Outcome data were pooled statistically into the following categories: positive affect 
(i.e. positive emotions such as happiness), negative affect (i.e. low mood, anxiety 
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and depression), stress and general emotional distress and QoL. The independence 
rather than bipolarity of positive and negative well-being has been supported 
empirically; these constructs are differently related to demographic, health and 
social variables and there is evidence of individuals scoring as high, or low, on both 
at the same time (Huppert & Whittington, 2003).  
 
Where studies reported more than one relevant outcome for each category, for 
example depression and anxiety, which represent different features of a tendency to 
experience negative affect, these were combined since treating them independently 
would give the study too much weight in a meta-analysis (Slavin, 1995). Individual 
effects were thus calculated for each measure and then combined within study. 
  
Effect measures 
As outcomes were reported as continuous data, standardized difference in means 
(SMDs) and 95% confidence intervals (95% CIs)27 were calculated (Revman 5.0), 
for which effect sizes of .2, .5 and .8 are conventionally interpreted as small, 
medium and large, respectively (Cohen, 1988; 1992). Cohen’s conventions for 
interpreting effect sizes are grounded in logic, reflect observable effects and are 
important for comparing effect sizes across studies. However, their use is 
controversial, and it is crucial to further interpret effect sizes in terms of clinical 
importance (Ellis, 2010). As discussed later on, it is difficult to interpret the clinical 
significance of effects based on SMDs, yet even small SMDs of .15 can have a 
substantial impact on outcomes at the population level. Consequently, to avoid 
omission of potentially clinically important effects, effect sizes greater than .15 were 
considered potentially meaningful, regardless of statistical significance as 
recommended (Altman, 2005). Weighted mean differences could not be estimated 
                                                             
27 Confidence intervals (i.e. 95%) reflect the imprecision and thus range of possible values of the 
estimate when a 5% risk that these intervals do not contain the population effect is accepted; if the 
intervals were estimated many times 95% would contain the true parameter and 5% would not. 
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as identical measures were not employed within each outcome category (Cochrane, 
2009).  
 
Effects were based on final endpoint values, unadjusted or adjusted as available, 
with one exception where group means and associated standard deviations (SDs) 
had been averaged across five follow ups (de Moor, Sterner, Hall, Warneke, Gilani, 
Amato & Cohen,  2002). The authors of this trial were unable to provide final 
endpoint data owing to the time that had elapsed since the data were analysed. 
However, they did provide assurance that the absolute differences between groups 
did not vary over time. Change scores were not included because they are 
influenced when outcomes are unstable or difficult to measure precisely, as is the 
case with patient reported outcomes such as psychological health and QoL 
(Cochrane, 2009). Moreover, change scores cannot be combined with final end-
point data as SMDs because the SDs reflect differences in reliability for the different 
types of data rather than differences in the measurement scale used (Cochrane, 
2009). Unreported SDs were derived by converting reported standard errors (SEs)28 
(Cochrane, 2009).  
 
For ease of interpretation, effects were computed so that a positive value 
represented a superior effect in the WED group and a negative value a superior 
effect in the control comparison (i.e. the direction of scoring of the outcome 
measures was accounted for).  
 
 
 
                                                             
28 SD= nSE   (where n is the number of participants in that group). 
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Heterogeneity assessment 
Effect heterogeneity for each outcome category was assessed by visual inspection 
of forest plots and statistical test (Revman 5.0). The I² index represents the 
percentage of variability amongst effect estimates above that expected by chance. 
Percentages of 25%, 50% and 75% indicate low, medium and high heterogeneity 
respectively (Higgins, Thompson, Deeks & Altman, 2003).  
 
Data synthesis and sub-group analyses 
Effects were combined in random effects meta-analyses, which presumes different 
but related effects are being estimated and accounts for these differences even in 
the absence of statistically significant heterogeneity (Cochrane, 2009). This was 
appropriate in view of the anticipated heterogeneity between trials. This was 
supplemented with pre-planned narrative sub-group analyses based on sub-groups 
of study stratified by condition type. Pre-planned sub-group analyses based on sub-
groups of study stratified by the type of QoL outcome measured were additionally 
performed given the heterogeneity between measures of health-related QoL (i.e. the 
general experience of QoL in relation to health status) and disease-specific QoL (i.e. 
the general experience of QoL in relation to disease-specific health status). 
Insufficient data prohibited statistical sub-group comparisons. 
 
Sensitivity analysis 
The robustness of results to variations in trial methodology: a) comparison type 
(neutral writing versus no writing) and b) length of follow-up (<3 versus ≥3 months) 
was investigated narratively.  
 
Risk of publication bias was assessed by visual inspection of funnel symmetry in the 
plots of each trial’s SMD against its SE (i.e. funnel plots). 
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Results  
Available data 
10, 693 references were retrieved, 2035 duplicates were removed and 8, 658 
unique titles/abstracts were screened for potential relevance, of which 8, 592 were 
excluded. Full texts were sought for 66 references, five of which were conference 
abstracts for which further information could not be obtained from authors (listed in 
the appendix).   
 
Full text of 61 papers were thus obtained and independently screened. Fifteen trials 
met the inclusion criteria: 12 from the electronic database search, two from hand 
searching conference proceedings/author contact and one retrieved in 
journal/search alerts after completion of searching. Study flow is illustrated in Figure 
1.  The included trials contained a total of 27 outcomes for psychological health or 
QoL, with a mean of two per study (range of one to three). There was no evidence 
of publication bias as endorsed by symmetrical funnel plots at the outcome-level 
(presented in the appendix) and numerous small, non-significant studies. 
  
Five additional trials met the inclusion criteria describing relevant outcomes as 
measured in the methods section, yet did not report data sufficient for statistical 
synthesis (Broderick, Junghaenel & Schwartz, 2005; Broderick et al, 2004; Rivkin et 
al, 2006; Stanton et al, 2002; Wagner et al, 2008). For a further trial data were 
insufficient but it additionally could not be clarified whether the final follow up was 
measured at least one week post-intervention (Cepeda, Chapman, Miranda, 
Sanchez, Rodriguez, Restrepo, Ferrer, Linares & Carr, 2008). Moreover, one of the 
included trials did not provide sufficient data for some additional relevant outcomes 
that were measured (Rosenberg, Rosenberg, Ernstoff, Wolford, Amdur, Elshamy, 
Bauer-Wu, Ahles & Pennebaker, 2002).   
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Figure 1 Study flow diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
8, 658 unique references 
Full copies of 66 potentially 
relevant references sought  
61 full texts independently  
screened 
46 excluded (including 
5 with inadequately 
reported data & 1 with 
inadequately reported 
data but uncertainty 
about design)  
5 could not be 
obtained 
15 included 
8, 592 titles & 
abstracts excluded  
 10,611 references 
retrieved via electronic 
reference databases  
2035 duplicates 
removed  
82 references retrieved via hand 
searching & obtained since 
search (search alert n=2) 
3 included in 
positive affect 
outcome category 
13 included in 
negative affect 
outcome category 
4 included in 
distress outcome 
category 
7 included in 
QoL outcome 
category 
10, 693 references retrieved  
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Omissions ranged from not reporting data at all and stating instead that there was 
no significant effect, to reporting some data but not group final endpoint data for 
composite measures or the main sub-scales (i.e. change scores, differences 
between means, regression co-efficients and final endpoint data but for numerous 
individual sub-scales e.g. the eight Short Form-36 (SF-36) sub-scales). Primary 
authors were contacted once for unreported data.  
 
Three included trials did not report adequate data in the published paper but 
provided this for all (Danoff-Burg et al, 2006; Hamilton-West & Quine, 2007), or 
again some (Rosenberg et al, 2002), of the unreported relevant outcomes on 
request. 
 
Description of studies 
Descriptive details of the included trials are provided in Table 3. Thirteen trials were 
published between 1999 and 2010, one was in preparation and one was under 
review. The data extracted for the individual studies are presented in the appendix. 
The total number of participants that were randomised to the intervention groups 
included in the present review was 1174; range 30 to 179 with a mean of 78. The 
length of the final follow up ranged from eight weeks to seven months; twelve trials 
assessed outcomes at 12 or more weeks.  
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Table 3 Trial details29 30 
   
                                                             
29 NW=neutral writing, UC=usual care control, TM=writing about time management, LTPC-F=writing about LTPC facts, HB=writing about health behaviours, PT/F=writing about 
thoughts and feelings about positive life events. CD=consecutive days. ?=unreported. 
30 *Three studies included more than the two intervention groups included in the present review thus sample sizes are presented for only the included groups. Where studies 
presented data by group, demographic data are presented for the full sample (i.e. the average was taken). 
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Mean age 
(years) 
56 58 54 70 54 60 50 38 54 51 52 61 50 69% 
≥19   
62 
Gender  
(% female) 
14 100 100 0 100 52 97 100 87 83 32 83 37 ? 16 
Time since 
diagnosis 
(years) 
? 100% 
≤12 
months 
7.9 ? ? 1.4  5.9 12.7 12 15 16 14.7 22 ? ? 
Country USA UK USA USA USA USA USA USA USA USA UK USA UK USA UK 
N 42 93 76 30 35  127 83 60 113   48  107 42 69 70 179 
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Participants 
Six trials evaluated WEDs effects in cancer patients (breast, prostate, 
gynaecological and renal cell cancer), four trials in patients with rheumatic 
conditions (i.e. ankylosing spondylitis, lupus and or rheumatoid arthritis), two trials in 
chronic pain patients (pelvic pain and fibromyalgia), and WEDs effects in psoriasis 
patients, cystic fibrosis patients and patients recovering from their first MI were 
investigated in one trial in each instance. Samples had mean ages ranging from 38 
to 62 years, were predominantly female ranging from 14% to an entirely female 
sample, and the mean duration of patients’ illness ranged from less than one year to 
22 years.  Trials were either conducted in the USA (10) or the UK (5). 
 
It is noteworthy that one trial included some participants that were younger than 18 
years of age (i.e. 15-18) (Taylor, Wallander, Anderson, Beasley & Brown, 2003). 
However, this trial was included because the proportion of participants that fell in to 
this category was small and unlikely to substantially influence the findings. 
 
Intervention  
In the majority of trials participants wrote for 20 minutes per session (10), over three 
(8) or four (7) writing sessions. The spacing of writing sessions across studies was 
consecutive days (7), within five days/one week (2), either of the latter (1), within 
three or four weeks (3), or this was not reported (2).  Trials directed participants to 
write about any stressful event (5), their condition (9) or this was unreported (1).  
 
It should be noted that in three trials either a small number of participants verbally 
disclosed (Cohen et al, in preparation; Wetherell, Byrne-Davis, Dieppe, Donovan, 
Brookes, Byron, Vedhara, Horne, Weinman & Miles, 2005), or the intervention 
included writing about thoughts and any emotions (i.e. negative or positive) 
(Willmott et al, under review) or more guided writing instructions than in the original 
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WED paradigm, namely emotional disclosure with cognitive appraisal, benefit-
finding and looking to the future encouraged across writing sessions (Gellaitry et al, 
2010). However, these trials were included because the proportion of participants 
that verbally disclosed was small and although adapted slightly the basic WED 
paradigm was dominant. These deviations were thus unlikely to substantially 
influence the findings. 
 
Comparison exposure 
Where more than one control comparison was investigated in a study, placebo 
writing tasks were given preference to non-writing controls. Where more than one 
writing control comparison was reported, the most emotionally neutral was included 
(i.e. writing about the facts relating to a LTPC rather than positive thoughts and 
feelings about a LTPC). Control comparisons included usual care (4) or placebo 
writing (11), for example writing about time management (7), facts about the LTPC 
(i.e. non-emotional) (2) and health behaviours (1). It is notable that in one additional 
trial only one comparison was available in which control participants wrote about 
thoughts and feelings about positive life events. This was justified by the authors as 
a superior placebo writing task in that it controls for writing about an emotionally 
engaging topic, has face validity and will not create a negative response. 
 
Outcomes and outcome measures 
Three trials measured positive affect with the Positive and Negative Affect Schedule 
(PANAS) positive affect sub-scale (Cohen et al, in preparation; Norman et al, 2004) 
and Positive and Negative Affect Schedule (expanded version) (PANAS-X) positive 
affect sub-scale (Walker et al, 1999). One further trial measured positive affect but 
with only one sub-scale from a measure comprised of many sub-scales and 
generally representative of different outcome category (i.e. only the Vigor sub-scale 
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of the Profile of Mood States (POMS), principally a measure of mood disturbance) 
(Danoff-Burg et al, 2006). This outcome was thus excluded. 
 
Thirteen trials measured negative affect with the PANAS negative affect sub-scale 
(Cohen et al, in preparation; Walker et al, 1999), PANAS-X negative affect sub-
scale (Gillis et al, 2006; Norman et al, 2004), Centre for Epidemiological Studies 
Depression (CES-D) scale (Danoff-Burg et al, 2006; Low et al, 2010), HADS 
(Hamilton-West & Quine, 2007; Vedhara, Morris, Booth, Horgan, Lawrence & 
Birchall, 2007), Profile of Moods States (POMS) (de Moor, Sterner, Hall, Warneke, 
Gilani, Amato & Cohen, 2002; Gellaitry et al, 2010; Vedhara et al, 2007), Short 
Form of the Profile of Mood States (POMS-SF) (Wetherell et al, 2005; Rosenberg et 
al, 2002), and PHQ (i.e. anxiety and depression sub-scales) (Taylor et al, 2003).  
 
Four trials measured distress with the Perceived Stress Scale (PSS) (Cohen et al, in 
preparation; de Moor et al, 2002), Brief Symptom Inventory (BSI) general severity 
index (Zakowski et al, 2004) and PHQ stressful life events sub-scale (Taylor et al, 
2003). Four trials additionally reported outcomes measured with the Impact of 
Events Scale (IES) (deMoor, Sterner, Hall, Gilani, Amato, Warneke & Cohen, 2002; 
Low et al, 2010; Walker et al, 1999; Zakowski et al, 2004). While occasionally 
described within papers as a measure of distress this is primarily a measure of 
intrusive thoughts and avoidance, which is less consistent with the general concept 
of distress (Horowitz, Wilner & Alvarez, 1979). These outcomes were thus excluded. 
 
Seven trials measured health-related QoL with the SF-36 (Willmott, Harris, Gellaitry 
& Horne, under review), Short Form-12 (SF-12) (Taylor et al, 2003), Fibromyalgia 
Impact Questionnaire (FIQ) (Gillis et al, 2006), Functional Assessment of Cancer 
Therapy -Breast (FACT-B) (Gellaitry et al, 2010) & -Prostate (FACT-P) (Rosenberg 
113 
 
et al, 2002) scales, Dermatology Life Quality Index (DLQI) (Vedhara et al, 2007), 
and Bath Ankylosing Spondylitis – Global Score (BAS-G) (Hamilton-West & Quine, 
2007).  
 
Studies reporting more than one relevant outcome for an outcome category 
Data were combined within study for four outcomes across three trials. The 
depression and anxiety sub-scales of the PHQ were combined in Taylor et al 
(2003), and the depression and anxiety sub-scales of the HADS, and the POMS 
(i.e. mood disturbance), were combined in Vedhara et al (2007) as they are all 
components of negative affect. In Taylor et al (2003) and Willmott et al (under 
review) the physical health and mental health sub-scales of the SF-12 or SF-36 
respectively were combined as these are both components of health-related QoL. 
The effects to be combined were usually in the same direction, yet there was one 
exception (Vedhara et al, 2007). The data for each sub-scale combined within study 
are provided in the appendix. 
 
Study-level risk of bias 
The risk of bias for the included trials is illustrated in Table 4. Risk was assessed as 
high in nine trials, moderate in four trials and low in only one trial. Risk of bias 
assessment was not undertaken for one trial, obtained as a conference 
presentation, owing to insufficient data (Cohen et al, in preparation).  However, 
earlier included trials undertaken by the same research group (Gillis et al, 2006; 
Norman et al, 2004) suggested that this presented at least a comparable risk of bias 
to the other included trials. Moreover, repeating the analysis without this study did 
not alter the results significantly, which in fact became slightly more positive; more 
notable effects emerged suggesting significantly less negative affect for the WED 
group relative to controls overall and less negative effect for the WED group relative 
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to controls specifically for rheumatic conditions which was approaching significance. 
This post-hoc sensitivity analysis is presented in the appendix. The inclusion of this 
trial therefore provided a more conservative estimate of effects. There was no 
heterogeneity in the risk of bias at the outcome-level; the risk of bias for each 
outcome category was generally consistently high. Issues associated with each 
criterion are summarised below, and the full risk of bias assessment for each 
individual study is presented in the appendix. 
 
Randomisation 
Six trials described the method used to generate the allocation sequence in 
sufficient detail to determine whether groups were likely comparable at baseline. In 
five trials the method was appropriate (i.e. computerised generated table of random 
numbers or minimisation) (deMoor et al, 2002; Gellaitry et al, 2010; Gillis et al, 
2006; Hamilton-West & Quine, 2007; Low et al, 2010). However, one reported an 
inadequate method (e.g. sequential assignment to groups) (Walker et al, 1999). The 
remaining eight stated that the trial was randomised yet did not report the method. 
 
Allocation concealment 
Three trials described the method used to conceal the allocation sequence in 
sufficient detail to determine whether group allocation could have been predicted 
before enrolment and reported an adequate method (e.g. sealed, opaque, 
sequentially numbered envelopes) (Gillis et al, 2006; Low et al, 2010; Norman et al, 
2004). Four trials stated enrolment was blind yet did not clearly report an 
appropriate method (Danoff-Burg et al, 2006; Hamilton-West & Quine, 2007) or did 
not describe how this was achieved at all  (Rosenberg et al, 2002; Wetherell et al, 
2005). Seven trials either stated that researchers were not blind (Willmott et al, 
under review) or did not describe an attempt at allocation concealment at all 
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(deMoor et al, 2002; Gellaitry et al, 2010; Taylor et al, 2003; Vedhara et al, 2007; 
Walker et al, 1999; Zakowski et al, 2004).  
 
Blinding 
In WED trials, the information provided to participants at enrolment must be vague 
with respect to the nature of the intervention/study purpose so that when the writing 
instructions are received participants are not able to infer their group assignment. 
For example, participants have previously been told that the study ‘is intended for us 
to learn more about writing and psychology’ (Pennebaker & Seagal 1999). Seven 
trials described an adequate attempt to blind participants (Danoff-Burg et al, 2006; 
Gillis et al, 2006; Hamilton-West & Quine, 2007; Norman et al, 2004; Vedhara et al, 
2007; Wetherell et al, 2005; Willmott et al, under review). Specifically, there was a 
placebo writing comparison and the information provided at enrolment was 
sufficiently vague. For example, participants were either informed that they would be 
writing with no information about topics (Norman et al, 2004; Vedhara et al, 2007; 
Wetherell et al, 2005; Willmott et al, under review), that they would be writing about 
aspects of life/experiences (Gillis et al, 2006; Hamilton-West & Quine, 2007) or that 
they would be writing about their condition, which both the intervention and control 
group were then instructed to write about (Danoff-Burg et al, 2006). In some 
instances participants were also informed that the objective was to simply examine 
whether writing influences adjustment and health (Gillis et al, 2006; Norman et al, 
2004; Wetherell et al, 2005).  
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Table 4 Study risk of bias assessment31 
 
 
                                                             
31 Criteria met (Y), criteria not met (N) or unclear whether criteria was met (?). Low = all items Y; Moderate = ≥1 items ?; High = ≥1 items N 
                                             Risk of Bias Item  
Study-
level Risk 
of Bias 
 
Study 
Randomisation Allocation 
concealment 
Blinding Completeness 
of outcome 
data 
de Moor et al (2002) Y N N ? High 
Gellaitry et al (2009) Y N N Y High 
Low et al (2010) Y Y N Y Moderate 
Rosenberg et al (2002) ? ? N Y High 
Walker et al (1999) N N N Y High 
Zakowski et al (2004) ? N N Y High 
Gillis et al (2006) Y Y Y Y Low 
Norman et al (2004) ? Y Y Y Moderate 
Danoff-Burg et al (2006) ? ? Y Y Moderate 
Hamilton-West & Quine (2007) Y ? Y N High 
Wetherell et al (2005) ? ? Y ? Moderate 
Vedhara et al (2007) ? N Y Y High 
Taylor et al (2003) ? N N Y High 
Willmott et al (under review) ? N Y Y High 
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However, in seven trials an adequate attempt was not described, namely the 
information provided at enrolment was not sufficiently vague. For example, the 
information provided was not described at all (deMoor et al, 2002; Low et al, 2010; 
Rosenberg et al, 2002; Walker et al, 1999; Zakowski et al, 2004) or potentially 
compromised blinding (i.e. participants were informed they would be randomised to 
a writing or non-writing group (Gellaitry et al, 2010) or that the study was about 
relationship between feelings and health (Taylor et al, 2003). In some instances 
there was also no placebo writing comparison (Gellaitry et al, 2010; Rosenberg et 
al, 2002; Taylor et al, 2003; Walker et al, 1999). As the included outcomes were 
subjective and self-administered, outcome assessment was blind only in instances 
where participant blinding was achieved.  
 
Completeness of outcome data 
In 10 trials, participants who were randomised but did not complete the final follow 
up were adequately described and there was less than 20% overall attrition and 
exclusions from analyses (Danoff-Burg et al, 2006; Gellaitry et al, 2010; Gillis et al, 
2006; Low et al, 2010; Norman et al, 2004; Rosenberg et al, 2002; Vedhara et al, 
2007; Walker et al, 1999; Willmott et al, under review; Zakowski et al, 2004). In one 
further trial there was again less than 20% overall attrition, but it is noteworthy that 
less than 80% of participants were included in analyses owing to exclusions of 
patients found not to be relevant post-randomization (Taylor et al, 2003). The extent 
of attrition was greater than 20% in one trial, yet there was no evidence of group 
imbalance in attrition and data were imputed for the randomised participants that 
completed the baseline assessment (i.e. last observation carried forward, LOCF) 
(Hamilton-West & Quine, 2007). The completeness of outcome data could not be 
accurately inferred in the remaining two trials (deMoor et al, 2002; Wetherell et al, 
2005).  
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It was initially intended that ITT analyses would be included where ever possible. 
However, only one trial stated that an ITT analysis was undertaken (i.e. missing 
data imputed with baseline observation carried forward (BCF), and in this trial group 
final end point data was reported only for the ‘completer’ analysis (Gillis et al, 2006). 
 
Intervention fidelity and compliance 
Intervention fidelity (i.e. contamination) 
Four studies reliably analysed participants’ writing to establish the extent to which 
emotional words were used in the intervention compared to the control group using 
appropriate software: the Linguistic Inquiry and Word Count (LIWC) (LIWC, 2007) 
(de Moor et al, 2002; Gillis et al, 2006; Vedhara et al, 2007; Willmott et al, under 
review). Eight trials employed other fidelity checks, five of which did so without 
conducting a LIWC analysis. These included a stress/arousal checklist completed 
by participants post-writing (Wetherell et al, 2005), examination of essay content 
(i.e. adherence to instructions and topics disclosed) (Danoff-Burg et al, 2006; Gillis 
et al, 2006; Low et al, 2010) and or participant testimony (e.g. the extent to which 
writing was personal, emotionally revealing, meaningful and previously undisclosed) 
(Low et al, 2010; Norman et al, 2004; Vedhara et al, 2007; Wetherell et al, 2005; 
Willmott et al, under review; Zakowski et al, 2004). Intervention fidelity was 
generally confirmed. However, one trial did not report on intervention fidelity 
(Hamilton-West & Quine, 2007), and in the remaining four trials this was not 
applicable owing to a usual care comparison. 
 
Compliance 
Nine trials (de Moor et al, 2002; Gellaitry et al, 2010; Gillis et al, 2006; Hamilton-
West & Quine, 2007; Low et al, 2010; Norman et al, 2004; Rosenberg et al, 2002; 
Taylor et al, 2003; Walker et al, 1999) clearly reported the proportion of randomised 
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patients failing to complete all writing sessions, which ranged from approximately 
three to 38% in the WED group and three to 33% in the control group. The 
remaining five trials did not clearly report this information. 
 
Intervention fidelity and compliance could not be inferred in one trial again owing to 
insufficient data (Cohen et al, in preparation). 
 
Synthesis 
The individual study data/effects, and the pooled effects for each outcome category 
and then each condition within each outcome category are presented in Figures 2 to 
10 below. No significant heterogeneity was detected. 
 
Positive affect 
Three studies reporting outcomes on positive affect were meta-analysed (n=189; 
WED=116, control= 73) (Cohen et al, in preparation; Norman et al, 2004, Walker et 
al, 1999), revealing a non-significant trend for a small negative effect (-.21; 95%CI (-
.57 to .15) (i.e. less positive affect for the WED group relative to controls), with some 
evidence to suggest effect heterogeneity (I²=24%).  
 
Specifically, non-significant trends for negative effects that were small (-.20) and 
medium-sized (-.54) were observed in rheumatic and chronic pain conditions 
respectively, while a non-significant trend for a small positive effect (i.e. more 
positive affect in the WED group relative to controls) was observed among cancer 
patients (.24).  
 
 
 
 
120 
 
Figure 2 Pooled effect for positive affect across conditions 
 
 
Negative affect 
Thirteen studies reporting outcomes on negative affect were meta-analysed (n=705; 
WED=387, control=318) (Cohen et al, in preparation; Danoff-Burg et al, 2006; de 
Moor et al, 2002; Gellaitry et al, 2010; Gillis et al, 2006; Hamilton-West & Quine, 
2007; Low et al, 2010; Norman et al, 2004; Rosenberg et al, 2002; Taylor et al, 
2003; Vedhara et al, 2007; Walker et al, 1999; Wetherell et al, 2005), revealing an 
effect that was marginally inconclusive yet approaching significance in a positive 
direction (.13; 95%CI (-.02 to .28) (i.e. less negative affect for the WED group 
relative to controls), with no evidence of effect heterogeneity (I²=0%).  
 
It is notable, however, that this effect comprised non-significant trends for small 
positive effects in chronic pain conditions (.21) and cystic fibrosis (.34), yet non-
significant and inconclusive effects in cancer (.11), rheumatic conditions (.12) and 
psoriasis (.07). 
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Figure 3 Pooled effect for negative affect across conditions 
 
 
Figure 4 Pooled effect for negative affect in cancer 
 
 
Figure 5 Pooled effect for negative affect in chronic pain 
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Figure 6 Pooled effect for negative affect in rheumatic conditions 
 
 
Distress 
Four studies reporting outcomes on distress were meta-analysed  (n=293; 
WED=173, control=120) (Cohen et al, in preparation; de Moor et al, 2002; Taylor et 
al, 2003; Zakowski et al, 2004), revealing an overall effect that was non-significant 
and inconclusive (-.04; 95%CI (-.27 to .20), with no evidence of effect heterogeneity 
in condition-specific sub-groups (I²=0%); cancer (.03), rheumatic conditions (-.11) 
and cystic fibrosis (-.09). 
 
Figure 7 Pooled effect for distress across conditions 
 
 
 
 
 
 
Study 
Cohen
deMoor 
Taylor
Zakowski
Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.58, df = 3 (P = 0.90); I² = 0%
Test for overall effect: Z = 0.32 (P = 0.75)
Mean 
-1.73 
-19.8 
-14.8 
-0.35 
SD
0.68
3.92
6.9 
0.4
Total 
74
19 
18
62
173
Mean 
  -1.66 
-20.5 
-14.3 
-0.34 
SD 
0.59 
3.82
3.1 
0.4 
Total 
39 
18
21
42
120
IV, Random, 95% CI
-0.11 [-0.49, 0.28]
0.18 [-0.47, 0.82] 
-0.09 [-0.72, 0.54]
-0.02 [-0.42, 0.37]
-0.04 [-0.27, 0.20]
WED SMD
IV, Random, 95% CI
-2 -1 0 1 2
Favours control Favours WED 
Study 
Cohen 
Danoff-Burg 
Hamilton-West & Quine 
Wetherell 
Total (95% CI) 
Heterogeneity: Tau² = 0.00; Chi² = 2.93, df = 3 (P = 0.40); I² = 0% 
Test for overall effect: Z = 0.90 (P = 0.37) 
Mean
 -1.92
 -12.53 
 - 5.33 
-33.9 
SD 
  0.72 
 10.8 
 3.57 
 26.1
Total 
74 
 20 
43 
  19 
156 
Mean 
-1.83 
-15.08 
-6.46 
-43.5 
SD 
 0.59
 11.5 
 3.49 
  19.9 
Total 
39 
20 
24 
 15 
98
IV, Random, 95% CI
-0.13 [-0.52, 0.26]
0.22 [-0.40, 0.85]
0.32 [-0.19, 0.82]
0.40 [-0.29, 1.08]
0.12 [-0.14, 0.37]
WED SMD 
IV, Random, 95% CI
-2 -1 0 1 2
Favours control Favours WED 
SMD
SMD Control 
Control 
123 
 
Figure 8 Pooled effect for distress in cancer 
 
 
QoL 
Seven studies reporting outcomes on QoL were meta-analysed (n=499; WED=261, 
control=238) (Gillis et al, 2006; Gellaitry et al, 2010; Hamilton-West & Quine, 2007; 
Rosenberg et al, 2002; Taylor et al, 2003; Vedhara, et al, 2007; Willmott et al, under 
review), revealing a small positive effect that was significant (.20; 95%CI (.02 to .38) 
(i.e. better QoL in the WED group relative to controls), with no evidence of effect 
heterogeneity (I²=0%). It is notable, however, that this effect comprised a marginally 
significant small positive effect in post MI patients (.31), non-significant trends for 
positive effects that were small in cancer (.17) and cystic fibrosis (.25) and medium-
sized in rheumatic conditions (.44), yet non-significant and inconclusive effects in 
chronic pain (.06) and psoriasis (-.13). 
 
Figure 9 Pooled effect for QoL across conditions 
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Figure 10 Pooled effect for QoL in cancer 
 
 
QoL sub-group analysis 
The pooled effects for each QoL outcome sub-category and then each condition 
within each QoL outcome sub-category are presented in Figures 11 to 13 below. No 
significant heterogeneity was detected.  
 
The two studies reporting outcomes on health-related QoL (n=195; WED=97, 
control=98) (Taylor et al, 2003; Willmott et al, under review) revealed a small 
positive effect that was significant (.31; 95%CI (.02 to .59) (i.e. better QoL in the 
WED group relative to controls), with no evidence of effect heterogeneity in 
condition-specific sub-groups (I²=0%). However, it is notable that this effect 
comprised a small positive effect that was significant for patients post first MI (.32) 
and a non-significant trend for a small positive effect in cystic fibrosis (.25). 
 
Figure 11 Pooled effect for health-related QoL across conditions 
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The five studies reporting outcomes on disease-specific QoL (n=304; WED=164, 
control=140) (Gillis et al, 2006; Gellaitry et al, 2010; Hamilton-West & Quine, 2007; 
Rosenberg et al, 2002; Vedhara et al, 2007) revealed an overall effect that was non-
significant and inconclusive (.14; 95%CI  (-.09 to .37), with no evidence of effect 
heterogeneity (I²=0%). However, it is notable that this effect comprised non-
significant and inconclusive effects in chronic pain conditions (.06) and psoriasis (-
.13), yet non-significant trends for positive effects that were small in cancer (.17), 
and a medium-sized in rheumatic conditions (.44) (i.e. better QoL for the WED 
group relative to controls). 
 
Figure 12 Pooled effect for disease-specific QoL across conditions 
 
 
Figure 13 Pooled effect for disease-specific QoL in cancer 
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exceptions. With regards to type of comparison, positive affect, negative affect and 
distress were apparently robust, whilst QoL was not. When only trials with a neutral 
writing comparison were included, the small positive and significant effect on QoL 
(.20; 95%CI (.02 to .38) (i.e. better QoL for the WED group relative to controls) was 
only approaching significance (.20; 95%CI (-.02 to .42). With regards to the length of 
follow up, negative affect, distress and QoL were apparently robust, whilst positive 
affect was not. When only trials with a follow up of three months or greater were 
included the non-significant trend for a small negative effect on positive affect (-.21; 
95%CI (-.57 to .15) (i.e. less positive affect for the WED group relative to controls) 
became non-significant and inconclusive (-.10; 95%CI (-.46 to .27). These sensitivity 
analyses are provided in the appendix. 
 
Discussion 
Summary of main findings 
The evidence relating to the effects of WED for psychological health and QoL in 
LTPCs is mixed. Some support for a beneficial effect was observed for QoL and 
negative affect. For QoL, a small yet significant effect was observed identifying 
better QoL for the WED group relative to controls. For negative affect, an effect that 
was marginally inconclusive yet approaching significance in a positive direction was 
observed (i.e. suggesting less negative affect for the WED group relative to 
controls). With respect to the effect of WED for these outcomes in distinct LTPCs, 
there were non-significant trends, and even marginally significant effects, indicating 
reduced negative affect or better QoL for the WED group for some conditions. There 
were, however, a number of non-significant and inconclusive effects in other 
conditions. Importantly, though, there was little evidence of a detrimental effect on 
these outcomes. Other outcomes demonstrated little evidence of an overall effect. 
In fact, a non-significant trend for reduced positive affect for the WED group relative 
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to controls was observed, albeit there was heterogeneity across different LTPCs 
with a trend for a slight improvement in positive affect in one condition. There was 
no evidence that WED influenced distress.  
 
Comparison with previous review findings 
The observed effects were of a comparable magnitude to those derived for 
psychological health outcomes in previous WED reviews, which included amongst 
other samples people with LTPCs; d=.12 (sig.)32 (Frattaroli, 2006) and d=.07 (non-
sig.) (Frisina et al, 2004). This may be taken to support the assertion that small yet 
clinically important effects can be expected in LTPCs (Baikie & Wilheim, 2005). 
Smyth and Pennebaker (2008) argue that for such a brief and inexpensive 
intervention to have any effect is impressive, thus should they be genuine these 
effects are encouraging. However, in contrast to previous endeavours, the present 
review investigated effect heterogeneity by outcome and condition type, highlighting 
the specific psychological health and QoL outcomes, and LTPCs within these, for 
which WED may be effective. Additionally in contrast to previous endeavours, the 
present review considered effects that were of a potentially clinically important 
magnitude regardless of significance, owing to ongoing deficiencies in sample size 
and thus statistical power. Consequently, a slightly more optimistic conclusion was 
derived. 
 
 
 
                                                             
32 Frattaroli (2006) reported r=.06, which can be converted to d using the following formula (Ellis, 
2010):   ݀ = (2r)
√1− r² 
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Interpretation of findings 
That WED may be more effective for negative than positive affect is unsurprising 
given that it is advocated to resolve the former rather than encourage elevated 
mood, and might imply that WED should be directed to people experiencing some 
existing level of low mood. However, that WED may potentially reduce positive 
affect in the long-term is not only surprising but concerning. This effect should be 
interpreted with caution, though, given that the largest negative effect on positive 
affect was for the trial in which the control comparison wrote about thoughts and 
feelings about positive events; it is unsurprising that positive effect was elevated for 
controls relative to WED participants.  
 
The apparent absence of an effect on distress is additionally surprising. As 
described in chapters one and two, illness-related stressors and general/illness-
related distress are associated with depression in LTPCs, thus targeting this may 
optimise improvement in depression. WED targets emotional aspects of stressors 
and presumably distress, consequently improvement in depression may be 
optimised. However, the present findings do not support the presumption that WED 
targets distress and influences depressive symptoms via a concurrent reduction in 
this in LTPCs. In fact, improvement in negative affect in the absence of an effect of 
WED upon distress has been reported in non-LTPC samples (Koopman, Ismailji, 
Holmes, Classen, Palesh & Wales, 2005; Smyth et al, 2008). Whether WED targets 
distress and may thus improve depression via a concurrent reduction in this in 
LTPCs should be clarified. 
 
Relative to controls, WED participants evidenced significantly better health-related 
QoL, yet only slightly better disease-specific QoL. Whilst this sub-group analysis 
was pre-specified, the comparison should be interpreted with caution in view of the 
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loss of randomisation between groups. Nonetheless, it is possible that WED may 
improve the general experience of health-related QoL (i.e. perceived functional 
health and well-being), with less influence on perceived disease-specific functional 
health and well-being.  It should be noted, however, that the effect heterogeneity 
observed across the sub-groups may merely reflect condition-specific differences in 
WEDs effect upon QoL. Indeed, the sub-groups comprised completely different 
conditions, and the disease-specific QoL sub-group actually comprised both non-
significant trends for positive effects and non-significant and inconclusive effects 
when LTPCs were considered separately. 
 
It should be acknowledged, though, that should they be genuine other phenomena 
may explain the observed effects. Positive effects indicating improvement for WED 
participants may reflect a worsening in controls and no change in the intervention 
group as a result of a) a protective effect of WED against variation in symptoms, but 
also b) a negative response to the control task or c) pre-disclosure priming, wherein 
participants are advised, or derive an expectation, that they may be asked to 
emotionally disclose after which controls are forced to inhibit rather than resolve 
evoked stressors. That neutral writing in WED trials can be emotive and in such 
instances related to deterioration in disease activity has been reported in arthritis 
patients (Byrne-Davis et al, 2006). Moreover, in some of the included trials 
participants were warned that it was possible they could find their writing topic 
upsetting (Vedhara et al, 2007; Wetherell et al, 2005). In fact in one of these trials, 
improvements were apparently due to a slight improvement in the WED group 
relative to a decline in controls, and pre-disclosure priming was confirmed by 
participants’ anecdotal reports (i.e. frustration owing to an urge to emotionally 
disclose in the absence of an opportunity for this) (Wetherell et al, 2005). Further 
examination of exactly how effects are derived is thus indicated. 
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Moreover, the null effects, and again should they again be genuine the non-
significant trends for positive effects, that were observed may be due to a ceiling 
effect such that there was little room for improvement; none of the samples in the 
included trials were selected for having psychological problems. Pre-intervention 
distress is an established moderator of psychosocial treatment effectiveness in 
LTPCs, for example cancer (Schneider, Moyer, Knapp-Oliver, Sohl, Cannella & 
Targhetta, 2010). Indeed, negative affect has emerged as a significant moderator of 
WEDs effects in non-LTPC samples (Koopman et al, 2005). In fact, some of the 
included studies offered some support for this assertion; one reported greater 
effects for those reporting higher baseline negative affect in a moderation analysis 
(discussed later) (Norman et al, 2004), and for another that reported a trend for a 
positive effect on negative affect the baseline data indicated that a large proportion 
of participants had a history of depression (Danoff-Burg et al, 2006). Frattaroli’s 
(2006) review identified a greater effect of ED for some outcomes for individuals 
with higher baseline stress and worse physical health, albeit no moderating effect of 
mood. However, the latter analysis was based on only one or two studies of ED. 
Indeed, it is acknowledged that this evidence base is inconsistent, yet suggests on a 
whole that WED is more effective for psychological health when patients’ symptoms 
are clinically more prominent (Baikie & Wilheim, 2005). Furthermore, arthritis 
patients reporting subjective benefits of WED have been shown to exhibit greater 
mood disturbance and more disease activity than those deriving no such benefit, 
although this association was not upheld for actual improvement (Byrne-Davis et al, 
2006).  
 
Chapter two reported that the evidence suggests, and widespread clinical opinion is, 
that it is not appropriate to use WED unsupervised with patients with more severe 
psychological problems. It therefore seems that WED may be most appropriate and 
effective for individuals with LTPCs and lower-level negative affect. The evidence 
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does not, however, provide any indication of, or importantly any means of 
operationalising, the level of negative affect for which WED is likely to be most 
effective. 
 
Effects may have additionally been influenced by compliance issues, namely slight 
deficiencies in completion of the intervention. There was also evidence of a bias 
towards female participants, who arguably emotionally disclose more readily than 
males (Kring & Gordon, 1998). Some WED studies have reported a superior effect 
for men (Manier & Olivares, 2005), yet the evidence is inconsistent and others 
report a superior effect for women (Pennebaker et al, 1990) or no moderating effect 
(Epstein, Sloan & Marx, 2005). The relationship between gender and WED is likely 
complex and requires further study (Langer, 2010; Range & Jenkins, 2010; 
Stickney, 2010).  Studies were additionally predominantly conducted in the USA. It 
has been argued that popularisation of WED in the lay literature as a self-help 
strategy may explain positive effects in USA samples (Greenhalgh, 1999); in many 
of the included trials participants may have deduced their group assignment upon 
receiving the instructions thus potentially compromising blinding. More UK based 
trials are therefore indicated. 
 
Issues associated with included trials 
The observed effects should, however, be interpreted with caution. Firstly, a 
moderate to high risk of bias was consistently identified for the included studies. 
This substantially undermines the findings. This is in agreement with an earlier 
systematic review (Meads et al, 2003), suggesting that risk of bias is an ongoing 
problem. Effects may have been influenced by selection, detection and performance 
bias, and systematic attrition/exclusions from analyses (discussed further in chapter 
nine). A higher risk of bias has been demonstrated to be associated with 
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overestimated intervention effects (Schultz et al, 1995; Moher, Jones, Cook, Jadad, 
Moher, Tugwell & Klassen, 1998). The observed effects may have been consistently 
overestimated, and in fact a high risk of bias was identified for the trials with the 
greatest effects for negative affect and QoL.  
 
It should be noted, however, that poor reporting hindered risk of bias assessment 
and may have actually masked adequate trial implementation (Huwiler-Műntener, 
Jűni, Junker & Egger, 2002). A substantial number of studies satisfying the inclusion 
criteria were also currently lacking in their contribution to the evidence base; despite 
requesting it from authors, adequate data were not provided for the relevant 
outcomes that were measured. As such the review may be biased owing to the 
omission of small, non-significant but potentially clinically important effects. Omitting 
this detail is considered unethical practice (Moher, Schultz & Altman, 2001). It 
should also be noted that the 95% CIs associated with the effects were wide, 
suggesting that the observed effects were relatively unstable and should be 
interpreted with caution. 
 
Limitations of the review 
Condition-specific differences in WEDs effects may be considered surprising given 
the relatively generic psychosocial burden associated with LTPCs (WHO, 2002). 
Consequently, while effect heterogeneity was seemingly explained by condition-
specific differences, it should be noted that this may be attributable to other sources 
of heterogeneity. Individual studies generate effects sizes that vary owing to study 
specific artefacts and risk of bias (Ellis, 2010), which is certainly true for WED 
studies (as described in chapter two). Indeed, whilst the focus of the review was 
intended to minimise the methodological heterogeneity between the included 
studies, heterogeneity in study characteristics, and to a lesser extent risk of bias, 
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was identified amongst the included trials. Moreover, effects for some outcomes 
were somewhat influenced by the sources of heterogeneity investigated (i.e. trial 
methodology). Whether the risk of bias associated with the included trials influenced 
the observed pattern of results could not be investigated as too few were assessed 
as low risk. Nonetheless, given the small number of trials included in each 
condition-specific sub-group, this offers a plausible, alternative explanation for the 
apparent condition-specific differences.  
 
The approach adopted where studies reported more than one relevant outcome for 
an outcome category was not ideal, for example in one trial the effects combined 
within study for the negative affect outcome category were in different directions. 
However, sub-scales from the same measures were combined, none of the 
combined effects were significant, the difference in the point estimates was usually 
small and the 95% CIs were wide and overlapped considerably. While tentative, it 
could be argued that if the studies were repeated in a different sample from the 
same population, the point estimates could fall anywhere within their respective 
confidence limits potentially reducing any difference in the direction and or 
magnitude of effects. Whilst not ideal, the data for the separate sub-scales 
combined within studies is again provided in the appendix, and this approach was 
considered preferable to selectively including outcomes. 
 
It is additionally unclear what influence the potentially relevant yet unobtainable 
trials, and the dissertations that were largely unobtainable and thus excluded, might 
have had. Furthermore, despite a concerted effort it was not feasible to duplicate 
the entire review process in order to further reduce risk of bias. The results of the 
present review can additionally only be generalised to the LTPCs included, the 
standard WED paradigm, and psychological health outcomes (i.e. not physical 
health). 
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Implications for practice 
The present review suggests that, should the observed effects be genuine, in 
LTPCs WED may deliver beneficial effects that are modest yet potentially clinically 
important on some outcomes, perhaps for certain LTPCs. Specifically WED may 
hold potential as a low-intensity psychological intervention for improving depressive 
symptoms, and some associated outcomes namely health-related QoL, in adults 
with LTPCs. As mentioned earlier, it is crucial to interpret effect sizes in terms of 
their clinical importance. The clinical importance of effects based on SMDs is, 
however, difficult to interpret as the difference is expressed in SD units rather than 
the measurement scale employed. Even then differences are difficult to interpret as 
the change in a person’s actual state that corresponds with a unit change on these 
self-report symptom measures is not known (Ellis, 2010; Nezu & Nezu, 2008). 
Regardless, though, when produced for a number of people even small and 
seemingly unimportant effects can accumulate to large effects that have a 
substantial impact on outcomes at the population level (Ellis, 2010). As such, again 
should they be genuine, the slight improvements observed in depressive symptoms 
could have a large, favourable impact on the range of important clinical and service 
level outcomes adversely impact by depression in LTPCs (see chapter one).  
 
To illustrate that the observed effects could have a substantial impact at the 
population level, SMDs can be expressed as the percentage of non-overlap of the 
distribution of scores for the intervention groups, namely the U3 statistic (Cohen, 
1988). Specifically, this illustrates the proportion/percentage of scores in the WED 
group that are lower/higher than the average score in the control group.33 The 
SMDs of .13 for negative affect and .31 for health-related QoL are equivalent to 
                                                             
33 It should be noted that this relies on the intervention groups being normally distributed and equally 
variable/numerous. 
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55% and 62% of WED participants having lower depressive symptom severity and 
better health-related QoL than the average control participant. Put another way, 5% 
and 12% respectively of the population may do better than would be expected by 
chance alone (i.e. U3=.55 and .62 respectively34). Before WED can be 
recommended in practice, however, methodologically sound studies are required. 
 
Recommendations for future research 
Twenty-one potentially relevant ongoing trials were identified indicating a strong 
interest in this area.  Importantly, future RCTs may benefit from adherence to the 
Consolidated Standards of Reporting Trials (CONSORT) statement (Schultz, 
Altman & Moher, 2010). Specifically, trials should investigate the effectiveness of 
WED for reducing negative affect, for example depressive symptoms, for LTPCs 
that are associated with negative affect and in which negative affect has a 
significant impact. Ideally, patients should be experiencing lower-level negative 
affect. This is consistent with the appropriate clinical application of WED, and as 
such would enhance the relevance of trials whilst importantly protecting patient 
safety. It would also potentially maximise effectiveness. The effect of WED on 
associated outcomes, particularly health-related QoL, should also be investigated, 
and again, whether WED targets distress and may thus improve depression via a 
concurrent reduction in this in LTPCs should additionally be clarified. 
 
It was initially intended that the present review would identify within study evidence 
of moderators (i.e. variables that determine whether and to what extent WED is 
effective), mechanisms of change (i.e. measures of intervention processes that may 
underlie WEDs benefits), mediators (i.e. variables that may be changed by WED to 
produce benefits) and cost-effectiveness. It was anticipated this would identify 
whether WED works differently for different people and for whom it works best, and 
                                                             
34 These statistics are derived from Cohen’s table of equivalents of d (Cohen, 1988). 
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the effective intervention components (Mackinnon & Luecken, 2008). As suggested 
earlier, this information can then be used to optimise improvements in outcomes. 
Valuable health resources can be directed to patients with the greatest anticipated 
benefit or prognostic traits could be manipulated before applying WED. Effective 
intervention components can also be targeted. The cost-effectiveness of 
psychological health interventions must be proven before implementation in practice 
can be considered, the importance of which has been advocated for some time 
(Glasgow, 2008; Taylor, 1987).  
 
However, only a few trials investigated a heterogeneous range of moderators, 
mechanisms of change and mediators.35 These could not be meaningfully combined 
and interpreted, and because the trials were likely underpowered to detect effects in 
these analyses they were of limited utility, Furthermore, no trials undertook a cost-
effectiveness evaluation, and only one provided cost data that was of limited utility.36 
Consequently, future trials must incorporate such exploratory/cost-effectiveness 
analyses. In fact, if moderators are not examined effects may be missed (i.e. where 
heterogeneous effects for distinct sub-groups are essentially averaged). This 
recommendation is underscored by current opinion in the field, which purports that 
research has shown WED does work ‘at least some of the time for some people’, 
thus examination of moderators and ideographic implementation of WED are a 
priority (Pennebaker, 2004; Sloan & Marx, 2004a; Smyth & Pennebaker, 2008). 
Potential moderating traits and explanatory processes were derived from the WED 
evidence base reported in chapter two. However, it was noted that this evidence 
base is under-developed, inconsistent, ambiguous and yet to be adequately tested. 
                                                             
35 The included trials undertook the following exploratory analyses  a) moderators; social support and 
time since diagnosis (Low et al, 2010), perceived social constraints over emotional expression 
(Zakowski et al, 2004), ambivalence over emotional expression, catastrophizing and negative affect 
(Norman et al, 2004) and trait anxiety (Danoff-Burg et al, 2006), b) mechanisms of change; association 
between change in emotional and cognitive word use and change in outcomes (Hamilton-West & 
Quine, 2007; Walker, 1999) and c) mediators; avoidance and intrusive thoughts (Zakowski et al, 2004). 
36 This trial reported costs based on psychologist fees associated with administration of WED, which is 
of limited utility given that WED is intended to be self-administered (Taylor et al, 2003). 
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Further exploration of these specific moderating traits and explanatory processes in 
this context is therefore warranted. 
 
Conclusions 
The evidence suggests that, should the effects be genuine, in LTPCs WED may be 
effective for some outcomes, perhaps in particular for reducing negative affect 
including depressive symptoms and improving some associated outcomes, namely 
health-related QoL, and perhaps specifically for some LTPCs. However, the 
moderate to high risk of bias consistently identified for the included studies and 
certainly present for the trials reporting the greatest effects for these outcomes, 
suggests that the effects may be overestimated and substantially undermines the 
findings. Consequently, before firm conclusions about effectiveness can be drawn, 
in agreement with previous reviews, it is crucial that further methodologically 
rigorous and adequately reported trials are undertaken. These must be directed, 
with investigation in the populations and for the outcomes for which benefits may be 
anticipated. Future trials must additionally be inquisitive about the mechanisms of 
change and the moderators and mediators of WEDs effects, derived from the WED 
evidence base, and cost-effectiveness.  
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Chapter 4 Methodology for an exploratory RCT evaluating WED for 
improving depressive symptom severity in adults with Type 2 diabetes 
 
Chapter overview 
This chapter identifies the appropriate the methodology for a trial of WED for 
improving depression in adults with a LTPC, which meets the requirements 
specified in chapter three. The appropriate design, population, intervention 
implementation, comparison exposure, outcomes, approach to effectiveness 
analyses, exploratory analyses, measures, data collection schedule and feasibility 
investigation are considered, in addition to the substantial patient safety issues 
encountered in this context and the measures required to address them. Finally, the 
user and expert consultation process is described briefly. 
 
Design 
The MRC framework for complex interventions is an established framework that 
delineates the sequential phases of investigation in the evaluation of complex 
interventions, identifying the objectives to be met before progressing to the next 
stage (Campbell, Fitzpatrick, Haines, Kinmouth, Sandercock, Speigelhalter & Tyer, 
2000; Craig, Dieppe, Macintyre, Michie, Nazareth & Petticrew, 2008; MRC, 2000). 
In phase one trials, the intervention is modelled, which entails improving 
understanding of the intervention and identifying and defining the key components 
(i.e. the active ingredients). For example, these data might be obtained via 
qualitative interviews and focus groups with patients and HCPs. In phase two 
‘exploratory’ trials design-related issues are identified prior to a full effectiveness 
trial; the optimal trial and intervention design are defined. Specifically, the 
anticipated treatment effect is identified and tested, intervention and trial parameters 
are piloted, and other feasibility issues are identified (i.e. the feasibility/effectiveness 
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of delivering the intervention and the trial protocol is established). Importantly, 
variations of the intervention can be tested to identify which seem to be the most 
appropriate for a full scale trial. This entails a direct comparison of two of more 
variations of an intervention; the only way to provide conclusive evidence of the 
utility, practicality or desirability of one approach over another (MRC, 2000).  
 
Chapters two and three identified that the WED evidence base is confounded by 
heterogeneity, as study parameters have been unsystematically manipulated in 
search of the most effective design. Few studies have modelled WED and 
systematically manipulated it’s parameters to identify the optimal design or ‘recipe’ 
(e.g. manipulated the number of writing sessions or the spacing of sessions within 
study). Such studies, consistent with phase one trials and the intervention 
development element of phase two trials, are certainly required. This would have 
been an interesting and important piece of research. However, it would entail a 
dedicated programme of research addressing each of the many parameters of 
WED, which given the constraints on time was beyond the scope of the present 
study. The objective of the present study was additionally to identify the preliminary 
effectiveness and feasibility of WED when applied to the clinical issue of depression 
in LTPCs.  
 
Consequently, it was decided that given the remit and objectives of the present 
endeavour the most appropriate study design was a phase two trial, focussing on 
testing preliminary effectiveness, piloting intervention and trial parameters and 
identifying other feasibility issues, with some further exploration of the former. 
Consistent with the objective of testing the evidence gained thus far the anticipated 
effect should be explored further, specifically whether WED works as anticipated 
and whether it works differently for different people as anticipated should be 
explored, and a prior economic analysis should be undertaken. Some of the trials 
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considered in the systematic review specifically investigated feasibility (Broderick et 
al, 2004; Gellaitry et al, 2010; Taylor et al, 2003; Walker et al, 1999), yet these were 
few and are required. Whilst not the ideal scenario, the WED evidence base was 
considered as a whole and the optimal parameters of WED were inferred from this 
(discussed below). The MRC phases and corresponding objectives, and the status 
of the investigation of WED for improving depression for adults with LTPCs in 
relation to each phase are illustrated in Table 5.  
 
It is typical for phase two trials to include a before and after design in order to gauge 
the preliminary effectiveness of an intervention. However, in the absence of a 
control group any change observed cannot be attributed specifically to the 
intervention. In these designs internal validity is compromised; causal inferences 
cannot be drawn (Nezu & Nezu, 2008). It is not uncommon, however, for a RCT 
design to be employed in feasibility trials including those testing WED (Klapow, 
Schmidt, Taylor, Roller, Li, Calhoun, Wallander & Pennebaker, 2001) and other 
psycho-social interventions in diabetes (Sturt, Whitlock, Hearneshaw, Farmer, 
Wakelin, Eldridge, Griffiths & Dale, 2008). A RCT provides the most robust 
investigation of effectiveness to inform evidence-based practice (Barton, 2000); 
randomization minimizes systematic variation between groups promoting the equal 
distribution of confounding variables and thus enhancing the degree to which any 
effect can be attributed to the intervention. In order to provide the most informative 
assessment of WEDs preliminary effectiveness for improving depression in LTPCs, 
a RCT was considered appropriate.37  
 
 
                                                             
37 Incidentally a RCT was preferable to natural and quasi-experimental designs as WED is not 
currently employed in practice thus natural allocation to groups is unavailable and in the absence of 
controlled manipulation and or randomisation alternative explanations for observed effects cannot be 
ruled out (again internal validity is compromised and causal inferences cannot be drawn) (Nezu & 
Nezu, 2008).  
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Table 5 MRC framework for complex interventions and the status of WED in LTPCs 
Phase/objectives for each phase Status of WED & how objectives have been/should be met 
Pre-clinical/theoretical phase  
Establish the theoretical basis/evidence 
base that the intervention is likely to have 
the anticipated effect (i.e. before 
substantial evaluation an intervention 
must be developed to a point where it can 
reasonably expected to be effective) 
Satisfied: The WED evidence base is inconsistent and the 
mechanisms of WEDs effects are unclear. However, there is 
reason to believe that it may be effective for improving 
depression in LTPCs and it is seemingly associated with various 
empirically supported influencing mechanisms, which are similar 
to those underpinning other effective psychotherapies. Hence it 
may be considered to have a sound theoretical grounding for 
improving health (chapter two). There is also evidence that 
interventions like WED which target emotional aspects of 
stressors and thus presumably distress may optimise 
improvement in depression in LTPCs (chapters one & two) 
If there is no high quality systematic 
review evidence  of the relevant evidence 
one should be conducted  
Satisfied: Previous systematic reviews have been limited in their 
utility for determining the effect of WED for depression in LTPCs 
(chapter two). A more focussed review with more appropriate 
methodology was thus conducted, and identified that WED may 
be effective for improving depression and associated outcomes 
perhaps for specific LTPCs (chapter three). 
Identify the likely/anticipated processes of 
change  
Satisfied: The likely/anticipated mechanisms of 
change/mediating processes underpinning WEDs effects have 
been offered and again somewhat supported empirically yet 
require further testing (chapter two). 
Identify strategic design issues Satisfied: The systematic review (chapter three) and the 
LTPC/depression & WED evidence (presented below) provide 
some indication of the methodological parameters within which 
WED should be tested. Ethical review identified further design-
related issues (discussed below). 
Phase 1: Modelling  
Improving understanding of the intervention and 
identifying and defining the key components (i.e. 
the active ingredients) 
 Required but beyond the scope of and not consistent 
with the objectives of the present study. 
Phase 2: Exploratory trial: defining optimum trial and intervention design 
Testing variations of the intervention to identify 
which seem to be the most appropriate for a 
full scale trial 
Required but beyond the scope of and not consistent with 
the objectives of the present study. 
Testing the evidence gathered thus far (e.g. 
obtaining evidence to support theoretically 
expected treatment effect and anticipated 
effect sizes) 
Required: Whether WED is likely effective for improving 
depression, and associated outcomes, in LTPCs, and the 
anticipated effect sizes should be estimated.  
Whether WED works as anticipated and whether it works 
differently for different people as anticipated should also 
be explored. 
Undertake a prior economic evaluation Required: This should be attempted for WED in LTPCs. 
Investigating the feasibility/effectiveness of 
intervention delivery (e.g. compliance, 
intervention fidelity & acceptability) 
Required: These issues must be established for WED in 
LTPCs. 
Investigating the feasibility/effectiveness of a 
trial protocol (i.e. identifying an appropriate 
control group, follow up, outcome measures, 
estimates of recruitment/retention & other 
issues that may undermine a main 
effectiveness trial e.g. feasibility and 
effectiveness of the randomization method) 
Required: These issues must be established for WED in 
LTPCs. 
Phase 3: Main effectiveness RCT  
Testing a fully defined intervention  with a 
theoretically defensible protocol, and with 
attention to achieving adequate statistical 
power and standard features of well-designed 
trials (e.g. randomisation, blinding & allocation 
concealment)  
Requires completion of phase 2. 
Phase 4: Long-term surveillance  
Determining whether the intervention and 
results can be reliably replicated in 
uncontrolled settings in the long-term 
Requires completion of phase 2. 
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Indeed, randomization is advocated to identify and estimate anticipated effect sizes, 
which inform sample size calculations (Campbell et al, 2000). Piloting of the method 
of randomization and as such establishing the feasibility and effectiveness of this 
prior to a full effectiveness trial is also recommended practice (MRC, 2000).  
 
The RCT design should be parallel groups, wherein the intervention and control are 
applied simultaneously to two separate groups of participants. This is preferable to 
alternative designs, for example cross-over RCTs in which participants are 
randomly assigned to a sequence of treatments (i.e. they all receive the same 
treatments in a different order). This design affords further control of confounders 
yet requires long ‘wash-out periods’ to avoid carry-over of treatment effects and is 
susceptible to order effects (i.e. the order in which people receive the treatments 
may influence effects) and learning effects (i.e.  WED participants may react to a 
neutral writing control task in a different way than naive controls). Moreover, 
withholding WED from controls was justified (discussed below). 
 
Phase two exploratory trials do not normally attend to issues such as internal 
validity/risk of bias and statistical power. These issues could additionally be 
considered in a preliminary manner, however, to further maximise the informative 
potential of the trial with respect to identifying and estimating anticipated effects and 
feasibility issues with regards to achieving these standards. Specifically, trials could 
endeavour to adhere to the CONSORT standards of randomisation, allocation 
concealment (i.e. preventing researcher’s prediction of group allocations before 
enrolment and thus allocation based on baseline characteristics) and blinding (i.e. 
preventing participants’ inference of group assignment) (Moher et al, 2001). An à 
priori sample size calculation could additionally be specified, with the feasibility of 
achieving the sample size requirements and the appropriateness of the parameters 
identified.  
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As identified in chapter three, achieving blinding in WED trials is particularly 
complicated. Ideally, the trial should be double blind. In endeavouring to achieve 
this, a placebo comparison must be employed and the information received at 
enrolment must be sufficiently vague to prevent participants’ inference of allocations 
on receipt of writing; the exact nature of the intervention and the existence of an 
intervention and control group must be withheld. This additionally prevents 
contamination in controls and pre-disclosure priming (i.e. protecting patent safety, 
discussed in chapter three). Given the difficulty in achieving blinding, the success of 
participant blinding should be specifically assessed. Participants should also self-
administer the intervention and self-reported outcome measures, such that 
intervention implementation/outcome assessment is additionally blind.  
 
HCPs will need to be aware of the study purpose but should not be informed of 
participating patients’ group allocation, and the risk of discussion between patients 
and HCPs about the study should be minimised.  
 
Population 
Piloting WED for improving depression in diabetes 
WED should be considered for improving depression in diabetes. The research 
team had a keen clinical interest in diabetes, and incidentally to date, no published 
studies had investigated this. This investigation is, however, timely and warranted, 
the reasons for which are discussed below. 
 
Diabetes 
The amount of glucose in the blood is controlled by insulin, a hormone produced by 
the pancreas. This moves glucose derived from the food we eat, from the blood 
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stream into cells where it is broken down to energy. Diabetes is a metabolic disorder 
in which the body is unable to break glucose down to energy.  In type 1 diabetes the 
pancreas is unable to produce insulin (insulin-dependent diabetes) and in Type 2 
diabetes the pancreas is unable to produce enough insulin or the cells in the body 
are unable to utilise the insulin that is produced (i.e. cells require insulin to absorb 
glucose); termed insulin resistance (i.e. non-insulin dependent diabetes). In both, 
hyperglycemia (i.e. high blood glucose levels) can result and produce long-term 
microvascular complications including retinopathy (i.e. damage to the retina at the 
back of the eye), neuropathy (i.e. nerve damage), foot ulcers (i.e. damage to the 
nerves of the foot) nephropathy (i.e. kidney disease), sexual dysfunction (i.e. 
erectile problems owing to damage to nerves and blood vessels), and 
macrovascular complications such as CAD and stroke.  Diabetes cannot be cured, 
instead the treatment goal is to maintain blood glucose levels as close to normal as 
possible to prevent the development of the aforementioned medical complications 
later in life.  In Type 1 diabetes this is achieved via patient initiated SMBs including 
adjustment in diet and exercise, self-monitoring of blood glucose and importantly 
self-administering insulin. Type 2 diabetes is usually managed initially via 
adjustment in diet and exercise, and weight loss, yet some cases additionally 
require oral hypoglycemic agents and perhaps insulin (i.e. it is a progressive 
condition). 
 
Diabetes is one of the biggest health challenges facing the UK (DUK, 2010a). The 
UK is facing an obesity epidemic, which is a particular risk factor for Type 2 diabetes 
(DUK, 2010a). Indeed, it is estimated 2.6 million people have diabetes (DUK, 
2010a), with many more cases unrecognised (Holt, Stables, Hippisley-Cox, 
O’Hanlon & Majeed, 2008; NHS The Information Centre for Health and Social Care, 
2008). Indeed, the incidence (Shaw, Sicree & Zimmet, 2010) and thus prevalence 
(Wild, Sicree, Roglic, King & Green, 2004) of diabetes is increasing, more notably 
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than for other LTCPs (DoH, 2009). Again, diabetes is a major risk factor for further 
LTPCs (Fillenbaum et al, 2000; WHO, 2002) and with the aging population people 
are now living longer hence the impact of complications is increasing (Rubin, Walen 
& Ellis, 1990). Indeed, a decline in mortality rates is reported for some LTPCs (see 
chapter one), yet not diabetes.  
 
Depression in diabetes 
To maximise effectiveness, the systematic review recommended investigation of 
WED for reducing negative affect, for example depressive symptoms, in LTPCs that 
are associated with negative affect and in which negative affect has a significant 
impact. Systematic reviews of cross-sectional studies have consistently indicated 
that having diabetes doubles the risk of elevated depressive symptoms and MDD, 
which is consistent across diabetes type and equates to one in six people with 
diabetes (17.6%) being likely to experience depression of a magnitude that may 
impair functional health (Anderson, Freedland, Clouse & Lustman, 2001; Ali et al, 
2006). Depression is also particularly persistent in diabetes; at follow up, up to 47% 
still report significant depressive symptoms (Fisher, Skaff, Mullan, Arean, Glasgow 
& Masharani, 2008; Hermanns, Kulzer, Kubiaz & Haak, 2004; Peyrot & Rubin, 1999; 
Pibernik-Okanovic et al, 2008) and 79% of those with MDD report dysthymia or at 
least one recurrent episode (average 4.2 episodes) despite some form of treatment 
during this period (Lustman, Griffith & Clouse, 1988). Indeed, 37% of patients 
indicating remission experience significant symptoms at follow up (Peyrot & Rubin, 
1999). The substantial impact of depression upon important outcomes in diabetes 
was presented in chapter one.  
 
Current access to E&P support in diabetes 
Whilst an improvement on previous years, in 2008 only just over half of the PCTs in 
the UK agreed that psychological support was provided to adults with diabetes 
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(DUK, 2007d; 2009a). A survey of psychological input into secondary care diabetes 
services for UK adults also reported that only 15% have access to specialist service 
provision, thus 85% of people with diabetes have no defined access to E&P support 
or at best have access to local generic services (i.e. with no diabetes input). 
Moreover, where specialist services do exist, only 13% have input into primary care, 
17% report unacceptable waiting times and 3% comply with all relevant NSF 
standards (DUK, 2008). Indeed, HCPs report that they can recognise E&P need yet 
they lack the time and skill to deal with this and insist more training and 
psychological input is required; only 38-61% feel able to meet this need and 51-65% 
perceive external support (DUK, 2008; DUK, 2007c; DUK, 2006a; DUK, 2005b; 
Pouwer et al, 2006). This unmet need consistently ranks amongst the top concerns 
reported by people with diabetes and HCPs (DUK, 2007a; 2009c; 2010b), and has 
been confirmed in a number of patient surveys reported in Table 6.  
 
Policy imperatives for improving provision of E&P support in diabetes 
As the prevalence of diabetes rises, the impact of depression will increase and the 
unmet support need will worsen, thus action is required now (DUK, 2008). There 
have been a number of diabetes specific-initiatives prioritising E&P support, 
recognising this as a barrier to SMBs and advocating that this should be integral in 
diabetes care, and receive Government investment, increased resource allocation 
and research investigating the benefits associated with different types of support 
(DUK, 2007c; DUK, 2006a; DUK, 2005a; DUK, 2005b; DUK, 2008). DUK have 
joined the campaign advocating the importance of talking therapies described in 
chapter one (Mental Health Foundation, Mind, Rethink, The Sainsbury Centre for 
Mental Health & Young Minds, 2006) and advocates that all self-management, 
education and empowerment programmes should comprise components targeting 
E&P need (DUK, 2007c). Indeed, as reported in chapter one provision of E&P 
support is a diabetes NSF standard. 
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Table 6 Patient surveys identifying an unmet need for E&P support in diabetes 
Year Survey Finding 
2005 Diabetes Dialogue38 A lack of E&P support available is a significant 
gap in the provision of diabetes services. 
2006 Diabetes Listening Project 239 At diagnosis 40% report receiving E&P support 
but 36% reported wanting and not receiving 
this. 
2006 Health Care Commission 
diabetes patient survey40 
3% expressed a need for specialist 
psychological support yet only 53% received 
this. 
2006 DUK Membership Survey41 48% reported receiving emotional support and 
4% expressed a need for specialist 
psychological support yet 51% could not access 
this.  
2006 A UK service development 
consultation in diabetes42 
Access to psychological support was the most 
requested priority (identified by 36% of 
responders), and people that wanted to talk 
about emotional problems were those 
experiencing significant depressive symptoms. 
2009 DUK Membership Survey43 42% of members report wanting to talk primarily 
to their HCP, of which 74% were able to do so. 
 
Recent changes in UK clinical practice with respect to E&P support in diabetes 
These imperatives have spurred endeavours to improve service delivery. In addition 
to the introduction of the QoF indicators for depression in LTPCs including diabetes, 
the NICE guidelines for the treatment of depression in LTPCs and the IAPT 
programme (described in chapter one), NHS Diabetes have published a 
commissioning toolkit which outlines a means of integrating E&P support into 
diabetes services (NHS Diabetes, 2009). Moreover, NHS Diabetes and DUK have 
established an E&P Working Group, which has developed an evidence-based 
model of E&P support that can be integrated into diabetes services. This is based 
on a five level pyramid model of E&P need in diabetes, illustrated in Figure 14, in 
which there is an inverse relationship between the prevalence and severity of need 
with the latter determining the intervention required (NHS Diabetes & DUK, 2010).44  
                                                             
38 DUK (2005a). 
39 DUK (2006b). 
40 Health Care Commission (2007). 
41 DUK (2007b). 
42 Davies, Dempster & Malone (2006). 
43 DUK (2009b). 
44 The researcher was a member of the working group from 2008 to 2009, and contributed 
much of the evidence synthesis contained within the report. This is acknowledged in the 
report (NHS Diabetes & DUK, 2010). 
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WED and depression in diabetes 
WED is appropriate specifically in diabetes 
SMBs are particularly important in diabetes and owing to its simplicity WED 
presents minimal interruption to these, which is important given the interruption 
already imposed by depression. WED also overcomes HCPs lack of confidence in 
addressing E&P need and provides a means of empowering patients to meet the 
substantial day to day demands they face. WED is also consistent with the service 
model proposed by NHS Diabetes and DUK (2010); it is a low-intensity 
psychological intervention that may provide a means of serving the large proportion 
of people with diabetes and lower-level E&P need.  
 
It is important to note that there are some reasons why WED may not be 
appropriate for use with the diabetes population in the UK. Firstly, diabetes is 
particularly prevalent in ethnic minorities, for example South Asians (DUK, 2009). 
WED is apparently likely to be culturally acceptable; as discussed in chapter nine 
WED has demonstrated improvements across samples that are heterogeneous on 
ethnicity, and there is evidence that it may be particularly effective for ethnic 
minorities perhaps as the privacy of WED may offer an acceptable means of 
disclosure (Lu & Stanton, 2010). However, WED may be pragmatically inappropriate 
for such individuals as English is not their first language and they may not possess 
sufficient English writing ability. In these instances it would be necessary adapt 
WED for ethnic minorities, yet this was beyond the scope of the present study.  
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Figure 14 The NHS Diabetes and DUK E&P Working Group pyramid model of E&P 
support in diabetes 
 
 
Level 5
Severe
& 
complex
mental illness  
requiring  
psychiatric 
intervention(s).
Level 4
More severe 
psychological 
problems that are 
diagnosable
and require biological 
treatments,
medication & specialist
psychological 
interventions.
Level 3
Psychological problems which are 
diagnosable / classifiable but can be 
treated solely through psychological 
interventions e.g. mild & some 
moderate cases of depression, anxiety 
states & obsessive / compulsive 
disorders.
Level 2
More severe difficulties with coping, causing 
significant anxiety or lowered mood, with impaired 
ability to care for self as a result.
Level 1
General difficulties coping with diabetes & the perceived 
consequences of this for the person’s lifestyle, etc. Problems at a 
level common to many or most people receiving the diagnosis.
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WED is also likely to be pragmatically inappropriate for individuals with very 
advanced medical complications, for example individuals with advanced retinopathy 
and those hospitalised for more severe nephropathy (i.e. receiving dialysis or a 
kidney transplant), CAD and stroke. WED should additionally not be implemented 
for individual with more severe psychological problems (as discussed in chapters 
two and three), yet the literature suggests that significant depression is prevalent in 
diabetes (discussed in chapter one and above). These issues must be reflected in 
the study exclusion criteria (discussed below). 
 
WED may be specifically effective in diabetes 
As described in earlier chapters, illness-related stressors and general/illness-related 
distress are associated with depression in LTPCs, thus targeting this may optimise 
improvement in depression. WED targets emotional aspects of stressors and 
presumably distress, consequently improvement in depression may be optimised. 
Specifically in diabetes, diabetes-related emotional problems and thus DSED are 
prevalent. In the UK, 81% of primary care patients report ‘some degree’ of DSED 
(West & McDonald, 2002), and at least one serious emotional problem is reported 
by 60% of patients seen in diabetes clinics (Polonsky, Anderson, Lohrer, Welch, 
Jacobson, Aponte & Schwartz, 1995). The emotional problems most frequently 
relate to worry about high blood sugar, hypoglycemia and the risk of future 
complications (Delahanty et al, 2007; Hermanns, Kulzer, Krichbaum, Kubiak & 
Haak, 2006; Kokoszka, Pouwer, Jodko, Radzio, Mućko, Bienkowska, Kuligowska, 
Smoczynska & Skłodowska, 2009; Polonsky et al, 1995; Snoek, Welch, Pouwer & 
Polonsky, 2000; Welch, Jacobson & Polonsky, 1997; West & McDonald, 2002) and 
feeling guilty when getting off track with diabetes management (Delahanty et al, 
2007; Hermanns et al, 2006; Polonsky et al, 1995; Pouwer, Skinner, Pibernik-
Okanovic, Beekman, Cradock, Szabo, Metelko & Snoek, 2005; Snoek et al, 2000; 
West & McDonald, 2002). 
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As mentioned in chapter one, a large body of research has also demonstrated that 
DSED is associated with depression; DSED is more common in patients with high 
levels of depressive symptoms compared to those with low levels (Adriaanse et al, 
2008; Connell et al, 1990; Fisher, Skaff, Mullan, Arean, Mohr, Maharani, Glasgow & 
Laurencin, 2007; Hermanns et al, 2006; Lee, Chiu, Tsang, Chow & Chan, 2006; 
Polonsky, Fisher, Earles, Dudl, Lees, Mullan & Jackson, 2005; Pouwer et al, 2005; 
Gonzalez, Delahanty, Safreb, Meigs & Grant, 2008a; Kokoszka et al, 2009; Zhang, 
Ye & Deng, 2006; Zhang, Tse, Ye, Lin, Chen & Chen, 2009). In fact, as also 
described in chapter one, a bi-directional relationship between DSED and 
depression is likely. Indeed, it is acknowledged specifically in diabetes that 
interventions that target DSED may also improve mood (Pouwer et al, 2005; 
Kokoszka et al, 2009; DUK, 2006a; DUK, 2007c) and the unacceptable absence of 
RCTs testing this assumption is noted (Pouwer, 2009).  
 
It is additionally noteworthy that should it improve both DSED and depression, WED 
would also address two independent influences on important outcomes maximising 
any improvement in them (Polonsky et al, 1995). Indeed, DSED has an adverse 
impact upon SMBs and clinical outcomes (i.e. HbA1c and complications) 
(Nakahara, Yoshiuchi, Kumano, Hara, Suematsu & Kuboki, 2006; Nichols, Hillier, 
Javour & Brown, 2000; Pouwer et al, 2005), which is independent of the impact of 
depressive symptoms (Fisher et al, 2007) and MDD (Fisher et al, 2008). In fact, it is 
agreed DSED and depressive symptoms are related yet independent constructs 
with both shared and different relationships with diabetes endpoints (Gonzalez et al, 
2008a).  
 
There are additional reasons to believe WED may be effective in diabetes. Some 
research suggests people may inhibit their diabetes (i.e. do not discuss their 
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condition/feelings with others), which is associated with depression (Cheng & Boey, 
2000; Lee et al, 2006). These studies were, however, conducted in China, thus 
cultural differences somewhat limit generalization to the UK. 
 
Indeed, two unpublished dissertations from the USA investigating WED have 
reported fewer incidences of physical illness and fewer depressive symptoms, but 
no effect on glycaemic control, in Type 1 diabetes (Bodor, 2002), and a trend for 
decreased DSED and improved well-being in seniors with Type 2 diabetes (Taylor, 
2001). However, owing to small samples and thus potentially unstable 
effects/inadequate statistical power, the effect of WED for adults with diabetes is 
unclear. Furthermore, these studies were conducted in the USA and may have 
suffered compromised blinding as identified in chapter three, which advocated that 
UK studies are needed. It is also important to identify the effect of WED across the 
entire age range of adults with Type 2 diabetes. Finally, these studies did not report 
on feasibility, nor identify moderators and mediators of effects, mechanisms of 
change and cost-effectiveness. 
 
Piloting WED for improving depression in Type 2 diabetes 
It is more appropriate to investigate WED for improving depression in Type 2 rather 
than Type 1 diabetes. These conditions differ in their aetiology, onset, course and 
treatment requirements and should not be considered as a whole. In Type 2 
diabetes, depressive symptoms are more persistent (Peyrot & Rubin, 1999) and 
have a stronger association with DSED (Aikens, Perkins, Piette & Lipton, 2008). 
Furthermore, WED for adults with LTPCs was of interest and examined in the 
systematic review, and Type 2 diabetes affects the majority of adults with diabetes 
in England (90%) (Forouhi, Merrick, Goyder, Ferguson, Abbas, Lachowycz & Wild, 
2005). Targeting individuals with Type 2 diabetes may derive an older study 
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population. There is little evidence that age moderates WEDs effects (Frattaroli, 
2006). Moreover, as described above a preliminary WED trial in seniors with Type 2 
diabetes identified trends for beneficial effects (Taylor, 2001). However, WED may 
not be pragmatically appropriate for those with age-related difficulties with writing.  
 
Piloting WED for improving depression in established Type 2 diabetes 
WED should be piloted for patients six months post Type 2 diabetes diagnosis. 
Research has suggested distress and depression emerge in diabetes once people 
have realised its implications and have begun to experience long-term 
complications, whereas those with a new diagnosis are still accessing information 
and relatively naive to the condition (Tellez-Zenteno & Cardiel, 2002; West & 
McDowell, 2002). Indeed, within the first six months people with diabetes are still 
relatively well-supported by the NHS.  
 
Piloting WED for lower-level depression in Type 2 diabetes  
WED should be piloted specifically for lower-level depression in Type 2 diabetes. 
Chapter three identified that patients should be experiencing lower-level negative 
affect. This is consistent with the appropriate clinical application of WED, and as 
such would enhance the applied relevance of trials whilst importantly protecting 
patient safety. It would also potentially optimise effectiveness. This is additionally 
warranted because, consistent with the evidence reported in chapter one and 
above, the diabetes evidence base suggests lower-level depressive symptoms are 
particularly prevalent, have a significant impact, are a national priority and whilst 
access to low-intensity E&P support has improved some barriers persist. This is 
discussed in more detail below.  
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Prevalence 
Having diabetes significantly increases, and potentially doubles, the risk of having 
lower-level depression (Almawi, Tamim, Al-Sayed, Arekat, Al-Khateeb, Tutanji & 
Kamel, 2008; Lin & Von Korff, 2008), and the risk of incident lower-level depression, 
controlling for past history of depression preceding diabetes (Aarts, van den Akker, 
van Boxtel, Jolles, Winkens & Metsemakers, 2009). Prevalence rates from cross-
sectional studies of lower-level depression in diabetes are presented in Table 7. A 
distinction is made for the method of depression assessment as this has varied 
greatly between studies such that the estimates represent different 
operationalisations and severities of lower-level need; some have applied diagnostic 
clinical interviews (i.e. ICD-10/DSM-IV criteria) while others have employed various 
self-report symptom measures and thresholds, which tap slightly different 
conceptualisations of lower-level depressive symptoms, and others have combined 
these approaches. Studies have also varied on a number of characteristics that may 
further explain the variation in estimates (see chapter one for examples). In fact, 
lower-level depressive symptoms are a known precursor of more severe symptoms 
(Judd, Akiskal & Paulus, 1997; Kessler, Zhao, Blazer & Swartz, 1997), the 
progression of which must be prevented in diabetes (Hermanns et al, 2006). 
 
Impact 
Cross-sectional evidence indicates that in diabetes lower-level depressive 
symptoms have an adverse effect upon self-care (Ciechanowski, Katon, Russo & 
Hirsch, 2003; Ciechanowski, Katon & Russo, 2000; Egede, Ellis & Grubaugh, 2009; 
Gonzalez et al, 2007), symptom reporting (Ciechanowski et a, 2003), disability (Von 
Korff, Katon, Lin, Simon, Ludman, Oliver, Chiechanowski, Rutter & Bush, 2005), 
complications (Katon et al, 2004a), and early mortality (Ismail et al, 2007; Katon et 
al, 2005; Zhang et al, 2005). Prospective studies are few yet suggest an increased 
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risk for incident long-term complications, disability and mortality along a gradient 
wherein increasing symptoms confers a greater risk (Black et al, 2003). 
 
Table 7 Prevalence of lower-level depression in diabetes 
Depression assessment method Prevalence 
Diagnostic clinical interview  Minor depression: 8.1%; 
Dysthymia: 9.2%45 
Symptom measures incorporating DSM-IV 
diagnostic criteria 
Minor depression: 7.9% to 8.5%46 
Scoring above threshold for significant 
symptoms on symptom measures but not 
MDD by diagnostic clinical interviews 
19 to 24%47 
Scoring below threshold for significant 
depressive symptoms yet above an arbitrary 
lower threshold on various symptom 
measures 
Minimal/mild symptoms: 12.3% to 
19.7%; mild to moderate or 
moderate symptoms 6% to 8.5%48  
Scoring below threshold for significant 
depressive symptoms but not scoring as 
having no symptoms on various symptom 
scales (i.e. at least some depressive 
symptoms) 
64%49 
 
Current provision of low-intensity E&P support 
It is also apparent that access to E&P support is particularly limited for lower-level 
depression in diabetes. As described in chapter one, antidepressants are not 
advocated and have limited effectiveness for lower-level depressive symptoms in 
diabetes, whereas the low-intensity psychological intervention recommended has 
improved outcomes. However, in diabetes people with minor depression are more 
likely to experience a poorer quality of care than those with MDD (Egede et al, 
2009).  Indeed, diabetes service teams report needing help with this level of E&P 
                                                             
45 Ismail, Winkley, Stahl, Chalder & Edmonds (2007); Larijani, Bayat, Gorgani, Bandarian 
Akhondzadeh & Sadjadi (2004). 
46 Katon, Von Korff, Ciechanowski, Russo, Lin, Simon, Ludman, Walker, Bush & Young (2004a); 
Katon, Rutter, Simon, Lin, Ludman, Ciechanowski, Kinder, Young & Von Korff (2005); Li, Ford, Strine 
& Mokdad (2008); Lin, Heckbert, Rutter, Katon, Ciechanowski, Ludman, Oliver, Young, McCulloch & 
Von Korff (2009). 
47 Kokoszka et al (2009); Hermanns, Kulzer, Krichbaum & Haak (2005); Hermanns et al (2006). 
48 Black, Markides & Ray (2003); Collins, Corcoran & Perry (2009); Egede et al (2009); Lloyd, Dyer & 
Barnett (2000); Ruddoch, Fosbury, Smith, Meadows & Crown (2010); Yu, Y-Hua & Hong (2010). 
49 Gonzalez, Safren, Cagliero, Wexler, Delahanty, Wittenberg, Blais, Meigs & Grant (2007). 
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need for which reported referral pathways are especially lacking (DUK, 2008). 
Moreover, policy documents advocate lower-level E&P need is as important to treat 
as more severe manifestations, yet is usually afforded less consideration (DUK, 
2008; NHS Diabetes & DUK, 2010). Again, IAPT has likely improved the situation 
yet there is still work to do (see chapter one). 
 
Ensuring inclusion of participants with lower-level depression 
The study selection criteria should therefore ensure that participants with lower-level 
depression are included. To achieve this, it could be required that primary care 
patients have screened positive to the QoF depression-screening questions within 
the previous 12 months. This data is routinely obtained in general practice 
(described in chapter one). This ‘ultra short’ instrument was developed as previously 
validated tools are too cumbersome and time consuming to be feasibly implemented 
in primary care (Mitchell & Coyne, 2007). The questions were taken from the 
Primary Care Evaluation of Mental Disorders (PRIME-MD) designed to facilitate the 
identification of common mental disorders in primary care (on which the PHQ-9 is 
based). A positive screen is a yes response to either of the two questions, which 
ask about depressed mood and anhedonia (i.e. loss of interest or pleasure in doing 
things). These questions are employed because according to DSM-IV criteria the 
essential feature of MDD is a period of at least two weeks during which there is 
either of these symptoms; they are designed to inform on DSM-IV criteria based 
psychiatric diagnosis (Whooley, Avins, Miranda & Browner, 1997).  
 
As noted in chapter one, NICE recommends screening for depression in at risk 
groups and suggests that this can be achieved with these two screening questions, 
albeit no specific evidence is cited (Mitchell & Coyne, 2007). Consequently, 
validation studies have since examined whether this case-finding instrument can 
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accurately detect depression in primary care. Studies in which the QoF questions 
were self-administered (Spitzer, Williams, Kroenke, Linzer, deGruy, Hahn, Brody & 
Johnson, 1994; Whooley et al, 1997) and administered verbally by GPs (Arroll, Khin 
& Kerse, 2003) have reported high sensitivity for detecting MDD (86-97%) 
compared to diagnostic clinical interview. Negative predictive values have also been 
high (98 and 99%) and likelihood ratios for a negative test low (.05 and .07), 
suggesting that depression is highly unlikely for those responding negatively.  Such 
studies have thus concluded that the questions are sufficient as they detect most 
cases of depression.  
 
However, these studies additionally report only reasonable specificity (57-75%), and 
importantly they consistently demonstrate low positive predictive values (18 and 
33%) and relatively low likelihood ratios for a positive test (2.2 and 2.9) compared to 
diagnostic clinical interview (Arroll et al, 2003; Spitzer et al, 1994; Whooley et al, 
1997). Thus most of those screening positively are not actually depressed, and may 
be inappropriately treated or referred should these questions be relied on alone. 
This is an important limitation because in primary care where screening is 
widespread such a high rate of false positives would be unmanageable, over-
treatment is a current concern, and there is the added complication that the 
additional symptoms identified for false positive individuals must also be dealt with 
(Gilbody, Richards, Brealey & Hewitt, 2007; Mitchell & Coyne, 2007). Indeed, a 
relatively recent systematic review of two and three item ‘ultra short’ screening 
instruments including the QoF questions identified that at best they provide a means 
of ruling out depression (i.e. they are adequate only for this purpose) (Mitchell & 
Coyne, 2007). It is hence widely advocated that these questions should only be 
employed when there are sufficient resources to follow up positive screening results 
with a more accurate case finding instrument (Arroll et al, 2003; McManus, Pipkin & 
Whooley, 2005; Mitchell & Coyne, 2007; Whooley et al, 1997).  
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The diagnostic accuracy of the QoF questions for identifying depression specifically 
in LTPCS, and for additionally identifying lower-level depression (i.e. any disorder 
rather than only MDD) has not been established (Mitchell & Coyne, 2007). 
Nonetheless, this criterion could be implemented as it is anticipated this would 
identify patients with both lower- and higher-level depression. However, due to 
feasibility issues associated with this criterion it had to be removed early in the 
recruitment phase of the present trial, the reasons for which are described in detail 
in chapter six. 
 
Piloting recruitment approaches 
The effect of WED for adults with Type 2 diabetes in primary care was of interest as 
this is where the majority of those with Type 2 diabetes, and indeed those with 
lower-level depression, are managed. As described in chapter one, there are now 
policy imperatives in LTPCs that advocate a shift in delivery of mental health care to 
primary care. However, numerous recruitment problems were encountered in 
primary care, thus recruitment was also piloted in secondary care and then in 
support groups owing to further recruitment problems experienced in secondary 
care (discussed in chapter six). 
 
This was considered justified as WED has been implemented in support groups for 
LTPCs including Type 2 diabetes (i.e. online and local meetings) (Craft, 2006; 
Possemato, 2007; Taylor, 2001), primary care (Hannay & Bolton, 1999; Klapow et 
al, 2001) and secondary care LTPC clinics (Morgan et al, 2008; Taylor et al, 2003), 
demonstrating acceptability, feasibility, benefits and no apparent adverse effects. 
Moreover, it is advocated that RCTs should widen their selection criteria and include 
more heterogeneous samples to enhance their external validity and applied 
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relevance (Coates, 2010; Glasgow, 2008; Nezu & Nezu, 2008). Such participants 
represent the continuum of lower-level E&P need; presumably better adjusted 
individuals (e.g. support seeking individuals and patients managed in primary care) 
to those with more diabetes-related problems (e.g. secondary care patients). These 
three distinct routes to accessing participants should therefore be piloted. 
 
The recruitment approaches adopted by the studies that were included in the 
systematic review were considered in terms of identifying the most appropriate and 
efficient strategies. The recruitment strategies employed by the included studies are 
reported within the data extracted for the individual studies (again presented in the 
appendix). The studies typically recruited in secondary care and support group 
contexts. The studies that reported the largest initial samples sizes (i.e. ≥90 
randomised participants) were a) those that recruited in outpatient clinics where the 
consultant either provided patients with the study information or referred them to the 
study which was followed up by researchers (Cohen et al, in preparation; Gellaitry et 
al, 2010; Zakowski et al, 2004), and b) those that advertised the study in a disease-
specific charitable organisation newsletter and presented the study information to 
disease-specific support groups (Hamilton-West & Quine, 2007). The studies that 
reported the smallest initial sample sizes (<50 randomised participants) were those 
that recruited in outpatient clinics yet researchers approached patients (Rosenberg 
et al, 2002), who were occasionally identified by consultants (Wetherell et al, 2005). 
Other relatively successful strategies (i.e. from studies that recruited >70 to <90 
participants) included advertising the study on disease-specific online resources 
(Low et al, 2010). 
 
It is noteworthy that some of the studies included in the systematic review employed 
community based recruitment methods amongst other methods, for example mass 
media advertisements (Norman et al, 2004) and advertisement in a local newspaper 
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(Vedhara et al, 2007) with some success (i.e. approximately 60 participants). 
However in response to the recruitment problems experienced in primary then 
secondary care, support groups were attempted initially given that the studies 
included in the systematic review suggested this to be a potentially successful 
recruitment context. An attempt at recruiting in the community was then not feasible 
within the time scale for the study. 
 
Consequently, the present study sought to employ the successful recruitment 
strategies identified; consultants introducing the study to patients in secondary care 
rather than having the researcher be the first point of contact, and advertising the 
study on disease-specific online resources, in disease-specific charitable 
organisation newsletters and presenting the study information to disease-specific 
support groups.  This was achieved with variable degrees of success owing to the 
recruitment and feasibility issues identified. These issues are again reported in 
chapter six, and the final methodology that was employed is reported in chapter five. 
 
None of the studies included in the systematic review were executed specifically in 
primary care. Consequently for primary care the recruitment strategy was adapted 
from that employed in other WED studies undertaken in primary care and other 
areas of primary care research. In a WED feasibility study undertaken in primary 
care clinics in the USA, patients were identified in consultation by their HCP and 
then recruited by a project manager with minimal refusal reported (n=45), albeit this 
study offered a financial reimbursement to patients for participation (Klapow et al, 
2001). An Israeli study of an ED intervention based on WED in primary care had 
physicians recruit patients directly, and again reported minimal refusal (n=50) 
(Gidron, Duncan, Lazar, Biderman, Tandeter & Shvartzman 2002). However, a UK 
feasibility study of therapeutic writing in primary care in which GPs similarly directly 
recruited patients, reported that four GPs recruited 23 patients while two failed to 
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recruit any owing to an inability to complete the additional study-related paper work 
given non-study related workload, an inability to integrate recruitment into their 
consulting pattern, and a concern about intruding on patients. GPs also reported 
reservations of opening up issues with which it would be difficult to deal (Hannay & 
Bolton, 1999).   
 
In contrast, a primary care study of an ED intervention based on WED in the 
Netherlands recruited by means of an initial mass mail out of a screening 
questionnaire, and recruited a more substantial number of eligible patients despite 
significant loss during screening (n=161) (Schilte, Portegijs, Blankenstein, van der 
Horst, Latour, van Eijk & Knottnerus, 2001). Consequently, the most appropriate 
and likely effective approach in primary care was deemed to be a mass mail out. 
This was also the most time and cost efficient means of practices identifying 
participants.  
 
This strategy is consistent with other diabetes studies, namely epidemiological 
depression studies and psycho-social intervention studies undertaken in primary 
care, including in the UK, which have recruited high numbers of participants (Katon 
et al, 2004a; 2005; Sturt et al, 2008). Incidentally, it is also in accordance with 
recent UK guidelines to assist recruitment in primary care published by the NIHR 
School for Primary Research and Primary Care Research Network (PCRN) (NIHR & 
PCRN, 2010). 
 
Intervention and comparison exposure 
Piloting WED instructions 
Participants should receive the original WED instructions (Pennebaker & Beall, 
1986), which entail writing about thoughts and feelings about the most traumatic 
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experience in life, in an attempt to resolve some of the heterogeneity in the 
implementation of WED which currently plagues the evidence base and its 
interpretation (discussed in chapter two). Many WED studies have employed these 
instructions reporting benefits and no apparent adverse effects (reported in chapter 
two), which are in fact more acceptable to patients with elevated levels of 
depression than currently implemented interventions in terms of attrition rates (Stice 
et al, 2006).  
 
Identifying an appropriate control group task 
The control group should engage in a neutral writing activity (i.e. time management), 
without discussing thoughts or feelings. This is consistent with the majority of the 
studies included in the systematic review (see chapter three). Patients with a LTPC 
report that the standard time management task is not experienced negatively 
(Byrne-Davis et al, 2006). This offers face validity as meaningful task to protect 
blinding (Nezu & Nezu, 2008) and distinguishes writing from content (Smyth & 
Helm, 2003). WED compared to no active treatment was appropriate for 
establishing whether it can deliver ‘any’ benefit and because there was no sensible 
treatment comparison. Whilst effective treatment must not be withheld from patients 
with depression in RCTs (Rifkin, 1999; Shorr & Miller, 1999), this is justified where 
no patients are experiencing substantial depression and given that it is not known 
whether WED is effective in this context. Nonetheless, usual care and treatment 
seeking should not be restricted in any way.  
 
Piloting writing parameters 
Both groups should write at home for 20 minutes on three days over the course of 
one week. This is consistent with the majority of the studies included in the 
systematic review (see chapter three). Writing at home also offers greater ecological 
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validity as it is anticipated WED would be implemented in this way. Studies have 
typically employed three or four 15-20 minute sessions with no evidence of 
differential benefit (Frattaroli, 2006). Writing has usually been over consecutive 
days, however there is no evidence that one week is less effective (Sheese, Brown 
& Graziano, 2004) and some indication it may be more effective (Smyth, 1998). 
Importantly, WED should be adapted to the constraints of a situation (i.e. reducing 
participant burden) (Smyth & Helm, 2003; Klapow et al, 2001). Consistent with the 
original paradigm and the parameters that apparently derive greatest benefit (Baikie 
& Wilheim, 2005; Frattaroli, 2006), patients should write in private, switch topics 
across sessions if desired, impose their own structure with minimal examples 
provided and write continuously with repetition if necessary and no regard for 
spelling or grammar. 
 
Importantly, participants should self-select the disclosure topic. It is advocated that 
the content of writing is unimportant, rather exploration of thoughts and feelings is 
key (Pennebaker, 2000), and benefits are apparently observed in WED whether a 
LTPC or unrelated topics are disclosed (Baikie & Wilheim, 2005). Indeed, this 
seemed to be the case in the systematic review. Self-selection additionally 
facilitates universal coverage of the wide range of personally salient diabetes-
related stressors (see chapter one) and diabetes-related emotional problems 
(discussed above) associated with depression. It is noteworthy that should non-
diabetes-related stressors be disclosed, an improvement in DSED and depression 
can still be anticipated because general stressors/stress are associated with 
incident DSED (Fisher et al, 2009) and depression in diabetes independent of the 
influence of diabetes-related stressors (Fisher, Chesla, Mullan, Skaff & Kanter, 
2001). In fact, person centred interventions, which address the full spectrum of 
stressors impacting on depression in diabetes are advocated (Fisher et al, 2001). 
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Piloting the mode of disclosure 
Handwriting is consistent with the majority of the WED evidence base, and certainly 
the studies included in the systematic review where the mode of disclosure was 
reported. Logically, it seems that handwriting would slow people down and facilitate 
proper processing. However, it seems there are only subtle differences between 
handwriting and typing. Recent studies have delivered WED by email, reporting 
benefits and no apparent negative effects (Sheese et al, 2004) and demonstrating 
acceptability to patients (Johnston et al, 2010). Moreover, no moderating effect of 
handwriting versus typing has been identified (Frattaroli, 2006).  
 
Piloting the approach to intervention delivery 
Intervention delivery should be by post or email as personal contact and extensive 
discourse with the researcher risks additional intervention, influences from 
experimenter expectancies/bias, compromised blinding, treatment diffusion and 
pre−disclosure priming (Nezu & Nezu, 2008).  This is typical in WED studies and 
consistent with the likely implementation of WED, thus enhancing the applied 
relevance of the trial (Coates, 2010). 
 
Identifying and estimating the anticipated effect: preliminary 
effectiveness analysis 
Piloting the outcome specification  
Pennebaker (2004) argues WED research should adopt the ‘taxpayer’s perspective’ 
investigating economically relevant outcomes (e.g. physical health, health 
behaviours and HCU). However, psychological outcomes such as QoL are 
important to patients (Ghandi, Murad, Fujiyoshi, Mullan, Flynn, Elamin, Swiglo, 
Isley, Guyatt & Montori, 2008), and ultimately represent the way in which physical 
symptoms are negatively experienced (Kaplan, 1990).  
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Primary outcome 
Depressive symptom severity should be the primary outcome, because as 
described in chapter one and above, depression is a significant problem in diabetes 
and a national health care objective, with an adverse effect on economically 
relevant outcomes. Importantly, the systematic review suggested WED may 
improve depression. Depressive symptom severity is specifically appropriate 
because measures of this were employed in the studies that examined depression 
in the systematic review (see chapter three). Moreover, given that WED should be 
implemented for lower-level depression; MDD is not applicable. In fact, elevated 
depressive symptoms are actually more prevalent, persistent and potentially more 
related to diabetes endpoints (i.e. SMBs and HbA1c) than MDD in Type 2 diabetes 
(Fisher et al, 2007; Fisher, et al, 2008). It is noteworthy that assessment of sub-
threshold and minor depressive disorders is additionally not appropriate because 
the gold standard for identifying depressive disorder, diagnostic clinical interview 
based on DSM-IV criteria (Lustman, Harper, Griffith & Clouse, 1986), is expensive 
and requires administration by trained professionals.  
 
Secondary outcomes 
DSED should be a secondary outcome. As above, WED is anticipated to be 
specifically effective in diabetes because it targets emotional aspects of stressors 
and presumably DSED, which are associated with depression. Consequently, 
improvement in depression may be optimised. However, the systematic review 
reported in chapter three identified an effect of WED on negative affect yet not 
distress, which has additionally been observed in non-LTPC samples. It was 
therefore advocated that whether WED targets distress and thus improves 
depression via a concurrent reduction in this in LTPCs should be clarified. Whether 
WED can reduce DSED is also worthy of investigation. As discussed above, DSED 
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is prevalent in diabetes and it has an independent adverse effect on economically 
relevant outcomes. Despite this, however, screening for DSED is not a QoF 
indicator, neither is it addressed in the NICE guidelines. Occasionally, the Problem 
Areas in Diabetes (PAID) scale which assesses DSED is employed in clinical 
practice, but this is not an enforced standard. Indeed, DSED is less likely treated 
than depression in diabetes (Fisher et al, 2007).  
 
Health-related QoL and diabetes SMBs should additionally be secondary outcomes 
because, as described in earlier chapters and above, they are adversely impacted 
by high and low-level depression in diabetes, thus improving depression, even at 
lower levels, may produce improvements in these associated outcomes. Indeed, 
low- and high-intensity depression treatment has produced concurrent 
improvements in these outcomes, albeit again as described in earlier chapters, 
whether these changes are related to improvement in depression is unclear.50 
Furthermore, the systematic review identified that WED may improve health-related 
QoL and it is unclear whether WED may influence SMBs in LTPCs (health 
behaviour change theory; chapter two).  
 
Piloting outcome measures 
Selection of measures was informed by relevance to theory, practice and research, 
and minimising participant burden. The European Depression in Diabetes (EDID) 
Research Consortium is an internationally represented group committed to 
achieving consensus on issues relating to depression in diabetes, which 
                                                             
50 It was initially intended that HbA1c would be included as an outcome measure for this reason, and 
because WED has been demonstrated to produce clinically significant changes in physiological 
parameters in LTPCs (Smyth et al, 1999; see chapter two). However it was considered unlikely that 
any change over a three to 12 month period could be attributable to WED and in general practice 
HbA1c is routinely checked six monthly or annually.  Another outcome that was intended to be 
included was HCU, but this had to be removed owing to delays experienced in implementing the study 
(reported in chapter five) 
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recommends use of a number of key measures (EDID, 2011). These were 
employed wherever possible. 
 
Primary outcome 
Depressive symptom severity should be measured with the CES-D. This was 
amongst the measures used to assess negative affect within the systematic review 
(see chapter three). This assesses current level of depressive symptoms, with an 
emphasis on the affective component of depressed mood (Radloff, 1977). It has 20 
items scored on a Likert scale. A total score is derived, with scores ranging from 0-
60 and higher scores representing more symptom severity. The CES-D has 
demonstrated content, concurrent and discriminant validity, and sensitivity to 
change resulting from psychotrophic medication in community, depressed and 
psychiatric samples (Weismann, Sholomskas, Pottenger, Prusoff, & Locke, 1977).  
The CES-D has been validated in Type 2 diabetes (Fisher et al, 2001), and internal 
and test-retest reliability have been demonstrated in LTPCs (Devins, Orme, 
Costello, Binik, Frizzell, Stam & Pullin, 1988) 
 
Unlike other measures of depressive symptom severity scores are not confounded 
by physical symptoms related to LTPCs (Devins et al, 1988), at no cost to predictive 
efficacy in diabetes (McHale, Hendrikz, Dann & Kenardy, 2008; Peyrot & Rubin, 
1997). The CES-D is a core EDID measure that is consistently employed in 
diabetes studies. Moreover, both general and diabetes-related stressors and DSED, 
which are purportedly targeted by WED, have specifically been demonstrated to be 
related to depressive symptom severity measured via the CES-D (Fisher et al, 
2001; Fisher et al, 2007).  It was therefore selected over the plethora of alternative 
depressive symptom severity measures available, including those derived from 
DSM-IV criteria (i.e. the BDI and PHQ-9). In fact many of the alternative depressive 
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symptom severity measures are typically employed for screening purposes or must 
be purchased (i.e. the BDI). 
 
Secondary outcomes 
DSED could be measured with the PAID Scale (Polonsky et al, 1995). This taps the 
extent to which emotional responses to diabetes (i.e. negative emotions, treatment-
related problems, food-related problems and lack of social support) are currently 
problematic. It has 20 items scored on a Likert scale. A total score is calculated and 
transformed to scale of 0-100, higher scores indicating more DSED. In  diabetes, 
the PAID has demonstrated internal (Polonsky et al, 1995; Welch et al, 1997) and 
test-retest (Snoek et al, 2000) reliability, concurrent, convergent (Polonsky et al, 
1995; Snoek et al, 2000; Welch et al, 1997) and discriminant validity (Snoek et al, 
2000; Welch et al, 1997), and responsiveness to change (Welch, Weinger, 
Anderson & Polonsky, 2003). This is an EDID core measure that has been more 
widely employed in diabetes studies than alternatives. 
 
Health-related QoL should be measured with the EuroQoL (EQ-5D). This taps five 
dimensions relevant to health-related QoL (i.e. mobility, usual activities, pain, 
anxiety/depression and self-care). For each, people rate their agreement with three 
statements representing different levels of severity in relation to their health state 
that day (i.e. no problems, some problems or severe problems). Responses are 
converted to a utility index by applying a formula in which a weight is attached to the 
level indicated for each dimension, these weights having been derived from 
valuations of each level for each dimension from the general population. A 
maximum score of 1 can be derived (i.e. no problems for any dimension).  
Respondents also indicate their current health state on a visual analogue scale 
(VAS) ranging from 0 (worst possible state) to 100 (best possible state). Both 
measures have demonstrated convergent and discriminant validity with respect to 
169 
 
groups of patients with different diabetes-related characteristics in Type 2 diabetes 
(Matza, Boye & Yurgin, 2007). The EQ-5D has been used extensively in Type 2 
diabetes, is brief and produces utilities used to compute quality adjusted life years 
(QALYS) for undertaking a cost effectiveness evaluation, which again should be 
considered in line with the recommendations in chapter three. 
 
Diabetes SMBs should be measured with the revised version of the Summary of 
Diabetes Self-care Activities Questionnaire (SDSCA) (Toobert, Hampson, & 
Glasgow, 2000).  This measures diabetes SMBs; general diet, specific diet, 
exercise, blood glucose monitoring, foot care and smoking. For the first five sub-
scales people rate the frequency with which each activity was performed within the 
previous seven days or per week over the past month. For the additional smoking 
sub-scale people indicate whether they smoked cigarettes in the past seven days, 
and if so how many were smoked per day. In the interest of including only 
continuous outcome variables in analyses, however, this sub-scale should be 
excluded. The SDSCA has demonstrated adequate internal and test-retest 
reliability, sensitivity to change in relation to interventions targeting SMB change, 
and concurrent validity (Toobert et al, 2000). The revised scale is briefer yet 
contains the core and optimally performing items from the original scale (Toobert et 
al, 2000). This is again an EDID core measure and has been more widely employed 
in diabetes studies than alternatives. 
 
Piloting the approach for preliminary effectiveness analysis 
Primary outcome 
ITT effectiveness analyses should be undertaken, analysing all of the participants 
that were randomised according to their original group assignment. This enhances 
statistical power and preserves randomisation avoiding bias associated with non-
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random loss of participants potentially related to treatment response (Moher, 
Hopewell, Schultz, Montori, Gøtsche, Devereaux, Elbourne, Egger & Altman, 2010). 
Where some participants do not complete the intervention or follow up as intended, 
strict ITT analysis is not possible yet it is next best practice to impute missing 
observations. This should be by means of baseline observations carried forward, 
therefore assuming no change and providing a conservative estimate of effect as is 
typically employed in RCTs (Moher et al, 2010). Disappointingly few of the studies 
included in the systematic review adopted this approach (see chapter three). 
 
Where baseline observations are missing these should be replaced with follow up 
observations, thus again assuming no change. An alternative approach is to replace 
missing baseline values with the mean baseline score for the same variable and 
group (i.e. provided the participant’s follow up score was comparable to the mean at 
follow up for the same variable and group). However, this suppresses the true value 
of the SD and thus SE (i.e. for replaced cases there is no difference between the 
score and the mean, which is unlikely had the data been collected). This presents a 
serious problem when samples are small and a number of values are missing; 
smaller SEs may derive significant effects that are a result of imputation rather than 
a genuine effect (Field, 2005).  
 
A pre-specified sensitivity analysis should then be performed to identify the validity 
of the ITT assumptions, which may underestimate effectiveness (Moher et al, 2010). 
Specifically, effectiveness analyses should be repeated with participants that 
provide both baseline and follow up observations (i.e. complete case analysis). Per 
protocol analysis is not necessary (i.e. excluding participants that did not complete 
the intervention), because whether participants completed the writing sessions as 
intended was self-report, rather the effect of offering the intervention was of interest. 
Instead, intervention fidelity data should be presented. 
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Analysis of covariance (ANCOVA) should be employed assessing the between-
groups difference in depressive symptom severity at follow up, controlling for 
baseline depressive symptom severity (i.e. accidental bias; the chance variation 
between groups on this prognostic variable which if substantial enough may 
otherwise bias effects based on analysis of final end-point scores) (Vickers & 
Altman, 2001).51  Including covariates in analysis of variance (ANOVA) additionally 
reduces the within-group error variance in the dependent variable (i.e. the 
unexplained variance). This enhances the statistical power of the F test, which 
compares the variance explained by the between-group effect to the unexplained 
variance; the effect can be more reliably determined (Field, 2005). Inclusion of 
additional covariates is therefore also justified, provided that they are a) not 
influenced by the independent variable, b) not correlated with one another thus 
ensuring unique adjustments and avoiding computational difficulties due to 
multicollinearity, and c) related to the outcome and reliably measured (i.e. 
maximizing the adjustment/preventing under adjustment). Age and gender would 
meet these criteria in diabetes and depression (Larijani et al, 2004).52 
 
ANCOVA is superior to ANOVA based on change from baseline scores (Vickers & 
Altman, 2001). This is because, owing to regression to the mean, the latter does not 
actually control for chance variation between groups at baseline; baseline values 
are negatively correlated with change in that people with lower scores generally 
improve more than those with high scores (Vickers & Altman, 2001). In contrast, 
ANCOVA simply adjusts each score for the baseline value (i.e. the linear effects of 
                                                             
51 This has been employed in numerous WED studies with LTPC samples (Danoff-Burg et al, 2006; 
Gellaitry et al, 2010; Hamilton-West & Quine, 2007; Low et al, 2010; Walker et al, 1999; Willmott et al, 
under review). 
52 Given their anticipated association with the primary outcome, age and gender are potentially related 
to the baseline levels of this (i.e. another covariate). However, the potential benefit of including these 
covariates likely outweighs the potential for an absence of unique adjustment or multicollinearity 
issues. 
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the covariates are removed before the ANOVA is performed). ANOVA is preferable 
to multiple regression because it is fairly robust where data are not normally 
distributed and it is less sensitive to small samples sizes (Field, 2005).53 
 
A standardized estimate of the anticipated effect, and the associated 95% CIs, 
should also be derived to identify the magnitude and direction, and uncertainty, of 
the effect, consistent with the CONSORT guidelines for reporting parallel group 
RCTs (Moher et al, 2010).  The effect size estimate typically derived for ANCOVA is 
eta squared (η²); the proportion of the total variability in the dependent variable (i.e. 
the variance to be explained) that is accounted for (i.e. explained) by variation in the 
independent variable (Ellis, 2010; Levine & Hullett, 2002). It is calculated with the 
following formula (Field, 2005; Levine & Hullett, 2002): 
 
η² = SSm (between − groups effect)SSt  
 
SPSS (version 17) also provides partial eta squared (η୮
² ); the proportion of 
unexplained variance explained by the between-groups effect (i.e. ignoring the 
variance explained by other variables), which prevents underestimation of effects. It 
is calculated with the following formula (Levine & Hullett, 2002): 
 
η୮
² = SSm (between − groups effect)SSm (between −  groups effect) +  SSr 
 
However, η୮
²  artificially inflates effect size estimates compared to η², especially in 
complex ANOVA designs (Levine & Hullett, 2002). Moreover, η² is more easily 
                                                             
53 For regression 15 participants per variable are typically recommended, however many more are 
actually required to reliably gauge the effect estimate (R²) and achieve adequate statistical power 
when effects are small (Field, 2005).  
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interpreted; when there is one degree of freedom in the numerator (i.e. a focussed 
effect), the square root of η² is analogous to the Pearson’s correlation co-efficient r 
(described in chapter five) (Ellis, 2010; Levine & Hullett, 2002), and in η² all 
components of variation sum to 1 which represents 100% of the variance in the 
dependent variable. Therefore η² can be converted to a percentage of the total 
variance in the dependent variable. However, η² is also upwardly biased, especially 
where samples are small; it is inflated by sampling error or rather chance/random 
fluctuations in the data which do not reflect the population effect, known as 
shrinkage (Ellis, 2010).  
 
A corrected, unbiased estimate of η² is omega squared (ω²), which adjusts for the 
fact that the effect is an estimate of the population effect. Specifically,  ω² 
incorporates the error variance or rather the unsystematic variance explained by 
unsystematic factors/not explained by the model.  ω² for ANCOVA with a single 
between-groups contrast is calculated with the following formula (Olejnik & Algina, 
2000): 
 
ω² = SSm(between− groups effect) −  MSrSSt + MSr  
 
Therefore ω² is preferable as it is the most conservative estimate, which provides 
the best estimate of the population effect. Ideally though all three effect sizes should 
be estimated (Ellis, 2010). The adjusted estimated marginal means and SEs for 
each group should be inspected to identify whether there is a potentially clinically 
important difference on the primary outcome and thus gage the applied relevance of 
any effect. This has been addressed in a few WED trials with LTPC samples, albeit 
only in relation to physical health outcomes (Broderick et al, 2004; Hamilton-West & 
Quine, 2007; Harris et al, 2005; Smyth et al, 1999).   
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Secondary outcomes 
The same analytic strategy should be employed for secondary outcomes, including 
the same covariates to promote consistency. It is not necessary to control for the 
Type 1 error rate, for example by applying a Bonferroni correction (i.e. 
p<.05/number of tests) or conducting a multivariate analysis of covariance 
(MANCOVA), provided that the primary outcome is pre-specified and analyses for 
pre-specified and theoretically relevant secondary outcomes are interpreted as 
exploratory. In fact, the Bonferroni correction indicates whether there is less than 
5% chance that the groups differ by chance on all variables measured rather than 
on specific variables, which is of limited utility, it means interpretation of effects is 
dependent on the number of variables and it increases the risk of Type 2 errors 
(Ellis, 2010; Perneger, 1998). 
 
Exploratory analyses 
Exploring whether WED works differently for different people as 
anticipated: testing anticipated moderators and piloting moderator 
measures 
As described in chapters two and three it is important to investigate moderators of 
WEDs effects (i.e. variables that determine whether and to what extent WED is 
effective). If this is not investigated, it is not possible to use this information to 
optimise improvement in outcomes and effects may be missed (i.e. when effects for 
distinct sub-groups are essentially averaged). It is also apparent that interpersonal 
traits may be relevant, particularly alexithymia (i.e. an inability to process and 
describe emotions) and dispositional optimism (i.e. generalized expectancies for 
positive outcomes). However, the evidence base, particularly for optimism, is 
underdeveloped and requires replication in LTPCs.  
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Alexithymia should therefore be measured with the Toronto Alexithymia Scale 
(revised version) (TAS-20) (Bagby, Parker & Taylor, 1994). This has 20 items 
scored on a Likert scale, with three factor sub-scales; difficulty identifying feelings, 
difficulty describing feelings and externally oriented feelings. A total score can be 
derived with higher scores indicating greater alexithymia.  The TAS-20 has 
demonstrated internal and test-retest reliability in student and psychiatric samples 
(Bagby et al, 1994) and convergent, discriminant and concurrent validity (Bagby, 
Taylor & Parker, 1994). Dispositional optimism should be measured with the Life 
Orientation Test-Revised (LOT-R) (Scheier, Carver & Bridges, 1994). It has 10 
items scored on a Likert scale, four of which are fillers. A total score is derived for 
the six non-fillers, with higher scores indicating more optimism. The LOT-R has 
demonstrated good internal and test-retest reliability, and convergent and 
discriminant validity (Schieier et al, 1994). 
 
Exploring whether WED works as anticipated: testing anticipated 
explanatory processes and piloting explanatory measures 
As described in chapters two and three it is important to identify how WED 
influences health by investigating mechanisms of change (i.e. measures of 
intervention processes that may underlie benefits) and mediators (i.e. variables that 
may be changed by WED to produce benefits). If this is not investigated, it is not 
possible to use this information to optimise improvement in outcomes. 
 
Mechanisms of change 
Specification of mechanisms of change  
As described in chapter two, it seems that WED may improve health via E&CP of 
stressors; reflected in an increase in words reflecting cognitive processing and 
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positive emotion, and a decrease in words reflecting negative emotion, across 
writing sessions (i.e. cognitive processing and self-regulatory approaches). The 
evidence for this theory is, however, under-developed, inconsistent, ambiguous, and 
requires replication in LTPCs. Moreover, should an overall intervention effect and 
these changes be observed, their absence in controls should be confirmed and 
whether they explain WED effects should be established in formal mediation 
analyses (again discussed in chapter five). This has infrequently been explored to 
date. It is also apparent that WED may improve health via EA&H; specifically 
subjective EA to the initial WED session then a reduction in this across writing 
sessions (i.e. exposure and self-regulatory approaches). However, the evidence for 
this theory is underdeveloped and inconsistent specifically in LTPCs, thus it requires 
replication.  
 
Measurement of mechanisms of change  
E&CP should be measured via analysis of written texts with the LIWC 2007 
software (LIWC2007). This counts the number of words in a text that are included in 
pre-defined categories of word use within its internal dictionary, which comprises 
almost 4, 500 words/word stems. It derives the percentage of the total number of 
words that belong to each category of word use (i.e. deriving a percentage controls 
for the variable length of texts). Typically 80% of words in a text are identified by the 
dictionary. The positive emotion category includes words such as love, nice and 
sweet, the negative emotion category includes words such as hurt, ugly and nasty, 
the insight category includes words such as think, how and consider and the 
causation category includes words such as because, effect and hence 
(Pennebaker, Booth & Francis, 2007a; Pennebaker, Chung, Ireland, Gonzalez & 
Booth, 2007b).  
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LIWC analysis has consistently been employed in WED research for this purpose, 
from the original studies (Pennebaker & Francis, 1996; Pennebaker et al, 1997) to 
those including LTPC samples (Hamilton-West & Quine, 2007; Rivkin et al, 2006; 
Walker et al, 1999) (as reported in chapter two). The LIWC software has 
demonstrated internal reliability for the aforementioned categories of word use (i.e. 
an adequate item-total correlation between the percentage word use for a single 
word and the percentage word use for all other words in that category) (Pennebaker 
et al, 2007b; Tausczik & Pennebaker, 2010), construct validity with a similar profile 
of word use across emotional texts in LTPCs (Alpers, Winzelberg, Classen, 
Roberts, Dev, Koopman & Taylor, 2005), and concurrent (Alpers et al, 2005) and 
convergent validity (Bantum & Owen, 2009) in terms of good agreement with judges 
ratings of the degree of emotional expression in texts, with superior properties to 
alternative computerized coding methods (Bantum & Owen, 2009).   
 
EA&H should be measured with the negative affect sub-scale of the PANAS 
(Watson, Clark & Tellegen, 1988). This is a 20 item mood adjective checklist; 10 
reflect negative affect (i.e. aversive mood states) and 10 reflect positive affect (i.e. 
the extent to which a person feels enthusiastic, active and alert). The instructions 
can be changed such that people rate each adjective from 1 (very slightly or not at 
all) to 5 (extremely) depending on how they feel ‘right then’, in which format the 
scale is sensitive to mood fluctuations. The PANAS has demonstrated adequate 
internal and test-retest reliability for both sub-scales in student and psychiatric 
samples, and convergent and discriminant validity (Watson et al, 1988). It is often 
employed for measuring the short-term influence of WED on immediate negative 
mood and even EA&H in LTPC samples (D’Souza et al, 2008; Gillis et al, 2006; 
Norman et al, 2004). 
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Mediators 
Specification of mediators  
As described in chapter two, it seems that WED may deliver benefits by 
improvement in perceived social support, specifically emotional support, and 
perceived control over experiences, including self-efficacy for managing LTPCs. It is 
also reasonable to speculate that resolution of stressors in WED may reduce the 
extent to which diabetes is perceived to intrude on life (i.e. illness interference), 
which is different to health-related QoL as it refers to the stressors resulting from 
LTPCs (i.e. the disruption they cause to meaningful activities) rather than the impact 
of this upon perceived health status (i.e. functional health and well-being (Devins, 
2010).    
 
Indeed, cross-sectional evidence in diabetes suggests that depressive symptoms 
are associated with lower self-efficacy for diabetes SMBs (Sacco, Wells, Vaughan, 
Friedman, Perez & Matthew, 2005; Sacco, Wells, Friedman, Matthew, Perez & 
Vaughan, 2007), lower perceived emotional support yet not diabetes-related social 
support (i.e. assistance specifically with diabetes needs) (Cheng & Boey, 2000; 
Connell, Davis, Gallant Sharpe, 1994) and more perceived interference of diabetes 
with life (Bailey, 1996; Brooks & Roxburg, 1999; Cheng & Boey, 2000; Paschalides, 
Wearden, Dunkerley, Bundy, Davies & Dickens, 2004). In fact, structural equation 
modelling in such studies has demonstrated that stress is associated with 
depressive symptoms via greater perceived illness interference, albeit causality 
cannot be inferred here (Talbot, Nouwen, Gingras, Bélanger & Audet, 1999). 
Interventions to improve self-efficacy (Sturt et al, 2008) and social support (Huang, 
Song & Li, 2001) have additionally improved psychological health including 
depression.  
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However, these mediating processes have yet to be properly tested, namely should 
an overall intervention effect be observed in formal meditation analyses, with 
variables measured such that causality can be inferred; variables should be 
measured such that they demonstrate WED produces a change the mediator which 
is then related to health (again formal mediation analysis is discussed in chapter 
five). 
 
Mediator measures 
Self-efficacy for diabetes SMBs could be measured with the UK version of the 
Diabetes Management Self-efficacy Scale (DMSES UK) (Sturt, Hearneshaw & 
Wakelin, 2010). This assesses efficacy expectations for performing SMBs known to 
influence blood glucose. It has 15 items scored on a Likert scale. A total score is 
derived, with higher scores indicating greater self-efficacy. The DMSES UK has 
demonstrated internal and test-retest reliability, criterion-related and construct 
validity (Sturt et al, 2010), and sensitivity to change resulting from a diabetes self-
management intervention in Type 2 diabetes (Sturt et al, 2008). 
 
Perceived emotional support should be measured with the six item version of the 
Social Support Questionnaire (SSQ6) (Sarason, Sarason, Shearin & Pierce, 1987). 
Each item has two parts; the number of available others in different situations and 
then the degree of satisfaction with support available in each situation, each scored 
on a Likert scale. Total scores are derived for the two sub-scales, higher scores 
indicating more perceived support. The SSQ6 is briefer than the original measure 
yet has demonstrated a strong association with it, and each sub-scale indicates 
equivocal psychometric properties; it has demonstrated internal and test-retest 
reliability and construct validity in a student sample (Sarason et al, 1987). This is the 
measure of social support recommended by the EDID. 
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Perceived illness-interference should be measured with the Illness Intrusiveness 
Rating Scale (IIRS) (Lorig, Sobel, Ritter, Laurent & Hobbs, 2001). This assesses the 
extent to which people feel their LTPC and or its treatment interferes with 
meaningful activity (i.e. lifestyle, activities and interests). It has 13 items scored on a 
Likert scale, with five sub-scales; physical well-being and diet, work and finances, 
marital, family and sexual relations, recreation and social relations, and other 
aspects of life. A total score can be derived, higher scores indicating more 
interference. The IIRS has demonstrated internal consistency in Type 2 diabetes, 
and test-retest reliability, construct, discriminant and criterion-related validity, and 
sensitivity to change resulting from interventions designed to impact QoL in LTPCs 
(Devins, 2010).  
 
Prior economic evaluation  
As described in chapter three, the cost-effectiveness of WED in LTPCs, and indeed 
any sample, has yet to be investigated. Should effectiveness be demonstrated, a 
prior cost-effectiveness analysis should be undertaken. 
 
Piloting the data collection schedule 
Measurement of mediator variables post-intervention but preceding the outcome 
assessment is again required to establish mediation. Mediators should therefore be 
measured at two weeks post-intervention because, as described in chapter three, 
the evidence suggests WED effects can emerge around this time. Follow up should 
then be three months post-intervention, which is consistent with the original WED 
study (Pennebaker & Beall, 1986), the wider evidence base (Frattaroli, 2006), a 
substantial proportion of the trials included in the systematic review (see chapter 
three) and other WED trials in LTPCs indicating improvement at around this interval 
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which is not maintained longer-term (Broderick et al, 2005; Sloan, Feinstein & Marx, 
2009).  
 
Feasibility investigation 
Piloting intervention and trial parameters 
The appropriate intervention and trial parameters specified throughout this chapter 
should be piloted. 
 
Investigating the feasibility/effectiveness of intervention delivery 
This data is important when WED is not implemented in the laboratory and thus 
experimental control is attenuated. Compliance with the writing instructions should 
be obtained, and as patients continuing writing following completion of WED has 
been noted previously (Baikie & Wilheim, 2005) this should additionally be 
identified.  Intervention fidelity, or rather contamination data (i.e. whether ED and EA 
are observed in the WED group only), should also be obtained, using the LIWC and 
PANAS data already collected. As described in chapter three, other WED studies 
with LTPC samples have sought intervention fidelity via measures of post-writing 
EA, including the PANAS-X, and or LIWC analysis of the four aforementioned 
categories of word use (D’Souza et al, 2008; Willmott et al, under review). The latter 
is recommended practice. The acceptability of the intervention and comparison 
exposure should also be explored (i.e. reasons for not writing as instructed and for 
not writing at all). 
 
Investigating the feasibility/effectiveness of the trial protocol 
In addition to identifying the feasibility/effectiveness of the randomisation and 
allocation concealment methods, checking blinding success and reporting on the 
feasibility/appropriateness of the sample size calculation (as described earlier), 
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estimates of and issues associated with recruitment and retention should be 
obtained. 
 
Qualitative data collection 
Consistent with the objectives of a phase two exploratory trial, to investigate the 
feasibility of and barriers and opportunities for recruitment interviews should be 
conducted with primary care providers whose recruitment falls outside one SD of 
the norm. The feasibility of implementing the intervention and the acceptability of 
both the intervention and control condition should additionally be examined by 
conducting interviews with participants. This was therefore an original objective of 
the thesis. However an upgrading panel, which reviewed the thesis at an early 
stage, advised that this be removed owing to the volume of work proposed and the 
time constraints of the study. 
 
Patient safety issues and changes necessitated by ethical review 
An initial application to an NHS Research Ethics Committee (REC) for the 
exploratory RCT based on the aforementioned methodology with recruitment in 
primary care was rejected (September 2008), and major revisions to the study 
protocol were required and resubmitted (December 2008). The ethical rejection and 
approval letters are presented in the appendix. Patient safety issues, the issues 
raised by the REC in relation to these and the changes necessitated are presented 
below.  
 
REC concern 1: Exclusion of at risk participants 
Original application:  
As described in earlier chapters and above, the evidence suggests, and widespread 
clinical opinion is, that it is not appropriate to use WED unsupervised with patients 
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with more severe psychological problems. People experiencing significant 
symptoms of depression and at risk of self-harm may experience re-traumatisation 
as a result of engaging in WED. Exclusion of individuals for whom WED is 
unsuitable is therefore important, for example individuals with a psychiatric disorder, 
those who are acutely ill and those already receiving treatment for depression or 
any other psychological therapy. These exclusion criteria were presumed to be 
sufficient to exclude patients at risk of re-traumatisation. However, the REC felt that 
the screening process was not sufficiently robust to ensure exclusion of such 
patients (i.e. some instances of significant depression may not have already been 
identified and treated). 
 
Revised application: 
It was therefore acknowledged that additional inclusion criteria should be enforced 
such that patients are excluded if they are at risk of self-harm/suicide, or had any 
other psychological vulnerabilities. The need to implement an eligibility check was 
also acknowledged (i.e. to ensure that patients indicating significant depressive 
symptoms and thus at risk of re−traumatisation were excluded). Specifically, 
participants should complete a DSQ prior to enrolment with those scoring above a 
threshold for significant symptoms being excluded. A score of ≥16 on the CES-D 
has good sensitivity, 99%, for detecting MDD (Weismann et al, 1977). Specifically in 
Type 2 diabetes it provides adequate indication of significant depressive symptoms 
(i.e. sensitivity) (Fisher et al, 2007; Stahl, Sum, Lum, Liow, Chan, Verma, Chua & 
Chong, 2008) and has preferable predictive efficacy to many other self-report 
symptom measures (McHale et al, 2008). Similar measures have been taken in 
other WED trials including patients with elevated but not significant depressive 
symptoms (Gortner et al, 2006; Stice et al, 2006). Patients scoring as experiencing 
significant symptoms must then be referred to an appropriate HCP.  This should be 
arranged with GPs when practices are recruited to the study. 
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REC concern 2: Potential negative emotional response to writing, or 
screening, and clinical support in the event of contact with patients 
experiencing concerns/soliciting emotional support 
Original application:  
Patients may develop concerns as a result of completing WED. As described in 
chapter two, an immediate yet mild and transient increase in negative affect is usual 
and necessary to produce health benefits that outweigh this. It was therefore initially 
intended that participants would be warned about this, advised to stop writing if they 
were worried about how they felt and provided with contact details of potentially 
helpful organisations. This is consistent with implementation of the original 
paradigm, WED trials with mildly depressed samples (Stice et al, 2006) and other ‘at 
risk’ samples (i.e. students screened for suicidality) (Kovac & Range, 2002), and 
opinion in the field (Baikie & Wilheim, 2005). It was also intended that participants 
would have the research teams contact details for further information about the 
study. However, the REC was concerned because the research team did not 
possess the skill to evaluate participants at potential risk; there was no clinical 
support in place should participants experience problems/contact the research team 
soliciting emotional support.  
 
Revised application 
It was therefore acknowledged that participants should additionally be encouraged 
to contact their GP should they experience any concerns as a result of writing, or 
indeed should the depression-screen (i.e. introduced post-ethical review) raise 
concerns or should they wish to discuss their DSQ score. This should again be 
arranged with GPs when practices are recruited to the study. Furthermore, 
participants should be encouraged to contact their GP rather than the research 
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team about anything other than information about the trial. However, should 
participants contact the research team about any other issues, a procedure must be 
in place for obtaining immediate clinical support from an appropriate professional.   
Such emergency response plans are consistent with WED trials with mildly 
depressed samples (Stice et al, 2006). 
 
REC concern 3: Procedure for disclosures requiring action and 
disclosure of limits to confidentiality 
Original application 
It is possible that participants may disclose in writing information which suggests a 
risk to themselves or others, and requires action. It was therefore initially intended 
that should disclosures requiring action be evidenced in writing, for example relating 
to self-harm, the researcher would make a subjective judgement upon reading 
essays about whether to refer them to the study supervisors and then a patient 
safety group including appropriate professionals. Moreover, there were no plans for 
participants to be advised about this potential breach of confidentiality prior to 
providing consent. The REC was again concerned that the research team did not 
possess the skill to evaluate participants at potential risk, and that there was a lack 
of understanding of the limits to confidentiality where participants and/or others may 
be at serious risk of harm. 
 
Revised application 
It was therefore acknowledged that a procedure, which entails immediate 
consultation with appropriate professionals, should be implemented should 
disclosures requiring action arise. This is consistent with implementation of the 
original paradigm and WED studies with ‘at risk’ samples (Kovac & Range, 2002). It 
was also intended that participants would be advised prior to consent that if they 
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disclosed information of a certain nature in their writing, for example indicating a 
serious risk to themselves or others, this could be disclosed to an appropriate party. 
 
REC concern 4: Issues surrounding previously undisclosed trauma 
Original application: 
Again, it was initially intended that participants would receive the original WED 
instructions advocated by Pennebaker and Beall (1986), which entail writing about 
the most traumatic experience in life. However, the REC was concerned about the 
research team’s lack of understanding of the issues surrounding previously 
undisclosed trauma; they felt that these instructions may unearth serious, previously 
undisclosed trauma such as childhood abuse, which is not appropriate outside the 
clinical setting.  
 
Revised application: 
It was therefore acknowledged that it is more appropriate for participants to write 
about only current or very recent stressors, which is less likely to evoke serious, 
previously undisclosed trauma. In retrospect, the original WED studies typically 
involved participants writing in the laboratory and the researcher, usually 
Pennebaker himself, discussing the study with participants (i.e. any problems and 
psychotherapy options available).  Moreover, as described in chapter two, some 
individuals in samples not necessarily defined by distress have experienced a 
negative response to WED when traumatic events are disclosed.   Indeed, more 
recent studies advocate the importance of providing adequate care when people 
disclose about the most stressful experiences of their lives, which cannot easily be 
achieved when implementation of WED is by post or email and there is a loss of 
interaction with the experimenter (Sheese et al, 2004). It is noteworthy that 
implementing the original instructions but improving the adequacy of support was 
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not feasible in view if the limited availability of relevant clinical expertise for the 
present study. It is also apparent that writing about past trauma many not be 
important (Smyth & Pennebaker, 2008) and in fact some assert that greater benefits 
have been observed when current stress is disclosed, at least for samples not 
defined by trauma history (Frattaroli, 2006; Pennebaker, 1997; Sloan & Marx, 
2004a; Smyth, 1998). Indeed, other WED trials with LTPC (Hamilton-West & Quine, 
2007; Lee, 2002) and mildly depressed (Gortner et al, 2006; Stice et al, 2006; Lu & 
Stanton, 2010) samples have employed similar instructions reporting some benefits 
and no adverse effects.  
 
Consultation 
User 
The Warwick Diabetes Research and Education User Group (WDREUG) is a group 
of lay people with an active interest in diabetes research (i.e. individuals with 
diabetes or their carers). The group was involved in the development of the study 
and suggested additional E&P support is wanted and needed by people with 
diabetes. They reviewed the acceptability of and provided recommendations for all 
study materials, which included completion of the study questionnaires so that 
participants could be informed about the anticipated burden prior to providing 
consent. They also considered ethical issues associated with the trial design, for 
example they indicated withholding information about the exact nature of the study 
(described earlier) would not concern participants. 
 
Expert 
Research nurses based at Warwick Medical School (WMS) advised on the 
identification of potential primary care practices, the feasibility of the recruitment 
strategy in primary care, appropriate exclusion criteria and study materials.   Local 
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GPs advised about potential practices and the clinical parameters of the sample 
size calculation. Indeed, research into the incentives and disincentives for GPs to 
participate in primary care research has indicated that input from practitioners at the 
design stage is crucial to maximising recruitment later on (Graham, Spano, Stewart, 
Staton, Meers & Pace, 2007). A local GP and an associate clinical professor and 
honorary consultant physician in diabetes was consulted about the recruitment 
strategy for secondary care, and again the clinical parameters of the sample size 
calculation. The WMS Clinical Trials Unit (CTU) was consulted to identify primary 
care practices that had previously participated in diabetes trials, and about trial 
procedures and the appearance of study materials. An honorary consultant 
psychiatrist and a GP and expert in clinical ethics at WMS were consulted about the 
eligibility check, the appropriateness of the intervention instructions, the process of 
screening essays for disclosure requiring action and the other patient safety 
issues/measures. The analytic strategy and again the sample size calculation were 
informed by consultation with a professor of medical statistics and statistician at 
WMS, and the director of the University of Warwick Risk Initiative and Statistical 
Consultancy Unit.  Finally, the study website for recruitment via online support 
groups (discussed in chapter five) was developed in consultation with the e-learning 
advisor for WMS. 
 
Conclusions 
An exploratory RCT of WED for improving depressive symptom severity and 
associated outcomes for adults with Type 2 diabetes was timely and warranted, and 
should follow the methodology outlined above.  
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Chapter 5 Methods for the exploratory RCT evaluating WED for 
improving depressive symptom severity in adults with Type 2 diabetes 
 
Chapter overview 
This chapter describes the operationalisation of the methodology presented in 
chapter four, outlining the objectives and methods for the exploratory RCT of WED 
for improving depressive symptom severity, and associated outcomes, for adults 
with Type 2 diabetes. 
 
Objectives 
Preliminary effectiveness analysis 
1. Does WED produce the anticipated effect? 
Identifying and estimating the anticipated effect of WED on the primary outcome 
depressive symptom severity, and a range of secondary psychological and 
behavioural outcomes in adults with Type 2 diabetes.  
 
Exploratory analyses 
2. WED work differently for different people as anticipated and who does it 
work best for? 
Test whether anticipated interpersonal traits moderate whether and to what 
extent WED is effective. 
 
3. Does WED work as anticipated? 
Improve understanding of how WED influences health by testing anticipated 
mechanisms of change and mediators (i.e. explanatory processes). 
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4. Prior economic evaluation 
 Undertake a prior cost-effectiveness evaluation.  
 
Feasibility investigation 
5. Pilot appropriate trial and intervention parameters 
 
6. Feasibility/effectiveness of intervention delivery 
Collect information about compliance, contamination and the acceptability of the 
intervention and comparison exposure. 
 
7. Feasibility/effectiveness of the trial protocol  
Estimate recruitment and retention, identify associated issues, report on the 
feasibility of achieving sample size requirement and the appropriateness of the 
sample size calculation parameters, identify the feasibility/effectiveness of the 
randomisation and allocation concealment methods and check the success of 
blinding. 
 
Design 
The study design was an exploratory parallel group RCT (ISRCTN 18442976). 
 
Participants 
Recruited were adults with Type 2 diabetes aged ≥18 years diagnosed for at least 
six months. 
 
Exclusion criteria included:  
 Ever received a diagnosis of psychotic or bipolar disorder. 
191 
 
 Receiving any treatment for depression or psychological therapy for any 
reason. 
 Any history of self harm, suicidal ideation or suicide attempts. 
 A HCP (e.g. GP) assessment as unsuitable (e.g. receiving end of life care, 
acutely ill, or any past or present psychological vulnerabilities).  
 
Recruitment approaches  
As explained in chapter four, participants were recruited from primary and 
secondary care, and support groups. The recruitment strategy was necessarily 
adapted to each setting. 
 
Recruitment strategy 
Primary care 
Practices 
A comprehensive list of practices was obtained from Research and Development 
(R&D) leads for Coventry, Warwickshire and Worcestershire PCTs. Those with a 
relevant specialist interest were identified by means of searching a practice website 
or if this was unavailable information on the NHS website and then contacted. The 
specialist interests identified are listed in Table 8. 
 
Further practices in these PCTs were identified by: 
 Obtaining information about practices that had previously participated in 
diabetes trials at WMS.54 
 Consultation with a local GP with a specialist interest in diabetes. 
 Consultation with a research nurse at WMS about practices recently 
accepting money to consider research.   
                                                             
54 Practices that had previously participated in diabetes trials at WMS were thanked. 
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Table 8 Relevant specialist interests for primary care practices 
 
 
 
 
 
 
 
 
 
 
 
Practice managers (PMs) were sent a letter and practice information sheet (PrIS) 
explaining the study background, required involvement and potential benefit to 
them, which was followed up with telephone calls (or emails where there was no 
response to calls) until a definite answer was obtained.55 Direct contact with GPs 
and practice visits were requested and arranged wherever possible. 
 
The Data Protection Act (1998) has made it difficult to limit the imposition of 
research on practices. Within current guidelines only members of the clinical care 
team may search electronic records in primary care to identify potentially eligible 
patients and the list of potentially eligible patients should only be seen by those with 
a legitimate right to see these patient details. Consequently, practice involvement 
was limited to minimal work that the researcher was unable to do themselves in an 
attempt to maximise recruitment, and this was emphasised in the information 
practices received about the study. Specifically, researchers prepared as much of 
the study materials as was possible without seeing identifiable patient data for 
                                                             
55 Where practices advised they had not received the information it was re-sent and followed up again. 
 
 Diabetes (i.e. a diabetes clinic, support and education offered to patients 
with diabetes, or staff (i.e. diabetes specialist nurses (DSNs) or GPs) with 
an additional interest or training in diabetes). 
 
 Mental health (i.e. a counselling clinic, a mental health care professional in 
post, a professed holistic practice, or staff (i.e. DSNs or GPs) with 
additional interest or training in mental health). 
 
 Clinical trials. 
 
 Research (i.e. including diabetes studies). 
 
 Patient initiative programmes (i.e. Expert Patient Programme). 
 
 Practices with GPs in post that lecture and or hold honorary posts at WMS. 
 
193 
 
practices to then mail out.56 This is consistent with recent UK guidelines to assist 
recruitment in primary care (NIHR & PCRN, 2010). Indeed research into the 
incentives and disincentives for GPs to participate in primary care research has 
consistently indicated that demonstrating studies to be feasible to implement in 
practices is important to maximise recruitment (Graham et al, 2007). 
 
Patients 
Practice staff screened diabetes registers (i.e. computerised search) and compiled a 
list of potentially eligible patients, which was checked by a clinician (i.e. typically a 
GP) and any unsuitable patients were removed. Staff then mailed pre-prepared 
invitation packs to the remaining patients. It was anticipated patients would be 
recruited over a six month period. 
 
Secondary care57 
Clinics 
Consultants with a specialist interest in diabetes and an affiliation with WMS based 
at teaching hospitals in Coventry and Warwick were approached with a letter and 
clinic information sheet, as in primary care, and a meeting was arranged to discuss 
the study.  
 
Patients 
Health care assistants (HCAs) identified people with Type 2 diabetes from clinic 
notes. The researcher then approached them in a waiting room prior to their 
consultation offering more information about the study. Eligibility was checked 
against five questions for those agreeing to this: 
                                                             
56 The cost of consumables (i.e. producing materials and postage) were covered by the university; 
practices and clinics provided a template for materials to be sent by them to be produced on headed 
paper. Practices were asked only to print labels with patients’ details for invitation and consent packs. 
57 Ethical approval to recruit via secondary care was obtained from the NHS REC that approved the 
protocol for primary care (i.e. a substantial amendment was submitted). 
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 Do you have Type 2 diabetes? (yes required) 
 Have you been diagnosed more than six months? (yes required) 
 Are you at least 18 years old? (yes required) 
 Have you ever been asked to see a member of a mental health team? (no 
required) 
 Are you currently taking antidepressants? (no required) 
 
Consultation with a local GP confirmed these questions would satisfy the study 
exclusion criteria. Patients satisfying all of the questions were provided with an 
invitation pack. It was anticipated clinics would be attended daily for one month 
initially in order to gage the feasibility of recruitment, with more time invested should 
this be deemed effective. 
 
Online support groups58 
Groups 
Online diabetes forums were identified via the DUK website and a Google search. 
Site moderators for each were contacted for permission to post information about 
the study.  
 
Participants 
The study was posted with a link to a study website59, which included summary 
information and direction to an icon for the full information (i.e. the patient/participant 
information sheet, PaIS), for approximately one month. The study website was set 
to close one month from the date that the last forum was posted on. The study 
website was developed using site builder and piloted before going live. The pages 
comprising the webpage are presented in the appendix. Interested members 
                                                             
58 Ethical approval to recruit via support groups was obtained from the University of Warwick Human 
and Social Sciences Research Ethics Committee (HSSREC). 
59 http://www2.warwick.ac.uk/fac/med/staff/dennick/ 
195 
 
submitted a form confirming that they met the five eligibility questions described 
earlier, and provided an email address. Responses were checked daily and eligible 
individuals were emailed an invitation pack. 
 
Local support groups (Identified via DUK) 
Permission was sought to present the study at a local support group via DUK. Any 
interested members were to be asked the five eligibility questions, and eligible 
patients would have been provided with an invitation pack. However, permission 
was not obtained (see chapter six). 
 
Eligibility check60 
Primary care 
Invitation packs included a letter, PaIS, expression of interest form (EOIF) and the 
DSQ. Interested patients returned the EOIF and DSQ in business reply envelopes 
to the university, which were then forwarded, unopened, to the appropriate practice 
(i.e. noted on the envelope). Returned DSQs were screened by the researcher at 
two-day intervals, which was appropriate as no items asked about self-harm.61 This 
was anonymous because practice staff had assigned personal identification 
numbers (PINs) to potentially eligible patients, and this was the only identifying 
information on the DSQ; the PIN assignments and EOIFs were never seen by the 
researcher. Thus, no identifiable patient data was seen by the research team prior 
to obtaining consent.   
 
Practice staff mailed consent packs (i.e. two consent forms; one collecting contact 
details for return to the research team and one to be retained by patients, and a 
                                                             
60 In secondary care and the support groups, exclusion criteria was confirmed by self-report, and for 
support groups the HCP assessment exclusion criteria could additionally not be enforced, thus it was 
even more important that the eligibility check was in place. 
61 For any patients returning only an EOIF or a partially completed DSQ that could not be scored, 
practices re-sent the DSQ with a letter requesting that it be completed properly. 
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baseline questionnaire) to eligible patients (CES-D <16) for return to the 
researcher.62 For ineligible patients (CES-D ≥16) staff passed their DSQ to a GP to 
be dealt with by them, for which their agreement was obtained at recruitment.63 
Patients were not referred to GPs as cases as the CES-D only identifies potentially 
significant symptoms and is not a diagnostic tool. Instead they were informed that 
the patient may be experiencing potentially significant symptoms. All CES-D scores 
and their corresponding PINs were recorded by the researcher. 
 
Secondary care 
The invitation pack contained a letter, PaIS, the DSQ and the two consent forms 
described above. Interested patients were to return the relevant consent form and 
DSQ to the researcher. Eligible patients (CES-D <16) were to be sent a baseline 
questionnaire, once an HCP assessment as suitable was obtained. Ineligible 
patients (CES-D ≥16) were to be dealt with accordingly by their GP (i.e. contacted 
by the research team). However, no patients returned an invitation pack (see 
chapter six). 
 
Support groups 
The invitation pack included the DSQ and two consent forms. Interested patients 
returned the relevant consent form and DSQ to the researcher. Eligible patients 
(CES-D <16) were sent a baseline questionnaire, and ineligible patients (CES-D 
≥16) received a standard letter advising that they were unable to participate and to 
contact their HCP. Contact could not be made by the researcher as recruitment via 
support groups did not entail interfacing with HCPs. In an attempt to prevent 
causing undue distress, people were not informed that they were cases as again the 
                                                             
62 In instances where patients returned a consent form with no address, practices were asked to send 
subsequent materials and reminders with a request for the address until this was obtained. 
63 This afforded patients more opportunity to discuss any problems with their GP than advising them to 
contact their GP themselves. 
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CES-D is not a diagnostic tool. Instead they were informed that they were unable to 
participate as the study was only suitable for some people thus they may not 
benefit, and that everyone unable to participate was being advised to contact their 
HCP, as there was a possibility that they may not be coping as well as they could 
be.  
 
Trial procedure/enrolment 
Figures 15 to 17 illustrate the trial design in primary and secondary care and 
support groups respectively. Consented participants were randomized to either the 
intervention or control group, and received the appropriate writing pack for 
completion after the baseline questionnaire.64 At this point, primary care practices 
were contacted for enrolled patients PINs so that their DSQ could be identified and 
used as baseline depressive symptom severity data (i.e. DSQs for eligible patients 
were retained by the researcher for this purpose).  
 
With participants consent obtained in the consent form, GPs received a letter 
advising them of primary care patients’ enrolment into the trial (plus a copy of the 
returned consent form). Again, as the researcher did not interface with HCPs, 
support group participants were advised to notify their HCP of their enrolment into 
the trial.  
 
 
  
                                                             
64 Writing packs were sent out as quickly as possible after the receipt of consent and or baseline to 
ensure that this was provided to patients while they were still enthusiastic and able to take part, which 
was considered to be particularly important given the demands of the task. 
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Figure 15 Trial design in primary care 
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Figure 16 Trial design in secondary care 
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Figure 17 Trial design in support groups 
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Intervention and comparison exposure 
The intervention group wrote their thoughts and feelings about any stressful 
experience encountered over the last month, or any worries or concerns that were 
currently troubling them.   The control group wrote a fact-based description of the 
previous days’ activities, without discussing thoughts or feelings.  Both groups wrote 
at home for 20 minutes on three days over the course of one week. Patients self-
selected the disclosure topic, wrote in private, were allowed to switch topics across 
sessions, imposed their own structure (i.e. with minimal examples provided, e.g. 
suggestions to link the topic to relationships with others) and wrote continuously 
with repetition if necessary and no regard for spelling or grammar. The WED group 
wrote by hand, whereas online support group participants received WED by email 
and thus typed their essays, albeit they were offered the opportunity to receive 
hardcopies. Usual care and treatment seeking was not restricted in any way. 
 
Randomisation and allocation concealment 
Randomisation was at the individual rather than practice level as the feasibility of 
recruiting a sufficient number of practices was not known. The allocation ratio was 
1:1 and randomisation was blocked to protect against unbalanced group sizes, 
which is likely with unrestricted randomisation in small RCTs and reduces statistical 
power and complicates the use of ANOVA. Random block sizes of four, six and 
eight were employed to protect against selection bias (i.e. the possibility that the 
researcher could predict some of the next treatment assignments should they infer 
the block size). Randomisation was stratified by recruitment approach to ensure that 
the groups were balanced on recruitment approach. The project supervisor (CB) 
generated a list of random numbers via Clinstat, which the researcher never saw. 
To achieve allocation concealment in primary care the list was used to allocate 
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sealed, opaque, serially numbered writing packs. The researcher mailed the next 
pack in the sequence each time a participant was enrolled. As online support group 
participants received writing packs electronically, the project supervisor was 
contacted for the next allocation in the sequence each time a participant was 
enrolled. The order of participant enrolment, and thus the consistency with the 
allocation sequence, was assured by the date and time of receipt of the email to 
which the returned consent form and DSQ was attached. 
 
Blinding 
The study was double blind. The control group received a neutral writing task 
(identical to the WED groups except for the writing foci) and participants were 
informed that the study was looking at ways of improving the health of people with 
Type 2 diabetes and whether and how writing about different aspects of life might 
affect their health. This was consistent with a study that was included in the 
systematic review and was the only one assessed as having a low risk of bias 
overall (Gillis et al, 2006). They were also informed that a treatment comparison 
was being drawn. Participants also self-administered the intervention and self-report 
baseline and follow up measures at home, receiving and returning these by 
post/email. In primary care, HCPs were informed about the nature of the study but 
not participating patients’ group allocation. Significant contact with patients after 
receipt of the information pack was not anticipated. Nonetheless, staff were 
instructed to encourage any patients requesting information about the study to 
contact the researcher. 
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Variables 
Preliminary effectiveness analysis 
Primary outcome 
The primary outcome was depressive symptom severity measured with the CES-D. 
 
Secondary outcomes 
DSED was measured with the PAID scale, health-related QoL was measured with 
the EQ-5D and diabetes SMBs was measured with the SDSCA.  
 
Exploratory analyses 
Moderators  
Alexithymia was measured with the TAS-20 and dispositional optimism was 
measured with the LOT-R.  
 
Explanatory processes 
Mechanism of change  
EA&H was measured as change in post-writing negative affect across writing 
sessions via the PANAS negative affect sub-scale, completed after each writing 
session. E&CP was measured as change in percentage word use reflecting positive 
emotion, negative emotion, insight and cause across writing sessions, obtained via 
LIWC software. Texts for each writing session for each participant were transcribed 
in accordance with the instructions for preparing essays for LIWC analysis, for 
example Microsoft Word’s Spellchecker was used to correct misspellings, important 
abbreviations were spelt out and inappropriate word use was corrected (i.e. ‘gotta 
was change to ‘got to’). Words that could not be identified were transcribed as a 
non-sense word (i.e. xxxx), which the LIWC recognises yet does not assign to a 
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category. Texts were saved as text files, processed by the LIWC software and the 
data were exported to SPSS (version 17).  
 
Mediators 
Self-efficacy for diabetes SMBs was measured with the DMSES UK, perceived 
emotional support was measured with the SSQ6 and perceived interference of 
illness was measured with the IIRS.  
 
Feasibility investigation 
Feasibility/effectiveness of intervention delivery 
Compliance data 
The number of days writing completed and the time spent writing per session were 
obtained within writing packs. Whether participants undertook further self-directed 
writing was collected in the three month follow up questionnaire.   
 
Contamination data  
To check the presence of ED and EA in the WED group only, groups were 
compared on the average degree of ED (i.e. LIWC data; average percentage word 
use for each of the four aforementioned categories) and EA (i.e. PANAS data; 
average post-writing negative affect) across sessions.  
 
Acceptability 
Reasons for not writing at all or following the protocol as instructed were noted with 
respect to the acceptability of the intervention and comparison exposure. 
 
Feasibility/effectiveness of the trial protocol 
Randomisation and allocation concealment methods 
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The feasibility/effectiveness of the randomisation and allocation concealment 
methods was noted. 
 
Blinding success 
Blinding success was checked with three questions at debriefing, namely whether 
patients inferred the true nature of the study and their group assignment: 
 Were you aware that there were two different groups? 
 Having read this debriefing sheet had you guessed what the other group was 
writing about?             
 Having read this debriefing sheet and now knowing what group you were in, 
had you already guessed the purpose of your writing task? 
 
Recruitment, retention and sample size 
Recruitment flow and recruitment/retention issues were noted, and an à priori 
sample size calculation was specified (described below) with the feasibility of 
achieving sample size requirement and the appropriateness of the sample size 
calculation parameters also noted. 
 
Data collection schedule 
Data were collected at baseline, during the intervention, post-intervention (i.e. two 
weeks), three months and debriefing. Table 9 depicts the schedule.65  
 
It should be noted that mediators were additionally measured at three months for 
primary care patients. This is because they were the first sample recruited and 
initially a six month follow up was intended for which mediators at three months 
were to be measured. However a decision was made not to implement this 
                                                             
65 Postal/email delivery facilitated recruitment across a greater distance and reached participants that 
are physically restricted and requiring support. Pre-paid envelopes were provided for return of 
materials by post. 
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additional follow up (i.e. it was removed owing to the delays imposed by the ethical 
review (described in chapter four) and the recruitment difficulties experienced 
(reported in chapter six)66, yet collection of the three month mediator data had 
already been initiated for these participants. 
 
Table 9 Data collection schedule  
 
 
 
 
  
                                                             
66 It was initially intended that HCU would be included as an outcome as this is adversely impacted by 
high- and low-level depression in diabetes thus improving depression, even at lower levels, may 
produce improvement in this outcome (see chapter one). Additionally, the WED evidence base 
suggests that HCU may be improved by WED at least for healthy patients (as reported in chapter two). 
However, this was intended to be measured at six months as the Stanford Patient Education Research 
Centre Diabetes Health Care Utilisation measure employed asks about HCU during the previous six 
months. This outcome was therefore lost when the six month follow up was removed. 
 
Time 1 (Baseline):  
 Demographic (i.e. age, gender, ethnicity, education & relationship status) (& 
nationality/country of residence for online support group participants should non-
UK participants be recruited). 
 Clinical (i.e. time since diagnosis, diabetes complications, diabetes medication & 
HCU. BMI (i.e. height and weight) and HbA1c were collected from routine medical 
records for primary care patients and were self-report for support group 
participants. 
 Moderator and mediator measures. 
 Baseline assessment of outcome variables. 
 
Time 2 (During intervention): Written essays, mechanisms of change measures 
and compliance, contamination and acceptability data. 
 
Time 3 (2 weeks): Mediator measures.  
 
Time 4 (3 months): Outcome measures and compliance data (& mediator 
measures for primary care patients).  
 
Debriefing: Check of blinding success. 
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The practice letter, PrIS, patient letter, PaIS, EOIF, DSQ, consent forms and 
debriefing sheet administered in primary care are provided in the appendix. The 
materials administered specifically in secondary care and support groups were 
essentially the same with only minor changes where necessary and are therefore 
not presented. The writing packs and baseline/follow up questionnaires are also 
provided in the appendix, albeit it is noteworthy that these are the hardcopies rather 
than the electronic versions administered to support group participants. Materials 
administered electronically merely had a slightly different response format to the 
hardcopies, for example in the questionnaires  participants were required to 
embolden and italicise rather than circle responses and place an X in boxes rather 
than ticking them. 
 
Schedule for reminders 
Reminders were sent to, and reasons for withdrawal sought from, consenting 
participants who failed to return subsequent materials. The schedules for reminders 
in primary care and support groups are illustrated in Tables 10 and 11. Right to 
withdraw without indicating reasons was always emphasised. 
 
Primary care 
A reminder letter and additional writing pack/questionnaire as appropriate was 
mailed initially, followed by up to two telephone calls in the event of no response.67  
 
Support groups 
Participants were sent a reminder email with the offer of additional materials, and in 
the event of no response reasons for non-return were sought when subsequent 
materials were forwarded.  
                                                             
67 Where no contact could be made, these materials were chased again should patients be contacted 
about non-return of subsequent materials. 
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Table 10 Schedule for reminders for primary care 
 
 
 
 
 
 
 
 
 
 
 
 
Table 11 Schedule for reminders for support groups 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Writing pack: 
Sent immediately after return of baseline questionnaire.  
REMINDER: letter 21 days after sending; if no response after another 21 days 
telephone call (2 attempts). 
 
Follow up questionnaires: 
2 week -sent 14 days after receipt of writing pack (or 14 days after patient responds 
to writing letter reminder and advises no longer wishes to write or 14 days after 2 
unsuccessful writing telephone reminders). 
3 month -sent on the same date 3 months after receipt of writing e.g. if received 1st 
January sent 1st April (or 3 months after patient responds to writing letter reminder 
and advises no longer wishes to write or 3 months after 2 unsuccessful writing 
telephone reminders). 
REMINDER: letter 14 days after sending; if no response after another 14 days 
telephone call (2 attempts). 
 
Debriefing: 
Sent immediately after receipt of 3 month follow up questionnaire. 
REMINDER: letter 21 days after sending; if no response after another 21 days 
telephone call (2 attempts). 
 
Writing pack: 
Sent immediately after return of baseline questionnaire.  
REMINDER: email 21 days after sending; if no response request feedback at 2 
week follow up. 
 
Follow up questionnaires: 
2 week follow up –sent 14 days after receipt of writing pack (or 14 days after patient 
responds to writing email reminder and advises no longer wishes to write or if no 
response to writing email reminder 14 days from the date of that reminder). 
3 month follow up -sent on the same date 3 months after receipt of writing e.g. if 
received 1st January sent 1st April (or 3 months after patient responds to writing 
email reminder and advises no longer wishes to write or if no response to writing 
email reminder 3 months from the date of that reminder). 
REMINDER: email 14 days after sending; if no response request feedback at 3 
month follow up or debriefing respectively. 
 
Debriefing: 
Sent immediately after receipt of 3 month follow up questionnaire. 
REMINDER: email 21 days after sending. 
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À priori sample size calculation  
An anticipated effect size from a trial consistent with the present study was not 
available. However, a 5-point difference on the primary outcome as measured with 
the CES-D (SD=8.5; derived in a representative community sample of adults 
(Radloff, 1991), discriminates between important levels of severity and is potentially 
clinically meaningful. To detect this difference at a .05 significance level (two tailed 
such that an effect in either direction could be detected)68 with 80% power69 110 
participants were required, assuming 20% attrition.  
 
Primary care (& secondary care) 
It was assumed each practice would have approximately 200 adults with Type 2 
diabetes registered, that at most 20% of invited patients would be recruited and that 
no more than 15% would receiving intervention for depression already (i.e. 
estimated by a local GP). Thus each practice could provide 34 eligible and 
interested patients. The proportion of individuals excluded during the eligibility check 
was expected to be negligible, rather this was a precaution to protect patients.  
 
People within practices are related and this correlation reduces statistical power, 
thus potential clustering within practices was accounted for. An intra-class 
correlation (ICC) of .03 was assumed based on the pattern of ICCs typically 
observed in cluster based studies in primary care (Adams, Gulliford, Ukoumunne, 
Eldridge, Chinn & Campbell, 2004). With a cluster size of 34, and thus inflation 
                                                             
68 Statistical significance is the risk of a Type 1 error (i.e. the probability of an effect at least that large if 
the null hypothesis is true; the risk that the sample based estimate represents sampling error (i.e. 
random fluctuations in the data/between the groups) rather than the population effect). The acceptable 
level of risk is 5% (i.e. p<.05). 
69 The power of a statistical test is the likelihood that a genuine effect will be detected as significant 
(i.e. as there being less than a 5% risk that the effect is due to sampling error; p<.05), and is inversely 
related to the risk of making a Type 2 error (i.e. missing a genuine effect), the acceptable level of which 
is set at 20% (i.e. 80% power).   
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factor of 1.99, a sample of at least 219 was actually required.70 Recruitment of eight 
practices was thus estimated to provide 272 eligible and interested patients, albeit a 
small proportion may have been diagnosed for less than six months. 
 
It is noteworthy that for secondary care a diabetes clinician estimated that 
approximately 20% of patients with diabetes attending a secondary care clinic would 
have Type 2 diabetes; 40 of the 200 patients typically seen in one month. Moreover, 
a similar proportion to that in primary care would be receiving intervention for 
depression, yet few patients diagnosed less than six months ago would be attending 
secondary care. Thus, again assuming a conservative recruitment rate of 20%, it 
was anticipated secondary care recruitment would additionally provide seven 
patients per month per clinic. 
 
Online support groups 
The online support groups that were approached indicated that the average 
membership at the time they were approached was 12, 364, of which it was 
indicated on the websites that approximately 28% would log in within one month 
(i.e. average of 3, 462 per forum). It was assumed most would be adults and thus 
have Type 2 diabetes (i.e. 75%), as children/parents of children with Type 1 would 
access specialised websites. An average of 2, 597 adults with Type 2 diabetes was 
therefore anticipated per forum per month. Assuming a conservative recruitment 
rate of 1% (i.e. indicated by the proposed websites), it was expected an average of 
26 people viewing the post would answer the eligibility questions per forum. It was 
also assumed that of these people the proportion receiving treatment for depression 
would be similar to primary care; if it were less because users were treatment 
                                                             
70 The inflation factor is computed with the following equation; 1+[(cluster size-1)xICC]. The required 
sample size (i.e. 110) is then multiplied by the inflation factor.  
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seeking by visiting the groups (and expressing an interest in the study)71 or because 
visiting the group was satisfying any treatment need, this would be a conservative 
estimate. This would leave an average of 22 people per site. Presuming that 10% 
would then have been diagnosed for less than six months (i.e. again for the first six 
months people with diabetes are relatively well supported by the NHS), 20 eligible 
and interested participants were expected to be identified per site in one month.  
Thus recruitment of six sites could provide a sample of 120 participants within one 
month. 
 
Handling of patient safety issues 
A number of patient safety issues were identified in chapter four. The handling of 
these is either described earlier (i.e. the eligibility check) or below. 
 
Potential negative emotional response to writing or screening 
Participants were warned about this in the PaIS and advised to stop writing if they 
were worried about how they felt. GP contact was encouraged should patients 
experience any concerns or wish to discuss their screening score (in the PaIS and 
debriefing sheet), with specific contact details provided and GP agreement obtained 
during practice recruitment. Contact details of potentially helpful organisations (i.e. 
local citizen’s advice bureaus, Mind, NHS Direct and Samaritans) were also 
provided. Where participant recruitment was not via the NHS (e.g. support groups) 
participants were advised to contact their HCP, yet specific contact details could not 
be provided and this could not be arranged beforehand as recruitment would not 
involve in interfacing with HCPs. 
 
                                                             
71 Any people at risk but not currently treated would be excluded in the eligibility check. 
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Clinical support in the event of contact with patients experiencing 
concerns/soliciting emotional support 
All participants were encouraged to contact their HCP rather than the research team 
about anything other than information about the trial. However, should a patient 
contact the researcher about anything else, a procedure was in place. Specifically, 
honorary consultant psychiatrist, Professor Scott Weich, at WMS was consulted 
immediately for expert clinical advice and support with individual cases, for which 
his agreement was obtained.  
 
Review of essay content and procedure for disclosures requiring action 
and disclosure of limits to confidentiality 
Essays were read within one working day of receipt by the researcher, who 
assessed the risk of self-harm against a checklist of risk factors informed by 
Professor Scott Weich and a standard psychiatry resource recommended by him 
(Gelder, Harrison & Cowen, 2006) (presented in the appendix). Patients were 
required to show no evidence of distress or morbid thoughts in relation to each risk 
factor in their writing (e.g. in relation to bereavement, statements such as ‘I wish I 
was with the person’). If any of these risk factors, or any other concerning 
information, were evident the researcher immediately consulted a patient safety 
group, which was convened within one working day to consider the information and 
provide expert advice. Contact arrangements were made such that advice could 
always be sought within this time frame. Individuals that agreed to be included in 
this group were Professor Scott Weich, Dr Anne-Marie Slowther a GP and expert 
clinical ethics and Dr David Ellard a clinical trialist.72 Participants were advised in the 
                                                             
72 The patient safety group was also intended to evaluate and advise about any other issues that arose 
during the trial, such as new information about intervention safety. Ongoing information gathering 
strategies were employed during the course of the study (i.e. journal/database search alerts and 
subscription to professional list server groups). However no new, significant information about the 
intervention was identified. A data monitoring committee was not convened due to insufficient follow up 
to enable interim analyses.  
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PaIS that if they disclosed information of a certain nature in writing, for example 
indicating a serious risk to themselves or others, this may necessitate a breach of 
confidentiality and could be disclosed to an appropriate party.  
 
Handling of standard ethical issues73 
There were a number of standard ethical issues to be addressed and these are 
described below. 
 
Informed consent 
Informed written consent was obtained prior to enrolment and randomisation. The 
PaIS advised participants about the trial requirements, the risks and benefits and 
that they were free to reply if and when they chose. Research team contact details 
were provided for more information. The PaIS was considered at home allowing at 
least 24 hours consideration, and people were not coerced or contacted about the 
study. The consent form sought confirmation that participants had read the PaIS, 
understood this, had the opportunity to consider the information, ask questions, and 
have these answered satisfactorily.74 The study materials achieved a Flesch-Kincaid 
Readability score of 7 to 8 indicating they were easy to understand. 
 
Right to withdraw 
Participants were assured in the PaIS that they were free to withdraw at any time 
without giving a reason and that declining participation would not affect them.  
Confirmation that participants understood this was obtained in the consent form. 
                                                             
73 A number of ethical and good clinical practice (GCP) guidelines were consulted in the design of the 
trial and study materials; the WMS CTU Standard Operating Procedures guidelines, the NHS National 
Patient Safety Agency’s National Research Ethics Service guidelines, and the MRC guidelines for 
good clinical practice in clinical trials. The project researcher attended the Principles of GCP course at 
University Hospital Coventry and Warwickshire and the Chief Investigators course at the WMS CTU.  
74 This was particularly important for online support group participants because the PaIS was simply an 
icon on the study website to which people were directed. 
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Participants were also warned that should they withdraw after consent the 
information already provided would still be used.  
 
Procedure in the event of unreturned documents 
Participants were warned in the PaIS that should they not return documents they 
would still be followed up as per the protocol in the PaIS and therefore they could 
receive a reminder letter and telephone calls, unless they explicitly withdrew 
consent for this. 
 
Screening for eligibility 
Participants were advised in the PaIS (and on the study website) that they would be 
screened to assess their current well-being and that this would be used to 
determine their suitability for the trial (i.e. eligibility questions and or a DSQ). 
Participants were advised that their screening questionnaire data would be seen by 
their HCP and that this may be acted on (primary and secondary care), or that they 
may be required to advise their HCP about this (support groups). Confirmation that 
support group participants understood this was obtained in the consent form. For 
secondary care and support groups, the DSQ was returned to the researcher with 
the consent form. The consent form therefore obtained explicit permission for the 
researcher to screen for eligibility (and, for secondary care participants, permission 
for the researcher to pass the information to their HCP if necessary). In primary 
care, participants were advised that their screening data would be obtained by the 
research team for baseline data should they consent to take part. 
 
Advising HCPs about enrolment 
In primary and secondary care, patients were informed in the PaIS that HCPs would 
be advised about their entry into the trial, and confirmation that patients understood 
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this was obtained in the consent form. Support group participants were informed 
that they would be advised to inform their HCP about their participation, with 
confirmation that patients had understood this again collected in the consent form.  
 
Clinical data collection  
Primary and secondary care patients were advised in the PaIS that their HCPs 
would provide the researcher with information from their medical records unless 
they explicitly withdrew consent for this, and the consent form sought agreement 
that their medical records may be accessed by individuals from the University of 
Warwick. 
 
Withholding information 
Again, there was a need to withhold some information from participants (see 
chapter four). However, participants were fully debriefed once the study was 
completed.  
 
Postal/email consent and intervention delivery 
Although intervention delivery was by post or email, patient safety measures were in 
place such that any issues were dealt with as they would be in practice. Where 
consent was taken by email, consent forms could not be signed by hand thus they 
obtained additional confirmation that participants were providing signed consent (i.e. 
where an electronic signature could not be provided). 
 
Handling of participant data 
It was not possible to anonymise materials given the need to link data collected at 
different points and identify to whom materials should be forwarded and when. 
However, confidentiality was maintained. Materials received by email were printed 
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and the email destroyed. Consent forms contained participant’s details, yet other 
materials were marked only with a PIN (generated by participants; not the PIN 
assigned by practices). Materials were stored in a locked filing cabinet in a locked 
office on university premises and did not leave. Only information stored on a 
university computer, protected by a password, linked participant’s details and PINs. 
Only the research team had access to participant data.  Participants were informed 
about this in the PaIS, and also that their data may be seen by NHS R&D offices for 
monitoring and auditing purposes, for which consent was obtained in the consent 
form. The data obtained were only used in the present study, and once complete all 
electronic data were transferred to two CDs (i.e. and stored with the paper 
documentation with the project supervisor). This will be destroyed after five years. 
Participants were also informed about this in the PaIS. 
 
Provision of information on the study website 
Information provided on the study website was secure because the site was located 
on the researcher’s staff webpage, to which only the researcher and the WMS web 
management team had access. Security was assured by the eLearning advisor for 
WMS. Participants were assured about this, and that the information provided would 
not be used to forward anything other than the study materials, in privacy 
statements on the site.  
 
Process of obtaining clinical data  
Any information that left practices had participant’s details removed. Arbitrary 
information codes were used to facilitate this.  Participants were informed about this 
in the PaIS. 
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Data analysis plan 
Variable definition  
Variables analysed statistically 
The variable definition for those analysed statistically, including the demographic 
covariates to be included in effectiveness analyses, is provided in Table 12. The 
hypotheses for these analyses are provided below. 
 
Hypotheses for variables analysed statistically 
Outcomes: It was hypothesised that for the primary and secondary outcomes a 
difference in mean scores would be observed which favoured the intervention; 
participants that received WED would report lower depressive symptom severity, 
and improvements in DSED, health-related QoL and SMBs, compared to the control 
group. 
  
Moderators: It was hypothesised that the effect of WED on the primary outcome 
would be different at different levels of the moderator variables.  
 
Explanatory processes - mechanisms of change: It was hypothesised that WED 
would produce the anticipated EA&H and E&CP described in chapters two and four, 
specifically a) a decrease in post-writing negative affect across writing sessions and 
b) an increase in percentage word use reflecting cause, insight and positive 
emotion, and a decrease in percentage word use reflecting negative emotion, 
across writing sessions. This would be reflected by an increase/reduction in the 
mean values for each variable across successive writing sessions. 
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Table 12 Variable specification for those to be analysed statistically 
 
Variable Measure Direction of scoring of 
measure 
Self-report 
versus 
objective  
data 
Continuous 
versus 
dichotomous 
data  
Data obtained Assessment 
interval data 
obtained at 
Data obtained 
from measures at 
each assessment 
interval / score 
derived  
Primary outcome     
Depressive 
symptom severity 
CES-D Higher scores more 
depressive symptoms 
Self-report Continuous Means & SDs Baseline & 3 
months 
Total score 
Secondary outcomes     
DSED PAID Higher scores more 
DSED 
Self-report Continuous Means & SDs Baseline & 3 
months 
Total score 
Health-related QoL EQ-5D Higher scores better 
health-related QoL 
Self-report Continuous Means & SDs Baseline & 3 
months 
2 sub-scale 
scores: 
utility & VAS  
Diabetes SMBs SDSCA Higher scores better 
SMBs 
Self-report Continuous Means & SDs Baseline & 3 
months 
5 sub-scale 
scores: 
general diet, 
specific diet, 
exercise, blood 
glucose testing & 
foot care 
Confounding variables 
Age   Self-report Continuous Means & SDs Baseline   
Gender   Self-report Categorical Frequencies & % Baseline   
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Variable Measure Direction of scoring 
of measure 
Self-report 
versus 
objective  
data 
Continuous 
versus 
dichotomous 
data  
Data 
obtained 
Assessment interval 
data obtained at 
Data obtained 
from measures at 
each assessment 
interval / score 
derived  
Moderators        
Alexithymia TAS Higher scores 
more alexithymia 
Self-report Continuous Means & 
SDs 
Baseline  Total score 
Optimism LOT-R Higher scores 
more optimism 
Self-report Continuous Means & 
SDs 
Baseline  Total score 
Mechanisms of 
change variables 
       
EA&H: change in 
post-writing negative 
affect across writing 
sessions 
PANAS –
negative 
affect sub-
scale 
Higher scores 
more negative 
affect 
Self-report Continuous Means & 
SDs 
After each writing 
session  
Total score  
E&CP: change in % 
word use reflecting  
positive emotion, 
negative emotion, 
insight & cause across 
writing sessions 
LIWC  Higher scores 
greater % of words 
reflecting that 
category  
Objective Continuous Means & 
SDs 
Derived for each 
writing session 
 
4 category 
scores (positive 
emotion, 
negative 
emotion, insight 
& cause)  
Mediators    
Self-efficacy for 
diabetes SMBs 
DMSES 
UK 
Higher scores 
more self -efficacy 
Self-report Continuous Means & 
SDs 
Baseline & 2 weeks (& 
3 months for primary 
care patients) 
Total score 
Perceived illness-
interference 
IIRS Higher scores 
more interference 
Self-report Continuous Means & 
SDs 
Baseline & 2 weeks (& 
3 months for primary 
care patients) 
Total score 
Perceived emotional 
support 
SSQ6 Higher scores 
more support 
perceived 
Self-report Continuous Means & 
SDs 
Baseline & 2 weeks (& 
3 months for primary 
care patients) 
2 sub-scale 
scores: 
number & 
satisfaction  
  
219 
 
Variable Measure Direction of scoring 
of measure 
Self-report 
versus 
objective  
data 
Continuous 
versus 
dichotomous 
data  
Data 
obtained 
Assessment interval 
data obtained at 
Data obtained 
from measures at 
each assessment 
interval / score 
derived  
Contamination         
Average degree of  
ED:  average % word 
use reflecting  positive 
emotion, negative 
emotion, insight & 
cause across writing 
sessions 
LIWC  Higher scores 
greater % of words 
reflecting that 
category  
Objective Continuous Means & 
SDs 
Derived for each 
writing session 
4 category 
scores (positive 
emotion, 
negative 
emotion, insight 
& cause) / for 
each word use 
category mean of 
scores for each 
writing session 
derived  
Average degree of  
EA: average post-
writing negative affect 
across writing 
sessions 
PANAS –
negative 
affect 
sub-scale 
Higher scores more 
negative affect 
Self-report Continuous Means& 
SDs 
After each writing 
session 
Total score / 
mean of scores 
for each writing 
session derived 
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Explanatory processes - mediators: It was hypothesised that the effect of WED on 
the primary outcome would be mediated by these variables, reflected by a reduced 
association between the intervention and primary outcome when the mediator was 
controlled. 
 
Feasibility/effectiveness of intervention delivery - contamination: It was 
hypothesised that a difference in mean scores would be observed which indicated a 
greater degree of ED and EA in the intervention group compared to the control 
group. 
 
Variables analysed descriptively  
Feasibility/effectiveness of intervention delivery  
Compliance: The time spent writing per session was self-report and provided 
continuous data reported as the mean and SD, and the number of days writing 
completed was self-report and provided categorical data reported as frequencies 
and percentages (one, two or three days). Whether participants undertook further 
self-directed writing since completing the intervention was also self-report and 
provided categorical data (yes or no) reported as frequencies and percentages.   
 
Feasibility/effectiveness of the trial protocol  
Blinding success: Whether participants inferred the true nature of the study and their 
group assignment was self-report and provided categorical data (yes or no) reported 
as frequencies and percentages. A score was derived for each of three questions 
that were asked. 
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Data preparation 
Handling missing data on continuous measures 
Continuous measures were scored according to the scoring keys provided. Some 
included instructions to impute missing responses where these were below a certain 
threshold (e.g. ≤4 items). Others provided information about the acceptable extent 
of missing responses with which a score could still be derived (e.g. ≤4 items). For 
the remaining measures, scores were derived if responses to ≤5% of the items 
comprising the scale/sub-scale were missing. Otherwise, scores were considered 
missing. The availability of data was then described. To identify missing 
observations (i.e. individual participant scores) the frequencies for each measure 
were produced (i.e. reported as the number (and percentage) of observations 
missing for each measure each time the measure was administered). To identify 
missing item responses per observation, whether observations could or could not be 
derived, the dataset was visually inspected (i.e. reported as the number (and 
percentage) of item responses missing, or imputed, for each observation for each 
measure each time the measure was administered).  
 
Screening the data and checking assumptions for parametric tests: normality 
The continuous variables that were to be included in analyses were screened by 
group at baseline and follow up (i.e. each time they were administered), to establish 
whether the assumption of normality was met such that the parametric analyses 
would be accurate. Boxplots were visually inspected for outliers. Shapiro Wilk tests, 
considered more accurate than alternative deviation tests (Field, 2005) then tested 
whether the data were significantly different to a normal distribution, and the extent 
of deviation was identified via inspection of histograms and skewness and kurtosis 
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statistics converted to z scores75; values greater than 2.58 in small samples suggest 
the data are significantly different to a normal distribution (Field, 2005).  
 
Correcting distributional problems in the data 
The effectiveness analysis for the primary outcome was based on ANOVA 
(discussed below), which is again fairly robust to violations of normality. All other 
analyses were exploratory. Nonetheless, attempts were made to correct for any 
distributional problems in the data. Where outliers were identified the raw data was 
checked and any data entry errors were corrected.76 Variables that remained 
skewed were then transformed by taking the log or square root of each value, and 
adding a constant to all scores where some were zero. This reduces the impact of 
extreme scores and thus improves the distribution by squashing the right tail of the 
distribution and bringing larger values closer to the centre respectively (Field, 2005). 
Therefore, where data were negatively skewed scores were reversed prior to 
transforming them (i.e. all scores were subtracted from the highest score for that 
variable). Reversed scores were then converted back to facilitate interpretation of 
analyses. The transformation that best corrected the data was applied. Where a 
variable was transformed, all variables with which it was to be analysed were 
transformed, preferably in the same way, regardless of whether they were skewed 
initially. This was because transformation does not change the relationship between 
variables yet it does alter the unit of measurement of each variable.  
 
 
                                                             
75 This was achieved by dividing these statistics by their associated SE. 
76 Outliers were not removed as there was no reason to believe that they were not from the population 
that was intended to be sampled and singling out and altering individual scores was not justified (Field, 
2005).  
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Additional assumption checks 
Homogeneity of variance for between-participants analyses (i.e. that the variance of 
scores is the same for each level of the between-participants factor; Levene’s test) 
and sphericity for within-participants analyses (i.e. that the variance of the 
differences between different levels of the within-participants factor are the same; 
Mauchly’s test), were checked prior to conducting analyses. Where sphericity had 
been violated the degrees of freedom used to assess the observed F ratio were 
corrected using Greenhouse-Geisser estimates of sphericity (Field, 2005). 
Homogeneity of regression slopes (i.e. that the magnitude and direction of the 
relationship between the covariate and outcome is the same for each level of the 
between-participant factor) was checked prior to conducting ANCOVA.  
 
Preparation of the dataset 
For primary and secondary outcomes, ITT analysis was performed. Missing follow 
up observations were replaced by that participant’s baseline observation for that 
outcome (i.e. baseline carried forward) and missing baseline observations were 
replaced with that participants follow up observation for that outcome, as available. 
On the rare occasion that data were missing at both baseline and follow up for an 
outcome this participant was excluded from the analysis as complete imputation 
was not considered justified. A complete case analysis was then performed; 
effectiveness analyses were repeated with participants that provided both baseline 
and follow up observations. 
 
Baseline descriptive statistics 
Psychometric properties of each continuous measure are reported for the baseline 
data, or for the first writing session for the PANAS, as the mean, SD and range. 
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Internal reliability77 was reported as Cronbach’s alpha for scales/sub-scales that 
comprised ≥5 items. Cronbach’s alphas between .70 and .90 reflect a desirable 
balance between internal reliability and redundancy of items, which otherwise 
suggests limited scope and questionable validity (Streiner & Norman, 2003). The 
EQ-5D utility sub-scale comprises five items, however Cronbach’s alpha was not 
calculated as a single construct is not explicitly measured thus a substantial 
correlation was not anticipated.  
 
As random allocation can still result in chance variation between groups (i.e. 
accidental bias), which if substantial enough for prognostic variables may bias 
effects, the baseline comparability of the groups was examined (Moher et al, 2010). 
Statistical tests were not employed given that the trial was inadequately powered to 
detect small yet potentially important effects (see numbers recruited in chapter six) 
and thus Type 2 error was probable. Moreover, even when significant at p<.05 such 
tests could reflect the anticipated chance variation between groups and thus do not 
provide information about any other source of bias (i.e. they do not indicate whether 
the chance variation if substantial enough to bias effects) (Altman & Dore, 1990). 
Rather, it is systematic differences of a notable magnitude on important prognostic 
variables that is important. 
   
Data from primary care and support groups were combined in an attempt to 
increase statistical power and precision. However, it should be acknowledged that 
there are reasons why it might not be justified to combine these data. Support group 
participants represent support seeking individuals, which introduces further 
selection bias and constitutes a non-representative sample. Consequently, baseline 
data and psychometric properties were compared for these groups to rule out 
                                                             
77 Internal reliability/consistency refers to the degree to which the items in a scale are correlated and 
measure the same thing (i.e. the degree of common variance explained by a common source or rather 
the latent construct), and thus measure the intended construct. 
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systematic differences of a notable magnitude on important prognostic variables. 
Particular attention was paid to clinical data, namely HbA1c, as this was potentially 
affected by self-report biases for support group participants given that it could not be 
obtained from routine medical records as in primary care.  
 
Statistical analyses 
Preliminary effectiveness analysis78  
The summary measure of treatment effect was the between-groups difference in 
mean severity of depressive symptoms at three months, controlling for baseline 
variation in depressive symptom severity. ANCOVA thus tested the significance of 
variation in mean depressive symptom severity at three months, with group 
(intervention or control) as a fixed effect and baseline depressive symptom severity 
as a covariate. Age and gender were additionally included as covariates. 
 
Standardized estimates of the treatment effect were also derived, namely η², η୮
²  and 
ω² (see chapter four for calculations). ω²  is reported, however η² and η୮²  are 
reported in the appendix for comparative purposes and to maintain consistency with 
the existing evidence base. η², and thus η୮
²  and ω², are interpreted at .01, .06 and 
.14 as small, medium-sized and large respectively (Cohen, 1988). ω² may be 
negative when the F ratio is less than one. In such instances the effect size was 
considered to be .00 (Olejnik & Algina, 2000). The associated 95% CIs could not be 
estimated without bootstrapping (i.e. sampling the data many times to estimate the 
SE of the effect and thus the confidence intervals), which is difficult to perform. 
Consequently, the 95% confidence intervals associated with the regression 
                                                             
78 It was not considered necessary to account for clustering within practices in analyses as a small 
number of practices actually provided participants (i.e. three), and in fact most of the participants were 
from one practice (i.e. 22; 63%); the other two practices provided only three (9%) and 10 (29%) 
patients (see chapter six).  
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parameters for the between group effect provided an indication of the stability of the 
estimates. The adjusted estimated marginal means and their SEs were also 
inspected for each group. In line with the sample size calculation described above, a 
five point difference on the primary outcome/CES-D is considered potentially 
clinically important. To facilitate interpretation of any effect this was also 
represented graphically. 
 
The same analytic strategy was employed for the secondary outcomes of DSED, 
health-related QoL and diabetes SMBs. 
 
Exploratory analyses 
Sub-group (moderator) analyses   
To assess whether treatment effects on the primary outcome varied among pre-
specified sub-groups, formal tests of interaction were conducted within ANCOVAs. 
The median split was used to stratify alexithymia and optimism. Specifically, 
factorial ANCOVAs tested group differences in depressive symptom severity at 
three month follow up for each level of the moderator, with group (intervention or 
control) as the first between-participant variable and moderator (high versus low 
alexithymia or high versus low optimism) as the second between-participant 
variable.  This is consistent with current recommendations regarding sub-group 
analysis in RCTs (Moher et al, 2010).79 Baseline levels of the primary outcome were 
again controlled, yet given the exploratory nature of these analyses demographic 
characteristics were not controlled. Analyses were performed for the complete case 
dataset. Effect sizes were not derived for the interaction as this represents an 
unfocussed comparison, which is thus difficult to interpret and of limited utility (Field, 
                                                             
79 This approach has previously been employed in WED studies with LTPC samples (Danoff-Burg et 
al, 2006). 
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2005). Observed effects were explored with adjusted estimated marginal means 
and their SEs, and interaction plots (group x moderator).  
 
Explanatory analyses 
Mechanisms of change - E&CP: Change in percentage word use reflecting positive 
emotion, negative emotion, insight and cause across writing sessions was 
examined with a one-way repeated measures ANOVA for each category of word 
use, with writing session (session one, two and three) as the within-participants 
variable. Effect sizes were not derived for main effects as again these represent 
unfocussed comparisons, are difficult to interpret and are thus of limited utility.  
Repeated planned contrasts then compared each level of the independent variable 
to the previous level, which are recommended in instances of measurements at 
successive time intervals (Field, 2005).  
 
Contrasts for these analyses, and those described below, were undertaken 
regardless of the statistical significance of the overall effect, given the probable lack 
of power to detect small yet potentially clinically important effects (again see chapter 
six). Whilst genuine effects within contrasts were additionally unlikely to be detected 
as statistically significant, this enabled the effect size for each contrast (i.e. focused 
comparison), r, to be estimated. The effect size, r represents the Pearson’s 
correlation coefficient, yet this is also a measure of the strength of an experimental 
effect and is interpreted at .10, .30 and .50 as small, medium and large respectively 
(Cohen, 1988; Field, 2005). r² then indicates the proportion of the total variance in 
the dependent variable (i.e. the outcome) that is explained by the independent 
variable (i.e. the effect), for example an effect size of r=.30 explains .09 (9%) of the 
total variance (Field, 2005).  
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In these analyses, r was estimated by converting the F ratio for each contrast using 
the following equation, which was possible because the F ratios for the model had 
one degree of freedom (i.e. they represent a focused and interpretable comparison). 
F(1,dfR) refers to the F ratio and dfR refers to the degrees of freedom associated 
with the error term (Field, 2005): 
 
ݎ = √F(1, dfR)F(1, dfR) + dfR 
 
Means and SDs were additionally consulted to inform interpretation of effects. 
 
A factorial repeated measures ANOVA with writing session (session one, two and 
three) as one within-participants variable and word use category (positive emotion, 
negative emotion, insight and cause) as a second within-participants variable was 
not performed because effect sizes for the changes across writing sessions for each 
category of word use were of interest. Moreover, again all secondary analyses were 
exploratory and interpreted in view of an inflated Type 1 error rate relating to 
multiple analyses. 
 
Mechanisms of change - EA&H: It was intended that change in post-writing negative 
affect across successive writing sessions would also be examined in a one-way 
repeated measures ANOVA. However, this data remained highly skewed despite 
transformation (reported in chapters seven and eight, and the appendix), and 
distributional problems in small samples, as was obtained for the analyses based on 
the PANAS data (reported in chapter seven), are a cause for concern (Altman & 
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Bland, 2009). Given that a non-parametric equivalent to the repeated measures 
ANOVA is available, this test was performed.80  
 
A Freidman’s ANOVA was thus conducted, again with writing session (session one, 
two and three) as the within-participants variable. The exact significance test was 
applied as this is accurate even when samples are small and data are particularly 
poorly distributed (Field, 2005; SPSS v17). Effect sizes were not derived for main 
effects as again these represent unfocussed comparisons, are difficult to interpret 
and are thus of limited utility.   
 
Wilcoxon tests (i.e. contrasts) then compared session one and two, two and three, 
and one and three. Exact significance tests were again applied and the one tailed 
significance values were consulted as the direction of the effect had been 
anticipated (i.e. a decrease in negative affect across sessions). A Bonferroni 
correction was applied to control for the number of comparisons here; a critical 
significance value of .0167 was applied (i.e. .05/the number of comparisons) as 
recommended (Field, 2005). The effect size for the Wilcoxon tests, r, was estimated 
by dividing the Z score for each contrast by the square root of the total number of 
observations (Field, 2005).  
 
Medians, which are more appropriate than means for non-parametric tests, and 
ranges were additionally consulted to inform interpretation of effects. 
 
Should an overall intervention effect and the anticipated changes in percentage 
word use and post-writing negative affect be observed, it was intended that the 
absence of such changes in the control group would be explored. If this was 
                                                             
80 Parametric analyses do not require data to follow a particular distribution as they are based on 
ranked data; they utilize the rank order of observations rather than the measurements themselves 
(Altman & Bland, 2009). 
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additionally confirmed, it was intended that the changes observed for the 
intervention group would be examined as mediators of the effect of WED on the 
primary outcome, by means of the approach to formal mediation analysis described 
below.  
 
Mediators: Baron and Kenny’s (1986) three stage procedure assessed the extent to 
which the mediator variables  (i.e. self-efficacy for diabetes SMBs, perceived illness-
interference and perceived emotional support) (i.e. B) mediated any relationship 
between the intervention group (i.e. A) and the primary outcome (i.e. C), where a) A 
is correlated with C, b) B is correlated with C (controlling for A such that any 
observed relationship is not attributable to the fact that both are caused by this), and 
c) the strength of the relationship between A and C is reduced/eliminated when the 
effect of B is controlled (Baron & Kenny, 1986)81. Baseline levels of the primary 
outcome, but not demographic variables, were again controlled and analyses were 
performed for the complete case dataset. Missing values were excluded listwise; 
only participants with scores for all variables were included in the analyses, as 
advised (Field, 2005). 
 
Specifically, hierarchical multiple regression models were constructed to test each 
mediation step. For each model, variables that were to be controlled were entered in 
the first bock and the variable for which the additional contribution was sought was 
entered in the second block, with forced entry employed within each block (i.e. the 
predictors were forced into the model simultaneously). Stepwise entry wherein 
predictors are entered into the model in an order determined by computer-assessed 
mathematical criterion was not necessary as the purpose of the analysis was not to 
build exploratory models (Field, 2005).  
                                                             
81 This approach has previously been employed in WED studies with LTPC samples (Zakowski et al, 
2004).   
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The approach adopted is summarized in Table 13.  
 
Table 13 Approach to the mediation analyses 
 
Mediation step  Regression models 
Step 1 A – C Block 1  
Baseline depressive 
symptoms  
Block 2  
Baseline depressive 
symptoms 
Intervention group (A)    
Step 2 B – C (controlling A) Block 1  
Baseline depressive 
symptoms 
Intervention group (A)        
Block 2  
Baseline depressive 
symptoms 
Intervention group (A)        
Mediator variable (B)    
Step 3 A – C (controlling B) Block 1  
Baseline depressive 
symptoms 
Mediator variable (B)    
Block 2  
Baseline depressive 
symptoms 
Mediator variable (B)    
Intervention group (A)    
 
 
The parameters of interest for each mediation step and thus regression model were: 
 
a) The amount of variance explained by each model fitted to the data relative to how 
much variance there is to be explained (R²), specifically the change in the amount 
of variance explained by model with the addition of block two (i.e. the predictor of 
interest) (∆R²). R² is an effect size interpreted at .02, .13 and .26 as small, medium 
sized and large respectively (Cohen, 1988). It can also be converted to a 
percentage of the total variance in the dependent variable (Field, 2005).  
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b) The corresponding change in the F ratio; the ratio of improvement in prediction of 
the outcome resulting from fitting the model to the data relative to the inaccuracy 
that still exists in the model (i.e. the ability of the model to predict the outcome). If F 
>1 the improvement due to the model notably exceeds the inaccuracy in the 
model. 
 
c) The significance of any change in the F ratio; whether the change in the models 
ability to predict the outcome was significant (i.e. the significance of ∆R²). 
 
d) The unique contribution of the predictor of interest (i.e. entered in block two):  
i. The unstandardized regression co-efficient (b): the degree to which the 
outcome changes as a result of one unit change in the predictor when the 
effects of all other predictors are held constant; a positive value indicates a 
positive relationship and a negative value indicates a negative relationship. 
ii. The SE of the unstandardized regression co-efficient (SEb): the extent to 
which b would vary across different samples. 
iii. The standardized regression coefficient (ß): the number of SDs the outcome 
changes as a result of one SD change in the predictor when the effects of all 
other predictors are held constant.  
iv. The p value for the t-statistic (i.e. the test of whether the regression coefficient 
for this predictor is significantly different from zero): whether the predictor 
made a significant contribution to the model (i.e. contributes to the ability to 
predict the outcome). 
 
Where samples are small R² is inflated by sampling error or rather random 
fluctuations in the data which do not represent the population effect, again known as 
shrinkage (Field, 2005). Therefore, adjusted R² was also estimated; the amount of 
variance in the outcome that would be explained by model if it had been derived 
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from the population from which the sample was drawn (i.e. rather than the sample 
obtained). Where R² exceeds adjusted R² this indicates shrinkage and suggests the 
model obtained may not generalize to the target population. 
  
The mediation analyses were first performed for the mediator variables measured at 
two weeks; variables that were measured post-intervention but preceding the 
outcome assessment consistent with the conditions required to establish mediation. 
The analyses were then repeated where the mediator variables were measured at 
three months (i.e. for primary care patients). Although these variables were 
measured at the same time as the outcome, these analyses were exploratory and 
included to explore whether it may take longer than two weeks for WED to influence 
mediators and thus outcomes. 
 
Prior cost-effectiveness analysis 
Should effectiveness be demonstrated, cost-effectiveness was intended to be 
investigated based on the cost of programme implementation, cost per 1% 
reduction in depression risk and cost per QALY consistent with the approach 
currently adopted within the NHS.  
 
Feasibility investigation 
Feasibility/effectiveness of intervention delivery 
Contamination - average degree of ED: A mixed factorial ANOVA tested group 
differences in the average percentage word use for the four aforementioned 
categories across writing sessions, with group (intervention or control) as the 
between-participants variable and category of word use (positive emotion, negative 
emotion, insight or causation) as the within-participants variable. Effect sizes were 
not derived for the interaction effect as again these represent unfocussed 
comparisons, are difficult to interpret and are thus of limited utility.    
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Deviation (first) planned contrasts compared the effect of group for each word use 
category, except the first, with the overall experimental effect. The analysis was 
then re-run with deviation (last) planned contrasts, which compared the effect of 
group for each word use category, except the last, with the overall experimental 
effect. This ensured that the effect of group for each word use category was 
compared to the overall experimental effect. The effect size for the contrasts, r, was 
estimated by converting the F ratio for each contrast using the equation provided 
above, which was again possible because the F-ratios for the model had one 
degree of freedom (i.e. they represented a focused and interpretable comparison) 
(Field, 2005). 
 
The main effect of group across word use categories was additionally examined 
with effect size r derived via a simple contrast and again conversion of the F ratio as 
above, as recommended for complex factorial designs (Field, 2005). 
  
Means, SEs and an interaction plot (group x word use category) were additionally 
consulted. 
 
Contamination - average degree of EA: It was intended that group differences in 
average post-writing negative affect across writing sessions would be examined in 
an independent samples t-test. However, again this data remained highly skewed 
despite transformation (reported in chapters seven and eight, and the appendix). 
Given that a non-parametric equivalent to the independent samples t-test is 
available this was performed. A Mann Whitney U test therefore tested group 
differences in the average post-writing negative affect. Exact significance tests were 
applied for the aforementioned reasons, and again the one tailed significance 
values were consulted as the direction of the effect had been anticipated (i.e. a 
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higher average degree of EA for the WED group). The effect size, r, was estimated 
for the main effect. Effect size r was estimated by dividing the Z score associated 
with the Mann-Whitney U test statistic by the square root of the total number of 
observations (Field, 2005). 
 
Medians and ranges were additionally consulted to inform interpretation of effects. 
 
Descriptive analyses and qualitative data 
Feasibility investigation 
Feasibility/effectiveness of intervention delivery 
Compliance: The number of days writing completed, the time spent writing per 
session and whether or not participants undertook further self-directed writing since 
completing the intervention were tabulated by group (i.e. analysed descriptively). 
 
Acceptability: Reasons for not writing at all or following the protocol as instructed 
were described qualitatively. 
 
Feasibility/effectiveness of the trial protocol 
Randomisation and allocation concealment methods: The feasibility/effectiveness of 
the randomisation and allocation concealment methods was described qualitatively 
(i.e. with respect to the baseline comparability of the intervention groups). 
 
Blinding success: Responses to the three questions ascertaining whether patients 
had inferred the true nature of the study and their group assignment were tabulated 
by group per question (i.e. analysed descriptively). 
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Recruitment, retention and sample size: Recruitment flow, recruitment and retention 
issues, and the feasibility of achieving sample size requirement and the 
appropriateness of the sample size calculation parameters, were described 
qualitatively. 
 
The chapters that follow report the findings from the exploratory RCT described 
above. The findings relating to recruitment, retention and sample size are discussed 
initially, as this describes the target population that was intended to be sampled and 
the way in which the study sample was derived. The baseline characteristics of the 
sample obtained are then presented, followed by the pre-specified analyses and 
remaining feasibility investigation. Finally, the findings from some additional post-
hoc investigations and analyses are then presented, specifically feasibility data that 
was collated unintentionally and consideration of writing content with some 
exploratory analyses undertaken to facilitate interpretation of the pre-specified 
analyses. 
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Chapter 6 Recruitment, retention and sample size 
 
Chapter overview 
As part of the feasibility investigation, specifically the feasibility/effectiveness of the 
trial protocol, this chapter reports the recruitment flow for the relevant organisations 
and participants for each mode of recruitment (i.e. estimates of recruitment and 
retention). The recruitment and retention issues encountered in each context are 
additionally described, incorporating consideration of the sample size calculation 
initially specified; the feasibility of achieving the sample size requirement and the 
appropriateness of the sample size calculation parameters. Again, this data is 
presented here as it describes the target population that was intended to be 
sampled and the way in which the study sample, upon which the analyses and 
remaining feasibility investigation are based, was derived. The chapter closes with 
the specification of revisions required to the trial protocol, owing to the issues 
experienced in ethical review (reported in chapter four) and recruitment issues 
discussed in this chapter.  
 
Recruitment flow 
Primary care 
Practice recruitment and retention 
PMs of 113 general practices across Coventry, Warwickshire and Worcestershire 
were contacted about the study once ethical (December 2008) and R&D (March 
2009) approval had been obtained (i.e. between March 2009–January 2010; most 
were contacted between March 2009 and July 2009) (i.e. over 11 months). One 
practice contacted the researcher in response to the initial letter (i.e. before this was 
followed up), otherwise the average number of contacts abut recruitment post letter 
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was four (range 1-13).  Primary care practice recruitment and retention is illustrated 
in Figure 18, including reasons for non-participation where these could be obtained. 
 
One hundred and five of the practices were not recruited.   
 
A definite ‘no’ response was obtained for 61 (54%) of these practices, generally 
provided by the PM and typically on behalf of the practice GPs or nurses. In a small 
number of instances where it could be arranged, GPs or nurses were liaised with 
directly. Three of these practices did advise enquiring again at a later date, but not 
within the time allocated to recruitment.  
  
A definite response could not be obtained for the remaining 44 (39%) practices. 
Typically there was a series of unsuccessful attempts to speak with the PM, and in 
most instances receptionists advised that the research team would be contacted 
should the practice be interested yet no contact was made. In other instances, direct 
GP contact was advised by practice staff, yet they could not be reached82. In some 
instances, there was no appropriate person in post to speak with about the study. 
 
Eight (7%) practices were thus recruited initially. Four of these were visited to 
present the study in person (once n=2 and twice n=2). However, three of the eight 
recruited practices were lost before any patients were mailed invitation packs. Two 
of these practices did not perform the search to identify patients at all, despite initial 
agreement. For practice F completion of the search was delayed by a number of 
practice-related issues including swine flu related work load,83 depleted staff over 
the summer period and PM’s annual leave. Moreover, as the PM was unable to 
complete the search themselves assistance from a records clerk was required yet 
                                                             
82 GPs were difficult to reach by telephone and an email address for them could not be obtained. 
83 The recent swine flu epidemic coincided exactly with practice recruitment. 
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this was never achieved. Practice B dropped out due to pragmatic complications 
associated with performing the search (described further below). The remaining 
practice, practice C, completed the search yet did not mail invitation packs to 
identified patients as very few were identified and the practice did not perceive this 
number to be useful (discussed further below). 
 
Figure 18 Primary care practice recruitment and retention 
 
 
 
 
113 practices with relevant 
specialist interest identified 
61 practices not interested 
Reasons: Practice doesn’t normally get involved 
with research 
 Already involved in a diabetes study or too many 
studies generally 
Practice too busy (e.g. just started other 
initiatives, too much end of year work or 
generally swamped) (& one said would like to 
have said yes in about a year). 
Practice short staffed. 
Few patients with diabetes registered. 
Locum in Diabetes Clinical Lead post. 
Mixed response from practice GPs. 
 
8 practices recruited initially 
44 practices response could not be obtained 
 
2 practices did not complete search 
Reasons: Practice related delays in searching 
(n=1). 
Pragmatic complications performing the search 
(n=1). 
1 practice did not mail invitation packs to 
identified patients 
Reason: Practice felt too few patients identified. 
 
6 practices completed search & 
identified eligible patients  
5 practices mailed an invitation 
pack to identified patients 
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Characteristics of the eight primary care practices recruited initially, and the dates at 
which searches/mail outs were performed, the time and effort invested, and the 
dates at which attempts to involve practices ended, are illustrated in Table 14.  
 
Table 14 Characteristics of recruited primary care practices 
 
 
 
 
Practice PCT Specialist interest  Date search & mail out 
performed (or practice 
dropped out) 
Recruited & retained Search & mail out 
performed 
Practice A Warwickshire 
PCT 
(Leamington 
Spa) 
Previously took part in 
diabetes studies at the 
University of Warwick; 
Practice has GP with specialist 
interest in diabetes; 
Practice has diabetic clinic. 
January 2010 (initial 
search and mail out June 
2009; discussed later) 
Practice D Coventry PCT Practice has diabetic clinic. August 2009 (initial 
search May 2009; 
discussed later) 
Practice E Warwickshire 
PCT (Nuneaton) 
GP based at WMS; 
Practice has GP with specialist 
interest in diabetes; 
Practice offers support and 
education courses to patients 
with diabetes; 
Practice has diabetic clinic. 
August 2009  
Practice G Warwickshire 
PCT 
(Leamington 
Spa) 
Practice has chronic disease 
management clinic including 
diabetes; 
Practice has mental HCP in 
place. 
June 2009 
Practice H Coventry PCT Practice has GP with specialist 
interest in diabetes. 
September 2009 
Recruited but not retained Practice dropped out 
Practice B Coventry PCT Previously took part in 
diabetes studies at the 
University of Warwick. 
 
June 2009:  
contacted 13 times in 
relation to recruitment & 
organising the search but 
not visited. 
Practice C Warwickshire PCT 
(Leamington Spa) 
GPs lecture at Warwick 
University; 
Practice has diabetic clinic. 
December 2009:  
contacted 13 times in 
relation to recruitment & 
organising the search; 
visited once (initial 
search July 2009; 
discussed later). 
Practice F Worcestershire 
PCT 
Practice has diabetic clinic. December 2009: 
contacted 28 times in 
relation to recruitment & 
organising the search; 
visited twice. 
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Patient recruitment and retention  
Primary care patient recruitment and retention throughout the trial is illustrated in 
Figure 19, including reasons for non-participation where these could be obtained. 
Patient recruitment and retention by individual practices until consent was obtained 
is illustrated in Table 15. Patients were enrolled between August 2009 and April 
2010 (i.e. over nine months), and completed the trial between January 2010 and 
November 2010.84  
 
Together, the five retained practices identified 826 eligible patients and these were 
mailed an invitation pack.  Eighty one patients (10%) returned the initial materials; 
an EOIF and DSQ (from four of the practices). Forty nine (60%) scored below the 
cut point for significant symptoms of depression (CES-D <16; mean 7 (SD 4.9) in 
the eligibility check and were thus able to participate. However, 29 patients (36%) 
scored as ineligible (CES-D ≥16; mean 26 (SD 8.0), and these patients were 
excluded and identified to their GP.  The remaining three patients (4%) returned a 
DSQ that was partially completed yet did not return it completed when requested. 
Forty eight of the patients meeting the eligibility check were then mailed consent 
forms and a baseline questionnaire; one eligible patient was not mailed this 
because their DSQ could not be identified.85  
 
Thirty five patients (4%) then returned a consent form and baseline questionnaire 
(from three of the practices). Of the 35 consented patients, 22 (63%) returned the 
writing task, 28 (80%) returned the two week follow up questionnaire, 27 (77%) 
returned the three month follow up questionnaire and provided data for the primary 
outcome (i.e. CES-D), and 27 (77%) returned the debriefing sheet.   
                                                             
84 The reason for the variable time taken to complete the trial is that this depended upon whether and 
how quickly participants returned materials. 
85 This was an error that occurred when packs were prepared. 
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Figure 19 Primary care patient recruitment and retention86 
 
 
 
 
 
 
 
  
 
 
 
  
                                                             
86 The research team took a call from a patient who advised that they had received the writing pack but 
could not complete it as they had so many problems writing; this patient could not be identified but was 
one of those for whom the reason for non-return of writing was not obtained. 
81 patients returned EOIF & DSQ  
29 ineligible patients (CES-D ≥16) 49 eligible patients (CES-D <16) 
35 patients returned 
consent & randomised 
12 
returned 
writing 
3 returned a partially completed DSQ & did 
not provide when requested again 
8 WED did not return writing  
Reasons: ‘Do not want to write’ (n=1). 
‘Do not want to write about feelings’ (n=1). 
‘worried/stressed about what to write’ (n=1). 
 ‘Poor English writing ability/too much 
pressure & no time to write (n=1). 
‘Find it too difficult to write about 
relationships etc.’ (n=1). 
 No reason obtained (n=1 but reason 
provided at 3 months: ’don’t like writing/find 
it difficult to put feelings into words’). 
No reason obtained as no answer to call 
(n=1) 
No reason obtained as no telephone 
number provided (n=1). 
4 WED did not return 2 week follow up  
Reasons: No reason obtained (n=1 but 
reason provided at 3 months: ’don’t like 
writing/find it difficult to put feelings into 
words’). 
No reason obtained as no telephone 
number provided (n=3). 
4 WED did not return 3 month follow up  
Reasons: ‘don’t like writing/find it difficult to 
put feelings into words’ (n=1). 
 No reason obtained as no answer to call 
(n=1) 
No reason obtained no telephone number 
provided (n=1). 
Could not be sent (n=1). 
 
5 WED did not return debrief 
Reasons: No reason obtained (n=1 but 
reason provided at 3 months: ’don’t like 
writing/find it difficult to put feelings into 
words’). 
No reason obtained as no answer to call 
(n=1). 
No reason obtained as no telephone 
number provided (n=2). 
Could not be sent (n=1). 
1 eligible patient was not mailed 
consent/baseline 
Reason: DSQ could not be identified 
48 eligible patients mailed consent/baseline 
10 returned 
writing 
20 WED 15 Control 
826 patients identified & mailed invitation pack 
5 Control did not return 
writing 
Reasons: No time to 
write (n=1). 
Withdrew after receiving 
writing pack: reasons 
were workload (n=1) & 
no reason provided 
(n=1). 
No reason obtained as 
no telephone number 
provided (n=2). 
3 Control did not return 
2 week follow up  
Reasons: Withdrew 
(n=2) (as above). 
No reason obtained as 
no telephone number 
provided (n=1 but 
reason provided at 3 
months: already gave 
reason re: not writing 
‘no time to write’) 
4 Control did not return 
3 month follow up 
Reasons: Withdrew 
(n=2) (as above). 
 Withdrew: already gave 
reasons re: not writing 
’no time to write’ (n=1). 
No reason obtained as 
no telephone number 
provided (n=1). 
3 Control did not return 
debrief 
Reasons: Withdrew 
(n=3) (as above). 
 
16 returned 
2 week 
follow up 
 
12 returned 
2 week 
follow up 
11 returned 
3 month 
follow up 
(inc. 
primary 
outcome) 
16 returned 
3 month 
follow up 
(inc. 
primary 
outcome) 
15 returned 
debrief 
12 returned 
debrief 
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It should be noted that one patient was not sent some materials because they did 
not provide an address in the consent form; the three month follow up questionnaire 
and debrief questions. While practices usually agreed to forward materials in these 
instances with a request for an address each time, on this occasion they did not. 
 
It is notable that sometimes patients did not return any other materials if they did not 
return writing; five (38%) of the 13 patients that did not write. However, that left eight 
(62%) patients that did not write yet provided at least some of the follow up 
materials, namely both the questionnaires and the debrief questions (n=6), the two 
week questionnaire and the debrief questions only (n=1) or the two week 
questionnaire only (n=1). In fact, five of these eight patients actually advised when 
were chased about reasons for not writing that they did not mind ‘ticking boxes’, it 
was just the writing task they did not wish to complete. Of the 22 patients that did 
write, most returned both the questionnaires and debrief questions (n=20), however 
some returned the three month questionnaire only (n=1) or did not return any other 
materials (n=1).  
 
Reasons for non-return of materials were generally obtained unless contact 
telephone numbers were not provided in returned consent forms. For instance, 
reasons were not obtained for seven patients not returning materials at one or more 
stages; for most this was because they did not provide a contact number (n=6) 
otherwise there was no response to calls (n=1). 
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Table 15 Primary care patient recruitment and retention by individual practice prior 
to consent 
 
 
Secondary care 
Clinic recruitment   
One teaching hospital in Coventry and Warwick was approached prior to obtaining 
ethical and R&D approval (18th June 2009 –Hospital A), and another was 
approached once ethical approval had been obtained (20th July 2009 – Hospital 
B).87  
 
Hospital A (Nuneaton) was not recruited. While the consultant initially contacted was 
on board, other clinic staff declined when presented with the study at a staff meeting 
(3rd July 2009). Concerns were that patients were already being asked to take part 
in too many studies and that patients probably would not be willing and able to 
complete the writing intervention.  
 
Hospital B (Coventry) was recruited. Within a specialist centre for complex cases of 
diabetes, endocrine and metabolic conditions, permission was obtained to attend a 
weight management and a renal clinic held one day per week for four weeks during 
                                                             
87 Ethical approval for recruitment in secondary care (i.e. the substantial amendment) was obtained on 
the 6th July 2009). 
Pr
ac
tic
e 
No. 
patients 
identified 
Recruitment 
rate 
(expression 
of interest) 
Eligibility check  
(% of no. expressing interest) 
Recruitment 
rate 
(consent/ 
baseline 
returned) 
Eligible  Ineligible Partially 
complete (& 
not returned 
when 
requested 
again) 
A 239 20 (8%) 14 (70%) 5 (25%) 0 10 (4%) 
D 2 1 (50%) 0 1 (100%) 0 0 
E 438 55 (13%) 29 (53%) 20 (36%) 1 (2%) 22 (5%) 
G 3 0  0 0 0 0 
H 144 13 (9%) 6 (46%) 3 (23%) 2 (15%) 3 (2%) 
Total 826 81 (10%) 49 (60%)  29 (36%) 3 (4%) 35 (4%) 
245 
 
December 2009 (i.e. for one month).88 However, the renal clinic was attended once 
only because most patients had Type 1 diabetes and were thus ineligible. 
Consequently, five clinics were attended across four days within one month. 
 
Patient recruitment  
Secondary care patient recruitment and retention is illustrated in Figure 20, 
including reasons for non-participation where these could be obtained.  
 
Figure 20 Secondary care patient recruitment and retention 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Twenty potentially eligible patients were identified from clinic notes across the 
clinics attended.  Thirteen of these patients (65%) were approached and offered the 
opportunity to receive more information about the study/answer the eligibility 
questions. The remaining seven patients (35%) did not arrive for their schedule 
clinic appointment. Of the patients that were approached, 10 (77%) agreed to 
receive information about the study and answer the eligibility questions; three (23%) 
patients did not agree to this.  Of those that answered the eligibility questions, five 
                                                             
88 This was arranged and commenced once R&D approval had been obtained (October 2009). 
20 patients with Type 2 diabetes identified  
 10 agreed to answer eligibility questions 
 5 interested but ineligible (≥1 questions not 
answered ok)  
Reasons: All taking antidepressants and or 
previously asked to see mental health team  
7 Did not attend scheduled appointment 
3 not interested 
Reasons: No reason provided (n=1) 
Poor memory (carer answered) (n=1) 
One more thing to have to think about (n=1) 
13 approached  
5 interested & eligible (all questions answered 
0 patients returned further materials  
Reasons for ineligibility with respect to clinical 
notes was not explicitly know but some 
examples were mentioned by HCAs: a 
diagnosis of diabetes/Type 2 diabetes was not 
apparent or the patient had a recorded history 
of serious mental health problems. 
 
246 
 
(50%) met the study selection criteria and were provided with an invitation pack, 
while five (50%) did not satisfy one or more of the criteria. Unfortunately, no patients 
then returned consent forms and the baseline questionnaire. 
 
Support groups 
Online group recruitment 
Site moderators for 18 independent online support forums were approached about 
posting information about the study on their forums. DUK was also contacted about 
posting the study on their online forums; DUK Facebook and DUK Supporting 
Members Area.89 Twenty online support groups were thus approached (January 
2010-March 2010).90 Online support group recruitment and retention is illustrated in 
Figure 21. 
  
Permission to post was not obtained for 13 of the independent forums, most of 
which did not respond to the request (n=12). One provided permission subject to a 
review of further information about the study, which was provided but no response 
could be obtained thereafter. Permission to post in the DUK Supporting Members 
Area was not granted, no reason was provided.  
 
Six sites (30%) therefore provided permission to post the study information in their 
forum (five independent forums and DUK Facebook). However, DUK Facebook 
withdrew permission once the study had been posted for approximately one day. 
Written permission was initially obtained from DUK, yet once the study was posted 
DUK91 removed it advising the researcher that site policy prohibits such posts 
because it is not possible to check and accommodate all researchers wanting to do 
                                                             
89 This is an online resource including a discussion forum. 
90 Ethical approval for the study was obtained in February 2010. 
91 This was a different member of DUK to the person that initially provided consent. 
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this.  Thus only five (25%) of the sites that were approached agreed for the study to 
be posted for the full period of time. 
 
Characteristics of the initially recruited forums, the location of the study post (i.e. 
instructed by the site moderator) and the dates over which the study was posted are 
illustrated in Table 16.  
 
Figure 21 Online support group recruitment and retention 
 
 
 
 
 
  
 
 
 
 
 
 
 
20 websites approached for 
permission 
 5 sites retained the study post for 
one month 
1 site retracted permission/removed 
the post 
6 sites initially agreed 
14 sites permission not granted or did 
not respond to request; no reason 
obtained 
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Table 16 Characteristics of online support groups92 
Forum 
address 
Community Site membership 
(at recruitment) 
Location of 
study post 
Recruitment 
period (no. 
days study 
posted)  
No. of views 
during 
recruitment 
period Diabetes type Nationality 
Recruited and retained 
http://www.dia
betes-
support.org.uk 
 
Diabetes (all types) UK based but English language: 
presumably intended for that nationality 
but open to international membership 
1, 076  
(March 2010) 
Research sub-forum: 
‘Research’ 
12/03/10 – 
12/04/10  
(31 days) 
183 
http://www.dia
betes.co.uk 
 
Diabetes (all types) UK based but English language: 
presumably intended for that nationality 
but open to international membership 
21, 193 
(March 2010) 
Type 2 diabetes sub-
forum: ‘Type 2 diabetes’ 
12/03/10 – 
12/04/10  
(31 days) 
534 
http://www.dia
betesdaily.co
m 
 
Diabetes (all types) USA based but English language: 
presumably intended for that nationality 
but open to international membership 
21, 436 
(February 
2010) 
Research sub-forum: 
'Promotions, surveys & 
trial recruitment' 
08/03/10 – 
12/04/10  
(35 days) 
126 
http://www.dlif
e.com 
 
Diabetes (all types) USA based but English language: 
presumably intended for that nationality 
but open to international membership 
43, 155 
(February 
2010) 
Research sub-forum: 
'Community centre: 
diabetes events & 
fundraisers' 
08/03/10 – 
12/04/10  
(35 days) 
46 
http://www.dai
lystrength.org/ 
 
Open to 500+ communities (i.e. 
LTPCs including diabetes & 
mental health conditions) 
USA based but English language: 
presumably intended for that nationality 
but open to international membership 
Not reported Research sub-forum: 
'Medical Research & 
Clinical Trials' 
10/03/10-
12/04/10 
(33 days) 
Not reported 
Recruited but not retained 
http://www.fac
ebook.com/di
abetesuk 
 
Diabetes (all types) UK based but English language: 
presumably intended for that nationality 
but open to international membership 
10, 028 
(March 2010) 
No sub-forum: posted 
on main site 
08/03/10 – 
09/03/10  
(1 day) 
Not reported 
                                                             
92 The study was typically posted for a period of 31 to 35 days; this slight variation is because permission for some forums was obtained slightly later than for others and the 
study website was closed when the latest post had been on that forum for one month. 
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Online support group participant recruitment and retention  
The number of people viewing the study post on each forum is included in Table 16 
and online support group participant recruitment and retention is illustrated in Figure 
22, including reasons for non-participation where these could be obtained. It was 
not possible to identify the number of people from each forum that went on to visit 
the study website, answer the eligibility questions, complete the eligibility check and 
then provide consent. However, threads about the study on the two UK-based 
independent forums indicated that some were from these.93 Patients were enrolled 
during March 2010, and completed the trial between July 2010 and October 2010.94 
 
Over the recruitment period, at least 889 people viewed the study post (i.e. one of 
the five forums retained did not provide this information).  Of the people viewing the 
study post in the forum, 64 (7%) visited the study website and considered answering 
the eligibility questions.95 However, only 34 (4%) submitted responses to the 
eligibility questions, 25 (74%) of whom were eligible (i.e. all questions were 
satisfied) and nine (26%) were not (i.e. one or more questions were not satisfied).  
 
Eight people (1%) returned a consent form and the DSQ. Six (75%) scored below 
the threshold for significant depressive symptoms (CES-D <16; mean 6 (SD 3.87) 
and were thus able to participate. However, two (25%) scored as ineligible (CES-D 
≥16; mean 24 (SD 4.24), these patients were excluded and instead were advised to 
contact their HCP.  
 
                                                             
93 It is possible, albeit unlikely, that some participants were obtained via DUK Facebook because a 
small number of people from either this forum or the other forums posted in on the same date had 
answered the eligibility questions before the DUK Facebook post was removed. 
94 The reason for the variable time taken to complete the trial is that this depended upon whether and 
how quickly participants returned materials. 
95 This was known because the study website consisted of two pages; individuals read the information 
about the study on the first page and then when prompted visited a second page comprising the 
eligibility questions, which was recorded. The number of people that visited the study website but did 
not consider answering the eligibility questions was not known. 
250 
 
Figure 22 Online support group participant recruitment and retention 
 
 
 
 
 
 
 
 
 
 
  
34 answered eligibility questions 
25 eligible (all questions answered ok) & mailed 
consent/DSQ  
2 ineligible (CES-D ≥16) 
 6 eligible (CES-D <16): randomised & mailed 
baseline then writing 
3 WED 
3 returned 2 week 
follow up 
1 returned debrief  
1 did not return writing 
Reason: 'Did not feel had 
anything to write about at 
time’ (n=1). 
8 returned consent/DSQ  
2 returned writing  3 returned writing 
3 Control 
 1 did not return 2 week 
follow up  
 Reason: not obtained (no 
response to email). 
2 returned 2 week 
follow up  
2 returned 3 month 
follow up  
3 returned 3 month 
follow up  
 3 returned debrief  
2 did not return debrief  
 Reason: not obtained (no 
response to email) (n=1). 
Claimed returned/would not 
re-send (n=1). 
64 visited study website & considered 
answering eligibility questions 
9 ineligible (≥1 questions 
not answered ok) 
Reasons: Not diagnosed at 
least 6 months (n=4). 
Had either been asked to 
see a mental health team 
before or currently taking 
antidepressants (n=5). 
 1 did not return 3 month 
follow up  
 Reason: not obtained (no 
response to email). 
889 viewed study post on forum  
3 returned baseline 3 returned baseline 
17 did not return 
consent/DSQ 
30 did not answer the 
eligibility questions 
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Of the six consented patients, five (83%) returned the writing task, five (83%) 
returned the two week questionnaire, five (83%) returned the three month 
questionnaire and four (67%) returned the debrief questions. Of the five participants 
that did write, most returned both the follow up questionnaires and debrief questions 
(n=3), however some returned both questionnaires but not the debrief questions 
(n=1) or did not return any other materials (n=1).The participant that did not return 
their writing returned both the questionnaires and the debrief questions. 
 
As participants were emailed rather than called about reasons for non-return of 
materials, emails were often not responded to and thus reasons not obtained. 
 
Local group recruitment 
DUK was additionally contacted about the possibility of including the study in 
newsletters and visiting local DUK volunteer groups (January 2010). Only 
permission to approach DUK voluntary groups was granted. The Coventry DUK 
voluntary group was contacted (February 2010), via DUK, who provided them with 
information about the study (i.e. a PaIS) and the research teams contact details. 
However, no response was obtained. 
 
Interested and untreated yet too screen-depressed participants 
It is evident that a significant proportion of the primary care population of adults with 
Type 2 diabetes are currently not receiving the support they would like for some 
degree of E&P need. Primary care patients that expressed an interest in the study 
were not currently treated for depression or receiving psychological therapy for any 
other reason. However, expressing an interest in this study may be taken to reflect 
treatment seeking in that patients were informed that the study was looking at ways 
of improving the health of people with Type 2 diabetes and whether and how writing 
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about different aspects of life might affect their health; it is likely that they inferred 
psychological health was being targeted. In fact, feedback in support group forums 
supported this inference (reported later). Indeed, of those that expressed an interest 
36% screened as experiencing significant depressive symptoms. The mean CES-D 
score for these patients was 26 (SD 8.0), and one patient even scored 43.  
 
The recruitment and eligibility check data from the online support groups concurred. 
Of those that expressed an interest/answered the eligibility questions, 85% were not 
currently receiving E&P support. It is difficult to know how many of these individuals 
would then have demonstrated significant depressive symptoms and been excluded 
in the eligibility check because so few returned consent and completed the DSQ. 
However of those that did complete this, 25% screened as experiencing significant 
depressive symptoms; mean CES-D 24 (SD 4.24). It seems reasonable to 
speculate that the proportion would be similar, unless the reason people did not 
complete the DSQ was systematically related to mood (i.e. people were too 
depressed to complete it or conversely did not perceive it to be relevant to them).  
 
It is also noteworthy that E&P support is potentially sought not only by untreated 
patients with longer established diabetes, but also those within six months of their 
diagnosis (i.e. when one might presume these individuals were still being well 
supported by the NHS); 14% of the online support group members that expressed 
an interest in the study and were not currently treated had been diagnosed for less 
than six months.  
 
253 
 
Recruitment and retention issues 
Three routes to accessing participants were attempted. The unique issues 
experienced in terms of recruitment and retention at both an organisational and 
patient level are now described for each approach.     
 
Primary care recruitment and retention 
Primary care practice recruitment  
Feedback from practices 
The reasons provided by practices that declined to take part were reported earlier in 
this chapter (i.e. where these could be obtained). Additional feedback from practices 
during the course of recruitment served to further highlight the issues that were 
experienced and potentially explain reasons for non-participation where these were 
not otherwise obtained. The concerns frequently expressed by practices and the 
measures taken in attempting to address them are presented in Table 17. 
 
Research portfolio issue 
Recruitment of practices was also notably hindered by recent changes in 
regulations relating to health service research. Studies that are externally funded by 
NIHR funding partners (NIHR, 2010), are now eligible for inclusion in the NIHR 
Clinical Research Network (CRN) portfolio and as such receive support from the 
NIHR CRNs, for example the PCRN. Practices recruited for such studies are 
reimbursed for research activity, and a research nurse is made available to assist 
with practice and patient recruitment, and any other resource costs. Indeed, the 
value and contribution of primary care research networks is widely acknowledged 
(Graham et al, 2007).  
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Table 17 Concerns frequently expressed by primary care practices and the attempts 
to address them 
Primary care practice concerns Measures taken to address concerns 
The PrIS depicted the study as complex 
and necessitating a significant amount of 
practice involvement. 
It was explained that the study actually necessitated 
minimal practice involvement limited to help with 
identifying participants that would not significantly add to 
their workload. 
The PrIS indicated that GPs would be 
required to deal with patients 
demonstrating significant depressive 
symptoms, patients’ questions about 
their screening score and patients’ 
concerns as a result of screening or 
writing. 
It was explained that this was anticipated to be infrequent 
because most at-risk patients would be excluded by the 
study selection criteria, and that the evidence suggests 
most people report engaging in WED to a be a positive 
experience.    
 
 
Practices were deterred by the amount 
they were asked to do (even though 
practice involvement was kept to a 
minimum). 
The researcher offered to be present while practices 
performed the search and mailed envelopes (i.e. to help 
in any way without seeing identifiable patient data), and 
do any other work in order to free staff to undertake 
this.96  
Practices were concerned about the cost 
to be incurred by them (i.e. postage 
costs). 
 It was explained that the cost of consumables would be 
covered by the University. This was not explained in the 
PrIS, however, as in the absence of funding97 it was 
originally intended that they would be asked to cover 
these costs. The researcher later undertook paid work 
commissioned by the DoH (NHS Diabetes & DUK, 2010), 
which provided a means to cover these costs.  
 
However, the present study was not externally funded and therefore not eligible for 
adoption onto the portfolio. Indeed, it was apparent that some practices were 
deterred by this issue; some expressed an interest in the study yet indicated that 
they did not have the resources to participate and on occasion inquired about how 
much they would be paid. A stance of portfolio only studies was also apparent for 
some practices. This impact on institutionally or self-funded PhD research suggests 
that primary care research training experiences may be limited in the future. 
 
This finding confers with the literature that has explored the involvement of GPs in 
primary care, and the incentives and disincentives for GP participation. Specifically, 
one UK study interviewed GPs that declined participation in a primary care research 
study, reporting that practice participation is typically low and that GPs primarily 
                                                             
96 One practice agreed to this and to have the researcher search data with identifiable features 
removed, however they dropped out before this could be undertaken (practice F). 
97 The study was competitively awarded internal funding, which covered the stipend and fees for a PhD 
studentship yet did not provide a means of covering costs associated with the research.  
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expressed a lack of time for research and an already overwhelming workload. 
However, were they to be paid GPs would consider research in their own time, and 
in fact some commented that an indication of payment is sought before deciding 
whether the study information is worthy of further consideration. Indeed, research 
was considered low value in its potential to inform clinical practice and facilitate 
career progression within primary care (Salmon, Peters, Rogers, Gask, Clifford, 
Iredale, Dowrick & Morris, 2007). Despite mounting pressure for GPs to participate 
in research such that the NHS can become more evidence-based, as specified in 
recent policy imperatives for instance ‘Best research for best health’ (DoH, 2006a), 
this study additionally identified a sense of entitlement to non-participation since 
there are no such expectations of GPs (i.e. it is not in the GP contract) (Salmon et 
al, 2007). Indeed, it is widely acknowledged that many primary care practices will 
not consider collaboration without payment as research is not a core activity for 
primary care (NIHR & PCRN, 2010).  
 
The QoF criterion issue 
Practice recruitment and retention was further adversely influenced by a study 
design flaw. As reported in chapter four, the study selection criteria originally 
additionally required that within the past 12 months patients had screened positive 
(i.e. answered yes) to at least one of the two QoF depression-screening questions 
(introduced in chapter one). It was anticipated that this QoF criterion would promote 
practice recruitment, providing a means of treating patients indicating that they are 
experiencing lower-level depression in a climate of limited treatment options (as 
discussed in chapter one IAPT was not fully implemented when practices were 
recruited). Indeed, this potential benefit was emphasised in the PrIS as a means of 
incentivising GPs. Research into the incentives and disincentives for GPs to 
participate in primary care research has consistently indicated that studies must 
highlight the relevance of the research to practices and sell the potential benefits of 
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the study to practices beyond the merits of the research (Graham et al, 2007; 
Johnston, Liddy, Hogg, Donskov, Russell & Gyorfi-Dyke, 2010). However, two 
problems were encountered in relation to this criterion: 
 
1. Practices conducted computerised searches and many were unable to apply this 
criterion as responses to the QoF questions are recorded free text and they were 
not willing to search manually (practices B, E and H).  
 
2. Enforcing this criterion recovered no or very few participants; four of the eight 
practices recruited initially searched including this criterion; the numbers identified 
were 0 (Practice D), 3 (Practice G), 13 (Practice A) and the number was retained for 
one practice as it was low and considered by the practice not to be useful (Practice 
C). These practices indicated that it was this criterion which greatly reduced the 
number of eligible patients.  
 
It is noteworthy that because patients currently receiving depression/psychological 
treatment were excluded, it seems that either: 
 
a) There are virtually no people with Type 2 diabetes that have lower-level depression; 
all have no need or a significant need that obviously requires treatment. This is 
unlikely in view of the literature/evidence base outlined in chapter four, which 
suggests that lower-level need is experienced by the highest proportion of people 
with Type 2 diabetes (NHS Diabetes & DUK, 2010). Moreover, consultation with a 
local GP when developing the study protocol indicated that enforcing the QoF 
criterion and excluding patients with a significant need/currently receiving treatment 
was a valid approach for identifying these patients. 
 
257 
 
b) The QoF questions detect only higher-level depression, most of which most is 
currently being treated. Three observations in the present study may be taken to 
support this assertion. Firstly, one practice advised that most patients with diabetes 
say no when asked these questions hence a search based on this would identify 
few patients (Practice C). Secondly, of the patients that were identified via searches 
including the QoF criterion and mailed out to (n=16), one response was received 
and this patient was excluded in the eligibility check having screened as 
experiencing significant depressive symptoms. Finally, in practices that had 
achieved good QoF depression-screening scores (i.e. generally approximately 90% 
of patients having been screened on one occasion during the previous 15 months), 
a substantial number of patients with Type 2 diabetes were found to be 
experiencing significant depressive symptoms that were untreated. This may be 
taken to suggest that the QoF questions do not detect the full spectrum of 
depression. 
 
This scenario is unlikely, though, given the evidence reported in chapter four, which 
suggests that the QoF questions perform sensitively and detect most true cases of 
depression, but they also have a high false positive rate and thus additionally 
identify a substantial number of patients with lesser symptoms.  
 
c) The QoF questions do detect all levels of need including lower-level depression, yet 
most of these are currently treated. This explanation is consistent with the 
aforementioned diagnostic accuracy evidence (again as reported in chapter four), 
and provides some support for the concern that false positive cases identified by the 
QoF questions may result in ‘over-treatment’. As described in chapter one, although 
IAPT has recently improved access to psychological intervention this is still 
somewhat limited and indeed it was at the time of practice recruitment. Although 
again speculative this suggests antidepressants may have been prescribed for 
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lower-level need, which NICE specifies should be reserved for moderate to severe 
depression. As also described in chapter one, it has previously been speculated that 
practitioners may prescribe antidepressants where psychological treatment is less 
readily available (Kendrick et al, 2009). Indeed, the QoF depression indicators have 
now been retired owing to widespread complaints about poor diagnostic ability, 
specifically over-diagnosis of individuals as depressed and appropriate for 
antidepressants (PulseToday, 2011). 
 
Audits of eligible patients on the diabetes and CHD registers for two rural general 
practices in the UK, excluding those with known depression, have similarly identified 
that of those patients screened with the QoF questions (approximately 80%) only 
1% (Subramanian & Hopayian, 2008) and 2% (Croxford, 2008) responded 
positively. The explanations offered have included low detection rates for the QoF 
questions and adequate recognition of depression irrespective of the QoF 
questions, somewhat consistent with the explanations offered above (i.e. b) and c) 
respectively). Interestingly in one study of the two patients responding positively to 
the QoF one was assessed as having minimal depression whilst for the other 
moderate to severe depression was identified (Croxford, 2008), suggesting that the 
third assertion above is again more likely (i.e. that the QoF questions do detect 
lower-level depression yet most of these are currently treated).  Additional albeit 
seemingly less likely assertions offered are that patients with depression may be 
those refusing screening to avoid a probable diagnosis and errors in audit data 
collection/factors specific to the sample, yet this is unlikely given that this finding is 
emerging across different studies. 
 
It was not a pre-specified objective of the exploratory RCT to identify the feasibility 
of targeting patients with Type 2 diabetes and lower-level E&P need, yet this finding 
provides valuable information about the difficulty in achieving this; obviously other 
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means of achieving this must be identified. Owing to the problems encountered, a 
substantial amendment was obtained to remove the QoF criterion (July 2009), 
which indeed boosted the number of identified patients. However, this amendment 
meant that patients with none and some, rather than only some, level of E&P need 
were included. Thus the initial endeavour to enhance the applied relevance of the 
trial and maximise effectiveness was thwarted. Indeed, the level of need amongst 
interested and eligible, and then consented, patients was relatively low (CES-D 
mean 7; see chapter seven). 
 
In terms of the influence of the QoF criterion upon practice recruitment, it is likely 
the need for some practices to manually search responses to the QoF questions 
played a role in the 105 that chose not to participate. A number of practice retention 
problems can also be attributed this: 
 
 The loss of three practices: As described earlier one practice initially agreed to 
participate yet withdrew due to pragmatic complications associated with 
searching; they were amongst the practices that were unable to apply this 
criterion in a computerised search. By the time the amendment to remove this 
criterion had been organised, their situation had changed and they were no 
longer able to take part (Practice B). After removing the QoF criterion the four 
practices that had already completed the search were asked to re-search 
without it (and then mail out to any additional patients). However, two practices 
were unable to do this. For one the GP was performing the search, thus they 
had limited time and resource (due to QoF related workload); this was the 
practice for which the number of patients identified initially was very small and 
not retained (Practice C). The other practice was overrun with swine flu when 
the second search was requested; this was the practice that identified and 
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mailed to three patients initially, and who actually commented at the time that 
they had identified 80 patients before the QoF criterion was applied (Practice G). 
 
 The time delay in searching: the remaining practices that were unable to apply 
this criterion in a computerised search agreed to search once the criterion had 
been removed, yet there was an inevitably long delay from when the practice 
was approached to when the search was performed while ethical approval for 
the substantial amendment was obtained (Practices E & H).   Additionally, two 
practices agreed to repeat their initial search once the QoF criterion had been 
removed, but again there was a delay in arranging this and also finding the 
resources to search again (Practices A and D).98 
 
It is noteworthy that, as mentioned earlier, beside the complication of the QoF 
criterion, completion of searches by practices was often delayed for other reasons. 
The most notable, observed across practices, were swine flu related/QoF-related 
work overload, practices being short staffed over the summer when searches were 
attempted and PM annual leave.   
 
Additional efforts to recruit practices  
In view of the recruitment issues that were anticipated and then experienced, 
additional means of recruiting primary care practice were attempted. These are 
described below. 
 
                                                             
98 It is also noteworthy that despite being asked not to mail out to the same patients initially identified 
and mailed out to in the QoF search, when the search was repeated without the QoF criteria it was 
apparent that one of these practices may have done this (practice A); a patient that initially declined 
received a further invitation pack and called the research team to decline again. Consequently, the 
number mailed out to may have been slightly less than indicated; 814. Moreover, one of the 81 
patients that expressed an interest may be a duplicate; one patient from this practice expressed an 
interest and screened as ineligible in the first mail out and may have responded again had the pack 
been re-received. 
 
261 
 
Recruiting within additional PCTs 
It was initially intended that practices from Hereford PCT would additionally be 
approached. Consequently, an application to Hereford PCT R&D was intended. 
However, whilst enquiring about the application process it was discovered that local 
collaborators (i.e. general practices) were to be identified as a means of providing 
evidence that GPs would be happy to participate before an application could be 
made. Furthermore, detailed information was required about the costs to the NHS 
and sources of funding for covering this, and it was advised that studies were 
unlikely to be approved if there was a cost to practices in the absence of a financial 
incentive. 
 
A non-obligatory expression of interest was therefore sought from a small sample of 
practices in Hereford. Seven with evidence of a special interest in diabetes and or 
mental health were identified via a search of practice websites and as 
recommended by local research nurses, which included practices that had 
previously taken part in diabetes studies at WMS. Practices were mailed a letter and 
PrIS, which additionally outlined the cost implications for the practice and indicated 
these to be minimal (i.e. as agreement with this aspect of the study was required by 
R&D). They were advised to contact the research team should they be interested, 
yet were followed up once.  Only one practice responded to indicate that they were 
not interested, with no reason provided. Thus, in the event of no funding to cover 
the costs to practices, however minimal, and an inability to obtain support from local 
collaborators, the R&D application was not pursued.   
 
Attempts to obtain external funding 
Attempts to obtain funding to cover the cost to practices were made whilst preparing 
the application to Hereford PCT R&D, for example contacting the West Midlands 
South Comprehensive Local Research Network (CLRN) and local R&D managers, 
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for example for Hereford PCT. However, no support was obtained. The research 
team also submitted a funding bid to DUK, which was well received but 
unsuccessful in the absence of pilot data. 
 
Direct GP contact 
In addition to contacting practices, a departmental email was sent to GPs working 
within WMS explaining the recruitment difficulties and requesting assistance, 
reiterating the positive aspects of the study. Such an approach is advocated by 
studies that have identified the incentives and disincentives for GPs to participate in 
primary care research (Johnston et al, 2010). However, no additional responses 
were obtained. 
 
Attempts to minimise the impact upon practice resources 
As advised by a local GP, arrangements were made to advertise the study in a flyer 
made available at a meeting at the West Midlands Deenery for doctors undertaking 
GP speciality training. Specifically, this offered the study as a means of meeting a 
course requirement. However, no responses were received. 
 
Attempts to elicit minimal assistance from research nurses 
Local research nurses were approached for assistance in initiating contact with 
practices. However, they were unable to help because the study was not a NIHR 
CRN portfolio study. 
 
Primary care patient recruitment  
The research did not seek to formally collect data about reasons for patients not 
wanting to participate and therefore from an empirical stance these reasons are not 
known. However, issues that were raised by practices and patients contacting 
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practices or the research team about the study provide some insight into patient 
recruitment problems. The problems identified, and the supporting evidence, are 
provided in Table 18. 
 
Table 18 Primary care patient recruitment problems with supporting evidence 
Primary care patient recruitment 
problem 
Evidence 
The DSQ created some concerns 
amongst patients; some took it to 
imply they were unsuitable & some 
found it difficult to complete. 
Three patients contacted the research team to enquire 
whether they could still participate given that they did not 
really have any worries/were not depressed and therefore 
they were uncertain that they would be of any help (i.e. none 
of the depression-screening questions were relevant to 
them). In fact, another patient contacted the research team 
citing similar reservations as their reasons for not completing 
the baseline questionnaire (& thus not consenting to the 
study). 
Seven patients returned a DSQ that was partially completed 
& 3 of these did not complete/return it again when requested. 
Reasons were obtained for one patient who stated that they 
had ‘never really thought about these things’. 
Some patients were concerned 
about their writing ability. 
Despite re-assurances that it was unimportant in the PaIS, 
some patients expressed concerns about poor writing ability 
when they called the research team about the invitation pack. 
Some patients were confused & 
caused to question the authenticity 
of the project when they found 
practice reception staff were 
unaware of the study. 
One patient contacted a practice with a query about the 
study (even though the patient letter/PaIS advised contact 
with the research team) and then contacted the research 
team advising that no one at the practice seemed to know 
about the study.  
Patients were confused about an 
oversight in the study design; the 
PaIS instructed patients to return the 
EOIF and DSQ to their practice, yet 
the business reply envelope 
provided was addressed to the 
university. 
Some patients called the research team and practices 
confused about this oversight. 
Some patients were concerned that 
too much time had elapsed to reply 
to the invitation pack. 
One patient contacted the research team a few months after 
invitation packs were sent out to enquire whether it was too 
late to participate. 
Practices mailed out to some 
ineligible patients. 
Four patients contacted the research team to explain that 
they were ineligible because they had Type 1 diabetes, were 
blind or the patient invited had dementia (i.e. a carer called). 
Some patients were experiencing 
difficult personal situations, in which 
writing/study participation presented 
an additional burden. 
One participating patient noted on their returned materials 
that they were a full time carer for their disabled spouse.  
Other personal circumstances.  One patient contacted the research team to advice that the 
invitation pack was not wanted as they were ‘going away’. 
Many identified patients were likely 
from ethnic minorities and unable to 
participate owing to insufficient 
English writing ability (i.e. English 
writing ability was not an inclusion 
criterion). 
 One practice advised that they would probably identify few 
patients that could participate because approximately 80% of 
those on their diabetes registers were from ethnic minorities 
(based in Leamington Spa). Indeed, as noted in chapter four, 
diabetes is particularly prevalent in these groups, for instance 
South Asians. This was likely an even more substantial issue 
for practices from particularly multi-ethnic areas (e.g.  
Coventry).  
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Primary care patient retention  
The reasons why patients did not consent to take part in the study were not known 
other than because a large proportion of interested patients screened ineligible in 
the eligibility check. Reasons why patients did not return the writing pack and 
subsequent materials were sought and were reported earlier in this chapter, albeit 
again for some patients these were not obtained. However, a number of issues 
encountered during the trial provided some insight into patient retention problems. 
The problems identified, and the supporting evidence, are provided in Table 19. 
 
Table 19 Primary care patient retention problems with supporting evidence 
Primary care patient retention 
problem 
Evidence 
Practice administration issues. A significant number of eligible patients did not return the baseline 
questionnaire & consent; figures for individual practices were 21%, 
29% and 50% and for the latter practice the PM’s annual leave 
created a substantial delay in these materials being sent to 
patients. It may be important to send these straight away before 
patients lose interest. 
Inability to chase non-return of 
materials. 
Of the reminder letters that were sent, 50% resulted in returned 
materials. However, as no address was provided in their consent 
forms some patients could not be sent some reminders; three 
patients were not sent reminders about writing packs and or two 
week questionnaires that were never returned. While practices 
usually agreed to forward materials in these instances with a 
request for an address each time, on these occasions they did not. 
Telephone reminders also often resulted in return of materials. 
However, as patients often did not provide a contact telephone 
number, some could not be called about materials that were never 
returned. This not only meant that reasons were not obtained but 
these patients were additionally not encouraged to return the 
materials.  
Patient illness during the trial. Perhaps due to the age of some consented participants (i.e. range 
41-84 years) illness was occasionally mentioned in the follow up 
questionnaires or as reasons for delays in returning these. One 
patient mentioned not feeling well,  another had a double bypass 
operation and another was admitted to hospital with heart failure 
(i.e. atrial fibrillation) during the follow up period.  
Patient safety issues. GP referral as a result of a review of essay content may have 
deterred one patient who was referred as high risk/requiring 
action, as they did not then return any materials post-writing. 
 
Secondary care recruitment and retention 
In response to the recruitment problems experienced in primary care, recruitment in 
secondary care was organised and attempted.  
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Secondary care clinic recruitment and retention 
One secondary care clinic was initially recruited but not retained, the reasons for 
which were reported earlier. As described in chapter four, the recruitment strategy 
for secondary care was developed in consultation with an appropriate clinician, but 
from this unretained clinic. When recruitment was attempted in the clinic that was 
recruited a number of feasibility problems were encountered, namely because 
clinical support was much less available than initially anticipated. The recruitment 
strategy was thus adapted in consultation with the staff and consultant at the clinic 
that was recruited. The issues experienced and changes necessitated are described 
below, as they highlight the difficulties in undertaking recruitment in a clinical setting 
which is effective and satisfies ethical requirements when limited clinical support is 
available.  
 
Attendance at clinics 
It was also only possible for the researcher to attend a much smaller number of 
clinics over the course of the month than was originally intended (i.e. one day per 
week rather than daily), which hindered the pace of recruitment considerably. 
 
Identifying patients 
It was intended clinicians/clinic staff would initially identify patients meeting the 
study selection criteria and their subjective HCP assessment of suitability in 
consultations, inviting them to be introduced to the researcher in order to receive 
study information and screen for eligibility in the waiting room (as recommended in 
chapter four).  However, this was not possible as clinic staff did not have the time. 
Consequently, as described in chapter five, HCAs identified patients with Type 2 
diabetes from clinic notes, who the researcher then approached in the waiting room 
enquiring whether they would be willing to receive more information about the study 
266 
 
and screen for eligibility. As identified in chapter four, this strategy has typically 
been less successful in WED studies with LTPC samples recruited in secondary 
care. Indeed, recruitment to WED trials in pain clinics is noted to be particularly poor 
where researchers that are non clinic staff hand invitation packs to patients (Brown, 
Dick & Berry, 2010). 
 
This created also some ethical issues. Firstly, patients were approached by the 
researcher, without them having advised clinic staff that they would agree to this. It 
was emphasised, though, that this was not obligatory and they were free to say no. 
Secondly, patients were asked to provide information of sensitive nature in a waiting 
room, rather than them being assessed for eligibility in the privacy of their 
consultation. However, patients were asked to read the questions silently and 
respond only with yes or a no. Finally, if patients did not satisfy the eligibility 
questions, they had to be advised that because of the answers they gave they were 
not able to take part, rather than patients being informed about the study only if they 
were eligible. This was uncomfortable for patients and not appropriate in a waiting 
room. Whilst not ideal, it was advised as tactfully as possible that the questions 
were simply to ensure that the study was offered to suitable people. 
 
Eligibility check and negative emotional response to screening/writing 
It was intended that upon completion of the eligibility check, patients meeting the 
criteria for significant depressive symptoms would be dealt with accordingly by the 
secondary care clinician, for which specific agreement would be obtained at clinic 
recruitment. Moreover, contact with the clinician was to be encouraged should 
patients wish to discuss their screening score, or should they experience any 
concerns as a result of screening or writing, with specific contact details provided 
and specific agreement again obtained at clinic agreement. However, this was not 
agreed to as the consultant advised that they would refer such patients to their GP. 
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Consequently, the strategy was changed such that for ineligible patients GPs would 
be notified about their screening result. Patients were also signposted to their GP. 
This was potentially problematic in that GP agreement had not been obtained, and 
indeed GP contact details could not be offered to patients for this reason. 
 
Secondary care patient recruitment 
Both of the initially recruited consultants indicated that they expected a large 
number of eligible patients could be provided by their clinics. However, as described 
earlier, this was not the case. For the hospital that was retained, many patients did 
not attend for scheduled appointments, and clinic staff complained about 
consistently high rate of such ‘DNAs’. Moreover, for one clinic the patient notes did 
not arrive, thus eligible patients could not be identified. When patients did attend 
clinic and clinic notes were available, few potentially eligible patients were identified; 
the researcher attended weight management and renal clinics at which only some 
diabetes patients presented. Moreover, when potentially eligible and interested 
patients were identified, only half met the study exclusion criteria; it seems that 
many patients attending secondary care suffer from psychological problems that 
mean that they may be at risk of re-traumatisation from WED.  
 
Support group recruitment and retention 
In response to the recruitment problems experienced in primary and secondary 
care, recruitment from support groups was organised and attempted.  
 
Support group recruitment and retention  
A number of problems were experienced in relation to support group recruitment. 
With respect to the independent online forums, it was difficult to identify specific 
contact details for site moderators in order to request permission to post the study in 
268 
 
forums. Often messages were sent via forms provided on the websites which were 
easily ignored, hence most sites that were approached did not reply to the request. 
It was additionally difficult to identify the appropriate contact with regards to 
recruitment efforts via DUK. Indeed, as described earlier conflicting advice was 
obtained with respect to DUK Facebook. Conflicting advice was also obtained with 
respect to approaching DUK voluntary groups; one contact advised that this was not 
allowed, whereas another contacted a local support group on behalf of the research 
team giving the impression that direct contact with groups was not possible. Another 
contact later provided contact details for local groups, however further groups were 
not approached as by that time online recruitments efforts had provided few patients 
and it was considered unlikely this would identify many more. Given the time 
constraints of the project it was necessary to draw a line under recruitment. 
 
Support group participant recruitment 
As in primary care, the research did not seek to formally collect data about reasons 
for support group members not wanting to participate and therefore from an 
empirical stance these reasons are not known. However, a number of observations 
and feedback from participants provided some insight into support group participant 
recruitment problems. The problems identified, and the supporting evidence, are 
provided in Table 20. 
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Table 20 Support group participant recruitment problems with supporting evidence 
 
Support group participant recruitment 
problem 
Evidence 
Exposure to the study information was limited 
as the study often had to be posted in 
research sub-forums; individuals not 
routinely visiting these sections were not 
approached. 
The greatest response in terms of views of the 
post and comments in a thread about the study on 
the forum was achieved for the forum in which the 
study was posted in a Type 2 diabetes sub-forum. 
International forum users seemingly 
incorrectly inferred that the study was 
intended for UK residents only. 
 Recruitment was apparently more successful in 
UK based forums; there were many more views of 
the study post and more comments about the 
study in threads on these forums, and all of the 
individuals returning the consent form and the 
DSQ were from the UK. Indeed, one individual 
that returned these materials enquired about 
whether they could still participate as they were 
English but now lived in France. 
The DSQ created some concerns amongst 
patients; some took it to imply they were 
unsuitable (i.e. as in primary care). 
When one support group participant returned the 
consent form and DSQ they expressed concern 
that their responses may have been too positive. 
Formatting problems.  A large proportion of people did not return the 
consent form and DSQ. Reasons for this were not 
obtained, however some participants indicated 
that they chose not take part because the 
materials had somehow become confused and 
unanswerable without significant work to 
unscramble them. Hardcopies of the materials 
were offered to these patients, others that had 
already received them yet not replied and any 
people satisfying the eligibility questions 
thereafter. However, none agreed to this.  
Returning materials electronically sometimes 
lead to confusion. 
 There were a number of instances of participants 
accidently deleting materials and thus some 
requesting them again, and believing that they 
had returned materials when they had not. 
 
Support group participant retention  
The reasons why support group participants did not consent to take part in the study 
were not known other than as in primary care because a large proportion of 
interested patients screened ineligible in the eligibility check. Reasons why 
participants did not return the writing pack and subsequent materials were sought 
and were reported earlier in this chapter, albeit again for some patients these were 
not obtained. However, again a number of issues encountered during the trial 
provided some insight into participant retention problems. The problems identified, 
and the supporting evidence, are provided in Table 21. 
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Table 21 Support group participant recruitment problems with supporting evidence 
Support group participant retention problem Evidence 
Formatting problems were experienced with 
respect to all study questionnaires. 
Two participants commented that the forms were 
difficult to complete, particularly marking the text 
boxes (i.e. with an ‘X’) and completing the EQ-
5D. One support group participant that seemed to 
be particularly impacted by formatting problems in 
the baseline questionnaire that was returned, and 
who requested a hardcopy of the writing pack, did 
not return any materials post-writing.99 
Participants apparently grew tired of 
completing the same measures. 
One participant commented that they only 
partially completed a follow up questionnaire 
because they had recently completed the same 
questions and did not see the point in repeating 
this (i.e. the SSQ6). 
 
 
Comments on support group forums 
Some patients’ comments in threads about the study provided additionally insight 
into the reasons for support group members not wanting to participate. These are 
outlined below. The researcher replied only where questions were explicitly asked, 
yet was usually afforded opportunities to dispel misconceptions about the study 
without providing information beyond that presented in the PaIS.100 
 
Scepticism about the project  
Concerns about academic rather than patient gain 
Two members from different forums suggested that the study was principally 
intended to enhance academic study rather than help people with diabetes, given 
that the project researcher was a student and presumably a person without 
diabetes. 
                                                             
99 Electronic questionnaires were forwarded to this participant with hardcopies of questionnaires 
offered but not accepted. 
100 Individuals were assured that the project supervisors had academic and clinical expertise and were 
committed to diabetes care, the project was competitively awarded internal funding in a peer review 
process before the student researcher was involved, a large evidence base suggests writing may be 
helpful in LTPCs (perhaps even for physical health) yet better quality trials were required (information 
about  WED was not provided), the project was subject to rigorous internal and external (i.e. NHS) 
ethical review in which anticipated benefit for patients is paramount and must be proved, there was at 
that time a large scale five year externally funded trial being undertaken in the USA by an established 
research group (noted in chapter nine), a similar trial was already being run by the research team in 
primary care (i.e. with NHS support), the study was small yet it was a pilot intended to inform a funding 
bid for a larger trial which would add to the growing evidence base, and that such studies could 
potentially encourage Government investment should writing be shown to be effective given that it is 
relatively inexpensive. 
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Scepticism about anticipated benefit 
One member expressed they were unsure there would be any durable benefit for 
people with diabetes and as such wondered whether the study was worth being 
involved in. Another was sceptical that there could be any physical health benefit, 
only psychological benefit if any at all. 
 
Belief in benefit but concern about likely implementation/preference for other 
assistance 
One member stated that there was no point getting involved because while the 
benefits of writing are known, such a small scale study would not encourage 
Government investment, and in fact they would rather the Government provided 
free monitors and strips. 
 
Concern about study materials 
One member joked that having completed the baseline questionnaire they felt that 
somebody would know enough about them to ‘lock them up and throw away the 
key’. Another user commented that they had received the consent forms and DSQ, 
yet they were not intending to return this as they found the questions to be odd. 
 
Preference for writing in forums 
One member explained that they found little time for writing outside work, which was 
reserved for the online forums. 
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Absence of proper consideration of study information 
It was evident that some members made a decision about the study via the post and 
website having not read the PaIS. For example, one member enquired about 
whether written texts or the physical act of writing was being investigated. 
 
Concern about the connotations of the study 
Some members speculated that the study was derived from the notion that people 
with diabetes often suffer depression, and others read this indicating that they did 
not agree with this presumption about diabetes. These, and other, people may have 
been deterred by these initial posts.  
 
Concern about screening 
One patient commented that she had applied to take part yet was not able to 
because apparently she was slightly depressed, joking that she now felt more 
depressed. Reading this may have deterred others. 
 
In fact each of the aforementioned comments may have deterred others from taking 
part. However, it should be noted that there were some positive comments about 
the study, which may have encouraged participation. A few members expressed a 
general interest in the study and others articulated a belief in the beneficial effect of 
writing, in particular private disclosure of thoughts and feelings, whilst suggesting 
catharsis and other mechanisms of effect. One member involved in the discussion 
explicitly went on to disclose about some negative experiences. 
 
Additional potential recruitment issues  
It is noteworthy that there were some additional issues that may have prohibited 
recruitment and retention, even though supporting evidence was not obtained for 
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these issues. It is possible that participants may have been deterred by the PaIS 
given that it was relatively long and detailed. However, this information was again 
an ethical requirement. Patients may have additionally been deterred by their HCP 
seeing their screening data and perhaps being rejected from the trial on this basis, 
or the warning with respect to the potential negative response to writing or 
screening. It is also possible patients were deterred by the consent form, specifically 
signing to agree to people seeing their medical records. Support group participants 
may have been deterred by the need to contact their HCPs about their participation 
in the trial and possibly their screening score. Finally in view of feedback obtained 
from support group participants, it is possible that primary care practices and 
patients were similarly deterred by the researcher being a student. However, whilst 
the patient and practice letters indicated that the principle researcher was a student, 
they additionally noted that the project was supervised. 
 
Á priori sample size calculation 
The feasibility of achieving sample size requirement 
The sample size calculation indicated that at least 110 participants were required, 
presuming 20% attrition (as was observed). However, only 37% of the number 
required was recruited before attrition. In fact, when accounting for clustering within 
practices, at least 219 participants were required, yet only 16% of the number 
required was recruited in primary care. This was obviously owing to the recruitment 
and retention problems discussed above. The sample size was, however, consistent 
with many of those included in the systematic review (chapter three), and is 
attributed to the burden associated with WED (Sheese et al, 2004). 
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The appropriateness of the sample size calculation parameters 
The parameters of the sample size calculation initially specified require revision 
owing to observations made in the present study. 
 
Primary care 
As required, eight practices were recruited, yet three were lost. On average, each 
practice provided the anticipated number of patients with Type 2 diabetes not 
currently treated for depression (i.e. approximately 170). However, a 20% 
recruitment rate was anticipated, yet on average 10% was observed. Moreover, 
losses in the eligibility check (i.e. 36% of initially recruited patients were too screen-
depressed to participate) and between the eligibility check and consent (27% of the 
eligible patients did not return the consent form) were not originally accounted for. 
Perhaps having to agree twice was too much for interested but wary patients. 
 
Secondary care 
Attending clinics only once per week for one month identified 20 patients with Type 
2 diabetes, which was more than anticipated (i.e. 40 with daily attendance). 
However, the loss of potentially eligible patients owing to unattended appointments 
(i.e. 35%) or unwillingness to answer the eligibility questions seemingly because 
patients were already too burdened to consider the study (i.e. 23% of those 
approached) was not anticipated. The number of those answering the eligibility 
questions that would already be treated was also very much underestimated (i.e. 
50% not 15%). As anticipated, however, no patients were excluded for having been 
diagnosed for less than six months. Importantly though, the recruitment rate was 0% 
not 20%. 
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Online support groups 
As required, six sites were recruited, yet one was lost. However, the average 
number of people that were expected to view the study post per forum was 
overestimated (i.e. 222 not 3,462), which was likely because, unexpectedly, visiting 
the forum did not automatically equate to viewing the post; again this was in a 
specific sub-forum, typically research-related, which only some members visit and 
then view selected posts. However, all, rather than 75%, of those viewing the study 
post likely had Type 2 as the link to the post specified it was for people with Type 2. 
Recruitment was apparently better than anticipated (i.e. 4% rather than 1% of those 
viewing the post answered the eligibility questions), yet this is likely overestimated 
as number of people viewing the post for one forum was not known. It should be 
noted that 7% of those viewing the post actually visited the study website, yet of 
these only 53% then answered the eligibility questions.  
 
The proportion of those answering the eligibility questions that were currently 
treated was as expected and concordant with that anticipated for primary care (i.e. 
15%). While speculative, this may be taken to suggest that despite receiving 
treatment from the NHS some people were still seeking support elsewhere (i.e. 
support groups and the study). As anticipated approximately 10% had then been 
diagnosed for less than six months. However, losses between the eligibility 
questions and the eligibility check/consent (i.e. 68% of potentially eligible people did 
not return the consent form/DSQ) and again the in eligibility check (i.e. 25% of 
initially recruited individuals) was not accounted for. It seems that a one month 
recruitment period was appropriate; the forums were checked approximately five 
months after the close of the recruitment period and only 591 additional patients had 
viewed the post. 
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Conclusions 
A number of recruitment and retention issues were encountered. Some suggest the 
potential for significant barriers to primary care research training experiences in the 
future, while others that raise doubts about recent screening practices and suggest 
an unacceptable presence of untreated E&P need amongst adults with Type 2 
diabetes, particularly primary care patients. On a positive note, however, the 
problems identified provided a wealth of invaluable information to inform future 
endeavours. The sample size requirement was obviously not met owing to the 
recruitment and retention problems identified, and revisions to the parameters of the 
initial sample size calculation are required. Based on this data future attempts can 
set realistic expectations and better plan for contingencies that would otherwise 
greatly reduce the sample size obtained and limit the informative potential of the 
trial. Finally, alternative means of identifying people with Type 2 diabetes and at 
least some yet not significant depression are additionally required. 
 
Required revision of trial objectives 
The revisions that had to be made to the trial methodology as a result of the 
constraints applied by the ethical review (i.e. the eligibility check; additionally 
discussed in chapters four and nine) and the difficulties experienced in 
recruitment/retention (i.e. described above/in this chapter) meant that a very small 
sample was derived, with insufficient time and resource available to address these 
issues (i.e. in part owing to the delays imposed by the ethical review and 
recruitment difficulties experienced). This meant that the trial objectives delineated 
in chapter five had to be narrowed to those that the thesis was subsequently able to 
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address; a focus on the feasibility with a very much exploratory analysis of the 
effectiveness of WED.101  
 
As such, the original objective asking ‘does WED work as anticipated’ became too 
ambitious; no conclusions can be drawn from these explanatory analyses. 
Consequently, these analyses were proceeded with in a hypothesis generating way 
and because this may aid interpretation of any main effect. The original objective 
asking ‘does WED work differently for different for different people as anticipated 
and who does it work best for’ similarly became too ambitious. In fact, the 
informative potential of the moderation sub-groups analyses was particularly limited 
by the size of the database. Hence, these analyses are mentioned only very briefly 
in relation to the main effect again in a hypothesis generating way. The prior cost 
effectiveness analysis was no longer sensible or informative and was thus removed. 
 
The revised objectives were therefore: 
 
Feasibility investigation 
1. Pilot appropriate intervention and trial parameters  
 
2. Feasibility/effectiveness of intervention delivery 
Collect information about compliance, contamination and the acceptability of the 
intervention and comparison exposure. 
 
                                                             
101 It should be noted that specification of depressive symptom severity as a primary outcome became 
somewhat inappropriate given that patients with none or only very few symptoms were included, owing 
to the constraints applied by the REC and the failure of the QoF inclusion criteria to ensure inclusion of 
patients with at least some lower-level depression.  In fact, a focus on DSED, which WED is purported 
to target, perhaps became a more sensible primary outcome. However, as the effect of WED upon 
depressive symptom severity in LTPCs was the focus of the thesis as justified in chapters one (i.e. the 
problem specification), and three (i.e. the systematic review), this was still considered the outcome of 
primary interest. 
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3. Feasibility/effectiveness of the trial protocol  
Estimate recruitment and retention, identify associated issues, report on the 
feasibility of achieving sample size requirement and the appropriateness of the 
sample size calculation parameters (as discussed in the present chapter), 
identify the feasibility/effectiveness of the randomisation and allocation 
concealment methods and check the success of blinding. 
 
Preliminary effectiveness analysis 
An exploratory consideration of the potential effect of WED on depressive symptom 
severity and a range of other psychological and behavioural outcomes, with some 
exploration of the mechanisms of change and mediators anticipated to underpin 
WEDs effect on depressive symptom severity.  
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Chapter 7 Baseline characteristics, preliminary effectiveness analysis 
and exploratory explanatory analyses 
 
Chapter overview 
This chapter presents the baseline characteristics (i.e. descriptive statistics) of and 
describes the data that was available for the sample obtained. The preliminary 
effectiveness analysis are then presented, followed by the exploratory explanatory 
analyses proceeded with in a hypothesis generating way and simply to aid 
interpretation of any main effect. The findings from the moderation sub-group 
analyses are then mentioned very briefly in relation to the main effect again in a 
hypothesis generating way. 
 
Baseline descriptive statistics 
Demographic and clinical data, outcome, moderator and mediator data, and the 
internal reliability of the outcome, moderator, mediator and mechanisms of change 
(i.e. PANAS) measures for primary care patients and then support group 
participants are indicated in Tables 22 to 27.102 Data for the primary care and 
support group samples did not apparently exhibit systematic differences of a notable 
magnitude on important prognostic variables, although importantly the online 
support group participants had slightly more DSED. This may reflect the 
involvement of these support seeking individuals in the online groups. Specifically 
with regards to the clinical data it did not seem to be the case that self-reported 
HbA1c from support group participants had been under reported consistent with 
                                                             
102 It must be noted that there was a problem with baseline alexithymia questionnaire for some primary 
care patients. A typing error meant that for the first few patients receiving it, the response format was 
slightly ambiguous; there were two strongly agree options (i.e. and no strongly disagree option). 
However, the mean scores, SDs and Chronbach’s alphas were compared for the primary care patients 
for whom this was potentially a problem (n=12; 29%) and the remainder of the primary care sample, 
and no differences were apparent. It was thus considered appropriate to combine the data. This was 
also justified as those for whom this was potentially a problem had an equal chance of being 
randomised to each group. 
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social desirability bias (i.e. the tendency to respond in a manner that will be 
perceived favourably); the SDs and ranges were similar to those for the objectively 
derived data and thus apparently represented the true range of values. The 
psychometric properties of the measures employed were generally consistent 
across these groups, albeit lower reliability was observed for the DMSES UK 
completed by support group participants. This is likely owing to sampling differences 
rather than sample size (Peterson, 1994). Ultimately, though, self-efficacy for 
diabetes SMBs may not have been reliably measured for support group participants.  
 
Again there are a number of reasons why it might not be justified to combine these 
data (see chapter five). Indeed, the differences observed suggest that this may be 
the case. However, the number of support group participants recruited was very 
small and balanced across intervention groups (i.e. only three per group), thus any 
potential bias would hopefully have been equally distributed and diluted once the 
data were combined. Consequently, whilst not withstanding limitations combining 
the samples was considered to be the most sensible approach given the limited 
utility of separate analyses with such a small number of participants. The 
demographic and clinical data, outcome, moderator and mediator data, and the 
internal reliability of the outcome, moderator, mediator and mechanisms of change 
(i.e. PANAS) measures for the combined sample are reported in Tables 28 to 30. 
 
Psychometric properties  
Internal reliability, Cronbach’s alpha, for the outcome, mediator and moderator 
measures that were investigated was generally between .70 and .90 and was thus 
adequate.  
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Table 22 Primary care baseline demographic and clinical data103 
                                                             
103 EDUCATION: Level 1=1 to 4 O level passes, 1 to 4 CSE/ GCSE any grades, NVQ level 1 or Foundation GNVQ; Level 2=5 or more O level passes, 5 or more CSEs (grade 
1), 5 or more GCSEs (grades A-C), School Certificate, 1 A  level, 1 to 3 AS levels, NVQ level 2, Intermediate GNVQ; Level 3=2 or more A levels, 4 or more AS levels, Higher 
School Certificate, NVQ  level 3, Advanced GNVQ; Level 4/5= First degree, higher degree, NVQ levels 4 and 5, HNC, HND, Qualified Teacher Status, Qualified Medical 
Doctor, Qualified Dentist, Qualified Nurse, Midwife, Health Visitor. RELATIONSHIPS: S=single (inc. separated, divorced & widowed); CH=co-habiting 4; M=married/re-married. 
MEDICATION: D/E: diet & exercise; T=tablets; T/I=tablets & insulin; I=insulin. COMPLICATIONS: HD/S=heart disease/stroke; R=retinopathy; S/U=sexual & urological 
problems; KD/F=Kidney disease/failure; H=hypoglycemia. Where n is less than 35 (WED=20; Control=15) observations were missing for these patients. *Mean (SD; range) 
presented.              
 Total sample n WED n Control n 
Age* 67(10.1; 41-84) 35 70(10.4; 52-84) 20 64(9.4; 41-80) 15 
Gender Male 21(60%); Female 14 
(40%) 
35 Male 12(60%); Female 8 
(40%) 
20 Male 9 (60%); Female 6 
(40%) 
15 
Ethnicity  White/British 34(97%); Black 
Irish 1(3%) 
35 White/British 19(95%); Black 
Irish 1(5%) 
20 White/British 15(100%) 15 
Education Level 1 10(39%); Level 2 
7(26%); Level 3 2(8%); Level 
4/5 7(27%) 
26 Level 1 7(46.7%); Level 2 
3(20%); Level 3 2(13.3%); 
Level 4/5 3(20%) 
15 Level 1 3(27.3%); Level 2 
4(36.4%); Level 4/5 
4(36.4%) 
11 
Relationship S 6(17.1%); CH 4(11.4%); M 
25(71.4%) 
35 S 2(10%); CH 4(20%);   
M 14(70%) 
20 S 4(26.7%); M 11(73.3%) 15 
BMI*   31.3(6.3; 21.8-49.7) 34 31.5(5.8; 21.8-43.5) 20 31.2(7.0; 22.6-49.7) 14 
HbA1c 7.1(.96; 5.3-9.3) 27 7.2(.9; 5.3-9.3) 16 7.1(1.1; 5.8-9.3) 11 
Time since diagnosis  (months)*  87.3 (78.9;12-390) 34 74.6 (57.3; 12-192) 20 105.5 (102; 12-390) 14 
Medication D/E 11(31%); T 20(57%); T/I 
3(9%); I 1(3%) 
35 D/E 8(40%); T 11(55%); T/I 
1(5%) 
20 D/E 3(20%); T 9(60%); T/I 
2(13.3%); I 1(6.7%) 
15 
HCU: physician visits (in the last 6 months)*  2.7(3.6; 0-20) 34 2.9(4.4; .0-20) 19 2.5(2.1; .0-7) 15 
HCU: hospital emergency room (no. times in the last 6 months)*  .12(.33; 0-1) 33 .11(.32; 0-1) 19 .14(.36; 0-1) 14 
HCU: nights in hospital (in the last 6 months)*  1.8(7.0; 0-35) 34 1.8(7.8; 0-35) 20 1.9(5.8; 0-22) 14 
HCU: last eye examination (months)* 16.8(14.7; 0-58) 33 21.7(16.8; .0-58) 18 10.9(9.0; .0-24) 15 
HCU: feet examination (no. times in the last 6 months)*  1.0(.6; 0-2) 35 1.1(.55; 0-2) 20 .80(.56; 0-2) 15 
No. with 1 complication 9(26%): HD/S 4(44.4%); R 
2(22.2%); S/U 3(33.3%) 
3(15%): S/U 3(100%) 6(40%): HD/S 4(67%); R 2(33%) 
No. with 2 complications 7(20%): HD/S&R 2(28.6%); 
HD/S&S/U 2(28.6%); S/U&KD/F 
1(14.3%); S/U&R 2 (28.6%) 
6(30%): HD/S&R 2(33.3%); HD/S & 
S/U 2(33.3%); S/U&R 2 (33.3%) 
1(7%): S/U&KD/F 1(100%) 
No. with 3 complications 1(3%): HD/S, KD/F&H 1(100%) 
 
1(5%): HD/S, KD/F&H 1(100%) 
 
0 
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Table 23 Primary care baseline outcome, moderator and mediator data104 
                                                             
104 Where n is less than 35 (WED=20; Control=15) observations were missing for these patients. Mean (SD; range) presented. 
 Total sample n WED n Control n 
Depressive symptom severity  6.8 (5.1; 0-15) 35 7.0 (5.2; 0-15) 20 6.7 (5.1; 0-15) 15 
DSED 34.2 (9.0; 25-55) 33 35.2 (9.2; 25-53.8) 19 32.8 (9.0; 25-55) 14 
Health-related QoL: EQ-5D utility  .87 (.14; .62-1) 32 .85 (.14; .62-1) 19 .90 (.13; .69-1) 13 
Health-related QoL: EQ-5D VAS 77.8 (18.8; 39-99) 32 78.6 (19.1; 39-99) 19 76.6 (19.0; 41-99) 13 
Diabetes SMBs: general diet 5.7(1.5; 0-7) 34 5.6 (1.6; .0-7) 20 6.0 (1.4; 2.5-7) 14 
Diabetes SMBs: specific diet  4.8 (1.1; 1.5-7) 33 4.7 (1.1; 1.5-5.5) 19 5.0 (1.2; 2.5-7) 14 
Diabetes SMBs: exercise  3.3 (2.4; 0-7) 34 4.0 (2.4; .0-7) 20 2.2 (2.1; .0-5) 14 
Diabetes SMBs: blood glucose testing  1.4 (2.1; 0-7) 30 1.3 (1.8; .0-7) 17 1.6 (2.4; .0-6.5) 13 
Diabetes SMBs: foot care   2.8 (2.5; 0-7) 35 3.3 (2.7; .0-7) 20 2.0 (2.0; 0-7) 15 
Diabetes SMBs: smoking status / No. 
cigarettes   
No 33(94%); Yes 2(5.7%) 
/ 15 (7.1; 10-20) 
35 / 2 No 18(90%); Yes 2(10%)  
/ 15 (7.1; 10-20) 
20 / 2 No 15(100%) / 0 15 / 0 
Illness interference 22 (9.8; 3-51) 34 24.2 (10.9; 13-51) 20 18.9  (7.2; 3-32) 14 
Self-efficacy for diabetes SMBs 125.8 (27.5; 33-150) 34 124.9 (31.1; 33-150) 19 127 (23.2; 77-150) 15 
Perceived emotional support (number)   2.3 (1.6; 0-6.5) 33 2.6 (1.7; 1-6.7) 20 1.9 (1.3; .0-5) 13 
Perceived emotional support (satisfaction)   5.8 (.47; 4-6) 31 5.9 (.24; 5-6) 18 5.7 (.67; 4-6) 13 
Optimism  22.2 (4.4; 14-30) 32 21.4 (4.4; 14-30) 20 23.6 (4.2; 17-30) 12 
Alexithymia  49.4(14.4; 20-74) 34 49.4 (15.1; 20-74) 20 49.4 (14; 32-74) 14 
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Table 24 Internal reliability of outcome, moderator, mediator and mechanisms of change measures in primary care105 
                                                             
105 Where n is less than 35 (WED=20; Control=15) ≥1 item responses were missing for these patients thus the patient was excluded. 
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Table 25 Online support groups baseline demographic and clinical data106 
 
 Total sample n WED n Control n 
Age* 59.3(6.3; 54-71) 6 61.7(8.6; 54-71) 3 57(3; 54-60) 3 
Gender Male 4(67%); Female 2(33%) 6 Male 2(67%); Female 1(33%) 3 Male 2(67%); Female 
1(33%) 
3 
Ethnicity  White/British 6(100%) 6 White/British 3(100%) 3 White/British 3(100%) 3 
Education Level 1 1(16.7%); Level 3 
1(16.7%); Level 4/5 4(66.7%) 
6 Level 1 1(33%); Level 4/5 
2(67%) 
3 Level 3 1(33%); Level 4/5 
2(67%) 
3 
Relationship S 1(17%); M 5(83%) 6 M 3(100%) 3 S 1(33%); M 2(67%) 3 
Nationality British 5(100%) 5 British 3(100%) 3 British 2(100%) 2 
Country of residence UK 5(100%) 5 UK 3(100%) 3 UK 2(100%) 2 
BMI*   25 (4.4; 19.4-30.8) 6 24.9(4.0; 20.7-28.7) 3 25.2(5.7; 19.4-30.8) 3 
HbA1c  6(.6; 5.5-7.1) 5 6.2(.8; 5.6-7.1) 3 5.7(.3; 5.5-5.9) 2 
Time since diagnosis  (months)*  65.3 (36.9; 23-120) 6 92(30.2; 60-120) 3 38.7(19.1; 23-60) 3 
Medication D/E 1(17%); T 5(83%) 6 T 3(100%) 3 D/E 1(33%); T 2(67%) 3 
HCU: physician visits (in the last 6 months)*  2.2 (1.6; 1-5) 6 1.7(1.2; 1-3) 3 2.7(2.1; 1-5) 3 
HCU: hospital emergency room (no. times in the last 
6 months)*  
0 6 0 3 0 3 
HCU: nights in hospital (in the last 6 months)*  0 6 0  3 0  3 
HCU: last eye examination (months)* 28 (18.9; 4-48) 6 36 (10.6; 24-44) 3 20 (24.3; 4-48) 3 
HCU: feet examination (no. times in the last 6 
months)*  
.67 (.5; 0-1) 6 .67 (.6; 0-1) 3 .67 (.6; 0-1) 3 
No. with 1 complication 3(50%): R 2(67%); S/U 1(33%). 2(67%): R 2(100%)  1(33%): S/U 1(100%) 
No. with 4 complications 1(17%): R, N, S/U, KD/F 1 (100%) 0 1(33%): R, N, S/U, KD/F 1 
(100%) 
 
                                                             
106 EDUCATION: Level 1=1 to 4 O level passes, 1 to 4 CSE/ GCSE any grades, NVQ level 1 or Foundation GNVQ; Level 2=5 or more O level passes, 5 or more CSEs (grade 
1), 5 or more GCSEs (grades A-C), School Certificate, 1 A  level, 1 to 3 AS levels, NVQ level 2, Intermediate GNVQ; Level 3=2 or more A levels, 4 or more AS levels, Higher 
School Certificate, NVQ  level 3, Advanced GNVQ; Level 4/5= First degree, higher degree, NVQ levels 4 and 5, HNC, HND, Qualified Teacher Status, Qualified Medical 
Doctor, Qualified Dentist, Qualified Nurse, Midwife, Health Visitor. RELATIONSHIPS: S=single (inc. separated, divorced & widowed); CH=co-habiting 4; M=married/re-married. 
MEDICATION: D/E: diet & exercise; T=tablets; T/I=tablets & insulin; I=insulin. COMPLICATIONS: HD/S=heart disease/stroke; R=retinopathy; S/U=sexual & urological 
problems; KD/F=Kidney disease/failure; N=Neuropathies. Where n is less than 6 (WED=3; Control=3) observations were missing for these participants. *Mean (SD; range) 
presented.         
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Table 26 Online support groups baseline outcome, moderator and mediator data107 
 
                                                             
107 Where n is less than 6 (WED=3; Control=3) observations were missing for these participants. Mean (SD; range) presented. 
 Total sample n WED n Control n 
Depressive symptom severity  6.2 (3.9; 0-10) 6 7.0 (3.6; range 3-10) 3 5.3 (4.7; 0-9) 3 
DSED  43.5 (16.2; 28.8-73.8) 6 52.1 (19.4; 36.3-73.8) 3 35 (7.8; 28.8-43.8) 3 
Health-related QoL: EQ-5D utility   .95 (.09; .8-1.0) 6 .93  (.1; .8-1) 3 .96 ( .1; .9-1) 3 
Health-related QoL: EQ-5D VAS   91.5 (7.8; 79-100) 6 95.3 (6.4; 88-100) 3 87.7 (8.1; 79-95) 3 
Diabetes SMBs: general diet   5.8 (1.7; 2.5-7) 6 6.5 (.5; 6-7) 3 5.2 (2.4; 2.5-7) 3 
Diabetes SMBs: specific diet   4.7 (1.3; 3.5-6.5) 6 4.5 (1.3; 3.5-6) 3 4.8 (1.4; 4-6.5) 3 
Diabetes SMBs: exercise   3.6 (2.6; 0-7) 6 2 (1.8; 0-3.5) 3 5.2 (2.4; 2.5-7) 3 
Diabetes SMBs: blood glucose testing  5.5 (2.1; 3-7) 5 5.8 (2.0; 3.5-7) 3 5 (2.8; 3-7) 2 
Diabetes SMBs: foot care   3.1 (2.4; .5-6.5) 5 2.7 (3.3; .5-6.5) 3 3.8 (.4; 3.5-4) 2 
Diabetes SMBs: smoking status / No. 
cigarettes  
No 5(83%); Yes 1(17%)  
/ 13 (0.0;13-13) 
6 / 1 No 3(100%)  
/ 0 (0.0; 0-0) 
3 / 0 No 2(67%); Yes 1(33%)  
/ 13 (0.0; 13-13) 
3 / 1 
Illness interference 20.5 (5.2; 15-28) 6 22.7 (6.1; 16-28) 3 18.3 (4.2; 15-23) 3 
Self-efficacy   121.5 (11; 110-135) 6 120.3 (11.9; 112-134) 3 122.7 (12.5;110-135) 3 
Perceived emotional support (number)   1.7 (1.4; .3-4.3) 6 2.3 (1.8; 1-4.3) 3 1.2 (1.0; .3-2.3) 3 
Perceived emotional support (satisfaction)   5.2 (.9; 3.8-6) 6 4.8 (1.0; 3.8-5.8) 3 5.6 (.7; 4.8-6) 3 
Optimism   20.8 (3.5; 16-26) 6 21.7 (4; 18-26) 3 20 (3.6; 16-23) 3 
Alexithymia  48.3 (8.6; 34-61) 6 53 (6.9; 49-61) 3 43.7 (8.4; 34-49) 3 
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Table 27 Internal reliability of outcome, moderator, mediator and mechanisms of change measures in online support groups 108 
 
                                                             
108 Where n is less than 6 (WED=3; Control=3) ≥1 item responses were missing for these participants thus the participant was excluded. 
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Table 28 Combined baseline demographic and clinical data109
                                                             
109 EDUCATION: Level 1=1 to 4 O level passes, 1 to 4 CSE/ GCSE any grades, NVQ level 1 or Foundation GNVQ; Level 2=5 or more O level passes, 5 or more CSEs (grade 
1), 5 or more GCSEs (grades A-C), School Certificate, 1 A  level, 1 to 3 AS levels, NVQ level 2, Intermediate GNVQ; Level 3=2 or more A levels, 4 or more AS levels, Higher 
School Certificate, NVQ  level 3, Advanced GNVQ; Level 4/5= First degree, higher degree, NVQ levels 4 and 5, HNC, HND, Qualified Teacher Status, Qualified Medical 
Doctor, Qualified Dentist, Qualified Nurse, Midwife, Health Visitor. RELATIONSHIPS: S=single (inc. separated, divorced & widowed); CH=co-habiting 4; M=married/re-married. 
MEDICATION: D/E: diet & exercise; T=tablets; T/I=tablets & insulin; I=insulin. COMPLICATIONS: HD/S=heart disease/stroke; R=retinopathy; S/U=sexual & urological 
problems; KD/F=Kidney disease/failure; H=hypoglycemia. Where n is less than 41 (WED=23; Control=18) observations were missing for these participants. * Mean (SD; range 
presented).              
 Total sample n WED n Control n 
Age* 65.6 (9.9; 41-84) 41 63.9 (9.2; 41-80) 23 67.8 (10.7; 52-84) 18 
Gender Male 25(61%); Female 16(39%) 41 Male 14(61%); Female 9(39%) 23 Male 11(61%); Female 7(39%) 18 
Ethnicity  White/British 40(98%); Black Irish 
1(2%) 
41 White/British 22(96%); Black 
Irish 1(4%) 
23 White/British 18(100%) 18 
Education Level 1 11(34%); Level 2 7(22%); 
Level 3 3(9%); Level 4/5 11(34%) 
32 Level 1 8(44%); Level 2 3(17%); 
Level 3 2(11%); Level 4/5 
5(28%) 
18 Level 1 3(21%); Level 2 4(29%); 
Level 3 1(7%); Level 4/5 6(43%) 
14 
Relationship S 7(17%); CH 4(10%); M 30(73%) 41 S 2(9%); CH 4(17%);  
M 17(74%) 
23 S 5(28%); M 13(72%) 18 
BMI*   30.4 (6.4;  19.4-49.7) 40 30.6 (6; 20.7-43.6) 23 30.1 (7.1; 19.4–49.7) 17 
HbA1c  7.0 (1; 5.3-9.3) 32 7 (.96; 5.3-9.3) 19 6.9 (1.10; 5.5-9.3) 13 
Time since diagnosis  (months)*  84.0 (74.2; 12-390) 40 76.9 (54.4; 12-192) 23 93.7 (95.9; 12-390) 17 
Medication D/E 12(29%); T 25(61%); T/I 3(7%); I 
1(2%) 
41 D/E 8(35%); T 14(61%); T/I 
1(4%) 
23 D/E 4(22%); T 11(61%); T/I 
2(11%); I 1(6%) 
18 
HCU: physician visits (in the last 6 months)*  2.7(3.3; 0-20) 40 2.8(4.2; .0-20) 22 2.5(2.1; .0-7) 18 
HCU: hospital emergency room (no. times in 
the last 6 months)*  
.10 (.31; 0-1) 39 .1 (.3; 0-1) 22 .1 (.3; 0-1) 17 
HCU: nights in hospital (in the last 6 months)*  1.6 (6.4; 0-35) 40 1.6 (7.3; 0-35) 23 1.5 (5.3; 0-22) 17 
HCU: last eye examination (months)* 18.5 (15.7; 0-58) 39 23.8 (16.7; 0-58) 21 12.4 (12.2; 0-48) 18 
HCU: feet examination (no. times in the last 6 
months)*  
.93 (.57; 0-2) 41 1.0 (.6; 0-2) 23 .8 (.5; 0-2) 18 
No. with 1 complication 12(29%): HD/S 4(33%); R 4(33%); S/U 
4(33.3%) 
5(22%):  R 2(40%); S/U 3(60%) 7(39%): HD/S 4(57%); R 2(29%); S/U 
1(14%) 
No. with 2 complications 7(17%): HD/S&R 2(29%); HD/S&S/U 
2(29%); S/U&KD/F 1(14%); S/U&R 2 (29%) 
6(26%): HD/S&R 2(33%); HD/S&S/U 
2(33%); S/U&R 2 (33%) 
1(6%): S/U&KD/F 1(100%) 
No. with 3 complications 1(2%): HD/S, KD/F & H 1(100%) 
 
1(4%): HD/S, KD/F & H 1(100%) 
 
0 
No. with 4 complications 1(2%): R, N, S/U, KD/F 1 (100%) 0 1(6%): R, N, S/U, KD/F 1 (100%) 
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Table 29 Combined baseline outcome, moderator and mediator data110 
 
 
  
                                                             
110 Where n is less than 41 (WED=23; Control=18) observations were missing for these participants. Mean (SD; range) presented. 
 Total sample n WED n Control n 
Depressive symptom severity  6.7 (4.9; 0-15) 41 7 (4.9; 0-15) 23 6.4 (5; 0-15) 18 
DSED  35.6 (10.7; 25-73.8) 39 37.5 (12; 25-73.8) 22 33.1 (8.6; 25-55) 17 
Health-related QoL: EQ-5D utility   .89 (.13; .62-1) 38 .87 (.14; .62-1) 22 .91 (.12; .69-1) 16 
Health-related QoL: EQ-5D VAS 80 (18.1; 39-100) 38 80.9 (18.7; 39-100) 22 78.7 (17.8; 44-99) 16 
Diabetes SMBs: general diet  5.8 (1.5; 0-7) 40 5.7 (1.6; 0-7) 23 5.8 (1.5; 2.5-7) 17 
Diabetes SMBs: specific diet   4.8 (1.1; 1.5-7) 39 4.6 (1.1; 1.5-6) 22 4.9 (1.2; 2.5-7) 17 
Diabetes SMBs Diabetes SMBs: exercise   3.3 (2.4; 0-7) 40 3.8 (2.4; 0-7) 23 2.7 (2.4; 0-7) 17 
Diabetes SMBs: blood glucose testing  2 (2.5; 0-7) 35 2 (2.5; 0-7) 20 2.1 (2.7; 0-7) 15 
Diabetes SMBs: foot care   2.8 (2.4; 0-7) 40 3.2 (2.7; 0-7)  23 2.2 (1.9; 0-7) 17 
Diabetes SMBs: smoking status / No. 
cigarettes  
No 38(93%); Yes 3(7%) 
/ 14.3 (5.1; 10-20) 
41 
/ 3 
No 21(91%); Yes 2(9%) 
/ 15 (7.1; 10-20) 
23 
/ 2 
No 17(94%); Yes 1(6%) 
/ 13 (0; 13-13) 
18 
/ 1 
Illness interference 21.8 (9.2; 3-51) 40 24 (10.3; 13-51) 23 18.8 (6.7; 3-32) 17 
Self-efficacy   125.2 (25.6; 33-150) 40 124.3 (29.1; 33-150) 22 126.3 (21.5; 77-150) 18 
Perceived emotional support (number) 2.2 (1.6; 0-6.7) 39 2.6 (1.7; 1-6.7) 23 1.7  (1.3; 0-5) 16 
Perceived emotional support (satisfaction)   5.7 (.59; 3.8-6) 37 5.8 (.56; 3.8-6) 21 5.7 (.64; 4-6) 16 
Optimism  22 (4.2; 14-30) 38 21.4 (4.2; 14-30) 23 22.9 (4.2; 16-30) 15 
Alexithymia  49.3 (13.6; 20-74) 40 49.9 (14.2; 20-74) 23 48.4 (13.1; 32-74) 17 
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Table 30 Internal reliability of outcome, moderator, mediator and mechanisms of change measures in the combined sample111 
 
                                                             
111 Where n is less than 41 (WED=23; Control=18) ≥1 item responses were missing for these participants thus the participant was excluded. 
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Baseline comparability  
The intervention groups were additionally comparable on demographic and clinical 
data and outcome, moderator and mediator data at baseline. It seemed that the 
control group had a slightly higher level of education, were more likely to be single, 
had been diagnosed with diabetes for a longer period of time, were more likely to be 
on insulin, had an eye exam more recently and were less likely to have two 
complications. However, these differences were not substantial or prognostic. There 
were no apparent differences for the outcome, mediator and moderator variables.  
 
With respect to whether participants were currently involved in any other research, 
of those that answered this question in the baseline questionnaire (37, 90%), 31 
(84%) were not while six (16%) stated that they were. By group, four participants in 
the intervention group (17%) and two control participants (11%) stated that they 
were currently involved in other research. One intervention participant indicated that 
the research they were involved in was a longitudinal study of the aetiology of 
LTPCs, with no intervention. 
 
Available data 
Missing data on continuous measures 
The missing observations for each continuous measure and the missing/imputed 
item responses for each observation for each continuous measure at each 
administration are provided in Table 31. 
291 
 
Table 31 Extent of missing observations and missing item responses per observation for each continuous measure at each time point 
 
Measure Number of observations  
(number of items (% of total number of items) 
missing per observation where an observation 
could still be derived or imputed per observation)  
Number of items (% of total number of items) 
missing per missing observation 
Baseline (n=41 returned questionnaire pack) 
CES-D (scoring key: items scored if <4 missing) 41 (2 participants had only 1 item (5%) missing)  
PAID  39 (2  participants had only 1 item (5%) 
missing) 
1 participant with 12 (60%) missing;  
1 participant with 3 (15%) missing 
EQ-5D utility 38 1 participant with 5 (100%) missing;  
1 participant with 3 (60%) missing;  
1 participant with 1 (20%) missing 
EQ-5D VAS 38  3 participants missing response  
SDSCA: general diet   40 1 participant with 1 (50%) missing 
SDSCA: specific diet   39 2 participants with 1 (50%) missing 
SDSCA: exercise   40 1 participant with 2 (100%) missing 
SDSCA: blood glucose testing  35 6 participants with 1 (50%) missing 
SDSCA: foot care 40 1 participant with 1 (50%) missing 
LOT-R  
(items 2, 5, 6 & 8 are filler items & not included) 
38 1 participant with 2 (33%) missing;   
2 participants with 1 (16%) missing 
TAS-20 (scoring key: items imputed if ≤2/3 
missing from total scale & ≤1 missing per factor 
sub-scale (with mean of answered items for that 
person on the same factor sub-scale) 
40 (data imputed for 4 participants; each 1 item 
(5%) missing) 
1 participant with 7 (35%) missing 
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Measure Number of observations  
(number of items (% of total number of items) missing per 
observation where an observation could still be derived or 
imputed per observation)  
Number of items (% of total number of items) 
missing per missing observation 
During intervention (n=27 returned writing pack) 
PANAS (negative affect) session one 17 6 participants with 10 (100%) missing; 
3 participants with 9 (90%) missing; 
1 participants with 7 (70%) missing 
PANAS (negative affect) session two 17 7 participants with 10 (100%) missing; 
2 participants with 9 (90%) missing; 
1 participants with 7 (70%) missing 
PANAS (negative affect) session three 17 8 participants with 10 (100%) missing; 
1 participants with 9 (90%) missing; 
1 participants with 8 (80%) missing 
Two weeks (n=33 returned questionnaire pack) 
IIRS (scoring key: if responses are not 
consecutive do not score (thus if any items 
were missing scale not scored) 
33  
DMSES UK 
(scoring key: items imputed  if ≤4 missing 
(with mean of answered items for that 
person) (thus if more than 4 items missing 
scale not scored) 
33 (data imputed for 10 participants; 5 had 3 items 
(20%)  missing, 2 had 2 items (13%) missing; 3 had 1 
item (7%) missing) 
 
SSQ6 (number)  29 1 participant with 6 (100%) missing; 
1 participant with 4 (67%) missing;  
1 participant with 2 (33%) missing;  
1 participant with 1 (17%) missing 
SSQ6 (satisfaction)  29 1 participant with 6 (100%) missing;  
1 participant with 4 (67%) missing;  
1 participant with 2 (33%) missing;  
1 participant with 1 (17%) missing 
293 
 
Measure Number of observations  
(number of items (% of total number of items) 
missing per observation where an observation could 
still be derived or imputed per observation)  
Number of items (% of total number of items) 
missing per missing observation 
Three months (n=32 returned questionnaire pack) 
CES-D (scoring key: items scored if <4 missing) 32 (3  participants had only 1 item (5%) missing)  
PAID  32  
EQ-5D utility   32  
EQ-5D VAS 32  
SDSCA: general diet   32  
SDSCA: specific diet   32  
SDSCA: exercise   32  
SDSCA: blood glucose testing  28 3 participants with 1 (50%) missing;  
1 participant with 2 (100%) missing 
SDSCA: foot care 32  
Three month mediators; only collected for primary care patients (n=27 primary care patients returned questionnaire pack) 
IIRS (scoring key: if responses are not 
consecutive do not score (thus if any items were 
missing scale not scored) 
27  
DMSES UK (scoring key: items imputed  if ≤4 
missing (with mean of answered items for that 
person) (thus if more than 4 items missing scale 
not scored)  
27 (data imputed for 9 participants; 1 had 4 items 
(27%) missing; 2 had 3 (20%) items missing, 3 had 
2 items (13%) missing; 3 had 1 item (7%) missing) 
 
SSQ6 (number)  26 1 participant with 1 (17%) missing 
SSQ6 (satisfaction)  25 2 participants with 1 (17%) missing 
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Screening the data, checking the assumption of normality and 
correcting distributional problems in the data 
For some variables the distribution of scores was significantly/notably different to a 
normal distribution and this could not be attributed to data entry errors, thus 
transformation was performed. For all statistical analyses at least some variables 
were skewed therefore all variables were transformed. The types of transformation 
performed for the variables included in each analysis are provided in the appendix. 
Post-transformation, the assumption of normality was checked again to ensure any 
problems had been largely corrected. The initial and post-transformation 
assumption checks are also provided in the appendix. Transformation largely 
resolved problems in the data with the exception of the PANAS variables (i.e. per 
session and the average across sessions), for which non parametric analysis was 
thus performed (as reported in chapters five and eight).112   
 
Preliminary effectiveness analysis113 
ITT analysis  
For ease of interpretation the results for the analyses with the untransformed data 
are reported. The conclusions were generally consistent with those for the 
transformed data, with some exceptions where artificially inflated effect sizes and 
smaller p values were derived from analyses with transformed data, albeit the 
                                                             
112 Transformation did not entirely resolve the distributional problems for some other variables for 
which equivalent non-parametric analyses were not available, namely the EQ-5D utility variables 
examined in ANCOVAs and perceived emotional support satisfaction variables examined in regression 
analyses. Again, ANOVA is is fairly robust where data are not normally distributed, nonetheless the 
findings for the variables may be slightly inaccurate. 
113 It is noteworthy that, as anticipated, ω² provided the most conservative and thus best estimate of 
the population effect, which were at most of a medium size and were generally small (all effect size 
estimates are presented in the appendix for visual inspection). Interestingly, as anticipated η୮
²  
consistently overestimated both η² and ω² and on occasion derived the conclusion of a larger effect, as 
this compares the variance explained by the between-groups effect to the unexplained variance, 
ignoring any variance explained by other variables (i.e. reducing the denominator). η² was additionally 
consistently inflated compared to ω², which reflects shrinkage resulting from sampling error owing to 
the small sample obtained (i.e. ω²corrects for this), albeit this was slight and did not often derive 
different conclusions. 
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discrepancies were slight and infrequent. This was unsurprising given that 
transformation reduces the variance in the data and improves its symmetry, which 
increases statistical power. In addition, as the distribution of the data is altered the 
group means are ‘moved’ differentially, which can inflate or decrease the difference 
between them and thus the effect size. The most conservative approach was thus to 
report the findings for the untransformed data. The adjusted group means and the 
associated SEs for the ITT analysis on the primary and secondary outcomes at 
three month follow up are presented in Table 32. 
 
Table 32 Adjusted group endpoint data for the ITT analyses on the primary and 
secondary outcomes at three month follow up114 
Outcome WED n Control n 
Mean SE Mean SE 
Depressive symptom severity 9.9 1.08 23 5.1 1.2 18 
DSED 35.3 1.41 23 34.4 1.6 18 
Health-related QoL: EQ-5D utility .86 .03 23 .87 .03 18 
Health-related QoL: EQ-5D VAS 77.4 2.75 22 82.1 3.0 18 
Diabetes SMBs: general diet 5.8 .24 23 5.8 .27 18 
Diabetes SMBs: specific diet 4.5 .19 23 5.1 .21 18 
Diabetes SMBs: exercise 3.5 .28 23 4.0 .31 18 
Diabetes SMBs: blood glucose testing 2.5 .39 22 2.5 .46 16 
Diabetes SMBs: foot care 3.2 .24 23 3.0 .27 18 
 
Primary outcome 
Depressive symptom severity 
Assumption checks indicated homogeneity of variance (F(1,39)=3.20, p=.081) and 
regression slopes for the covariates (baseline depressive symptom severity 
F(1,33)=2.10, p=.157); age (F1,33)=.06, p=.808); gender (F(1,33)=.02, p=.886). 
Baseline depressive symptom severity was significantly related to depressive 
symptom severity at three month follow up F(1,36)=33.34, p=.000. There was also a 
significant effect of WED on depressive symptom severity at follow up, controlling 
                                                             
114 There was one participant (WED) for whom both baseline and follow up EQ-5D VAS scores were 
missing and three participants (one WED & two control) for whom both baseline and follow up blood 
glucose testing scores were missing. 
296 
 
for baseline depressive symptom severity F(1,36)=8.47, p=.006. The adjusted group 
means at three month follow up indicated greater depressive symptom severity in 
the WED group compared to the control group, which represented a potentially 
clinically important difference: 4.8. In fact, the 95% CIs associated with these means 
for the WED group (7.7 to 12.1) and control group (2.7 to 7.6) did not overlap at all. 
The change in depressive symptom severity from baseline to three month follow up 
by group in the ITT analysis is illustrated in Figure 23. It is apparent that the 
observed effect represents an increase in depressive symptom severity for the WED 
group but also a decrease in depressive symptom severity for the control group. 
The effect size ω² was .09, which represents a medium sized effect. η² derived the 
same conclusion while η୮
²  indicated a large effect at .19 (b=-4.8, 95%CIs -8.1 to -
1.4).  
 
Figure 23 Change in depressive symptom severity from baseline to three month 
follow up by group in the ITT analysis  
 
 
 
Secondary outcomes 
DSED  
Assumption checks indicated homogeneity of variance (F(1,39)=.63, p=.431) and 
regression slopes for the covariates (baseline DSED F(1,33)=1.71, p=.200); age 
(F1,33)=.29, p=.592); gender (F(1,33)=.00, p=.987). Baseline level of DSED was 
significantly related to DSED at three month follow up F(1,36)=77.46, p=.000. There 
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was no significant effect of WED on DSED at follow up, controlling for baseline 
levels of DSED F(1,36)=.20, p=.658. The adjusted group means at three month 
follow up confirmed that there was no important difference. The effect size ω² was 
.00, which indicates no effect. η² derived the same conclusion while η୮
²  indicated a 
small effect at .01 (b=-.97, 95%CIs -5.4 to 3.4). 
 
Health-related QoL 
EQ-5D utility: Assumption checks indicated homogeneity of variance (F(1,39)=.05, 
p=.829) and regression slopes for the covariates (baseline health-related QoL 
F(1,33)=1.50, p=.230); age (F1,33)=.49, p=.488); gender (F(1,33)=1.61, p=.214). 
Baseline level of health-related QoL was significantly related to health-related QoL 
at three month follow up F(1,36)=49.66, p=.000. There was no significant effect of 
WED on health-related QoL at follow up, controlling for baseline levels of health-
related QoL F(1,36)=.01, p=.907. The adjusted group means at three month follow 
up confirmed that there was no important difference. The effect size ω² was .00, 
which represents no effect. η² and η୮
²  derived the same conclusions (b=.01, 95%CIs 
-.07 to .08). 
 
EQ-5D VAS: Assumption checks indicated homogeneity of variance (F(1,38)=.62, 
p=.436) and regression slopes for the covariates (baseline health-related QoL 
F(1,32)=.00, p=.984; age (F1,32)=3.53, p=.069); gender (F(1,32)=.820, p=.372). 
Baseline level of health-related QoL was significantly related to health-related QoL 
at three month follow up F(1,35)=43.40, p=.000. There was no significant effect of 
WED on health-related QoL at follow up, controlling for baseline levels of health-
related QoL F(1,35)=1.27, p=.268. The adjusted group means at three month follow 
up confirmed that the WED group had marginally worse health-related QoL 
compared to the control group. The change in health-related QoL from baseline to 
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three month follow up by group in the ITT analysis is illustrated in Figure 24. It is 
apparent that the observed effect represents a decrease in health-related QoL for 
the WED group but also an increase for the control group.  The effect size ω² was 
.01, which represents a small effect. η² and η୮
²  derived the same conclusions 
(b=4.7, 95%CIs -3.7 to 13.1).  
 
Figure 24 Change in EQ-5D VAS from baseline to three month follow up by group in 
the ITT analysis  
 
 
 
Diabetes SMBs 
General diet: Assumption checks indicated homogeneity of variance (F(1,39)=.28, 
p=.598) and regression slopes for  most of the covariates (age (F1,33)=1.51, 
p=.228); gender (F(1,33)=.1.04, p=.316). The assumption of homogeneity of 
regression slopes for baseline general diet was apparently violated for the 
untransformed data (F(1,33)=9.73, p=.004), yet this was not the case for the 
transformed data, analysis of which generally derived the same conclusions. Thus, 
for ease of interpretation the untransformed data is reported.  Baseline level of 
general diet was significantly related to general diet at three month follow up 
F(1,36)=15.38, p=.000. There was no significant effect of WED on general diet at 
follow up, controlling for baseline levels of general diet F(1,36)=.05, p=.826. The 
adjusted group means at three month follow up confirmed that there was no 
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important difference. The effect size ω² was .00, which represents no effect. η² and 
η୮
²  derived the same conclusions (b=.08, 95%CIs -.66 to .82). 
 
Specific diet: Assumption checks indicated homogeneity of variance (F(1,39)=.03, 
p=.869) and regression slopes for the covariates (baseline specific diet F(1,33)=.17, 
p=.684); age (F1,33)=1.98, p=.169); gender (F(1,33)=.06, p=.806). Baseline level of 
specific diet was significantly related to specific diet at three month follow up 
F(1,36)=37.77, p=.000. There was a marginally significant effect of WED on specific 
diet at follow up, controlling for baseline levels of specific diet F(1,36)=3.87, p=.057. 
The adjusted group means at three month follow up confirmed that there was a 
slight difference such that the intervention group had a slightly poorer specific diet 
than controls. Moreover, the 95% confidence intervals associated with these means 
for the WED group (4.12 to 4.88) and control group (4.63 to 5.49) only marginally 
overlapped. The change in specific diet from baseline to three month follow up by 
group in the ITT analysis is illustrated in Figure 25. It is apparent that the observed 
effect represents a decline in specific diet for the WED group but also an 
improvement for the control group. The effect size ω² was .03, which represents a 
small effect. η² derived the same conclusion, while η୮
²  indicated a medium-sized 
effect at .10 (b=.56, 95%CIs -.02 to 1.1). 
 
Figure 25 Change in specific diet from baseline to three month follow up by group in 
the ITT analysis  
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Exercise: Assumption checks indicated homogeneity of variance (F(1,39)=.10, 
p=.753) and regression slopes for the covariates (baseline exercise F(1,33)=.24, 
p=.624); age (F1,33)=.09, p=.765); gender (F(1,33)=2.37, p=.134). Baseline level of 
exercise was significantly related to exercise at three month follow up 
F(1,36)=98.54, p=.000. There was no significant effect of WED on exercise at follow 
up, controlling for baseline levels of exercise F(1,36)=1.40, p=.245. The adjusted 
group means at three month follow up confirmed that there was no important 
difference. The effect size ω² was .00, which represents no effect. η² and η୮
²  derived 
the same conclusions (b=.50, 95%CIs -.36 to 1.4). 
 
Blood glucose testing: Assumption checks indicated homogeneity of variance 
(F(1,36)=.24, p=.628) and regression slopes for the covariates (baseline blood 
glucose testing F(1,30)=.02, p=890); age (F1,30)=2.78, p=.106); gender 
(F(1,30)=.85, p=.364). Baseline level of blood glucose testing was significantly 
related to blood glucose testing at three month follow up F(1,33)=54.14, p=.000. 
There was no significant effect of WED on blood glucose testing at follow up, 
controlling for baseline levels of blood glucose testing F(1,33)=.01, p=.922. The 
adjusted group means at three month follow up confirmed that there was no 
important difference. The effect size ω² was .00, which represents no effect. η² and 
η୮
²  derived the same conclusions (b=-.06, 95%CIs -1.3 to 1.2). 
 
Foot care: Assumption checks indicated homogeneity of variance (F(1,39)=.003, 
p=.957) and regression slopes for the covariates (baseline foot care F(1,33)=.2.10, 
p=.156); age (F1,33)=.21, p=.653); gender (F(1,33)=.06, p=.807). Baseline level of 
foot care was significantly related to foot care at three month follow up 
F(1,36)=139.57, p=.000. There was no significant effect of WED on foot care at 
follow up, controlling for baseline levels of foot care F(1,36)=.10, p=.755. The 
301 
 
adjusted group means at three month follow up confirmed that there was no 
important difference. The effect size ω² was .00, which represents no effect. η² and 
η୮
²  derived the same conclusions (b=-.12, 95%CIs -.87 to .63). 
 
Pre-specified sensitivity analyses: complete case analysis 
Again, for ease of interpretation the results for the analyses with the untransformed 
data are reported. The conclusions were again generally consistent with those for 
the transformed data, with some exceptions where artificially inflated effect sizes 
were derived from analyses with transformed data, albeit the discrepancies were 
again slight and infrequent. The most conservative approach was thus again to 
report the findings for the untransformed data.  
 
The adjusted group means and associated SEs for the complete case analysis on 
the primary and secondary outcomes at three month follow up are presented in 
Table 33. 
 
Table 33 Adjusted group endpoint data for the complete case analyses on the 
primary and secondary outcomes at three month follow up 
Outcome WED n Control n 
Mean SE Mean SE 
Depressive symptom severity 10.6 1.4 18 5.1 1.5 14 
DSED 33.5 1.8 17 32.8 2.1 13 
Health-related QoL: EQ-5D: utility .83 .03 17 .84 .04 12 
Health-related QoL: EQ-5D: VAS 74.8 3.5 18 82.2 4.3 12 
Diabetes SMBs: general diet 5.6 .31 18 5.6 .36 13 
Diabetes SMBs: specific diet 4.2 .25 17 5.0 .28 13 
Diabetes SMBs: exercise 3.6 .36 18 4.0 .43 13 
Diabetes SMBs: blood glucose testing 3.2 .60 13 2.7 .62 12 
Diabetes SMBs: foot care 2.9 .31 18 2.7 .37 13 
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Primary outcome 
Depressive symptom severity 
Assumption checks indicated homogeneity of variance (F(1,30)=3.12, p=.087) and 
regression slopes for the covariates (baseline depressive symptom severity 
(F(1,24)=1.36, p=.255); age (F1,24)=.00, p=.982); gender (F(1,24)=.05, p=.819). 
Baseline depressive symptom severity was significantly related to depressive 
symptom severity at three month follow up F(1,27)=21.45, p=.000. There was also a 
significant effect of WED on depressive symptom severity at follow up, controlling 
for baseline depressive symptom severity F(1,27)=7.18, p=.012. The adjusted group 
means at three month follow up indicated greater depressive symptom severity in 
the WED group compared to the control group, which represented a potentially 
clinically important difference: 5.5.  Moreover, the 95% confidence intervals 
associated with these means for the WED group (7.84 to 13.42) and control group 
(1.96 to 8.28) only marginally overlapped. The effect size ω² was .10, which 
represents a medium-sized effect. η² derived the same conclusion while η୮
²  
indicated a large effect at .21 (b=-5.5, 95%CIs -9.7 to -1.3). 
 
It is noteworthy that further investigation of the changes in depressive symptom 
severity over time for the WED group identified that seven participants actually 
exhibited a potentially clinically important increase in depressive symptom severity 
(i.e. ≥5 point increase on the CES-D), five (71%) of whom increased such that they 
scored above the cut point indicative of significant symptoms at follow up (i.e. CESD 
≥16). 
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Secondary outcomes 
DSED  
Assumption checks indicated homogeneity of variance (F(1,28)=.74, p=.398) and 
regression slopes for the covariates (baseline DSED F(1,22)=.84, p=.368); age 
(F1,22)=.07, p=.799); gender (F(1,22)=.06 p=.817). Baseline level of DSED was 
significantly related to DSED at three month follow up F(1,25)=12.58, p=.002. There 
was no significant effect of WED on DSED at follow up, controlling for baseline 
levels of DSED F(1,25)=.06, p=.815. The adjusted group means at three month 
follow up confirmed that there was no important difference. The effect size ω² was 
.00, which represents no effect. η² and η୮
²  derived the same conclusions (b=-.65, 
95%CIs -6.4 to 5.0). 
 
Health-related QoL 
EQ-5D utility: Assumption checks indicated homogeneity of variance (F(1,27)=.19, 
p=.671) and regression slopes for the covariates (baseline health-related QoL 
F(1,21)=.28, p=.600); age (F1,21)=.69, p=.416); gender (F(1,21)=1.87, p=.186). 
Baseline level of health-related QoL was significantly related to health-related QoL 
at three month follow up F(1,24)=24.03, p=.000. There was no significant effect of 
WED on health-related QoL at follow up, controlling for baseline levels of health-
related QoL F(1,24)=.01, p=.917. The adjusted group means at three month follow 
up confirmed that there was no important difference. The effect size ω² was .00, 
which represents no effect. η² and η୮
²  derived the same conclusions (b=.01, 95%CIs 
-.10 to .12). 
 
EQ-5D VAS: Assumption checks indicated homogeneity of variance (F(1,28)=.19, 
p=.664) and regression slopes for the covariates (baseline health-related QoL 
F(1,22)=.00, p=.968); age (F1,22)=3.85, p=.062); gender (F(1,22)=.88, p=.358). 
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Baseline level of health-related QoL was significantly related to health-related QoL 
at three month follow up F(1,25)=25.70, p=.000. There was no significant effect of 
WED on health-related QoL at follow up, controlling for baseline levels of health-
related QoL F(1,25)=1.84, p=.187. The adjusted group means at three month follow 
up confirmed that the WED group had very slightly worse health-related QoL 
compared to the control group. The effect size ω² was .02, which represents a small 
effect. η² derived the same conclusion while η୮
²  indicated a medium sized effect at 
.07 (b=7.5, 95%CIs -3.9 to 18.8). 
 
Diabetes SMBs 
General diet: Assumption checks indicated homogeneity of variance (F(1,29)=.00, 
p=.970) and regression slopes for  most of the covariates (age (F1,23)=5.60, 
p=.121); gender (F(1,23)=.83, p=.373). However, for baseline general diet the 
assumption of homogeneity of regression slopes was apparently violated for the 
untransformed data (F(1,23)=5.55, p=.027), yet this was not the case for the 
transformed data, analysis of which generally derived the same conclusions. Thus, 
for ease of interpretation the untransformed data is reported.  Baseline level of 
general diet was significantly related to general diet at three month follow up 
F(1,26)=6.49, p=.017. There was no significant effect of WED on general diet at 
follow up, controlling for baseline levels of general diet F(1,69)=.00, p=.999. The 
adjusted group means at three month follow up confirmed that there was no 
important difference. The effect size ω² was .00, which represents no effect. η² and 
η୮
²  derived the same conclusions (b=.001, 95%CIs -.97 to .97). 
 
Specific diet: Assumption checks indicated homogeneity of variance (F(1,28)=.35, 
p=.562) and regression slopes for the covariates (baseline specific diet F(1,22)=.11, 
p=.746); age (F1,22)=2.45, p=.132); gender (F(1,22)=.13, p=.719). Baseline level of 
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specific diet was significantly related to specific diet at three month follow up 
F(1,25)=18.79, p=.000. There was a significant effect of WED on specific diet at 
follow up, controlling for baseline levels of specific diet F(1,25)=4.59, p=.042. The 
adjusted group means at three month follow up confirmed that there was a slight 
difference such that the intervention group had a slightly poorer specific diet than 
controls. Moreover, the 95% confidence intervals associated with these means for 
the WED group (3.65 to 4.66) and control group (4.38 to 5.54) only marginally 
overlapped. The effect size ω² was .07, which represents a medium-sized effect. η² 
derived the same conclusion while η୮
²  indicated a large effect at .16 (b=.80, 95%CIs 
.03 to 1.6). 
 
Exercise: Assumption checks indicated homogeneity of variance (F(1,29)=.00, 
p=.985) and regression slopes for the covariates (baseline exercise F(1,23)=.07, 
p=.971); age (F1,23)=.04, p=.844); gender (F(1,23)=2.58, p=.122). Baseline level of 
exercise was significantly related to exercise at three month follow up 
F(1,26)=54.33, p=.000. There was no significant effect of WED on exercise at follow 
up, controlling for baseline levels of exercise F(1,26)=.68, p=.417. The adjusted 
group means at three month follow up confirmed that there was no important 
difference. The effect size ω² was .00, which represents no effect, while η² and η୮²  
indicated a small effect at .01 and .03 respectively (b=.47, 95%CIs -.70 to 1.6). 
 
Blood glucose testing: Assumption checks indicated homogeneity of variance 
(F(1,23)=.26, p=.616) and regression slopes for the covariates (baseline blood 
glucose testing F(1,17)=.01, p=.908); age (F1,17)=3.60, p=.075); gender 
(F(1,17)=.96, p=.341). Baseline level of blood glucose testing was significantly 
related to blood glucose testing at three month follow up F(1,20)=23.36, p=.000. 
There was no significant effect of WED on blood glucose testing at follow up, 
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controlling for baseline levels of blood glucose testing F(1,20)=.34, p=.564. The 
adjusted group means at three month follow up confirmed that there was no 
important difference. The effect size ω² was .00, which represents no effect, while 
η² and η୮
²  indicated a small effect at .01 and .02 respectively (b= -.51, 95%CIs -2.3 
to 1.3). 
 
Foot care: Assumption checks indicated homogeneity of variance (F(1,29)=.17, 
p=.680) and regression slopes for the covariates (baseline foot care F(1,23)=.2.08, 
p=.163); age (F1,23)=.28, p=.603); gender (F(1,23)=.16, p=.696). Baseline level of 
foot care was significantly related to foot care at three month follow up 
F(1,26)=58.57, p=.000. There was no significant effect of WED on foot care at follow 
up, controlling for baseline levels of foot care F(1,26)=.22, p=.641. The adjusted 
group means at three month follow up confirmed that there was no important 
difference. The effect size ω² was .00, which represents no effect, while η² and η୮²  
indicated a small effect at .01 (b=-.23, 95%CIs -1.2 to .78). 
 
Exploratory explanatory analyses   
Mechanisms of change 
EA&H 
As transformation did not influence the distributional problems in the PANAS data 
non-parametric tests were performed with the untransformed data (as described in 
chapters five and seven, and the appendix). The medians, range, means, 
associated SDs and mean ranks for post-writing negative affect for each writing 
session for the WED group are reported in Table 34. 
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Table 34 Post-writing negative affect for each writing session for the WED group115 
Session Median  Range  Mean SD Mean rank n 
10 1 16.0  10-35  17.3 7.6 1.9 
2 14.5 10-40  19.0 11.0 1.9 
3 17.5  10-45  21.0 11.8 2.3 
 
Post-writing negative affect did not change significantly across the writing sessions 
(χ²(2)=1.45, p=.516). Contrasts revealed that post-writing negative affect did not 
change significantly from session one to session two (T=17, p=.273, r= -.15), from 
session two to session three (T=12.5, p=.242, r= -.17) or from session one to 
session three (T=12, p=.063, r= -.35). The effect sizes indicated an increase in 
negative affect across writing days (i.e. session one < session two; session two < 
session three; session one < session three). The increase was small between 
sessions but medium-sized overall. This was consistent with the pattern indicated 
by the means. However, it is noteworthy that the medians indicated a decrease from 
session one to two and then an increase from session two to three. This was 
because for session two the scores were generally close to the lower bound yet 
there were a small number of large outliers, which are accounted for more by the 
means than the medians. Regardless however, the effect of an important magnitude 
was the change from the first to last session. 
 
E&CP 
Again, for ease of interpretation the results for the analyses with the untransformed 
data are reported as the conclusions were the same as those for the transformed 
data. There was one exception where analyses with the untransformed data 
produced effect sizes that were more consistent with the raw data than those 
derived from analyses from the transformed data. Specifically, for the ‘insight’ word 
use category the transformed data suggested a more substantial difference 
                                                             
115 Fourteen WED participants returned their writing and 10 of these provided observations for the 
PANAS negative affect sub-scale. 
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between sessions two and three compared to one and two whereas the raw data 
and the analyses with the untransformed data suggested the reverse; a more 
substantial difference between sessions one and two compared to two and three. 
The probable reasons for such discrepancies in effect size estimates resulting from 
transformation were described in relation to the preliminary effectiveness analysis 
reported in chapter seven.  
 
The means and associated SDs reflecting the percentage word use for the four 
categories indicative of E&CP for each writing session for the WED group are 
reported in Table 35. 
 
Table 35 Percentage word use for the four categories indicative of E&CP for each 
writing session for the WED group116 
Word use category Session Mean SD n 
Positive emotion (%) 1 3.1 1.2 12 
2 3.9 3.0 
3 4.0 1.8 
Negative emotion (%) 1 2.5 1.0 12 
2 2.6 1.6 
3 2.3 1.2 
Insight (%) 1 2.1 1.0 12 
2 2.5 1.5 
3 2.7 1.4 
Cause (%) 1 1.0 .49 12 
2 1.5 .82 
3 1.1 .67 
 
 
Positive emotion 
Mauchly’s test indicated that the assumption of sphericity had been violated 
χ²(2)=.50, p=.032, therefore degrees of freedom used to assess the F ratio were 
corrected using Greenhouse-Geisser estimates of sphericity (ε=.67). There was no 
significant effect of writing session upon percentage word use reflecting positive 
emotion F(1.33, 14.68)=1.14, p=.324. Contrasts revealed no significant change in 
                                                             
116 Fourteen WED participants returned their writing pack, twelve of whom completed all three sessions 
and could be included in analyses. 
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percentage word use reflecting positive emotion from session one to session two 
(F(1,11)=.94, p=.354, r=.28) or from session two to session three (F(1,11)=.01, 
p=.922, r=.03). However, the mean percentage word use scores for each writing 
session and effect sizes for the contrasts suggested a slight increase in positive 
emotion words across successive writing sessions, in particular between sessions 
one and two for which a small effect size was estimated. 
 
Negative emotion 
Mauchly’s test indicated that the assumption of sphericity had not been violated 
χ²(2)=.93, p=.687. There was no significant effect of writing session upon 
percentage word use reflecting negative emotion F(2,22)=.31, p=.738. Contrasts 
revealed no significant change in percentage word use reflecting negative emotion 
from session one to session two (F(1,11)=.03, p=.871, r=.05) or from session two to 
session three (F(1,11)=.77, p=.399, r=.26). The mean percentage word use scores 
for each writing session and effect sizes for the contrasts confirmed that there were 
no differences between sessions with respect to negative emotion words, only a 
slight decrease from session two to three for which a small effect size was 
estimated. 
 
Insight 
Mauchly’s test indicated that the assumption of sphericity had not been violated 
χ²(2)=.98, p=.913. There was no significant effect of writing session upon 
percentage word use reflecting insight F(2,22)=.94, p=.406. Contrasts revealed no 
significant change in percentage word use reflecting insight from session one to 
session two (F(1,11)=.92, p=.357, r=.28) or from session two to session three 
(F(1,11)=.10, p=.753, r=.10). However, the mean percentage word use scores for 
each writing session and effect sizes for the contrasts suggested a slight increase in 
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insight related words across successive writing sessions, in particular between 
sessions one and two. The increases between each session were estimated as 
small effect sizes. 
 
Cause 
Mauchly’s test indicated that the assumption of sphericity had not been violated 
χ²(2)=.89, p=.544. There was no significant effect of writing session upon 
percentage word use reflecting cause F(2,22)=2.03, p=.155. Contrasts revealed a 
change in percentage word use reflecting cause from session one to session two 
that was approaching significance (F(1,11)=4.09, p=.068, r=.52) yet no significant 
change from session two to session three (F(1,11)=1.92, p=.193, r=.39). The mean 
percentage word use scores for each writing session and effect sizes for the 
contrasts suggested an increase in causal words from session one to two estimated 
as a large effect size, and a reduction from session two to three estimated as a 
medium effect size.  
 
In the absence of adequate confirmation of the anticipated changes in post-writing 
negative affect and percentage word use presumed to reflect E&CP across writing 
sessions the presence or absence of such changes in the control group, and then 
the potential mediating effect of these change on the primary outcome were not 
explored.  
 
Mediators 
Again, for ease of interpretation the results for the analyses with the untransformed 
data are reported as the conclusions were generally consistent with those for the 
transformed data. There were a small number of exceptions for certain mediation 
steps for certain mediators tested at certain intervals, namely very slightly artificially 
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inflated effect sizes and slightly smaller p values (as in chapter seven); if at step two 
the mediator was apparently a slightly better predictor of the outcome and if at step 
three the relationship between the intervention and outcome was very slightly less 
attenuated (i.e. a slightly smaller p value was observed), and one instance of a 
slightly underestimated effect size and slightly larger  p value (in step two the 
mediator was slightly less predictive of the outcome) in analyses with transformed 
data. The most conservative approach was to report the findings for the 
untransformed data. Regardless, however, the overall conclusions about mediation 
were unaffected by the discrepancies thus they were not considered to be 
important.  
 
The model for the first mediation step (i.e. intervention group as a predictor of 
depressive symptom severity at three months, controlling for baseline depressive 
symptom severity), which applies to all of the mediation analyses, is presented in 
Table 36.  
 
Table 36 Model for the first step in all mediation analyses117 118 
Mediation 
step 
Model R² adj
R² 
∆R² ∆F (p) b SEb ß (p) n 
Step 1 A - C Block 1  
Baseline depressive symptoms 
.40 .38      32 
Block 2  
Baseline depressive symptoms 
.53 .49 .12 7.6 
(.010) 
Intervention group (A) 5.6 2.0 .35 
(.010) 
 
 
 
 
 
                                                             
117 A=intervention group and C=primary outcome (depressive symptom severity at three months). 
adjR²=adjusted R². ∆R²=change in R². ∆F(p)=change in F ratio (and significance of ∆F). 
b=unstandardized regression coefficient. SEb=standard error of b. ß(p)=standardized regression 
coefficient  (and significance of ß). 
118  Where n is less than 41 participants were missing because they did not have scores for all 
variables included in the analysis. 
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Two weeks 
Self-efficacy for diabetes SMBs 
Controlling for baseline depressive symptom severity  and intervention group, self-
efficacy for diabetes SMBs was not a significant predictor of depressive symptom 
severity  at three months (ß=.02, p=.902) and explained no additional variance in 
the outcome (∆R²=.00). The model for the final mediation step is presented in Table 
37; the relationship between the intervention group and outcome (p=.010) was not 
notably attenuated by controlling for self-efficacy for diabetes SMBs (p=.020) and 
the amount of variance in the outcome explained by intervention group (∆R²=.12) 
was reduced by only .01 representing no effect (∆R²=.11).  
 
Table 37 Model for the final mediation step for self-efficacy for diabetes SMBs 
measured at two weeks post-intervention 
Mediation step Model R² adj 
R² 
∆R² ∆F (p) b SEb ß (p) n 
Step 3 A – C 
(controlling B) 
Block 1  
Baseline depressive symptoms 
.42 .38      31 
Self-efficacy (B) 
Block 2  
Baseline depressive symptoms 
.53 .48 .11 6.2 
(.020) 
Self-efficacy (B) 
Intervention group (A) 5.6 2.3 .35 
(.020) 
 
 
Perceived illness interference  
Controlling for baseline depressive symptom severity and intervention group, 
perceived illness interference was not a significant predictor of depressive symptom 
severity at three month follow up (ß=.21, p=.165), and explained a small amount of 
additional variance in the outcome (∆R²=.03). The model for the final mediation step 
is presented in Table 38; the relationship between the intervention group and 
outcome (p=.010) was not notably attenuated by controlling for perceived illness 
interference (p=.013) and the amount of variance in the outcome explained by 
intervention group (∆R²=.12) was not reduced (∆R²=.12). 
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Table 38 Model for the final mediation step for perceived illness interference 
measured at two weeks post-intervention 
Mediation step Model R² adj
R² 
∆R² ∆F (p) B SEb ß (p) n 
Step 3  
A – C  
(controlling B) 
Block 1  
Baseline depressive symptoms 
.45 .41      31 
Perceived illness interference (B) 
Block 2  
Baseline depressive symptoms 
.56 .51 .12 7.0 
(.013) 
Perceived illness interference (B) 
Intervention group (A)    5.4 2.1 .34 
(.013) 
 
Perceived emotional support (number)  
Controlling for baseline depressive symptom severity and intervention group, 
perceived emotional support (number) was not a significant predictor of depressive 
symptom severity at three months (ß=.16, p=.303), and explained a small amount of 
additional variance in the outcome (∆R²=.02). The model for the final mediation step 
is presented in Table 39; the relationship between the intervention group and 
outcome (p=.010) was not notably attenuated by controlling for perceived social 
emotional (number) (p=.016) and the amount of variance in the outcome explained 
by intervention group (∆R²=.12) was not reduced (∆R²=.12). 
 
Table 39 Model for the final mediation step for perceived emotional support 
(number) measured at two weeks post-intervention 
Mediation step Model R² adj
R² 
∆R² ∆F (p) B SEb ß (p) n 
Step 3 A – C 
(controlling B) 
Block 1  
Baseline depressive symptoms 
.44 .40      28 
Perceived emotional support 
(number) (B)    
Block 2  
Baseline depressive symptoms 
.56 .51 .12 6.7 
(.016) 
Perceived emotional support 
(number) (B)    
Intervention group (A)    5.9 2.3 .36 
(.016) 
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Perceived emotional support (satisfaction) 
Controlling for baseline depressive symptom severity and intervention group, 
perceived emotional support (satisfaction) was not a significant predictor of 
depressive symptom severity  at three months (ß=.05, p=.703), and explained no 
additional variance in the outcome (∆R²=.00). The model for the final mediation step 
is presented in Table 40; the relationship between the intervention group and 
outcome (p=.010) was not attenuated by controlling for perceived emotional support 
(satisfaction) (p=.009) and the amount of variance in the outcome explained by 
intervention group (∆R²=.12) was not reduced (∆R²=.15). 
 
Table 40 Model for the final mediation step for perceived emotional support 
(satisfaction) measured at two weeks post-intervention 
Mediation step  Model R² adj 
R² 
∆R² ∆F (p) b SEb ß (p) n 
Step 3 A – C 
(controlling B) 
Block 1  
Baseline depressive symptoms 
.39 .34      28 
Perceived emotional support  
(satisfaction) (B)    
Block 2  
Baseline depressive symptoms 
.55 .49 .15 8.1 
(.009) 
Perceived emotional support  
(satisfaction) (B)    
Intervention group (A)    6.4 2.3 .39 
(.009) 
 
 
Three months 
Self-efficacy for diabetes SMBs 
Controlling for baseline depressive symptom severity and intervention group, self-
efficacy for diabetes SMBs was potentially related to depressive symptom severity 
at three months but did not emerge as a significant predictor (ß=-.27, p=.089), and 
explained a small amount of additional variance in the outcome (∆R²=.05). 
However, this was unimportant given that the relationship between the intervention 
group and outcome (p=.010) was not attenuated by controlling for self-efficacy for 
diabetes SMBs (p=.007) and the amount of variance in the outcome explained by 
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intervention group (∆R²=.12) was not reduced (∆R²=.15). The model for the final 
mediation step is presented in Table 41. 
 
Table 41 Model for the final mediation step for self-efficacy for diabetes SMBs 
measured at three months post-intervention 
Mediation step Models R² adj
R² 
∆R² ∆F (p) b SEb ß (p) n 
Step 3 A – C 
(controlling B) 
Block 1  
Baseline depressive symptoms 
.47 .42      27 
Self-efficacy (B) 
Block 2  
Baseline depressive symptoms 
.62 .56 .15 8.9 
(.007) 
Self-efficacy (B) 
Intervention group (A) 6.8 2.3 .41 
(.007) 
 
 
Perceived illness interference  
Controlling for baseline depressive symptom severity and intervention group, 
perceived illness interference was not a significant predictor of depressive symptom 
severity at three months (ß=-.06, p=.753), and explained no additional variance in 
the outcome (∆R²=.00). The model for the final mediation step is presented in Table 
42; the relationship between the intervention group and outcome (p=.010) was not 
notably attenuated by controlling for perceived illness interference (p=.024) and the 
amount of variance in the outcome explained by intervention group (∆R²=.12) was 
reduced by only .01 representing no effect (∆R²=.11). 
 
Table 42 Model for the final mediation step for perceived illness interference 
measured at three months post-intervention 
Mediation step Model R² adj
R² 
∆R² ∆F (p) b SEb ß (p) n 
Step 3 A – C 
(controlling B) 
Block 1  
Baseline depressive symptoms 
.45 .41      27 
Perceived illness interference (B) 
Block 2  
Baseline depressive symptoms 
.56 .51 .11 5.8 
(.024) 
Perceived illness interference (B) 
Intervention group (A) 5.8 2.4 .34 
(.024) 
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Perceived emotional support (number) 
Controlling for baseline depressive symptom severity and intervention group, 
perceived emotional support (number) measured was not a significant predictor of 
depressive symptom severity at three months (ß=-.07, p=.657), and explained no 
additional variance in the outcome (∆R²=.00). The model for the final mediation step 
is presented in Table 43; the relationship between the intervention group and 
outcome (p=.010) was very slightly attenuated by controlling for perceived 
emotional support (number) (p=.035) and the amount of variance in the outcome 
explained by intervention group (∆R²=.12) was reduced by .02 representing a small 
effect (∆R²=.10).  
 
Table 43 Model for the final mediation step for perceived emotional support 
(number) measured at three months post-intervention 
Mediation step Models R² adj
R² 
∆R² ∆ F (p) b SEb ß (p) n 
Step 3 A – C 
(controlling B) 
Block 1  
Baseline depressives 
.45 .40      26 
Perceived emotional support  
(number) (B) 
Block 2  
Baseline depressive symptoms 
.55 .49 .10 5.1 
(.035) 
Perceived emotional support  
(number) (B) 
Intervention group (A) 5.2 2.3 .33 
(.035) 
 
Perceived emotional support (satisfaction)  
Controlling for baseline depressive symptom severity and intervention group, 
perceived emotional support (satisfaction) was potentially related to depressive 
symptom severity at three months but did not emerge as a significant predictor (ß =-
.27, p=.094), and explained a small amount of additional variance in the outcome 
(∆R²=.06). However, this was unimportant given that the relationship between the 
intervention group and outcome (p=.010) was not attenuated by controlling for 
perceived emotional support (satisfaction) (p=.009) and the amount of variance in 
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the outcome explained by intervention group (∆R²=.12) was not reduced (∆R²=.15). 
The model for the final mediation step is presented in Table 44. 
 
Table 44 Model for the final mediation step for perceived emotional support 
(satisfaction) measured at three months post-intervention 
Mediation step Model R² adj
R² 
∆R²  ∆F (p) B SEb ß (p) n 
Step 3 A – C 
(controlling B) 
Block 1  
Baseline depressive symptoms 
.47 .42      25 
Perceived emotional support  
(satisfaction) (B) 
Block 2  
Baseline depressive symptoms 
.62 .56 .15 8.4 
(.009) 
Perceived emotional support  
(satisfaction) (B) 
Intervention group (A) 6.6 2.3 .40 
(.009) 
 
 
Sub-group (moderator) analyses 
No significant interaction effects were observed (p>.05), yet there was a tentative 
indication in the pattern of the means (and the interaction plots) that WED may have 
been associated with greater depressive symptom severity compared to controls at 
follow up for individuals with high alexithymia (WED: Mean=11.2, SE=1.7 versus 
control: Mean=3.8, SE=2.6) but not low alexithymia (WED: Mean=9.3, SE=2.4 
versus control: Mean=5.0, SE=2.0) and low optimism (WED: Mean=12.6, SE=1.9 
versus control: Mean=5.2, SE=3.0) but not high optimism (WED: Mean=8.7, SE=1.9 
versus control: Mean=4.8, SE=2.1). 
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Chapter 8 Feasibility findings and post-hoc investigation and analyses 
 
Chapter overview 
This chapter presents the remaining feasibility investigation; the investigation of the 
feasibility/effectiveness of intervention delivery (i.e. compliance, contamination and 
acceptability data), and the remaining aspects of the investigation of the 
feasibility/effectiveness of the trial protocol (i.e. the feasibility/effectiveness of the 
randomisation and allocation concealment methods and the check of blinding 
success). The findings from some additional post-hoc investigations and analyses 
are then presented, specifically feasibility data that was collated unintentionally yet 
is nonetheless consistent with the objectives of an exploratory trial (as described in 
chapter four), and consideration of writing content with some exploratory analyses 
undertaken to facilitate interpretation of the pre-specified analyses. 
 
Feasibility investigation 
Feasibility/effectiveness of intervention delivery 
Contamination  
Average degree of EA 
Again as transformation did not influence the distributional problems in the PANAS 
data non-parametric tests were performed with the untransformed data (as 
described in chapters five and seven, and the appendix). The medians and mean 
ranks for post-writing negative affect averaged across writing sessions and by group 
are reported in Table 45. 
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Table 45 Average degree of post-writing negative affect across writing sessions by 
group119 
 
 
 
Average post-writing negative affect was significantly different for the WED group 
compared to the control group (U=6.0, z= -2.853, p=.001). The average post-writing 
negative affect scores indicated more post-writing negative affect for the WED 
group compared to the control group. This represented a large effect (r=-.69).  
 
Average degree of ED 
For ease of interpretation the results for the analyses with the untransformed data 
are reported. The conclusions were generally consistent with those for the 
transformed data, with some exceptions where artificially inflated effect sizes and 
slightly smaller p values were derived from analyses with transformed data (again 
as in chapter seven).  
 
The most conservative approach was thus to report the findings for the 
untransformed data. The means and associated SEs reflecting the average 
percentage word use for the four categories indicative of ED across writing sessions 
by group are reported in Table 46. 
 
 
 
 
                                                             
119 Twenty-seven participants returned their writing (WED 14; Control 13) and 17 (WED 10; Control 7) 
of these provided an observation for the PANAS negative affect sub-scale. 
Session Median (range) Mean rank n 
WED 16.7(10.3–40.0) 11.9 10 
Control 10.0 (10.0-14.3) 4.9 7 
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Table 46 Average percentage word use for the four categories indicative of ED 
across writing sessions by group120 
 
Assumption checks indicated homogeneity of variance for percentage word use 
reflecting positive emotion (F(1,25)=1.99, p=.171), negative emotion (F(1,25)=1.61, 
p=.216) and cause (F(1,25)=.35, p=.562). The assumption of homogeneity of 
variance was apparently violated for percentage word use reflecting insight for the 
untransformed data (F(1,25)=4.74, p=.039), yet this was not the case for the 
transformed data, analysis of which derived the same conclusions. Thus, for ease of 
interpretation the untransformed data is reported.  Mauchly’s test indicated that the 
assumption of sphericity had been violated χ²(5)=.53, p=.011, therefore degrees of 
freedom used to assess the F ratio were corrected using Greenhouse-Geisser 
estimates of sphericity (ε=.69). 
 
There was a significant effect of group (F(1,25)=58.10, p=.000).  This was a large 
effect (r=.84). The intervention group included more words reflecting ED than the 
control group across all categories. 
 
There was additionally a significant interaction between group and category of word 
use (F(2.079, 51.977)=3.83, p=.027). Contrasts revealed that there was no 
difference between the main effect of group across word use categories (i.e. greater 
percentage word use for the WED group compared to the control group) and the 
                                                             
120 Twenty-seven participants returned their writing (WED 14; Control 13). 
Word use category Total 
sample 
(Mean; SE) 
n WED 
(Mean; SE) 
n Control 
(Mean; SE) 
n 
All word use categories   2.4 (.12) 14 1.0 (.13) 13 
Positive emotion (%) 2.5 (.25) 27 3.5 (.35) 14 1.6 (.36) 13 
Negative emotion (%) 1.6 (.16) 27 2.4 (.22) 14 .79 (.22) 13 
Insight (%) 1.5 (.18) 27 2.2 (.25) 14 .82 (.26) 13 
Cause (%)  1.1 (.09) 27 1.3 (.12) 14 .98 (.13) 13 
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effect of group specifically for the positive emotion (F(1,25)=2,14, p=.156, r=.28), 
negative emotion (F(1,25)=1.27, p=.270, r=.22) and insight (F(1,25)=.05, p=.832, 
r=.04) word use categories. However, there was a significant difference between 
main effect of group across word use categories and the effect of group for the 
causal word use category (F(1,25)=18.65, p=.000). This was a large effect (r=.65). 
Examination of the means revealed that while there was greater percentage word 
use reflecting cause for the WED group compared to the control group this 
difference was reduced compared to the overall effect of group. The average 
percentage word use by group and word use category is presented in Figure 26. 
 
Figure 26 Average percentage word use across writing sessions by group and word 
use category  
 
 
 
Compliance 
The number of days writing completed 
The number of writing sessions that participants completed is illustrated in Table 47. 
Participants that returned their writing generally wrote for three sessions. It is 
noteworthy that one intervention patient noted in their pack that they wrote for ‘3+’ 
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sessions. Support group participants all completed three writing sessions as 
instructed. 
 
Table 47 Number of writing sessions participants completed121 
 
 
 
 
 
 
The length of time spent writing per session 
The length of time participants spent writing per session is illustrated in Table 48. In 
general, participants only marginally deviated from the instructions to write for 20 
minutes per session. However there were some outliers. In one of the worst 
instances of this, a primary care patient in the intervention group wrote for 120 
minutes in session two and noted that they took long breaks within each session for 
meals, household jobs and spending time with their wife.  Another primary care 
patient in the control group wrote for 781 minutes in session one and commented 
that the time taken varied as they felt they had something to say and couldn’t stop 
until they had finished. Presumably this participant also took breaks.122 
 
 
                                                             
121 Twenty-seven participants returned their writing (WED 14; Control 13). 
122 It is also noteworthy that participants were required to indicate the time at which they started and 
finished writing, specifying whether this was am or pm in each instance (i.e. deleting as appropriate). 
This led to some discrepancies for some patients in that it was not clear whether the start and or finish 
times were am or pm or there were obvious errors (e.g. the start time was 8:00 am and the finish time 
was 8:20 pm). Such discrepancies were interpreted logically (i.e. in view of that participant’s writing in 
other sessions, the length of the text and the times provided, e.g. 4:00 was considered less likely to be 
am), yet a presumption was made nonetheless. For example, the patient that wrote for 120 minutes in 
session two indicated that for session three they wrote from 9:40 to 10:20; both were presumed to be 
am and therefore 40 minutes but had one time been am and the other pm this session would have 
been considerably  longer. Consequently, it may be that some patients actually wrote for longer for 
some sessions.  
 
No. days 
completed 
Total sample (n=27) WED (n=14) Control (n=13) 
Three  24 (89%) 12 (86%) 12 (92%) 
Two  
(session 1 & 2) 
1 (4%) 1 (7%) 0  
Three 
(session 1 only) 
2 (7%) 1 (7%) 1 (8%) 
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Table 48 Length of time participants spent writing per session123  
 
 
 
Overall, for those that returned their writing compliance with the instructions in terms 
of both the number of days completed and amount of time spent writing was 
relatively good. However, 14 (34%) participants failed to return their writing at all. 
 
Further self-directed writing  
Whether participants carried on writing after completing the writing task is illustrated 
in Table 49.  A significant proportion of patients indicated that they had undertaken 
further writing since the intervention task, especially in the WED group. However, it 
is notable that this could reflect other forms of writing (i.e. not ED); two WED 
patients responding positively to this question also commented in their writing/stated 
in a follow up questionnaire that they were currently writing a book/family history 
and or that they kept a daily diary. Moreover, the majority of support group 
participants responded positively to this question. However, this may reflect writing 
within the forum from which they were recruited.  
 
 
 
  
                                                             
123 Twenty seven participants returned their writing: where n is less than 27 (WED=14; Control=13) 
patients did not return writing for that day. 
Writing 
session 
Total sample 
(Mean minutes 
(SD; range) 
n WED 
(Mean minutes 
(SD; range) 
n Control 
(Mean minutes 
(SD; range) 
n 
1   55.4 
(145.6; 10-781) 
27 30.4  
(15.4; 20-70) 
14 82.4 
(210.1; 10-781) 
13 
2  29.1  
(20.5; 15-120) 
25 31.0 
(27.0; 19-120) 
13 27.1  
(10.5; 15-55) 
12 
3  26.0  
(8.6; 15-45) 
24 24.9  
(9.0; 15-45) 
12 27  
(8.5; 17-45) 
12 
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Table 49 Whether participants carried on writing since completing the writing task124 
 
 
 
 
Acceptability 
Reasons participants provided for not writing at all were presented in chapter six. 
The reasons provided for not undertaking the intervention as instructed were as 
follows. The two WED participants that did not complete all three sessions 
commented that this was because they found it difficult to write (completed two 
sessions) or had better things to do than keep repeating themselves (completed one 
session). The control patient that completed only one session commented that he 
considered the task to be juvenile and could not identify its relevance or use with 
respect to diabetes. 
 
Feasibility/effectiveness of the trial protocol 
Randomisation and allocation concealment methods 
The randomisation and allocation concealment methods were easily implemented 
and were apparently successful as there were no substantial systematic differences 
on prognostic variables apparent at baseline (i.e. there was no evidence of selection 
bias – as reported in chapter seven).  
 
Check of blinding success 
Whether participants inferred the true nature of the study and their group 
assignment was again collated at debriefing and is illustrated in Table 50.  Blinding 
was apparently successful for the majority of participants. However, a number 
                                                             
124 Twenty seven participants returned their writing (WED=14; Control=13) and 23 (WED=11; 
Control=12) of these answered the question asking whether they had carried on writing since the initial 
task.  
Carried on 
writing? 
Total sample (n=23) WED (n=11) Control (n=12) 
Yes 10 (43%) 6 (55%) 4 (33%) 
No 13 (57%) 5 (45%) 8 (67%) 
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indicated that they were aware of the two groups, what the other group was writing 
about and that they had guessed the purpose of their writing task. No group 
differences were apparent with respect to compromised blinding. It is noteworthy, 
however, that for both groups slightly more participants agreed to being aware of 
the purpose of the other group’s task and of their own tasks purpose than to being 
aware of there being two groups; while blinding was apparently completely 
compromised for some participants it seems that others may have merely guessed 
theirs was an active or inert task. Blinding was apparently consistently successful 
for support group participants that answered these questions (i.e. none responded 
positively to any of the questions). In fact, two support group participants provided 
additional comments about the blinding aspect of the study in the debriefing sheet. 
One intervention participant reiterated that they had not identified the two groups 
and a control group participant indicated that they had not thought about possible 
study groupings, but having read the debriefing sheet it seemed obvious what the 
purpose of the study was. 
 
Table 50 Whether participants inferred the true nature of the study and their group 
assignment125 
 
                                                             
125 Forty one participants were randomised (WED=23; Control=18) and 31 (WED=16; Control=15) of 
these returned and answered the debrief questions. 
 
Question asked Total sample 
(n=31) 
WED  
(n=16) 
Control  
(n=15) 
Yes No Yes No Yes No 
Were you aware that there were 2 
different groups? 
3 
(10%) 
28 
(90%) 
1 
(6%) 
15 
(94%) 
2 
(13%) 
13 
(87%) 
Having read this debriefing sheet 
had you guessed what the other 
group was writing about? 
9 
(29%) 
22 
(71%) 
5 
(31%) 
11 
(69%) 
4 
(27%) 
11 
(73%) 
Having read the debriefing sheet & 
now knowing what group you were 
in, had you already guessed the 
purpose of your writing task? 
7 
(23%) 
24 
(77%) 
4 
(25%) 
12 
(75%) 
3 
(20%) 
12 
(80%) 
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Post-hoc investigation/analyses: additional feasibility data 
Valuable additional information about intervention fidelity, the acceptability of the 
intervention and comparison exposure, participants’ general experience of the 
study, the appropriateness of the measures employed and the feasibility of the data 
collection schedule was collated unintentionally and is presented below. 
 
Intervention fidelity: self-reports of negative emotional response post-
writing 
A number of intervention participants provided comments in their writing pack that 
supported intervention fidelity. One acknowledged a ‘lowering of spirit’, another 
stated that thinking about what they were concerned about enough to write about 
notably diminished their positive mood, and another indicated that despite usually 
being a positive person, writing evoked negativity and contemplation of stressful 
issues in the following days. 
 
Acceptability of the intervention and comparison exposure 
A number of participants provided comments about their writing task in the packs 
provided. These are described below.  
 
Acceptability of writing per se 
Poor health prohibiting writing 
One participant wrote for three days yet commented that they experienced difficulty 
due to arthritic pain in both hands, sight problems and generally not being well 
(control).                                                                                                                                                           
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Feeling restricted by the time allocated 
One participant commented that they could have written more had they had more 
time (control). Another commented that the allocated time passed quickly and that 
they did not feel they had actually said anything (WED). 
 
Finding writing difficult to fit in with life 
One participant commented that they had found it difficult to find time to start writing 
(WED). Another commented that it was difficult to complete the writing sessions 
within one week due to work commitments (WED). However, control participants did 
not experience this problem; one noted that they had managed to complete their 
writing task within one week and another noted that they had actually written on 
consecutive days. 
 
Negative feelings about handwriting 
Some participants commented that they were not used to handwriting, joked about 
having cramp in their hand after writing, and one actually requested that they typed 
their disclosure (one WED & one control). Despite the apparent preference for 
typing however, one support group intervention participant requested a hardcopy of 
the writing pack as they felt their thoughts would flow more freely (i.e. again all 
support group participants were offered this). 
 
Acceptability of WED content 
A number of participants indicated that they found it difficult to relate to the WED 
task and that they were uncertain about what was required or what they could write 
about as they did not dwell on emotions or stressful experiences, did not have any 
problems, were not stressed or depressed and were optimistic and able to make the 
best of life even when faced with difficulties (seven WED). It is noteworthy that a 
number of these participants were amongst those that also wrote about positive 
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issues (discussed later), and this may explain why. Interestingly, one intervention 
participant commented that they found writing about their innermost thoughts to be 
difficult as they usually concealed their problems to avoid worrying others.  
 
Acceptability of the comparison exposure: time management 
One participant explained that they did not follow the allotted task because they 
would have found that too boring; this was the control participant who wrote for 781 
minutes in session one and who also seemingly emotionally disclosed (discussed 
below). Another commented that they had added the term ‘bored’ to the list of mood 
adjectives which participants were required to rate post-writing in terms of their 
current mood, as this better represented how they felt. 
 
Possible restriction owing to readership 
Some participants expressed concern about the quality of their writing despite 
stating that they were aware this was not important, often apologising for writing 
which they felt was illegible (two control). Other participants returned their writing 
packs with a note to say that they hoped their writing was as required and 
informative (one control) and apologised as they felt they had rambled and that their 
writing was uninteresting (one WED). Indeed, most patients wrote as if it were a 
narrative for a reader, for example introducing themselves and using the term ‘dear 
reader’, and some explicitly questioned whether their writing would be read within 
their text.  
 
General feedback about the study 
One intervention participant commented in the three month questionnaire that they 
did not expect their diabetic control would be influenced (WED). Other participants 
provided additional comments about their experience of the study within the 
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debriefing sheet that was returned; two control participants stated that they found 
the writing task/study to be interesting and one expressed that it had been a 
pleasure to take part.  
 
Appropriateness of measures 
Participants’ comments in the questionnaires and the debriefing sheet provided 
some insight into the acceptability of the measures employed and suggested some 
interpretative issues. The researcher additionally observed some interpretative 
problems associated with the measures employed that warrant a mention. 
 
Participant comments 
General 
One elderly primary care patient noted that they felt many of the questions were not 
applicable given their age. Another patient commented that they felt they were 
constantly repeating themselves, that the questionnaires were based on the 
assumption that everyone felt negatively about diabetes, and that few of the 
questions felt relevant to them as they were not concerned about diabetes, were 
managing this well and were more concerned about other conditions such as mental 
deterioration.  
 
It was evident that the incident illness unrelated to diabetes reported by some 
participants within the trial may have influenced responses to questionnaires given 
the nature of the questions. As mentioned in chapter six, one patient had a double 
bypass operation and another was admitted to hospital with heart failure (i.e. atrial 
fibrillation) during the follow up period. Both noted in the three month questionnaire 
that their answers were likely influenced by this/this would explain the change in 
their answers.  
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Measure-specific 
Comments associated with missing responses: To identify whether missing item 
responses were missing at random or related to certain items, the dataset was 
visually inspected and frequencies for each item within each measure were 
produced (i.e. reported as the number (and percentage) of observations missing for 
each item for each measure each time the measure was administered). 
 
The missing observations per item for each continuous measure at each 
administration are illustrated in Table 51. Missing item responses were not entirely 
missing at random; they were related to certain items within certain continuous 
measures (i.e. responses for certain items were commonly missing across 
participants). Missing responses were most notable for the items in the SDSCA that 
ask about blood glucose monitoring (items 7 and 8126), and the items in the DMSES 
UK that ask about blood glucose monitoring (items 1-3127) and adjusting medication 
when ill (item 15128). Patients often commented adjacently to missing responses that 
these items were not applicable to them, for instance because their HCP does not 
advise them to monitor their blood glucose levels or they check more than that 
recommended by their HCP (SDSCA items 7 and 8), they rely on their HCP to 
monitor their blood glucose and they do not experience problems with high/low 
blood sugar that would require correction (DMSES UK items 1-3), and they do not 
adjust their medication on their own/without professional advice or a situation in 
which they have been ill and required to do this has not arisen (DMSES UK item 
15).  
                                                             
126SDSCA item 7: On how many of the last seven days did you test your blood sugar? SDSCA item 8: 
On how many of the last seven days did you test your blood sugar the number of times recommended 
by your health care provider? 
127  DMSES UK item 1: I am able to check my blood sugar if necessary. DMSES UK item 2: I am able 
to correct my blood sugar when the sugar level is too high. DMSES UK item 3: I am able to correct my 
blood sugar when the blood sugar level is too low. 
128 DMSES UK item 15: I am able to adjust my medication when I am ill. 
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Moreover, missing responses for the SSQ6 items that asked about being down in 
the dumps and upset (items 9 and 11129) were notable. Indeed, participants often 
commented adjacently to missing responses that these items were not applicable 
(i.e. “don’t get very upset” & “never down in the dumps”). Similarly, participants often 
commented adjacently to missing responses to a DMSES UK item that asks about 
self-efficacy for diabetes SMBs when feeling stressed or anxious (item 13130) that 
this is was not applicable to them. 
 
The PANAS measure (i.e. list of mood adjectives which participants were required 
to rate in terms of their current mood post-writing) was often not completed at all or 
very few adjectives were rated such that no score for the negative affect sub-scale 
could be derived. Indeed, data for the PANAS exhibited the highest degree of 
missing observations; of the 41 participants that were enrolled, 27 returned their 
writing pack and for 10 (37%) of these a total PANAS negative affect sub-scale 
score could not be derived. As mentioned above, one control participant 
commented in their writing pack that none of the adjectives represented how they 
felt.  This may explain why others omitted this measure. It is noteworthy that the full 
PANAS measure was actually administered (i.e. the positive and negative affect 
sub-scales), and where people completed only a few of the adjectives they 
answered either only positive or only negative adjectives. It therefore seems that 
these people only responded to the few adjectives that represented their current 
mood. 
 
Comments about certain measures: The IIRS asks how much your illness and/or its 
treatment interferes with your life and thus did not specifically refer to diabetes. One 
                                                             
129 SSQ6 item 9: Whom can you really count on to help you feel better when you are feeling generally 
down-in-the dumps? SSQ6 item 11: Who can you count on to console you when you are very upset? 
130 DMSES UK item 13: I am able to adjust my eating plan when I am feeling stressed or anxious. 
336 
 
participant stated that they had answered this with respect to other health problems; 
for example a recent double bypass operation (as above) and angina. The SSQ6 
was also apparently somewhat tedious for some patients.  As mentioned in chapter 
six, one participant indicated that while they had completed all other measures in 
the two week questionnaire, they did not complete the SSQ6 as they answered it in 
a previous questionnaire and did not wish to repeat it.  
 
Comments about certain items in certain measures: Consistent with the comments 
associated with missing responses, for a DMSES UK item that asks about taking 
medication as prescribed (item 14), participants commented adjacently to 
responses that this item was not applicable and commented that they did not take 
medication for diabetes. Participants also often commented adjacently to responses 
to the IIRS item enquiring about the impact of illness on sex life (item 8) that this 
was not applicable due to age and that this information was private (i.e. they felt 
uncomfortable providing it). Finally, participants commented that they found other 
items in SDSCA and DMSES UK difficult to answer because they did not have an 
eating plan as presumed, they were unable to exercise due to health problems/old 
age or they were not advised by their HCP to exercise. 
 
Receipt of materials electronically: As described in chapter six, some support group 
participants noted formatting problems when completing questionnaires as these 
were received electronically/by email, especially for the EQ-5D. Participants 
experienced difficulties where they were required to mark text boxes (i.e. with an 
‘X’), and indeed the EQ-5D requires such responses. It also requires the use of an 
arrow to indicate a point on a vertical scale, which was additionally susceptible to 
substantial formatting problems. Formatting problems were also experienced for the 
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SSQ6, which already has a relatively complex response format (presented in the 
appendix and discussed below). 
 
Interpretation of responses 
The most substantial interpretative problems observed for the materials employed 
were for the SSQ6. Again, the response format for this measure is relatively 
complex, and indeed participants varied in their approach to completing it often 
deviating from the instructions/example provided. It was, however, usually possible 
to decipher the intended responses, and a conservative approach was adopted 
applying the same logic in each instance in order to promote consistency in 
interpretation. Other measures for which participants varied in their approach to 
completion included the SDSCA (i.e. participants did not always circle only the 
number of days for which a behaviour was performed as required) and the EQ-5D 
VAS measure (i.e. participants did not always precisely indicate a point on the 
vertical scale with the arrow as required). However, these problems were less 
notable and again it was typically possible to decipher the intended response. It is 
also noteworthy that across the measures employed participants occasionally wrote 
their responses as comments or underlined text rather than responding to the items 
as instructed. In these instances no response was presumed.  
 
The formatting problems experienced by support group participants additionally 
created interpretative problems. Indeed, responses were often not initially 
interpretable, especially for the EQ-5D, yet they could usually be deciphered. 
Electronic materials were also vulnerable to participants not answering in the correct 
response format, for example unsystematically deleting proportions of Likert scales 
to indicate a response rather than simply marking the appropriate number as 
instructed.  
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Table 51 Extent of missing observations per item for each continuous measure at each time point 
  
Measure Item no. with missing responses (x number of missing observations; % of total 
number of observations) 
Baseline (n=41 returned questionnaire pack) 
CES-D (scoring key: items scored if <4 missing) 16(x1; 2%); 17(x1; 2%) 
PAID 1(x1; 2%); 6(x1; 2%); 9(x1; 2%); 10(x1; 2%); 11(x1; 2%); 12(x1; 2%); 13(x1; 2%); 14(x2; 
5%); 15(x2; 5%); 16(x1; 2%); 17(x1; 2%); 18(x2; 5%); 19(x1; 2%); 20(x1; 2%) 
EQ-5D utility Mobility (x3; 7%); Self-care (x2; 5%); Usual activities (x1; 2%); Pain & discomfort (x2; 5%); 
Anxiety & depression (x1; 2%) 
SDSCA: general diet: items 1&2 2(x1; 2%) 
SDSCA: specific diet: items 3&4 4(x2; 5%) 
SDSCA: exercise: items 5&6  5(x1; 2%); 6(x1; 2%) 
SDSCA: blood glucose testing (items 7&8)  8(x6; 15%) 
SDSCA: foot care (items 9&10) 9(x1; 2%) 
LOT-R (items 2, 5, 6 & 8 are filler items & not included) 1(x2; 5%); 7(x1; 2%); 9(x1; 2%) 
TAS-20 (scoring key: items imputed if no more than 2 or 3 
missing from total scale & no more than 1 missing per factor 
sub-scale (with mean of answered items for that person on 
the same factor sub-scale) 
NOT IMPUTED: 6(x1; 2%); 10(x1; 2%); 15(x1; 2%); 16(x1; 2%); 17(x1; 2%); 19(x1; 2%); 
20(x1; 2%) 
 
IMPUTED: 10(x1; 2%); 14(x1; 2%); 1(x1; 2%); 16(x1; 2%) 
During intervention (n= 27 returned writing pack) 
PANAS (negative affect) session 1 3(x9; 33%); 6(x7; 23%); 8(x10; 37%); 9(x9; 33%); 10(x10; 37%); 11(x9; 33%); 15(x10; 
37%); 16(x10; 37%); 17(x10; 37%); 19(x10; 37%) 
PANAS (negative affect) session 2 3(x9; 33%); 6(x9; 33%); 8(x9; 33%); 9(x10; 37%); 10(x10; 37%); 11(x9; 33%); 15(x10; 
37%); 16(x9; 33%); 17(x10; 37%); 19(x10; 37%) 
PANAS (negative affect) session 3 3(x9; 33%); 6(x9; 33%); 8(x10; 37%); 9(x10; 37%); 10(x10; 37%); 11(x9; 33%); 15(x10; 
37%); 16(x10; 37%); 17(x10; 37%); 19(x10; 37%) 
339 
 
Measure Item no. with missing responses (x number of missing observations; % of total 
number of observations) 
Two weeks (n=33 returned questionnaire pack) 
IIRS (scoring key: if responses are not consecutive do not 
score (thus if any items were missing scale not scored) 
 
DMSES UK (scoring key: items imputed  if ≤4 missing (with 
mean of answered items for that person) (thus if more than 4 
items missing scale not scored) 
IMPUTED: 1(x4; 12%); 2(x4; 12%); 3(x5; 15%); 7(x1; 3%); 10(x1; 3%); 13(x3; 9%); 14(x1; 
3%); 15(x3; 9%) 
SSQ6 (number): items 1, 3, 5, 7, 9 & 11 1(x1; 3%); 3(x2; 6%); 5(x2; 6%); 7(x1; 3%); 9(x3; 9%); 11(x4; 12%)  
SSQ6 (satisfaction): items 2, 4, 6, 8, 10 & 12 2(x1; 3%); 4(x2; 6%); 6(x2; 6%); 8(x1; 3%); 10(x3; 9%); 12(x4; 12%) 
Three months (n=32 returned questionnaire pack) 
CES-D (scoring key: items scored if <4 missing) 3(x1; 3%); 5(x1; 3%); 7(x1; 3%) 
PAID  
EQ-5D utility  
SDSCA: general diet: items 1&2  
SDSCA: specific diet: items 3&4  
SDSCA: exercise: items 5&6   
SDSCA: blood glucose testing (items 7&8)  7(x1; 3%); 8(x4; 13%) 
SDSCA: foot care (items 9&10)  
Three month mediators; only collected for primary care patients (n=27 primary care patients returned questionnaire pack) 
IIR 
(scoring key: if responses are not consecutive do not score 
(thus if any items were missing scale not scored) 
 
DMSES UK (scoring key: items imputed  if ≤4 missing (with 
mean of answered items for that person) (thus if more than 4 
items missing scale not scored) 
IMPUTED: 1(x2; 7%); 2(x5; 19%); 3(x5; 19%); 7(x1; 4%); 10(x2; 7%); 13(x1; 4%); 15(x3; 
11%) 
SSQ6 (number) items 1, 3, 5, 7, 9 & 11 5(x1; 4%) 
SSQ6 ( satisfaction): items 2, 4, 6, 8, 10 & 12 6(x1; 4%); 10(x1; 4%) 
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Importantly, any uncertainties were checked with another person (CB) to promote 
accuracy and consistency in interpretation. 
 
Feasibility of the data collection schedule131 
Primary care 
For primary care patients that received materials by post there were some issues 
that meant follow up questionnaires were not completed at the intended time (i.e. 
two weeks and three months post-intervention132). The two week questionnaire (i.e. 
intended at approximately 14 days post-intervention) was returned on average 29 
days (i.e. four weeks) post-intervention (range 17 to 71 days). The three month 
questionnaire (i.e. intended at approximately 90 days/three calendar months post 
intervention) was returned on average 106 days (i.e. 3.5 months) post-intervention 
(range 96-139 days). It is notable that while there was a delay for some patients in 
returning the questionnaires this may not necessarily mean that they were 
completed this late; whilst somewhat unlikely some patients may have completed it 
but then delayed posting.  
 
Probable reasons for the delay were that patients were sent materials on the day 
that they were due to complete them, materials were sent second class to reduce 
postage costs, and there was a delay in sending some follow up materials for some 
patients; again practices were asked to do this where patients had not provided an 
address in their consent form yet there was an instance of a notable delay obtaining 
their agreement (i.e. four patients were sent the two week questionnaire an average 
of 20 days after the date at which they were due to complete it (range 13-42 days). 
                                                             
131 These data are presented separately for primary care and support group participants given the 
differences in the means of obtaining data. 
132 Post-intervention equated to the return of writing, once patients had confirmed that they were not 
intending to return their writing when chased or once a decision that writing was unlikely to be returned 
was made owing to unsuccessful reminders. 
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There was additionally a delay in patients completing and returning materials, 
reasons for which were provided when patients were chased or in returned 
materials. These included a) illness; one patient was admitted to hospital with heart 
failure (as mentioned earlier; the three month questionnaire was received late), and 
b) circumstantial reasons; two patients returned their writing pack late explaining 
that they had misplaced the return envelope and or the pack. It is noteworthy that 
one patient indicated at the end of their writing pack that they wanted a break for a 
few weeks; this may explain the delay in some patients returning the two week 
follow up, and indeed not returning it at all where reasons for this were not obtained.  
Moreover, the three month follow up was the one at which most reminders were 
sent and successful in retrieving materials; given that this questionnaire was 
received some time after patients consented to the study and completed materials, 
they may have lost interest and only responded when prompted.   
 
Support groups 
No problems with respect to timing of follow up were evident for support group 
participants that typically received materials electronically; the two week follow up 
questionnaire was returned on average 20 days post intervention and the three 
month follow up was returned on average 95 days post intervention.  
 
Post-hoc investigation/analyses: consideration of writing content 
To facilitate interpretation of the findings from the pre-specified analyses, the 
content of the intervention and control participants’ essays was considered and 
some exploratory analyses of the writing content were undertaken. 
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What participants wrote about 
WED  
Of the 14 intervention participants that returned their writing, it is notable one 
support group participant did not apparently personally disclose rather they 
discussed a number of issues (i.e. music, persecution, and politics, war and 
terrorism) from a religious perspective, which was more akin to a sermon (in fact 
this participant noted his involvement in such work). The topics disclosed with 
quotes providing examples of each are indicated in Tables 52 and 53. 
 
Participants did not consistently write about diabetes-related topics, and 
interestingly a number of positive (or neutral) diabetes and non-diabetes related 
topics were discussed in addition to stressful experiences (see Tables 52 and 53). 
The extent to which people wrote about diabetes and positive topics was thus 
derived. Specifically, writing sessions were inspected to identify whether diabetes-
related/positive topics were discussed at all in each session, and then individuals 
were classified as having written about diabetes/positive issues if they had written 
about this in at least two of the three writing sessions (or in at least one session 
where only one or two were completed). Given that diabetes-related/positive topics 
may still have been discussed relatively infrequently for these participants, the 
proportion of the total number of topics disclosed by these participants across the 
writing sessions that related to diabetes or were positive was then estimated and 
averaged across participants. 
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Table 52 Diabetes-related topics disclosed by participants 
 
Diabetes-related  
Stressful Positive 
Diabetes SMBs 
Frustration with respect to dietary constraints and speculation about the necessity of this 
“I am finding it hard to motivate myself about food – it just seems to be a real headache thinking about it 
and preparing it. In fact the last week I have tried just about every ready meal in Marks and Spencer’s 
and I am feeling quite sorry for myself lately and I am wondering if I really am a diabetic because I am 
not on any medication and I have been like this for 16 months I have blood tests and have had my eye 
test at the hospital and I don’t feel any different apart from being frustrated with food”. (P13; session 2)  
“Ok change the subject – let’s consider my diabetes for a while. For the first few years I thought I was 
doing ok because the clinic said as much, but a couple of years ago quite by accident I discovered a 
diet which actually helped me to lose weight and as a real bonus my blood sugar / glucose readings 
improved beyond recognition. So why – oh why have I gradually slipped into eating the kind of diet I 
used to eat. I know I’m putting weight back on, I know my readings are rising: I have decided it is a 
‘blip’. I hope it is. I need to get back into the low carbohydrate foods again – soon. I have a check up in 
July – I really – really should be back into the 5 club.” (P6; session 2) 
Frustration about weight loss 
“I love clothes always buying them wish I could lose some weight but although I don’t take sugar (never 
have) I do like evening meal so I suppose that is why I do not lose weight, I do not smoke drink very 
occasionally so I might as well cut my throat if I can’t have a nice meal.” (P8; session 1) 
“I wish I could just will away a lot of weight, I think it would help my knee, although I’m not excessively 
over weight but I do have to be careful which is very boring.” (P10; session 3) 
Tension between medication & weight loss 
 “I think the thing that bothers me the most is my weight, when my general practitioner changed my 
medication a few months ago, the weight I had managed to lose went straight back on! and more. I am 
trying very hard and the problems with my tooth (I hope) has helped because I had trouble eating. I 
don’t eat sweets or chocolate but do like crisps and cheese. I also try to eat healthily but find it difficult 
to eat my 5 a day.” (P10; session 1)  
 
Impact of diabetes 
Problems relating to diabetes complications 
“I had my eyes photographed at my surgery two years ago. The operator thought I had had diabetes 
longer than I said due to slight blood veins in the eyes. September 2008 I had a blood vessel leak, and 
the sight in the left eye was affected. It was lazered December of that year.” (P3; session 1) 
Diabetes SMBs 
Success achieving dietary restraint 
“I have, on diagnosis, totally changed my eating habits to meet the 
new requirements. I do not make concessions to sweet items as a 
favour to myself. With that discipline my tastes have changed and 
savoury food is now the norm. “ (P14; session 2) 
“I was diagnosed with type 2 diabetes in 2000. I took this on board 
and followed the diet and exercise, and medication to keep my 
weight down and my blood sugar levels under control. I did this and 
did quite well.”  (P12; session 1) 
 
Impact of diabetes 
No impact/coping with the impact of diabetes on health 
“To date the disorder has been managed with no external or internal 
apparent affect on my general state of health. Long may it continue.” 
(P14; session 2) 
I then developed a sight problem over the years I have had 
numerous laser treatments to keep this under control but the whole 
world is blurred to me. Again I took this on board and continued to 
keep my weight and blood levels under control.” (P12; session 1) 
 
Relationships 
Good relationship with HCPs 
“My doctor tells me that it is the pills that are keeping me on the path 
of good health, I do wonder, but he is a good man and I trust him 
with my health.” (P7; session 1) 
“As far as the medical service is concerned I have had excellent 
attention from the practice for now, over 70 years.” (P14; session 2)  
Feeling supported by work colleagues  
“I’m very fortunate to have good work colleagues and a boss who 
are all very supportive. And allow me regular breaks to eat as I am 
supposed to because of my diabetes.“ (P13; session 1) 
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Stressful Positive 
Relationships 
Negative experience with/lack of confidence in HCP 
“My blood pressure over the years since the operation has been slightly raised, the doctor did not bring it 
down, but at that time suited me, thinking the doctor does not really think I need tablets. September 2003 
before going on holiday I asked the doctor for blood pressure tablets, which he refused to give, and on 
holiday a blood vessel in the eye leaked, and my sight has been affected. The optician considered it was 
the blood pressure – He wrote to the doctor saying as much, which the doctor did not take likely - The 
problem here is all the concerns I had asked him about, and dismissed are now worrying – I would have 
thought this doctor would have been thinking heart disease, diabetes etc. The blood pressure should have 
been much lower. I have now changed my doctor and my condition checked regularly.” (P3; session 2) 
 
Control of diabetes  
Worry about high blood sugar levels 
“My blood sugar is a little high I test it three times a week. I wonder if this is due to the fact that I am not 
active because of my knee operation.” (P1; session 1) 
“My own health continues to jog along had a good winter not even a really bad cold and haven’t had lost 
any ”sick” time at work, had a scare in January when having my six monthly check it was found that my 
Blood Sugar levels had risen, that was a panic for a while.” (P7; session 1) 
Concern about change in diabetes medication (i.e. more tablets/initiating insulin) 
“Sometimes I worry in case I need to have insulin instead of the tablets.” (P1; session 1) 
“Have 3 months to try and get it (blood sugar) down before we start talking about more tablets, you will 
gather as you go on through this exercise that I don’t really like tablets.” (P7; session 1) 
 
Impact of stress and low mood on diabetes SMBs 
 “Having the extra worry I find that I am losing control of my weight, because I am eating more at night 
when I am up. I am still keeping blood levels ok but unfortunately eat too much although is the correct 
food.” (P12; session 1) 
I’m really fed up and food just doesn’t seem important right now, I haven’t really been eating the way I 
should during the week and when I do at the weekend it doesn’t really make any difference, I still feel 
down.” (P13; session 2) 
 
Illness representations  
Speculation about the cause of diabetes 
“I have been treated for relatively modest raised blood pressure for the last 35 years. It was considered, 
from the outset, to be in my long-term interest. I wonder whether that treatment has had any effect on 
weakening the effectiveness of the pancreas. I have never been overweight, eaten regularly and modestly. 
Never smoked, only very modest alcohol consumption and have no known family history of the condition 
before 80 years of age.” (P14; session 2) 
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Table 53 Non-diabetes related topics disclosed by participants 
Non-diabetes related  
Stressful Positive 
Relationships 
Marital issues  
“Married a great woman, my second marriage –only problem is she has two sons, both in 20’s 
who are morons. This has something to do with the father. I have my own two, polite, well 
educated who went to university and both got B.A.’s and M.A.’s, the boy now doing his PhD. She 
feels that hers deserve more than mine and having spent thousands on them I don’t want anything 
to do with them as they are ungrateful and use their mother to try and get more out of me.  This 
causes stress between us, but I will live with it. Oh the joys of married life. Grown up step children, 
who needs them.” (P2; session 1). 
“I have been happily married next year for 40 years, she is eleven years older, and I am confused 
why I have been suffering erectile dysfunction over many years.” (P3; session 1) 
Concern about/ disappointment in children 
 “I have three children (grown up, and left home) a daughter living in New Zealand with husband 
troubles, a son married to a stock broker, he is ok, and my eldest son who is a big problem – he 
has a drinking problem, does not work, is on a sex register, and is appealing a 2 year prison 
sentence in Germany, he has three children he cannot see, and lives away – I have not seen or 
heard from him in 10 weeks – I have made it clear there is no home here, and I am not prepared 
to give him money sub-consciously this is very stressful.” (P3; session 3) 
“Granddaughter starts new job today hope she likes it I worry about her she has a daughter of 11 
months [daughter’s name] who is lovely but it is hard does not want to have benefits, still that is 
how my family are we have always worked for our living which gives me great pride.“ (P8; session 
2) 
Emotional reaction to children moving on 
“My daughter and husband emigrated to Grand Cayman having lived in Guernsey for the previous 
nine years (left for career reasons). It was a big wrench for me to see her leave these shores 
knowing that once moved on, she was unlikely to return and settle in England in our life time.” 
(P14; session 3) 
Difficult relatives 
“[sister’s name] is my only relative apart from her daughter [niece’s name] who is married to a self-
indulgent, ignorant big head. And I haven’t much time for my niece either – a completely 
dysfunctional couple...My sister is divorced from a successful dentist she was completely 
unreasonable in her demands. They both are manipulative (sister and daughter).“ (P9; session 2) 
Relationships 
Good relationships with loved ones  
“I have 2 children and four grandchildren and must say I am very fortunate 
with my family I get on well with my son who is separated from his wife 
and he has been back at home for nearly 2 years now. His two sons come 
for tea every Thursday and stay all weekend unless my son has to go to 
work. My daughter lives within walking distance and her 2 daughters 
usually stay with me on a Saturday night while their mum is at work. So 
little time for a rest! at the weekend.” (P10; session 1) 
“I live with my wife and we are in daily companionship and go out together 
several times.....We also lead independent lives with certain separate 
interests.”(P14; session 1) 
Support from loved ones 
“Went for a walk today with boyfriend went to Crakly Woods in Kenilworth 
it was nice and romantic, it is nice when he surprises me which is not very 
often as he is not really romantic even after 15 years together but I love 
him, he makes me feel special, loved and he loves me for me. He is very 
supportive and will be with me every step of the way when I eventually go 
and have my fibroids done going to book a couple of days off work to look 
after me, bless him I would be lost without him and I wouldn’t meet 
anybody like him again.” (P11; session 2) 
Pride for loved ones 
“My other granddaughter is going to Birmingham University on my 
birthday [date of birthday] which will be a wonderful experience for her I’m 
very proud of them all. Jack my 14 years grandson wants to do medicine, 
he is very bright but we were laughing he would have to sell A KIDNEY 
TO PAY for it, still we’ll see. Thank god for your children and 
grandchildren although I’ve only got a small family it is great to have 
them.“ (P8; session 2) 
Affection for pets 
“I have 2 cats who I find very comforting. The eldest is Tootsie (mummy) 
and her son Yogy.” (P10; session 1) 
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Stressful Positive 
Bereavement 
“I think at the moment my husband is causing me the most concerns in my life, and this may sound strange 
and not that stressful to some people, but to me it is, it is something that cannot be shared with everyone as 
only people who have been through a similar experience would understand. I am now a widow, although I 
am living with a new partner. My husband died 2 and a half years ago aged 59 years, and last weekend 
September 6th would have been our 40th wedding anniversary, I had a lovely flower arrangement made – all 
red! And went off to the crematoria and sat and talked to the spot where we have a tree where my husband’s 
ashes are scattered, I felt sad and guilty and wondered if I could have been a better wife, I also felt that my 
sadness was not fair on my new partner so most of my feelings were kept in my head and my heart.” (P5; 
session 1) 
 “I really miss my husband although its eight years since he died it still feels like yesterday.” (P8; session 1) 
 
Health-related concerns 
Current health concerns and their impact on daily life  
 “I had an appointment with a consultant about my mild angina following two stints about 4 - 5 years ago. 
Luckily I am of a contented nature and outwardly more cheerful than is perhaps the case. I thought the 
consultant would say that my angina was not too bad and I should continue with the tablets for it (I take 15 a 
day including 6 for diabetes which incidentally is now so well controlled that sometimes my urine is sugar 
free). Much to my surprise he said that my heart was in a poor way and he wanted me in the hospital for a 
double bypass operation. I felt no fear but mild excitement at the prospects of a major operation but 
disappointment that I would be out of action for a couple of months –there is so much to do. Rotary, charity 
work (two mornings a week), gardening, reading etc.” (P9; session 1) 
 “The thing that is concerning me at the moment is coping with my illness...I now have developed an irritable 
bladder problem and the side effects increased my nightly visits to the toilet, and this has made me very tired 
in the mornings. I walk to work about 3 miles daily, and I find that the prostate and bladder problems give me 
some pain and soreness and discomfort....I think I have a fairly active social life with my family but I now find 
that due to my prostate - bladder problems have curtailed my travel, and I feel I have  slowed down. I am 
always mindful for the need to be near a toilet so we now travel a lot by train, and I find it difficult to fly.” (P12; 
session 1) 
Worry related to poor health of loved ones 
 “If I have one real concern at this time it is my partners’ health, we think it may be the onset of the change 
she has consulted the doctor about it and is awaiting test results” (P7; session 1) 
“I am concerned about my sister-in-law who is terminally ill with cancer, and her time is getting near. She has 
3 young children and my brother is coping well. I have a feeling of helplessness, that I cannot help more, this 
is a strange feeling of guilt and futility. My sister-in-law has been very brave, but I am anxious how my 
brother will cope without her, with the children. Subconsciously you try to put this out of your mind but I dread 
the phone call.” (P12; session 2) 
Attitudes towards the future 
No concerns about future physical health problems 
“Looking to the future, I have no special reason for viewing it 
with great concern. As part of a large family and 70 years 
hindsight I have seen many family and relatives pass on. Some 
have experienced serious disorders from a young age and 
lived into their eighties. Others have died from totally unrelated 
disorders from the long-term medical condition.” (P14; session 
2) 
 
Recreation 
Active social life 
“Had to arrange my ladies club meeting (I’m on the 
committees) 80 ladies are in this club and they are all like one 
big family. I moved to Nuneaton 4 years ago and deem myself 
lucky to have come among them they are GREAT.” (P8; 
session 1) 
Got a lot of shows to see, I’m going to see ‘Oliver in London, 
“Scrooge” in Birmingham and ‘Les Miserable’s” in Birmingham 
so I feel that life has always got something to look forward to. I 
enjoy life very much (as best I can) it is all so short and 
perhaps when I’m older I will not want to go out so much.” (P8; 
session 3) 
Holidays 
“Been thinking must sort my clothes out what I’m taking on 
holiday, always get to my destination and wish I‘d got other 
things with me. I have about four small holidays a year which 
breaks the year up nicely.2  (P8; session 3)  
Hobbies and recreational activities 
“My interests particularly are the Parish Council, Community 
Hall Management, golf, walking, travel, entertaining at home, 
computer work mainly for the preparation of the Family History 
which I have written over the last few years. I have followed 
politics virtually all my life. I have read extensively on the 
personalities of the last fifty years. I am not emotionally 
involved with any of it. It is an interest.” (P14; session 1) 
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Stressful Positive 
Guilt related to not being able to care for sick relatives 
“Over the past couple of years my mother has developed dementia....things have got 
progressively worse ....[relatives’ names] are no longer able to cope and have, reluctantly, 
had to find a suitable residential care home for mum...The atmosphere is pleasant but I’m 
pleased that mum, although she already calls it home, is probably unable to understand 
quite where she is. I would hate to think that she gets really lucid recollections and realises 
where she has ended up. Two years ago she would not have believed she would be in a 
home let alone one that specialises in dementia patients.” (P6; session 1) 
 
Concerns about the future  
Worries related to aging and future physical health problems 
 “I find my age very stressful and do worry about the slightest health problems – I always 
find the worst scenario. I cannot reassure myself about my future, and therefore anxiety 
can set in.” (P3; session 3) 
“Yes I am concerned about growing old but I try to do it disgracefully hate the thought of 
not being fit and able to be like I am now, I don’t want to be dependent on others.” (P7; 
session 2) 
Worry related to aging and mental deterioration 
 “I reflect that I take 15 pills a day for my problems, heart, blood pressure, angina, chronic 
indigestion - luckily now almost completely controlled, diabetes and for me life is great but 
the thought of a heart attack carrying me off doesn’t worry me a bit and I would really like it 
since I don’t want my faculties to degenerate. I don’t consider suicide. I don’t want [wife’s 
name] to have to nurse me and look after me which she would, and does do, marvellously 
just to be left on her own with no family but good friends to face the future.” (P9; session 3) 
Thoughts and feelings about mortality 
“My day to day routine sometimes feels pointless and a feeling of what is the use creeps 
in....I am quite aware that dying is a fact of life, but I push these feelings to the back of your 
mind and then try to keep your mind busy, but when I am up in the night I sometimes dwell 
on these worries.“ (P12; session 2) 
Education, work and finances 
Education 
“I hated school from day one. Was so pleased to be able to leave at the age of 
fifteen, straight into work on a farm. Over the years of various employments I 
have come to learn the value of education, and taken advantage of work related 
education courses, at the ripe old age of 63 recently achieved an N.V.Q. 
certificate, so the old “ish” must still be working (sometimes).” (P7; session 3) 
Employment 
“I had quite a varied time at work until I married at the age of 23. Then I went to 
work for the Air Ministry, then moved house and went to the Inland Revenue. I 
had time off while I had the children unfortunately the marriage broke down in 
1980 so I found a new home with my children and went to work for the National 
Health Service where I stayed until I retired at 61.” (P10; session 2) 
Retirement & volunteer work 
“Having retired from a well paid and rewarding career as a finance manager in 
the motor industry and subsequently experiencing nearly fourteen years of 
enjoyable retirement I have no particular concerns.” (P14; session 1)  
“After a year of retiring I felt I needed to do something so I got a part time job at a 
garden nursery...which I loved but it was only seasonal. So I went to work with 
meals on wheels which I did for nearly 4 years and thoroughly enjoyed and am 
still in touch with everyone. I also did some voluntary work at the hospital 
museum...I found this very interesting and only left when the Health Authority 
closed the museum due to cuts in expenditure.“ (P10; session 2) 
“I have in the past always been involved within the community doing various 
work, but now over the years I have curtailed my various works. I have tried not 
to get depressed and throw myself into various into work.”(P12, session 1) 
Financial security 
“With financial things life is much better, and I calm things down by meditations.” 
(P3; session 3) 
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Stressful Positive 
Faith  
Speculation about the meaning of life, life after death and questioning religious faith in view of loved ones 
becoming ill 
“My brother-in-law is now at his mother’s – and gradually feeling a little better, I just wish that he could get 
better, he is a kind gentle person, never cause any hurt to anyone, and doesn’t deserve to be ill – it 
sometimes makes me think is there a god? I know so many people who have recently been taken from us by 
cancer good people, people who did the ‘right’ things with their lives, people who were loved and a credit to 
society – worked hard, raised happy families, so why are they taken? There are so many idle yobs roaming 
around, they are no good to anyone and wouldn’t be missed so what is god playing at?? It shakes your faith 
but I still hold on to it, we have to believe that there is more than this. When someone dies and you are left to 
sort things out, the banks, insurance companies, even the television licensing, just treat it as matter of fact 
OK we will take their name off, it is as if they never mattered, and you think of all the things they did, worried 
about, tried to change, the help they gave to everyone, it is as if none of it counted for anything, and you look 
around and think why? Why do I worry about this and that? Why am I bothered about getting the house 
decorated? Sometimes it seems pointless.“ (P5; session 3) 
 “This puts all my other concerns in perspective, life is like a lottery sometimes, it wears you down and I often 
wonder if there is life after this one and if so will we have to go through so much pain, I hope not.” (P13; 
session 3) 
 
Work and finance 
Work-related stress and  fear of redundancy 
 “I work in a bank which has recently been taken over, I am very conscious not to be a nuisance or cause 
any problems for my colleagues. We all work hard and have to support each other. Today one of them has 
found out she is being made redundant at the end of the year. No point worrying now, can’t afford to get 
depressed – I am worried about my job, but we would manage as long as my husband kept his.” (P13; 
session 1) 
Sadness about retirement 
“I decided to retire this year – most stressful.”(P3; session 3) 
Financial concerns 
“Talking about afford I’ve lost a lot of money in Bonds and I.S.A.’s in this recession still I’m alive and kicking it 
is only money. We have to spare a thought for the poor souls who are losing their homes and jobs.” (P8; 
session 1)  
Positive events 
Happy childhood 
“I suppose I should be telling you about my childhood well it 
was basically a very happy one, the youngest of a family of 
five. Spoilt by my three sisters and mother, lived in a lovely 
country village. I think I am very lucky to have had what is to 
me a normal happy childhood preparing me for a hardworking 
adult life.” (P7; session 3) 
“I had a very happy childhood. I lived with my grandparents for 
a few years as my mother was working during the war and my 
father was in the Royal Air Force...I attended grammar school 
in the 50’s then was enrolled at a secretarial school.” (P10; 
session 2) 
 
Religion 
Religious beliefs  
“Although brought up in the Church of England with twenty 
years in the boy’s / men’s choir I am an atheist.....We live in a 
universe 4.5 billion years old and is likely to continue for as 
long again or eternity. The earth is as insignificant in this 
concept as one bucket of water in the Atlantic Ocean...My, and 
the current generation of mankind, are unlikely to have any 
special significance in the overall scheme of things. We 
therefore are unlikely to have a God that we can prey to and be 
in personal communication with. I find the works of Professor 
Dawkins (The God Delusion) in time with my feelings.”(P14; 
session 2) 
Music from a religious perspective  
“Singing is a very important part of my life... I am a scientist, 
with a keen interest in conservation matters, and a Christian 
with a concern for people. Music is of tremendous importance 
in conveying the message.”(P4; session 1) 
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Stressful Positive 
Adverse events 
Negative childhood experience  
“The only the only sad part [of childhood] was my father suffered with chronic asthma, which at that time was 
very frightening to see, “none of the magic drugs like we have today” (P7; session 3) 
Traumatic events 
“My house caught fire in December and I was at home alone for the weekend and fortunately my cats woke 
me up at 2:30 a.m. and I rang for the Fire Brigade...The mess was horrific. In fact I don’t think I’ve really got 
over it all yet and there are still some jobs to finish but I can’t bring myself to get on with it all now, but I’m 
gradually getting there.” (P10; session 1) 
“In September 2004 I (with my wife) were cruising on the Norfolk Broads when I received a telephone call 
from her (daughter) to say that Hurricane Ivan was heading for the island and they would be evacuated to 
Montreal within hours, by their employer. The hurricane struck at force 4 - 5 and devastated the island. They 
were safe but their vision of a paradise in the Caribbean was shattered in hours. We visited six weeks later. 
The devastation was horrific.” (P14; session 3) 
“My sorrow, shock, sadness this week, at work – a fatality at work, although I didn’t actually know the man 
the whole place is shocked. Nobody expects to go to work in the morning and not go home at night do they?” 
(P6; session 3) 
Current events 
 “Tomorrow a young 18 year old soldier is being buried in our town, he died in the war! This puts problems 
into perspective. What a sad world we live in.” (P13, session 1) 
 
Emotional issues 
Loneliness 
“I hate the dark nights they are so long and lonely I don’t go out much in the evenings and like to go out to 
lunch and back home before dark. Thank god for telephone and flat screen Television Codebreakers, 
crosswords and of course a good book.”(P8; session 1) 
“I’ve been thinking about Christmas although it is weeks away...Christmas really isn’t the same for me 
without David (he loved it) but for the families sake I enter into the spirit of the occasion. Fancy thinking of 
Christmas in September, still when live on your own you spend many a moment thinking it is better than 
talking to yourself) AH! .” (P8; session 3) 
Feeling depressed 
“I am worrying about everything lately and I don’t seem to be able to relax, when I go to bed I can’t sleep, 
when I try to read a book I can’t concentrate everything seems like such an effort.....I’m trying very hard to 
keep up with washing, ironing, and I’ve given up trying to Hoover or dust I don’t see the point anymore.....In 
fact this last month has probably been one of the worst times in a long time (years). My husband thinks I am 
getting depressed.”(P13; session 2) 
Politics, war and terrorism from a religious perspective 
“Gordon Brown and the Iraq enquiry. 'We' were all sure that the 
real reason for the Iraq war was George Bush's obsession with 
finishing the job his father 'failed' to do...The church of which I 
share the leadership has a few English in membership. We 
seek to bring the Gospel of peace to those around us....As for 
Brown – he was so blatantly lying about his role in the affair – it 
was unthinkable that the right hand man with Blair did not 
realise the web of lies that were being woven to try to convince 
Parliament and win public support...The net result is that 
millions of Iraqi and Afghanis are suffering and have died 
because of an obsession. They have dug our countries into a 
pit that we cannot climb out of, as killing terrorists only makes 
more terrorists - and builds ever more hatred.” (P4; session 2) 
Persecution from a religious perspective 
“Persecution of Christians. In many countries around the world, 
Christians are suffering persecution.... Why?... A Christian 
owes his allegiance to the Lord Jesus Christ. That in a way 
separates him at every level. He also has a message for 
society: “we are all sinners in the sight of a holy God. We need 
forgiveness of sin...That places every Christian apart. However 
compliant he is within society, society see him as an outsider. 
He will not bow down to family gods, and will not acknowledge 
any other god. Jesus is Lord. A lonely Christian poses no threat 
to society, but it is a matter of pride that they demand that he 
conform... Mohand Ghandi was horrified at the proposal to 
have separate countries for Muslim and Hindu as he insisted 
that everything they needed was common to all regardless of 
religion. Hopefully we can demonstrate this in England where 
in towns like Southall we co-exist & work, shop and go to 
school together without problems.” (P4 session 3) 
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Writing about diabetes-related topics 
Of the 14 intervention participants, four (29%) were classified as having written 
about diabetes-related topics over the sessions (i.e. whereas 10 (71%) were not. On 
average, of the number of topics disclosed by these participants across the 
sessions, 28% related to diabetes. 
 
Writing about positive topics 
Of the 14 intervention participants, seven (50%) were classified as having 
additionally written about positive topics whereas seven (50%) were not. On 
average, of the number of topics disclosed by these participants across the 
sessions, 56% related to positive topics). 
 
Topic switching 
WED participants typically discussed a number of topics both within and across 
sessions. There was little evidence of consistency in the topics discussed across 
sessions. Ten (77%) of the WED participants mentioned one or more topics in more 
than one session, yet only two (15%) participants discussed a topic in all three 
sessions. However, even when topics were mentioned in more than one session, 
they were typically amongst a number of other topics in each session.  
 
Control 
Of the 13 control participants that returned their writing, 10 (77%) provided an 
objective description of the previous day as requested. The remaining three 
participants seemed to exhibit some degree of ED. Two described some stressful 
issues, yet briefly and in the context of their daily activities. The remaining 
participant apparently disclosed in a similar manner to patients in the intervention 
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group, with minimal reference to daily activities.133 This participant justified their 
deviation from the instructed topic by explaining that the problems described 
represented the mundaneness of daily life, and that they could not help but discuss 
these things. They also added that writing about these problems had helped.  
 
Exploration of WED writing content  
As a means of providing some insight into and facilitating interpretation of the 
preliminary effectiveness analysis, exploratory analyses were conducted to identify 
whether the linguistic features of WED presumed to reflect E&CP were related to 
changes in depressive symptom severity and the secondary outcomes investigated. 
Consequently, the linguistic parameters investigated and demonstrated to be 
related to changes in health outcomes in previous WED studies (i.e. presumed to 
reflect E&CP; see chapter two); a) change in word use reflecting insight and cause 
across writing sessions and b) average/change in positive emotion and negative 
emotion words across writing sessions were correlated with change from baseline to 
follow up in each of the outcome variables. 
 
Change scores were derived by subtracting baseline/first writing session scores 
from follow up/third writing session scores. Computed variables were screened for 
normality (see chapter five), and some were identified to be skewed thus non-
parametric correlations were employed (Spearman’s Rho).134 The assumption 
checks for the additional variables that were computed are presented in the 
appendix. Given the very small number of participants included in analyses, 
correlations of a potentially important magnitude were considered regardless of 
significance, namely where ≥9% of the variance in the change in the outcome 
                                                             
133 This was the participant that wrote for 781 minutes in session one and explained that they did not 
follow the allotted task because they would have found that too boring. 
134 Two tailed significance tests were employed given that the direction of the associations was not 
predicted. 
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variable is explained by the LIWC variable tested (i.e. r>.30; see conventions 
specified in chapter five).  
 
 These correlations are presented in Table 54. They suggested that a higher 
average use of negative emotion words (r=.55, p=.063), a change in the direction of 
more insight words across writing sessions (r=.50, p=.141) and a change in the 
direction of fewer causal words across writing sessions (r=-.42, p=.226) were 
apparently associated with a change in the direction of an increase in depressive 
symptom severity over time. The correlations were of a medium-sized to large 
magnitude, and approached significance for the average use of negative emotion 
words. 
 
The correlations for the secondary outcomes investigated generally concurred. A 
change in the direction of a reduction in health-related QoL (EQ-5D utility and VAS) 
and specific diet, exercise, blood glucose testing and foot care SMBs were 
apparently associated with a change in the direction of an increase in insight words 
and or a change in the direction of a decrease in causal words.  
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Table 54 Exploratory associations between LIWC variables and change in the outcome variables over time135 136 
 
                                                             
135 Positive correlations reflect an increase in the LIWC score (higher mean usage/a change in the direction of an increase over time) and a change in the direction of an 
increase in the outcome variable over time (i.e. an increase in depressive symptom severity and DSED, and an improvement in health-related QoL and SMBs). Negative 
correlations reflect a reduction in the LIWC score (i.e. lower mean usage/a change in the direction of a decrease over time) and a change in the direction of an increase in the 
outcome variable over time). An increase/decrease in change scores was interpreted as a change in the direction of an increase/decrease in the scores respectively because 
change scores for each variable typically comprised both increases (i.e. positive scores) and decreases (i.e. negative scores) and no change. *Significant correlation (p<.05). 
136 Fourteen WED participants returned their writing, 12 of who completed all sessions and thus for whom LIWC change scores could be computed. Where n is less than 14 for 
LIWC average variables and 12 for LIWC change variables  outcome changes scores could not be computed for these participants (i.e. owing to missing data at one or both 
time points). 
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Cognitive processing          
Insight r=.50 
(p=.141) 
n=10 
r=.20 
(p=.606) 
n=9 
r=-.75* 
 (p=.019) 
n=9 
r=-.41  
(p=.241) 
n=10 
r=-.22 
(p=.538) 
n=10 
r=.16 
(p=.673) 
n=9 
r=-.50 
(p=.141) 
n=10 
r=-.40  
(p=.373) 
n=7 
r=-.20 
(p=.583) 
n=10 
Cause r=-.42 
(p=.226) 
n=10 
r=-.13 
(p=.732) 
n=9 
r=.77* 
(p=.015) 
N=9 
r=.38  
(p=.281) 
n=10 
r=.05 
(p=.893) 
n=10 
r=.46 
(p=.217) 
n=9 
r=.07 
(p=.852) 
n=10 
r=.76* 
 (p=.049) 
n=7 
r=.56 
(p=.094) 
n=10 
Positive emotion          
Average r=.07 
(p=.828) 
n=12 
r=-.31 
(p=.354) 
n=11 
r=.36 
(p=.281) 
n=11 
r=.31 
(p=.329) 
n=12 
r=.07 
(p=.825) 
n=12 
r=-.25 
(p=.461) 
n=11 
r=.25 
(p=.429) 
n=12 
r=.16  
(p=.673) 
n=9 
r=.54 
(p=.069) 
n=12 
Change r=-.04 
(p=.920) 
n=10 
r=-.10 
(p=.798) 
n=9 
r=.37 
(p=.332) 
n=9 
r=-.30  
(p=.402) 
n=10 
r=-.61 
(p=.061) 
n=10 
r=-.24 
(p=.539) 
n=9 
r=.60 
(p=.067) 
n=10 
r=.80* 
(p=.030) 
n=7 
r=-.17 
(p=.632) 
n=10 
Negative emotion          
Average r=.55 
(p=.063) 
n=12 
r=-.21 
(p=.545) 
n=11 
r=-.29  
(p=.383) 
n=11 
r=-.17 
(p=.609) 
n=12 
r=-.28 
(p=.374) 
n=12 
r=-.15 
(p=.651) 
n=11 
r=-.09 
(p=.784) 
n=12 
r=-.66* 
(p=.054) 
n=9 
r=-.50 
(p=.102) 
n=12 
Change r=-.01 
(p=.973) 
n=10 
r=.28 
(p=.460) 
n=9 
r=-.31 
(p=.422) 
n=9 
r=.01 
(p=.987) 
n=10 
r=.34 
(p=.339) 
n=10 
r=-.09 
(p=.815) 
n=9 
r=-.25 
(p=.492) 
n=10 
r=-.54 
(p=.216) 
n=7 
r=-.20 
(p=.571) 
n=10 
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A higher average use of negative emotion words and or a change in the direction of 
an increase in negative emotion words was apparently associated with a change in 
the direction of a reduction in health-related QoL (EQ-5D utility), and blood glucose 
testing and foot care SMBs.137 It should be pointed out that negative emotion words 
were not apparently associated with change in the outcome variables for which a 
trend for a negative effect of WED was observed (i.e. EQ-5D VAS and specific diet 
SMBs), however the correlations were typically in the anticipated direction.  
 
Associations between the positive emotion word use variables and change in 
outcomes were more heterogeneous. However, it is noteworthy that a higher 
average use of/a change in the direction of a increase in positive emotion words 
was typically associated with a change in the direction of improvement in the 
outcome variables for which no apparent negative effect of WED was observed (i.e. 
a change in the direction of a reduction in DSED and an improvement in health-
related QoL (i.e. EQ-5D utility) and exercise, blood glucose testing and foot care 
SMBs).138 However, this was not typically apparent for those outcomes for which it 
seems that WED may have had a negative effect; changes in these outcomes 
demonstrated no association with positive emotion words use (i.e. depressive 
symptom severity and specific diet) or at most marginal heterogeneous associations 
(i.e. EQ-5D VAS). 
 
                                                             
137 There was one exception in which a change in the direction of a reduction in negative emotion 
words was apparently associated with a change in the direction of a reduction in general diet SMBs. 
However, this was marginal, was not an outcome for which a trend for a negative effect of WED was 
observed and owing to the applicability issues described earlier the data for this sub-scale are 
particularly ambiguous.  
138 There was one exception in which a change in the direction of an increase in positive emotion 
words was associated with a reduction in general diet SMBs, yet again owing to the acceptability 
issues described earlier data for this sub-scale are particularly ambiguous. 
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Summary 
Intervention fidelity was confirmed, and was most pronounced for positive emotion 
word use closely followed by negative emotion word use yet was least pronounced 
for causal word use. As such it was apparent that both groups had adhered to their 
assigned instructions, and there was little evidence of contamination for controls. 
Moreover, in line with the instructions provided, issues that were currently stressful, 
rather than traumatic events, were disclosed. A third of the participants that were 
randomised did not return their writing pack, yet participants that did generally 
complied with the instructions. However, some apparently exceeded the request 
(i.e. wrote for longer than requested with breaks within sessions and may have 
written for more than three sessions). Moreover, approximately half of the 
participants may have engaged in further self-directed writing. Reasons for not 
completing all writing sessions related to difficulty writing and a negative evaluation 
of the nature of the WED and control tasks. However, the post-hoc feasibility data 
provided some valuable additional information about intervention fidelity but most 
importantly the acceptability of both the intervention and control tasks, and 
participant’s experience of the study. A particularly notable finding was that many 
WED participants indicated that they were unsure what to write about as they did 
not feel they had any stressors to discuss, many of whom were amongst those that 
also wrote about positive issues perhaps for this reason. In sum, negative feedback 
about WED seemed to be related to the sample obtained. 
 
The methods of randomisation and allocation concealment were demonstrated to be 
feasible and apparently effective, yet there was some evidence that blinding may 
have been compromised to some degree for approximately a quarter of the 
participants. The post-hoc feasibility data additionally provided some valuable 
information about the appropriateness of the study questionnaires. A key finding 
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was that items asking about issues which participants felt were not applicable to 
them lead to missing and or ambiguous responses. Indeed, a number of 
acceptability and interpretative issues were identified for the measures employed 
and thus the data obtained, and problems associated with administering materials 
electronically were highlighted. Issues were also identified with respect to 
administration of materials by post (i.e. delays), and the importance of prompting 
participants was underscored. 
 
To facilitate exploration of the findings from the pre-specified analyses, the content 
of the participants’ essays was considered. Relatively few WED participants were 
considered to have discussed diabetes and those that did not discuss it extensively. 
However, half of the WED participants were considered to have discussed positive 
diabetes and non-diabetes related topics in additional to stressors, and for those 
that did positive topics accounted for approximately half of the topics disclosed 
across writing sessions. WED participants also exhibited little evidence of continuity 
in the topics discussed across writing sessions. Nonetheless, the topics disclosed 
by WED participants afforded a valuable insight into the emotional factors impinging 
upon life in Type 2 diabetes (i.e. what people with Type 2 diabetes talk about when 
asked to emotionally disclose). In fact, there was face validity in these topics given 
that these are the issues that people with diabetes typically discuss in consultation 
(JS).  A small proportion of control participants exhibited some degree of ED, 
seemingly because writing about daily activities very occasionally evoked emotion 
where these were experienced as such.   
 
Finally, exploratory correlations identified that a change in the direction of an 
increase in depressive symptom severity was generally associated with a higher 
use of negative emotion words and changes in the direction of an increase in insight 
words yet a decrease in causal words across writing sessions. Correlations between 
357 
 
the linguistic features of WED and the secondary outcome variables generally 
concurred, including for the outcomes for which it seems that WED may have had a 
negative effect (although there were limited associations between negative emotion 
word use and change in these outcomes). Interestingly more use of and an 
increasing focus on positive emotion words was generally associated with a change 
in the direction of an improvement in outcomes, yet this was typically not the case 
for those outcomes for which WED may have had a negative effect. Importantly, 
that a) a higher use of positive emotion words, b) a lower use of negative emotion 
words, c) a change in the direction of an increase in causal and positive emotion 
words and d) a change in the direction of an decrease in negative emotion words 
were typically associated with a change in the direction of improvement in outcomes 
was somewhat consistent with the literature reported in chapter two.    
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Chapter 9 Exploratory RCT discussion 
 
Chapter overview 
This chapter initially includes a discussion of the feasibility findings relating to 
research into WED and the implementation of WED in primary care in the UK, given 
that in view of the limitations observed this was the primary focus of the thesis. The 
interpretation of the preliminary effectiveness analysis is then presented, informed 
by the feasibility findings, the pre-specified exploratory explanatory analyses and 
the post-hoc exploratory investigation and analyses employed, namely the 
consideration of writing content. The study strengths and limitations are then 
discussed, focussing initially on additional limitations associated with the research 
design and methods employed, and then the preliminary effectiveness analysis and 
further exploration of the observed effect, specifically issues such as statistical 
conclusion, internal and external validity and problems associated with the analytical 
approach.  
 
Summary of feasibility findings 
Feasibility of WED for use in general practice in the UK whether for 
diabetes or other patient groups 
The present study demonstrated that WED may be acceptably and feasibly 
implemented as part of general practice in the UK. GP practices did not cite WED 
as their reason for not participating, rather reasons related to practice workload, 
costs (i.e. resource and materials) and occasionally payment, with some practices 
indicating that they would have liked to take part in the future.  When spoken to GPs 
were also generally positive about WED. However, one practice was unable to 
participate owing to a ‘mixed response from GPs’, should this related to WED it 
indicates that acceptability to GPs may be mixed. 
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For patients, willingness to engage in WED was less than initially anticipated (i.e. 
than indicated in the user consultation). Recruitment rates were relatively low 
especially for support groups, which may be owing to the fact that the invitation was 
not received from their GP practice and that these individuals were already writing 
within the forums.  Negative posts within the support group forum may have 
additionally deterred participants. Although this data could not be formally collected, 
the feedback that was obtained from patients at recruitment was not apparently 
related to writing; at most some people were concerned about whether their writing 
ability would suffice. There was evidence of scepticism about the study and writing 
within the support group forums, yet others expressed interest in the study and a 
belief in the potential benefit of writing. These heterogeneous opinions may have 
additionally been present amongst primary care patients. Regardless, though, many 
patients were interested and an unmet treatment need was identified, suggesting 
that there may be a place for WED.  
 
Only about two thirds of the sample returned their WED writing pack, however, and 
the feedback that was obtained indicated non-return was due to a dislike for writing 
and or the content of WED and age-related problems with writing but also not 
having anything to write about; non-return may have partly been due to the sample 
obtained. Those that apparently engaged in WED were however typically willing and 
able to do so (i.e. the topics disclosed had face validity, intervention fidelity was 
confirmed and compliance with the instructions was good). Similar compliance was 
observed amongst the studies included in the systematic review (see chapter three). 
Some participants even exceeded the request. This is encouraging considering the 
associated burden.  Negative feedback from those that returned their writing was 
again apparently largely due to the sample obtained; age-related difficulties with 
writing and not having anything to write about.  There was also some positive 
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feedback in that some participants implied they could have written more had they 
had the opportunity, and feedback about participating in the study was positive with 
many participants taking it upon themselves to provide additional information within 
the materials. Evidently, patient acceptability is also mixed, yet there is a sub-group 
of individuals for whom WED may be a welcome source of support.   
 
Importantly, there was minimal evidence of a negative subjective response to WED.  
One participant was deemed high risk/requiring action and referred to their GP 
advising that they should be seen or referred to a specialist as a result of the 
content of their writing (as mentioned in chapter six and later on). However, this 
response was at least partly owing to a friend having been diagnosed with cancer 
during their writing period. As anticipated, it seems important that WED is 
administered to those with some current problems yet not to those potentially at risk 
of re-traumatisation. There were no reports of individuals seeing their GP with 
problems as a result of writing, although this data was not purposefully collated.  
This finding is consistent with a previous feasibility study of therapeutic writing in 
primary care in the UK; GPs felt that some people may require additional support as 
writing can evoke issues that one must possess the skills to deal with, yet that this is 
infrequent and may well have happened under other circumstances (Hannay & 
Bolton, 1999).  
 
Finally, any resource costs were associated with the study protocol, rather than 
WED. This is again consistent with the previous feasibility study of therapeutic 
writing in primary care in the UK (Hannay & Bolton, 1999). As reported in chapter 
four, that acceptability and feasibility of WED based interventions to patients and 
providers in primary care including in the UK has been demonstrated previously 
(Gidron et al, 2002; Hannay & Bolton, 1999; Klapow et al, 2001; Schilte et al, 2001). 
In some of these studies the intervention was incorporated into routine clinical 
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practice thus enhancing ecological validity; writing was offered in practice and then 
completed at home (Hannay & Bolton, 1999; Klapow et al, 2001). Consultation time 
associated with the intervention was minimal and consistent with the time allotted 
for consultations, suggesting that WED need not be costly and time consuming to 
GPs.  
 
Insights gained about the difficulties of undertaking research into WED 
A number of insights were gained about the difficulties of undertaking research into 
WED. Importantly, there are a number of ethical issues that must be acknowledged, 
some of which were highlighted by the patient safety issues raised by the NHS REC 
and the changes necessitated, for instance the requirement for detailed preventative 
measures and contingency plans when implementing an intervention with 
psychologically vulnerable samples and the importance of acknowledging the 
limitations faced when such research is conducted by a non-clinician/student. This 
review also identified a contention between designing studies that are feasible in 
clinical settings and consistent with ideal methodology derived from the evidence 
base, yet which satisfy ethical requirements. For example, the eligibility check that 
was introduced in accordance with the RECs recommendations exacerbated the 
imposition of the research on primary care practices (i.e. two mail outs were 
required). 
 
The study also identified that the constraints imposed in ethical review and the 
measures taken to address them can be impactful, yet are nonetheless required. 
The eligibility check that was implemented meant the loss of a significant number of 
interested participants, some of whom may have actually been able to participate 
(discussed below), and importantly was apparently partly responsible for 
inadvertently deriving a sample for who WED is potentially contraindicated 
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(discussed later in relation to the findings from the preliminary effectiveness 
analysis). That is not to say that the check was not necessary; without something in 
place it is possible that at risk participants could have been inappropriately included. 
Indeed, a significant proportion of primary care patients expressing an interest in the 
study scored as experiencing significant depressive symptoms in the eligibility 
check, some of whom scored very highly on the CES-D (i.e. 43). Evidently some 
patients with significant depressive symptoms had not been identified and treated 
by GPs already, thus the RECs concern and addition of the eligibility check was 
justified.139  
 
It is worth pointing out that a number of the other changes necessitated by the 
review were additionally observed to be important.  The REC were right to insist that 
the researcher should not be the point of contact for any problems and that clinical 
support was in place should this occur; there was an instance of a patient calling for 
more information about the study yet stating that they felt depressed and exhibiting 
suicidal ideation in relation to completing the DSQ.  Perhaps it was necessary to 
place an even greater emphasis on the fact that participants should contact relevant 
professionals not the researcher about such issues. This occurrence additionally 
highlighted the importance of planning for contingencies; Professor Weich was on 
annual leave at this time,140 consequently arrangements were made for immediate 
consultation in such instances. Furthermore, ensuring participants were fully 
informed about the potential breach of confidentiality owing to the content of their 
                                                             
139 It is noteworthy that GPs were notified about those patients exhibiting a potentially clinically 
important increase in depressive symptom severity such that they exhibited significant symptoms at 
follow up (all were primary care patients), yet not those that exhibited a clinically important increase but 
did not score above the threshold for significant symptoms at follow up as they were not deemed to be 
clinically at risk. This was consistent with the study protocol approved by NHS ethics (i.e. GPs were 
notified about participants meeting this threshold/clinically at risk in the eligibility screen), and 
consultation with the study’s clinical advisor, Professor Weich. 
140 Fortunately on this occasion advice was sought from another psychiatrist. 
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writing was justified as this did indeed occur and in some albeit few instances 
contact with GPs was made (mentioned in chapter six and above).141 
 
A related insight was that it is difficult to find an appropriate means of ensuring 
inclusion of participants with lower-level albeit not higher-level depression. The 
strategy employed, namely including those responding positively to the QoF 
questions yet excluding those currently being treated, failed to ensure the inclusion 
of patients with lower-level depression to enhance the applied relevance of the trial 
and maximise effectiveness (i.e. seemingly owing to the over-treatment of false 
positive cases identified by these questions that has now resulted in their 
retirement). In fact, this criterion also had a substantial adverse impact upon 
practice recruitment and retention. Secondly, with regards to the eligibility check it 
seems that the CES-D and the threshold of ≥16 may have excluded some people 
who could have actually taken part. The CES-D is more reflective of general 
distress than MDD, and indeed 70% of people with Type 2 diabetes meeting CES-D 
≥16 do not meet criteria for MDD according to diagnostic clinical interview; while 
sensitivity is good the positive predictive value is low (Fisher et al, 2007; Stahl et al, 
2003).  
 
Randomisation and allocation concealment were not apparently problematic. 
However, as anticipated, achieving patient blinding in WED trials is particularly 
difficult. Blinding was apparently compromised for approximately a quarter of 
                                                             
141 Seven primary care patients’ essays were reviewed by Professor Weich. In instances where 
concern was confirmed the researcher was advised to contact the GP and inform them that the patient 
was either, a) potentially at risk; three patients were not currently depressed but at risk in the event of 
future distressing events, or b) high risk/requiring action: one patient demonstrated numerous risk 
factors for moderate to severe depression (as mentioned in chapter six and above). In the latter 
instance, the researcher was advised to contact the patient’s GP that day advising that they should be 
seen/referred to specialist. This patient did not then return any materials after the writing pack 
(mentioned in chapter six & above). Whilst potentially because of their state of well-being at that time it 
is also possible that they were unhappy about their GP being informed about their writing.  
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primary care participants; it was apparently completely compromised for some of 
these participants whereas it seems that others may have merely guessed theirs 
was an active or inert task. Perhaps the information provided was not sufficiently 
vague to prevent participants’ inference of their group assignment. While initially 
anticipated to offer face validity and having been employed in numerous WED trials 
in LTPCs (see chapter three), perhaps the control task was too obviously a placebo; 
indeed one participant commented that they found it to be juvenile and irrelevant. 
Furthermore, discussion between primary care patients and practice staff/GPs that 
were aware of the study purpose was minimised, yet may have occurred. However, 
that this explains the substantial extent of apparently compromised blinding is 
unlikely. Regardless, though, the apparently compromised participant blinding may 
explain the observed effect of WED in the present study (discussed later). 
 
Identifying an appropriate control group is also difficult. Where WED was associated 
with a worsening in outcomes, this was consistently partly accounted for by an 
improvement for controls. There was no notable evidence of treatment diffusion, 
although there may be a potential contamination issue such that writing about daily 
activities very occasionally evokes emotion where these are experienced as such. 
Many control participants did carry on writing post-intervention though, and may 
have emotionally disclosed there. In other WED studies with LTPC samples, 
patients have similarly exhibited/reported difficulty restricting emotion in describing 
daily events (Byrne-Davis et al, 2006; Rivkin et al, 2006). In fact in such studies, 
even in the absence of evoked emotion these tasks have been described as 
meditative (Rivkin et al, 2006) and are posited to facilitate self-discovery (i.e. 
realisation that one is able to cope with the condition) (Byrne-Davis et al, 2006) and 
derive a transient increase in perceptions of control, which positively influences 
outcomes yet this effect dissipates when such control beliefs are not realised (Gillis 
et al, 2006). Writing without the ‘clouding effect’ of emotion is purportedly helpful 
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(Byrne-Davis et al, 2006). That placebos can have a positive effect is also widely 
acknowledged (Dixon, Sweeny & Gray, 2008).  Should this be the case, there is 
apparently a contention between employing a task that has face validity to protect 
blinding yet one which is inert to avoid intervention for controls.  
 
However, some participant feedback about the control task was unfavourable, and 
of the 18 control participants, only 13 (72%) returned their writing and 12 (67%) 
completed all sessions; the observed improvement may not be due to the task. The 
improvement may therefore be attributable to the natural progression of depressive 
symptoms (i.e. maturation), practice effects (i.e. familiarity with the experimental 
situation and or the measures being used) (Field, 2005; Nezu & Nezu, 2008), or 
even simply the fact that they were being studied (i.e. owing to the interest shown in 
them; the ‘Hawthorne’ effect). 
 
Submission of writing is typical in WED studies and was necessary to examine 
mechanisms of change, intervention fidelity and compliance given that experimental 
control was limited. However, an additional insight derived was that this meant that 
participants expected their writing would be read. Indeed, this was very much 
evident in participants writing. It is not clear what impact this might have had upon 
the observed effect of WED in the present study (discussed later). Indeed, clinicians 
advocate against submission of WED transcripts in practice (Baikie & Wilheim, 
2005).  
 
Summary of preliminary effectiveness analysis findings 
Severity of depression was significantly higher for the intervention (WED) 
participants compared to control participants at three month follow up, which 
represented a potentially clinically important difference and an increase in 
366 
 
depressive symptom severity for the WED group yet also an improvement for 
controls. Differences on other measures were non-significant, albeit there were 
trends for small effects suggesting poorer specific diet SMBs and lower health-
related QoL respectively for the WED group relative to controls. 
 
Interpretation of preliminary effectiveness analysis findings 
Depressive symptom severity  
A possible explanation for the effect on the primary outcome, should it be genuine, 
is that the sample was selected as not experiencing any significant depressive 
symptoms, in an attempt to enhance the applied relevance of the trial but primarily 
protect patient safety. Moreover, inclusion of those with at least some symptoms 
(i.e. again to enhance the applied relevance of the trial but also to potentially 
maximise effectiveness), was not achieved. Indeed, the sample was generally well-
adjusted at baseline; the average CES-D score (i.e. 6.7) was below that reported for 
people with diabetes in the community (i.e. 11.5) (Zhang et al, 2005) and secondary 
care (i.e. 15.6) (Hermanns et al, 2006). Hence, the sample did not represent the 
target population requiring support. It is possible that WED as it was delivered in the 
present study may have evoked rather than resolved current stressors that were not 
previously acknowledged. Participant feedback somewhat supported this 
explanation. A number reported not being stressed and thus being unsure what to 
write about and one participant did not return their writing for this reason. Some also 
commented that they were not depressed but when they thought about what they 
could write about and did so they noticed diminished positive mood and more 
contemplation of the stressors (i.e. during and after writing). Indeed, despite being 
generally well-adjusted, many participants went on to discuss some troubling 
issues, for example terminal illness amongst relatives, worry about mental 
deterioration and bereavement. To some extent the WED literature also supports 
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this explanation. Frattaroli (2006) commented in her review that some researchers 
have noted a distinct subset of participants who report never having experienced 
trauma (Frattaroli, 2001), not having anything to write about and even annoyance at 
having to repeatedly write about such an event. That WED is only beneficial where 
people have something to disclose is additionally acknowledged (Lumley, 2004).  
 
Should this be the case it is noteworthy that WED could have evoked current 
stressors that were not previously acknowledged specifically for people at risk. It 
could be that some participants had few depressive symptoms when screened, yet 
they were at risk for this. Indeed, as described in chapter four, depression in 
diabetes is known to fluctuate and people self-selected into the study which, as 
noted in chapter six, may be taken to reflect treatment seeking. Indeed, one WED 
participant that scored only nine on the CES-D at baseline was deemed to be at 
high risk of experiencing clinical depression as a result of their writing content (as 
noted previously and in chapter six).  
 
That an array of psychological treatments can cause iatrogenic, or rather ‘doctor-
induced’, harm has been acknowledged, albeit this has typically been reported for 
samples with existing psychological problems consistent with appropriate 
application of such treatments (Lilienfeld, 2007).   
 
As described in chapter two, previous WED studies with healthy samples and 
diabetes patients have typically reported positive effects of WED on outcomes 
including depressive symptoms. Moreover, chapter three did not identify any 
notable evidence of a negative effect of WED on negative affect including 
depressive symptoms in LTPCs, albeit again these studies were associated with a 
substantial risk of bias which may have overestimated the effects. Nonetheless, in 
none of these studies were participants selected because they were not 
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experiencing any significant depressive symptoms. As described in chapter two, 
however, WED has evidenced some negative effects, typically for samples defined 
by high distress or individuals experiencing highly stressful situations, yet also for 
unselected students. Importantly, the studies reported in chapter two, and some 
additional studies, have suggested that negative effects across these sampling 
contexts may potentially be due to some underlying processes that reflect evocation 
yet avoidance and or an absence resolution of stressors.  There was some 
indication that these processes may have been present in this study. The processes 
purported to underpin WEDs negative effects in these studies142 and possible 
evidence of their operation in the present study is reported below. 
 
Processes purported to underpin negative effects in WED 
As described in chapter two, it seems that WED may increase avoidance in very 
distressed samples, which may be taken to reflect early yet incomplete processing 
of evoked stressors. At least for samples defined by high distress/highly stressful 
situations WED may merely activate distress, which is too upsetting to confront or 
for which more disclosure sessions and/or additional assistance are required to 
achieve resolution. In both distressed and unselected student samples, some 
evidence of avoidance has been observed in the writing of people for whom WED is 
associated with worse outcomes, for example emotional suppression (Greenberg et 
al, 1996), thought suppression (Rogers et al, 2007), denial and rejection of feelings 
(Solano et al, 2007) and discussion of trauma only in the last session with little 
opportunity for genuine integration (Honos-Webb et al, 2000). Indeed, it is asserted 
that over-regulation after an initial evocation of emotion would explain the negative 
effects observed in WED from the self-regulatory perspective (self-regulatory 
approach; chapter two) (Greenberg et al, 1996).  
                                                             
142 This additional information is presented here rather than where some of the studies were initially 
reported in chapter two because an emphasis on the negative effects of WED was not appropriate at 
that point; positive effects were anticipated. 
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Where WED derives negative effects in both distressed and unselected student 
samples there is additionally some evidence of a short-term, disproportionate and  
superficial increase in positive affect which may be taken to reflect a failure to fully 
confront stressors/denial, a ‘cheerful facade’ and sugar-coating, for example greater 
use of positive emotion words (Batten, Follette, Hall & Palm, 2002; Holmes, Alpers, 
Ismailji, Classen, Wales, Cheasty, Miller & Koopman, 2007) an increase in positive 
emotion words (Pennebaker et al, 1997), increases in positive affect post-writing 
(Gallagher & MacLachlan, 2002), and a prefabricated and superficial positive 
conclusion at the close of writing (Honos-Webb et al, 2000).  
 
As described in chapter two, the initial increase in negative mood in WED should 
dissipate quickly. In distressed, depressed and LTPC samples, negative WED 
effects have also been demonstrated to be associated with an apparent over 
involvement in negative emotion without resolution, manifested as a higher use of 
negative emotion words overall (Fernàndez & Pàez, 2008; Holmes et al, 2007; Lee 
& Cohn, 2010; Pennebaker et al, 1997; Smith, Anderson-Hanley, Langrock & 
Compas, 2005). Indeed, as noted in chapter two, it seems that only a moderate 
reference to negative emotion words may be preferable. Emotional expression with 
a focus on negative emotion without cognitive processing has also demonstrated a 
negative effect on outcomes (Ullrich & Lutgendorf, 2002). 
 
Moreover, increases in cognitive processing words have occasionally been shown 
to be related to negative effects of WED in distressed samples (Baikie et al, 2006; 
Batten et al, 2002; Pennebaker et al, 1997), where this is taken to reflect initiation 
but not completion of cognitive processing (Baikie et al, 2006). Should this be the 
case it is noteworthy that these maladaptive processes may be operating when 
intervention fidelity (Rogers et al, 2007) and the anticipated mechanisms of change 
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are apparently observed (Honos-Webb et al, 2000). Indeed, as argued in chapter 
two, it is possible that the linguistic changes observed in WED could reflect 
processes other than E&CP.  
 
It is also speculated that WED derives negative effects for distressed samples 
because they topic switch; staying focussed on the traumatic event may be difficult 
whereas topic switching would presumably relive this distress (Sloan & Marx, 2006). 
As described in chapter two, topic switching prohibits EA&H in these samples (i.e. 
exposure approach). Indeed, in a detailed case study Sloan and Marx (2006) 
observed topic switching to apparently be associated with an absence of resolution 
of disclosed distress for a participant with significant problems. However, the 
exposure approach (i.e. EA&H) and the inherent assumption that topic switching 
has a detrimental effect upon outcomes (i.e. as it interferes with EA&H) has not 
been consistently supported in WED studies, at least in non-traumatised samples 
(discussed in chapter two).  
 
Evidence for the processes purported to underpin negative effects in WED 
Intervention fidelity and mechanisms of change 
In the present study two mechanisms of change were investigated; E&CP of 
stressors, specifically an increase in words reflecting cognitive processing and 
positive emotion, and a decrease in words reflecting negative emotion, across 
writing sessions (i.e. cognitive processing and self-regulatory approaches) and 
EA&H, specifically a reduction in post-writing negative affect across writing sessions 
(i.e. exposure and self-regulatory approaches). As described in chapter six, no 
conclusions can be drawn from the exploratory explanatory analyses owing to the 
sample obtained, yet they were proceeded with in a hypothesis generating way and 
because this may additionally aid interpretation of any main effect.  
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Indeed, the changes observed provided some information that could be used in 
endeavouring to interpret the main effect. It seems that ED and initial EA was 
achieved as intervention fidelity was confirmed; there was greater use of positive 
and negative emotion and cognitive processing words, and more post-writing 
negative affect, for the WED group compared to the control group overall. However, 
while the E&CP changes were in the right direction they were somewhat 
incomplete, and there was no reduction in post-writing negative affect across 
sessions. It should be pointed out that these findings did not necessarily discern the 
initial hypotheses, though. This is because again no conclusive inferences can be 
drawn from these analyses, but additionally because the failure to confirm the 
anticipated mechanisms of change was somewhat unsurprising given that this was 
expected in the event of a positive not negative effect.  
 
While tentative, the intervention fidelity and pattern of change in LIWC variables that 
was observed may be interpreted as being somewhat consistent with the 
aforementioned maladaptive processes reflecting evocation yet avoidance and an 
absence of resolution. Intervention fidelity was greatest for the positive emotion 
word category (yet closely followed by negative emotion word use), and in fact 
within the WED group for each session participants used more positive emotion 
words than any other category. Indeed, many participants wrote about positive 
issues in addition to stressors within their essays, seemingly because they were 
generally well-adjusted. In fact, again a number of the participants that reported not 
being stressed and unsure what to write about additionally wrote about positive 
issues (see chapter eight). 
 
Across writing sessions, there was a small increase in positive emotion word use 
which then plateaued, and increases in insight and causal word use, albeit this later 
plateaued for insight and was followed by a notable decrease in causal word use. 
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There was no change in negative emotion word use, only a slight reduction towards 
the last writing session, and again a slight increase in post-writing negative affect 
was observed.  In sum, it seems that there was clear consideration of negative 
emotion yet a definite, somewhat increasing focus on positive emotion, with a 
concurrent increase in post-writing negative affect. There was also an apparent  
initial increase in cognitive processing, yet this dissipated in particular with respect 
to finding meaning in the event.  
 
Additional observations from post-hoc exploratory analyses 
There were some additional related observations that potentially supported the 
assertion that the aforementioned maladaptive processes may have been operating 
in the present study. Exploratory correlations identified that a change in the direction 
of an increase in depressive symptom severity was possibly associated with a 
higher use of negative emotion words and changes in the direction of an increase in 
insight words yet a decrease in causal words across writing sessions. Correlations 
between the linguistic features of WED and the secondary outcome variables 
generally concurred with this pattern of associations, including those for the 
outcomes for which it seems that WED may have had a negative effect, albeit there 
were limited associations between negative emotion word use and change in these 
outcomes. Interestingly more use of and an increasing focus on positive emotion 
words was generally associated with a change in the direction of an improvement in 
outcomes, yet this was typically not the case for those outcomes for which it seems 
that WED may have had a negative effect. There was also clear, consistent 
evidence of excessive topic switching, with issues rarely discussed more than once 
in WED participants writing.  
 
Whilst again speculative, these findings may be taken to suggest that perhaps 
stressful issues were evoked, yet participants felt they had no significant stressors 
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to discuss in depth and thus did not attempt this. Alternatively, perhaps when 
participants thought about stressful issues not previously considered they realised 
they were unhappy about them, felt uncomfortable with the emotions evoked and 
then avoided discussing them. Consequently, many wrote about positive topics and 
emotions, and displayed little continuity in the content of their disclosures. For those 
that additionally engaged in notable disclosure of negative emotions and 
endeavoured to some degree to  understand the events disclosed and ultimately 
derive meaning from them yet did not succeed in this, perhaps as a result of this 
avoidance, current stressors that were previously not acknowledged may have been 
evoked and not resolved.  Indeed, one WED participant commented that they felt 
they had not achieved anything by the close of writing. It should be pointed out that, 
as described in chapter two, writing about positive aspects of stressors and positive 
issues/experiences has demonstrated benefits. However, in none of these studies 
did participants elect to additionally write about such positive issues when instructed 
to disclose stressors. 
 
Additional potential explanations 
Sampling bias 
The sample comprised more males than females. It could be argued that perhaps 
males experienced difficulties with processing and resolving the evoked stressors. 
Most of the participants that exhibited a potentially clinically important increase in 
depressive symptom severity were men (71%). Moreover, some participants, 
predominantly males, explained that they did not complete the intervention, or had 
difficulty completing it, because they did not wish to/found it too difficult discussing 
emotions. While the systematic review described in chapter three indicated a 
possible beneficial effect of WED upon negative affect, there was a bias to female 
participants.  Indeed, as also described in chapter three, some research has 
identified a superior effect of WED for women, yet the evidence is again inconsistent 
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and others suggest men benefit more or no moderating effect. Again, the 
relationship between gender and WED is likely complex and requires further study. 
Nonetheless, while clinicians report WED is acceptable to men in practice (Baikie & 
Wilheim, 2005), finding WED difficult and subjectively reporting no benefit has been 
observed for male research participants with arthritis (Byrne-Davis et al, 2006). This 
explanation is also consistent with the literature, and tentative preliminary 
observation in the present study, that suggest WED may increase depressive 
symptom severity particularly for people with lower emotional processing ability (i.e. 
high alexithymia).  
 
Protocol deviations 
Again WED was not consistently implemented exactly as intended, however. 
Perhaps this somehow prohibited proper processing, and explains the negative 
effects. WED has evidenced improvement when the number, spacing and length of 
sessions have deviated significantly from the original paradigm, for example three 
sessions spaced out over an hour (Chung & Pennebaker, 2008). Indeed spacing is 
reportedly not important (Sheese et al, 2004), hence one week was allowed in the 
present study. However, no studies have examined WED with the deviations 
observed in the present study. Such severe deviations were, however, relatively 
infrequent, which weakens this assertion.  
 
Constrained disclosure 
As mentioned earlier, participants were additionally aware their writing would be 
read, and this was very much evident in their essays. Some assert the greater the 
presumed audience the more constrained the disclosure (Baikie & Wilheim, 2005; 
Frattaroli, 2006; Smyth & Helm, 2003). Others argue, though, that WEDs effects are 
not related to the presumed audience (Czajka, 1987; Pennebaker, 2000) and even 
375 
 
more positive when writing is submitted (Radcliffe, Lumley, Kendall, Stevenson & 
Beltran, 2007).  
 
Factors external to WED 
However, the observed effect may not be the result of WED again given the 
proportion of enrolled participants returning a writing pack was low. In fact, of those 
that exhibited a clinically important increase in depressive symptom severity, 43% 
did write at all (see chapter eight). It should be noted that it may be that some 
participants who did not return the intervention actually started or even completed it, 
in which case they may have been affected as those that completed it were. Indeed, 
some reasons for non-return of writing were finding it too difficult discussing 
feelings. Otherwise, simply receiving WED and considering it may have evoked 
negative emotion that was not resolved, and thus been harmful to generally well-
adjusted participants whether it was completed or not.  Indeed, one participant 
explained that they had not returned their writing as they found it too stressful trying 
to think of something to write about.  
 
Alternatively though, there could be some other reason altogether for the increase in 
depressive symptom severity in only the WED group, which was unrelated to the 
intervention. Indeed, the finding of an increase in negative affect related to WED is 
perplexing, and this finding should be interpreted with caution given the small 
number of participants in the intervention group (i.e. again no conclusions can be 
drawn from the exploratory analyses in the present study). In fact, a number of WED 
participants reported experiencing events that may have impacted upon negative 
affect during the study, whereas this was generally not observed for controls. As 
mentioned earlier, two WED participants became quite seriously ill between writing 
and three month follow up (i.e. heart failure and double bypass operation) and even 
noted that this may explain their answers/why these have changed from the 
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previous questionnaire (see chapters six and eight). Other potentially confounding 
issues reported by WED participants during the trial included new stressful events 
(i.e. as noted earlier one participant’s friend was diagnosed with cancer during their 
writing period, another participant’s sister-in-law died during their writing period and 
another avid church goer noted in their three month questionnaire that there may be 
a small negative change in their responses owing to the recent loss of their parish’s 
church building). 
 
To identify whether the observed effects were robust to the responses of these 
participants, sensitivity analyses were performed excluding these five WED 
participants and a control participant that reported experiencing potentially 
confounding events during the study143 from the preliminary effectiveness analysis 
for depressive symptom severity. However, once these participants were excluded, 
the effects observed from the ITT and complete case analyses became slightly 
more significant and the mean differences and effect sizes became slightly larger 
(and as with the original analyses, the 95% CIs associated with the means for the 
WED and control group did not or at most marginally overlapped). The conclusions 
derived were generally unchanged, though.144 The original mean differences, p 
values and effects size estimates and those derived in the sensitivity analysis are 
reported in Table 55.  
 
                                                             
143 This was the participant that reported not feeling well at baseline and in their writing (see chapters 
six and eight), and they also reported being frustrated by their current diabetes control in their three 
month questionnaire. 
144 Assumption checks for both the ITT and complete case analysis indicated homogeneity of 
regression slopes for the covariates, namely age, gender and baseline depressive symptom severity 
(p>.05). However, the assumption of homogeneity of variance was apparently violated for the 
untransformed data for both the ITT and complete case analysis (p<.05), yet this was not the case for 
the transformed data. Analyses with the transformed and untransformed data generally derived the 
same conclusions with one exception; ω² for the complete case analysis with the untransformed data 
just met the cut-point for a large effect (see chapter five) (.14), whereas ω² for the transformed 
indicated a medium-sized effect (.12). For ease of interpretation the untransformed data is reported, 
yet the magnitude of the effects for both analyses were presumed not to have changed with the 
exclusion of these participants.   
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It should be noted, however, that given their age and that poor health was 
discussed within the WED essays relatively frequently (see chapter eight), a number 
of participants may have experienced yet did not report potentially confounding 
events, which may have systematically affected the WED group. 
 
Table 55 Mean differences, p values and effect size estimates for the original ITT 
and complete case analyses and the sensitivity analyses excluding participants 
reporting potentially confounding events during the study  
Analysis Mean 
difference 
P value ૑² 
Sensitivity analysis    
ITT 5.8 .004 .12 
Complete case 6.8 .008 .14 
Original analysis    
ITT 4.8 .006 .09 
Complete case 5.5 .012 .10 
 
 
Additional attempts to understand the observed effect 
There was no evidence of mediation in the present study; the anticipated mediating 
processes did not offer any further understanding of the observed effect. It should 
be noted that as with the mechanisms of change investigated, these findings did not 
necessarily discern the initial hypotheses though. This is because again no 
conclusive inferences can be drawn from these analyses, but also because these 
findings were somewhat unsurprising in that mediation of a positive not negative 
intervention effect was anticipated. These mediating processes had not been 
confidentially established (as reported in chapter four), thus it may be that they are 
not as important in explaining WEDs effects as was initially anticipated. Such 
assertions are speculative, however, as again no conclusions can be drawn from 
these analyses. 
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Sub-group (moderator) analyses 
As explained in chapter six, these analyses were particularly limited and as such 
were considered only very briefly in a hypothesis generating way. To this end, it was 
notable that the findings were consistent with the literature in chapter two; for 
alexithymics WED may have evoked stressors without resolution increasing 
awareness of distress and symptom perception, and pessimists undertaking WED 
may have ruminated on the negative aspects of an issue without resolution and 
derived negative expectations about the impact of WED resulting in increased 
symptom perception. It may be worth investigating these moderators in future 
studies. 
 
Potentially meaningful effects: health-related QoL and diet 
As described in chapter four, SMBs and health-related QoL were included as 
outcomes as it was unclear whether or anticipated respectively that WED may 
influence them. Additionally, the diabetes literature suggested that even lower-level 
depression adversely influences these outcomes, and that depression treatment 
can improve them concurrently, albeit whether these changes are related to change 
in depression is unclear. In the present study, WED additionally produced trends for 
poorer specific diet behaviour, possibly reflecting comfort eating, and poorer health-
related QoL. A possible explanation for these effects, should they be genuine, is 
that WED evoked rather than resolved current stressors, which adversely affected 
depressive symptom severity but also these outcomes. Indeed, the baseline EQ-5D 
scores also indicated participants were generally well-adjusted; the average utility 
(i.e. .89) and VAS (i.e. 80) scores were above the average reported for UK adults 
with Type 2 diabetes (i.e. .75 and 68.8 respectively) (Matza et al, 2007). Whether 
these trends were associated with the increase in depressive symptom severity is 
unknown yet as such remains a possibility. The systematic review reported in 
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chapter three did not suggest any adverse effect on WED on health-related QoL, yet 
again these studies were associated with an unacceptable risk of bias. Nonetheless, 
none of the included studies included participants selected for not experiencing any 
significant depressive symptoms. 
 
It is notable that no effect on general diet behaviour was observed. However, a 
number of participants noted that they experienced difficulty answering items in this 
sub-scale as they ask about following an eating plan which they did not have (as 
noted in chapter eight), yet they answered them nonetheless. These data are 
therefore ambiguous. Additionally, should it be the case that WED evoked rather 
than resolved current stressors and thus exacerbated comfort eating, directly or 
indirectly by increasing depressive symptom severity, questions asking specifically 
about these behaviours may be considered to be more sensitive to this change than 
more generic questions about healthy eating. There was also no effect on the EQ-
5D utility outcome. However, it is acknowledged that this measure is prone to ceiling 
effects; not all health problems, especially those unrelated to the domains 
assessed, are detected (i.e. some variation in the independent variable is not 
captured). Its responsiveness to change in clinical trials may therefore be limited 
and is yet to be established (Matza et al, 2007). Indeed, a substantial proportion of 
people with Type 2 diabetes indicate perfect health on this measure (i.e. a score of 
1) (Matza et al, 2007), as was observed in the present study. 
 
Other SMBs 
As described in chapter two, there is limited evidence that WED influences health 
behaviours, which is seemingly limited to effects upon addictive behaviours only for 
some populations (e.g. psychologically stressed/problematic populations). There is 
equivocal evidence regarding SMBs in LTPCs but this is underdeveloped. Chapter 
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one reported that the depression intervention literature in diabetes suggests some, 
albeit few, SMBs may be influenced, namely diet and exercise. Incidentally the 
present study identified a potential effect for diet yet not exercise, and the 
aforementioned unpublished study of WED in Type 1 diabetes identified the 
opposite pattern of effects. In the present study, participants often commented that 
the questions about exercise were not applicable to them owing their age and 
associated health problems (again noted in chapter eight). Moreover, individuals 
with Type 2 diabetes are more prone to weight problems than those with Type 1, 
and indeed the average BMI in the present study was 30. The absence of an effect 
on exercise in the present study is therefore unsurprising. Whilst speculative, the 
study in Type 1 diabetes may have similarly omitted an effect on diet, given that the 
sample was small (n=22) and effects were considered in terms of significance 
suggesting a risk for a Type 2 error. However, the effect on diet in the present study 
was negative, possibly owing to the sample obtained. Moreover, and most 
importantly, as noted earlier as a result of the small sample obtained no conclusions 
can be drawn from the exploratory analyses in the present study.  
 
DSED 
DSED was included as an outcome because as highlighted in chapters one to four, 
WED was anticipated to be specifically effective in diabetes. This was because 
WED targets emotional aspects of stressors and presumably DSED, which are 
associated with depression. Consequently, improvement in depression may be 
optimised. However, the systematic review reported in chapter three suggested an 
effect of WED on negative affect yet not distress, which has additionally been 
observed in some non-LTPC samples. It was therefore advocated that whether 
WED might target distress and improve depression via a concurrent reduction in this 
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in LTPCs should be clarified. Consistent with the systematic review, the present 
findings do not support this presumption. 
 
There are a number of potential explanations for the apparent adverse effect of 
WED on depressive symptom severity yet not DSED. Diabetes-related stressors 
were infrequently discussed, and where they were evoked, given the data presented 
below, it seems that these may have already been in people’s minds. Thus an 
exacerbation of DSED could be considered to have been unlikely whereas writing 
about diabetes-related stressors may have stirred depressive feelings. As described 
in chapter four, in diabetes general stressors/stress are associated with both DSED 
and depression, thus evocation rather than resolution of this might reasonably be 
expected to adversely influence both of these outcomes. However, it seems logical 
that depressive symptom severity might be more readily influenced. There may 
have also been a ceiling effect such that there was less room for worsening in 
DSED. Furthermore, a number of the factors external to WED that may have 
increased depressive symptom severity for WED participants, for example serious 
illness and new general life stresses during the trial, are again arguably more likely 
to have influenced depressive symptom severity than DSED. 
 
It should additionally be pointed out that the apparent adverse effect of WED on 
depressive symptom severity but not DSED may be taken to suggest that perhaps 
DSED and depressive symptoms are not as closely related as is anticipated; 
changes in depressive symptom severity may not necessarily equate to a change in 
DSED. Indeed, chapter four noted that it is generally agreed these are related yet 
independent constructs. While speculative perhaps the association is less evident 
for certain sub-groups. This is consistent with clinical observation that people with 
diabetes and depression typically do not discuss diabetes as the main cause rather 
it can be a contributory factor (JS). Indeed, the study identified that it is possible to 
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have DSED in the absence of notable depressive symptoms. The average baseline 
PAID scores indicated moderate DSED (i.e. 36), and the mean was close to the 
lower bound indicating most participants exhibited this level and some even scored 
74. In a general outpatient diabetes population a screened sample scores between 
20-30 (Papathanasiou, Shea, Koutsovasilis, Melidonis, Papavasiliou & Lionis, 2008; 
Polonsky et al, 1995; Welch et al, 1997), and scores of 30-50 are observed in 
secondary care diabetes samples (Hermanns et al, 2006; Papathanasiou et al, 
2008). In fact, scores of ≥33 and ≥38 are also reported to have adequate sensitivity 
and specificity for detecting elevated depressive symptoms and MDD according to 
diagnostic clinical interview in diabetes (Hermanns et al, 2006).  
 
Comparison with previous reviews 
To facilitate comparison with the effects observed in the previous WED systematic 
reviews and the effects from the systematic review reported in chapter three, for the 
potentially important effects observed in the exploratory RCT η² was converted to r, 
by taking the square root, and then d was computed (see chapter three for formula). 
These are reported for the ITT analysis in Table 56 below. 
 
Table 56 Potentially important effects converted to r and d (ITT analysis) 
 
 
 
 
 
The effects observed were generally larger than the positive effects derived for 
psychological health outcomes in previous WED reviews that included many 
samples including those with an LTPC; d=.07 (non-sig.) (psychological health) 
(Frisina et al, 2004), d=.12 (sig.) (psychological health) and d=.15 (sig.) (depressive 
Outcome ITT analysis 
R D 
Depressive symptoms .32 .67 
Specific diet SMBs  .20 .41 
Health-related QoL (EQ-5D VAS) .14 .28 
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symptoms) (Frattaroli, 2006)145, and the potentially important positive effects derived 
in the systematic review; d=.13 (negative affect) and d=.31 (health-related QoL). 
However, they were of a similar magnitude to the larger positive effect reported for 
healthy samples in Smyth’s (1998) review (d=.66). Interestingly, in Meads et al’s 
(2003) review, there was actually a slight trend for more negative mood for people 
with pre-existing physical conditions. However, this was seemingly attributable to a 
single study which caused effect heterogeneity amongst studies; a trial of WED in 
cancer (Walker et al, 1999). This was the only study in the systematic review 
presented in chapter three that reported a non-significant trend for a medium-sized 
effect indicating more negative affect for WED participants (d=.47) (i.e. before meta-
analysis). Together with the present findings, this may be taken to suggest that 
WED might occasionally produce negative effects that are of a relatively large 
magnitude perhaps owing to sample-specific quirks. It should be noted, however, 
that the Walker et al (1999) study comprised a similarly small sample (n=35), and 
was assessed as having a high risk of bias such that other factors may explain the 
observed effects. 
 
Study strengths 
Before discussing the study limitations, it is important to additionally consider the 
strengths of the present endeavour. This was one of only a very small number of 
studies to investigate therapeutic writing for use in general practice in the UK, and 
the only one to consider the feasibility and preliminary effectiveness of WED for 
LTPCs and specifically Type 2 diabetes in primary care in the UK. This is important 
given the clinical issue of unmet lower-level E&P need in LTPCs, and specifically in 
Type 2 diabetes, which requires management in primary care. The study 
                                                             
145 Frattaroli (2006) reported r=.06 (psychological health) and r=.07 (depression), which can be 
converted to d (again see chapter three for formula). 
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endeavoured to obtain and report on thorough process data, albeit it was not 
possible to compile as much information as would have been liked (i.e. qualitative 
interviews had to be dropped from the protocol as reported in chapter four). This 
identified a wealth of invaluable information to inform future endeavours. For 
example, the study highlighted some key recruitment issues particularly for primary 
care practices, derived some valuable insights into the challenges to be addressed 
when undertaking research into WED, and potentially identified some conditions 
under which WED may not be safe to implement.  
 
The study also initially attempted to enhance the informative potential of the trial and 
obtain a more accurate estimate of the anticipated effectiveness of WED by 
addressing issues not normally considered within MRC phase two exploratory trials 
(e.g. internal validity and bias). Conclusive inferences were, however, prohibited by 
the sample obtained. The study was also designed on the basis of a rigorous 
systematic review of effectiveness, and a thorough consultation process was 
implemented in which advice from users and a range of relevant experts was sought 
and proceeded with.  
 
Study limitations: research design and methods 
Problems associated with the recruitment strategies employed 
As reported in chapter four, recruitment in primary care was initially sought yet 
extended to secondary care and then support groups owing to the recruitment 
problems experienced. This was argued to be justified in terms of enhancing the 
external validity and applied relevance of the trial, and because WED has also been 
successfully implemented in these contexts. Ultimately, though, the samples derived 
were not representative of the intended primary care population. There is also a 
threat to ecological validity in that the setting of the study should approximate the 
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real-life situation that is under investigation. Furthermore, by opening recruitment to 
online support groups it was possible that international participants may have been 
enrolled when ideally UK participants were required (consistent with the 
recommendations reported in chapters three and four). Indeed, research into the 
feasibility of recruiting GP practices has indicated that often there is a need to 
balance scientific rigor against the reality of clinical practice and practical application 
(Graham et al, 2007).  
 
Moreover, the decision to combine data from primary care and the online support 
groups was considered the most appropriate approach because this would increase 
statistical power and precision, it was anticipated that any bias would be equally 
distributed and diluted and analyses based on the small number of support group 
participants recruited would be of limited utility. However, there was some evidence 
of a difference at baseline that seemed to reflect involvement in the forums (i.e. 
support seeking), and it was acknowledged that there are many reasons why these 
samples should not be combined; support group participants represent support 
seeking individuals, which introduces further selection bias and constitutes a non-
representative sample. Indeed, some additionally argue that use of online support 
groups may dilute WEDs effects (Atkinson, Hare, Merriman & Vogel, 2009; Murray, 
2009; Smyth & Pennebaker, 2008). 
 
The feasibility of multiple questionnaires: participant burden 
Multiple questionnaires were employed as the initial objectives of the thesis were to 
provide a comprehensive preliminary exploratory investigation of WEDs effects. The 
WDREUG were consulted about the acceptability of the study materials and the 
burden associated with the questionnaires so that participants could be informed 
about this prior to providing consent. Nonetheless, participant burden was noted to 
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explain some missing data (as reported in chapter eight), and may explain the 
participation rates observed (i.e. the third of the eligible participants that did not 
return the baseline questionnaire in primary care and losses to follow up). Indeed, 
one participant reported that they found completing the questionnaires to be 
repetitive. 
 
Issues associated with the data collection schedule 
Perhaps three months was insufficient to observe the full trajectory of WEDs effects 
(Nezu & Nezu, 2008). A six month follow up was intended but removed due to the 
delay in acquiring ethical approval and recruitment; should it be genuine, whether 
the negative effect observed would have been maintained or changed at a longer 
follow up is of interest. Indeed, follow up at any other interval may not have 
evidenced the same effect. It is advocated studies should contain multiple follow 
ups to identify at exactly which points WED is effective and whether the effects are 
fleeting (Sloan & Marx, 2004a). Moreover, whilst again speculative, the tentative 
evidence of negative associations between some mediator variables measured at 
three months146 and depressive symptom severity may be taken to suggest that 
perhaps two weeks to one month is an insufficient follow up for mediators, and that 
three months may be insufficient to then observe the influence of mediating 
processes.  
 
 
 
  
                                                             
146 Self-efficacy for diabetes SMBs and perceived satisfaction with emotional support. 
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Study limitations: preliminary effectiveness analysis and further 
exploration of the observed effect 
Statistical conclusion validity 
Sample size 
As described in chapter six, the sample size obtained was much less than that 
required to ensure adequate statistical power to detect a potentially clinically 
important difference on the CES-D as statistically significant at p<.05  (i.e. as there 
being less than 5% risk the effect is a Type 1 error (i.e. due to sampling 
error/random fluctuations). Smaller samples give rise to more sampling error (i.e. 
nosier data sets with more variation and thus random fluctuations), whereas in 
larger samples these fluctuations cancel one another out; the average value better 
reflects the population value (Ellis, 2010). It is therefore more difficult to detect a 
potentially clinically important effect as not likely due to sampling error with a 
smaller sample; the power to detect it as significant is reduced increasing the risk of 
a Type 2 error. The effect for depressive symptom severity was detected as not 
likely due to sampling error, however, as the effect size was large; the anticipated 
difference between the group means was observed yet their SDs were smaller147 
and indeed the associated 95% CIs barely overlapped. There was evidence, 
however, of small yet potentially important effects, which were not detected as 
significant. It should be acknowledged, however, that these effects were still 
associated with an unacceptable risk that they reflect random fluctuations/the null 
hypothesis is true, and should be interpreted as inconclusive warranting 
investigation in a larger trial. 
 
Effects that were detected as statistically significant may additionally not be 
genuine; while the null hypothesis is ‘probably’ false there is still up to a 5% (1 in 20) 
                                                             
147 5.2 rather than 8.5. 
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risk of a Type 1 error (i.e. that random fluctuations were detected as significant)  
(Ellis, 2010). In fact, the risk of Type 1 error was substantially inflated owing to the 
multiple exploratory tests performed on the same dataset. For example, the ITT 
preliminary effectiveness analysis alone entailed 10 tests, thus the probability of no 
Type 1 error decreased from .95 to .60 (i.e. . 95ଵ଴) and the accepted risk of making a 
Type 1 error increased from 5% to 40% (Field, 2005). All of the statistical analyses 
performed were pre-specified and thus do not reflect finishing for effects. 
Nonetheless, the significant effects may not have been observed had only one test 
been performed.  Ultimately, the only means of determining whether an effect is 
genuine is to repeat it in a different sample (Ellis, 2010). 
 
Owing to the small sample size achieved, the effects whether detected as significant 
or not were also very much imprecise and thus likely not representative of the 
population effect; the 95% CIs associated with the regression parameters for the 
effect of group in the preliminary effectiveness analysis were wide indicating a range 
of possible effect estimates and thus conclusions.148 For the non-significant effects, 
95% CIs suggested positive or negative effects, or indeed a null effect (i.e. the 
intervals crossed 0 hence it could not be assured that there was only a 5% risk that 
the null hypothesis was true consistent with the significance test). For the significant 
effects, the negative effect could have been larger than observed but importantly 
also trivial. Similar if not greater imprecision likely applied to the other statistical 
analyses, which included even smaller samples and indeed evidenced uncertainly 
around the means and medians derived. 
 
 
 
                                                             
148 As expected, the ITT analysis consistently derived slightly narrower confidence intervals than the 
complete case analysis, probably owing to the slightly larger sample included in analyses. 
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Internal reliability 
Interestingly, the Cronbach’s alpha for the CES-D scale was slightly below the lower 
bound of acceptability. Moreover, this was not calculated for the EQ-5D measures 
and SDSCA sub-scales as they comprised too few items. Indeed, internal reliability 
is typically reduced for scales comprising less than three items (Peterson, 1994), 
and the SDSCA authors acknowledge this problem for the diet sub-scales (Toobert 
et al, 2000). As such, the items in the measures for which potentially important 
effects were observed may not have been measuring the same thing; the intended 
construct. Measurement error typically underestimates the association between 
variables and thus effect sizes, and introduces additional noise (i.e. random 
fluctuations) into a dataset making it more difficult to detect effects (i.e. reducing 
statistical power) (Ellis, 2010; Nezu & Nezu, 2008). This might not explain the effect 
on depressive symptom severity, but it may be taken to suggest that the non-
significant trends observed could reflect Type 2 errors. 
 
Validity  
The acceptability and interpretative issues reported in chapter eight suggest that the 
validity of some of the measures employed may have been compromised; some 
data were ambiguous and or may not have reflected the intended construct. 
Problems were reported for the SDSCA, DMSES UK, SSQ6 and IIRS (i.e. certain 
items within these scales were reported to be difficult to answer as they were not 
explicitly applicable yet they were answered nonetheless (i.e. typically with no 
option indicting inapplicability within the response format), the items were answered 
ambiguously owing to a complex response format, or the items were explicitly 
answered with respect to a different construct from that intended).  
 
Furthermore, whilst it was ensured that validated tools were employed there are 
some potential issues associated with the measures employed. No problems were 
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observed with the PAID in the present study, but this scale has been criticised with 
respect to content validity (i.e. covering some areas of interest too briefly or not at 
all) and ambiguity in the meaning of some items (Polonsky et al, 2005). At the time 
that the protocol was developed the PAID had been subject to more extensive 
psychometric testing than alternatives, for example the Diabetes Distress Scale; a 
revision of the PAID recently developed by the same research group (Polonsky et 
al, 2005). However, this scale addresses these issues and may perhaps now be a 
preferable alternative. Furthermore, the DMSES UK is a revised version of the 
original DMSES measure validated for use in the USA and Netherlands; face and 
content validity were assessed, and redundant items removed.  However, the UK 
version has not been subject to extensive psychometric testing. Indeed, internal 
reliability was not demonstrated for support group participants.  
 
In fact, that missing and ambiguous responses were often related to items within the 
SDSCA and DMSES UK asking about management of diabetes that were not 
applicable suggests that perhaps alternatives should be employed to measure these 
constructs.  The SDSCA and DMSES UK were employed, however, as no plausible 
alternative were available; The Self-Care Inventory - Revised (Weinger, Welch, 
Butler & La Greca, 2005) has been validated for use in Type 2 diabetes, however it 
was initially developed to assess the treatment regimen for Type 1 diabetes thus 
many items are not appropriate for Type 2. Similarly, the Diabetes Empowerment 
Scale (Anderson, Fitzgerald, Funnell & Marrero, 2000) assesses empowerment in 
relation to diabetes generally, including the managing psychosocial aspects rather 
than only SMBs, and the Confidence in Diabetes Scale (van der Ven, Ader, 
Weinger, van der Ploeg, Yi, Snoek & Pouwer, 2003) is for use in Type 1 diabetes. 
Should perceived emotional support be re-examined as a mediator, a measure with 
a less complex response format is absolutely required. The SSQ6 was employed as 
typically other scales had not been validated in diabetes, whilst the SSQ is a core 
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EDID measure. Nonetheless, a plethora of general perceived emotional support 
measures were available. 
 
It is additionally unclear whether the PANAS was the right measure to tap EA&H. 
Such self-report measures should have been developed to assess fear activation 
and responding and must be validated (i.e. demonstrated to co-vary with 
physiological responses to emotion) (Sloan & Marx, 2004b). Indeed, WED studies 
that have additionally failed to observe EA&H have employed state anxiety 
measures (Kloss & Lisman, 2002) and the PANAS (D’Souza et al, 2008; Gillis et al, 
2006; Norman et al, 2004).  
 
Finally, self-report measures are potentially inaccurate and reliance on them 
introduces mono-method bias hence they should be accompanied by objective 
measures, although it is encouraging that the self-report and objectively determined 
clinical data obtained in the present study did apparently corroborate.  
 
Internal validity 
Randomisation and allocation concealment 
Again, there were no substantial systematic differences on prognostic variables 
apparent at baseline that could explain effects (i.e. no selection bias was apparent).  
 
Blinding149 
However, blinding was again apparently compromised for a number of primary care 
patients, some of who it seems may have merely guessed theirs was an active or 
inert task. Again, this may explain the observed effects. Demand characteristics 
may be implicated; some participants may have unconsciously responded in a way 
                                                             
149 It should be noted that with respect to the withholding information about the study to protect 
blinding, no participants reported concerns about this at debriefing. 
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that discerned, rather than confirmed, the study hypothesis (i.e. adopting the 
negative participant role; Weber & Cook, 1972). Indeed, there was some evidence 
of cynicism and negative expectations about the intervention and study. 
Compensatory rivalry may have additionally come into play had controls worked 
extra hard to see that the expected superiority of the intervention group was not 
demonstrated. Moreover, controls may have sought treatment from their GP. 
Incidentally, the IAPT programme (see chapter one) was initiated in Coventry and 
Warwickshire while participants were still being recruited to and participating in the 
trial (i.e. October 2009). However, such treatment diffusion is unlikely given the 
sample was relatively well adjusted at baseline.  
 
Attrition  
There was some evidence of self-selection at follow up; approximately 20% of 
participants were lost at each follow up. Consistent with the majority of the studies 
included in the systematic review (chapter three) though, this was acceptable and 
not indicative of substantial attrition bias (i.e. selection bias caused by attrition). 
Nonetheless, those who stayed in may have differed systematically from the sample 
initially recruited, and had attrition been related to a negative experience of the 
intervention the negative effect associated with WED may have been 
underestimated. There was no notable evidence of imbalance in attrition at two 
weeks (WED 22%; control 17%) or three months (WED 22%; control 22%), or 
reasons for attrition (i.e. whether theses were related to the task) at two weeks 
(WED 33%; control 33%) and three months (WED 25%; control 25%), albeit 
reasons could not be obtained for all dropouts.  There was therefore little evidence 
of selective attrition bias; systematic group differences in attrition that are potentially 
related to some aspect of the study (e.g. treatment response) and may have 
influenced the observed effect.  
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Problems associated with the analytical approach 
Strict ITT analysis was not possible as some participants did not complete the 
intervention as intended, but also because attrition and missing data meant that 
some observations were imputed. Additionally, data could not be imputed for some 
albeit few participants for the EQ-5D VAS and SDSCA blood glucose testing sub-
scale; selective attrition bias cannot be ruled out. Moreover, the extent of missing 
data and thus imputation was notable for the blood glucose testing measure; 
particular caution must be exercised in interpretation of these analyses.  
 
The approach to imputation was additionally not ideal; no change was presumed as 
a conservative approach. The natural course of depression in diabetes is unknown 
yet the evidence suggests it is probably unstable (see chapter four). However, 
imputation is always an estimate, and a sensitivity analysis was performed to 
identify the impact. As expected the effect of WED was slightly underestimated. 
Importantly though, given that the observed effect was negative assuming no 
change was not a conservative approach. The ideal approach would have been 
multiple imputation (i.e. generating possible values for missing values and thus 
estimating several complete sets of data, then using the pooled output from 
analyses), yet this is difficult to perform.   
 
The contamination, and again the mechanisms of change, analyses must 
additionally be interpreted with caution. The extent of missing data for the PANAS 
negative affect sub-scale was substantial, and indeed the numbers included in 
these and also the LIWC analyses were very small; it is highly likely these analyses 
were underpowered and the effects derived imprecise (i.e. not representative of the 
population effect). The PANAS variables were notably influenced by high scoring 
outliers, which introduced ambiguity in the mechanisms of change analyses 
(reported in chapter eight). Moreover, the non-parametric analyses employed 
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disposed of valuable information resulting in a loss of power; only the order of the 
data was retained (Ellis, 2010). Nonetheless, these were considered more accurate 
than parametric analyses with severely skewed data. 
 
Again, caution must additionally be exercised in interpreting the mediation analyses. 
The regression analyses included almost 15 participants per variable as typically 
recommended, yet as mentioned in chapter four many more are actually required to 
reliably gauge the effect estimate (R² and thus ∆R²) and achieve adequate statistical 
power when effects are small. Indeed, adjusted R² consistently overestimated the 
population effect indicating shrinkage. There was also some limited evidence of 
non-significant trends (mentioned above), although these may be inaccurate and in 
fact could be explained by external variables correlated with the predictors (Field, 
2005).  
 
Finally, the correlations investigating whether the linguistic features of WED 
presumed to reflect E&CP were related to changes in outcomes were not pre-
specified or formal mediation analyses (again as described in chapter five). While 
this provided interesting information to aid interpretation of the pre-specified 
analyses, mediation cannot be presumed and again no conclusions can be drawn 
from these exploratory analyses.  
 
External validity 
The small sample size also reduces the external validity and thus generalizability of 
the findings. The sample was also highly self-selected; of those invited to participate 
only 10% of the primary care patients and 4% of support group participants 
expressed an interest. This suggests sampling bias; participant’s decisions about 
whether to participate may have been related to motivations or traits that derived an 
unrepresentative sample. Participant feedback indicated that the motivation for 
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taking part for some was curiosity and an interest in furthering understanding and 
management of diabetes.150 Indeed, again it seemed that most participants were 
generally well-adjusted. However, interest in the study may reflect treatment 
seeking, and indeed some people were excluded owing to high depressive 
symptom severity (as described in chapter six). Moreover, PAID levels were 
notable, and one participant commented that they were frustrated by their current 
diabetes control (as reported earlier). However, few patients choose to write about 
diabetes as a stressor. While speculative, perhaps those excluded in the eligibility 
check were motivated by treatment seeking, whereas the sample obtained 
acknowledged diabetes-related problems yet was predominantly motivated by 
curiosity and a desire to further understanding and management of the condition. 
There may also have been an element of treatment seeking for some participants 
though. In sum, should this be the case, the sample would only be representative of 
individuals exhibiting these motivations. Interestingly, others report WED is less 
effective where individuals are not motivated by a desire to disclose, for example 
those responding to a researchers request (Lumley, 2004).  
 
The results can also only be generalised within the selection criteria employed, for 
example only to individuals with Type 2 diabetes experiencing nothing more than 
minimal depressive symptoms. Individuals recently diagnosed with Type 2 diabetes 
were also not represented, and indeed there is preliminary evidence that WED may 
be less effective and even contraindicated when LTPC patients have been 
diagnosed for a longer period (Low et al, 2010). The sample was also biased to 
older participants, although this is unlikely to explain the negative effect observed 
given that there is preliminary evidence of positive effects of WED in seniors with 
                                                             
150 One patient commented that they hoped their writing would be useful and that they would like to 
think they had done something to rid others of the dreadful complaint (WED, primary care). Another 
patient commented that they hoped the study would shine some light onto coping with the condition 
(WED, primary care). In threads on the online support group forums some people stated that their 
motivation to take part was because they were curious to see how writing could possibly help people 
manage and cope with diabetes/wanted to know the outcome of the research. 
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Type 2 diabetes (as described in chapter four) (Taylor, 2001). It is noteworthy 
however that some WED participants reported problems with writing and either did 
not return their writing pack for this reason or found the task to be difficult. Hence, 
as anticipated WED may not be pragmatically appropriate for some older individuals 
with Type 2 diabetes.  
 
Moreover, as no patients were recruited in secondary care individuals with more 
serious diabetes complications were not represented. Moreover, only the socio-
demographic characteristics of the PCTs from which practices, and then patients, 
were recruited are represented. This and the English writing ability and literacy 
requirements of the present study meant that lower socio-economic groups, ethnic 
minorities and less educated individuals were under/not represented. WED has 
demonstrated effectiveness across samples that are heterogeneous on these 
characteristics (Frattaroli, 2006; Pennebaker, 1997; Pennebaker & Graybeal, 2001; 
Smyth & Helm, 2003; Yogo & Fujihara, 2008), however there is some evidence 
WED is differentially effective with respect to ethnicity (Lu & Stanton, 2010); the 
privacy of WED may again offer an acceptable means of disclosure for Asian 
patients, and education (Junghaenal, Schwartz & Broderick, 2008); expressing 
thoughts and feelings by writing may be less suitable for individuals with lower 
education.  
 
The implications for service delivery and research, effective strategies, potential 
means of addressing the limitations observed and the conclusions derived from the 
exploratory RCT are considered in the following chapters in the context of the thesis 
findings as a whole. 
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Chapter 10 Overall conclusions 
 
Chapter overview 
This chapter presents the broader implications for service delivery and research, 
drawing on the findings and conclusions from the previous chapters. The current 
position regarding the implementation of WED in Type 2 diabetes and LTPCs 
generally is therefore clarified, and the overarching recommendations for further 
research into WED in LTPCs are specified. A discussion of how the limitations 
associated with the present endeavour could be addressed follows, and some 
further recommendations for future research born out of the present trial are then 
mentioned. The chapter closes with a summary of the findings and 
recommendations from the thesis as a whole, with consideration of what was learnt 
and the potential contribution to knowledge. 
 
Broader implications for service delivery 
The findings from the exploratory RCT suggested that WED may be acceptably and 
feasibly implemented as part of general practice in the UK and for use with LTPCs 
in this context, specifically Type 2 diabetes. The systematic review suggested that, 
should the observed effects be genuine, in adults with LTPCs WED may produce 
slight improvements in depressive symptoms that could have a large, favourable 
impact on the range of important clinical and service level outcomes adversely 
impact by depression at the population level (discussed in chapter one). Indeed, as 
mentioned in chapter three, when produced for a number of people even small and 
seemingly unimportant effects can accumulate to large effects that have a 
substantial impact on outcomes at the population level (Ellis, 2010). The U3 statistics 
that were derived indicated WED may produce improvements in depressive 
symptoms, and some associated outcomes namely health-related QoL, such that 5 
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to 10% of the population may do better than would be expected by chance. This 
effect may additionally be more prominent for certain LTPCs. The effect sizes were 
consistent with the previous albeit limited systematic reviews, and may be taken to 
support the assertion that WED can be expected to deliver small yet clinically 
important beneficial effects in LTPCs (Baikie & Wilheim, 2005). Smyth and 
Pennebaker (2008) argue that for such a brief and inexpensive intervention to have 
any effect is impressive, thus again should they be genuine these effects are 
encouraging. 
  
The preliminary effectiveness analysis in the exploratory RCT suggested that, 
should the observed effects be genuine, delivering WED as it was implemented in 
the present exploratory trial to patients with Type 2 diabetes may promote an 
increase in depressive symptom severity and a slight worsening in health-related 
QoL and dietary behaviour. As described in chapter three, while Cohen’s 
conventions for interpreting effects sizes are grounded in logic, reflect observable 
effects and are important for comparing effect sizes across studies, their use is 
controversial and it is crucial to further interpret effects in terms of clinical 
importance, and additionally their contribution to knowledge (Ellis, 2010).  
 
Investigation of whether a clinically important effect on depressive symptom severity 
was observed in the exploratory trial was thus pre-specified. Again, the clinical 
importance of effects based on SMDs is difficult to interpret as the difference is 
expressed in SD units rather than the measurement scale employed. A five point 
difference on the CES-D was therefore considered potentially clinically important 
given that a score of 16 is taken to indicate significant symptoms (i.e. this 
discriminates between important levels of severity and is potentially clinically 
meaningful). This difference was observed. However, as also mentioned in chapter 
three, the change in a person’s actual depressive state that corresponds with a unit 
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change on such self-report symptom measures is not known. Certainly, no sensible 
inferences could be made about the clinical significance of a five to eight point 
difference on the EQ-5D VAS. The effect for specific diet was, however, more easily 
interpreted; the group difference equated to half a day per week spent eating more 
high fat foods and less fruit and vegetables for the WED group compared to the 
control group.  
 
Regardless though, as above should they be genuine the effects observed in the 
present study could have a substantial impact at the population level, for example in 
terms of the health service implications of unhealthy eating in diabetes. That WED 
may additionally produce a comparatively large and potentially clinically important 
increase in depressive symptom severity is especially concerning given the 
aforementioned impact of depressive symptoms in adults with LTPCs and 
specifically diabetes (see chapters one and four). As in chapter three, to illustrate 
that the effects observed in the exploratory trial could have a substantial impact at 
the population level, SMDs can be expressed as the U3 statistic. For the ITT 
analysis, the SMDs of .67 for depressive symptom severity, .41 for specific diet 
behaviour and .28 for health-related QoL are equivalent to 75%, 66% and 61% of 
WED participants having greater depressive symptom severity, poorer specific diet 
behaviour and lower health-related QoL respectively than the average control 
participant. Put another way, 25%, 16% and 11% respectively of the population may 
do worse than would be expected by chance alone (i.e. U3=.75, .66 & .61 
respectively).   
 
Importantly, though, there were a number of methodological issues which 
substantially undermine the findings and necessitate that the observed effects are 
interpreted with caution; again no conclusions can be drawn from this analysis. The 
effects may not be genuine and cannot be confidently accepted without replication, 
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although given that effects were negative this presents an ethical dilemma 
(Lilienfeld, 2007). Indeed, some statisticians have referred to statistically significant 
findings in the opposite direction to that anticipated as Type 3 errors (Lilienfeld, 
2007).  
 
In sum, it is not justified to dismiss WED as a potentially valuable intervention for 
adults with Type 2 diabetes on the strength of this analysis alone. Further research 
addressing the pitfalls associated with the present endeavour is clearly required.  
Until then, however, caution must be exercised in considering WED for Type 2 
diabetes. In fact, given the substantial risk of bias identified for the studies included 
in the systematic review, which suggested that the effects may have been 
overestimated, and the present findings it seems that WED should not be widely 
disseminated for LTPCs at all outside further high quality research. It should also be 
noted that the present study identified that while there seems to be is a sub-group of 
individuals for whom WED may be a welcome source of support, patient 
acceptability is mixed. Indeed, the compliance that was observed echoed that in 
previous WED trials in LTPCs suggesting that patients’ acceptability may be mixed 
in LTPCs generally. Evidently, it must be acknowledged that WED may not be 
acceptable to all patients with LTPCs.  
 
Broader implications for research 
Future trials must therefore address the limitations identified in the systematic 
review and the present endeavour. In fact, the exploratory trial attempted to address 
the limitations observed in this evidence base, yet despite concerted efforts did 
identify with some of them (i.e. initial sample size, difficultly implementing participant 
blinding and completion of the intervention). Obviously, future trials must secure 
external funding and thus adoption onto the research portfolio/assistance from the 
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Research Networks, so that WED can be properly investigated. The acceptability 
and feasibility information and this presence of an unmet need documented in the 
present study suggest that this is a worthy endeavour. Indeed, interest in WED for 
LTPCs is still evident. Many ongoing trials were identified in the systematic review, 
and in fact two more published studies in patients with chronic lung disease 
(Sharifabad, Hurewitz, Spiegler, Bernstein, Feuerman & Smyth, 2010) and psoriasis 
(Paradisi, Abeni, Finore, Di Pietro, Sampogna, Mazzanti, Pilla & Tabolli, 2010) that 
would have met the criteria for the review were identified after the cut off for 
inclusion. In fact, there is also a large scale, ongoing trial of WED for diabetes by an 
established research group yet this is in the USA (Smyth et al.). 
 
An important issue identified in the present endeavour is that WED must be tested 
with a more appropriate sample of adults with Type 2 diabetes; should the observed 
effects be genuine WED may be differently effective in a more appropriate sample. 
Indeed, as above, the systematic review suggested that WED derives positive, and 
no negative effects, on depressive symptoms, and some associated outcomes, 
across unselected samples of adults with LTPCs.  There is additionally preliminary 
research that has suggested the same in diabetes (reported in chapter four). 
However, these studies are again limited and the effects may have been 
overestimated. 
 
Nonetheless, the findings from the present study may be taken to support the 
assertion made in the systematic review that WED should be administered to 
patients with at least some, albeit not significant, depressive symptoms. 
Consequently, the research priorities specified in the systematic review still hold; 
trials should investigate the effectiveness of WED for reducing negative affect, for 
example depressive symptoms, and associated outcomes such as health-related 
QoL, for LTPCs that are associated with negative affect and in which negative affect 
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has a significant impact, perhaps still diabetes. Patients should be experiencing 
lower-level negative affect. This is consistent with the appropriate clinical application 
of WED and would enhance the applied relevance of trials whilst importantly 
protecting patient safety. It would also potentially optimise effectiveness.  
 
Such trials should again be exploratory, informed by the invaluable data acquired in 
the present exploratory trial, this time delineating the conditions under which WED 
should rather than should not be implemented. Indeed, the issues encountered in 
the present exploratory RCT underscore the importance of feasibility trials. Indeed, 
it seems important to examine acceptability and feasibility again given that much of 
the negative patient feedback about WED may have related to the sample obtained. 
Further qualitative investigation into acceptability and feasibility would also be 
fruitful, for example the planned interviews that were not possible in the present 
endeavour. Importantly, the anticipated effectiveness of WED should also be re-
assessed but in a larger, more appropriate sample. 
 
How the limitations associated with the present endeavour could be 
addressed 
What worked well 
The recruitment strategy employed in primary care was actually relatively effective 
rather it was circumstantial factors and study design flaws that apparently created 
problems. For example, eight GP practices were recruited as required, yet three 
were lost owing to swine flu related workload and the QoF inclusion criterion 
employed. Of the remaining five practices, three actually identified many patients, 
typically more than that anticipated for a practice, and for one of those that identified 
few patients this was again owing to the QoF inclusion criterion and swine flu 
related workload. The patient recruitment rate was lower than anticipated, but 
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should a means of covering resource costs to practices be acquired recruitment of 
more practices would potentially overcome this. In fact, resource costs to practices 
were proven to be minimal, which dispels some of the initial concerns expressed 
about the study by practices. Indeed, this strategy was apparently more effective 
than the strategy tested in secondary care.  
 
Having GPs offer WED in consultation would offer greater ecological validity (i.e. 
ascertaining whether WED can feasibly and effectively be implemented as part of 
routine general practice). However, this activity would require significant 
reimbursement and there may be a risk of compromising participant blinding. The 
pace of recruitment would additionally almost certainly be slower (i.e. as suggested 
by the previous feasibility trial of WED based interventions in primary care including 
in the UK; reported in chapter four).  
 
Unsurprisingly, recruitment, albeit not retention, was seemingly better when 
practices were visited and GPs (and to a lesser extent nurses) were spoken to. This 
should therefore be fervently sought. Other observations were that having 
participants write at home, which afforded greater ecological validity, was relatively 
successful given the limited experimental control (i.e. the instructions were typically 
adhered to). Typing disclosure was also well accepted and executed by support 
group participants, hence there does not seem to be any reason why this could not 
be offered to those requesting it in primary care. Email administration in support 
groups resulted in speedier return of materials, although to offset formatting 
problems that may deter participants and introduce interpretative problems an 
encrypted online resource would be required for administration of materials 
electronically. Finally, reminders were generally effective in obtaining materials. In 
fact, participants seemed to engage more with the study when spoken and value the 
opportunity to speak with the researcher, with some even requesting this; personal 
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contact with the researcher seems to be helpful. However, as reported in chapter 
four, caution must be exercised as personal contact and extensive discourse with 
the researcher risks additional intervention, influences from experimenter 
expectancies/bias, compromised blinding, treatment diffusion and pre−disclosure 
priming. It was also an ethical requirement that the researcher avoided situations in 
which clinical support was being sought.  
 
What worked less well and what would be done differently knowing 
what is now known 
Recruitment and sample size 
The most notable caveat related to practice and patient recruitment and ultimately 
the small sample size, statistical power and imprecision observed. In primary care, 
practices were apparently unable to participate owing to practice workload, resource 
costs and occasionally payment; the imposition to practices whilst at the minimum 
possible was still considered too great. Some means of reimbursing primary care 
practices for the resource costs associated with the study must be implemented (i.e. 
further limiting the imposition to practices). Assistance for the research networks, in 
particular having an appropriate person introduce the study to practices and be 
available to go into practices to support searches would be ideal. Indeed, previous 
research suggesting means of encouraging GPs to participate in research has 
indicated that they must be encouraged to see value in research participation (as 
noted in chapter six), an effective strategy for which may be to confer value by 
payment for participation (Graham et al, 2007; Johnston et al, 2010; Salmon et al, 
2007). This is consistent with the economic drivers inherent within the QoF (Salmon 
et al, 2007).  
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Even when funding and assistance from the research networks are secured, 
however, recruiting practices can still be challenging. As noted in chapter six, the 
aforementioned studies suggest that emphasising the relevance and potential 
benefits of the study is crucial. Furthermore, they advocate that as a means of 
recognising and rewarding GPs for their time in studies additional indirect and 
personal incentives may maximise participation, for example providing feedback on 
patient health outcomes and practices processes, and incorporating an element of 
continued professional development (CPD) into the study (Johnston et al, 2010). 
Perhaps, then, it could be emphasised that whilst this was perceived to be barrier to 
recruitment amongst practices in the present study, pro-actively screening and 
identifying patients with potentially significant depressive symptoms is actually 
consistent with NICE guidelines (see chapter one) and may provide useful 
information for audit (NIHR PCRN, 2010). It could then be enthused that having 
been identified in the eligibility check patients beyond the study may additionally 
derive benefit, and that the study would provide early access to novel treatments 
and additional time and monitoring for patients (NIHR PCRN, 2010). Other 
potentially useful approaches advocated by these studies are recruiting a GP 
champion to the research team who could champion the study to colleagues 
(Johnston et al, 2010). 
 
In online support groups, the most notable barriers to patient recruitment specifically 
in this context were limited exposure to the study information owing to posting in 
research sub-forums. Posting within Type 2 diabetes sub-forums is apparently 
important. Recruitment in local support groups could also be pursued. In secondary 
care, clinical support was much less available than anticipated thus the ideal 
recruitment strategy had to be changed considerably. Clinician agreement that they 
will at least mention the study to patients initially as was initially intended may be 
important. However, the limited availability of clinical support and the many other 
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barriers to recruitment in secondary care suggest that perhaps recruitment in this 
context should not be pursued. In fact, to promote ecological validity and 
consistency with the anticipated implementation of WED, and to avoid the 
inappropriate combination of data from different sources, recruitment should ideally 
be constrained to primary care.  
 
Finally, across recruitment contexts, the eligibility questions and or the DSQ 
seemed to deter participants. Such measures are unavoidable, yet participants 
should be assured that this is merely a check required to satisfy relatively standard 
ethical requirements and is not intended to select only individuals experiencing 
problems.  
 
Eligibility check 
The eligibility check in place to ensure the exclusion of participants potentially at risk 
may have excluded some who could have actually taken place. With regards to 
identifying a more appropriate sample, the only workable and acceptable option 
may be for appropriately qualified clinicians to test WED in Type 2 diabetes, such 
that ethical requirements can be satisfied without the need to exclude people for 
who WED may be suitable and include those for whom it may not. This is not, 
however, consistent with the anticipated application of WED as a self-administered, 
low-intensity psychological intervention. Perhaps another option then is the 
exclusion of individuals scoring above a threshold for significant symptoms on a 
symptom measure derived from DSM-V diagnostic criteria. As described in chapter 
four, other WED trials have sought to identify patients with elevated but not 
significant depressive symptoms using a similar approach with different measures to 
exclude at risk participants, for example the BDI (Stice et al, 2006). These studies 
report improvement in depressive symptoms and no negative effect. In fact, the BDI 
has demonstrated predictive efficacy in Type 2 diabetes, specifically a superior 
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positive predictive value whilst maintaining sensitivity (Lustman, Clouse, Griffith, 
Carney & Freedland, 1997). The gold standard is again the diagnostic clinical 
interview and should be conducted where feasible. 
 
Ensuring inclusion of participants with lower-level depression 
The present study initially sought patients with at least some lower-level depressive 
symptoms, yet identified that this cannot be achieved by enforcing the QoF 
depression-screening questions employed in primary care as an inclusion criteria. 
Some alternative means of identifying such individuals is thus warranted. Perhaps 
an alternative worthy of investigation is the inclusion of individuals scoring above a 
threshold for mild symptoms yet below that for significant symptoms on a symptom 
measure derived from DSM-V diagnostic criteria. This has been employed in some 
other WED studies reporting benefits and no negative effects (discussed in chapter 
nine). 
 
Participant burden  
In order to reduce the participant burden that was apparently associated with the 
use of multiple questionnaires, issues such as moderators, mediators and 
mechanisms of change should perhaps be shelved and examined in the context of a 
full effectiveness trial. When this is re-examined, though, more appropriate 
measures of EA&H should be sought, it may be advisable to measure mediators 
later than two weeks post-intervention, and in view of the limited support for the 
mediators tested exploration of alternative mediators may be more productive. 
 
The data collection schedule 
The follow up employed was insufficient to observe the full trajectory of WEDs 
effects. Consequently, follow ups that extend beyond three months are advocated.  
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Reliability and validity of study measures 
Estimation of effects with more reliable measures, especially in relation to diet 
behaviour, is important. The validity of some of the measures employed was 
additionally uncertain, and owing to acceptability issues for certain measures 
missing data were problematic. Alternative measures should be considered where 
they exist (as discussed in chapter nine), and instructions to complete all questions 
including those which are not applicable indicating (i.e. this within the required 
format where this is possible) are required. Assessment beyond self-report 
measures is also indicated (e.g. depressive symptoms by clinician ratings). 
 
Acceptability of writing 
Some participants reported that they found it difficult to fit writing in with life. In view 
of this and the observed effect, it may be prudent to allow people write as and when 
they need to. Whilst non-return of writing packs may reflect patient acceptability, 
strategies to promote completion of WED/return of writing packs should be 
identified. Perhaps assistance in getting people started with WED would be helpful. 
Contact with the researcher may help but again should be implemented with 
caution. In fact, many, albeit not all participants, reported a dislike for 
handwriting/preference for typing. Perhaps offering the opportunity to type if 
preferred would be advisable. Indeed, this is advocated (Baikie & Wilheim, 2005). 
 
Blinding 
Again, blinding was apparently compromised for a number of primary care patients, 
some of who it seems may have merely guessed theirs was an active or inert task. 
Given the requirement to involve them in relation to patient safety, practice 
staff/GPs should be specifically advised not to disclose the study purpose to 
patients. However, provision of even less information to participants is not ethically 
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justifiable, and caution must be exercised in using a more engaging writing task 
which is less noticeably a placebo yet risks intervention. Exactly how participant 
blinding can be improved is thus unclear and must be explored.  
 
Control group comparison 
Again, where WED was associated with a worsening in outcomes, this was 
consistently partly explained by an improvement for controls. Additional inclusion of 
a usual care control group is thus also warranted, to establish whether any 
improvement for controls is due to the time management task or external factors, 
and thus whether an alternative inert control writing task is required. Should this be 
the case, a task that may further compromise blinding should be avoided. 
 
Further recommendations for future research born out of the present 
trial  
Further recommendations for future research born out of the present trial are 
presented in Table 57. 
 
Conclusions: what was learnt 
The thesis suggested that WED may be acceptably and feasibly implemented as 
part of general practice in the UK and for use with LTPCs in this context, specifically 
Type 2 diabetes, and provided a wealth of invaluable process data to inform future 
endeavours. Given that this has not previously been investigated, the present study 
may be considered to offer a notable addition to the evidence base. 
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Table 57 Further recommendations for future research 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The feasibility demonstrated and, should they be genuine, the findings of a 
generally positive effect of WED for negative affect and associated outcomes in the 
systematic review are encouraging. The effects observed in the present exploratory 
 
 Enhance the external validity of the findings by seeking to ensure the inclusion of 
the full age range of adults with Type 2 diabetes and adapting WED for ethnic 
minorities , for example South Asians. The latter may also serve to boost participant 
recruitment. For this group diabetes is particularly prevalent (as reported in chapter 
four), depression in diabetes is particularly under diagnosed and treated (Ali, 
Davies, Taub, Stone & Khunti, 2009), and WED may be culturally acceptable and 
particularly effective (as discussed in chapters four and nine). It is asserted that 
translating stressful experiences into language is beneficial regardless of the 
language employed (Smyth & Pennebaker, 2008). 
 
 The exploratory trial suggested men may require some additional assistance with 
WED. There is some evidence that additional instruction facilitating cognitive 
processing can derive further improvement from WED (see chapter two). Perhaps 
this could be helpful. 
 
 Explore whether and reasons why WED does not seem to target distress and 
produce improvement via a concurrent reduction in this in LTPCs. 
 
 WED could be used to obtain a valuable insight into the emotional factors impinging 
upon life for patients with Type 2 diabetes, which would inform future intervention 
efforts. 
 
 Address the impact of recent changes in regulations relating to health service 
research on institutionally or self-funded PhD research, which suggests that primary 
care research training experiences may be limited.  
 
 Explore further the finding that a substantial number of adults including primary care 
patients with Type 2 diabetes may be seeking support for unmet E&P need, many 
of whom are experiencing significant depressive symptoms and that there may also 
be an element of dissatisfaction where treatment is currently provided. 
 
 Clarify the precise nature and magnitude of the relationship between depressive 
symptoms and DSED, and explore the finding that some people with diabetes 
apparently experience DSED in the absence of depressive symptoms given that 
DSED additionally warrants intervention yet is less likely identified and treated than 
depression in diabetes (see chapter 4). 
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RCTs also potentially serve as a notable addition to the existing evidence base, 
though. Should they be genuine, they suggest that while the systematic review 
indicated that positive effects of WED are generally observed in LTPCs there may 
be instances in which WED may not be safe to implement; WED may cause 
iatrogenic harm perhaps owing to sample-specific quirks. Thus identification of such 
predisposing factors could be a priority. Specifically, when implemented for 
individuals with Type 2 diabetes selected for not having any significant depressive 
symptoms and without ensuring at least some symptoms, writing about current 
stressors may evoke rather than resolve previously unacknowledged issues. The 
effect may also extend beyond depressive symptoms, for example to diet behaviour 
potentially reflective of comfort eating and health-related QoL.  
 
However, methodological problems that are common to WED trials and are difficult 
to resolve mean that no conclusions can be drawn from this or indeed previous 
studies in LTPCs. In sum, there is as yet insufficient evidence on a whole to suggest 
that WED should be implemented in primary care for LTPCs including Type 2 
diabetes. Further research addressing the pitfalls associated with previous 
endeavours is necessary, specifically feasibility trials initially. However, this will 
require significant investment in and efforts to advance on existing attempts to 
prevent the succession of inconclusive trials that is currently apparent. Indeed, a 
principal learning from this thesis was that research into WED and recruitment of 
primary care practices without access to the research networks was more difficult 
than was initially anticipated. The issues experienced and reported within this thesis 
must now be overcome.  
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Publication strategy 
 
The following papers will be written up and submitted for peer reviewed publication: 
 The systematic review. 
 The findings from the exploratory RCT; feasibility and preliminary 
effectiveness. 
 The ethical difficulties in undertaking research into WED and the impact of 
changes necessitated by ethical review and the measures taken to address 
them. 
 What adults with Type 2 diabetes talk about when asked to emotionally 
disclose. 
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Appendix A: Data extraction for previous WED systematic reviews 
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categories of physical health & 
psychological health.  
 
Mixture of positive, negative null & 
negative effects; outcomes showed some 
positive intervention effects however these 
were offset by null and or unreported 
effects (a third of all outcomes measured 
were unreported), for example for 
depressive symptoms. There was a 
slight trend for worse psychological 
outcomes for people with pre-existing 
physical conditions (i.e. more negative 
mood and intrusions). 
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20
06
) 
30 Original WED 
paradigm (but if 
more than 1 
disclosure group 
averaged). 
 
Neutral writing. 
 
>1 month post 
intervention. 
 
 
X 
Electronic database 
search (but limited). 
Author contact. 
Search terms relatively 
comprehensive. 
Bibliographies of 
reviews. 
Journal hand 
searching. 
Author contact. 
X  
(collected 
data about 
‘biasing 
characteristi
cs’ e.g. 
randomisatio
n but not 
used in 
interpretation 
of evidence). 
Data 
extraction 
(subset of 
studies). 
Calculated effects if studies 
reported means/SDs, F-
scores, t-tests, significance 
levels & number if 
participants. If odds ratios 
provided effects presumed to 
be 0.  
 
Attempts to obtain missing 
data from authors reported. 
X  Overall effect g=.04 (95%CI -.8 to .15), 
psychological health g=.01 (95%CI -.17 
to .19) (PTSD symptoms g=.10 (95%CI 
.25 to .46), somatic health g=.07 (95%CI -
.06 to .19) & health behaviours g=.02 
(95%CI .04 to .36).  
 
Clinical samples g=-.08 (95%CI -.15 to 
.31), high risk samples g=-.03 (95%CI -.06 
to .20), healthy g=.07 (95%CI -.03 to .22). 
H
ar
ris
 (2
00
6)
 
30 Original WED 
paradigm only. 
 
Neutral writing or 
no writing. 
 
>1 month post 
intervention. 
 
Electronic database 
search (including 
dissertation 
databases). 
Search terms relatively 
comprehensive. 
Bibliographies of 
theoretical articles, 
reviews, primary 
studies. 
Conference 
proceedings hand 
searching. 
Author contact.  
 
(but only 
examined 
whether 
method of 
randomisatio
n stated & 
evidence of 
blinding as 
moderators 
of effects). 
X Studies were required to 
provide an estimate of effect 
size or data that permitted 
calculation of Hedges g.  
 
Attempts to obtain missing 
data from authors reported. 
 Health care use: healthy samples g=.16 
(95%CI .02 to .31 (exc. 1 outlier), medical 
samples g=.21 (95%CI -.03 to .43), 
psychological samples g=.06 (95%CI -
.12 to .24). 
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146  Any variant of 
emotional 
disclosure (e.g. 
written or verbal, 
real or imagined & 
negative or 
positive). 
 
Neutral writing or 
no activity. 
  
>1 day post 
intervention. 
 
 
 
Electronic database 
search (including 
dissertation 
databases). 
Search terms 
comprehensive. 
Citation search. 
Bibliographies of 
books, reviews & 
primary studies. 
Conference 
proceedings hand 
searching. 
Author contact. 
 
(but 
examined 
whether 
attrition, 
delivery of 
instructions 
(proxy for 
experimenter 
blinding) and 
overall 
quality score 
were 
moderators 
of effects). 
Extraction of 
moderator 
variables & 
effect size 
estimates 
(subset of 
studies).  
Studies were required to 
provide sufficient statistical 
information to calculate 
effects and then for included 
studies effect sizes were 
calculated if significant p 
values reported or effects 
presumed to be zero if non-
significant p values reported. 
If only F tests reported or it 
outcomes only stated as 
significant or not, outcomes 
coded as unreported.  
 
Attempts to obtain missing 
data from authors reported. 
 Overall effect r=.075 (95%CI .051 to .98), 
reported health r=.072 (95%CI .36 to 
.107), psychological health r=.056 
(95%CI .026 to .086) (anger r=.183 
(95%CI -.70 to .84), bereavement/grief 
r=.137 (95%CI -.40 to .60), distress 
r=.102 (95%CI .04 to .16), depressive 
symptoms r=.073 (95%CI -.01 to .16), 
anxiety r=.051 (95% -.09 to .19), positive 
functioning r=.045 (95% CI .01 to .08), 
stress r=.029 (95%CI -.02 to .08), coping 
r=.002 (95%CI -.08 to .08), cognitive 
schemas/core beliefs r=-.005 (95%CI -
.04 to .04), post-traumatic growth r=-
.009 (95%CI -.15 to .14), eating disorder 
problems r=-.020 (95%CI -.07 to .03),  
dissociative experiences r=--.041 (one 
study), post-traumatic stress symptoms 
r= .032, (p=.130) & self-regulation r=-
.077 (p=.124), physiological functioning 
r=.060 (95%CI .013 to .106), health 
behaviours r=.007 (95%CI -.091 to .104. 
 
Larger effect if physically ill (r=.131) than if 
not (r=.054) on reported health (r=.188; 
p=.034) but not other outcomes (i.e. 
psychological health, r=.075; p=.21).  
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Systematic review: Study identification, extraction and assessment  
 
Appendix B: Search strategies 
 
Original search strategies151 
        
Downloaded to Endnote 
 
Medline (MeSH terms focussed/not exploded) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PsychINFO (MeSH terms focussed/not exploded) 
  
                                                             
151 Where possible terms were focussed and not exploded, terms indexing relevant trials and reviews in 
each database were included in strategies, and where searches restricted the number of text words 
that could be searched the most comprehensive were selected. 
1. Writing/ 
2. Disclosure/ 
3. Self disclosure/ 
4. Expressed emotion/ 
5. Catharsis/ 
6. pennebaker.tw 
7. ((emotive or affective or therapeutic or express$ or disclos$) adj2 
writ$).tw 
8. (emotional adj (express$ or disclos$)).tw 
9. (written emotional adj (express$ or disclos$)).tw 
10. (emotional disclosure adj2 writing).tw 
11. (emotional expression adj2 writing).tw 
12. ((stressful life events or critical life events) adj2 writing).tw 
13. or/1-12 
14. health.tw 
15. 13 and 14 
16. limit 15 to yr="1986 - 2007" 
 
1. Expressed emotion/ 
2. Catharsis/ 
3. Self disclosure/ 
4. Emotional content/ 
5. Narrative therapy/ 
6. pennebaker.tw 
7. ((emotive or affective or therapeutic or express$ or disclos$) adj2 
writ$).tw 
8. (emotional adj (express$ or disclos$)).tw 
9. (written emotional adj (express$ or disclos$)).tw 
10. (emotional disclosure adj2 writing).tw 
11. (emotional expression adj2 writing).tw 
12. ((stressful life events or critical life events) adj2 writing).tw 
13. or/1-12 
14. health.tw 
15. 13 and 14 
16. limit 15 to yr="1986 - 2007" 
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Cinahl and Embase (MeSH terms focussed/not exploded) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PsychARTICLES (MeSH terms focussed/not exploded) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
1. Writing/ 
2. Self disclosure/ 
3. pennebaker.tw 
4. ((emotive or affective or therapeutic or express$ or disclos$) 
adj2 writ$).tw 
5. (emotional adj (express$ or disclos$)).tw 
6. (written emotional adj (express$ or disclos$)).tw 
7. (emotional disclosure adj2 writing).tw 
8. (emotional expression adj2 writing).tw 
9. ((stressful life events or critical life events) adj2 writing).tw 
10. or/1-9 
11. health.tw 
12. 13 and 14 
13. limit 12 to yr="1986 - 2007" 
 
1. Pennebaker.tw 
2. limit 1 to psycharticles 
3. catharsis.tw 
4. limit 3 to psycharticles 
5. ((emotive or affective or therapeutic or express$ or disclos$) 
adj2 writ$).tw 
6. limit 5 to psycharticles 
7. (emotional adj (express$ or disclos$)).tw 
8. limit 7 to psycharticles 
9. (written emotional adj (express$ or disclos$)).tw 
10. limit 9 to psycharticles 
11. (emotional disclosure adj2 writing).tw 
12. limit 11 to psycharticles 
13. (emotional expression adj2 writing).tw 
14. limit 13 to psycharticles 
15. ((stressful life events or critical life events) adj2 writing).tw 
16. limit 15 to psycharticles 
17. or/ 2, 4, 6, 8, 10, 12, 14, 16 
18. health.tw. 
19. limit 10 to psycharticles 
20. 18 and 20 
21. limit 20 to yr="1986 - 2007" 
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CCRCT (clinical trials only, 2007 Issue 2) (‘search this term only’ for Index terms) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SCI, SSCI, and ISI Proceedings 
 
 
 
 
 
 
 
 
 
 
 
 
 
Francis and Eric  
1. Narration/ 
2. Writing/ 
3. Expressed emotion/ 
4. Disclosure/ 
5. ((emotive or affective or therapeutic or express* or disclos*) 
NEAR/2 writ*):ti,ab,kw, from 1986 to 2007 in clinical trials 
6. (emotional NEXT (express* or disclos*)):ti,ab,kw, from 1986 to 
2007 in clinical trials 
7. (“written emotional” NEXT (express* or disclos*)):ti,ab,kw, from 
1986 to 2007 in clinical trials 
8. (“emotional disclosure” NEAR/2 writing):ti,ab,kw, from 1986 to 
2007 in clinical trials 
9. (“emotional expression” NEAR/2 writing):ti,ab,kw, from 1986 to 
2007 in clinical trials 
10. ( “stressful life events” or “critical life events”) NEAR/2 
writing:ti,ab,kw, from 1986 to 2007 in clinical trials 
11. or/1-10 limit 
12. limit 11 to 1986-2007 
 
1. TS=(Pennebaker) 
2. TS=((emotive or affective or therapeutic or express* or disclos*) 
SAME writ*) 
3. TS=(("stressful life events" or "critical life events") SAME writing) 
4. TS=(emotional SAME (express* or disclos*)) 
5. TS=("written emotional" SAME (express* or disclos*)) 
6. TS=("emotional disclosure" SAME writing) 
7. TS=("emotional expression" SAME writing) 
8. or/1-7 
9. TS=Health 
10. 8 and 9 
11. limit 10 to 1986-2007 
 
1. kw: Pennebaker  
2. kw: emotive w writing 
3. kw: affective w writing  
4. kw: therapeutic w writing  
5. kw: disclos* n writ*  
6. kw: express* n writ*  
7. kw: emotional w express*  
8. kw: emotional w disclos*  
9. kw: written w emotional w express*  
10. kw: written w emotional w disclos*  
11. kw: emotional w disclosure n1 writing  
12. kw: emotional w expression n1 writing  
13. kw: stressful w life w events n1 writing 
14. kw: critical w life w events n1 writing or  
15. or/1-14 
16. limit 15 to 1986-2009 
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Proceedings First and Papers First 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sociological Abstracts (could not be date limited –left as earliest to latest) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conference Papers Index  
 
 
 
 
 
 
 
 
 
 
 
 
 
Citation search 
Performed for J.W. Pennebaker, M.A. Lumley, J.M. Smyth and S.J. Lepore 
(performed via Science Citation Index, Social Science Citation Index databases). 
 
1. kw: Pennebaker  
2. kw: emotive w writing 
3. kw: affective w writing  
4. kw: therapeutic w writing  
5. kw: disclos* n writ*  
6. kw: express* n writ*  
7. kw: emotional w express*  
8. kw: emotional w disclos*  
9. kw: written w emotional w express*  
10. kw: written w emotional w disclos*  
11. kw: emotional w disclosure n1 writing  
12. kw: emotional w expression n1 writing  
13. kw: stressful w life w events n1 writing 
14. kw: critical w life w events n1 writing or  
15. or/1-14 
16. limit 15 to 1993-2009 
 
1. DE=Emotional expression 
2. DE=Disclosure (individuals)  
3. DE=Self disclosure  
4. KW=Pennebaker  
5. KW=(emotive or affective or therapeutic or express* or disclos*) 
WITHIN2 writ* 
6. KW=emotional (disclos* or express*)  
7. KW=written emotional (disclos* or express*) 
8. KW=emotional expression WITHIN2 writing  
9. KW=emotional disclosure WITHIN2 writing 
10. KW=(stressful life events or critical life events) WITHIN2 writing 
11. or/1-10 
 
1. KW=Pennebaker  
2. KW=(emotive or affective or therapeutic or express* or disclos*) 
WITHIN2 writ* 
3. KW=emotional (disclos* or express*)  
4. KW=written emotional (disclos* or express*) 
5. KW=emotional expression WITHIN2 writing  
6. KW=emotional disclosure WITHIN2 writing 
7. KW=(stressful life events or critical life events) WITHIN2 writing 
8. or/1-7 
9. limit 8 to 1986-2007 
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ProQuest (limited to Interdisciplinary dissertations and theses/index terms and key 
words) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hand Searching (electronically) 
The British Library Integrated Catalogue (catalogue subset search/document supply 
(all) (any word/not exact phrases) 
 
 
 
 
 
 
 
 
 
Index to Theses (standard search/any field) 
 
 
 
 
 
 
 
 
 
 
 
NDLTD (all subject areas/complete document/exact phrase) 
 
 
 
 
 
 
 
 
 
Google 
The first 100 references of each individual search for the terms ‘emotional 
disclosure’, ‘expressive writing’ and ‘written disclosure’ (all exact phrases and latter 
two searched within results for ‘health’ as the links retrieved initially were not 
generally related to health). 
1. IF(Pennebaker) 
2. IF(emotive or affective or therapeutic or express* or disclos* w/2 
writ*) 
3. IF(emotional w/1 express* or disclos*)  
4. IF(written emotional w/1 express* or disclos*) 
5. IF(emotional expression w/2 writing)  
6. IF(emotional disclosure w/2 writing) 
7. IF(“stressful life events” or “critical life events” w/2 writing) 
8. or/1-7 
9. PDN(>1/1/1986) and PDN(<31/12/2007) 
10. 8 and 9 
 
1. writ? disclos? 
2. express? writ? 
3. emotional? disclos? 
4. or/1-3 
5. limit 4 to 1986-2007 
 
1. Pennebaker 
2. (emotive or affective or therapeutic or express* or disclos*) w/2 writ* 
3. emotional w/1 (express* or disclos*)  
4. “written emotional” w/1 (express* or disclos*) 
5. “emotional expression” w/2 writing  
6. “emotional disclosure” w/2 writing 
7. (“stressful life events” or “critical life events”) w/2 writing 
8. or/1-7 
 
1. “emotional disclosure” 
2. “expressive writing” 
3. “written disclosure” 
4. or/1-3 
5. limit 4 to 1986-2007 
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HSRproj 
 
 
 
 
 
 
 
 
 
 
 
 
MRC Research Register (full text searched for text words) 
 
 
 
 
 
 
 
 
 
 
 
 
 
NRR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
1. “Truth disclosure” [mh] 
2. Writing [mh] 
3. Emotions [mh] 
4. personal log/diary [kw] 
5. “emotional disclosure” [kw] 
6. “expressive writing” [kw] 
7. “written disclosure” [kw] 
8. or/1-7 
 
1. Writing (Mesh Term) 
2. Evaluation w/1 studies  (Mesh Term) 
3. Clinical w/1 trials  (Mesh Term) 
4. Stress  (Mesh Term) 
5. Stress w/1 psychological  (Mesh Term) 
6. emotion* w/1 disclos*   
7. express* w/2 writ* 
8. writ* w/2 disclos* 
9. or/1-8 
 
1. WRITING (MeSH) 
2. EXPRESSED EMOTION (MeSH) 
3. SELF DISCLOSURE (MeSH) 
4. DISCLOSURE (MeSH) 
5. EMOTIONS (MeSH) 
6. emotive next writing 
7. affective next writing 
8. therapeutic next writing 
9. express* next writ* 
10. disclos* next writ* 
11. emotional next disclos* 
12. emotional next express* 
13. written next emotional next disclos* 
14. written next emotional next express* 
15. emotional next expression next writing 
16. emotional next disclosure next writing 
17. stressful next life next events next writing 
18. critical next life next events next writing 
19. or/1-18 
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mRCT (all active registers searched). Individual searches for: 
1. Pennebaker 
2. “affective writing” 
3. “emotive writing” 
4. “therapeutic writing” 
5. “expressive writing” 
6. “disclosive writing” 
7. writing therap% 
8. written expression 
9. written expression 
10. written disclosure 
11. disclos% in writing 
12. express% in writing 
13. written emotional expression 
14. written emotional disclosure 
15. “emotional express%” 
16. “emotional disclosure in writing” 
17. “emotional expression in writing” 
18. “stressful life events and writing” 
19. “critical life events and writing” 
 
CRISP Individual searches for: 
1. PERSONAL LOG/DIARY (MeSH term) 
2. emotional & disclos% 
3. express% and writ% 
4. writ% & disclos% 
 
 
Updated search strategies152 
 
Downloaded to Endnote 
 
Medline (MeSH terms focussed/not exploded) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
                                                             
152 Where possible terms were focussed and not exploded, terms indexing relevant trials and reviews in 
each database were included in strategies, and where searches restricted the number of text words 
that could be searched the most comprehensive were selected. 
1. Writing/ 
2. Disclosure/ 
3. Self disclosure/ 
4. Expressed emotion/ 
5. Catharsis/ 
6. pennebaker.tw 
7. ((emotive or affective or therapeutic or express$ or disclos$) 
adj2 writ$).tw 
8. (emotional adj (express$ or disclos$)).tw 
9. (written emotional adj (express$ or disclos$)).tw 
10. (emotional disclosure adj2 writing).tw 
11. (emotional expression adj2 writing).tw 
12. ((stressful life events or critical life events) adj2 writing).tw 
13. or/1-12 
14. health.tw 
15. 13 and 14 
16. limit 15 to yr="2007-2009" 
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PsychINFO (now CSA) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Embase (MeSH terms focussed/not exploded) 
 
 
 
 
 
 
 
 
 
 
 
 
  
1. DE=Expressed emotion 
2. DE=Catharsis 
3. DE=Self disclosure 
4. DE=Emotional content 
5. DE=Narrative therapy 
6. KW=Pennebaker  
7. KW=(emotive or affective or therapeutic or express* or disclos*) 
WITHIN2 writ* 
8. KW=emotional (disclos* or express*)  
9. KW=written emotional (disclos* or express*) 
10. KW=emotional expression WITHIN2 writing  
11. KW=emotional disclosure WITHIN2 writing 
12. KW=(stressful life events or critical life events) WITHIN2 writing 
13. or/1-12 
14. KW=health.tw 
15. 13 and 14 
16. limit 15 to  2007-2009 
 
1. Writing/ 
2. Self disclosure/ 
3. pennebaker.tw 
4. ((emotive or affective or therapeutic or express$ or disclos$) 
adj2 writ$).tw 
5. (emotional adj (express$ or disclos$)).tw 
6. (written emotional adj (express$ or disclos$)).tw 
7. (emotional disclosure adj2 writing).tw 
8. (emotional expression adj2 writing).tw 
9. ((stressful life events or critical life events) adj2 writing).tw 
10. or/1-9 
11. health.tw 
12. 13 and 14 
13. limit 12 to yr=”2007-2009” 
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Cinahl (now EBSCO Host) (boolean/phrase search mode) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PsychARTICLES (now CSA) 
 
 
 
 
 
 
 
 
 
 
 
  
1. MM Writing 
2. MM Self Disclosure 
3. TX emotive writ* 
4. TX affective writ* 
5. TX therapeutic writ* 
6. TX express* N2 writ* 
7. TX disclos* N2 writ* 
8. TX emotional express* 
9. TX emotional disclos* 
10. TX written emotional express*  
11. TX written emotional disclos* 
12. TX emotional expression W2 writing 
13. TX emotional disclosure W2 writing 
14. TX stressful life events and TX writing 
15. TX critical life events and TX writing 
16. or/1-8 
17. TX health 
18. 9 and 10 
19. limit 18 to January 2008–May 2009 
 
1. KW=Pennebaker  
2. KW=Catharsis 
3. KW=(emotive or affective or therapeutic or express* or disclos*) 
WITHIN2 writ* 
4. KW=emotional (disclos* or express*)  
5. KW=written emotional (disclos* or express*) 
6. KW=emotional expression WITHIN2 writing  
7. KW=emotional disclosure WITHIN2 writing 
8. KW=(stressful life events or critical life events) WITHIN2 writing 
9. or/1-12 
10. KW=health 
11. 9 and 10 
12. limit 11 to 2007–2009 
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CCRCT (clinical trials only, 2009 Issue 3) (‘search this term only’ for Index terms) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SCI, SSCI, and Conference Proceedings Citation Index- Science 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
1. Narration/ 
2. Writing/ 
3. Expressed emotion/ 
4. Disclosure/ 
5. ((emotive or affective or therapeutic or express* or disclos*) 
NEAR/2 writ*):ti,ab,kw, from 2007 to 2009 in clinical trials 
6. (emotional NEXT (express* or disclos*)):ti,ab,kw, from 2007 to 
2009 in clinical trials 
7. (“written emotional” NEXT (express* or disclos*)):ti,ab,kw, from 
2007 to 2009 in clinical trials 
8.  (“emotional disclosure” NEAR/2 writing):ti,ab,kw, from 2007 to 
2009 in clinical trials 
9. (“emotional expression” NEAR/2 writing):ti,ab,kw, from 2007 to 
2009 in clinical trials 
10.  (“stressful life events” or “critical life events”) NEAR/2 
writing:ti,ab,kw, from 2007 to 2009 in clinical trials 
11. or/1-10 
12. limit 11 to 2007–2009 
 
1. TS=(Pennebaker) 
2. TS=((emotive or affective or therapeutic or express* or disclos*) 
SAME writ*) 
3. TS=(("stressful life events" or "critical life events") SAME 
writing) 
4. TS=(emotional SAME (express* or disclos*)) 
5. TS=("written emotional" SAME (express* or disclos*)) 
6. TS=("emotional disclosure" SAME writing) 
7. TS=("emotional expression" SAME writing) 
8. or/1-7 
9. TS=Health 
10. 8 and 9 
11. limit 10 to  2007–2009 
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Francis, Eric, and Proceedings First, and Papers First 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sociological Abstracts  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conference Papers Index 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
1. kw: Pennebaker  
2. kw: emotive w writing 
3. kw: affective w writing  
4. kw: therapeutic w writing  
5. kw: disclos* n writ*  
6. kw: express* n writ*  
7. kw: emotional w express*  
8. kw: emotional w disclos*  
9. kw: written w emotional w express*  
10. kw: written w emotional w disclos*  
11. kw: emotional w disclosure n1 writing  
12. kw: emotional w expression n1 writing  
13. kw: stressful w life w events n1 writing 
14. kw: critical w life w events n1 writing or  
15. or/1-14 
16. limit 15 to 2007-2009 
 
12. DE=Emotional expression 
13. DE=Disclosure (individuals)  
14. DE=Self disclosure  
15. KW=Pennebaker  
16. KW=(emotive or affective or therapeutic or express* or 
disclos*) WITHIN2 writ* 
17. KW=emotional (disclos* or express*)  
18. KW=written emotional (disclos* or express*) 
19. KW=emotional expression WITHIN2 writing  
20. KW=emotional disclosure WITHIN2 writing 
21. KW=(stressful life events or critical life events) WITHIN2 
writing 
22. or/1-10 
23. limit 11 to 2007-2009 
 
1. KW=Pennebaker  
2. KW=(emotive or affective or therapeutic or express* or 
disclos*) WITHIN2 writ* 
3. KW=emotional (disclos* or express*)  
4. KW=written emotional (disclos* or express*) 
5. KW=emotional expression WITHIN2 writing  
6. KW=emotional disclosure WITHIN2 writing 
7. KW=(stressful life events or critical life events) WITHIN2 
writing 
8. or/1-7 
9. limit 8 to 2007-2009 
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Citation search 
Limited to 2007-2009. 
 
ProQuest (limited to Interdisciplinary dissertations and theses/index terms and key 
words) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hand Searching (electronically) – cross checked and removed duplicates from 
original search initially (except Google as original results not available in detail but 
did exclude known duplicates of original search –can’t guarantee all duplicates 
removed). 
 
The British Library Integrated Catalogue (catalogue subset search/document supply 
(all) (any word/not exact phrases)  
 
 
 
 
 
 
 
 
Index to Theses (standard search/any field). Individual searches for (unable to 
combine using OR?): 
1. Pennebaker 
2. (emotive or affective or therapeutic or express* or disclos*) w/2 writ* 
3. emotional w/1 (express* or disclos*)  
4. “written emotional” w/1 (express* or disclos*) 
5. “emotional expression” w/2 writing  
6. “emotional disclosure” w/2 writing 
7. (“stressful life events” or “critical life events”) w/2 writing 
 
NDLTD (all subject areas/complete document/exact phrases) 
 
 
 
 
 
 
 
 
1. IF(Pennebaker) 
2. IF(emotive or affective or therapeutic or express* 
or disclos* w/2 writ*) 
3. IF(emotional w/1 express* or disclos*)  
4. IF(written emotional w/1 express* or disclos*) 
5. IF(emotional expression w/2 writing)  
6. IF(emotional disclosure w/2 writing) 
7. IF(“stressful life events” or “critical life events” w/2 
writing) 
8. or/1-7 
9. PDN(>31/12/2007) and PDN(<31/5/2009) 
10. 8 and 9 
 
1. writ? disclos? 
2. express? writ? 
3. emotional? disclos? 
4. or/1-3 
5. limit 4 to 2007-2009 
 
1. “emotional disclosure” 
2. “expressive writing” 
3. “written disclosure” 
4. or/1-3 
5. limit 4 to 2007-2009 
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Google 
The first 100 references of each individual search for the terms ‘emotional 
disclosure’, ‘expressive writing’ and ‘written disclosure’ (all exact phrases and latter 
two searched within results for ‘health’ as the links retrieved initially were not 
generally related to health). Limited to previous 24 months (i.e. May 2008 to May 
2009 –small gap as last search undertaken Jan 2008). 
 
HSRproj 
 
 
 
 
 
 
 
 
 
 
 
 
MRC Research Register (full text searched for text words) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NIHR portfolio (research summary field) (exact phrases). Individual searches for: 
1. emotive writing 
2. affective writing 
3. therapeutic writing 
4. expressive writing 
5. disclosive writing 
6. emotional disclosure 
7. emotional expression 
8. written emotional disclosure 
9. written emotional expression 
10. emotional expression in writing 
11. emotional disclosure in writing 
12. stressful life events in writing 
13. critical life events in writing 
 
No date restriction function (and no truncation, proximity or index terms available) –
NRR database terminated in 2007 now NIHR (UKCRN) portfolio database (some 
existing data not fully updated yet and trials added in last 30 days not included in this 
search –thus take search as undertaken Start of May 2009). 
 
1. “Truth disclosure” [mh] 
2. Writing [mh] 
3. Emotions [mh] 
4. personal log/diary [kw] 
5. “emotional disclosure” [kw] 
6. “expressive writing” [kw] 
7. “written disclosure” [kw] 
8. or/1-7 
9. limit 8 to 2007-2009 
 
1. Writing (Mesh Term) 
2. Evaluation w/1 studies  (Mesh Term) 
3. Clinical w/1 trials  (Mesh Term) 
4. Stress  (Mesh Term) 
5. Stress w/1 psychological  (Mesh Term) 
6. emotion* w/1 disclos*   
7. express* w/2 writ* 
8. writ* w/2 disclos* 
9. or/1-8 
10. limit 9 to 01 December 2007-31 May 2009 
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mRCT (all active registers searched). Individual searches for: 
20. Pennebaker 
21. “affective writing” 
22. “emotive writing” 
23. “therapeutic writing” 
24. “expressive writing” 
25. “disclosive writing” 
26. writing therap% 
27. written expression 
28. written disclosure 
29. disclos% in writing 
30. express% in writing 
31. written emotional expression 
32. written emotional disclosure 
33. “emotional express%” 
34. “emotional disclosure in writing” 
35. “emotional expression in writing” 
36. “stressful life events and writing” 
37. “critical life events and writing” 
 
No date restriction function 
 
CRISP. Individual searches for: 
5. PERSONAL LOG/DIARY (MeSH term) 
6. emotional & disclos% 
7. express% and writ% 
8. writ% & disclos% 
 
No date restriction function –each restricted to fiscal years 2008-2009 (year research 
funding awarded) 
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Appendix C: Identified but unobtainable studies 
 
Potentially eligible but unobtainable conference proceedings 
 
Arden-Close, Gidron, Y., Moss-Morris, R. & Bayne, L. Effects of guided written 
disclosure on wellbeing in ovarian cancer patients and their partners. Division of 
Health Psychology and European Health Psychology Society (abstract) 2008. 
 
Gidron, Y., Duncan, E., Jenkins, E. & Arden-Close. Effects of a written guided 
disclosure protocol on various health outcomes in four studies (inc. effect on 
infectious symptoms): Rational & Evidence. International Congress of Behavioural 
Medicine (abstract) 2004. 
 
Ironson, G., Leserman, J, O’Clerigh, C., Schniederman, N. Patient evaluations 
including self-reported symptom burden in a randomised placebo controlled 
emotional disclosure intervention in HIV. International Congress of Behavioural 
Medicine (abstract) 2006. 
 
Jessen, I.B., Johansen, M.B., Christensen, S., Zachariae, R., Jensen, A.B., 
Valdimarsdottir, H., Bovjerg, D, Zakowski, S.  Disclosure of negative and positive 
emotions and changes in mood following expressive writing intervention (EWI) in a 
group of breast cancer patients. International Congress of Behavioural Medicine 
(abstract) 2006. 
 
Johansen, M.B., Zachariae, R., Christensen, S., Jessen, I.B., Jensen, A.B., 
Valdimarsdottir, H., Bovjerg, D, Zakowski, S.  Expressive writing intervention, 
depression, and health related quality of life of breast cancer patients –results from a 
pilot study. International Congress of Behavioural Medicine (abstract) 2006. 
 
Dissertations 
 
Unobtainable 
Adams, J.H. (2001). Effects of written disclosure and problem solving in women with 
breast cancer. University of Houston, MA. 
 
Anderson, S.S. (2008). The effect of written emotional expression on depression 
following mild traumatic brain injury : a pilot study. Drexel University, PhD. 
 
Balderson, B.H.K. (2000). The effects of written disclosure on physical and mental 
health in individuals with asthma. Oklahoma State University, PhD. 
 
Davidson, K. (2003). The effect of emotional disclosure on symptom reporting in 
repressive coping style. Ohio State University, Hons. 
 
Horgan, M.G. (2004). The effects of written emotional disclosure on disease activity 
in patients with psoriasis. University of Auckland, MSc. 
 
Khin, N.R. (1996). The influence of thought suppression, writing and emotional 
disclosure on headache and migraine frequency, duration and severity. University of 
Auckland, MA. 
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Lynch, T.J. (2004). The effects of a modified written disclosure protocol on individual 
bone marrow transplant recipients: psychological and behavioral functioning. 
Eastern Michigan University, MS. 
 
Macklem, D.J. (2008). Exploration of emotion regulation styles as potential 
moderators of emotional disclosure in patients with rheumatoid arthritis: Testing a 
model of emotional expression. Wayne State University, PhD.  
 
Metzger, A. (1991. A comparison of verbal and written expression in early 
Alzheimer's disease. University of Cincinnati, MA. 
 
Stout, R.A. (2008). An analysis of writing content in a web-based guided writing 
intervention for migraine headaches. Wayne State University, PhD.   
 
McLaughlin, M.S. (2000). The impact of written disclosure on hypertension. 
Oklahoma State University, MSc. 
 
Wilson, K. Effect of emotional disclosure on cardiac rehabilitation. Ohio State 
University, MSc thesis, ongoing research (2002). 
 
Hughes, K.N. (2006). Expressive writing and breast cancer: outcomes and linguistic 
analyses. Utah State University, PhD.  
 
Marston, C.B. (2003). Written emotional expression, and its relation to psychological 
and physical health variables among people with HIV disease. Alliant International 
University, PhD.  
 
McElligott, M.D. (2006). Expressive writing as an intervention for adolescents with 
sickle cell disease. Virginia Consortium for Professional Psychology –Old Dominion 
University, PhD.  
 
McKenna, M.H. (1997). Symptom as a story teller: migraine headaches and journal 
writing. Pacifica Graduate Institute, PhD. 
 
Siegel, K.M. (2003). The effects of emotional disclosure on the physical symptoms, 
healthcare utilization, and psychosocial adjustment in patients with irritable bowel 
syndrome. Alliant International University -California School of Professional 
Psychology, San Diego, PhD.  
 
Stark, H.G. (2009). Expressive writing as an adjunct to multidisciplinary pain 
treatment in chronic pain patients. Alliant International University, PhD. 
 
Obtainable and eligible yet excluded 
Averill, A. J. (2007). Emotional disclosure in patients with amyotrophic lateral 
sclerosis: A randomized, controlled trial. University of Kentucky, PhD.  
 
Bodor, N. Z. (2002). The health effects of emotional disclosure for individuals with 
type 1 diabetes. The University of Texas at Austin, PhD.  
 
Craft, M. (2006) Expressive writing in newly diagnosed breast cancer patients. 
Texas Woman's University, PhD.  
 
Gadler, D. (2005). The effects of written emotional expression on health-related 
quality of life and cognitive processing in early-stage breast cancer patients: an 
exploratory study. Alliant International University, PhD.  
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Possemato, K. A. 2007 An Internet-based expressive writing intervention for kidney 
transplant recipients Drexel University, Ph.D.  
 
Taylor, E. (2001). Improving the perceived psychological well-being of seniors with 
Type 2 diabetes through participation in two innovative programs. California School 
of Professional Psychology - Fresno, Psy.D.  
 
Woods, K. (2010). The effects of written and verbal emotional expression on cancer 
patients’ health. Indiana University of Pennsylvania. Psy.D. 
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Appendix D: Screening decision check tables 
 
Original search: Spotcheck of references for which no clear decision could be made 
 
Study Search Type (article type) Obtained 
(Title or 
abstract?) 
Reviewer 
1 
(I=include/
obtain 
further info 
E=exclude) 
 Reviewer 
2 
(I=include/
obtain 
further info 
E=exclude) 
 Agreement 
A=agreed 
D=disagreed 
 
Consensus  
(if initially D) 
Anonymous 
(1999) 
Endnote (published article). Title E News article unlikely 
writing intervention trial. 
E News article unlikely 
writing intervention trial. 
 
A  
Agee et al 
(2003) 
Google (conference 
proceeding –Association 
for Behavioural and 
Cognitive Therapies). 
Title E No indication physically 
ill sample. 
E No indication physically 
ill sample.  
A  
Agee et al 
(2006)  
Google (conference 
proceeding – association 
for the Advancement of 
Behavior Therapy). 
Title E No indication physically 
ill sample and unlikely 
experimental design.  
E No indication physically 
ill sample.  
A  
Allen, RK 
(1993) 
Google (published article). Title E No indication physically 
ill sample or 
experimental study. 
E No indication physically 
ill sample or 
experimental study. 
A  
Anderson et al 
(2006) 
Endnote (conference 
proceeding). 
Title E Theoretical article –not 
an intervention study. 
E Theoretical article –not 
an intervention study. 
A  
Antoni, MH 
(1995) 
Endnote (APS conference 
proceeding). 
Title E Nothing in title to 
indicate sample 
physically ill.  
E Unlikely sample 
physically ill. 
A  
Baker & 
Guttfreund 
(1993) 
Endnote (published article). Abstract E Unlikely sample 
physically ill if not 
mentioned in abstract. 
E Unlikely sample 
physically ill if not 
mentioned in abstract. 
A  
Bolton, et al 
(2000) 
Endnote (published article). Title E More likely literature 
review as 2 pages and 
title doesn’t suggest 
intervention study. 
E Not likely intervention 
study. 
A   
Bower, et al Endnote (published paper). Title E Bereavement – unlikely E Bereavement – unlikely A  
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(2003) sample physically ill. sample physically ill. 
Burshteyn, D 
(2006) 
Hand searching (APS 2006 
conference poster). 
Abstract E No indication physically 
ill sample from abstract 
so unlikely. 
E No indication physically 
ill sample from abstract 
so unlikely. 
A  
Burt, CDB 
(1994) 
Endnote (published article). Abstract E Anxious/stressed 
sample –unlikely 
physically ill if not 
mentioned in abstract. 
E Unlikely sample 
physically ill if not 
mentioned in abstract. 
A  
Caplan et al 
(2005) 
Endnote (published article). 
 
Abstract E 
 
Loss in later life –
sample unlikely 
physically ill if not 
mentioned in abstract. 
E 
 
Loss in later life –
sample unlikely 
physically ill if not 
mentioned in abstract. 
A 
 
 
Carey, L (2005) 
 
Endnote (published article). 
 
Abstract 
 
E 
 
Not an experimental 
design. 
E 
 
Not an experimental 
design. 
A 
 
 
Danoff-Burg et 
al (2001) 
 
Google (APA conference 
proceeding). 
 
Title 
 
E 
 
No indication writing 
intervention and benefit 
finding.  
E 
 
No indication writing 
intervention. 
 
A 
 
 
da Vicente et al 
(2004) 
 
Google (published article). 
 
Abstract E 
 
Homeless people –not 
physically ill. 
 
E 
 
Homeless people –not 
physically ill. 
 
A 
 
 
Davison & 
Pennebaker 
(1992) 
Google (published article). 
 
Title 
 
E 
 
No indication physically 
ill sample. 
 
E 
 
No indication physically 
ill sample. 
 
A 
 
 
Dellasega, CA 
(2001) 
Endnote (published article). 
 
Abstract 
 
E 
 
Unlikely sample 
physically ill if not 
mentioned in abstract. 
E 
 
Unlikely sample 
physically ill if not 
mentioned in abstract. 
A 
 
 
Dickerhoof  
(2004) 
 
Hand searching (APA 
conference proceeding). 
 
Title 
 
E 
 
No indication physically 
ill. 
 
E 
 
No indication physically 
ill. 
A 
 
 
Donnelly & 
Murray (1991) 
Endnote (published article). 
 
Title E 
 
Unlikely intervention 
trial or physically ill. 
E 
 
Unlikely intervention 
trial or physically ill. 
A 
 
 
Esterling et al 
(1995) 
 
Google (APS conference 
proceeding). 
 
Title 
 
I 
 
Latent herpes virus 
infection –could 
possibly be considered 
a physical condition 
(i.e. is a chronic 
infection that flares up 
occasionally). 
E 
 
Not a physically ill 
sample. 
 
D 
 
E 
Possibly 
chronically 
physically ill 
sample but 
title does not 
suggest writing 
478 
 
 or 
experimental 
design, and is 
conference 
proceeding 
from 1995. 
Likely study 
not published 
as not picked 
up by search. 
Not worth 
attempting to 
find. 
Evers et al 
(1999) 
Endnote (published article). 
 
Title 
 
I 
 
Although not explicit 
from title likely 
experimental study with 
health outcomes. 
I 
 
May meet criteria. 
 
A 
 
E 
Got 
conference 
abstract - not 
an intervention 
in which 
participants 
write (receive 
written 
information) 
Francis & 
Pennebaker 
(1992) 
Google (published article). 
 
Title 
 
E 
 
Illness prevention -no 
indication physically ill 
sample. 
E 
 
Illness prevention -no 
indication physically ill 
sample. 
A 
 
 
Frattaroli, J 
(2004) 
Hand searching (APA 
conference proceeding). 
Title 
 
E 
 
No indication physically 
ill. 
E 
 
No indication physically 
ill. 
A 
 
 
Gallagher & 
MacLachlan 
(2002) 
Endnote (published article) 
 
Abstract 
 
I 
 
Include for now –lower 
limb amputees 
physically ill?  
 
E 
 
Not an experimental 
design? 
 
D 
 
I 
Not clear 
obtain further 
information  
Gidron et al 
(2002) 
 
Endnote (published paper). 
 
Abstract 
 
E 
 
Frequent clinic 
attenders –don’t have a 
physical condition?  
 
I 
 
Physically ill sample – 
may meet criteria. 
 
D 
 
I 
Include for 
now as could 
have somatic 
illness 
Gidron et al 
(2004) 
Hand searching (ICBM 
2004 conference 
Abstract 
 
I 
 
Refers to a study of 
written guided 
I 
 
Refers to a study of 
written guided 
A 
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 proceeding). 
 
disclosure on infectious 
symptoms –physically 
ill sample? Also 
experimental design / 
writing and talking? 
disclosure on infectious 
symptoms –physically 
ill sample? 
 
Greenberg et al 
(1996) 
 
Pennebaker ref (published 
article). 
 
Title 
 
E 
 
No indication physically 
ill sample from title – 
unlikely. 
E 
 
No indication physically 
ill sample from title – 
unlikely. 
A 
 
 
Greenberg & 
Stone (1990) 
 
Endnote (published article). 
 
Title 
 
E 
 
No indication from title 
sample physically ill –
esp. given date.  
E 
 
No indication from title 
sample physically ill. 
A 
 
 
Hannay & Gillie 
(1999) 
Hand searching (published 
article). 
Title 
 
I 
 
May meet criteria. 
 
I 
 
May meet criteria. 
 
A 
 
 
Harvey & 
Farrrell (2003) 
Endnote (published article).  
 
Title 
 
I 
 
Poor sleepers - 
counting this as a 
physical condition for 
now. 
I 
 
Poor sleepers -counting 
this as a physical 
condition for now. 
 
A 
 
 
Heffner et al 
(2006) 
 
Hand searching (APS 
conference poster). 
 
Abstract 
 
E 
 
Older adults -unlikely 
sample physically ill if 
not mentioned in 
abstract.  
E 
 
Unlikely sample 
physically ill if not 
mentioned in abstract.  
 
A 
 
 
Hockemeyer & 
Smith (2002) 
Endnote (published article). 
 
Abstract 
 
I 
 
For now – may meet 
criteria. 
I 
 
For now – may meet 
criteria. 
A 
 
 
Horowitz, S 
(2000) 
 
Endnote (published article). 
 
Title 
 
E 
 
No indication writing 
intervention trial or 
sample physically ill 
from title. 
E 
 
No indication writing 
intervention trial or 
sample physically ill 
from title. 
A 
 
 
Junghaenel et 
al (2008) 
Hand searching (published 
article). 
Abstract 
 
I 
 
May meet criteria. 
 
I 
 
May meet criteria. 
 
A 
 
 
Kalb, C (1999) 
 
Endnote (published article). 
 
Title 
 
E 
 
Likely literature 
overview rather than 
intervention trial and 
unlikely sample is 
physically ill. 
E 
 
Likely literature 
overview rather than 
intervention trial and 
unlikely sample is 
physically ill. 
A 
 
 
Kellogg, RT 
(2006) 
 
Hand searching (APS 2006 
conference poster). 
 
Abstract 
 
E 
 
No indication physically 
ill sample from abstract 
so unlikely. 
E 
 
No indication physically 
ill sample from abstract 
so unlikely. 
A 
 
 
Klapow et al Endnote (published article). Title E Physical symptoms not I Older primary care A E 
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(2001) 
 
   used as selection 
criteria –included both 
healthy and with 
somatic 
symptoms…but don’t 
know whether this 
means they had 
physical conditions just 
assuming this is likely 
given their age? 
 patients. 
 
 Sample not 
physically ill –
whole sample 
required to be 
defined by 
illness –if 
some healthy 
people 
included do 
not include. 
Kraft et al 
(2008) 
Hand searching (published 
article). 
Abstract 
 
I 
 
May meet criteria. 
 
I 
 
May meet criteria. 
 
A 
 
 
Kroner-Herwig 
et al (2004) 
 
Endnote (published article). 
 
Abstract 
 
E 
 
Unlikely sample 
physically ill if not 
mentioned in abstract. 
E 
 
Unlikely sample 
physically ill if not 
mentioned in abstract. 
A 
 
 
Kroner-Herwig 
et al (2004) 
Translated title/hand 
searching (published 
article). 
Title 
 
E 
 
Same as reference 
below -unlikely sample 
physically ill.  
E 
 
Unlikely sample 
physically ill.  
A 
 
 
L’Abate et al (in 
press) 
Hand searching (article in 
press). 
 
Title 
 
E 
 
Unlikely physically ill 
participants and 
experimental design. 
E 
 
Unlikely physically ill 
participants and 
experimental design. 
A 
 
 
Laccetti, M 
(2007) 
Endnote (published article). 
 
Abstract  
 
E 
 
Correlational study –not 
experimental design. 
E 
 
Correlational study –not 
experimental design. 
A 
 
 
Lammerts van 
Bueren, N 
(2007) 
 
Endnote (published article). 
 
Abstract 
 
E 
 
Patients with anxiety 
disorder –unlikely 
physically ill if not 
mentioned in abstract. 
E 
 
Patients with anxiety 
disorder –unlikely 
physically ill if not 
mentioned in abstract. 
A 
 
 
Lanceley, A  
(1995) 
 
Endnote (conference 
proceeding).   
 
Title 
 
E 
 
Unlikely a writing 
intervention –disclosure 
between people. 
E 
 
Unlikely a writing 
intervention. 
 
A 
 
 
Landhuis, E 
(2004) 
 
Hand searching (ICBM 
2004 conference 
proceeding). 
 
Abstract 
 
E 
 
No indication of sample 
used – unlikely 
physically ill if not 
mentioned in abstract. 
E 
 
No indication of sample 
used – unlikely 
physically ill if not 
mentioned in abstract. 
A 
 
 
Lowe et al 
(2003) 
Google (published article). 
 
Title 
 
E 
 
No indication physically 
ill sample. 
E 
 
No indication physically 
ill sample. 
A 
 
 
Low et al (2006) Endnote (published article). Abstract I 
 
May meet criteria. I May meet criteria. A  
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Lumley et al 
(1999) 
 
Hand searching (APS 
conference proceeding). 
 
Abstract 
 
E 
 
College students with 
high physical 
symptoms –not 
physical condition. 
E 
 
College students with 
high physical 
symptoms –not 
physical condition. 
A 
 
 
Lumley & 
Provenzano 
(2003) 
Endnote (published article). 
 
Abstract 
 
E 
 
College students with 
physical symptoms –
not physical condition. 
E 
 
College students with 
physical symptoms –
not physical condition. 
A 
 
 
MacDuff & West 
(2002) 
 
Google (published article). 
 
Title 
 
E 
 
No indication physically 
ill sample or 
experimental study. 
E 
 
No indication physically 
ill sample or 
experimental study. 
A 
 
 
Mackenzie et al 
(2007) 
 
Pennebaker ref (published 
article). 
 
Title 
 
E 
 
Family caregivers of 
older adults –not 
physically ill. 
E 
 
Family caregivers of 
older adults –not 
physically ill. 
A 
 
 
Manier & 
Olivares (2005) 
 
Pennebaker ref (published 
article). 
 
Title 
 
E 
 
No indication physically 
ill sample from title – 
unlikely. 
E 
 
No indication physically 
ill sample from title – 
unlikely. 
A 
 
 
Marston, CB 
(2004) 
Hand searching (APA 
conference proceeding). 
Title 
 
E 
 
No indication physically 
ill. 
E 
 
No indication physically 
ill. 
A 
 
 
Martinez-
Sanchez  
 
Translated title/hand 
searching (published 
article). 
Title 
 
E 
 
No indication physically 
ill or writing 
intervention. 
 
E 
 
No indication physically 
ill or writing 
intervention. 
A 
 
 
Mastel-Smith 
(2004) 
 
Endnote (published 
article?). 
Abstract 
 
E 
 
People over 60 years –
unlikely sample 
physically ill if not 
mentioned in abstract. 
E 
 
People over 60 years –
unlikely sample 
physically ill if not 
mentioned in abstract. 
A 
 
 
Mastel-Smith et 
al (2007) 
 
Endnote (published 
article?). 
 
Abstract 
 
E 
 
People over 60 years –
unlikely sample 
physically ill if not 
mentioned in abstract. 
E 
 
People over 60 years –
unlikely sample 
physically ill if not 
mentioned in abstract. 
A 
 
 
McGihon, NN 
(1996) 
 
Endnote (published article). 
 
Abstract 
 
E 
 
Unlikely sample 
physically ill if not 
mentioned in abstract. 
E 
 
Unlikely sample 
physically ill if not 
mentioned in abstract. 
A 
 
 
Mosher et al 
(2004) 
 
Google (APA conference 
proceeding). 
Title 
 
E 
 
No indication physically 
ill sample, and although 
1 author has done 
WED research with 
cancer patients unlikely 
this is a separate trial. 
E 
 
No indication physically 
ill sample. 
A 
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Murray et al 
(1989) 
 
Endnote (published article). 
 
Title 
 
E 
 
No indication physically 
ill sample from title esp. 
given the date- unlikely. 
E 
 
No indication physically 
ill sample from title – 
unlikely. 
A 
 
 
Nazarian et al 
(2006) 
 
Endnote (APS conference 
proceeding). 
 
Abstract 
 
E 
 
Community adults –
unlikely physically ill if 
not mentioned in 
abstract. 
E 
 
Community adults –
unlikely physically ill if 
not mentioned in 
abstract. 
A 
 
 
O’Cleirigh, C 
(2000) 
 
Endnote (published article). 
 
Abstract 
 
I 
 
Not possible to identify 
whether experimental 
trial or correlational 
study. 
I 
 
Not possible to identify 
whether experimental 
trial or correlational 
study. 
A  
O’Cleirigh et al 
(2002) 
 
Hand searching 
(conference proceeding). 
 
Title 
 
I 
 
Not possible to identify 
whether experimental 
trial or correlational 
study. 
I 
 
Not possible to identify 
whether experimental 
trial or correlational 
study. 
A 
 
 
O’Cleirigh et al 
(2008) 
 
Handsearch (published 
article). 
 
Abstract 
 
I 
 
Not possible to identify 
whether experimental 
trial or correlational 
study. 
I 
 
Not possible to identify 
whether experimental 
trial or correlational 
study. 
A 
 
 
O’Connor 
(2006) 
 
Google (conference 
proceeding). 
Title 
 
E 
 
No indication physically 
ill sample from title – 
unlikely. 
E 
 
No indication physically 
ill sample from title – 
unlikely. 
A 
 
 
O’Connor & 
Ashley (2007) 
 
Google (published article). 
 
Abstract 
 
E 
 
No indication of sample 
used – unlikely 
physically ill if not 
mentioned in abstract. 
E 
 
No indication of sample 
used – unlikely 
physically ill if not 
mentioned in abstract. 
A 
 
 
O’Heeron, RC 
(1992) 
Hand searching (APA 
conference proceeding). 
Title 
 
E 
 
No indication physically 
ill. 
E 
 
No indication physically 
ill. 
A 
 
 
Pace, BJ (2002) 
 
Endnote (thesis). 
 
Abstract 
 
E 
 
Smokers -unlikely 
physically ill if not 
mentioned in abstract. 
E 
 
Smokers –unlikely 
physically ill if not 
mentioned in abstract. 
A 
 
 
Palmer & Braud 
(2002) 
 
Pennebaker ref (published 
article). 
 
Title 
 
E 
 
No indication physically 
ill sample from title – 
unlikely. Unlikely writing 
intervention of 
experimental design. 
E 
 
No indication physically 
ill sample from title – 
unlikely. 
 
A 
 
 
Pennebaker, 
JW (1991) 
Google (published article). 
 
Title 
 
E 
 
No indication physically 
ill sample. 
E 
 
No indication physically 
ill sample. 
A 
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Pennebaker, 
JW (1998) 
Endnote (published article). 
 
Title 
 
E 
 
2 pages –more likely 
literature overview. 
E 
 
Unlikely writing 
intervention trial. 
A 
 
 
Pennebaker, 
JW (1999) 
 
Translated title/hand 
searching (published 
article). 
Title 
 
E 
 
No indication physically 
ill. 
E 
 
No indication physically 
ill. 
 
A 
 
 
Pennebaker, 
JW (2001) 
Google (published article). 
 
Title 
 
E 
 
No indication physically 
ill sample. 
E 
 
No indication physically 
ill sample. 
A 
 
 
Pennebaker & 
Campbell 
(2000) 
Google (published article). 
 
Title 
 
E 
 
No indication physically 
ill sample. 
E 
 
No indication physically 
ill sample. 
A 
 
 
Pizarro, J 
(2004) 
 
Endnote (published article). 
 
Abstract E 
 
Unlikely sample 
physically ill if not 
mentioned in abstract. 
E 
 
Unlikely sample 
physically ill if not 
mentioned in abstract. 
A 
 
 
Ritz et al (1995) 
 
Hand searching 
(conference proceeding). 
 
Title 
 
I 
 
Not possible to identify 
whether experimental 
trial or correlational 
study. 
I 
 
Not possible to identify 
whether experimental 
trial or correlational 
study. 
A 
 
E 
Got abstract –
not a writing 
intervention. 
Rivkin & 
Stanton (1998) 
 
Endnote (APS conference 
proceeding). 
 
Title 
 
E 
 
Nothing to indicate 
physically ill sample 
from title. 
E 
 
Unlikely physically ill 
sample. 
A 
 
 
Sangsue, J 
(1999) 
Translated title/ hand 
searching (thesis).  
Title 
 
E 
 
No indication physically 
ill. 
E 
 
No indication physically 
ill. 
A 
 
 
Schilte et al 
(2001) 
Endnote (published article). 
 
Abstract 
 
I 
 
May meet criteria. 
 
I 
 
May meet criteria. 
 
A 
 
 
Schoutrop et al  
(1999) 
 
Hand searching 
(conference proceeding). 
 
Abstract 
 
E 
 
Traumatised persons 
unlikely physically ill if 
not mentioned in 
abstract.  
E 
 
Traumatised people. 
 
A 
 
 
Schoutroup et 
al (2002) 
 
Hand searching (published 
article). 
 
Abstract 
 
E 
 
Unlikely sample 
physically ill if not 
mentioned in abstract. 
E 
 
Unlikely sample 
physically ill if not 
mentioned in abstract. 
A 
 
 
Schwartz & 
Kline (1994) 
 
Endnote (APA conference 
proceeding). 
 
Title 
 
E 
 
More likely a literature 
review than intervention 
trial. 
E 
 
More likely a literature 
review than an 
intervention trial. 
A 
 
 
Segal et al 
(1999) 
 
Pennebaker ref (published 
article). 
 
Title 
 
E 
 
Spousal loss among 
older adults –unlikely 
physically ill. 
E 
 
Spousal loss among 
older adults –unlikely 
physically ill. 
A 
 
 
Segal et al Pennebaker ref (published Title E Bereaved older adults – E Bereaved older adults – A  
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(2001) 
 
article).   unlikely physically ill.  unlikely physically ill.  
Sloan & Marx 
(2006) 
 
Google (published article). 
 
Abstract 
 
E 
 
Trauma related 
psychopathology –not 
physically ill. 
E 
 
Trauma related 
psychopathology –not 
physically ill. 
A 
 
 
Sloan et al 
(2002) 
Hand searching (published 
article). 
Title 
 
E 
 
Unlikely physically ill 
sample. 
E 
 
Unlikely physically ill 
sample. 
A 
 
 
Smith et al 
(2005) 
Endnote (published article). Abstract 
 
E 
 
Not an experimental 
design. 
E 
 
Realised not an 
experimental design. 
A 
 
 
Smyth & 
Nazarian (2006) 
Endnote (published article). 
 
Title 
 
I 
 
Title meets criteria.  
 
I 
 
Title meets criteria. 
 
A 
 
 
Smyth et al 
(2002) 
Endnote (published article). Abstract 
 
I 
 
May meet criteria. 
 
I 
 
May meet criteria. 
 
A 
 
 
Solano et al 
(2003) 
 
Endnote (published article). 
 
Abstract 
 
I 
 
Urology inpatients 
waiting to undergo 
papilloma resection – 
physically ill? 
I 
 
Urology inpatients 
waiting to undergo 
papilloma resection – 
physically ill? 
A 
 
 
Stanton, AL 
(2005) 
 
Google (APS 2005 
conference poster). 
 
Abstract 
 
I 
 
No indication of sample 
used – but author 
known to conduct WED 
studies with cancer 
patients. 
E 
 
No indication of sample 
used – unlikely 
physically ill if not 
mentioned in abstract. 
 
D 
 
E 
Unlikely 
physically ill if 
not mentioned 
in abstract. 
Stanton et al 
(1997) 
 
Hand searching 
(conference proceeding). 
 
Title 
 
I 
 
Not possible to identify 
whether experimental 
trial or correlational 
study. 
I 
 
Not possible to identify 
whether experimental 
trial or correlational 
study. 
A 
 
 
Stanton et al 
(1999) 
 
Had already (conference 
proceeding). 
Title 
 
I 
 
Possibly experimental 
intervention or 
correlational study.  
I 
 
Possibly experimental 
intervention or 
correlational study. 
A 
 
 
Stone et al 
(2000 
Endnote (published article). 
 
Abstract 
 
I 
 
May meet criteria. 
 
I 
 
May meet criteria. 
 
A 
 
 
Taylor, DN 
(1995) 
 
Hand searching (published 
paper). 
 
Title 
 
I 
 
Title indicates could 
meet criteria obtain 
further info. 
I 
 
Title indicates could 
meet criteria obtain 
further info. 
A 
 
 
Uhlmann et al 
(1995) 
 
Translated title/google 
(published article). 
 
Title 
 
E 
 
No indication physically 
ill and possibly verbal 
disclosure. 
E 
 
No indication physically 
ill and possibly verbal 
disclosure. 
 A 
 
Ullrich & Pennebaker ref (published Title E No indication physically E No indication physically A  
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Lutendorf 
(2002) 
article). 
 
  ill sample from title – 
unlikely. 
 ill sample from title – 
unlikely. 
 
Van 
Middendorp et 
al (2007) 
 
Endnote (published article). 
 
Abstract 
 
I 
 
May meet criteria. 
 
I 
 
May meet criteria. 
 
A 
 
 
Vance, T (1999) 
 
Endnote (published article). 
 
Title 
 
E 
 
More likely literature 
review –unlikely 
experimental study with 
physically ill sample. 
E 
 
More likely literature 
review –unlikely 
experimental study with 
physically ill sample. 
A 
 
 
Vedhara, K 
(2004) 
 
Hand searching (?). 
 
Title 
 
E 
 
No indication sample 
likely physically ill from 
title and even if it was 
unlikely to be a different 
trial to later psoriasis 
trial (2007) by same 
author. 
E 
 
Unlikely sample 
physically ill. 
 
A 
 
 
Wetherell, MA 
et al (2005) 
Endnote (published article). 
 
Abstract I 
 
May meet criteria. I 
 
May meet criteria. 
 
A 
 
 
Wolf, M (1999) 
 
Endnote (published article). 
 
Title 
 
E 
 
Nothing to indicate 
likely physically ill 
sample from title. 
E 
 
Nothing to indicate 
likely physically ill 
sample from title. 
A 
 
 
Woods et al 
(1999) 
 
Endnote (Annual Congress 
of the Oncology Nursing 
Society 1999 conference 
proceeding). 
Title 
 
E 
 
Title doesn’t suggest 
this is an intervention. 
 
E 
 
Title doesn’t suggest 
this is an intervention. 
 
A 
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Original search: Full papers obtained 
 
Study Search Type (article type) Obtained 
(Title or 
abstract?) 
Reviewer 
1 
(I=include/
obtain 
further info 
E=exclude) 
 Reviewer 
2 
(I=include/
obtain 
further info 
E=exclude) 
 Agreement 
A=agreed 
D=disagreed 
 
Consensus  
(if initially D) 
Broderick et al 
(2004) 
Endnote (published article). 
 
Full paper I Meets all criteria.  I Meets all criteria. A  
Broderick et al 
(2005) 
Endnote (published article). 
 
Full paper 
 
I 
 
Meets all criteria. I 
 
Meets all criteria. 
 
A 
 
 
Bruera et al 
(2008) 
 
Cited ref search alert post 
download to Endnote 
(published article). 
 
Full paper 
 
I 
 
Meets all criteria. 
 
I 
 
Meets all criteria. 
 
A 
 
E 
Decided at 
data extraction 
to impose at 
least 1 week 
post int. follow 
up restriction. 
Cameron, LD 
(1998) 
 
Hand searching (EHPS 
conference proceeding). 
 
Abstract 
(detailed) 
 
E 
 
Intervention is WED 
plus other aspects of 
self regulation. 
E 
 
Self regulation 
intervention. 
A 
 
 
Cepeda et al 
(in press) 
 
Ongoing Research 
Database –now completed 
(in press, published article 
obtained in search update). 
Full paper 
 
I 
 
Meets all criteria.  
 
I 
 
Meets all criteria.  
 
A 
 
 
Cohen et al (in 
preparation) 
Endnote (published article). 
 
Full paper 
 
I 
 
Meets all criteria. 
 
I 
 
Meets all criteria. 
 
A 
 
 
Creswell et al 
(2007) 
 
Endnote (published article). 
 
Full paper 
 
I 
 
Meets all criteria 
(length of writing 
sessions not reported 
but says same as 
Pennebaker & Beall). 
I 
 
Meets all criteria.  
 
A 
 
E 
Later realised 
secondary 
analysis for 
Stanton 2002 
paper. 
Danoff-Burg et 
al (2006) 
Endnote (published article). 
 
Full paper 
 
I 
 
Meets all criteria.  
 
I 
 
Meets all criteria.  
 
A 
 
 
DeMoor et al 
(2002) 
Endnote (published article). 
 
Full paper 
 
I 
 
Meets all criteria.  
 
I 
 
Meets all criteria.  
 
A 
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D’Souza et al 
(under review) 
 
Endnote (under review, 
published article obtained in 
search update). 
Full paper 
 
E 
 
Meets all criteria –but 
no psychological 
health/QoL outcome. 
E 
 
Meets all criteria –but 
no psychological 
health/QoL outcome. 
A 
 
 
Freyd et al 
(2005) 
 
Endnote (published article). 
 
Full paper 
 
I 
 
Meets all criteria.  
 
I 
 
Meets all criteria.  
 
A 
 
E 
Later decision  
to exclude as 
the 
comparison 
and results 
presented do 
not allow for 
isolating the 
effects of WED 
(i.e. 2 WED & 
2 CTL groups 
–different 
treatment 
within WED 
and control 
groups so 
cannot 
combine -but 
results 
presented for 
overall WED 
and control 
groups only) 
Gallagher & 
MacLachlan 
(2002) 
 
Endnote (published article). 
 
Full paper 
 
E 
 
Intended to be an 
experimental design 
but both groups 
emotionally disclosed 
so treated writing as 
one continuous 
variable. 
E 
 
Intended to be an 
experimental design 
but both groups 
emotionally disclosed 
so treated writing as 
one continuous 
variable. 
A 
 
 
Gidron et al 
(2002) 
 
Endnote (published paper). 
 
Full paper 
 
E 
 
Frequent clinic 
attenders with no 
known chronic physical 
illness –whole sample 
not defined by a 
E 
 
Whole sample not 
defined by a chronic 
physical condition. 
A 
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chronic physical 
condition. 
Gillis et al 
(2006) 
Endnote (published article). 
 
Full paper 
 
I 
 
Meets all criteria. 
 
I 
 
Meets all criteria. 
 
A 
 
 
Graham, JE 
(2004) 
 
Endnote (dissertation –later 
received draft article, 
obtained published paper in 
search update). 
Full paper 
 
E 
 
Don’t write for at least 3 
days –only 2 and 
directed letter 
format/anger 
expression component. 
E 
 
Don’t write for at least 3 
days –only 2 and 
directed letter 
format/anger 
expression component. 
A 
 
 
Hamilton-West 
& Quine (2007) 
Endnote (published article). 
 
Full paper 
 
I 
 
Meets all criteria. 
 
I 
 
Meets all criteria. 
 
A 
 
 
Hannay & Gillie 
(1999) 
 
Hand searching (published 
article). 
 
Full paper E 
 
Anxious depressed 
sample –no mention 
physically ill. 
E 
 
Anxious depressed 
sample –no mention 
physically ill. 
A 
 
 
Hartke et al 
(2007) 
 
Hand searching (published 
article). 
 
Full paper 
 
E 
 
No indication whole trial 
RCT –just initial phase 
that is barely described 
–paper describes the 
second phase and 
writing groups. 
E No indication whole trial 
RCT –just initial phase 
that is barely described 
–paper describes the 
second phase and 
writing groups. 
A 
 
 
Harris et al 
(2005) 
 
Endnote (published article). 
 
Full paper E 
 
Meets all criteria –but 
no psychological 
health/QoL outcome. 
E 
 
Meets all criteria –but 
no psychological 
health/QoL outcome. 
A 
 
 
Harvey & 
Farrell (2003) 
 
Endnote (published article). 
 
Full paper 
 
I 
 
Include for now – 
meets all criteria. 
 
I 
 
Include for now - meets 
all criteria. 
 
A 
 
E 
Later decision  
to exclude as 
unclear 
whether poor 
sleep is 
chronic 
physical  
condition –
may be acute 
(i.e. exam 
stress) so 
otherwise 
health sample 
(& no 
psychological 
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outcome). 
Hockemeyer & 
Smyth (2002) 
 
Endnote (published article). 
 
Full paper 
 
E 
 
Emotional disclosure 
writing included as part 
of CBT intervention.  
 
I 
 
Meets all criteria. 
 
D 
 
E 
Later decision  
to exclude as 
effect of WED 
cannot be 
isolated from 
relaxation/CBT 
intervention –
groups 
received 
different 
treatment 
other than 
WED 
Junghaenel et 
al (2008) 
Hand searching (published 
article). 
Full paper 
 
E 
 
Secondary analysis of 
a trial already received. 
E 
 
Secondary analysis of 
a trial already received. 
A 
 
 
Kraft et al 
(2008) 
Hand searching (published 
article). 
Full paper E 
 
Secondary analysis of 
a trial already received. 
E 
 
Secondary analysis of 
a trial already received. 
A 
 
 
Low et al 
(2006) 
Endnote (published article). 
 
Full paper 
 
E 
 
Secondary analysis of 
a trial already received. 
E 
 
Secondary analysis of 
a trial already received. 
A 
 
 
Mann, T (2001) 
 
Endnote (published article). 
 
Full paper 
 
E 
 
Writing about a positive 
future not disclosing 
emotions about a 
traumatic event. 
E 
 
Writing about a positive 
future not disclosing 
emotions about a 
traumatic event. 
A 
 
 
McGuire et al 
(2005) 
 
Endnote (published article). Full paper 
 
E 
 
High to moderately 
elevated blood 
pressure –not a chronic 
physical illness. 
E 
 
Not a chronic physical 
illness. 
A 
 
 
Norman et al 
(2004) 
Endnote (published article). 
 
Full paper 
 
I 
 
Meets all criteria. 
 
I 
 
Meets all criteria. 
 
A 
 
 
O’Cleirigh, C 
(2000) 
 
Endnote (published article). 
 
Full paper 
 
E 
 
Not an experimental 
design –2 different 
groups compared –
relationship between 
level of emotional 
disclosure and health 
status. 
E 
 
Not an experimental 
design –2 different 
groups compared –
relationship between 
level of emotional 
disclosure and health 
status. 
A 
 
 
O’Clerigh et al Hand searching Full paper E Not an experimental E Not an experimental A  
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(2002) 
 
(conference proceeding). 
 
  study of writing 
intervention –case 
control.  
 study of writing 
intervention –case 
control. 
 
O’Cleirigh et al 
(2008) 
 
Handsearch (published 
article). 
 
Full paper 
 
E 
 
Not an experimental 
design –2 different 
groups compared –
relationship between 
level of emotional 
disclosure and health 
status. 
E 
 
Not an experimental 
design –2 different 
groups compared –
relationship between 
level of emotional 
disclosure and health 
status. 
A 
 
 
Panagopoulou 
et al (in 
preparation) 
 
Hand searching (ICBM 
conference proceeding). 
 
Powerpoint 
presentatio
n –study 
not yet 
written up? 
I 
 
Meets all criteria –info 
limited author offered to 
provide more. 
 
E 
 
IVF is a chronic 
condition but not 
physical illness –
sample not physically 
ill. 
 
D 
 
E 
IVF is a 
chronic 
condition but 
not physical 
illness 
Petrie et al 
(2004) 
 
Endnote (published article). 
 
Full paper 
 
E 
 
Meets all criteria –but 
no psychological 
health/QoL outcome. 
E 
 
Meets all criteria –but 
no psychological 
health/QoL outcome. 
A 
 
 
Rivkin et al 
(2006) 
Endnote (published article). 
 
Full paper 
 
I 
 
Meets all criteria.  
 
I 
 
Meets all criteria.  
 
A 
 
 
Rosenberg et 
al (2002) 
Endnote (published article). 
 
Full paper 
 
I 
 
Meets all criteria. 
 
I 
 
Meets all criteria.  
 
A 
 
 
Schilte et al 
(2001) 
Endnote (published article). 
 
Full paper 
 
E 
 
Not a writing 
intervention –verbal 
disclosure in meetings 
with Dr and diary 
keeping in between. 
Frequent clinic 
attendees with 
somatisation symptoms 
not explained by 
organic disease and 
serious physical 
conditions excluded. 
E 
 
Not a writing 
intervention –verbal 
disclosure in meetings 
with Dr and diary 
keeping in between. 
Frequent clinic 
attendees with 
somatisation symptoms 
not explained by 
organic disease and 
serious physical 
conditions excluded. 
A 
 
 
Smyth et al 
(1999) 
 
Endnote (published article). 
 
Full paper 
 
E 
 
Meets all criteria –but 
no psychological 
health/QoL outcome. 
E 
 
Meets all criteria –but 
no psychological 
health/QoL outcome. 
A 
 
 
Smyth et al Endnote (published article). Full paper E Secondary analysis of E Secondary analysis of A  
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(2002)    a trial already received  a trial already received.  
Smyth & 
Nazarian 
(2006) 
 
Endnote (published article). 
 
Full paper 
 
E 
 
Not a RCT –case 
control (2 trauma 
writing and 2 neutral 
writing). 
E 
 
Not a RCT. 
 
A 
 
 
Solano et al 
(2003) 
 
Endnote (published article). 
 
Full paper 
 
E 
 
Urology patients 
waiting to undergo 
papilloma resection –
but exclusion criteria 
was total absence of 
any chronic disease 
that may influence post 
operative course. 
E 
 
Authors specifically 
chose to investigate the 
effect of writing on 
surgical course rather 
than chronic conditions. 
 
A 
 
 
Solano et al 
(2007)  
 
Endnote (published article). Full paper 
 
E 
 
Sample undergoing 
endoscopic operation 
TURP for benign 
prostatic hypertrophy –
not cancerous –not 
chronic physical illness.  
E 
 
Not a chronic physical 
illness. 
A 
 
 
Stanton et al 
(1997) 
 
Hand searching 
(conference proceeding). 
 
Full paper 
 
E 
 
Preliminary report of 
later published trial 
(Stanton et al). 
E 
 
Preliminary report of 
later published trial 
(Stanton et al). 
A 
 
 
Stanton et al 
(1999) 
 
Had already (conference 
proceeding). 
 
Neither 
 
E 
 
Author contacted for full 
paper and confirmed 
longitudinal design. 
E 
 
Author contacted for full 
paper and confirmed 
longitudinal design. 
A 
 
 
Stanton et al 
(2002) 
 
Endnote (published article). 
 
Full paper 
 
I 
 
Meets all criteria. I 
 
Meets all criteria. 
 
A 
 
 
Stone et al 
(2000 
Endnote (published article). 
 
Full paper 
 
E 
 
Secondary analysis of 
a trial already received. 
E 
 
Secondary analysis of 
a trial already received. 
A 
 
 
Taylor, DN 
(1995)  
Hand searching (published 
paper). 
Full paper 
 
E 
 
Not a writing 
intervention. 
E 
 
Not a writing 
intervention. 
A 
 
 
Taylor et al 
(2003) 
 
Endnote (published article). 
 
Full paper 
 
E 
 
Meets all criteria but 
NB 1/3 of participants 
aged 15 and above. 
I 
 
Meets all criteria. 
 
D 
 
I 
 
Van 
Middendorp et 
al (2007) 
Endnote (published article). 
 
Full paper 
 
E 
 
Verbal disclosure 
intervention. 
 
E 
 
Verbal disclosure 
intervention. 
 
A 
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Vedhara et al 
(2007) 
Endnote (published article). 
 
Full paper 
 
I 
 
Meets all criteria. I 
 
Meets all criteria.  
 
A 
 
 
Walker et al 
(1999) 
Endnote (published article). 
 
Full paper 
 
I 
 
Meets all criteria.  
 
I 
 
Meets all criteria.  
 
A 
 
 
Warner et al 
(2006) 
Endnote (published article). Full paper 
 
E 
 
Sample aged 12-17 –
not adults over 18. 
E 
 
Sample not adults over 
18. 
A 
 
 
Wetherell et al 
(2005) 
 
Endnote (published article). Full paper 
 
I 
 
Meets all criteria (some 
participants verbally 
disclosed but very few 
and only as could not 
write). 
I 
 
Meets all criteria. A 
 
 
Zakowski et al 
(2004) 
Endnote (published article). Full paper 
 
I 
 
Meets all criteria. 
 
I 
 
Meets all criteria. 
 
A 
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Search update: Spotcheck of references for which no clear decision could be made 
 
Study Search Type (article type) Obtained 
(Title or 
abstract?) 
Reviewer 
1 
(I=include/
obtain 
further info 
E=exclude) 
 Reviewer 
2 
(I=include/
obtain 
further info 
E=exclude) 
 Agreement 
A=agreed 
D=disagreed 
 
Consensus  
(if initially D) 
? Girl Talk 
 
Endnote (published article). 
 
Title 
 
E 
 
Title does not indicate 
this is a writing 
intervention with 
experimental design 
and health outcome 
assessed. 
E 
 
Title does not indicate 
this is a writing 
intervention with 
experimental design 
and health outcome 
assessed. 
A 
 
 
NAMI (2008) 
 
Endnote (published article). 
 
Title 
 
E 
 
Nothing in title to 
indicate sample 
physically ill. 
E 
 
Nothing in title to 
indicate sample 
physically ill. 
A 
 
 
Ames et al 
(2007) 
 
Endnote (published article). 
 
Title 
 
E 
 
Nothing in abstract to 
indicate sample 
physically ill. 
E 
 
Nothing in abstract to 
indicate sample 
physically ill. 
A 
 
 
Ames et al 
(2008) 
 
Endnote (published article). Abstract 
 
E 
 
Nothing in abstract to 
indicate sample 
physically ill. 
E 
 
Nothing in abstract to 
indicate sample 
physically ill. 
A 
 
 
Andersen et al 
(2007) 
 
Journal hand searching 
(published article). 
 
Abstract 
 
I 
 
May meet criteria –
can’t tell if writing 
intervention? 
 
E 
 
Not likely writing 
intervention.  
 
D 
 
E 
Not likely 
writing 
intervention  
Arden-Close 
et al (2008) 
 
Conference proceedings 
hand searching (DHP/EHPS 
conference abstract). 
Abstract 
 
I 
 
May meet criteria. 
 
E 
 
Couples write rather 
than one person. 
 
D 
 
I 
May meet 
criteria 
Austenfeld & 
Stanton 
(2008) 
Endnote (published article). 
 
Title E 
 
Not physically ill. 
 
E 
 
Not physically ill. 
 
A 
 
 
Baikie (2008) Endnote (published article). Title E Not physically ill. E Not physically ill. A  
Baker & 
Berenbaum 
(2008) 
Endnote (published article). Title 
 
E 
 
Not physically ill and 
not clear whether 
writing intervention. 
E 
 
Not physically ill. 
 
A 
 
 
Bantum & Endnote (published article). Abstract E Unlikely experimental E Unlikely experimental A  
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Owen (2009)    design or health 
outcome assessed. 
design or health 
outcome assessed. 
 
Barak et al 
(2008) 
 
Endnote (published article). 
 
Abstract 
 
E 
 
Review –and not 
physically ill / unlikely 
experimental design. 
E 
 
Review –and not 
physically ill / unlikely 
experimental design. 
A 
 
 
Barrowclough 
et al (2008) 
 
Endnote (published article). 
 
Abstract 
 
E 
 
Not physically ill, not 
writing intervention and 
not experimental 
design. 
E 
 
Not physically ill, not 
writing intervention and 
not experimental 
design. 
A 
 
 
Barton & 
Jackson 
(2008) 
Endnote (published article). 
 
Abstract 
 
E 
 
Not physically ill. 
 
E 
 
Not physically ill. A 
 
 
Basso &  
Peach(2008) 
Endnote (published article). 
 
Abstract 
 
E 
 
Not writing intervention 
or experimental design. 
E 
 
Not writing intervention 
or experimental design. 
A 
 
 
Bingley et al 
(2008) 
Endnote (published article). 
 
Abstract 
 
E 
 
Review –and not 
experimental design. 
E 
 
Review. 
 
A 
 
 
Blank & 
Adams-
Blodnieks 
(2007) 
Endnote (published article). 
 
Abstract 
 
E 
 
Not an experimental 
design and no health 
outcome assessed. 
E 
 
Not an experimental 
design and no health 
outcome assessed. 
A 
 
 
Brown et al 
(2010) 
 
Search Alert POST UPDATE 
(published article). 
 
Abstract 
 
I 
 
Not clear whether a 
RCT –get further 
information. 
I 
 
Not clear whether a 
RCT –get further 
information. 
A 
 
 
Brun, A (2008) 
 
Endnote (published article). 
 
Abstract 
 
E 
 
Nothing in the title to 
indicate physically ill, 
experimental design 
and no health outcome 
assessed. 
E 
 
Nothing in the title to 
indicate physically ill, 
experimental design 
and no health outcome 
assessed. 
A 
 
 
Bonanno et al 
(2007) 
 
Endnote (published article). 
 
Abstract 
 
E 
 
Not physically ill, 
experimental design or 
writing intervention. 
E 
 
Not physically ill, 
experimental design or 
writing intervention. 
A 
 
 
Butcher, H 
(2008) 
Endnote (published article). 
 
Abstract 
 
E 
 
Nothing in title to 
indicate physically ill or 
experimental design. 
E 
 
Nothing in title to 
indicate physically ill or 
experimental design. 
A 
 
 
Cameron & 
Jago (2008) 
Endnote (published article). Abstract 
 
E 
 
Review. 
 
E 
 
Review. 
 
A 
 
 
Carlson & 
Bultz (2008) 
Endnote (published article). 
 
Abstract 
 
E 
 
Review –and not 
physically ill or writing 
E 
 
Review. 
 
A 
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 intervention. 
Chung & 
Pennebaker 
(2008) 
Endnote (published article). 
 
Abstract 
 
E 
 
Not physically ill. 
 
E  
 
Not physically ill. 
 
A 
 
 
Cohen et al 
(2008) 
Endnote (published article). 
 
Abstract 
 
E 
 
Not physically ill. 
 
E  
 
Not physically ill. 
 
A 
 
 
Crogan at al 
(2008) 
Endnote (published article). 
 
Abstract 
 
E 
 
Not writing intervention. 
 
E 
 
Not writing intervention. 
 
A 
 
 
Cushen, N (?) 
 
Contacting authors re: 
potentially completed 
ongoing trial found in hand 
searching for update (i.e. 
now completed) (NRR 
document). 
Title 
 
E 
 
Unlikely experimental 
design. 
 
E 
 
Unlikely experimental 
design. 
 
A 
 
 
Dalton & 
Glenwick 
(2009) 
Endnote (published article). 
 
Abstract 
 
E 
 
Not physically ill. 
 
E Not physically ill. 
 
A 
 
 
Dean & 
Rotenberg 
(2008) 
Endnote (conference 
abstract?). 
 
Abstract 
 
E 
 
Unlikely physically ill if 
not mentioned in 
abstract. 
E 
 
Unlikely physically ill if 
not mentioned in 
abstract. 
A 
 
 
De Ridder et 
al (2008)  
 
Endnote (published article). 
 
Abstract 
 
E 
 
Review –and not 
experimental design or 
writing intervention. 
E 
 
Review. 
 
A 
 
 
Dennis et al 
(2008) 
 
Endnote (published article). Abstract 
 
E 
 
Not writing intervention, 
experimental design 
and no health outcome 
assessed. 
E 
 
Not writing intervention, 
experimental design 
and no health outcome 
assessed. 
A 
 
 
Dorr et al 
(2007) 
Endnote (published article). 
 
Abstract 
 
E 
 
Not writing intervention 
or experimental design.  
E 
 
Not writing intervention 
or experimental design.  
A 
 
 
Ehrenreich et 
al (2007) 
 
Endnote (published article). 
 
Abstract 
 
E 
 
Not experimental 
design and no health 
outcome assessed. 
E 
 
Not experimental 
design and no health 
outcome assessed. 
A 
 
 
Evans et al 
(2008) 
 
Endnote (published article). Abstract 
 
E 
 
Not writing intervention 
and no health outcome 
assessed. 
E 
 
Not writing intervention 
and no health outcome 
assessed. 
A 
 
 
Finset, A 
(2007) 
 
Endnote (World Congress on 
Psychosomatic Medicine 
conference abstract). 
Title 
 
E 
 
Not writing intervention, 
experimental design 
and no health outcome 
E 
 
Not writing intervention, 
experimental design 
and no health outcome 
A 
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 assessed. assessed. 
Fraas & Balz 
(2008) 
Endnote (published article). Abstract 
 
E 
 
Unlikely experimental 
design.  
E 
 
Unlikely experimental 
design.  
A 
 
 
Garlock M 
(2008) 
 
Endnote (published article). 
 
Title 
 
E 
 
Nothing in title to say 
sample physically ill or 
health outcome 
assessed. 
E 
 
Nothing in title to say 
sample physically ill or 
health outcome 
assessed. 
A 
 
 
Giese-Davis 
et al (2008) 
Endnote (published article). Abstract 
 
E  
 
Not a writing 
intervention or 
experimental design. 
E  
 
Not a writing 
intervention or 
experimental design. 
A 
 
 
Gillanders et 
al (2008) 
 
Endnote (published article). 
 
Abstract 
 
E  
 
Not a writing 
intervention or 
experimental design. 
E  
 
Not a writing 
intervention or 
experimental design. 
A 
 
 
Gordon JS 
(2008) 
Endnote (published article). Abstract 
 
E  
 
Review –and not a 
writing intervention. 
E  
 
Review. 
 
A 
 
 
Gortner, et al 
(2005) 
 
Endnote (Conference on 
Clinical Cognition 
conference abstract). 
Abstract 
 
E 
 
Unlikely physically ill if 
not mentioned in 
abstract. 
E 
 
Unlikely physically ill if 
not mentioned in 
abstract. 
A 
 
 
Greenberg 
MA (2008) 
 
Endnote (published article). 
 
Abstract 
 
E 
 
Book - not physically ill. 
 
E 
 
Book. 
 
A 
 
 
Guastella & 
Dadds (2008) 
 
Endnote (published article). 
 
Abstract 
 
E 
 
Not physically ill and no 
health outcome 
assessed. 
E  
 
Not physically ill and no 
health outcome 
assessed. 
A 
 
 
Hamill et al 
(2008) 
Endnote (published article). 
 
Abstract 
 
E 
 
Not physically ill, 
experimental design 
and no health outcome 
assessed. 
E  
 
Not physically ill, 
experimental design 
and no health outcome 
assessed. 
A 
 
 
Harrison, & 
Barlow (2009) 
Endnote (published article). 
 
Abstract 
 
E 
 
Not physically ill or 
experimental design. 
E  
 
Not physically ill or 
experimental design. 
A 
 
 
Hathaway et 
al (2008) 
Conference proceedings 
hand searching (Association 
for Psychological Science 
conference abstract). 
 
Abstract 
 
E 
 
Unlikely physically ill if 
not mentioned in 
abstract and unlikely 
health outcome 
assessed. 
E 
 
Unlikely physically ill if 
not mentioned in 
abstract and unlikely 
health outcome 
assessed. 
A 
 
 
Haug et al 
(2008) 
 
Endnote (published article). 
 
Abstract 
 
E 
 
Not physically ill, 
experimental design 
and no health outcome 
E  
 
Not physically ill, 
experimental design 
and no health outcome 
A 
 
 
497 
 
assessed. assessed. 
Hauwel-
Fantini & 
Pedinielli 
(2008) 
 
Endnote (published article). 
 
Title E 
 
Nothing in the title to 
indicate sample 
physically ill, writing 
intervention, 
experimental design 
and health outcome 
assessed. 
E 
 
Nothing in the title to 
indicate sample 
physically ill, writing 
intervention, 
experimental design 
and health outcome 
assessed. 
A  
Henry et al 
(2009) 
 
Endnote (published article). 
 
Abstract 
 
E 
 
Not writing intervention 
and no health outcome 
assessed. 
E  
 
Not writing intervention 
and no health outcome 
assessed. 
A 
 
 
Holtslander & 
Duggleby 
(2008) 
 
Endnote (published article). Abstract 
 
E 
 
Not physically ill, 
experimental design 
and no health outcome 
assessed. 
E  
 
Not physically ill, 
experimental design 
and no health outcome 
assessed. 
A 
 
 
Horn et al 
(2007) 
 
Endnote (conference 
abstract?). 
Title 
 
I 
 
May meet criteria –
can’t tell if sample 
physically ill, 
experimental design or 
health outcome 
assessed? 
E 
 
Unlikely sample 
physically ill, 
experimental design or 
health outcome 
assessed. 
D 
 
E 
Unlikely 
sample 
physically ill, 
experimental 
design or 
health 
outcome 
assessed 
Horneffer & 
Chen (2009) 
 
Endnote (published article). 
 
Abstract 
 
E 
 
Unlikely physically ill if 
not mentioned in 
abstract. 
E 
 
Unlikely physically ill if 
not mentioned in 
abstract. 
A 
 
 
Horowitz, S 
(2008) 
Endnote (published article). 
 
Title 
 
E 
 
Review. 
 
E  
 
Review. 
 
A 
 
 
Kay-raining 
Bird et al 
(2008) 
Endnote (published article). 
 
Abstract 
 
E 
 
Not physically ill and no 
health outcome 
assessed. 
E  
 
Not physically ill and no 
health outcome 
assessed. 
A 
 
 
Keefe et al 
(2008) 
Endnote (published article). 
 
Abstract 
 
E 
 
Not writing intervention. E  
 
Not writing intervention.   
 
A 
 
 
Kerner & 
Fitzpatrick 
(2007) 
 
Endnote (published article). 
 
Abstract 
 
E 
 
Review –and not 
physically ill, 
experimental design 
and no health outcome 
assessed. 
E  
 
Review. 
 
A 
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Kim, Y (2008) Endnote (published article). Abstract E Not physically ill. E  Not physically ill. A  
Kloos & Daly 
(2008) 
Endnote (published article). 
 
Abstract 
 
E 
 
Not physically ill. 
 
E Not physically ill. A 
 
 
Ko & Kuo 
(2009) 
Endnote (published article). 
 
Abstract E 
 
Not physically ill or 
experimental design. 
E  
 
Not physically ill or 
experimental design.  
A 
 
 
Krantz & 
Pennebaker 
(2007) 
Endnote (published article). 
 
Abstract 
 
E 
 
Book - not physically ill. 
 
E 
 
Book. 
 
A 
 
 
Kusumi et al 
(2008) 
 
Endnote (International 
Symposium on Universal 
Communication conference 
abstract). 
Abstract 
 
E 
 
Not experimental 
design. 
E  
 
Not experimental 
design. 
A 
 
 
Lieberman, M 
(2007) 
Endnote (published article). 
 
Abstract 
 
E Not experimental 
design and no health 
outcome assessed. 
E  
 
Not experimental 
design and no health 
outcome assessed. 
A 
 
 
Lieberman, 
MA (2008) 
Endnote (published article). Abstract E 
 
Not experimental 
design. 
E  
 
Not experimental 
design. 
A 
 
 
Lieberman, 
MA (2008) 
Endnote (published article). Abstract E 
 
Not experimental 
design. 
E  
 
Not experimental 
design.  
A 
 
 
Liess et al 
(2008) 
 
Endnote (published article). 
 
Abstract 
 
E 
 
Not experimental 
design and no health 
outcome assessed. 
E  
 
Not experimental 
design and no health 
outcome assessed. 
A 
 
 
Litt et al 
(2009) 
 
Contacting authors re: 
potentially completed 
ongoing trial found in hand 
searching for update (i.e. 
now completed) (published 
article). 
 
Abstract 
 
E 
 
This paper reports the 
process of rather than 
final outcomes of the 
ongoing trial that was 
requested (i.e. final 
outcomes not available 
yet). However, not a 
writing intervention. 
E 
 
This paper reports the 
process of rather than 
final outcomes of the 
ongoing trial that was 
requested (i.e. final 
outcomes not available 
yet). However, not a 
writing intervention. 
A 
 
 
Lonardi, C 
(2007) 
 
Endnote (published article). 
 
Abstract 
 
E 
 
Not a writing 
intervention, 
experimental design 
and no health outcome 
assessed. 
E  
 
Not a writing 
intervention, 
experimental design 
and no health outcome 
assessed. 
A 
 
 
Lumley et al 
(2008) 
 
Google (published article). 
 
Abstract 
 
I 
 
May meet criteria –
can’t tell if writing 
intervention/experiment
E 
 
Not likely writing 
intervention. 
D 
 
E 
Not likely 
writing 
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al design. intervention. 
Mackenzie et 
al (2008) 
Endnote (published article). 
 
Abstract 
 
E 
 
Not physically ill. 
 
E  
 
Not physically ill. 
 
A 
 
 
Magai et al 
(2009) 
Endnote (published article). 
 
Abstract 
 
E 
 
Not physically ill. 
 
E  
 
Not physically ill. 
 
A 
 
 
Mainous et al 
(2009) 
 
Endnote (published article). 
 
Title 
 
E 
 
Nothing in the title to 
indicate sample 
physically ill, writing 
intervention, 
experimental design 
and health outcome 
assessed. 
E 
 
Nothing in the title to 
indicate sample 
physically ill, writing 
intervention, 
experimental design 
and health outcome 
assessed. 
A 
 
 
Manna et al 
(2007) 
 
Endnote (published article). 
 
Title 
 
E 
 
Book – and not clear 
whether writing 
intervention or 
experimental design. 
E 
 
Book. 
 
A 
 
 
Manne et al 
(2007) 
Endnote (published article). 
 
Abstract 
 
E 
 
Not writing intervention.  
 
E  
 
Not writing intervention.  
 
A 
 
 
Manne et al 
(2008) 
Endnote (published article). Abstract 
 
E 
 
Not writing intervention.  
 
E  
 
Not writing intervention. A 
 
 
Mantel, H 
(2009) 
 
Endnote (published article). Title 
 
E Nothing in the title to 
indicate experimental 
design and health 
outcome assessed. 
E 
 
Nothing in the title to 
indicate experimental 
design and health 
outcome assessed. 
A 
 
 
Mathews, P 
(2008) 
 
Endnote (published article). 
 
Title 
 
E 
 
Nothing in the title to 
indicate sample 
physically ill, 
experimental design 
and health outcome 
assessed. 
E 
 
Nothing in the title to 
indicate sample 
physically ill, 
experimental design 
and health outcome 
assessed. 
A 
 
 
McGuire, B 
(2009) 
Google (Cochrane  review 
protocol). 
Abstract 
 
E 
 
Review. 
 
E 
 
Review. 
 
A 
 
 
McNess, A 
(2008) 
 
Endnote (published article). 
 
Abstract 
 
E 
 
Not a writing 
intervention, physically 
ill, experimental design 
and no health outcome 
assessed. 
E  
 
Not a writing 
intervention, physically 
ill, experimental design 
and no health outcome 
assessed. 
A  
Mehl- Endnote (published article). Abstract E Not writing intervention E Not writing intervention A  
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Madrona, L 
(2007) 
   or experimental design. or experimental design.  
Meier et al 
(2007) 
Endnote (published article). Abstract E Not experimental 
design and no health 
outcome assessed. 
E Not experimental 
design and no health 
outcome assessed. 
A  
Mills et al 
(2007) 
 
Endnote (Society of 
Neuroscience conference 
abstract). 
Title 
 
E 
 
Not writing intervention.  
 
E  
 
Not writing intervention.  
 
A 
 
 
Moreira et al 
(2008) 
 
Endnote (published article). Abstract 
 
E 
 
Not a writing 
intervention, physically 
ill or experimental 
design.  
E  
 
Not a writing 
intervention, physically 
ill or experimental 
design. 
A 
 
 
Morgan et al 
(2008) 
Endnote (published article). Abstract 
 
E 
 
Not experimental 
design.  
E  
 
Not experimental 
design. 
A 
 
 
Murray et al 
(2008) 
Endnote (published article). 
 
Abstract 
 
E 
 
Review –and not 
physically ill. 
E  
 
Review. 
 
A 
 
 
Neidtfield et al 
(2008) 
 
Endnote (published article). 
 
Abstract 
 
E 
 
Unlikely physically ill if 
not mentioned in 
abstract. 
E 
 
Unlikely physically ill if 
not mentioned in 
abstract. 
A 
 
 
Nicholls, S 
(2009) 
Endnote (published article). Abstract E Review –and not 
physically ill. 
E Review. 
 
A 
 
 
O’Clerigh & 
Safren (2008) 
Endnote (published article). 
 
Abstract 
 
E 
 
Review –and not 
writing intervention. 
E Review. 
 
A 
 
 
O’Connor & 
Ashley (2008) 
 
Endnote (published article). 
 
Abstract 
 
E 
 
Unlikely physically ill if 
not mentioned in 
abstract. 
E 
 
Unlikely physically ill if 
not mentioned in 
abstract. 
A 
 
 
Page & 
Fletcher 
(2008) 
Endnote (published article). 
 
Abstract 
 
E 
 
Unlikely physically ill if 
not mentioned in 
abstract. 
E Unlikely physically ill if 
not mentioned in 
abstract. 
A 
 
 
Pakenham, KI 
(2008) 
 
Journal hand searching 
(published article). 
 
Abstract 
 
I 
 
May meet criteria –
can’t tell if writing 
intervention/experiment
al design? 
E 
 
Not likely writing 
intervention or 
experimental design. 
D 
 
E 
Not likely 
writing 
intervention or 
experimental 
design. 
Panton & 
Marshall 
(2008) 
Endnote (published article). Abstract 
 
E 
 
Not physically ill, 
experimental design 
and no health outcome 
E  
 
Not physically ill, 
experimental design 
and no health outcome 
A 
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 assessed. assessed. 
Papousek & 
Schulter 
(2008) 
 
Endnote (published article). 
 
Abstract 
 
E 
 
Not a writing 
intervention, 
experimental design 
and no health outcome 
assessed. 
E  
 
Not a writing 
intervention, 
experimental design 
and no health outcome 
assessed. 
A 
 
 
Park, CL 
(2008) 
Endnote (published article). 
 
Abstract 
 
E Not physically ill, writing 
intervention and no 
health outcome 
assessed. 
E  
 
Not physically ill, writing 
intervention and no 
health outcome 
assessed. 
A 
 
 
Patterson et al 
(2007) 
Endnote (published article). 
 
Abstract 
 
E 
 
Not physically ill. 
 
E  
 
Not physically ill. 
 
A 
 
 
Perry, N 
(2008) 
 
Endnote (published article). 
 
Title 
 
E 
 
Not physically ill, 
experimental design 
and no health outcome 
assessed. 
E Not physically ill, 
experimental design 
and no health outcome 
assessed. 
A 
 
 
Preau et al 
(2008) 
 
Endnote (published article). 
 
Abstract E 
 
Not a writing 
intervention, 
experimental design 
and no health outcome 
assessed. 
E  
 
Not a writing 
intervention, 
experimental design 
and no health outcome 
assessed. 
A 
 
 
Provine et al 
(2007) 
 
Endnote (published article). 
 
Abstract 
 
E 
 
Not a writing 
intervention, 
experimental design 
and no health outcome 
assessed. 
E  
 
Not a writing 
intervention, 
experimental design 
and no health outcome 
assessed. 
A 
 
 
Ravert & 
Crowell (2008) 
Endnote (published article). 
 
Abstract 
 
E 
 
Not an experimental 
design and no health 
outcome assessed. 
E Not an experimental 
design and no health 
outcome assessed. 
A 
 
 
Reinhold-
Hurley & 
Kroner-Herwig 
(2007) 
 
Endnote (published article). 
 
Title 
 
E 
 
Not physically ill. 
 
E Not physically ill. 
 
A 
 
 
Resick et al 
(2008) 
Endnote (published article). Abstract E 
 
Not physically ill. E  
 
Not physically ill. A  
Robinson & 
Serfaty (2008) 
Endnote (published article). 
 
Abstract 
 
E 
 
Not physically ill. 
 
E  
 
Not physically ill. 
 
A 
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Roy, EC 
(2008) 
Endnote (published article). 
 
Title 
 
E 
 
Not physically ill. 
 
E Not physically ill. 
 
A 
 
 
Rubin et al 
(2008) 
Google (published article). 
 
Abstract 
 
E 
 
Unlikely physically ill if 
not mentioned in 
abstract. 
 
E 
 
Unlikely physically ill if 
not mentioned in 
abstract. 
 
A 
 
 
Rullkoetter et 
al (2009) 
 
Endnote (published article). 
 
Abstract 
 
E 
 
Not experimental 
design and no health 
outcome assessed. 
E  
 
Not experimental 
design and no health 
outcome assessed. 
A 
 
 
Sandgren & 
McCaul 
(2007) 
Endnote (published article). 
 
Abstract E 
 
Not writing intervention. E 
 
Not writing intervention. A 
 
 
Schneider et 
al (2008) 
Endnote (published article). 
 
Abstract 
 
E 
 
Not physically ill or 
experimental design. 
E  
 
Not physically ill or 
experimental design. 
A 
 
 
Schuler et al 
(2008) 
 
Endnote (International 
congress of psychology 
conference abstract). 
Abstract 
 
E 
 
Unlikely physically ill if 
not mentioned in 
abstract. 
E 
 
Unlikely physically ill if 
not mentioned in 
abstract. 
A 
 
 
Seery et al 
(2008) 
Endnote (published article). 
 
Abstract 
 
E 
 
Not physically ill or 
experimental design. 
E  
 
Not physically ill or 
experimental design. 
A 
 
 
Seih et al 
(2008) 
Endnote (published article). 
 
Abstract E Not physically ill or 
experimental design. 
E  
 
Not physically ill or 
experimental design. 
A  
Shaw et al 
(2008) 
Endnote (published article). Abstract E 
 
Not experimental 
design. 
E  
 
Not experimental 
design. 
A 
 
 
Sierpina et al 
(2007) 
 
Endnote (published article). 
 
Title 
 
E 
 
Review –and not 
experimental design or 
writing intervention. 
E  
 
Review. 
 
A 
 
 
Sloan et al 
(2007) 
Endnote (published article). 
 
Abstract 
 
E 
 
Not physically ill. 
 
E  
 
Not physically ill. 
 
A 
 
 
Sloan, DM 
(2008) 
Endnote (published article). 
 
Abstract 
 
E 
 
Not physically ill. 
 
E  
 
Not physically ill. 
 
A 
 
 
Smith et al 
(2007) 
Endnote (published article). 
 
Abstract 
 
E 
 
Not physically ill. 
 
E  
 
Not physically ill. 
 
A 
 
 
Smith, B 
(2007) 
 
Endnote (published article). Title 
 
E 
 
Nothing in the title to 
indicate sample 
physically ill, 
experimental design 
and health outcome 
assessed. 
E 
 
Nothing in the title to 
indicate sample 
physically ill, 
experimental design 
and health outcome 
assessed. 
A 
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Smyth & Arigo 
(2009) 
Endnote (published article). 
 
Abstract 
 
E 
 
Review. 
 
E  
 
Review. 
 
A 
 
 
Smyth et al 
(2008) 
Endnote (published article). 
 
Abstract 
 
E 
 
Not physically ill. 
 
E  
 
Not physically ill. 
 
A 
 
 
Smyth & 
Pennebaker 
(2008) 
Endnote (published article). 
 
Title 
 
E 
 
Review -and not 
physically ill. 
 
E Review. 
 
A 
 
 
Solano et al 
(2008) 
Endnote (published article). 
 
Abstract 
 
E 
 
Book. 
 
E  
 
Book. 
 
A 
 
 
Steinhauser et 
al (2008) 
Endnote (published article). 
 
Abstract 
 
E 
 
Not writing intervention.  
 
E  
 
Not writing intervention. A 
 
 
Stice et al 
(2007) 
Endnote (published article). 
 
Abstract 
 
E 
 
Not physically ill. 
 
E  
 
Not physically ill. 
 
A 
 
 
Stice et al 
(2008) 
Endnote (published article). 
 
Abstract 
 
E 
 
Not physically ill. 
 
E  
 
Not physically ill. 
 
A 
 
 
Stice et al 
(2008) 
Endnote (published article). 
 
Abstract 
 
E 
 
Not physically ill. 
 
E  
 
Not physically ill. 
 
A 
 
 
Swanbon et al 
(2008) 
Endnote (published article). 
 
Abstract 
 
E 
 
Not physically ill. 
 
E  
 
Not physically ill. 
 
A 
 
 
Tabibnia et al 
(2008) 
Endnote (published article). 
 
Abstract 
 
E 
 
Not physically ill or 
writing intervention. 
E Not physically ill or 
writing intervention. 
A 
 
 
Talusan, G 
(2008) 
Endnote (published article). Title 
 
E 
 
Not physically ill or 
experimental design. 
E  
 
Not physically ill or 
experimental design. 
A 
 
 
Tan, L (2008) 
 
Endnote (published article). 
 
Abstract 
 
E 
 
Not physically ill or 
experimental design. 
E  
 
Not physically ill or 
experimental design. 
A 
 
 
Tanis, M 
(2007) 
 
Endnote (published article). 
 
Abstract 
 
E 
 
Not physically ill, 
experimental design 
and no health outcome 
assessed. 
E Not physically ill, 
experimental design 
and no health outcome 
assessed. 
A 
 
 
Tanis, M 
(2008) 
 
Endnote (published article). 
 
Abstract 
 
E 
 
Not physically ill, 
experimental design 
and no health outcome 
assessed. 
E  
 
Not physically ill, 
experimental design 
and no health outcome 
assessed. 
A 
 
 
Tannenbaum, 
J (2007) 
Endnote (published article). 
 
Title 
 
E 
 
Not a writing 
intervention, physically 
ill, experimental design 
and no health outcome 
E  
 
Not a writing 
intervention, physically 
ill, experimental design 
and no health outcome 
A 
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assessed. assessed. 
Theadom et al 
(2009) 
Google (Cochrane review 
protocol). 
Abstract 
 
E 
 
Review. 
 
E 
 
Review. 
 
A 
 
 
Thomsen & 
Jensen (2007) 
 
Endnote (published article). 
 
Abstract 
 
E  
 
Not a writing 
intervention or 
experimental design. 
E  
 
Not a writing 
intervention or 
experimental design. 
A 
 
 
Tsao et al 
(2008) 
 
Conference proceedings 
hand searching (Association 
for Psychological Science 
conference abstract). 
Abstract 
 
E 
 
Unlikely physically ill if 
not mentioned in 
abstract. 
 
E 
 
Unlikely physically ill if 
not mentioned in 
abstract. 
 
A 
 
 
van Emmerick 
et al (2008) 
Endnote (published article). 
 
Abstract 
 
E 
 
Not physically ill. 
 
E  
 
Not physically ill. 
 
A 
 
 
Van 
Middendorp et 
al (2008) 
Endnote (published article). 
 
Abstract 
 
E  
 
Not a writing 
intervention or 
experimental design. 
E Not a writing 
intervention or 
experimental design. 
A 
 
 
Van 
Middendorp et 
al (2009) 
Endnote (published article). 
 
Abstract 
 
E Not a writing 
intervention. 
E  
 
Not a writing 
intervention. 
A 
 
 
Ward et al 
(2008) 
 
Journal hand searching 
(published article). 
 
Abstract 
 
I 
 
May meet criteria –
can’t tell if writing 
intervention? 
E 
 
Not likely writing 
intervention.  
D 
 
E 
Not likely 
writing 
intervention  
Watine, P 
(2007) 
 
Endnote (published article). 
 
Title 
 
E 
 
Not a writing 
intervention, 
experimental design 
and no health outcome 
assessed. 
E  
 
Not a writing 
intervention, 
experimental design 
and no health outcome 
assessed. 
A 
 
 
Watkins et al 
(2008) 
 
Conference proceedings 
hand searching (Association 
for Psychological Science 
conference abstract). 
Abstract 
 
E 
 
Unlikely physically ill if 
not mentioned in 
abstract. 
 
E 
 
Unlikely physically ill if 
not mentioned in 
abstract. 
 
A 
 
 
Watkins et al 
(2008) 
 
Conference proceedings 
hand searching (Association 
for Psychological Science 
conference abstract). 
Abstract 
 
E 
 
Secondary analysis of 
the above trial.  
 
E 
 
Secondary analysis of 
the above trial. 
 
A 
 
 
Weber & 
Solomon 
(2008) 
Endnote (published article). Abstract E 
 
Not an experimental 
design and no health 
outcome assessed. 
E  
 
Not an experimental 
design and no health 
outcome assessed. 
A 
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Weinman et al 
(2008) 
Endnote (published article). 
 
Abstract 
 
E 
 
Not physically ill. 
 
E  
 
Not physically ill. 
 
A 
 
 
Weinstein & 
Hodgins 
(2009) 
Endnote (published article). Abstract 
 
E 
 
Unlikely physically ill or 
experimental design. 
 
E  
 
Unlikely physically ill or 
experimental design. 
 
A 
 
 
Westling et al 
(2007) 
Endnote (published article). 
 
Title 
 
E 
 
Not an experimental 
design.  
E  
 
Not an experimental 
design. 
A 
 
 
Willig et al 
(2007) 
 
Endnote (published article). Abstract E Not an experimental 
design and no health 
outcome assessed. 
E  
 
Not an experimental 
design and no health 
outcome assessed. 
 
A 
 
Wise et al 
(2008) 
 
Endnote (published article). 
 
Abstract 
 
E  
 
Not a writing 
intervention or 
experimental design. 
E  
 
Not a writing 
intervention or 
experimental design. 
A 
 
 
Wolf et al 
(2008) 
 
Endnote (published article). 
 
Abstract E 
 
Not physically ill, 
experimental design 
and no health outcome 
assessed. 
E 
 
Not physically ill, 
experimental design 
and no health outcome 
assessed. 
A 
 
 
Wray et al 
(2007) 
 
Endnote (published article). 
 
Abstract 
 
E 
 
Not a writing 
intervention, 
experimental design 
and no health outcome 
assessed. 
E  
 
Not a writing 
intervention, 
experimental design 
and no health outcome 
assessed. 
A 
 
 
Yamaski et al 
(2008) 
 
Endnote (published article). 
 
Abstract 
 
E 
 
Not physically ill. 
 
E  
 
Not physically ill. 
 
A 
 
 
Yeh et al 
(2008) 
 
Endnote (published article). 
 
Title 
 
E 
 
Book –and not a writing 
intervention, physically 
ill, experimental design 
and no health outcome 
assessed. 
E  
 
Book. 
 
A 
 
 
Yogo & 
Fujihara 
(2008) 
Endnote (published article). 
 
Abstract E 
 
Not physically ill and no 
health outcome 
assessed. 
E 
 
Not physically ill and no 
health outcome 
assessed. 
A  
Yukawa, S 
(2008) 
 
Endnote (published article). 
 
Abstract 
 
E 
 
Not a writing 
intervention, physically 
ill, experimental design 
and no health outcome 
assessed. 
E 
 
Not a writing 
intervention, physically 
ill, experimental design 
and no health outcome 
assessed. 
A 
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Zolowere et al 
(2008) 
Endnote (published article). 
 
Abstract 
 
E 
 
Not physically ill, writing 
intervention or 
experimental design. 
E 
 
Not physically ill, writing 
intervention or 
experimental design. 
A 
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Search update: Full papers obtained 
 
Study Search Type (article type) Obtained 
(Title or 
abstract?) 
Reviewer 
1 
(I=include/
obtain 
further info 
E=exclude) 
 Reviewer 
2 
(I=include/
obtain 
further info 
E=exclude) 
 Agreement 
A=agreed 
D=disagreed 
 
Consensus  
(if initially D) 
Brown et al 
(2010) 
 
Search Alert POST UPDATE 
(published article). 
Full paper 
 
E 
 
Not a RCT, no relevant 
psychological outcome 
and intervention 
content not entirely 
consistent with WED? 
E 
 
Not a RCT, no relevant 
psychological outcome 
and intervention 
content not entirely 
consistent with WED? 
A 
 
 
Bugg et al 
(2009) 
Endnote (published article). 
 
Full paper 
 
E 
 
Sample not chronically 
ill. 
E 
 
Sample not chronically 
ill. 
A 
 
 
Gellaitry et al 
(2010) 
 
Contacting authors re: 
potentially completed 
ongoing trial found in hand 
searching for update (i.e. 
now completed)/conference 
proceeding from original 
search that was 
unobtainable (published 
article). 
Full paper 
 
I 
 
Meets all criteria. 
 
E 
 
Women not chronically 
ill –completed 
treatment? 
 
D 
 
I 
Does meet all 
criteria –not 
necessarily 
cured 
 
Jones et al 
(2008) 
Google (conference 
proceeding). 
Abstract 
 
E 
 
Contacted author –still 
ongoing. 
E 
 
Contacted author –still 
ongoing. 
A 
 
 
Low et al 
(2010) 
Search Alert POST UPDATE 
(published article). 
Full paper 
 
I 
 
Meets all criteria. 
 
I 
 
Meets all criteria. 
 
A 
 
 
Mallett, K 
(2009) 
 
Endnote (published article). 
 
Full paper 
 
E 
 
Description of trial  -but 
not experimental 
design. 
E 
 
Description of trial  -but 
not experimental 
design. 
A 
 
 
Theadom et al 
(2009) 
 
Conference proceedings 
hand searching (i.e. looking 
for more details about a 
relevant abstract and came 
across this). 
Full paper 
 
E 
 
No psychological health 
outcome assessed. 
 
E 
 
No psychological health 
outcome assessed. 
 
A 
 
 
Wagner et al 
(2008) 
Google/dissertation from 
original search that was 
Full paper 
 
I 
 
Meets all criteria. 
 
I 
 
Meets all criteria. 
 
A 
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 unobtainable (published 
article). 
Willmott et al 
(under review) 
 
Contacting authors re: 
conference proceeding 
(found via bibliographies of 
included trials in search in 
update)/potentially 
completed ongoing 
trial/manuscript in prep from 
original search that was 
unobtainable (paper under 
review). 
Full paper 
 
I 
 
Meets all criteria. 
 
I 
 
Meets all criteria. 
 
A 
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Appendix E: Data extraction table 
Study design and participant characteristics 
(Some studies included more than the two intervention groups that were included in the present review, thus sample sizes are additionally presented for only the included 
groups. Where studies did not present it by group demographic data are presented for the full sample) 
Author 
(year) 
Country Follow 
up 
No. randomised Condition Mean age 
& 
Time since diagnosis 
(SD)  
Gender,  
Ethnicity,  
Education &  
Marital Status  
Method of 
recruitment 
de Moor et al 
(2002) 
 
 
USA. 10 
weeks. 
42 (WED=21, 
NEUTRAL 
WRITING=21). 
Metastatic renal 
cell carcinoma. 
Average age: 56.4yrs. 
 
Time since diagnosis NOT 
REPORTED (but cancer 
advanced). 
 
Gender: 14% Female. 
 
Ethnicity  NOT REPORTED. 
 
Education  NOT REPORTED. 
 
Marital status  NOT REPORTED. 
Already enrolled in 
RCT of vaccine 
therapy. 
Gellaitry et al 
(2010) 
 
 
 
UK. 6 
months. 
93 (WED=45, 
CONTROL=48). 
Breast cancer. Mean age: 58 (10)yrs. 
 
All diagnosed within 
previous 12 months 
(stage I or II). 
 
 
Gender: 100% Female 
 
Ethnicity  NOT REPORTED 
 
Education  NOT REPORTED 
 
Marital status  NOT REPORTED 
Patients attending 
last radiotherapy 
appointment at out-
patient clinic (i.e. 
penultimate week of 
therapy) –provided 
with study 
information by 
consultant. 
Low et al 
(2010) 
 
 
USA. 3  
months. 
76 (38 WED; 38 
NEUTRAL 
WRITING). 
Metastatic 
breast cancer. 
Mean age: 53.8 (10.3)yrs 
 
First diagnosed with 
cancer 7.9 years ago (67 
months); first diagnosed 
with Stage IV 3.3 years 
ago (SD 28.1 months). 
Gender: 100% Female. 
 
 Ethnicity: 87% White. 
 
Education: 74% college educated. 
 
Marital status: 71% married or 
living as married. 
Patients that took 
part in a previous 
study if consented to 
be contacted about 
future studies; flyers 
posted in oncology 
clinics and 
community breast 
cancer practice; 
advertisement 
posted on online 
resource for people 
with metastatic 
breast cancer. 
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Rosenberg et 
al (2002) 
 
 
 
USA. 6  
months. 
30 -implied 15 per 
group. 
 
But when obtained 
data from authors 
seems WED=16; 
CONTROL=14. 
Prostate 
cancer. 
Mean age: 70.5(5.4)yrs. 
 
Time since diagnosis NOT 
REPORTED (but not 
acute phase). 
Gender: 0% Female. 
 
Ethnicity: 97% Caucasian. 
 
Education: 97% 12+ yrs. 
 
Marital Status: 90% married. 
Registered hospital 
outpatients under 
observation–
researcher 
approached at 
appointments. 
Walker et al 
(1999) 
 
 
 
USA. 28 
weeks. 
50 (total sample). 
 
For included 
groups: 35 
(WED=19, 
CONTROL=16). 
Breast cancer. For total sample: 
  
Mean age: 53.6 (29-
76)yrs.  
 
Time since diagnosis NOT 
REPORTED (but stage I 
or II). 
 
 
For total sample: 
 
Gender 100% Women. 
 
Ethnicity: 95% Caucasian. 
 
Education: 79% beyond high 
school. 
 
Marital status: 71% married. 
Approached during 
scheduled visits to 
university based 
treatment centres. 
 
 
Zakowski et 
al (2004) 
 
 
USA. 6  
months. 
127 (WED=74, 
NEUTRAL 
WRITING=53). 
Gynaecological
/ 
prostate 
cancer. 
Mean age: 59.8 (11.1)yrs. 
 
Mean time since 
diagnosis: 1.4 (1.2)yrs 
(stage I-IV). 
Gender: 52% Female. 
 
 Ethnicity: 95% Caucasian. 
 
Education: 46% at least college 
education. 
 
Marital Status: 80% married. 
Referred by treating 
physician at clinics – 
those interested then 
contacted by a 
member of the 
research group. 
 
 
Gillis et al 
(2006) 
 
 
USA. 3  
months. 
83 (WED=45, 
NEUTRAL 
WRITING=38). 
Fibromyalgia. Mean age: 50.3 (23-
72)yrs. 
 
Time since diagnosis: 
5.9(1-20)yrs. 
 
 
Gender: 97% Female. 
 
Ethnicity: 93% White. 
 
Mean education: 2.6 yrs college 
(all 10th grade ed.). 
 
Marital status: 72% married. 
Flyers in 
Rheumatology clinic, 
announcements at 
FM support groups 
and advertisements 
in AF newsletter. 
Norman et al 
(2004) 
 
 
 
USA. 2  
months. 
60 (WED=32, 
PW=28). 
Chronic pelvic 
pain. 
Mean age: 38.2(11.5)yrs. 
 
Duration of CPP 12.7(2.3) 
yrs. 
Gender: 100% Female. 
 
Ethnicity: 83% European 
American. 
 
Education: 14.7(2.1)yrs. 
Brochures at 
gynaecology/ 
pain clinics, mass 
media 
advertisements, EA 
announcements. 
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Marital status NOT REPORTED. 
Cohen et al 
(in prep) 
 
 
 
USA. 6  
months. 
150 (total sample). 
 
For included 
groups: 113 (WED: 
74 (written=37; 
verbal=37), 
CONTROL: 39 
(written=19; 
verbal=20). 
Rheumatoid 
arthritis. 
For total sample: 
 
Mean age: 54.1(11.2)yrs. 
  
Mean duration of time with 
RA: 12(10.6)yrs. 
For total sample: 
 
Gender:87% Females.  
 
Ethnicity: 59% Caucasian. 
 
Mean education: 13.5(2.7)yrs. 
 
Marital status: 59% married/living 
together. 
Directly recruited 
from 5 local clinics. 
Danoff-Burg 
et al (2006) 
 
 
 
USA. 3  
months. 
75 (total sample). 
 
For included 
groups: 48 
(WED=24, 
NEUTRAL 
WRITING=24). 
Systemic lupus  
erythematosus 
or Rheumatoid 
Arthritis. 
For total sample: 
 
Mean age: 51.2(13.3)yrs. 
 
Time since diagnosis: 
15yrs/modal time <10yrs. 
 
 
For total sample: 
 
Gender: 83% Female.  
 
Ethnicity: 87% White. 
 
Mean education: 15.2(yrs). 
 
Marital status: 68% married/long 
term relationship. 
Brochures posted in 
rheumatologist’s 
offices/sent to 
mailing lists of local 
chapters of AF/LFA. 
Hamilton-
West & 
Quine (2007) 
 
 
 
UK. 3  
months. 
107 (WED=71, 
NEUTRAL 
WRITING=36). 
Ankylosing 
Spondylitis. 
Mean age: 52(22-78)yrs. 
 
Mean time since 
diagnosis: 16(0-46)yrs. 
 
Gender: 32% Female.  
 
Ethnicity: 97% White. 
 
Education NOT REPORTED. 
 
Marital status: 72% married. 
Charitable 
organisation (NASS) 
–newsletter 
advertisement/ 
information sent to 
support groups. 
Wetherell et 
al (2005) 
 
 
 
UK. 10 
weeks. 
Unclear -42 
assessed at 
baseline 
-no. per group NOT 
REPORTED. 
Rheumatoid 
arthritis. 
Mean age: 60.7 yrs. 
 
Mean disease duration: 
14.7 yrs. 
 
 
Gender: 83% Female. 
 
Ethnicity NOT REPORTED. 
 
Education NOT REPORTED. 
 
Marital status: 67% married. 
 
 
Identified by 
consultant 
rheumatologist and 
approached by 
researcher. 
Vedhara et al UK. 12 69 –no. per group Psoriasis. Mean age: 50(+/-13)yrs. Gender: 37% Female. Recruited from 
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(2007) 
 
 
weeks. NOT REPORTED.  
Mean length of diagnosis: 
22(+-15)yrs. 
 
 
 
Ethnicity: 88% White European. 
 
Marital status: 73% married. 
 
Education: 42% up to university 
diploma or degree. 
dermatology 
clinics/psoriasis 
patient 
groups/advert in 
local newspaper. 
Taylor et al 
(2003) 
 
 
 
USA. 3  
months. 
70 –no. per group 
NOT REPORTED. 
Cystic fibrosis. 15-18yrs (31%) & 19-
>37yrs (69%). 
 
Time since diagnosis NOT 
REPORTED. 
 
Gender NR. 
 
Ethnicity: 90% Caucasian. 
 
Education NR. 
 
Marital status: 38% married. 
 
Information mailed to 
eligible patients and 
approached during 
routine clinic visits –
2 cystic fibrosis 
centres in children’s 
hospitals. 
Willmott et al 
(under 
review) 
 
 
UK. 5  
months. 
179 (WED=88, 
NEUTRAL 
WRITING=91). 
Post 1st MI. Mean age: 62.3 (10.9)yrs. 
 
Time since diagnosis NOT 
REPORTED. 
 
 
Gender: 16% Female.  
 
Ethnicity: 98% White. 
 
Education NOT REPORTED. 
 
Relationship status: 79% currently 
in relationship. 
National Health 
Service Trust (2 
acute clinics) –
patients approached 
by cardiac 
rehabilitation service 
or cardiac research 
nurse on day 5 of 
admission to hospital 
–given written 
invitation then 
approached the 
following day. 
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Intervention, comparison exposure, outcome and results 
(Some studies included more than the two intervention groups that were included in the present review, thus completion of the intervention, intervention fidelity, numbers of 
participants included in analyses and effects are presented for only the included groups)  
Author 
(year) 
 
 
Writing topic / 
Number, length & 
spacing of sessions 
Comparison Completion  of intervention / 
Fidelity of intervention  
No. analysed 
(% of no. 
randomised)  
 
 
Outcomes measured / 
Effect(s) (reported in 
paper/final end point data) 
Author Conclusions /  
Commentary (for 
entire study) 
de Moor et 
al (2002) 
 
Cancer. 
 
Instructions consistent 
with original WED 
paradigm. 
 
4 sessions/ over 4-6 
weeks –length NOT 
REPORTED but state 
followed Pennebaker & 
Beall (1986) model. 
Neutral writing 
–different 
health 
behaviour per 
session 
 (NEUTRAL 
WRITING). 
Of the no. randomised WED=3 (14%), 
NEUTRAL WRITING=4 (19%) did not 
complete all 4 sessions (all completed 
at least 1 writing session –average no. 
WED=3.7(.8) NEUTRAL 
WRITING=3.8 (.5).  
 
LIWC for both groups –confirmed: sig. 
difference in 24/32 word categories 
inc. affective/cognitive/social 
processing, time, and meta-physical. 
WED=19 (90%), 
NEUTRAL 
WRITING=18 
(86%). 
 
 
Perceived stress (PS); 
Perceived Stress Scale 
(PSS). 
Mood disturbance (MD); 
Profile Of Mood States 
(POMS). 
Psychological distress (PD); 
Impact of Events Scale (IES). 
 
No sig. effects on main 
outcomes. 
 
Effect sizes based on means 
across all follow ups adjusted 
for baseline values (and SEs): 
 
PS:  
WED=19.8(.9) 
NEUTRAL WRITING=20.5(.9)   
MD: 
WED=15.7(4.7) 
NEUTRAL  
WRITING=19.8(5.2)       
WED may have some 
sleep related health 
benefits in terminally ill 
patients (but not other 
outcomes). 
Gellaitry et 
al (2009) 
Experience of cancer. 
 
Instructions consistent 
with original WED 
paradigm 
BUT guided 
instructions - day 1 
Usual care 
control 
(CONTROL). 
 
Of the no. randomised - WED: 3 did 
not return any writing and 1 completed 
2/4 writing days. Therefore – 4 (9%) 
did not report writing according to the 
protocol. 
 
WED=38 (84%); 
CONTROL=42 
(87.5%). 
 
 
 
 
Mood disturbance (MD); 
Profile of Mood States 
(POMS). 
Disease specific QoL 
(DSQoL); Functional 
Assessment of Cancer 
Therapy –Breast (FACT-B). 
WED was associated 
with higher levels of 
perceptions of social 
support (emotional) for 
women recently 
completing treatment for 
early stage breast 
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emotional disclosure 
(deepest thoughts and 
feelings), day 2 
cognitive appraisal 
(making sense of 
cancer), day 3 benefit 
finding (perceived 
benefits of cancer 
experience) & day 4 
looking to the future 
(coping strategies).  
 
20 minutes/4 
consecutive days. 
Patient self-report (but re: the impact 
of WED post-writing) -4 categories 
easy/no adverse effects, 
apprehensive but +ve effects, difficult 
and challenging but beneficial effects, 
difficult not helpful and no benefit –but 
–ve effects not prolonged & benefits 
realised later.  At follow up –valued 
being able to express feelings not 
previously acknowledged, process/ 
deal with cancer experience, positive 
effect on relationships and perception 
of social support –no neutral writing 
condition to compare to. 
 
 
 
 
No sig. main effect on 
outcomes (all p>.05). 
 
Effect sizes based on adjusted 
means at final follow up (and 
SDs): 
 
MD:  
WED=20.63(32.28) 
CONTROL= 24.21(36.97) 
 
DSQoL:  
WED=109.56(19.81) 
CONTROL=108.03(21.36)      
cancer....but there was 
no main effect of the 
intervention on women’s 
overall QoL or 
psychological well-
being. 
Low et al 
(2010) 
 
Cancer related 
emotions. 
 
Specific instructions not 
reported at all (just 
advises instructions 
adapted from 
Pennebaker & Beall 
(1986) and Stanton et 
al (2002). 
 
4 sessions over 3 week 
interval – 20 minute 
sessions. 
Neutral writing 
–facts about 
condition and 
it’s treatment 
(NEUTRAL 
WRITING). 
All but one participant did not 
complete writing within the intended 
time frame (i.e. 3 weeks) and so was 
dropped from the study (not clear 
whether completed all, some or none 
of the sessions though); implied all 
others completed all sessions  as 
required. 
 
Review of essay content; independent 
rater read essays and recorded which 
instructions they most reflected 
(fidelity confirmed -94% of essays 
correctly classified) and participant 
testimony; extent to which participants 
had thought about what they wrote, 
talked to others about what they 
wrote, felt the research project had 
positive or negative long lasting 
effects and felt the study had 
increased their understanding of their 
experience (fidelity only partially 
confirmed –no significant group 
differences but higher mean ratings 
WED=31 (82%), 
NEUTRAL 
WRITING=31 
(82%).  
 
 
Depressive symptoms (DS); 
Centre for Epidemiological 
Studies –Depression (CES-
D) scale. 
Cancer related intrusive 
thoughts (CRIT); Impact of 
Events Scale (IES). 
 
No significant main effect of 
experimental condition for any 
outcome. 
 
Effect sizes based on adjusted 
means at final follow up (and 
SEs): 
 
DS:  
WED=12.8 (1.48) 
NEUTRAL  
WRITING= 13.2 (1.48) 
Although there was no 
main effect of WED on 
health among the 
current metastatic breast 
cancer sample, WED 
may be beneficial for a 
subset of patients 
including women with 
low levels of emotional 
support and who have 
been more recently 
diagnosed. WED may 
be contraindicated for 
others (i.e. those who 
have been living with the 
diagnosis for years). 
 
Significant proportion of 
the sample had 
experience journaling 
about their cancer 
experience (two thirds), 
had talked to a mental 
health care professional 
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for ‘thought about’ and ‘understanding’ 
items for WED group relative to 
NEUTRAL WRITING group). 
about cancer (two thirds) 
and had attended a 
cancer support group 
(three quarters); authors 
acknowledge this may 
explain lack of effect. 
 
Neutral writing control 
was facts of diagnosis 
and treatment –
potentially not inert. 
 
Mean CES-D 12.4 (34% 
≥16). 
Rosenberg 
et al (2002) 
 
Cancer/treatment and 
any traumatic event. 
 
Instructions consistent 
with original WED 
paradigm. 
 
20-30 minutes/4 
sessions –spacing NOT 
REPORTED. 
Non-writing 
control 
(CONTROL). 
Implied of the no. randomised all 
completed writing assignments 
(unclear whether all completed all 
sessions as required but presume 
they did). 
 
None reported –no neutral writing 
condition to compare to anyway.  
Implied 
WED=16 
(100%), 
CONTROL=14 
(100%).  
 
 
 
Psychological symptoms 
(PS); Symptom Checklist 90 
–Revised. 
Mood (M); The Brief Profile 
Of Mood States (Brief 
POMS). 
Health related QoL (HRQoL); 
Short Form-36 (SF-36) -
mental health component 
(MHC) & physical health 
component (PHC). 
Disease specific QoL (DSQ 
OL); Functional Assessment 
of Cancer Therapy –P 
(FACT-P). 
 
PS, M, HRQoL and DSQoL no 
data reported at all; just stated 
no significant group effect (no 
data reported at all). 
 
 
Requested data from authors 
& obtained for some 
outcomes. 
Results support the 
feasibility of expressive 
disclosure for men with 
prostate cancer but 
limited support for its 
positive impact on health 
and quality of life 
outcomes. 
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Effect sizes based on adjusted 
means at final follow up (and 
SDs): 
 
M:          
WED=2.38 (12.60) 
CONTROL=6.21 (7.41) 
DSQoL:   
WED=130.16 (12.60) 
CONTROL=107.92 (69.03) 
 
Still missing for PS & HRQoL: 
authors did not provide data 
for PS at all & provided group 
means/SDs for SF-36 but only 
for 8 separate sub-scales (& 
health transition 
score)....decided that is it not 
ok just to sum these within 
study to derive mental/physical 
health component scores): if 
they all had same SD10 then 
perhaps could have combined 
but they do not (when they are 
combined means & SDs for 
two main sub-scales are 
similar to the other trial that 
included the SF-36 but made 
the decision that this is not 
worth it). 
Walker et 
al (1999) 
 
Cancer. 
 
Instructions consistent 
with original WED 
paradigm. 
 
30 minutes/3 sessions 
spaced over 3-4 days 
Usual care 
control 
(CONTROL). 
For included groups: 
 
Of no. randomised   
WED= 3 (16%) did not complete all 3 
writing sessions.  
 
LIWC for 3WED –no neutral writing 
condition to compare to.   
For included 
groups: 
 
WED=14 (74%), 
CONTROL=14 
(87.5%). 
 
 
Positive Affect (PA); 
(Positive And Negative 
Affect Schedule (PANAS) 
+ve sub-scale). 
Negative Affect (NA); 
(Positive And Negative 
Affect Schedule (PANAS) -ve 
sub-scale). 
Emotional expression is 
feasible for patients with 
cancer, but the efficacy 
of the intervention in 
improving mood was not 
supported. 
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for 1st 8 participants -
then spaced over 5 
days. 
Cancer related intrusive 
thoughts and avoidance 
(CRIT&A); Impact of Events 
Scale (IES). 
 
No sig. group effect across all 
follow ups or for each 
individual follow up for any 
outcome. 
 
Effects sizes based on 
adjusted means at final follow 
up (and SEs): 
 
PA:    
WED=36.4(1.6) 
CONTROL=34.8(1.8) 
NA:   
WED=17.1(1.6) 
CONTROL=14.1(1.7)  
Zakowski 
et al (2004) 
 
Cancer. 
 
Instructions consistent 
with original WED 
paradigm. 
 
20 minutes/3 
consecutive days 
(within 1 week if not 
possible). 
Neutral writing 
–time 
management 
(NEUTRAL 
WRITING). 
Of the no. randomised WED=9 (12%), 
NEUTRAL WRITING=8 (15%) 
dropped out after baseline 
assessment/before writing (& WED=3 
(4%); NEUTRAL WRITING=3 (6%) 
dropped out after completing writing) –
unclear whether those staying in after 
baseline (regardless of whether they 
dropped out after writing or not) 
completed all writing sessions as 
planned? 
 
Participant self-report –confirmed: 
WED rated essays as sig. more 
personal and revealing emotions 
compared to NEUTRAL WRITING. 
Implied 
WED=62 (84%), 
NEUTRAL 
WRITING=42 
(79%). 
 
 
Distress (D); Brief Symptom 
Inventory (BSI) –global 
severity index. 
Clinically significant cases 
defined as 1 SD above the t 
score norm for female and 
male adult non-patients, 
scores of .62 and .42 
respectively.  
Cancer related intrusive 
thoughts and avoidance 
(CRIT&A); Impact of Events 
Scale (IES) (more as a 
mediator but final end point 
data provided for follow up). 
 
No sig. group effect on 
distress (F(1,100)=.98, p>.1), 
or cases of clinically sig. D at 6 
WED was not effective 
for reducing distress for 
all cancer patients 
instead it may be helpful 
in aiding patients in their 
psychological 
adjustment if they are 
lacking opportunities in 
their social environment. 
 
 
518 
 
months (latter not reported 
alone as data not provided).   
 
Effect size based on 
unadjusted means at final 
follow up (and SDs): 
 
D:  
WED=.35(.4) 
NEUTRAL WRITING=.34(.4) 
Gillis et al 
(2006) 
 
Any stressful 
experience. 
 
Instructions consistent 
with original WED 
paradigm 
BUT instructions for 
selecting bothersome 
stressor/disclosing e.g. 
how condition affected 
by stressor/resolve 
each stressor one at a 
time. 
 
15-20 minutes/4 
consecutive days. 
Neutral writing 
–time 
management 
(NEUTRAL 
WRITING). 
Of those randomised (WED=7(16%), 
NEUTRAL WRITING=4(11%)) did not 
complete any follow up (& stated 
those not completing a follow up 
‘typically did not write’...presume they 
didn’t complete all sessions as 
required?) & of those who provided 
some follow up1 WED (3%) and 1 
NEUTRAL WRITING (3%) did not 
complete writing. Thus (WED=8(18%), 
NEUTRAL WRITING=5(16%)) did not 
complete writing as required. 
 
LIWC both groups and review of 
essay content –all  38 WED wrote 
about a stressful topic but only 5/34 
(15%) NEUTRAL WRITING did not 
write about time management and 
mentioned something stressful. WED 
contained substantially more affect, 
cognitive, bodily related words than 
NEUTRAL WRITING. 
ITT: WED=45 
(100%), 
NEUTRAL 
WRITING=38 
(100%).    
 
WED=36 (80%), 
NEUTRAL 
WRITING=32 
(84%) included 
in completer 
analysis.  
Negative Affect (NA); 
(Positive And Negative 
Affect Schedule (PANAS) -ve 
sub-scale). 
Global health status (GHS); 
Fibromyalgia Impact 
Questionnaire (FIQ) –global 
health status. 
 
From baseline to 3 month 
follow up more improvement 
for WED compared to 
NEUTRAL WRITING in GHS 
(F(1,81)=4.23, p=.04) 
(improvement for WED/no 
change for NEUTRAL 
WRITING). Positive effect. No 
sig. effect on NA (p=.64). 
 
Inadequate data to calculate 
SMD for ITT so effect sizes 
based on unadjusted means at 
final follow up for completer 
sample (and SDs) (all still 
sig.): 
 
GHS:  
WED=52.70(20.35) 
NEUTRAL 
At home WED leads to a 
greater degree of 
improvement on various 
health indexes 3 months 
after writing than does 
emotionally neutral 
writing for individuals 
with FM. 
 
Baseline group 
differences in health 
may have confounded 
effects –greater 
improvement for WED 
as poorer health at 
baseline–3 month 
scores similar in both 
groups suggests effect 
of limited clinical 
significance. 
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WRITING=53.79(18.13) 
NA:     
WED=1.91(.71) 
NEUTRAL 
WRITING=2.14(.78) 
Norman et 
al (2004) 
 
Negative emotional 
experiences related to 
pain. 
 
Instructions consistent 
with original WED 
paradigm. 
 
20 minutes/3 
consecutive days. 
Neutral writing 
but writing 
about positive 
life events 
unrelated to 
pain (i.e. 
positive 
thoughts and 
feelings) -  
described as a 
superior 
control task 
compared to 
trivial/time 
management 
topics; 
provides a 
control for 
writing about 
an emotionally 
engaging 
topic, has face 
validity for 
reducing 
stress/being 
meaningful 
and will not 
create a 
negative 
response 
(NEUTRAL 
WRITING). 
Of the no. randomised 10 (17%) 
(WED=2 (6%), PW=8 (29%)) dropped 
out before finishing writing and of 
those completing writing and follow up 
48 (WED=28, PW=20) all but WED 
1/32 did not complete writing as 
required –thus WED=3(9%) and 
NEUTRAL WRITING=8(29%) did not 
complete writing as required –(but 
unclear whether the additional 2 
patients who dropped out after writing 
but before follow up completed all 
sessions as required....CB/KD 
decision assume they did thus 
WED=3(9%) and NEUTRAL 
WRITING=8(29%) did not complete 
writing as required). 
 
Participant self-report and review of 
essay content. WED reported 
previously holding back more than 
NEUTRAL WRITING yet both 
perceived writing to be meaningful 
(i.e. control was to write about 
pleasant events). All but 1 patient 
classified correctly re: group 
assignment. 
WED=28 
(87.5%), PW=20 
(71%). 
 
. 
Positive Affect (PA); 
(Positive And Negative 
Affect Schedule (PANAS) 
+ve sub-scale). 
Negative Affect (NA); 
(Positive And Negative 
Affect Schedule (PANAS) -ve 
sub-scale). 
 
No sig. effects for main 
outcomes. 
 
Effects based on unadjusted 
means at final follow up (and 
SDs): 
 
PA:   
WED=2.43(.84) 
NEUTRAL 
WRITING=2.89(.84) 
NA:   
WED=2.09(.59) 
NEUTRAL 
WRITING=2.11(.80) 
Writing about stressful 
effects of CPP leads to 
limited reductions in pain 
compared with writing 
about positive 
experiences, and 
mood/functioning appear 
to improve for women 
who are ambivalent over 
emotional expression or 
have elevated negative 
affect. 
 
Generalizability limited 
to primarily depressed 
sample of women with 
CPP; mental health: 
75% history of 
depression & 64.6% 
previous mental health 
treatment. 
Cohen et 
al (in prep) 
Data not available. Neutral writing 
–time 
For included groups: 
 
For included 
groups: 
Perceived stress (PS); 
Perceived Stress Scale 
Despite sufficient power, 
multiple assessment 
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 management 
(NEUTRAL 
WRITING). 
Data not available. 
 
 
Data not 
available 
(presumed no. 
randomised; 
(WED: 74 
(written=37; 
verbal=37), 
CONTROL: 39 
(written=19; 
verbal=20). 
 
 
(PSS). 
Positive Affect (PA); 
(Positive And Negative 
Affect Schedule (PANAS) 
+ve sub-scale). 
Negative Affect (NA); 
(Positive And Negative 
Affect Schedule (PANAS) -ve 
sub-scale). 
 
No sig. group effects on main 
outcomes (PS F=.162, p=.851;  
PA F=.316, p=.730, NA 
F=.783, p=.459). 
 
Effects based on unadjusted 
means at final follow up (and 
SDs): 
 
PA:     
WED=2.83(.78) 
NEUTRAL 
WRITING=2.98(.71) 
NA:     
WED=1.92(.72) 
NEUTRAL 
WRITING=1.83(.59) 
PS:   
WED=1.73(.68) 
NEUTRAL 
WRITING=1.66(.59) 
points, a range of 
measures, failed to find 
consistent evidence for 
the benefits of 
disclosure –may be 
disclosure conducted in 
the field has weaker 
effects than found in 
more highly controlled 
supervised 
environments. 
 
Both intervention and 
control condition 
contained both written 
and verbal tasks –found 
no differences in effect 
between the 2 methods 
across the follow 
ups/outcomes thus 
collapsed the 
categories. 
 
Danoff-
Burg et al 
(2006) 
 
Experience with 
rheumatic disease. 
 
Instructions consistent 
with original WED 
paradigm. 
 
20 minutes/4 sessions 
Neutral writing 
–facts about 
condition (non-
emotional) 
(NEUTRAL 
WRITING). 
For included groups: 
 
No. per group NOT REPORTED  (for 
total sample off the no. randomised 2 
(3%) dropped out having completed 
less than 3 of the 4 writing sessions 
(unclear whether those staying in 
completed all sessions as required -
For included 
groups: 
 
No. per group 
for included 
groups NOT 
REPORTED 
(total sample 
Depressive symptoms (DS); 
Centre for Epidemiological 
Studies –Depression (CES-
D) scale. 
Positive mood (PM); Profile 
Of Mood States (POMS) –
vigor sub-scale. 
 
Reduction in fatigue 
three months following 
the intervention was 
evident among patients 
assigned to standard 
WED and people with 
lower levels of trait 
anxiety may be more 
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20 minutes/within 3 
weeks. 
implied some completed only 3)? 
 
No. per group NOT REPORTED (for 
total sample review of essay content 
(essays ordered randomly and raters 
blind to group assignment) -86.9% 
essays correctly classified); 2 people 
in NEUTRAL WRITING revealed 
emotions despite being instructed to 
focus only on the facts). 
implied 64 
completing final 
follow up). 
 
No. included in 
analyses for 
DS (WED=20 
(83%), 
NEUTRAL 
WRITING=20 
(83%) & PM 
(WED=21(88%); 
NEUTRAL 
WRITING=20 
(83%) provided 
by author when 
final endpoint 
data provided. 
No sig. main effects. 
 
Inadequate data to calculate 
SMD; stated no significant 
difference, statistical test 
reported and means/SDs 
reported but not by group.  
 
Requested data from authors 
and obtained.   
 
Effects based on unadjusted 
means at final follow up (and 
SEs): 
 
DS:  WED=12.53 (2.42)  
         NEUTRAL 
WRITING=15.08 (2.57) 
comfortable processing 
and expressing emotion 
in the context of a WED 
intervention than those 
with high trait anxiety. 
 
Did not test for 
differences between 
disease groups due to 
small no. with SLE –may 
have influenced main 
effects found. 
Hamilton-
West & 
Quine 
(2007) 
 
Any stressful 
experience. 
 
20 minutes/3 
consecutive days. 
Neutral writing 
– time 
management 
(NEUTRAL 
WRITING). 
Of the no. randomised 39 (WED=27 
(38%), NEUTRAL WRITING=12 
(33%)) did not complete baseline 
measures/writing (unclear whether the 
remaining participants completed all 
writing sessions as required?)....but 
CB/KD decision that as the authors 
said these participants ‘completed 
baseline measures and diary writing 
exercise’ take this to mean that they 
did complete all sessions as required. 
 
None reported. 
ITT/LOCF so 
presumed 
WED=71 
(100%); 
NEUTRAL 
WRITING=36 
(100%) 
 
BUT when 
obtained data 
from author no. 
included in 3 
month follow 
up was 
WED=43 & 
NEUTRAL 
WRITING=24.  
Depression (D); Hospital 
Anxiety and Depression 
Scale (HADS). 
Global health (GH); Bath 
Ankylosing Spondylitis –
Global Score (BAS-G).  
 
Clinically important change 
defined as change of 2.6 
points on BAS-G (GH). 
 
(GH alone not reported as 
based on only 2 items & data 
NOT REPORTED). 
 
No sig. changes. 
 
Inadequate data to calculate 
SMD; stated no significant 
group effect. 
 
The results do not 
provide support for the 
use of emotional 
disclosure intervention 
for all patients with AS, 
although it may be 
useful for some patients 
on some outcomes (i.e. 
functional limitations). 
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Requested data from authors 
and obtained.   
 
Effects based on unadjusted 
means at final follow up (and 
SDs): 
 
D:     
WED=5.33 (3.57) 
NEUTRAL WRITING=6.46 
(3.49) 
GH: 
WED=4.82 (1.94) 
NEUTRAL WRITING=5.77 
(2.47) 
Wetherell 
et al (2005) 
 
Most upsetting 
experience in life. 
 
Instructions consistent 
with original WED 
paradigm. 
 
20 minutes/4 
consecutive days –
breaks during writing 
sessions allowed. 
Neutral writing 
– time 
management 
(NEUTRAL 
WRITING). 
Of the 42 randomised and assessed 
at baseline, implied 8 (19%) (but not 
completely clear/could be 9 (21%)) 
dropped out during intervention (but 
unclear whether those staying in 
completed writing sessions as 
required...implied they did?). 
 
Patient self-report and checklist (i.e. 
stress/arousal) –WED rated disclosure 
as more personal, emotional and 
stressful than NEUTRAL WRITING 
and a greater wish to share their 
information yet they had actively held 
back from doing this (all sig.). 
Implied 
WED=19, 
NEUTRAL 
WRITING=15 
(81% of total 
sample –
proportion per 
group not 
known).  
 
Mood disturbance (MD); 
Short Form Profile Of Mood 
States (POMS-SF).  
 
Sig. trend for improvement for 
WED compared to NEUTRAL 
WRITING at 10 weeks for MD 
F(1,28)=4.56, p=.04, ε=.14).  
 
Effects based on unadjusted 
means at final follow up (and 
SDs): 
 
MD:  
WED=33.9(26.1) 
NEUTRAL 
WRITING=43.5(19.9) 
 
The study provides 
preliminary evidence for 
a beneficial effect of 
emotional disclosure on 
mood outcomes in RA, 
but not on clinical and 
physiological measures 
of disease status. 
 
7/34 (21%) verbal not 
written disclosure. 
Vedhara et 
al (2007) 
 
Most traumatic 
experience of life. 
 
Instructions consistent 
with original WED 
paradigm. 
Neutral writing 
–time 
management 
(NEUTRAL 
WRITING). 
4 (6%) dropped out after baseline –the 
remaining participants ‘completed the 
study’ but unclear whether they 
completed any or all writing sessions 
as required. 
 
WED=31, 
NEUTRAL 
WRITING=28 
(86% of total 
sample –
proportion per 
Disease specific QoL 
(DSQoL); Dermatology Life 
Quality Index (DLQI). 
 
Mood; HADS and POMS (not 
described as an outcome in 
Disease severity and 
quality of life in patients 
with psoriasis improved 
in both the intervention 
and control patients over 
the follow up period and 
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20 minutes/4 
consecutive days. 
LIWC both groups and patient self-
report. WED rated writing as more 
personal, emotionally revealing, 
meaningful, and more likely to report 
having wanted to tell another person 
about the topic, having engaged in 
some disclosure of the topic 
previously but having held back re: 
what they had disclosed. WED used 
sig. more affective (overall), -ve affect, 
cognitive/insight words and pronouns 
than NEUTRAL WRITING (and 
NEUTRAL WRITING used more 
words re: time management). 
group not 
known). 
 
 
the paper but group end 
point data for final follow up 
reported). 
 
No sig. group difference at 12 
weeks for DS or DSQoL. 
 
Effects based on unadjusted 
means at final follow up (and 
SDs): 
 
DSQoL:  
WED=5.39(4.59) 
NEUTRAL 
WRITING=4.82(3.82) 
 
POMS  
WED=38.20(26.83) 
NEUTRAL WRITING 
=40.27(21.05) 
 
HADS depression 
WED=4.38(4.44) 
NEUTRAL WRITING 
=3.68(3.36) 
 
HADS anxiety 
WED=5.81(3.14) 
NEUTRAL WRITING 
=6.54(3.66) 
the magnitude of 
improvement was 
comparable between the 
groups –ED did result in 
improvements in these 
outcomes but these did 
not exceed those 
observed in the control 
group. 
Taylor et al 
(2003) 
 
Most distressing 
experience of life. 
 
Instructions consistent 
with original WED 
paradigm. 
 
20 minutes/3 
sessions/5 day period. 
Usual care 
(CONTROL). 
Of the no. randomised 5 (7%) didn’t 
complete all writing sessions and 
unclear whether 9 dropping out (some 
dropped because they didn’t complete 
follow up) completed the 
intervention....CB/KD decision authors 
say all 14 did not complete the 
intervention so take this (i.e. 20% of 
those randomised did not complete 
WED=18, 
CONTROL=21 
(56% of total 
sample –
proportion per 
group not 
known). 
 
 
Depression (D); Patient 
Health Questionnaire (PHQ) 
–depression sub-scale. 
Anxiety (A); Patient Health 
Questionnaire (PHQ) -
anxiety sub-scale. 
Psychological distress (PD); 
Patient Health Questionnaire 
(PHQ) –stressful life events 
The findings 
demonstrate an effect of 
written-self-disclosure 
on health care 
utilization. 
 
12(31%) completers 
aged 15-18yrs –sample 
had wide age span (i.e. 
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the intervention). 
 
Patient self-report (but re: feasibility 
and acceptability) –WED rated level of 
comfort while writing as very good and 
rated value for mental, physic al and 
overall health as fair  –no neutral 
writing condition to compare to. 
sub-scale. 
Health related QoL (HRQoL); 
Short Form-12 (SF-12) -
mental health component 
(MHC) & physical health 
component (PHC). 
 
No sig. effects for main 
outcomes. 
 
Effects based on unadjusted 
means at final follow up (and 
SDs): 
 
D:      
WED=12.4(4.1) 
CONTROL=13.9(4.2) 
A:      
WED=15.3(1.4) 
 CONTROL=16.1(3.1) 
PD:   
WED=14.8(6.9) 
CONTROL=14.3(3.1) 
MHC:  
WED=53.7(7.5) 
 CONTROL=49.5(9.1) 
PHC:   
WED=43.8(10.3) 
 CONTROL=43.3(10.0) 
adults and adolescents). 
Willmott et 
al (under 
review) 
 
Experience of having a 
heart attack. 
 
Instructions consistent 
with original WED 
paradigm 
BUT instructions to 
write about any 
emotions +ve or –ve, 
thoughts about how 
Neutral writing 
–time 
management 
(NEUTRAL 
WRITING). 
Stated most attrition occurred before 
writing (implied WED=8(9%); 
NEUTRAL WRITING=14(15%) (but no 
indication whether those who stayed 
in/started writing completed all writing 
sessions as required?). 
 
Participant self-report –WED reported 
writing sig more personal, secret, 
emotionally expressive and 
WED=79 (90%), 
NEUTRAL 
WRITING=77 
(85%). 
 
 
Health related QoL (HRQoL) 
–Short Form-36 (SF-36); 
mental health component 
(MHC) & physical health 
component (PHC). 
 
Group difference in change 
over time was non-sig. for 
PHC (F(2, 2258)=.17, P>.01) 
and marginal for MHC 
Findings suggest that 
written emotional 
disclosure is a beneficial 
strategy which could be 
incorporated into 
existing rehabilitation 
programs to help 
individuals adjust after 
first MI. 
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they might cope, and in 
last session 
encouraged to try and 
wrap things up (i.e. 
think about the future). 
 
Minimum 10 minutes– 
maximum 20 minutes/3 
consecutive days. 
meaningful/valuable than NEUTRAL 
WRITING. LIWC both groups –WED 
more +ve emotion, -ve emotion, 
insight, and causal words than 
NEUTRAL WRITING (all p<.001). 
(F(2,258)=2.94, p=.055) –inc 
in WED but dec. in  NEUTRAL 
WRITING at 5 months but no 
sig. group difference in MHC 
at 5 months (F(1,137)=3.40, 
p>.05). 
 
Effects based on adjusted 
means at final follow up (and 
SDs): 
 
MHC: 
WED=71.28(20.50) 
NEUTRAL 
WRITING=63.12(22.01) 
PHC:  
WED=67.91(22.61) 
NEUTRAL 
WRITING=62.48(23.17) 
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Appendix F: Risk of bias decisions table 
(Some studies included more than the two intervention groups that were included in the present review, thus attrition and numbers of participants included in analyses are 
presented for only the included groups) 
Study Randomisation Score Allocation concealment  Score Blinding Score Completeness of outcome data Score 
de Moor et 
al (2002) 
 
Randomisation 
stated and 
sequence 
generated by 
minimisation. 
Y Method of randomly 
allocating participants not 
described thus not known 
whether concealed. 
N Neutral writing control but no 
indication information received 
at enrolment sufficiently vague 
to ensure blinding. 
 
Participants also outcome 
assessors thus possibly not 
blind. 
N Attrition: 5 (12%) (WED=2(10%), 
NEUTRAL WRITING=3(14%)) did 
not provide data for at least 1 
follow up –attrition for final follow 
up not reported.  
 
Thus, number providing data for 
at least 1 follow up reported per 
group: (88%) (EW=90%, 
NW=86%) - but number not 
completing final follow up not 
known. 
 
Average number of follow ups 
completed also reported: EW=3.4 
(SD1.7) and NW=3.1 (SD 2.1). 
 
Included in analyses: 37 (88%) 
WED=19 (90%), NEUTRAL 
WRITING=18 (86%). Implied data 
partially included where available. 
The number included in analyses 
was the number providing data 
for at least 1 follow up & 
’correlations among observations 
were modelled thus the group 
effect represented the average 
intervention effect across all time 
points. 
? 
Gellaitry et 
al (2009) 
Computer 
generated 
random number 
table used. 
Y No mention of whether 
allocation concealed. 
 
N No neutral writing control and 
no indication information at 
enrolment sufficiently vague to 
ensure participant blinding: 
stated participants informed 
N Attrition: 13 (14%) (WED=7(16%), 
CONTROL=6(12.5%)) did not 
provide complete data  - attrition 
for final follow up not reported but 
can be somewhat inferred:  
Y 
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they would be randomised to a 
writing or non-writing group. 
 
Participants also outcome 
assessors thus possibly not 
blind. 
 
Not reported whether 
interviewer ‘monitoring’ 
telephone calls post 
intervention was blind. 
 
Only 3 of the lost patients were 
excluded for incomplete data 
rather than dropped out (i.e. and 
thus likely did not complete final 
follow up) -unclear which follow 
up these patients did not 
complete (i.e. whether final follow 
up was completed) but this 
number is conservative and 
presumes they did not complete 
the final follow up (i.e. if these 3 
patients did complete final follow 
up attrition would be less than is 
reported here). 
 
Thus, number providing complete 
follow up data (& likely the final 
follow up) reported by group: 86% 
(EW=84%, NW=87%)   
 
Included in analyses: 80 (86%) 
WED=38 (84%); CONTROL=42 
(87.5%). Implied complete case 
analysis. 
Low et al 
(2010) 
 
Computerised 
random 
numbers 
generator. 
Y Sealed sequentially 
numbered envelopes used 
to conceal allocation (& 
implied that different 
person generated 
randomisation schedule to 
the person enrolling 
patients). 
Y Neutral writing but no 
indication information received 
at enrolment sufficiently vague 
to ensure blinding. 
 
Participants also outcome 
assessors thus possibly not 
blind. 
 
N Attrition: 14 (18%) (WED=7 
(18%), NEUTRAL WRITING=7 
(18%) did not complete follow up 
(11 died, 2 did not return follow 
up no reason provided & 1 
dropped from the study as did not 
complete writing within the time 
interval allowed) (& only one 
follow up) . 
 
Thus, number providing complete 
follow up reported by group (& 
only one follow up): 82% (EW 
82%; NW 82%). 
Y 
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Included in analyses:  62 (82%) 
WED=31 (82%), NEUTRAL 
WRITING=31 (82%). Implied 
complete case & per protocol 
analysis (i.e. included in analysis 
if completed intervention and 
follow up). 
Rosenberg 
et al (2002) 
 
Randomisation 
stated but 
method not 
described. 
? Interviewers enrolling 
participants blind until 
writing but no indication of 
how this was achieved. 
? No attempt to blind 
participants (usual care 
control/no indication 
information at enrolment 
vague). 
 
Participants also outcome 
assessors thus possibly not 
blind. 
N Attrition: No attrition/all 
randomised completed study thus 
implied completed final follow up; 
complete data for most outcomes. 
 
Thus, number providing complete 
follow up reported: 30 (100%) 
(EW 100%; NW 100%). 
 
Included in analyses:  Implied 30 
(100%) (number per group 
provided by authors: WED=16 
(100%), CONTROL=14 (100%).  
Y 
Walker et al 
(1999) 
 
Randomised 
but method not 
appropriate –
assigned 
sequentially to 
groups. 
N No indication those 
enrolling/allocating 
participants to conditions 
were unaware of 
randomisation schedule. 
N No neutral writing control and 
no indication information at 
enrolment sufficiently vague to 
ensure participant blinding. 
 
Outcome assessors 
conducting follow up telephone 
interviews blind but outcomes 
subjective thus possibly not 
blind. 
N For included groups 
 
Attrition: 7(20%) WED=5(26%), 
CONTROL=2(13%) dropped as 
they did not complete the 
intervention as required/did not 
provide data at all follow ups –- 
attrition for final follow up not 
reported but can be somewhat 
inferred:  
 
The lost patients were excluded 
for not completing the 
intervention/incomplete follow up 
data -unclear whether final follow 
up was completed but this 
number is conservative and 
presumes they did not complete 
Y 
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the final follow up (i.e. if these 
patients did complete final follow 
up attrition would be less than is 
reported here). 
 
Thus, number completing the 
intervention/all follow ups 
reported by group: 80% 
(WED=74%, CONTROL=87%)  -
but number not completing final 
follow up not reported. 
 
Group differences in attrition 
apparent (CTL greater than 20%) 
–but not know for final follow up.  
 
Included in analyses:  28 (80%) 
WED=14 (74%), CONTROL=14 
(87.5%). Implied complete case & 
per protocol analysis. 
Zakowski et 
al (2004) 
Randomisation 
stated but 
method not 
described. 
? No description of the 
method of random 
allocation thus no 
indication of whether 
concealed. 
N Neutral writing control but no 
indication information at 
enrolment sufficiently vague to 
ensure participant blinding. 
 
Participants were outcome 
assessors except for 
telephone reminders from 
interviewer who administered 
intervention thus possibly not 
blind. 
N Attrition: 23 (18%) 
(WED=12(16%), NEUTRAL 
WRITING=11(21%) dropped out 
after baseline/the intervention & 
so did not provide data for final 
follow up. 
 
Thus, number completing final 
follow up reported by group: 82% 
(EW=84%, NW=79%). 
 
Very slight group differences in 
attrition (NW great than 20%). 
 
Included in analyses:  Implied 104 
(82%) WED=62 (84%), 
NEUTRAL WRITING=42 (79%). 
Implied data partially included 
were available. 
Y 
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Gillis et al 
(2006) 
 
Random 
numbers table –
stratified by 
gender. 
Y Packs given ID, 
randomised, and 
experimenter 
enrolling/allocating 
participants/mailing packs 
blind (but unclear whether 
this is because separate 
person to the one enrolling 
generated randomisation 
schedule).  
 
Also unclear whether 
packs sealed?  
Y Neutral writing control and 
information at enrolment 
designed to ensure participant 
blinding:  the study was 
described generically 
(to ensure blinding) as 
designed to see how writing 
about different aspects of a 
person’s life might influence 
their health and adjustment. 
 
Not informed of allocation to 
EW/NW group. 
 
Participants also outcome 
assessors thus blind. 
Y Attrition: 15 (18%) (WED=9(20%), 
NEUTRAL WRITING=6(16%)). 
  
Thus, number completing final 
follow up reported by group: 82% 
(EW=80%, NW=84%).  
 
Group differences in attrition 
formally assessed –no significant 
difference and appears to be true. 
 
Included in analyses:  
ITT: WED=45 (100%), NEUTRAL 
WRITING=38 (100%).    
 
68 (82%) WED=36 (80%), 
NEUTRAL WRITING=32 (84%) 
included in completer analysis for 
which group final end-point data 
were available. Implied data 
partially included where available. 
Y 
Norman et 
al (2004) 
 
Randomisation 
stated –
restricted by 
blocking but 
method of 
deriving random 
allocation within 
blocks not 
described. 
? Sealed packets numbered, 
randomised and 
interviewer 
enrolling/allocating 
participants blind (but 
unclear whether this is 
because separate person 
to the one enrolling 
generated randomisation 
schedule). 
 
But –block size only 2 thus 
person enrolling may have 
inferred some group 
assignment if deciphered 
box size (i.e. unclear 
whether researcher 
enrolling blind after 
Y Neutral writing control 
designed to have face validity 
for reducing stress/being 
meaningful, and information at 
enrolment sufficiently vague to 
ensure participant blinding; the 
study was described as 
designed to get a better 
understanding of the 
experience of pelvic pain and 
to explore the effects of a 
writing exercise on pain, 
mood, and functioning (NW 
involved writing about positive 
experiences/not pelvic pain –
slight risk of compromised 
blinding but not great). 
 
Y Attrition: 12 (20%) 
(WED=4(12.5%), PW=8(29%) did 
not provide data for final follow 
up. 
 
Thus, number not completing final 
follow up reported by group: 80% 
(EW=88%, NW=71%)  
 
Slight imbalance in attrition (NW 
less than 80%). 
 
Included in analyses:  48 (80%) 
WED=28 (88%), NW=20 (71%). 
Implied data partially included 
where available. 
Y 
531 
 
allocation concealment). Not informed of allocation to 
EW/NW group. 
 
Participants also outcome 
assessors thus blind. 
Danoff-Burg 
et al (2006) 
 
Randomisation 
stated in 
abstract but 
method not 
described. 
? Stated experimenter blind 
and handed instructions to 
participants in envelope –
but not clear whether 
envelopes were 
sealed/serially numbered? 
 
Also unclear whether blind 
because separate person 
to the one enrolling 
generated randomisation 
schedule. 
? Neutral writing control and 
information at enrolment 
sufficiently vague to ensure 
participant blinding:  
participants were informed that 
the study would involve 
completing questionnaires and 
writing about rheumatic 
disease (& both groups them 
wrote about the condition). 
 
Not informed of allocation to 
EW/NW group. 
 
Participant’s also outcome 
assessors thus blind. 
Y For included groups 
 
Attrition: Number per group for 
included groups NOT 
REPORTED (for total sample 
11(15%). 
 
Thus, number completing final 
follow up provided for total 
sample 85%  -but not by group or 
for included groups. 
  
Group differences in attrition 
somewhat assessed i.e. stated 
completion of follow up did not 
vary as a function of group 
assignment. 
 
No. included in analyses: Number 
per group for included groups 
NOT REPORTED (total sample 
implied 64 (85%) completing final 
follow up). 
 
No. included in analyses for 
depressive symptoms 40 (83%) 
(WED=20 (83%), NEUTRAL 
WRITING=20 (83%) provided by 
group by author when final end 
point data provided (i.e. 8 of the 
lost participants were to these 
groups, 4 (16%) per group). 
Implied data partially included 
where available. 
Y 
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Hamilton-
West & 
Quine 
(2007) 
 
Computer 
generated list –
restricted by 
blocking. 
Y Only one researcher who 
had no contact with 
participants knew 
randomisation schedule 
and does state person 
allocating participant’s 
blind but no indication of 
how this was achieved (& 
researcher that knew the 
schedule might have 
enrolled -don’t have to 
meet participants to do 
this). 
 
Also blocking (size 
unreported) –person 
enrolling may have 
inferred future allocations 
had they inferred block 
size (as don’t know 
whether researcher 
enrolling was blind after 
AC). 
? Neutral writing control and 
information at enrolment 
sufficiently vague to ensure 
participant blinding: 
participants were informed that 
that they would be asked to 
keep a detailed diary which 
would involve writing about 
their experiences (& control 
group wrote about plans for 
the following day). 
 
Not informed of allocation to 
EW/NW group. 
 
Participants also outcome 
assessors thus blind. 
Y Attrition: 62 (58%) (WED=41 
(58%); NEUTRAL WRITING=21 
(58%). 
 
Thus, number completing final 
follow up as planned reported by 
group: 42% (EW=42% NW=42%).  
 
Group differences in attrition 
formally assessed -no group 
differences and seems to be true. 
 
Included in analyses: ITT/LOCF 
so presumed WED=71 (100%); 
NEUTRAL WRITING=36 (100%). 
 
BUT when obtained data from 
authors no. included in 3 month 
follow up was WED=43 & 
NEUTRAL WRITING=24 (not the 
number competing follow up (i.e.  
WED=30 (42%), NEUTRAL 
WRITING=15 (42%). Implied 
missing data imputed for those 
completing baseline assessment 
NOT RANDOMISED (i.e. number 
randomised was 107 (WED=71, 
NEUTRAL WRITING=36) & 
number completing baseline 
assessment was WED=44 & 
NEUTRAL WRITING=24) minus 
one intervention participant 
excluded for some outcomes (i.e. 
must have been missing data for 
one participant on these 
outcomes). 
N 
Wetherell et 
al (2005) 
 
Randomisation 
stated but 
method not 
? Stated researcher 
enrolling participant’s blind 
to subsequent group 
? Neutral writing control and 
information at enrolment 
sufficiently vague to ensure 
Y Attrition: 8 (19%) (but not 
completely clear/could be 9 (21%) 
did not complete intervention or 
? 
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described. allocation but no 
description of how this was 
achieved. 
participant blinding:  
participants were informed it 
was a study to assess the 
effects of 
writing or talking about 
particular topics on the 
symptoms of RA and that of 
particular interest was how the 
topics make you feel and what 
effect this has on the 
symptoms of your RA. No 
information regarding 
individual topics was given but 
patients were informed that it 
was possible that they could 
find some of the topics 
upsetting –risk of pre-
disclosure priming but unlikely 
to have inferred group 
assignment. 
 
Not informed of allocation to 
EW/NW group. 
 
Participants also outcome 
assessors thus blind. 
provide data at final follow up - 
number per group not reported. 
 
Thus, exact number completing 
follow up 81% (but possibly 9 
dropped out, not 8, if so this 
would be 79%) - number per 
group not reported. 
 
Included in analyses:  Implied 34 
(81%) (WED=19, NEUTRAL 
WRITING=15 –proportion per 
group not known). Implied data 
partially included where available. 
Vedhara et 
al (2007) 
 
Randomisation 
stated –
restricted by 
blocking/stratifie
d by gender but 
method of 
generating 
random 
allocation within 
each block not 
described. 
? Method of random 
allocation not described 
thus no indication of 
whether concealed. 
 
NB blocks of 20 -some 
future allocations may 
have been inferred if block 
size deduced (i.e. don’t 
know whether researcher 
enrolling was blind after 
allocation 
concealment...unlikely as 
N Neutral writing control and 
implied information at 
enrolment sufficiently vague to 
ensure participant blinding:  
stated no information 
regarding individual topics was 
given patients were only 
informed that it was possible 
that they could find some of 
the topics upsetting –risk of 
pre-disclosure priming but 
unlikely to have inferred group 
assignment. 
Y Attrition: 4 (6%) dropped out after 
baseline/did not ‘complete the 
study’ & then 6 (9%) did 
‘complete the study’ but did not 
provide complete follow up data 
(& were excluded from analyses) 
–number per group not reported 
& number providing data at final 
follow up not known but can be 
somewhat inferred:  
 
Only 6 of the lost patients were 
excluded for incomplete data 
Y 
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patients were called with 
writing instructions –but 
don’t know whether this is 
the same as the person 
enrolling). 
 
Participants also outcome 
assessors thus blind. 
rather than dropped out (i.e. and 
thus likely did not complete final 
follow up) -unclear which follow 
up these patients did not 
complete (i.e. whether final follow 
up was completed) but this 
number is conservative and 
presumes they did not complete 
the final follow up (i.e. if these 6 
patients did complete final follow 
up attrition would be less than is 
reported here). 
 
Thus, number ‘completing study’ 
or providing complete follow up 
data reported (& likely the final 
follow up): 59 (85%) but not by 
group. 
 
Included in analyses: 59 (85%)  
WED=31, NEUTRAL 
WRITING=28 –proportion per 
group not known). Implied 
complete case analysis. 
Taylor et al 
(2003) 
 
Randomisation 
stated but 
method not 
described. 
? Method of randomly 
allocating not described 
thus no indication of 
whether concealed. 
N No neutral writing control and 
information at enrolment not 
sufficiently vague to ensure 
participant blinding: told study 
about relationship between 
feelings and physical health. 
 
Participants also outcome 
assessors thus possibly not 
blind. 
N 14 (20%) ‘did not complete the 
intervention/study’ (5 did not 
complete writing as required, 6 
did not return for follow up (& only 
one follow up) & 2 lung transplant 
(implied dropped out) –number 
per group not reported & number 
providing data at final follow up 
not known but can be somewhat 
inferred: 
 
Only 5 of the lost patients were 
excluded for incomplete data 
rather than dropped out (i.e. and 
thus likely did not complete final 
Y 
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follow up) -unclear which follow 
up these patients did not 
complete (i.e. whether final follow 
up was completed) but this 
number is conservative and 
presumes they did not complete 
the final follow up (i.e. if these 5 
patients did complete final follow 
up attrition would be less than is 
reported here). 
 
Thus. number completing follow 
up reported (& only one follow 
up): 80%.  
 
BUT additional 17 (24%) 
participants with unusually high or 
low health care use excluded 
from analysis to test the effect of 
WED for patients with typical 
utilization patterns (not known 
whether they completed follow up 
–implied they did). 
 
Included in analysis: 39 (56%) 
WED=18, CONTROL=21–
proportion per group not known). 
Implied per protocol analysis/data 
partially included where available. 
Willmott et 
al (under 
review) 
 
Randomisation 
stated but 
method not 
described. 
? No mention of whether 
allocation concealed & 
stated researchers not 
blind. 
N Neutral writing control and 
implied information at 
enrolment sufficiently vague to 
ensure participant blinding: 
stated participants informed 
they would be writing about 
potentially different topics. 
 
Not informed of allocation to 
EW/NW group. 
Y Attrition: 23 (13%) (WED=9(10%), 
CONTROL=14(15%)) did not 
complete follow up –attrition at 
final follow up can be somewhat 
inferred: 
 
Only 1 of the lost patients were 
lost to follow up (most were lost 
before writing) thus implied only 1 
patient did not complete all follow 
Y 
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Participants also outcome 
assessors thus blind. 
ups - unclear which follow up this 
was lost to (i.e. whether final 
follow up was completed) but this 
number is conservative and 
presumes this patient did not 
complete the final follow up (i.e. if 
this patient did complete final 
follow up attrition would be less 
than is reported here). 
 
Thus, number completing follow 
up reported by group 87% 
(EW=90%, NW=85%).   
 
Included in analyses:  156 (87%) 
WED=79 (90%), NEUTRAL 
WRITING=77 (85%). Implied 
complete case analysis (if one 
patient lost to follow up after 
writing provided some data) or 
data partially included as 
available (if this patient did not 
provide any data). 
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Appendix G: Within study data 
 
 
Trial/outcome Summary Data Individual 
Effects  
(SMD (95% CIs) 
WED                             Control 
Mean      SD N Mean SD N 
Taylor - negative affect 
Taylor et al (2003): PHQ depression -12.4  4,1 18 -13.9 4.2 21 .35 (-.28 to .99) 
Taylor et al (2003): PHQ anxiety -15.3 1.4 -16.1 3.1 .32 (-.32 to .95) 
Vedhara – negative affect 
Vedhara et al (2007): POMS -38.2 26.83 31 -40.27 21.05 28 .08 (-.43 to .60) 
Vedhara et al (2007): HADS depression -4.38 4.44 -3.68 3.36 -.17 (-.69 to .34) 
Vedhara et al (2007): HADS anxiety -5.81 3.14 -6.54 3.66 .21 (-.30 to .72) 
Taylor - health-related Sol 
Taylor et al (2003): physical 43.8 10.3 18 43.3 10 21 .05 (-.58 to .68) 
Taylor et al (2003): mental 53.7 7.5 49.5 9.1 .49 (-.15 to 1.13) 
Willmott - health-related Sol 
Willmott et al (under review): physical 67.91 22.61 79 62.48 23.17 77 .24 (-.08 to .55) 
Willmott et al (under review): mental  71.28 20.50 63.12 22.01 .38 (.07 to .70)* 
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Appendix H: Funnel plots 
 
Positive affect 
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Appendix I: Sensitivity analyses 
Running meta-analysis without Cohen et al (in prep) 
Positive affect without Cohen: no change (non-significant trend for a small negative 
effect). 
 
 
 
Negative affect without Cohen: change from trend for a positive effect that was 
small and marginally inconclusive yet approaching significance to a small positive 
and significant effect. 
 
 
 
 
  
Study 
Cohen 
Danoff-Burg
deMoor
Gellaitry
Gillis
Hamilton West & Quine 
Low
Norman
Rosenberg
Taylor
Vedhara
Walker
Wetherell
Total (95% CI) 
Heterogeneity: Tau² = 0.00; Chi² = 6.71, df = 11 (P = 0.82); I² = 0%
Test for overall effect: Z = 2.17 (P = 0.03) 
Mean 
-1.92
  -12.53
-15.7
  -20.63
-1.91
-5.33
 -12.8
 -2.09
 -2.38
 -13.85 
  -16.13
 -17.1
 -33.9
SD 
0.72 
10.8 
20.49 
32.28
0.71
3.57
8.24
0.59 
2.83 
2.75 
11.47 
5.99 
26.1
Total 
74
20 
19 
38 
36 
43 
31 
28 
16
  18
 31
14
 19
313
Mean 
-1.83 
-15.08 
-19.8 
-24.21 
-2.14 
-6.46
-13.2
-2.11
-6.21
-15 
-16.83 
-14.1
-43.5 
SD 
0.59 
11.5 
22.06 
36.97 
0.78 
3.49 
8.24
0.8 
7.41
3.65 
9.35 
6.36 
19.9 
Total 
39
20
18
42
32
24
31
 20 
14
21
28
14
15
279 
IV, Random, 95% CI
-0.13 [-0.52, 0.26]
0.22 [-0.40, 0.85] 
0.19 [-0.46, 0.83] 
0.10 [-0.34, 0.54] 
0.31 [-0.17, 0.78] 
0.32 [-0.19, 0.82] 
0.05 [-0.45, 0.55] 
0.03 [-0.55, 0.60] 
0.68 [-0.06, 1.42] 
0.34 [-0.29, 0.98] 
0.07 [-0.45, 0.58] 
-0.47 [-1.22, 0.28]
0.40 [-0.29, 1.08] 
0.18 [0.02, 0.34]
WED SMD 
IV, Random, 95% CI
-1 -0.5 0 0.5 1
Favours control Favours WED 
Control 
Study 
Cohen 
Norman 
Walker
Total (95% CI)
Heterogeneity: Tau² = 0.19; Chi² = 2.63, df = 1 (P = 0.11); I² = 62% 
Test for overall effect: Z = 0.47 (P = 0.64)
Mean
2.83
2.43
36.4
SD
  0.78 
0.84
5.99
Total
74
28
14
42
Mean
2.98
2.89
34.8
SD
0.71
0.84
6.73
Total
39
20 
14
34
IV, Random, 95% CI 
-0.20 [-0.59, 0.19]
-0.54 [-1.12, 0.05]
0.24 [-0.50, 0.99] 
-0.18 [-0.95, 0.58]
WED SMD SMD
IV, Random, 95% CI
-4 -2 0 2 4
Favours control Favours WED 
Control
SMD 
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Negative affect in rheumatic conditions without Cohen: changes from a non-
significant and inconclusive effect to a small positive effect that was approaching 
significance. 
 
 
 
 
Distress without Cohen: no change (non-significant trend for a small negative 
effect). 
 
 
 
 
Running meta-analysis with only neutral writing comparison (i.e. usual care 
removed)  
Positive affect without Walker: no change (a non-significant trend for a small 
negative effect). 
  
 
 
  
Study 
Cohen
Norman
Walker
Total (95% CI) 
Heterogeneity: Tau² = 0.00; Chi² = 0.91, df = 1 (P = 0.34); I² = 0% 
Test for overall effect: Z = 1.83 (P = 0.07)
Mean
2.83 
2.43 
36.4 
SD
0.78
0.84
5.99
Total
74 
28 
14 
102
Mean
2.98
2.89
34.8
SD
0.71
0.84
6.73
Total
39 
20 
14 
59 
IV, Random, 95% CI
-0.20 [-0.59, 0.19]
-0.54 [-1.12, 0.05]
0.24 [-0.50, 0.99]
-0.30 [-0.63, 0.02] 
WED SMD
IV, Random, 95% CI
-2 -1 0 1 2
Favours control Favours WED
Study 
Cohen 
deMoor
Taylor
Zakowski 
Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.39, df = 2 (P = 0.82); I² = 0%
Test for overall effect: Z = 0.01 (P = 0.99)
Mean
-1.73 
-19.8 
-14.8 
-0.35 
SD
0.68
3.92
6.9
0.4
 Total
74
19
18
62
99
Mean
-1.66 
-20.5
-14.3
-0.34
SD
0.59
3.82
3.1 
0.4 
Total 
39 
18 
21 
42 
81
IV, Random, 95% CI
-0.11 [-0.49, 0.28]
0.18 [-0.47, 0.82]
-0.09 [-0.72, 0.54]
-0.02 [-0.42, 0.37]
0.00 [-0.29, 0.30]
WED Control SMD SMD 
IV, Random, 95% CI
-2 -1 0 1 2
Favours control Favours WED 
Study 
Cohen 
Danoff-Burg
Hamilton West & Quine
Wetherell 
Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.14, df = 2 (P = 0.93); I² = 0%
Test for overall effect: Z = 1.78 (P = 0.07)
Mean
    -1.92
     -12.53
     -5.33
     -33.9
SD
   0.72 
   10.8 
   3.57 
   26.1 
  Total 
      74
      20
      43
      19
82
Mean
 -1.83 
 -15.08 
-6.46 
 -43.5 
SD 
  0.59
 11.5
  3.49
  19.9
Total 
39
20
24
15
59
IV, Random, 95% CI
-0.13 [-0.52, 0.26]
0.22 [-0.40, 0.85]
0.32 [-0.19, 0.82]
0.40 [-0.29, 1.08]
0.31 [-0.03, 0.65]
  Control SMD SMD
IV, Random, 95% CI 
-2 -1 0 1 2
Favours control Favours WED 
SMDControl
WED 
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Negative affect without Gellaitry, Rosenberg, Walker & Taylor: no change (a trend 
for a positive effect that was small and marginally inconclusive yet approaching 
significance; slightly less notable though). 
 
 
 
 
 
Negative affect in cancer without Gellaitry, Rosenberg & Walker: no change (non-
significant and inconclusive effect). 
 
 
 
  
Study 
deMoor 
Gellaitry
Low 
Rosenberg
Walker
Total (95% CI) 
Heterogeneity: Tau² = 0.00; Chi² = 0.11, df = 1 (P = 0.74); I² = 0% 
Test for overall effect: Z = 0.50 (P = 0.62) 
Mean 
-15.7
-20.63 
-12.8
-2.38
-17.1
SD
20.49 
32.28 
8.24
2.83
6.36
Total
19
38 
31 
16
14 
50 
Mean 
-19.8
-24.21 
-13.2
-6.21
-14.1
SD
22.06
36.97 
8.24
7.41 
5.99 
Total
18 
42 
31 
14 
14
49 
IV, Random, 95% CI 
0.19 [-0.46, 0.83]
0.10 [-0.34, 0.54]
0.05 [-0.45, 0.55]
0.68 [-0.06, 1.42]
-0.47 [-1.22, 0.28]
0.10 [-0.29, 0.49]
WED Control SMD SMD
IV, Random, 95% CI 
-4 -2 0 2 4
Favours controlFavours WED 
Study 
Cohen 
Danoff-Burg
deMoor 
Gellaitry 
Gillis 
Hamilton West & Quine 
Low 
Norman
Rosenberg 
Taylor
Vedhara
Walker
Wetherell
Total (95% CI) 
Heterogeneity: Tau² = 0.00; Chi² = 3.77, df = 8 (P = 0.88); I² = 0% 
Test for overall effect: Z = 1.41 (P = 0.16) 
Mean 
-1.92
 -12.53
 -15.7
 -20.63
-1.91
 -5.33
 -12.8
 -2.09
 -2.38
  -13.85
  -16.13
 -17.1
 -33.9
SD 
0.72 
10.8 
 20.49
 32.28
0.71
3.57
 8.24
 0.59 
 2.83 
 2.75
 11.47
 5.99 
26.1
Total
74 
20 
19 
38 
36 
43 
31
28 
16 
18 
31
14 
19 
301
Mean
-1.83 
-15.08 
-19.8 
-24.21
-2.14
-6.46 
-13.2 
-2.11
-6.21
-15
-16.83 
-14.1
-43.5
SD 
0.59 
11.5 
22.06 
36.97 
0.78 
 3.49 
8.24 
0.8 
7.41
3.65 
9.35 
 6.36 
19.9 
Total
39
20 
18
42
32
24
31
20
14
21
28
14
15
227
IV, Random, 95% CI 
-0.13 [-0.52, 0.26]
0.22 [-0.40, 0.85]
0.19 [-0.46, 0.83]
0.10 [-0.34, 0.54]
0.31 [-0.17, 0.78]
0.32 [-0.19, 0.82]
0.05 [-0.45, 0.55]
0.03 [-0.55, 0.60]
0.68 [-0.06, 1.42]
0.34 [-0.29, 0.98]
0.07 [-0.45, 0.58]
-0.47 [-1.22, 0.28]
0.40 [-0.29, 1.08]
0.12 [-0.05, 0.30]
Control SMD 
IV, Random, 95% CI
-1 -0.5 0 0.5 1
Favours control Favours WED 
WED SMD 
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Distress without Taylor: no change (non-significant and inconclusive effect). 
 
 
 
 
Quality of life without Gellaitry, Rosenberg & Taylor: a small positive effect that 
changed from being significant to approaching significance. 
 
 
 
 
Running meta-analysis with only follow up ≥3 months (i.e. <3 month removed) 
Positive affect without Norman: change from a non-significant trend for a small 
negative effect to a non-significant and inconclusive effect. 
 
 
 
 
  
Study 
Cohen
Norman
Walker
Total (95% CI)
Heterogeneity: Tau² = 0.01; Chi² = 1.06, df = 1 (P = 0.30); I² = 6% 
Test for overall effect: Z = 0.51 (P = 0.61)
Mean 
2.83 
2.43 
36.4 
SD
0.78 
0.84
5.99 
Total
74
28
14
88
Mean 
2.98 
2.89 
34.8 
SD
0.71 
0.84
6.73 
Total
39
20 
14 
53
IV, Random, 95% CI
-0.20 [-0.59, 0.19]
-0.54 [-1.12, 0.05]
0.24 [-0.50, 0.99]
-0.10 [-0.46, 0.27] 
WED Control SMD SMD
IV, Random, 95% CI
-2 -1 0 1 2 
Favours control Favours WED
Study 
Gellaitry
Gillis
Hamilton West & Quine
Rosenberg
Taylor 
Vedhara
Willmott
Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 3.27, df = 3 (P = 0.35); I² = 8%
Test for overall effect: Z = 1.75 (P = 0.08)
Mean
109.56
-52.7 
-4.82 
130.16
48.75 
 -5.39 
69.6 
SD 
19.81 
20.35 
 1.94 
12.6 
8.9
4.59
21.56
Total 
38
36
 43 
16 
18 
31
79
189
Mean
108.03
-53.79 
-5.77 
107.92 
46.4
-4.82
62.8 
SD 
21.36 
18.13 
2.47 
69.03 
9.55 
3.82 
22.59
Total 
 42 
32 
 24 
 14 
 21 
 28 
 77 
161
IV, Random, 95% CI
0.07 [-0.37, 0.51]
0.06 [-0.42, 0.53]
0.44 [-0.07, 0.94]
0.45 [-0.28, 1.18]
0.25 [-0.38, 0.88]
-0.13 [-0.64, 0.38]
0.31 [-0.01, 0.62]
0.20 [-0.02, 0.42]
WED SMD SMD 
IV, Random, 95% CI 
-1-0.5 0 0.5 1
Favours control Favours WED 
Control 
Study 
Cohen 
deMoor 
Taylor
Zakowski
Total (95% CI) 
Heterogeneity: Tau² = 0.00; Chi² = 0.55, df = 2 (P = 0.76); I² = 0% 
Test for overall effect: Z = 0.22 (P = 0.82)
Mean
-1.73 
-19.8 
-14.8
-0.35
SD
0.68 
3.92 
6.9
0.4
Total
74
19
18 
62
155
Mean 
-1.66 
-20.5 
-14.3
-0.34
SD
0.59
3.82
3.1
0.4
Total
39
18 
21 
42 
99
IV, Random, 95% CI 
-0.11 [-0.49, 0.28]
0.18 [-0.47, 0.82] 
-0.09 [-0.72, 0.54]
-0.02 [-0.42, 0.37]
-0.03 [-0.28, 0.22] 
Control SMD SMD
IV, Random, 95% CI
-2 -1 0 1 2
Favours controlFavours WED 
WED
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Negative affect without de Moor, Norman & Wetherell: no change (a trend for a 
positive effect that was small and marginally inconclusive yet approaching 
significance; slightly less notable though). 
 
 
 
 
Negative affect in cancer without de Moor: no change (a non-significant and 
inconclusive effect). 
 
 
 
Negative affect in chronic pain without Norman: no change (a non-significant trend 
for a small positive affect). 
 
 
 
  
Study 
Gillis
Norman
Total (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.38 (P = 0.17)
Mean
-1.91 
-2.09 
SD
0.71
0.59
Total
45
28
45
Mean
-2.14
-2.11 
SD 
0.78 
0.8
Total 
38
20 
38
IV, Random, 95% CI 
0.31 [-0.13, 0.74]
0.03 [-0.55, 0.60]
0.31 [-0.13, 0.74]
WED SMD
IV, Random, 95% CI
-4 -2 0 2 4
Favours control Favours WED 
Control 
Study 
deMoor
Gellaitry
Low 
Rosenberg 
Walker
Total (95% CI)
Heterogeneity: Tau² = 0.05; Chi² = 4.63, df = 3 (P = 0.20); I² = 35% 
Test for overall effect: Z = 0.49 (P = 0.63)
Mean
-15.7 
-20.63 
-12.8 
-2.38 
-17.1 
SD
20.49
32.28
8.24
2.83
6.36
Total 
19 
38
31
16
14
99 
Mean
-19.8 
-24.21
-13.2
-6.21 
-14.1
SD
22.06
 36.97
8.24
7.41
5.99
Total 
18
42
31
14
14
101
IV, Random, 95% CI
0.19 [-0.46, 0.83] 
0.10 [-0.34, 0.54] 
0.05 [-0.45, 0.55] 
0.68 [-0.06, 1.42] 
-0.47 [-1.22, 0.28]
0.09 [-0.27, 0.45]
WED SMD SMD
IV, Random, 95% CI
-4 -2 0 2 4
Favours control Favours WED 
Study 
Cohen
Danoff-Burg
deMoor
Gellaitry
Gillis
Hamilton West & Quine 
Low
Norman
Rosenberg
Taylor
Vedhara
Walker
Wetherell
Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 8.08, df = 9 (P = 0.53); I² = 0% 
Test for overall effect: Z = 1.47 (P = 0.14) 
Mean 
-1.92
 -12.53
-15.7
 -20.63
-1.91
 -5.33 
-12.8
-2.09
-2.38
 -13.85
 -16.13
-17.1
-33.9
SD 
0.72 
10.8 
20.49
32.28 
0.71
3.57
8.24 
0.59
2.83
2.75
11.47
5.99 
26.1
Total 
 74 
20 
 19 
38 
36 
 43 
31
 28 
 16 
 18 
31
14
 19
321 
Mean 
-1.83
-15.08 
-19.8 
-24.21
-2.14 
-6.46 
-13.2
-2.11
-6.21
-15 
-16.83 
-14.1 
-43.5 
SD
0.59
11.5
22.06 
36.97 
0.78
3.49
8.24
0.8 
7.41
3.65
9.35
6.36
19.9
Total 
39
20
18
42
32
24
31
20
14
21
28
14
15
265
IV, Random, 95% CI
-0.13 [-0.52, 0.26]
0.22 [-0.40, 0.85]
0.19 [-0.46, 0.83]
0.10 [-0.34, 0.54]
0.31 [-0.17, 0.78]
0.32 [-0.19, 0.82]
0.05 [-0.45, 0.55]
0.03 [-0.55, 0.60]
0.68 [-0.06, 1.42]
0.34 [-0.29, 0.98]
0.07 [-0.45, 0.58]
-0.47 [-1.22, 0.28]
0.40 [-0.29, 1.08]
0.12 [-0.04, 0.29]
WED Control SMD SMD 
IV, Random, 95% CI 
-1 -0.5 0 0.5 1
Favours control Favours WED 
Control 
SMD
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Negative affect in rheumatic conditions without Wetherell: no change (a non-
significant trend and inconclusive effect). 
 
 
 
 
Distress without de Moor: no change (a non-significant and inconclusive effect). 
 
  
  
Study 
Cohen 
deMoor
Taylor
Zakowski
Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.09, df = 2 (P = 0.96); I² = 0%
Test for overall effect: Z = 0.55 (P = 0.58)
Mean
-1.73 
-19.8 
-14.8 
-0.35 
SD 
0.68 
3.92
6.9
0.4
Total
74
19
18
62
154
Mean 
-1.66 
-20.5 
-14.3 
-0.34 
SD 
0.59
3.82
3.1
0.4
Total 
39
18
21
42
102
IV, Random, 95% CI
-0.11 [-0.49, 0.28]
0.18 [-0.47, 0.82]
-0.09 [-0.72, 0.54]
-0.02 [-0.42, 0.37]
-0.07 [-0.32, 0.18] 
WED Control SMD SMD
IV, Random, 95% CI
-2 -1 0 1 2
Favours control Favours WED 
Study 
Cohen 
Danoff-Burg
Hamilton West & Quine
Wetherell 
Total (95% CI)
Heterogeneity: Tau² = 0.01; Chi² = 2.19, df = 2 (P = 0.33); I² = 9%
Test for overall effect: Z = 0.53 (P = 0.59)
Mean
-1.92
-12.53 
 -5.33 
 -33.9 
SD
0.72
10.8
3.57
26.1
Total
74
20
43
19
137
Mean
-1.83 
-15.08 
-6.46 
-43.5 
  SD
0.59
11.5
3.49
19.9
  Total 
39
20
24
15
83
 IV, Random, 95% CI 
-0.13 [-0.52, 0.26]
0.22 [-0.40, 0.85]
0.32 [-0.19, 0.82]
0.40 [-0.29, 1.08]
0.08 [-0.21, 0.37]
Control SMD SMD
IV, Random, 95% CI
-2 -1 0 1 2
Favours control Favours WED 
WED
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Appendix K: Practice recruitment materials 
 
Practice letter 
 
 
 
Enter Date 
Practice Name & Address 
 
Dear [Enter Practice Name] 
 
Writing for People Living with Type 2 diabetes Study 
 
Practice Letter 
 
I am writing to invite you to participate in a research study. This study is being 
undertaken by me, Kathryn Dennick, a postgraduate researcher, supervised by Dr 
Chris Bridle and Dr Jackie Sturt, at Warwick Medical School. At Warwick Medical 
School, one of our research interests relates to innovative ways to help people living 
with diabetes cope with the consequences of the condition and manage their own 
care well.  
 
Having Type 2 diabetes often means considerable changes to lifestyle and can 
have a negative effect on psychological well-being. We know that many patients 
experience distress, which can have an adverse effect on their condition.  This 
study is investigating whether a writing intervention can influence the health of 
individuals with Type 2 diabetes. I have enclosed full details. 
 
I do hope that you will agree to help with this important study, which necessitates 
minimal practice involvement. Under the quality framework set up by the 
Department of Health the project would provide an alternative for responding to 
individuals who have indicated that they are experiencing some distress.  
 
If you have any further questions relating to the research please do not hesitate to 
contact the Project Researcher, Kathryn Dennick on 02476575132, or Project 
Supervisor, Chris Bridle, on 02476150222. Thank you in anticipation of your help 
with this study. I will be contacting you shortly about your decision to participate. 
 
Yours sincerely 
 
Kathryn Dennick 
Postgraduate Researcher 
University of Warwick, Coventry CV4 7AL 
E-mail: K.J.Dennick@warwick.ac.uk 
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Practice information sheet 
 
 
 
Writing for People Living with Type 2 diabetes Study 
 
 
Practice Information Sheet 
 
Background 
Having Type 2 diabetes often means considerable changes to lifestyle and can 
have a negative effect on psychological well-being. We know that many patients 
experience distress, which can have an adverse effect on their condition. Research 
suggests that writing about thoughts and feelings about a stressful topic, an 
intervention termed Written Emotional Disclosure (WED), can have a positive effect 
on health for many people including those with a long term physical condition and 
experiencing psychological distress. 
 
Aim 
To investigate whether WED influences the health of individuals with Type 2 
diabetes.  
 
Design 
Randomised controlled trial of WED with 6 month follow up. 
 
Selection Criteria 
Type 2 diabetes patients who have been diagnosed for at least 6 months, are aged 
18 years or over. Patients who have been diagnosed with a psychotic or bipolar 
disorder, are currently receiving treatment for depression or any psychological 
therapy as part of routine care or another research study, have any history of self 
harm, suicidal ideation or suicide attempts, or who you feel would be unsuitable 
(e.g. if they have past or present psychological vulnerabilities) will be excluded.  In 
the interest of patient safety, patients will undergo a further eligibility check in which 
those displaying significant depressive symptoms will be excluded. 
 
Intervention 
Participants in the intervention group will write at home about the emotional topic, 
while participants in a control group will write a fact based description of their day, 
for 20 minutes a day for 3 days over the course of one week.  Usual care will 
continue throughout the study and will not be restricted in any way.   
 
Follow up 
Postal questionnaire at 2 weeks, 3 months and 6 months after completion of the 
intervention. The longest questionnaire takes approximately 20 minutes to 
complete. With your co-operation, BMI and HbA1c will be collected from existing 
patient notes at baseline.  
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Practice Involvement 
This study requires minimal practice involvement, limited to help with identifying 
participants that will not significantly add to your practice workload.  All we ask is 
that you: 
 
a) Search practice registers to identify patients to participate in the study. 
 
b) Mail letters of invitation, patient information sheets, expression of interest forms and 
a depression-screening questionnaire, provided by the university, to potentially 
eligible patients. 
 
c) Allow research staff to promptly and anonymously score returned screening 
questionnaires to identify whether patients are eligible to take part. Alternatively, this 
can be undertaken by practice staff should that be preferred.  
 
d) Either mail participants consent forms and a baseline questionnaire booklet, or deal 
accordingly with patients who screen as experiencing significant depressive 
symptoms and are excluded from the trial. 
  
e) Agree that patient’s who screen as experiencing significant depression, or those 
who experience concerns arising from completing our depression screening 
questionnaire or the writing task, can be signposted back to their GP. 
  
f) Provide the screening questionnaires/some clinical data for consented participants 
at the start and or end of the study. You would be required to retain screening 
questionnaires for a couple of weeks for this purpose. 
 
Feedback to the practice 
With participants consent, GPs will be informed of their enrolment into the trial.  
                                                     
Additional Information 
 
a) Patient Complaints and Indemnity:  
Patients will be informed that any complaint relating to their participation should be 
initially directed to the research team where it will be dealt with accordingly. Should 
they remain unhappy and wish to complain formally please contact Ken Sloan, 
Deputy Registrar, on 02476524768, Ken.Sloan@warwick.ac.uk.  The University of 
Warwick will provide indemnification. 
 
b) Procedure for serious concern 
If at any point the research team obtains information that suggests a risk of serious 
harm to participants or others, they will follow a formal process referring this to a 
patient safety group. Members of this group include a community psychiatrist, a GP 
and expert in clinical ethics, a clinical trialist and a lay member of the Warwick 
University Diabetes User Group. 
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c) Access to Study Findings:  
Once the study is completed we will analyse the results and make participants 
aware of any benefits from writing. Each practice and participant involved in the 
study will be provided with a summary of findings. It is anticipated the study will also 
be published. 
 
d) Study Review:  
The study has been internally peer reviewed within Warwick Medical School, and 
also reviewed by the Warwick Diabetes Care User Group. This group provides 
patient perspectives on the validity of diabetes research. The study has additionally 
been reviewed and approved by the Warwickshire Research Ethics Committee. 
 
Please contact Kathryn Dennick on 02476575132, or Project Supervisor, Dr 
Chris Bridle, on 02476150222 if you wish to discuss any aspect of the study.   
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Study Flow Diagram 
Pre-Study Screening 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Trial Procedure 
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Anonymised screening 
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eligibility: CES-D ≥16 
excluded   
Writing content screened 
within 1 working day of 
receipt against a self harm 
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Initiate Close of Trial Procedures 
Debrief and summary of 
results 
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Appendix L: Patient recruitment materials 
 
Patient letter 
 
GP SURGERY LETTER HEAD TO BE INSERTED HERE 
 
 
 
Dear Patient, 
 
Writing for People Living with Type 2 diabetes Study 
 
 
Patient Letter 
 
I am a researcher at Warwick Medical School (WMS). I would like to invite you to 
take part in a study. A lot of our research looks at ways to help people cope with 
having diabetes. We are looking at whether writing affects the health of people with 
Type 2 diabetes.   
 
We would be grateful if you would think about taking part in this study. Full details 
are included with this letter. 
 
If you have any questions please do contact the Project Researcher, Kathryn 
Dennick on 02476575132, or Project Supervisor, Dr Chris Bridle, on 02476150222. 
Thank you for thinking about taking part. 
 
 
 
Yours sincerely 
 
 
Kathryn Dennick 
Postgraduate Researcher 
University of Warwick, Coventry CV4 7AL 
02476575132 
E-mail: K.J.Dennick@warwick.ac.uk 
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Patient information sheet 
 
GP SURGERY LETTER HEAD TO BE INSERTED HERE 
 
 
 
Writing for People Living with Type 2 diabetes Study 
 
 
Patient Information Sheet 
 
Before you decide whether you would like to take part in this study, you may want to 
understand why the research is being done and what it would involve for you. 
Please take time to read the information below carefully. This tells you about the 
purpose of the study and what will happen if you take part. Talk to others about the 
study if you wish. Please ask if there is anything that is not clear or if you would like 
more information. Contact details for the research team are provided below. Take 
time to decide whether or not you would like to take part.  
 
What is the purpose of the study? 
The study is looking at different ways of improving the health of people with Type 2 
diabetes. Research suggests that writing can affect health for many people 
including those with a long term condition. Sometimes, because we do not know 
which way of treating patients is best, we need to make comparisons. This study will 
look at whether and how writing about different topics affects the health of people 
with Type 2 diabetes.  
 
Why have I been chosen? 
You have been selected by staff at your GP practice because you are an adult who 
has been diagnosed with Type 2 diabetes for at least 6 months. About 150 similar 
adults with Type 2 diabetes are being asked to take part.  
 
Do I have to take part? 
No. It is up to you to decide whether or not you wish to take part. If you do, you will 
be asked to sign a consent form. You are free to withdraw at any time without giving 
a reason, even after you have signed the consent form. This would not affect the 
standard of care you receive. Information you have already provided may still be 
used. If you choose to withdraw from writing or not complete some documents once 
you have consented to take part in the study, we will continue to attempt to obtain 
information about you as described below, unless you ask us not to. We would 
appreciate it if you would continue to let us know about your progress.  
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What will happen to me if I take part? 
This study will run for 6 months. You will be asked to complete an intervention and 
questionnaires at different times. We will give you prepaid envelopes to return 
anything you are sent. 
 
1. You will first be asked to complete the form showing that you are interested in taking 
part and screening questionnaire to assess your current well-being, which will take 
about 3 minutes, which you received with this information sheet. You would then 
return this to your GP practice. At this point, no information that can be traced back 
to you will be seen by anyone outside the practice, including the research team. 
Your eligibility will be determined from your response, and if you are able to take 
part your practice will mail you a formal consent form and questionnaire booklet to 
complete, which will take about 20 minutes. As we are not able to discuss individual 
screening scores we suggest you contact your GP if you would like to discuss this. 
  
2. You will then return this booklet with a copy of the signed consent form to the 
research team, and we will mail you a writing pack. If you consent to take part in the 
study we will then contact your practice for your screening information. The writing 
pack will include instructions to write about some aspect of your life for 20 minutes 
each day for 3 days over the course of one week. There will also be some short 
questions about how you found the task. It is really important that you do the writing 
task as requested. This study is not concerned with your writing ability. In fact you 
will be asked not to pay attention to spelling and grammar etc. Once you have 
completed the task you will return the pack. 
 
3. To see whether writing has affected your health, you will then receive a 
questionnaire at 2 weeks, 3 months, and 6 months after you return the writing pack. 
The 3 month one will also take about 20 minutes to complete while the other 2 will 
take about 15 minutes each. You may receive a reminder letter or telephone call if 
you do not return some documents. With your permission your health care records 
will also be looked at by practice staff at the start of the study. They will then give us 
your height, weight and blood results, but if you do not want us to have this 
information you can record this on the consent form.  
 
What is the procedure being tested? 
We will ask you to write about different aspects of your life. 
 
Who will know that I am taking part? 
The only people who will know that you are taking part are the research team, and 
with your consent, your GP. 
 
What will you do with the findings? 
A summary of the results will be given to you at the end of the study. In addition the 
results of the study may be published, which we will let you know about. We will not 
use any details that could identify you in any report or publication. 
 
 
 
560 
 
What are the possible risks of taking part? 
We do not foresee any risks to your health in taking part. You will be asked to take 
time out of your daily routine to write for 20 minutes on three days and complete five 
questionnaires. However, you can stop at any time.  
 
What are the side effects of any treatment received whilst taking part? 
Most people will not experience any side-effects. If you feel that the screening 
questionnaire has raised some issues that you would like to discuss we advise that 
you contact your GP on................ Some people, depending on the topic they write 
about, may also experience a slightly lower mood than usual, like watching a sad 
film, but this would be temporary and pass very quickly. If you are worried about 
how you feel, you are free to stop writing at any time and talk to someone about this 
if you wish, including your GP on................. Potentially helpful contacts include: 
 
Citizens Advice Bureau 08451202920 (Coventry) 01926457900 (Warwick Districts) 
Mind 08457660163 
NHS Direct 08454647 
Samaritans 08457 90 90 90 
 
What are the possible benefits of taking part? 
We cannot promise the study will help you but you may experience some benefit 
from writing. The findings from the study will help us understand how to improve the 
treatment of people with Type 2 diabetes.  
 
Will my details be kept confidential? 
Yes. Any information you provide to the research team will be kept strictly 
confidential. Paper records will only have your participant number on so that you 
cannot be recognised from them except by the research team. Any information 
about you from your health care records that leaves your practice will have your 
name and address removed so that you cannot be recognised from it. It is possible, 
however, that if you reveal information of a certain nature once you have consented 
to take part in the study, for example if your writing includes information that 
suggests a risk to yourselves or others, we may need to break our confidentiality 
agreement and tell an appropriate party. 
 
How will records from the study be stored? 
All paper records will be stored in a locked filing cabinet in a locked office and will 
not leave the university premises. Information stored on a computer can only be 
viewed with a password. Only the research team will have access to information. 
Your information will only be used for this study and will be retained for 5 years once 
the study has finished. After this it will be securely destroyed.  
 
What will happen to the writing I do? 
This will be stored securely with the other paper records as described above. 
 
What happens if there is a problem? 
Any complaint about the way you have been dealt with during the study will be 
addressed.  
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1. You are first encouraged to speak to the research team who will do their best to 
answer your questions. 
2. If you are still unhappy and wish to complain formally please contact Ken Sloan, 
Deputy Registrar, on 02476524768, Ken.Sloan@warwick.ac.uk. The University of 
Warwick will provide indemnification. 
 
What if relevant new information becomes available? 
It is not expected that we will get new information about this writing intervention. 
However, if this happens, we will tell you and discuss whether you should continue 
in the study. If you decide to continue you may be asked to sign an updated consent 
form.  
 
What happens when the research stops? 
Once the study has finished we will analyse the data and let you know if we find any 
benefits from writing.  
 
Who has reviewed the study? 
All research involving the NHS is looked at by an independent group of people, 
called a Research Ethics Committee (REC). This is to protect your safety, rights, 
well-being and dignity. This study has been reviewed and approved by the 
Warwickshire REC.  
 
Who is paying for this study? 
The University of Warwick is sponsoring and funding the research. 
 
Contact Details 
For further information about the study please contact the researcher, Kathryn 
Dennick, on 02476575132, or Project Supervisor, Dr Chris Bridle, on 02476150222 
who will be happy to answer any questions.  
Our address for correspondence is Kathryn Dennick                                                         
                                                        Warwick Medical School 
                                                        The University of Warwick 
                                                        Gibbet Hill Road 
                                                        Coventry CV4 7AL 
                                                         
This is your information sheet to keep.  Thank you for taking time to read it. 
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Expression of interest form 
 
GP SURGERY LETTER HEAD TO BE INSERTED HERE 
 
 
 
 
 
 
 
 
Writing for People Living with Type 2 diabetes Study 
 
 
Expression of Interest Form 
 
 
Thank you again for considering taking part in this research. If you are interested 
please RETURN THIS FORM TO YOUR PRACTICE in the pre-paid envelope 
provided. 
 
 
 
 
 
 
 
I __________________(name) would like to express an interest in taking part in this 
study. 
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Screening questionnaire  
 
GP SURGERY LETTER HEAD TO BE INSERTED HERE     
 
 
                                        Participant Identification Number 
      
Writing for People Living with Type 2 diabetes Study 
 
 
Screening Questionnaire 
 
Thank you again for considering taking part in this research.  If you are interested 
please RETURN THIS QUESTIONNAIRE TO YOUR PRACTICE in the pre-paid 
envelope provided. 
 
Below is a list of some of the ways you may have felt or behaved. Please indicate 
how often you have felt this way during the past week by circling the appropriate 
number 
 
                                                                           Rarely or none     Some or a     Occasionally or a       Most or All 
                                                               of the time         little of the        moderate amount     of the time 
                                                         (less than 1 day)  time (1-2 days)  of  the time (3-4 days) (5-7 days) 
 
1. I was bothered by things that 1    2                3              4 
    usually don’t bother me. 
2. I did not feel like eating; my   1   2                3                    4 
    appetite was poor.  
3. I felt that I could not shake off the  1    2                    3                4 
    blues even with help from my  
    family or friends.       
4. I felt that I was as good as other  1   2                 3                   4 
    people.        
5. I had trouble keeping my mind on 1   2              3                     4 
    what I was doing. 
6. I felt depressed.       1   2               3                4 
7. I felt that everything I did was an  1     2               3                  4 
    effort.           
8. I felt hopeful about the future. 1           2                 3               4 
9. I thought my life had been a  1                  2                 3                   4 
     failure.          
10. I felt fearful.    1                 2               3               4 
11. My sleep was restless.  1                2                  3                   4 
12. I was happy.   1             2                   3              4 
13. I talked less than usual.  1                  2                   3                    4 
14. I felt lonely.   1                  2                  3                    4 
15. People were unfriendly.   1                 2                 3                    4 
16. I enjoyed life.    1                   2                    3                     4 
17. I had crying spells.   1                    2                     3                   4 
18. I felt sad.    1                    2                 3                     4 
19. I felt that people disliked me.  1                   2                   3                    4 
20. I could not get “going”.  1                    2                      3                      4 
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Appendix M: Consent forms 
 
GP SURGERY LETTER HEAD TO BE INSERTED HERE  
    
 
 
Writing for People Living with Type 2 diabetes Study 
 
 
Consent Form 
 
PLEASE KEEP THIS COPY 
                                      Please Initial Box 
 
1. I confirm that I have read and understand the information sheet  
    dated Dec 08 (version 2) for the above study. I have had  
    the opportunity to consider the information, ask questions, and 
    have had these answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free  
    to withdraw at any time without giving a reason, without my  
    medical care or legal rights being affected.  
 
3. I understand that sections of my medical notes and data collected  
    during the study may be looked at by individuals from the  
    University of Warwick, from regulatory authorities, or from the  
    NHS trust, where this is relevant to me taking part in this  
    research.  I give permission for these individuals to have access to  
    my records. 
 
4. I agree to my GP being informed of my participation in the study. 
 
5. I agree to take part in the above study. 
 
 
 
 
   Name of Patient                  Date                                       Signature    
 
 
 
   Name of Person                  Date                                               Signature 
   taking consent       
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GP SURGERY LETTER HEAD TO BE INSERTED HERE 
     
 
 
Writing for People Living with Type 2 diabetes Study 
 
 
Consent Form 
 
PLEASE RETURN THIS COPY TO THE RESEARCHER in the pre-paid envelope 
provided 
Please Initial Box 
1. I confirm that I have read and understand the information sheet  
    dated Dec 08 (version 2) for the above study. I have had  
    the opportunity to consider the information, ask questions, and 
    have had these answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free  
    to withdraw at any time without giving a reason, without my  
    medical care or legal rights being affected.  
 
3. I understand that sections of my medical notes and data collected  
    during the study may be looked at by individuals from the  
    University of Warwick, from regulatory authorities, or from the  
    NHS trust, where this is relevant to me taking part in this  
    research.  I give permission for these individuals to have access to  
    my records. 
 
4. I agree to my GP being informed of my participation in the study. 
 
5. I agree to take part in the above study. 
 
 
   Name of Patient                            Date                                      Signature    
 
 
   Name of person taking consent   Date                                       Signature 
 
We would be grateful if you would provide the following contact details so that we 
can collect the information we need as described in the patient information sheet.     
    
Address 
 
Telephone 
 
Name of GP practice 
 
 
 
 
 
566 
 
 
Appendix N: Debrief sheet 
 
 
 
 
Writing for People Living with Type 2 diabetes Study 
 
 
Debriefing Sheet 
 
Thank you for taking part in this study. Without your support it would not have been 
possible. The study looked at whether writing about aspects of life affects the health 
of people with Type 2 diabetes.  
 
Research shows writing about feelings of a stressful event can improve physical 
and mental health for people with long term conditions. The aim was to find out 
whether this procedure has the same effect for people with Type 2 diabetes. We 
looked at people with Type 2 diabetes as research shows they are at risk of 
depression.  
 
You were either in a group where you wrote about your feelings of a stressful event 
or in a group where you wrote about your daily routine with no feelings. These 
groups will be compared to see whether writing about feelings improves health more 
than just writing. Hence, the ‘no feelings’ writing task was crucial so that we can find 
out whether writing about feelings does improve health. 
 
We are sorry that we could not tell you about this until now. The decision was not 
taken likely. We spoke with people with Type 2 diabetes and experts in clinical 
ethics when designing our study. We also obtained NHS ethical approval. We 
withheld this from you to protect you and the quality of the research.  
 
So that we can analyse our results we would be grateful if you would answer the 
questions on the next page.  
 
If you have any problems talk to someone about this if you wish, including your GP 
on............ Potentially helpful contacts include: 
 
Citizens Advice Bureau 08451202920 (Coventry) 01926457900 (Warwick Districts) 
Mind 08457660163 
NHS Direct 08454647 
Samaritans 08457 90 90 90 
 
If you have any queries or concerns about the study please contact the researcher, 
Kathryn Dennick, on 02476575132, or Project Supervisor, Dr Chris Bridle, on 
02476150222.  
 
Thank you again. 
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PLEASE COMPLETE THE FOLLOWING QUESTIONS 
 
1. Were you aware that there were 2 different groups? 
 
Yes       No                          
 
2. Having read this debriefing sheet had you guessed what the other group was 
writing about?                  
                             
Yes       No                          
 
3. Having read this debriefing sheet and now knowing what group you were in, had 
you already guessed the purpose of your writing task? 
                             
Yes       No                          
 
 
 
 
May I take this opportunity to thank you for taking the time to help with this research.   
 
As you already know, we need to be able to compare your answers on each 
questionnaire you complete.  However, to protect your anonymity, we do not want 
your name to appear on any questionnaire you complete. For this reason everyone 
is provided with a unique identification code, which you can create yourself by using 
the following formula: 
 
In the space provided please write … 
 
1) … the first 2 letters of your mother’s first name, e.g. ‘SU’ for Susan    
 
2) … the month you were born, e.g. ‘07’ for July    
 
3) … the first 2 letters of your own first name, e.g. ‘JO’ for John.    
 
Once again, thank you very much for your help with this research. 
Please return this form in the pre-paid envelope provided. 
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Exploratory RCT: Questionnaires 
 
Appendix O: Baseline questionnaire 
 
 
                     Writing for People Living with Type 2 diabetes Study 
 
 
Questionnaire Booklet 1 
Please complete the following sections 
 
Section 1 
Which of the following diabetes issues are currently a problem for you? Circle the 
number that gives the best answer for you . Please provide an answer for each 
question. 
                                                                              Not a     Minor   Moderate  Somewhat serious Serious 
                                                                            problem problem  problem           problem       problem 
1. Not having clear and concrete                  1           2             3           4             5                             
    goals for your diabetes care?  
2. Feeling discouraged with your                   1          2             3           4             5 
    diabetes treatment  plan?                               
3. Feeling scared when you think                  1           2            3           4             5 
    about living with diabetes?                             
4. Uncomfortable social situations                 1           2            3           4             5 
     related to your diabetes care    
     (e.g. people telling you what to eat?)             
5. Feelings of deprivation                              1           2             3           4            5 
    regarding food and meals?                             
6. Feeling depressed when you                     1           2            3           4             5 
    think about living with diabetes?                     
7. Not knowing if your mood or                      1           2             3           4            5 
    feelings are  related to your diabetes?            
8. Feeling overwhelmed by your diabetes?    1          2             3            4            5      
9. Worrying about low blood sugar reaction? 1          2             3            4            5 
10. Feeling angry when you think                   1          2             3            4            5 
      about living with diabetes?                            
11. Feeling constantly concerned                   1          2             3            4            5 
      about food and eating?                                 
12. Worrying about the future and the            1           2             3            4           5 
     possibility of serious complications?             
13. Feelings of guilt or anxiety when you get  1          2             3            4            5 
      off track with your diabetes management?     
14. Not "accepting" your diabetes?                 1           2            3            4            5 
15. Feeling unsatisfied with your diabetes      1           2            3            4            5 
     doctor?                                                            
16. Feeling that diabetes is taking up too        1           2            3            4            5 
      much of your  mental and physical 
      energy every day?  
17. Feeling alone with your diabetes?              1          2            3            4            5 
18. Feeling that your friends and family are     1          2            3            4            5 
      not supportive of your diabetes  
      management efforts?                                      
19. Coping with complications of diabetes?     1           2            3            4            5 
20. Feeling "burned out" by the constant         1           2            3            4            5 
      effort needed to manage diabetes?                
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Section 2 
By placing a tick in one box in each group below, please indicate which statements 
best describe your own health state today. 
 
 
Mobility 
I have no problems in walking about  
I have some problems in walking about  
I am confined to bed  
 
 
 
Self-Care 
I have no problems with self-care  
I have some problems washing or dressing myself  
I am unable to wash or dress myself  
 
 
 
Usual Activities (e.g. work, study, housework, family or 
leisure activities) 
I have no problems with performing my usual activities  
I have some problems with performing my usual activities  
I am unable to perform my usual activities  
 
 
 
Pain/Discomfort 
I have no pain or discomfort  
I have moderate pain or discomfort  
I have extreme pain or discomfort  
 
 
 
Anxiety/Depression 
I am not anxious or depressed  
I am moderately anxious or depressed  
I am extremely anxious or depressed  
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To help people say how good or bad a health state is, we have  
drawn a scale (rather like a thermometer) on which the best state  
you can imagine is marked 100 and the worst state you can  
imagine is marked 0.  
 
We would like you to indicate on this scale how good or bad your  
own health is today, in your opinion. Please do this by drawing a line  
from the box below to whichever point on the scale indicates how good  
or bad your health state is today. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Your own 
health state 
today 
9 0 
8 0 
7 0 
6 0 
5 0 
4 0 
3 0 
2 0 
1 0 
100 
Worst 
imaginable 
health state 
0 
Best  
imaginable 
health state 
© EuroQoL Group 1990 
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Section 3 
The questions below ask you about your diabetes self care activities during the past 
7 days. If you were sick during the past 7 days,  please think back to the last 7 days 
that you were not sick.   
 
1. How many of the last SEVEN DAYS have you          0    1     2     3    4    5    6     7 
     followed a eating plan? 
2. On average, over the past month, how many days    0    1     2     3    4    5    6     7 
     per week have you followed your eating plan?  
3. On how many of the last SEVEN DAYS did you        0    1     2     3    4    5    6     7 
    eat five or more servings of fruits and vegetables? 
4. On how many of the last SEVEN DAYS did you        0    1     2     3    4    5    6     7 
    eat high fat foods such as red meat or full-fat  
    dairy products? 
5. On how many of the last SEVEN DAYS did you        0    1     2     3    4    5     6    7 
    participate in at least 30 minutes of physical activity?   
    (total minutes of continuous activity including walking). 
6. On how many of the last SEVEN DAYS did you        0    1     2     3    4    5     6    7 
    participate in a specific exercise session (such as  
    swimming, walking, biking) other than what you do  
    around the house or as part of your work?                     
7. On how many of the last SEVEN DAYS did you        0    1     2     3    4    5     6    7 
     test your blood sugar?                                                   
8. On how many of the last SEVEN DAYS did you        0    1     2     3    4    5     6    7 
    test your blood sugar the number of times  
    recommended by your health care provider? 
9. On how many of the last SEVEN DAYS did you        0    1     2     3    4    5     6    7 
    check your feet?                                                           
10. On how many of the last SEVEN DAYS did you      0    1     2     3    4    5     6    7 
    inspect the inside of your shoes? 
 
 
11. Have you smoked a cigarette—even one puff—during the past SEVEN DAYS? 
0. No 
1. Yes.  
If yes, how many cigarettes did you smoke on an average day?   Number of 
cigarettes.............. 
 
Section 4 
1. In the past 6 months, how many times did you visit a doctor? 
Do NOT include visits while in the hospital or the hospital emergency 
room....................visits  
 
2. In the past 6 months, how many times did you go to a hospital emergency 
room?..........times  
 
3. How many total NIGHTS did you spend in the hospital in the past 6 months? 
..........nights  
 
4. When was the last time you had your eyes examined?  
(example: for glaucoma or any other problem)................................month/yr 
  
5. How many times did the doctor or nurse examine your feet in the last 6 
months?......times 
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Section 5 
The following items ask about how much your illness and/or its treatment interferes 
with your life. Please circle the one number that best describes your current life 
situation. If an item is not applicable, please check the box to indicate that this 
aspect of your life is not affected. Please do not leave any item unanswered.  
 
How much does your illness and/or its treatment interfere with:  
 
1. Your feeling of being           Not very much►1 2 3 4 5 6 7 ◄Very much    Not applicable  
    healthy? 
2. The things you eat and        Not very much► 1 2 3 4 5 6 7 ◄Very much   Not applicable  
    drink? 
3. Your work, including job,     Not very much► 1 2 3 4 5 6 7 ◄Very much   Not applicable  
    house work, chores, or  
    errands? 
4. Playing sports, gardening,  Not very much► 1 2 3 4 5 6 7 ◄Very much    Not applicable  
    or other physical  
    recreation or hobbies?                                                                                       
5. Quiet recreation or               Not very much► 1 2 3 4 5 6 7 ◄Very much   Not applicable  
    hobbies such as reading,  
    TV, music, knitting, etc.?  
6. Your financial situation?      Not very much► 1 2 3 4 5 6 7 ◄Very much     Not applicable  
7. Your relationship with          Not very much► 1 2 3 4 5 6 7 ◄Very much     Not applicable  
    your spouse or   
    domestic partner?   
8. Your sex life?                       Not very much► 1 2 3 4 5 6 7 ◄Very much   Not applicable                     
9. Your relationship and           Not very much► 1 2 3 4 5 6 7 ◄Very much    Not applicable                    
    social activities with your  
    family?   
10. Social activities with          Not very much► 1 2 3 4 5 6 7 ◄Very much     Not applicable  
    your friends, neighbours,  
    or groups?  
11. Your religious or spiritual  
    activities?                            Not very much► 1 2 3 4 5 6 7 ◄Very much    Not applicable  
12. Your involvement in  
     community or                     Not very much► 1 2 3 4 5 6 7 ◄Very much      Not applicable  
     civic activities?  
13. Your self-improvement     Not very much► 1 2 3 4 5 6 7 ◄Very much       Not applicable  
     or self-expression  
     activities? 
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Section 6 
Below is a list of  activities you have to perform to manage your diabetes. Please 
read each one and then circle the number which best describes how confident you 
usually are that you could carry out that activity. For example, if you are completely 
confident that you are able to check your blood sugar levels when nessessary, circle 
10. If you feel  that most of the time you could not do it, circle 1 or 2. 
 
I am confident that…….. 
 
 
Cannot do                                           Maybe yes                                                    Certain 
At all                                                maybe no                                                      can do 
                                                       
 
1 I am able to check my blood sugar if necessary 
 0 1 2 3 4 5 6 7 8 9 10 
2 I am able to correct my blood sugar when the sugar level is too high. 
 0 1 2 3 4 5 6 7 8 9 10 
3 I am able to correct my blood sugar when the blood sugar level is too low. 
 0 1 2 3 4 5 6 7 8 9 10 
4 I am able to choose the correct foods. 
 0 1 2 3 4 5 6 7 8 9 10 
5 I am able to keep my weight under control. 
 0 1   2   3  4  5  6  7  8  9         10 
6 I am able to examine my feet for cuts. 
 0 1 2 3 4 5 6 7 8 9 10 
7 I am able to adjust my eating plan when ill. 
 0 1 2 3 4 5 6 7 8 9 10 
8 I am able to follow a healthy eating pattern most of the time. 
 0 1 2 3 4 5 6 7 8 9 10 
9 I am able to take more exercise if the doctor advises me to. 
 0 1 2 3 4 5 6 7 8 9 10 
10 When taking more exercise I am able to adjust my eating plan. 
 0 1 2 3 4 5 6 7 8 9 10 
11 I am able to follow a healthy eating pattern when I am away from home. 
 0 1 2 3 4 5 6 7 8 9 10 
12 I am able to follow a healthy eating pattern when I am eating out or at a 
            party. 
 0 1 2 3 4 5 6 7 8 9 10 
13 I am able to adjust my eating plan when I am feeling stressed or anxious. 
 0 1 2 3 4 5 6 7 8 9 10 
14 I am able to take my medication as prescribed. 
 0 1 2 3 4 5 6 7 8 9 10 
15 I am able to adjust my medication when I am ill. 
 0 1 2 3 4 5 6 7 8 9 10 
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Section 7 
The following questions ask about people in your environment who provide you with 
help or support. Each question has two parts. For the first part, list all the people you 
know, excluding yourself, whom you can count on for help and support in the 
manner described. Give the persons’ initials, their relationship to you (see example). 
Do not list more than one person next to each of the numbers beneath the question.   
 
For the second part, circle how satisfied you are with the overall support you have. 
 
If you have had no support for a question, check the words “No one”, but still rate 
your level of satisfaction.  
 
Do not list more than nine persons per question. 
 
Please answer all the questions as best you can.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Whom can you really count on to be dependable when you need help? 
 
   No one     1)                                                  4)                                                7)   
                    2)                                                  5)                                                8) 
                    3)                                                  6)                                                9) 
 
2. How satisfied? 
 
6-very                  5-fairly             4-a little             3-a little              2-fairly                 1-very 
satisfied             satisfied           satisfied           dissatisfied        dissatisfied          dissatisfied  
 
 
3. Whom can you really count on to help you feel more relaxed when you are under 
pressure or tense? 
 
    No one       1)                                                  4)                                                7)   
                       2)                                                  5)                                                8) 
                       3)                                                  6)                                                9) 
 
4. How satisfied? 
 
   6-very               5-fairly              4-a little              3-a little           2-fairly                     1-very  
   satisfied          satisfied            satisfied          dissatisfied      dissatisfied             dissatisfied
EXAMPLE:  
 
Who do you know whom you can trust with information that could get you in trouble? 
 
No one       1) T.N. (brother)        4) T.N. (father)           7)   
                   2) L.M. (friend)          5) L.M. (employer)      8) 
                   3) R.S. (friend)          6)                                9) 
 
How satisfied? 
 
6-very               5-fairly                4-a little                  3-a little                 2-fairly              1-very  
satisfied           satisfied               satisfied               dissatisfied          dissatisfied      dissatisfied 
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5. Who accepts you totally, including both your worst and best points? 
    No one       1)                                                  4)                                                7)   
                       2)                                                  5)                                                8) 
                       3)                                                  6)                                                9) 
 
6. How satisfied? 
 
6-very                5-fairly                4-a little               3-a little          2-fairly                     1-very 
satisfied            satisfied              satisfied          dissatisfied      dissatisfied           dissatisfied 
 
 
7. Whom can you really count on to care about you, regardless of what is happening 
to you? 
 
    No one       1)                                                  4)                                                7)   
                       2)                                                  5)                                                8) 
                       3)                                                  6)                                                9) 
 
8. How satisfied? 
 
 6-very               5-fairly                4-a little               3-a little            2-fairly                   1-very 
satisfied           satisfied               satisfied            dissatisfied      dissatisfied         dissatisfied  
 
 
9. Whom can you really count on to help you feel better when you are feeling 
generally down-in-the dumps? 
 
    No one       1)                                                  4)                                                7)   
                       2)                                                  5)                                                8) 
                       3)                                                  6)                                                9) 
 
10. How satisfied? 
 
 6-very                5-fairly                4-a little               3-a little             2-fairly                1-very 
satisfied            satisfied               satisfied            dissatisfied       dissatisfied        dissatisfied  
 
 
11. Who can you count on to console you when you are very upset? 
 
      No one       1)                                                  4)                                                7)   
                         2)                                                  5)                                                8) 
                         3)                                                  6)                                                9) 
 
12. How satisfied? 
 
 6-very               5-fairly                 4-a little                3-a little              2-fairly             1-very 
satisfied           satisfied                satisfied             dissatisfied       dissatisfied      dissatisfied 
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Section 8 
Please be as honest and accurate as you can throughout. Try not to let your 
response to one statement influence your responses to other statements. There are 
no "correct" or "incorrect" answers. Answer according to your own feelings, rather 
than how you think "most people" would answer. Circle the number that gives the 
best answer for you. 
 
                                                     1              2                 3                   4              5 
                                                              I agree      I agree a      I neither agree   I disagree   I disagree      
                                                                a lot            little             nor disagree        a lot 
    
 
1. In uncertain times, I usually      1               2                  3                  4              5 
    expect the best.                         
 
2. It's easy for me to relax             1              2                   3                 4              5 
 
3. If something can go wrong for   1              2                  3                  4              5 
    me, it will.                      
 
4. I'm always optimistic about       1              2                   3                  4              5 
    my future.                       
 
5. I enjoy my friends a lot.             1              2                   3                  4               5 
 
6. It's important for me to keep      1              2                   3                 4               5 
    busy.                                            
 
7. I hardly ever expect things to    1              2                    3                 4              5 
   go my way.                        
 
8. I don't get upset too easily.        1             2                    3                 4               5 
 
9. I rarely count on good things     1              2                    3                4               5 
    happening to me.                        
 
10. Overall, I expect more good    1              2                    3                4               5 
     things to happen to me than  
     bad.                                             
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Section 9 
Using the scale provided as a guide, indicate how much you agree or disagree with 
each of the following statements by circling the corresponding number.  Give only 
one answer for each statement.                     
                                               Circle 1 if you STRONGLY DISAGREE 
    Circle 2 if you MODERATELY DISAGREE 
    Circle 3 if you NEITHER DISAGREE NOR AGREE 
    Circle 4 if you MODERATELY AGREE 
    Circle 5 if you STRONGLY AGREE 
                  Neither 
                   Strongly     Moderately   Disagree    Moderately   Strongly        
                 Disagree     Disagree      Nor Agree      Agree          Agree         
1.  I am often confused about what          1               2             3              4            5 
     emotion I am feeling.                              
2.  It is difficult for me to find the right      1               2             3              4            5 
     words for my feelings.  
3.  I have physical sensations that           1               2             3              4            5 
     even doctors don’t understand.              
4.  I am able to describe my feelings        1               2            3               4           5 
     easily.                                                      
5.  I prefer to analyze problems rather      1              2             3               4           5 
     than just describe them.                          
6.  When I am upset, I don’t know if          1              2            3               4           5 
     I am sad, frightened, or angry. 
7.  I am often puzzled by sensations         1              2            3               4           5 
     in my body.                                              
8.  I prefer to just let things happen           1              2            3               4           5 
      rather than to understand why they  
      turned out that way.                                
9.  I have feelings that I can’t quite            1              2            3               4           5  
      identify.                                                    
10. Being in touch with emotions is           1               2            3              4           5 
      essential.                                                
11.  I find it hard to describe how I feel      1               2            3              4           5 
       about people.                                        
12.  People tell me to describe my             1              2             3              4          5 
       feelings more.                                       
13.  I don’t know what’s going on inside    1               2            3              4           5 
       me.                                                        
14.  I often don’t know why I am angry.      1               2           3              4           5 
15.  I prefer talking to people about            1               2           3              4           5 
       their daily activities rather than their  
       feelings.                                                 
16.  I prefer to watch “light”                         1               2           3              4           5 
       entertainment shows rather than  
       psychological dramas                            
17.  It is difficult for me to reveal my           1               2            3              4          5 
       innermost feelings, even to close  
       friends.                                                   
18.  I can feel close to someone, even       1                2            3             4          5 
       in moments of silence.                         
19.  I find examination of my feelings         1                2            3             4           5 
       useful in solving personal problems.    
20.  Looking for hidden meanings in           1               2              3           4           5 
      movies or plays distracts from their 
      enjoyment.                                             
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Section 10 
Please provide the following information about yourself (tick boxes as appropriate): 
 
 Age: …………yrs 
 
Gender:     Male             Female  
  
Ethnicity:   White 
                             British               
                             Irish 
                             Other             (please specify…………..............) 
                   
                 Asian or Asian British  
                       Indian                     
                  Pakistani 
                  Bangladeshi                 
                  Other                     (please specify…………………..) 
 
     Black or Black British 
                             Caribbean  
                  African 
                  Other                  (please specify…………..………) 
 
                 Mixed  
                             White and Black Caribbean 
                             White and Black African 
                             White and Asian 
                             Other                                              (please specify…………………) 
 
     Chinese or other ethnic group 
                 Chinese 
                 Other               (please specify……………………) 
 
Education:          
 
              Level 1                                                        Level 2 
(1 to 4 O level passes, 1 to 4 CSE/             (5 or more O level passes, 5 or more  
GCSE any grades, NVQ level 1 or              CSEs (grade 1), 5 or more GCSEs  
Foundation GNVQ)                                      (grades A-C), School Certificate, 1 A   
                                                                                  level, 1 to 3 AS levels, NVQ level 2,  
                                                                              Intermediate GNVQ)                                      
 
Level 3                                                         Level 4/5 
(2 or more A levels, 4 or more AS                (First degree, higher degree, NVQ levels 
levels, Higher School Certificate, NVQ        4 and 5, HNC, HND, Qualified Teacher 
level 3, Advanced GNVQ)                            Status, Qualified Medical Doctor, 
                                                                                  Qualified Dentist, Qualified Nurse, 
                                                                           Midwife, Health Visitor) 
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Relationship Status:         Single                    Co-habiting             Married/Remarried                
                      (including separated/ 
                     divorced and widowed) 
 
Time since diabetes diagnosis: ……………….yrs/months 
 
Diabetes complications:   
  
Heart disease/stroke                      Neuropathies (nerve damage)  
 
      Retinopathy (eye disease)    Kidney disease/failure 
 
Hypoglycemia                                Sexual/urologic Problems  
      (low blood glucose) 
 
      Other         (please specify……………………………..) 
 
 
 Diabetes medication:      Diet/exercise only                Tablets        
                                
                                                Tablets and insulin               Insulin 
        
Are you currently involved in any other research projects?    Yes          No 
 
You have now completed the questionnaire. 
 
May I take this opportunity to thank you for taking the time to help with this research.   
 
As you know, we will ask you to complete more questionnaires over the next few 
months, and we need to be able to compare your answers on each questionnaire 
you complete.  However, to protect your anonymity, we do not want your name to 
appear on any questionnaire you complete. For this reason everyone is provided 
with a unique identification code, which you can create yourself by using the 
following formula: 
 
In the space provided please write … 
 
1) … the first 2 letters of your mother’s first name, e.g. ‘SU’ for Susan    
 
2) … the month you were born, e.g. ‘07’ for July    
 
3) … the first 2 letters of your own first name, e.g. ‘JO’ for John.    
 
Once again, thank you very much for your help with this research. 
Please return this booklet with the researcher’s copy of your signed consent 
form in the pre-paid envelope provided. 
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Appendix P: Two week questionnaire 
 
 
 
Writing for People Living with Type 2 diabetes Study 
 
 
Questionnaire Booklet 2 
Please complete the following sections 
 
     Section 1 
The following items ask about how much your illness and/or its treatment interferes 
with your life. Please circle the one number that best describes your current life 
situation. If an item is not applicable, please check the box to indicate that this 
aspect of your life is not affected. Please do not leave any item unanswered.  
 
How much does your illness and/or its treatment interfere with:  
 
1. Your feeling of being           Not very much►1 2 3 4 5 6 7 ◄Very much     Not applicable  
    healthy? 
2. The things you eat and        Not very much► 1 2 3 4 5 6 7 ◄Very much   Not applicable  
    drink? 
3. Your work, including job,     Not very much► 1 2 3 4 5 6 7 ◄Very much    Not applicable  
    house work, chores, or  
    errands? 
4. Playing sports, gardening,  Not very much► 1 2 3 4 5 6 7 ◄Very much     Not applicable  
    or other physical  
    recreation or hobbies?                                                                                       
5. Quiet recreation or               Not very much► 1 2 3 4 5 6 7 ◄Very much   Not applicable  
    hobbies such as reading,  
    TV, music, knitting, etc.?  
6. Your financial situation?      Not very much► 1 2 3 4 5 6 7 ◄Very much     Not applicable  
7. Your relationship with          Not very much► 1 2 3 4 5 6 7 ◄Very much     Not applicable  
    your spouse or   
    domestic partner?   
8. Your sex life?                       Not very much► 1 2 3 4 5 6 7 ◄Very much   Not applicable                     
9. Your relationship and           Not very much► 1 2 3 4 5 6 7 ◄Very much    Not applicable                    
    social activities with your  
    family?   
10. Social activities with          Not very much► 1 2 3 4 5 6 7 ◄Very much     Not applicable  
    your friends, neighbours,  
    or groups?  
11. Your religious or spiritual  
    activities?                            Not very much► 1 2 3 4 5 6 7 ◄Very much    Not applicable  
12. Your involvement in  
     community or                     Not very much► 1 2 3 4 5 6 7 ◄Very much      Not applicable  
     civic activities?  
13. Your self-improvement     Not very much► 1 2 3 4 5 6 7 ◄Very much      Not applicable  
     or self-expression  
     activities?                 
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Section 2 
Below is a list of  activities you have to perform to manage your diabetes. Please 
read each one and then circle the number which best describes how confident you 
usually are that you could carry out that activity. For example, if you are completely 
confident that you are able to check your blood sugar levels when nessessary, circle 
10. If you feel  that most of the time you could not do it, circle 1 or 2. 
 
I am confident that…….. 
 
 
Cannot do                                           Maybe yes                                                    Certain 
At all                                                maybe no                                                      can do 
                                                       
 
1 I am able to check my blood sugar if necessary 
 0 1 2 3 4 5 6 7 8 9 10 
2 I am able to correct my blood sugar when the sugar level is too high. 
 0 1 2 3 4 5 6 7 8 9 10 
3 I am able to correct my blood sugar when the blood sugar level is too low. 
 0 1 2 3 4 5 6 7 8 9 10 
4 I am able to choose the correct foods. 
 0 1 2 3 4 5 6 7 8 9 10 
5 I am able to keep my weight under control. 
 0 1   2   3   4   5  6  7  8  9         10 
6 I am able to examine my feet for cuts. 
 0 1 2 3 4 5 6 7 8 9 10 
7 I am able to adjust my eating plan when ill. 
 0 1 2 3 4 5 6 7 8 9 10 
8 I am able to follow a healthy eating pattern most of the time. 
 0 1 2 3 4 5 6 7 8 9 10 
9 I am able to take more exercise if the doctor advises me to. 
 0 1 2 3 4 5 6 7 8 9 10 
10 When taking more exercise I am able to adjust my eating plan. 
 0 1 2 3 4 5 6 7 8 9 10 
11 I am able to follow a healthy eating pattern when I am away from home. 
 0 1 2 3 4 5 6 7 8 9 10 
12 I am able to follow a healthy eating pattern when I am eating out or at a 
            party. 
 0 1 2 3 4 5 6 7 8 9 10 
13 I am able to adjust my eating plan when I am feeling stressed or anxious. 
 0 1 2 3 4 5 6 7 8 9 10 
14 I am able to take my medication as prescribed. 
 0 1 2 3 4 5 6 7 8 9 10 
15 I am able to adjust my medication when I am ill. 
 0 1 2 3 4 5 6 7 8 9 10 
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Section 3 
The following questions ask about people in your environment who provide you with 
help or support. Each question has two parts. For the first part, list all the people you 
know, excluding yourself, whom you can count on for help and support in the 
manner described. Give the persons’ initials, their relationship to you (see example). 
Do not list more than one person next to each of the numbers beneath the question.   
 
For the second part, circle how satisfied you are with the overall support you have. 
 
If you have had no support for a question, check the words “No one”, but still rate 
your level of satisfaction.  
 
Do not list more than nine persons per question. 
 
Please answer all the questions as best you can.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Whom can you really count on to be dependable when you need help? 
 
   No one     1)                                                  4)                                                7)   
                    2)                                                  5)                                                8) 
                    3)                                                  6)                                                9) 
 
2. How satisfied? 
 
6-very                  5-fairly             4-a little             3-a little              2-fairly                 1-very 
satisfied             satisfied           satisfied           dissatisfied        dissatisfied          dissatisfied  
 
 
3. Whom can you really count on to help you feel more relaxed when you are under 
pressure or tense? 
 
    No one       1)                                                  4)                                                7)   
                       2)                                                  5)                                                8) 
                       3)                                                  6)                                                9) 
 
4. How satisfied? 
 
   6-very               5-fairly              4-a little              3-a little           2-fairly                     1-very  
   satisfied          satisfied            satisfied          dissatisfied      dissatisfied             dissatisfied
EXAMPLE:  
 
Who do you know whom you can trust with information that could get you in trouble? 
 
No one       1) T.N. (brother)        4) T.N. (father)           7)   
                   2) L.M. (friend)         5) L.M. (employer)      8) 
                   3) R.S. (friend)         6)                                9) 
 
How satisfied? 
 
6-very               5-fairly                4-a little                  3-a little                 2-fairly              1-very  
satisfied           satisfied               satisfied               dissatisfied          dissatisfied      dissatisfied 
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5. Who accepts you totally, including both your worst and best points? 
    No one       1)                                                  4)                                                7)   
                       2)                                                  5)                                                8) 
                       3)                                                  6)                                                9) 
 
6. How satisfied? 
 
6-very                5-fairly                4-a little               3-a little          2-fairly                     1-very 
satisfied            satisfied              satisfied          dissatisfied      dissatisfied           dissatisfied 
 
 
7. Whom can you really count on to care about you, regardless of what is happening 
to you? 
 
    No one       1)                                                  4)                                                7)   
                       2)                                                  5)                                                8) 
                       3)                                                  6)                                                9) 
 
8. How satisfied? 
 
 6-very               5-fairly                4-a little               3-a little            2-fairly                   1-very 
satisfied           satisfied               satisfied            dissatisfied      dissatisfied         dissatisfied  
 
 
9. Whom can you really count on to help you feel better when you are feeling 
generally down-in-the dumps? 
 
    No one       1)                                                  4)                                                7)   
                       2)                                                  5)                                                8) 
                       3)                                                  6)                                                9) 
 
10. How satisfied? 
 
 6-very                5-fairly                4-a little               3-a little             2-fairly                1-very 
satisfied            satisfied               satisfied            dissatisfied       dissatisfied        dissatisfied  
 
 
11. Who can you count on to console you when you are very upset? 
 
      No one       1)                                                  4)                                                7)   
                         2)                                                  5)                                                8) 
                         3)                                                  6)                                                9) 
 
12. How satisfied? 
 
 6-very               5-fairly                 4-a little                3-a little              2-fairly             1-very 
satisfied           satisfied                satisfied             dissatisfied       dissatisfied      dissatisfied 
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You have now completed the questionnaire. 
 
May I take this opportunity to thank you for taking the time to help with this research.   
 
As you know, we will ask you to complete more questionnaires over the next few 
months, and we need to be able to compare your answers on each questionnaire 
you complete.  However, to protect your anonymity, we do not want your name to 
appear on any questionnaire you complete. For this reason everyone is provided 
with a unique identification code, which you can create yourself by using the 
following formula: 
 
In the space provided please write … 
 
1) … the first 2 letters of your mother’s first name, e.g. ‘SU’ for Susan    
 
2) … the month you were born, e.g. ‘07’ for July    
 
3) … the first 2 letters of your own first name, e.g. ‘JO’ for John.    
 
Once again, thank you very much for your help with this research. 
Please return this booklet in the pre-paid envelope provided. 
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Appendix Q: Three month questionnaire 
 
 
 
 
Writing for People Living with Type 2 diabetes Study 
 
 
Questionnaire Booklet 3 
Please complete the following sections 
 
Section 1 
Below is a list of some of the ways you may have felt or behaved. Please indicate 
how often you have felt this way during the past week by circling the appropriate 
number 
 
                                                               Rarely or none     Some or a           Occasionally or a       Most or All 
                                                           of the time         little of the           moderate amount     of the time 
                                                       (less than 1 day)  time (1-2 days)  of  the time (3-4 days)    (5-7 days) 
 
1. I was bothered by things that 1   2                3              4 
    usually don’t bother me. 
2. I did not feel like eating; my   1   2                3                    4 
    appetite was poor.  
3. I felt that I could not shake off the  1    2                    3                4 
    blues even with help from my  
    family or friends.       
4. I felt that I was as good as other  1   2                 3                   4 
    people.        
5. I had trouble keeping my mind on 1   2              3                     4 
    what I was doing. 
6. I felt depressed.       1   2               3                4 
7. I felt that everything I did was an  1     2               3                  4 
    effort.           
8. I felt hopeful about the future. 1            2                 3               4 
9. I thought my life had been a  1                  2                 3                   4 
     failure.           
10. I felt fearful.    1                 2               3               4 
11. My sleep was restless.  1                2                  3                   4 
12. I was happy.   1             2                   3              4 
13. I talked less than usual.  1                  2                   3                    4 
14. I felt lonely.   1                  2                  3                    4 
15. People were unfriendly.   1                 2                 3                    4 
16. I enjoyed life.    1                   2                    3                     4 
17. I had crying spells.   1                    2                     3                   4 
18. I felt sad.    1                    2                 3                     4 
19. I felt that people disliked me.  1                   2                   3                    4 
20. I could not get “going”.  1                    2                      3                      4 
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Section 2 
Which of the following diabetes issues are currently a problem for you? Circle the 
number that gives the best answer for you . Please provide an answer for each 
question. 
                                                                              Not a     Minor   Moderate  Somewhat serious Serious 
                                                                            problem problem  problem           problem       problem 
 
1. Not having clear and concrete                  1           2            3            4           5                             
    goals for your diabetes care?  
2. Feeling discouraged with your                   1          2            3             4          5 
    diabetes treatment  plan?                               
3. Feeling scared when you think                  1           2            3            4          5 
    about living with diabetes?                             
4. Uncomfortable social situations                 1           2            3            4          5 
     related to your diabetes care    
     (e.g. people telling you what to eat?)             
5. Feelings of deprivation                              1           2            3             4          5 
    regarding food and meals?                             
6. Feeling depressed when you                     1           2            3            4          5 
    think about living with diabetes?                     
7. Not knowing if your mood or                      1           2            3             4          5 
    feelings are  related to your diabetes?            
8. Feeling overwhelmed by your diabetes?    1          2            3             4          5      
9. Worrying about low blood sugar reaction? 1          2            3             4          5 
10. Feeling angry when you think                   1          2            3             4          5 
      about living with diabetes?                            
11. Feeling constantly concerned                   1          2            3             4          5 
      about food and eating?                                 
12. Worrying about the future and the            1           2           3             4          5 
     possibility of serious complications?             
13. Feelings of guilt or anxiety when you get  1          2            3             4          5 
      off track with your diabetes management?     
14. Not "accepting" your diabetes?                 1           2            3            4          5 
15. Feeling unsatisfied with your diabetes      1           2            3            4          5 
     doctor?                                                            
16. Feeling that diabetes is taking up too        1           2           3             4          5 
      much of your  mental and physical 
      energy every day?  
17. Feeling alone with your diabetes?              1          2            3             4         5 
18. Feeling that your friends and family are     1          2            3             4         5 
      not supportive of your diabetes  
      management efforts?                                      
19. Coping with complications of diabetes?     1           2            3             4         5 
20. Feeling "burned out" by the constant         1           2            3             4         5 
      effort needed to manage diabetes?                
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Section 3 
By placing a tick in one box in each group below, please indicate which statements 
best describe your own health state today. 
 
 
Mobility 
I have no problems in walking about  
I have some problems in walking about  
I am confined to bed  
 
 
 
Self-Care 
I have no problems with self-care  
I have some problems washing or dressing myself  
I am unable to wash or dress myself  
 
 
 
Usual Activities (e.g. work, study, housework, family or 
leisure activities) 
I have no problems with performing my usual activities  
I have some problems with performing my usual activities  
I am unable to perform my usual activities  
 
 
 
Pain/Discomfort 
I have no pain or discomfort  
I have moderate pain or discomfort  
I have extreme pain or discomfort  
 
 
 
Anxiety/Depression 
I am not anxious or depressed  
I am moderately anxious or depressed  
I am extremely anxious or depressed  
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To help people say how good or bad a health state is, we have  
drawn a scale (rather like a thermometer) on which the best state  
you can imagine is marked 100 and the worst state you can  
imagine is marked 0.  
 
We would like you to indicate on this scale how good or bad your  
own health is today, in your opinion. Please do this by drawing a line  
from the box below to whichever point on the scale indicates how good  
or bad your health state is today. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Your own 
health state 
today 
9 0 
8 0 
7 0 
6 0 
5 0 
4 0 
3 0 
2 0 
1 0 
100 
Worst 
imaginable 
health state 
0 
Best  
imaginable 
health state 
© EuroQoL Group 1990 
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Section 4 
The questions below ask you about your diabetes self care activities during the past 
7 days. If you were sick during the past 7 days,  please think back to the last 7 days 
that you were not sick.   
 
 
1. How many of the last SEVEN DAYS have you          0    1     2     3    4    5    6     7 
     followed a eating plan? 
2. On average, over the past month, how many days    0    1     2     3    4    5    6     7 
     per week have you followed your eating plan?  
3. On how many of the last SEVEN DAYS did you        0    1     2     3    4    5    6     7 
    eat five or more servings of fruits and vegetables? 
4. On how many of the last SEVEN DAYS did you        0    1     2     3    4    5    6     7 
    eat high fat foods such as red meat or full-fat  
    dairy products? 
5. On how many of the last SEVEN DAYS did you        0    1     2     3    4    5     6    7 
    participate in at least 30 minutes of physical activity?   
    (total minutes of continuous activity including walking). 
6. On how many of the last SEVEN DAYS did you        0    1     2     3    4    5     6    7 
    participate in a specific exercise session (such as  
    swimming, walking, biking) other than what you do  
    around the house or as part of your work?                     
7. On how many of the last SEVEN DAYS did you        0    1     2     3    4    5     6    7 
     test your blood sugar?                                                   
8. On how many of the last SEVEN DAYS did you        0    1     2     3    4    5     6    7 
    test your blood sugar the number of times  
    recommended by your health care provider? 
9. On how many of the last SEVEN DAYS did you        0    1     2     3    4    5     6    7 
    check your feet?                                                           
10. On how many of the last SEVEN DAYS did you      0    1     2     3    4    5     6    7 
    inspect the inside of your shoes? 
 
11. Have you smoked a cigarette—even one puff—during the past SEVEN DAYS? 
0. No 
1. Yes.  
If yes, how many cigarettes did you smoke on an average day?   Number of 
cigarettes.............. 
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      Section 5 
The following items ask about how much your illness and/or its treatment interferes 
with your life. Please circle the one number that best describes your current life 
situation. If an item is not applicable, please check the box to indicate that this 
aspect of your life is not affected. Please do not leave any item unanswered.  
 
How much does your illness and/or its treatment interfere with:  
 
1. Your feeling of being           Not very much►1 2 3 4 5 6 7 ◄Very much     Not applicable  
    healthy? 
2. The things you eat and        Not very much► 1 2 3 4 5 6 7 ◄Very much   Not applicable  
    drink? 
3. Your work, including job,     Not very much► 1 2 3 4 5 6 7 ◄Very much    Not applicable  
    house work, chores, or  
    errands? 
4. Playing sports, gardening,  Not very much► 1 2 3 4 5 6 7 ◄Very much     Not applicable  
    or other physical  
    recreation or hobbies?                                                                                       
5. Quiet recreation or               Not very much► 1 2 3 4 5 6 7 ◄Very much   Not applicable  
    hobbies such as reading,  
    TV, music, knitting, etc.?  
6. Your financial situation?      Not very much► 1 2 3 4 5 6 7 ◄Very much     Not applicable  
7. Your relationship with          Not very much► 1 2 3 4 5 6 7 ◄Very much     Not applicable  
    your spouse or   
    domestic partner?   
8. Your sex life?                       Not very much► 1 2 3 4 5 6 7 ◄Very much   Not applicable                     
9. Your relationship and           Not very much► 1 2 3 4 5 6 7 ◄Very much    Not applicable                    
    social activities with your  
    family?   
10. Social activities with          Not very much► 1 2 3 4 5 6 7 ◄Very much     Not applicable  
    your friends, neighbours,  
    or groups?  
11. Your religious or spiritual  
    activities?                            Not very much► 1 2 3 4 5 6 7 ◄Very much     Not applicable  
12. Your involvement in  
     community or                     Not very much► 1 2 3 4 5 6 7 ◄Very much      Not applicable  
     civic activities?  
13. Your self-improvement     Not very much► 1 2 3 4 5 6 7 ◄Very much       Not applicable  
     or self-expression  
     activities?  
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Section 6 
Below is a list of activities you have to perform to manage your diabetes. Please 
read each one and then circle the number which best describes how confident you 
usually are that you could carry out that activity. For example, if you are completely 
confident that you are able to check your blood sugar levels when necessary, circle 
10. If you feel that most of the time you could not do it, circle 1 or 2. 
 
I am confident that…….. 
 
 
Cannot do                                           Maybe yes                                                    Certain 
At all                                                maybe no                                                      can do 
                                                       
 
1 I am able to check my blood sugar if necessary 
 0 1 2 3 4 5 6 7 8 9 10 
2 I am able to correct my blood sugar when the sugar level is too high. 
 0 1 2 3 4 5 6 7 8 9 10 
3 I am able to correct my blood sugar when the blood sugar level is too low. 
 0 1 2 3 4 5 6 7 8 9 10 
4 I am able to choose the correct foods. 
 0 1 2 3 4 5 6 7 8 9 10 
5 I am able to keep my weight under control. 
 0 1   2   3   4  5  6  7  8  9  10 
6 I am able to examine my feet for cuts. 
 0 1 2 3 4 5 6 7 8 9 10 
7 I am able to adjust my eating plan when ill. 
 0 1 2 3 4 5 6 7 8 9 10 
8 I am able to follow a healthy eating pattern most of the time. 
 0 1 2 3 4 5 6 7 8 9 10 
9 I am able to take more exercise if the doctor advises me to. 
 0 1 2 3 4 5 6 7 8 9 10 
10 When taking more exercise I am able to adjust my eating plan. 
 0 1 2 3 4 5 6 7 8 9 10 
11 I am able to follow a healthy eating pattern when I am away from home. 
 0 1 2 3 4 5 6 7 8 9 10 
12 I am able to follow a healthy eating pattern when I am eating out or at a 
            party. 
 0 1 2 3 4 5 6 7 8 9 10 
13 I am able to adjust my eating plan when I am feeling stressed or anxious. 
 0 1 2 3 4 5 6 7 8 9 10 
14 I am able to take my medication as prescribed. 
 0 1 2 3 4 5 6 7 8 9 10 
15 I am able to adjust my medication when I am ill. 
 0 1 2 3 4 5 6 7 8 9 10 
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Section 7 
The following questions ask about people in your environment who provide you with 
help or support. Each question has two parts. For the first part, list all the people you 
know, excluding yourself, whom you can count on for help and support in the 
manner described. Give the persons’ initials, their relationship to you (see example). 
Do not list more than one person next to each of the numbers beneath the question.   
 
For the second part, circle how satisfied you are with the overall support you have. 
 
If you have had no support for a question, check the words “No one”, but still rate 
your level of satisfaction.  
Do not list more than nine persons per question. 
 
Please answer all the questions as best you can.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Whom can you really count on to be dependable when you need help? 
 
   No one     1)                                                  4)                                                7)   
                    2)                                                  5)                                                8) 
                    3)                                                  6)                                                9) 
 
2. How satisfied? 
 
6-very                  5-fairly             4-a little             3-a little              2-fairly                 1-very 
satisfied             satisfied           satisfied           dissatisfied        dissatisfied          dissatisfied  
 
 
3. Whom can you really count on to help you feel more relaxed when you are under 
pressure or tense? 
 
    No one       1)                                                  4)                                                7)   
                       2)                                                  5)                                                8) 
                       3)                                                  6)                                                9) 
 
4. How satisfied? 
 
   6-very               5-fairly              4-a little              3-a little           2-fairly                     1-very  
   satisfied          satisfied            satisfied          dissatisfied      dissatisfied             dissatisfied
EXAMPLE:  
 
Who do you know whom you can trust with information that could get you in trouble? 
 
No one       1) T.N. (brother)        4) T.N. (father)           7)   
                   2) L.M. (friend)         5) L.M. (employer)      8) 
                   3) R.S. (friend)         6)                                9) 
 
How satisfied? 
 
6-very               5-fairly                4-a little                  3-a little                 2-fairly              1-very  
satisfied           satisfied               satisfied               dissatisfied          dissatisfied      dissatisfied 
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5. Who accepts you totally, including both your worst and best points? 
    No one       1)                                                  4)                                                7)   
                       2)                                                  5)                                                8) 
                       3)                                                  6)                                                9) 
 
6. How satisfied? 
 
6-very                5-fairly                4-a little               3-a little          2-fairly                     1-very 
satisfied            satisfied              satisfied          dissatisfied      dissatisfied           dissatisfied 
 
 
7. Whom can you really count on to care about you, regardless of what is happening 
to you? 
 
    No one       1)                                                  4)                                                7)   
                       2)                                                  5)                                                8) 
                       3)                                                  6)                                                9) 
 
8. How satisfied? 
 
 6-very               5-fairly                4-a little               3-a little            2-fairly                   1-very 
satisfied           satisfied               satisfied            dissatisfied      dissatisfied         dissatisfied  
 
 
9. Whom can you really count on to help you feel better when you are feeling 
generally down-in-the dumps? 
 
    No one       1)                                                  4)                                                7)   
                       2)                                                  5)                                                8) 
                       3)                                                  6)                                                9) 
 
10. How satisfied? 
 
 6-very                5-fairly                4-a little               3-a little             2-fairly                1-very 
satisfied            satisfied               satisfied            dissatisfied       dissatisfied        dissatisfied  
 
 
11. Who can you count on to console you when you are very upset? 
 
      No one       1)                                                  4)                                                7)   
                         2)                                                  5)                                                8) 
                         3)                                                  6)                                                9) 
 
12. How satisfied? 
 
 6-very               5-fairly                 4-a little                3-a little              2-fairly             1-very 
satisfied           satisfied                satisfied             dissatisfied       dissatisfied      dissatisfied 
 
 
  
594 
 
Section 8  
Have you carried on writing since completing the writing task we assigned?   
 
Yes             No  
    
 
 
You have now completed the questionnaire. 
 
May I take this opportunity to thank you for taking the time to help with this research.   
 
As you know, we will ask you to complete more questionnaires over the next few 
months, and we need to be able to compare your answers on each questionnaire 
you complete.  However, to protect your anonymity, we do not want your name to 
appear on any questionnaire you complete. For this reason everyone is provided 
with a unique identification code, which you can create yourself by using the 
following formula: 
 
In the space provided please write … 
 
1) … the first 2 letters of your mother’s first name, e.g. ‘SU’ for Susan    
 
2) … the month you were born, e.g. ‘07’ for July    
 
3) … the first 2 letters of your own first name, e.g. ‘JO’ for John.    
 
Once again, thank you very much for your help with this research. 
Please return this booklet in the pre-paid envelope provided. 
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Appendix R: Intervention 
 
WED  
 
 
 
Writing for People Living with Type 2 diabetes Study 
 
 
Study Writing Pack  
 
Please read the following instructions and complete the writing task for 20 minutes 
each day for three days over the course of one week. Please record the time at 
which you started and finished writing in the spaces provided for each day. After 
each day’s writing please also complete the questions at the end of the space 
provided for writing for that day.  
 
 
I would like you to write about your deepest thoughts and feelings about any 
stressful experience you have encountered over the last month, or any worries or 
concerns that are currently troubling you. 
 
In your writing, I’d like you to really let go and explore your very deepest emotions 
and thoughts. You might link your topic to your relationships with others, including 
parents, lovers, friends, or relatives. You might also like to link your experience to 
the present and future, who you are or who you would like to be. You may write 
about the same general issues or different experiences each day.  
 
Find a time and place where you won’t be disturbed. Ideally, pick a time at the end of 
your workday or before you go to bed. Once you begin writing, write continuously. 
Don’t worry about spelling or grammar –that is not important. If you run out of things 
to write about, just repeat what you have already written. 
 
 
 
 
Please turn over to begin writing 
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Control 
 
 
 
 
 
Writing for People Living with Type 2 diabetes Study 
 
 
Study Writing Pack  
 
Please read the following instructions and complete the writing task for 20 minutes 
each day for three days over the course of one week. Please record the time at 
which you started and finished writing in the spaces provided for each day. After 
each day’s writing please also complete the questions at the end of the space 
provided for writing for that day.  
 
 
I want you to write about how you use your time. In your writing, please go into as 
much detail as possible about how you have spent your days and managed your 
time. Please be as objective as possible. The most important thing is that you 
describe your activities in detail without discussing any of your thoughts or feelings 
related to the topic. 
 
In today’s writing I want you to describe what you did yesterday from the time you 
got up until the time you went to bed. You might include where you went and the 
tasks you had to complete.  
 
Find a time and place where you won’t be disturbed. Ideally, pick a time at the end of 
your workday or before you go to bed. Once you begin writing, write continuously. 
Don’t worry about spelling or grammar –that is not important. If you run out of things 
to write about, just repeat what you have already written. 
 
 
 
 
 
Please turn over to begin writing 
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Within writing packs  
Repeated for each writing session.     
Day X                          
 
Time you started writing: _______________am / pm 
 
(blank pages for writing) 
 
Time you finished writing: _______________am / pm 
 
How do you feel right now? 
It is important for us to know how you feel immediately after completing the writing 
task. To help us achieve this, below we have provided a list of words that describe 
different feelings and emotions, which you may be experiencing. For each word, we 
would like you to consider the extent to which you currently feel the way described, 
using the following scale to select the answer that best describes how you feel right 
now: 
  
1 2 3 4 5 
(very slightly 
or not at all) 
(a little) (moderately) (quite a bit) (extremely) 
 
For example, if you currently feel a little bit irritable, you should write 2 in the space 
provided next to the word irritable. Remember, your answer should reflect how you 
feel right now, that is, at the present moment. Please complete this task now.  
 
Right now I feel …  
 
………interested ………irritable  ………hostile  ………distressed 
 
………alert   ………enthusiastic ………excited  ………ashamed 
 
………jittery  ………upset  ………inspired        ………active 
 
………strong  ………nervous ………proud  ………guilty 
 
………determined ………afraid  ………scared  ………attentive 
 
You have now completed Day X. 
Thank you. 
 
Day 3 only 
 
How many days did you write for?    …………………………..days 
 
If you were not able to write for the required time each day and number of days, so 
that we can evaluate our study we would appreciate it if you would tell us why 
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You have now completed the task. 
 
May I take this opportunity to thank you for taking the time to help with this research.   
 
As you know, we will ask you to complete questionnaires over the next few months, 
and we need to be able to compare your writing to the questionnaires you complete.  
However, to protect your anonymity, we do not want your name to appear on 
anything you complete. For this reason everyone is provided with a unique 
identification code, which you can create yourself by using the following formula: 
 
In the space provided please write … 
 
1) … the first 2 letters of your mother’s first name, e.g. ‘SU’ for Susan    
 
2) … the month you were born, e.g. ‘07’ for July    
 
3) … the first 2 letters of your own first name, e.g. ‘JO’ for John.    
 
 
Once again, thank you very much for your help with this research. 
Please return this booklet in the pre-paid envelope provided. 
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Appendix S: Self-harm checklist 
 
 
Date writing received 
 
Date writing screened 
 
Patient Identification Number: 
 
 
Direct statement of suicidal intent    Yes              No  
 
Previous undocumented self-harm or suicide attempts Yes              No  
 
Marked hopelessness     Yes              No  
 
Images of death of self or others including bereavement Yes              No  
 
Alcohol and drug dependency    Yes              No  
 
Insomnia       Yes              No  
 
Social isolation      Yes              No  
 
Chronic painful illness     Yes              No  
 
Inability to concentrate     Yes              No  
 
Feeling generally stressed/overwhelmed   Yes              No  
 
 
 
Decision to refer?                                                                  Yes              No  
 
If yes 
Date of referral 
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Exploratory RCT: Additional support group materials  
 
Appendix T: Study website 
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Exploratory RCT: Data handling and analysis 
 
Appendix U: Transformation 
 
Types of transformation performed for each continuous variable included in analyses 
 
Analysis Continuous variables included in analyses Transformation 
performed 
Effectiveness analyses 
Depressive symptom severity   CES-D (baseline & follow up) & Age SQRT+1 
DSED PAID (baseline & follow up) & Age LOG 
Health-related QoL EQ-5D utility (baseline & follow up) & Age SQRT+1 
Health-related QoL EQ-5D VAS (baseline & follow up) Reversed & then 
SQRT+1 
Age SQRT+1 
Diabetes SMBs: general diet   SDSCA: general diet (baseline & follow up) Reversed & then 
LOG+1 
Age LOG+1 
Diabetes SMBs: specific diet   SDSCA: specific diet (baseline & follow up) Reversed & then 
LOG+1 
Age LOG+1 
Diabetes SMBs: exercise   SDSCA: exercise (baseline & follow up) Reversed & then 
SQRT+1 
Age SQRT+1 
Diabetes SMBs: blood 
glucose testing  
SDSCA: BG testing (baseline & follow up) & 
Age 
LOG+1 
Diabetes SMBs: foot care SDSCA: Foot care (baseline & follow up) & 
Age 
LOG+1 
Sub-group (moderator) analyses 
Alexithymia  TAS-20 & CES-D (baseline & follow up) SQRT + 1 
Optimism  LOT-R & CES-D (baseline & follow up) SQRT + 1 
Mediator analyses (same for 2 weeks & 3 months) 
Self-efficacy for diabetes 
SMBs 
DMSES UK Reversed & then 
SQRT+1 
CES-D (baseline & follow up) SQRT+1 
Perceived illness interference  Perceived illness interference LOG 
CES-D (baseline & follow up) SQRT+1 
Perceived emotional support 
(number) 
SSQ6 (number) LOG+1 
CES-D (baseline & follow up) SQRT+1 
Perceived emotional support 
(satisfaction) 
SSQ6 (satisfaction) &  
CES-D (baseline & follow up) 
SQRT+1 
Mechanisms of change 
PANAS (negative affect) session 1, 2 & 3 LOG+1 
LIWC positive emotion session 1, 2 & 3 LOG+1 
LIWC negative emotion session 1, 2 & 3 LOG+1 
LIWC insight session 1, 2 & 3 LOG+1 
LIWC cause session 1, 2 & 3 LOG+1 
Contamination analyses 
PANAS(negative affect) average LOG 
LIWC positive emotion, negative emotion, insight and cause averages LOG 
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Initial and post-transformation assumption checks 
 
 Before transformation Best 
transformation 
Post transformation 
Normality  Normality 
Effectiveness   
CES-D baseline Shapiro-Wilk:  
CTL D(18)=.937, p=.262 
WED D(23)=.921, p=.072 
Boxplots: ok 
Histograms: ok 
Skewness: 
CTL .241/.536 = .45 
WED -.124/.481 = -.26 
Kurtosis: 
CTL -1.079/1.039 = -1.04 
WED -1.319/.935 = -1.41 
SQRT + 1 Shapiro-Wilk:  
CTL D(18)=.932, p=.210 
WED D(23)=.889, p=.015 
Boxplots: -ve skew (WED only) 
Histograms: +ve skew 
Skewness: 
CTL -.282/.536 = -.53 
WED -.535/.481 = -1.11 
Kurtosis: 
CTL -1.109/1.038 = -1.07 
WED -1.117/.935 = -1.19 
CES-D follow up Shapiro-Wilk:  
CTL D(14)=.790, p=.004 
WED D(18)=.932, p=.212 
Boxplots: +ve skew 
Histograms: +ve skew (esp. CTL) 
Skewness: 
CTL 1.193/.597 = 1.99 
WED .615/.536 = 1.15 
Kurtosis: 
CTL -.018/1.154 = -.02 
WED .467/1.038 = -.45 
SQRT + 1 Shapiro-Wilk:  
CTL D(14)=.881, p=.060 
WED D(18)=.953, p=.475 
Boxplots: +ve skew (CTL only) 
Histograms: +ve skew (CTL only) 
Skewness: 
CTL .763/.597 = -1.28 
WED -.114/.536 = -.21 
Kurtosis: 
CTL -.604/1.154 = -.52 
WED -.842/1.038 = -.811 
PAID baseline Shapiro-Wilk:  
CTL D(17)=.831, p=.006 
WED D(22)=.876, p=.010 
Boxplots: +ve skew (esp. WED) 
Histograms: +ve skew (esp. WED) 
Skewness: 
CTL 1.452/.550 = 2.64 
WED 1.350/.491 = 2.75 
Kurtosis: 
LOG Shapiro-Wilk:  
CTL D(17)=.888, p=.043 
WED D(22)=.930, p=.124 
Boxplots: +ve skew 
Histograms: +ve skew 
Skewness: 
CTL 1.071/.550 = 1.95 
WED .514/.491 = 1.05 
Kurtosis:  
606 
 
CTL 1.522/1.063 = 1.43 
WED 2.684/.953 = 2.82 
CTL .417/1.063 = .39 
WED .017/.953 = .02 
PAID follow up Shapiro-Wilk:  
CTL D(14)=.869, p=.041 
WED D(18)=.760, p=.000 
Boxplots: +ve skew  
Histograms: +ve skew 
Skewness: 
CTL .980/.597 = 1.64 
WED 1.450/.536 = 2.70 
Kurtosis: 
CTL -.005/1.154 = -.004 
WED .924/1.038 = .89 
LOG Shapiro-Wilk:  
CTL D(14)=.904, p=.128 
WED D(18)=.808, p=.002 
Boxplots: +ve skew 
Histograms: +ve skew 
Skewness: 
CTL .624/.597 = 1.04 
WED 1.190/.536 = 2.22 
Kurtosis: 
CTL -.677/1.154 = -.59 
WED .162/1.038 = .16 
EQ-5D utility baseline Shapiro-Wilk:  
CTL D(16)=.701, p=.000 
WED D(22)=.821, p=.001 
Boxplots: -ve skew 
Histograms: -ve skew 
Skewness: 
CTL -.869/.594 = - 1.54 
WED -.226/.491 = -.46 
Kurtosis: 
CTL -1.138/1.091 = -1.04 
WED -1.584/.953 = -1.66 
SQRT + 1 Shapiro-Wilk:  
CTL D(16)=.702, p=.000 
WED D(22)=.824, p=.001 
Boxplots: -ve skew 
Histograms: -ve skew 
Skewness: 
CTL -.881/.564 = -1.56 
WED -.253/.491 = -.52 
Kurtosis: 
CTL -1.104/1.091 = -1.01 
WED -1.532/.953 = -1.62 
EQ-5D utility follow up Shapiro-Wilk:  
CTL D(14)=.638, p=000. 
WED D(18)=.839, p=.006 
Boxplots: -ve skew 
Histograms: -ve skew 
Skewness: 
CTL -2.214/.597 = -3.71 
WED .028/.536 = .05 
Kurtosis: 
CTL 5.358/1.154 = 4.64 
WED -1.730/1.038 = -1.67 
SQRT + 1 Shapiro-Wilk:  
CTL D(14)=.622, p=.000 
WED D(18)=.843, p=.007 
Boxplots: -ve skew 
Histograms: -ve skew 
Skewness: 
CTL -2.372/.597 = -.25 
WED .000/.536 = 0 
Kurtosis:  
CTL 6.236/1.154 = 5.40 
WED -1.702/1.038 = -1.6 
EQ-5D VAS baseline Shapiro-Wilk:  
CTL D(16)=.899, p=.078 
WED D(22)=.844, p=.003 
Boxplots: -ve skew 
REVERSED & 
SQRT + 1 
Shapiro-Wilk:  
CTL D(16)=.965, p=.750 
WED D(22)=.956, p=.420 
Boxplots: ok 
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Histograms: -ve skew 
Skewness: 
CTL -.897/.564 = -1.59 
WED -1.118/.491 = -2.28 
Kurtosis: 
CTL -.088/1.091 = -.08 
WED .155/.953 = .16 
Histograms: ok 
Skewness: 
CTL .160/.564 = .28 
WED .253/.491 = .52 
Kurtosis:  
CTL -.800/.564 = -1.42 
WED -.689/.953 = -.72 
EQ-5D VAS follow up Shapiro-Wilk:  
CTL D(14)=.943, p=.459 
WED D(18)=.802, p=.002 
Boxplots: -ve skew 
Histograms: -ve skew 
Skewness: 
CTL -.721/.597 = -1.21 
WED -1.783/.536 = -3.33 
Kurtosis: 
CTL .582/1.154 = .50 
WED 3.251/1.038 = 3.13 
REVERSED & 
SQRT + 1 
Shapiro-Wilk:  
CTL D(14)=.973, p=.911 
WED D(18)=.933 , p=.217 
Boxplots: ok 
Histograms: ok 
Skewness: 
CTL -.244/.597 = -.41 
WED .851/.536 = 1.59  
Kurtosis: 
CTL -.031/1.154 = -.03 
WED .551/1.038 = .53 
SDSCA general diet baseline Shapiro-Wilk:  
CTL D(17)=.776, p=.001 
WED D(23)=.748, p=.000 
Boxplots: -ve skew 
Histograms: -ve skew (esp. WED) 
Skewness: 
CTL -1.314/.550 = -2.39 
WED -2.356/.481 = -4.90 
Kurtosis: 
CTL .959/1.063 = .902 
WED 7.766/.935 = 8.30 
REVERSED & 
LOG + 1 
Shapiro-Wilk:  
CTL D(17)=.821, p=.004 
WED D(23)=.897, p=.022 
Boxplots: +ve skew 
Histograms: +ve skew 
Skewness: 
CTL .541/.550 = .98 
WED .444/.481 = .92 
Kurtosis: 
CTL -1.083/1.063 = -1.02 
WED =.065/.935 = -.07 
SDSCA general diet follow up Shapiro-Wilk:  
CTL D(14)=.817, p=.008 
WED D(18)=.908 , p=.081 
Boxplots: -ve skew  
Histograms: -ve skew (esp. CTL) 
Skewness: 
CTL -1.299/.597 = -2.18 
WED -.363/.536 = -.68 
Kurtosis: 
CTL .924/1.154 = .80 
REVERSED & 
LOG + 1 
Shapiro-Wilk:  
CTL D(14)=.885, p=.069 
WED D(18)=.883, p=.029 
Boxplots: +ve skew 
Histograms: +ve skew (esp. CTL) 
Skewness: 
CTL .415/.597 = .695 
WED -.267/.536 = -.498 
Kurtosis: 
CTL -.982/1.154 = -.85 
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WED -.881/1.038 = -.85 WED -1.328/1.038 = -1.28 
SDSCA specific diet baseline Shapiro-Wilk:  
CTL D(17)=.977, p=.922 
WED D(22)=.843, p=.003 
Boxplots: ok 
Histograms: -ve skew (WED only) 
Skewness: 
CTL -.171/.550 = -.31 
WED -1.534/.491 = -3.12 
Kurtosis: 
CTL -.261/1.063 = -.25 
WED 2.437/.953 = 2.56 
REVERSED & 
LOG + 1 
Shapiro-Wilk:  
CTL D(17)=.945, p=.377 
WED D(22)=.922, p=.085 
Boxplots: ok 
Histograms: +ve skew WED only 
Skewness:  
CTL -.806/.550 = -1.47 
WED .829/.491 = 1.69 
Kurtosis: 
CTL .538/1.063 = .51 
WED .551/.953 = .58 
SDSCA specific diet follow up Shapiro-Wilk:  
CTL D(14)=.945, p=.493 
WED D(18)=.908, p=.080 
Boxplots: ok 
Histograms: -ve skew (WED only) 
Skewness: 
CTL -.443/.597 = -.74 
WED -.726 /.536 = -1.35 
Kurtosis: 
CTL -.558/1.154 = -.48 
WED .132 /1.038 = .13 
REVERSED & 
LOG + 1 
Shapiro-Wilk:  
CTL D(14)=.940 , p=.415 
WED D(18)=.923 , p=.146 
Boxplots: ok 
Histograms: ok 
Skewness: 
CTL -.436/.597 = -.73 
WED .130/.536 = .24 
Kurtosis: 
CTL -.638/1.154 = -.55 
WED -.571/1.038 = -.55 
SDSCA exercise baseline Shapiro-Wilk:  
CTL D(17)=.897, p=.060 
WED D(23)=919, p=.063 
Boxplots: +ve skew for CTL & -ve skew for WED 
Histograms: +ve skew 
Skewness: 
CTL .201/.550 = .37 
WED -.130/.481 = -.27 
Kurtosis: 
CTL -1.333/1.063 = -1.25 
WED 1.255 / .935 = -1.34 
REVERSED & 
SQRT + 1 
Shapiro-Wilk:  
CTL D(17)=.899, p=.065 
WED D(23)=.914, p=.050 
Boxplots: -ve skew (CTL only) 
Histograms: -ve skew (CTL only) 
Skewness: 
CTL -.592/.550 = -1.08 
WED -.253/.481 = -.53 
Kurtosis: 
CTL -.522/1.063 = -.49 
WED -1.199/.935 = -1.28 
SDSCA exercise follow up Shapiro-Wilk:  
CTL D(14)=.924, p=.255 
WED D(18)=.858, p=.011 
Boxplots: -ve skew (WED only) 
Histograms: -ve skew (WED only) 
REVERSED & 
SQRT + 1 
Shapiro-Wilk:  
CTL D(14)=.927, p=.281 
WED D(18)=.854, p=.010 
Boxplots: -ve skew for CTL & +ve skew 
for WED 
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Skewness: 
CTL .051/.597 = .09 
WED -.208/.536 = -.39 
Kurtosis: 
CTL -1.337/1.154 = -1.16 
WED -1.672/1.038 = -1.61 
Histograms: -ve skew for CTL & +ve 
skew for WED 
Skewness: 
CTL -.422/.597 = -.71 
WED -.014/.536 = -.03 
Kurtosis: 
CTL  -.915/1.154 = -.79 
WED -1.796/1.038 = -1.7 
SDSCA blood glucose testing 
baseline  
Shapiro-Wilk:  
CTL D(15)=.772, p=.002 
WED D(20)=.765, p=.000 
Boxplots: +ve skew 
Histograms: +ve skew 
Skewness: 
CTL .929/.580 = 1.60 
WED 1.307/.512 = 2.55 
Kurtosis: 
CTL -.727/1.121 = -.65 
WED .597/.992 = .60 
LOG +1  Shapiro-Wilk:  
CTL D(15)=.789, p=.003 
WED D(20)=.849, p=.005 
Boxplots: +ve skew 
Histograms: +ve skew 
Skewness: 
CTL .473/.580 = .86 
WED .437/.512 = .85 
Kurtosis: 
CTL -1.669/1.121 = -1.49 
WED -1.146/.992 = -1.16 
SDSCA blood glucose testing 
follow up 
Shapiro-Wilk:  
CTL D(13)=.806, p=.008 
WED D(15)=.768, p=.001 
Boxplots: +ve skew 
Histograms: +ve skew 
Skewness: 
CTL .568/.616 = .90 
WED .354/.580 = .61 
Kurtosis: 
CTL -1.340/1.191 = -1.125 
WED -1.827/1.121 = -1.63 
LOG +1  Shapiro-Wilk:  
CTL D(15)=.746, p=.001 
WED D(13)=.781, p=.004 
Boxplots: +ve skew 
Histograms: +ve skew 
Skewness: 
CTL .090/.616 = .15 
WED .076/.580 = .13 
Kurtosis: 
CTL -2.032/1.191 = 1.71 
WED -2.121/1.121 = -1.89 
SDSCA foot care baseline Shapiro-Wilk:  
CTL D(17)=.910, p=.102 
WED D(23)=.853, p=.003 
Boxplots: +ve skew (CTL only) 
Histograms: +ve skew (CTL only) 
Skewness: 
CTL .867/.550 = 1.58 
WED .249/.481 = .52 
Kurtosis: 
LOG +1  Shapiro-Wilk:  
CTL D(17)=.935, p=.265 
WED D(23)=.883, p=.011 
Boxplots: +ve skew for CTL & -ve skew 
for WED 
Histograms: ok 
Skewness: 
CTL -.193/.550 = -.35 
WED -.201/.481 = -.42 
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CTL .581/1.063 = .55 
WED -1.727/.935 = 1.85 
Kurtosis: 
CTL -1.044/1.063 = -.98 
WED -1.531/.935 = -1.64 
SDSCA foot care follow up Shapiro-Wilk:  
CTL D(14)=.880, p=.059 
WED D(18)=.918, p=.120 
Boxplots: +ve skew 
Histograms: +ve skew 
Skewness: 
CTL .641/.597 = -1.25 
WED .248/.536 = .46 
Kurtosis: 
CTL -.904/1.154 = -.78 
WED -1.169/1.038 = -1.13 
LOG +1  Shapiro-Wilk:  
CTL D(14)=.906 , p=.136 
WED D(18)=.891, p=.040 
Boxplots: ok 
Histograms: +ve skew 
Skewness: 
CTL -.064/.597 = -.12 
WED -.370/.536 = -.69 
Kurtosis: 
CTL -1.558/1.154 = -1.35 
WED -1.342/1.038 = -1.29 
Covariates 
Age for CES-D/EQ-5D/SDSCA 
exercise 
Shapiro-Wilk:  
CTL D(18)=.925, p=.157 
WED D(23)=.977, p=.858 
Boxplots: ok 
Histograms: ok 
Skewness: 
CTL .204/.536 = .38 
WED -.520/.481 = 1.08 
Kurtosis: 
CTL -1.329/1.038 = 1.28 
WED .574/.935 = .61 
SQRT + 1 Shapiro-Wilk:  
CTL D(18)=.930, p=.192 
WED D(23)=.962, p=.514 
Boxplots: ok 
Histograms: ok 
Skewness: 
CTL .120/.536 = .22 
WED -.762/.481 = -1.58 
Kurtosis: 
CTL -1.323/1.038 = -1.27 
WED 1.060/.935 = 1.13 
Age for PAID LOG Shapiro-Wilk:  
CTL D(18)=.934, p=.224 
WED D(23)=.941, p=.187 
Boxplots: -ve skew (CTL only) 
Histograms: ok 
Skewness: 
CTL .030/.536 = .056 
WED -1.027/.481 = -2.14 
Kurtosis: 
CTL -1.300/1.038 = -1.25 
WED 1.738/.935 = 1.86 
Age for SDSCA general diet, LOG + 1 Shapiro-Wilk:  
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specific diet, blood glucose 
testing & foot care 
CTL D(18)=.933, p=.223 
WED D(23)=.942, p=.195 
Boxplots: ok 
Histograms: ok 
Skewness: 
CTL .033/.536 = .06 
WED -1.018/.481 = -2.12 
Kurtosis: 
CTL -1.301/1.038 = -.80 
WED 1.712/.935 = 1.83 
Moderators  
TAS-20 (to match CES-D) Shapiro-Wilk:  
CTL D(17)=.923, p=.165 
WED D(23)=.958 , p=.427 
Boxplots: ok 
Histograms: ok  
Skewness: 
CTL .623/.550 = 1.15 
WED -.460/.481 = -.96 
Kurtosis: 
CTL -.565/1.063 = -.53 
WED -.506/.935 = -.54 
SQRT + 1 Shapiro-Wilk:  
CTL D(17)=.937, p=.285 
WED D(23)=.935, p=.142 
Boxplots: ok 
Histograms: ok 
Skewness: 
CTL .447/.550 = .81 
WED -.750/.481 = -1.56 
Kurtosis: 
CTL -.824/1.063 = -.76 
WED -.099/.935 = -.11 
LOT-R (to match CES-D) Shapiro-Wilk:  
CTL D(15)=.952, p=.559 
WED D(23)=.932 , p=.120 
Boxplots: ok 
Histograms: ok 
Skewness: 
CTL -.096/.580 = -.17 
WED .477/.481 = .99 
Kurtosis: 
CTL -.787/1.121 = -.70 
WED -.735/.935 = -.79 
SQRT + 1 Shapiro-Wilk:  
CTL D(15)=.947, p=.480 
WED D(23)=.942, p=.200 
Boxplots: ok 
Histograms: ok 
Skewness: 
CTL -.251/.580 = -.43 
WED .324/.481 = .67 
Kurtosis: 
CTL -.753/1.121 = -.67 
WED -.724/.935 = -.77 
Mediators 
IIRS 2 weeks  Shapiro-Wilk:  
CTL D(15)=.797, p=.003 
WED D(18)=.857, p=.011 
Boxplots: +ve skew 
LOG Shapiro-Wilk:  
CTL D(15)=.922, p=.205 
WED D(18)=.905, p=.071 
Boxplots: +ve skew 
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Histograms: +ve skew 
Skewness: 
CTL 1.878/.580 = 3.24 
WED .769/.536 = 1.43 
Kurtosis: 
CTL 3.716/1.121 = 3.31 
WED -.851/1.038 = -.82 
Histograms: +ve skew 
Skewness: 
CTL 1.028/.580 = 1.77 
WED .317/.536 = .59 
Kurtosis: 
CTL .855/1.121 = .76 
WED -1.353/1.038 = -1.30 
IIRS 3 months Shapiro-Wilk:  
CTL D(11)=.805, p=.011 
WED D(16)=.845, p=.011 
Boxplots: +ve skew 
Histograms: +ve skew 
Skewness: 
CTL 1.450/.661 = 2.19 
WED 1.212/.564 = 2.15 
Kurtosis: 
CTL 1.812/1.279 = 1.42 
WED .797/1.091 = .73 
LOG Shapiro-Wilk:  
CTL D(11)=.870, p=.078 
WED D(16)=.907, p=.106 
Boxplots: +ve skew 
Histograms: +ve skew 
Skewness: 
CTL .835/.661 = 1.26 
WED .483/.564 = .86 
Kurtosis: 
CTL -.440/1.279 = -.34 
WED -1.048/1.091 = -.96 
DMSES UK 2 weeks Shapiro-Wilk:  
CTL D(15)=.937, p=.351 
WED D(18)=.904, p=.067 
Boxplots: -ve skew 
Histograms: ok 
Skewness: 
CTL -.757/.580 = -1.31 
WED -.821/.536 = -1.53 
Kurtosis: 
CTL .123/1.121 = .11 
WED -.007/1.038 = .007 
REVERSED & 
SQRT + 1 
Shapiro-Wilk:  
CTL D(15)=.981, p=.978 
WED D(18)=.939, p=.283 
Boxplots: ok 
Histograms: ok 
Skewness: 
CTL -.072/.580 = -.12 
WED .074/.536 = .14 
Kurtosis: 
CTL -.750/1.121 = -.67 
WED -1.131/1.038 = -1.09 
DMSES UK 3 months Shapiro-Wilk:  
CTL D(11)=.901, p=.190 
WED D(16)=.891, p=.058 
Boxplots: -ve skew (esp. WED) 
Histograms: -ve skew 
Skewness: 
CTL .034/.661 = .05 
WED -.817/.564 = -1.45 
Kurtosis: 
CTL -1.665/1.279 = -1.30 
REVERSED & 
SQRT + 1 
Shapiro-Wilk:  
CTL D(11)=.879, p=.100 
WED D(16)=.926, p=.213 
Boxplots: ok +ve skew (WED only) 
Histograms: ok +ve skew for WED & –
ve skew for CTL 
Skewness: 
CTL -.474/.661 = -.72 
WED .088/.564 = .16 
Kurtosis: 
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WED -.043/1.09 = -.04 CTL -1.521/1.279 = -.08 
WED -1.265/1.091 = -1.16 
SSQ6 (number) 2 weeks Shapiro-Wilk:  
CTL D14)=.829, p=.012 
WED D(15)=.729, p=.001 
Boxplots: +ve skew (esp. CTL) 
Histograms: +ve skew 
Skewness: 
CTL 1.351/.597 = -2.26 
WED 2.335/.580 = 4.03 
Kurtosis: 
CTL 1.280/1.154 = 1.11 
WED 6.454/1.121 = 5.76 
LOG + 1 Shapiro-Wilk:  
CTL D(14)=.908, p=.149 
WED D(15)=.869, p=.032 
Boxplots: +ve skew (WED only) 
Histograms: +ve skew (esp. WED) 
Skewness: 
CTL .588/.597 = .98 
WED 1.324/.580 = 2.28 
Kurtosis: 
CTL -.201/1.154 = -.17 
WED 1.839/1.121 = 1.64 
SSQ6 (number) 3 months Shapiro-Wilk:  
CTL D(11)=.889, p=.125 
WED D(15)=.716, p=.000 
Boxplots: ok 
Histograms: +ve skew (WED only) 
Skewness: 
CTL .208/.661 = .31 
WED 2.533/.580 = 4.37 
Kurtosis: 
CTL -1.590/1.279 = -1.24 
WED 8.022/1.121 = 7.16 
LOG + 1 Shapiro-Wilk:  
CTL D(11)=.902, p=.195 
WED D(15)=.877, p=.043 
Boxplots: -ve skew (CTL only) 
Histograms: +ve skew (WED only) 
Skewness: 
CTL -.222/.661 = -.34 
WED  1.203/.580 = 2.07 
Kurtosis: 
CTL -.995/1.279 = -.78 
WED -2.571/1.121 = -.44 
SSQ6 (satisfaction) 2 weeks Shapiro-Wilk:  
CTL D(14)=.689, p=.000 
WED D(15)=.544, p=.000 
Boxplots: -ve skew 
Histograms: -ve skew 
Skewness: 
CTL -.973/.597 =  -1.63 
WED -2.940/.580 = -5.07 
Kurtosis: 
CTL -1.032/1.154 = -.89 
WED 9.342/1.121 = 8.33 
SQRT + 1 Shapiro-Wilk:  
CTL D(11)=.688, p=.000 
WED D(15)=.523, p=.000 
Boxplots: -ve skew 
Histograms: -ve skew 
Skewness:  
CTL -.982/.597 = -1.64 
WED -3.081/.580 = -5.31 
Kurtosis: 
CTL -1.012/1.154 = -.88 
WED 10.211/1.121 = 9.11 
SSQ6 (satisfaction) 3 months Shapiro-Wilk:  
CTL D(10)=.623, p=.000 
WED D(15)=.425, p=.000 
Boxplots: -ve skew 
SQRT + 1 Shapiro-Wilk:  
CTL D(10)=.617, p=.000 
WED D(15)=.425, p=.000 
Boxplots: -ve skew 
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Histograms: -ve skew 
Skewness: 
CTL -2.076/.687 = -3.02 
WED -2.447/.580 = -4.22 
Kurtosis: 
CTL 4.059/1.334 = 3.04 
WED 4.690/1.121 = 4.18 
Histograms: -ve skew 
Skewness: 
CTL -2.140/.087 = -3.11 
WED -2.450/.580 = -4.22 
Kurtosis: 
CTL 4.418/1.334 = 3.31 
WED 4.775/1.121 = 4.26 
Mechanisms of change 
PANAS negative affect 
session 1 
Shapiro-Wilk:  
CTL D(7)=.560, p=.000 
WED D(10)=.860, p=.076 
Boxplots: +ve skew 
Histograms: +ve skew 
Skewness: 
CTL 2.447/.794 = 3.08 
WED 1.497/.687 = 2.18 
Kurtosis: 
CTL 6.081/1.587 = 3.83 
WED 2.654/1.334 = 1.99 
LOG Shapiro-Wilk:  
CTL D(7)=.576, p=.000 
WED D(10)=.943, p=.592 
Boxplots: ok 
Histograms: ok 
Skewness: 
CTL 2.378/.794 = 2.99 
WED .638/.687 = .93 
Kurtosis: 
CTL 5.739/1.587 = 3.62 
WED .107/1.334 = .08 
PANAS negative affect 
session 2  
Shapiro-Wilk:  
CTL D(7)=.671, p=.002 
WED D(10)=.792, p=.012 
Boxplots: +ve skew 
Histograms: +ve skew 
Skewness: 
CTL 2.122/.794 = 2.67 
WED 1.298/.687 = 1.89 
Kurtosis: 
CTL 4.735/1.587 = 2.98 
WED .408/1.334 = .31 
LOG Shapiro-Wilk:  
CTL D(7)=.963, p=.003 
WED D(10)=.875, p=.115 
Boxplots: +ve skew 
Histograms: +ve skew 
Skewness: 
CTL 1.991/.794 = 2.51 
WED .780/.687 = 1.14 
Kurtosis: 
CTL 4.155/1.587 = 2.62 
WED -.600/1.334 = -.45 
PANAS negative affect 
session 3 
Shapiro-Wilk:  
CTL D(7)=.582, p=.000 
WED D(10)=.868, p=.094 
Boxplots:+ve skew 
Histograms: +ve skew 
Skewness: 
CTL 2.347/.794 = 2.96 
WED .924/.687 = 1.35 
Kurtosis: 
LOG Shapiro-Wilk:  
CTL D(7)=.595, p=.000 
WED D(10)=.892, p=.179 
Boxplots: +ve skew  
Histograms: +ve skew 
Skewness: 
CTL 2.273/.794 = 2.86 
WED .294/.687 = .43 
Kurtosis: 
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CTL 5.580/1.587 = 3.52 
WED .107/1.334 = .08 
CTL 5.202/1.587 = 3.28 
WED -1.467/1.334 = -1.10 
LIWC positive emotion session 
1 
Shapiro-Wilk:  
CTL D(13)= .926, p=.298 
WED D(14)=.961 , p=.739 
Boxplots: +ve skew (CTL only) 
Histograms: +ve skew  
Skewness: 
CTL .465/.616 = .75 
WED .089/.597 = .15 
Kurtosis: 
CTL -.440/1.191 = -.37 
WED -1.027/1.154 = -.89 
LOG + 1 Shapiro-Wilk:  
CTL D(13)=.912, p=.195 
WED D(14)=.909, p=.195 
Boxplots: +ve skew 
Histograms: +ve skew (CTL only) 
Skewness: 
CTL 1.019/.616 = 1.65 
WED .665/.597 = 1.11 
Kurtosis: 
CTL .704/1.191 = .59 
WED -.603/1.154 = -.52 
LIWC positive emotion session 
2 
Shapiro-Wilk:  
CTL D(12)=.989 , p=.999 
WED D(13 )=.771, p=.003 
Boxplots: +ve skew (WED only) 
Histograms: +ve skew (WED only) 
Skewness: 
CTL .199/.637 = .31 
WED 2.062/.616 = 3.35 
Kurtosis: 
CTL -.082/1.232 = -.07 
WED 4.899/1.191 = 4.1 
LOG + 1 Shapiro-Wilk:  
CTL D(12)=.812, p=.013 
WED D(13)=.936, p=.407 
Boxplots: +ve skew (CTL only) 
Histograms: +ve skew (CTL only) 
Skewness: 
CTL 1.570/.637 = 2.46 
WED .061/.616 = .10 
Kurtosis: 
CTL 1.975/1.232 = 1.60 
WED -1.394/1.191 = -1.17 
LIWC positive emotion session 
3 
Shapiro-Wilk:  
CTL D(12)=.940, p=.494 
WED D(12)=.974, p=.948 
Boxplots: +ve skew 
Histograms: +ve skew (CTL only) 
Skewness: 
CTL .993/.637 = 1.56 
WED .303/.637 = .48 
Kurtosis: 
CTL 1.391/1.232 = 1.13 
WED .129/1.232 = .10 
LOG + 1 Shapiro-Wilk:  
CTL D(12)=.945, p=.567 
WED D(12)=.939, p=.482 
Boxplots: +ve skew (WED only) 
Histograms: +ve skew (esp. WED) 
Skewness: 
CTL .798/.637 = 1.25 
WED .731/.637 = 1.15 
Kurtosis: 
CTL 1.396 /1.232 = 1.13 
WED .109/1.232 = .09 
LIWC negative emotion 
session 1 
Shapiro-Wilk:  
CTL D(13)=.816, p=.011 
WED D(14)=.976, p=.949 
Boxplots: +ve skew (CTL only) 
LOG + 1 Shapiro-Wilk:  
CTL D(13)=.915, p=.213 
WED D(14)=.954, p=.631 
Boxplots: +ve skew (WED only) 
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Histograms: +ve skew (CTL only) 
Skewness: 
CTL  1.487/.616 = 2.41 
WED -.082/.597 = -.14 
Kurtosis: 
CTL 1.623/1.191 = 1.36 
WED -.512/1.154 = -.44 
Histograms: ok 
Skewness: 
CTL -.329/.616 = -.53 
WED -.322/.597 = -.54 
Kurtosis: 
CTL -1.048/1.191 = -.88 
WED -.907/1.154 = -.79 
LIWC negative emotion 
session 2 
Shapiro-Wilk:  
CTL D(12)=.766, p=.004 
WED D(13)=.908, p=.172 
Boxplots: +ve skew (WED only) 
Histograms: +ve skew (esp. CTL) 
Skewness: 
CTL 2.219/.637 = 3.48 
WED .817/.616 = 1.33 
Kurtosis: 
CTL 6.1 81/1.232 = 5.02 
WED -.363/1.191 = -.30 
LOG + 1 Shapiro-Wilk:  
CTL D(12)=.972, p=.950 
WED D(13)=.921, p=.263 
Boxplots: ok 
Histograms: +ve skew (WED only) 
Skewness: 
CTL -.629/.637 = -.99 
WED .860/.616 = 1.40 
Kurtosis: 
CTL .714/1.232 = 1.73 
WED .704/1.191 = -.59 
LIWC negative emotion 
session 3 
Shapiro-Wilk:  
CTL D(12)=.884, p=.100 
WED D(12)=.954, p=.701 
Boxplots: +ve skew (CTL only) 
Histograms: +ve skew (CTL only) 
Skewness: 
CTL  1.249/.637 = 1.96 
WED -.491/.637 = -.77 
Kurtosis: 
CTL 1.256/1.232 = 1.02 
WED .375/1.232 = .30 
LOG + 1 Shapiro-Wilk:  
CTL D(12)=.99, p=1.0 
WED D(12)= .951, p=.646 
Boxplots: ok 
Histograms: ok 
Skewness: 
CTL -.152/.637 = -.24 
WED -.747/.637 = -1.17 
Kurtosis: 
CTL .094/1.232 = .08 
WED .862/1.232 = .67  
LIWC insight session 1 Shapiro-Wilk:  
CTL D(13)=.869, p=.050 
WED D(14)=.882, p=.063 
Boxplots: +ve skew (esp. WED) 
Histograms: +ve skew 
Skewness: 
CTL 1.362/.616 = 2.21 
WED .886/.397 = 1.48 
Kurtosis: 
CTL 1.637/1.191 = 1.4 
LOG + 1 Shapiro-Wilk:  
CTL D(13)=.910, p=.186 
WED D(14)=.950, p=.562 
Boxplots:+ve skew for CTL &  -ve skew 
for WED 
Histograms: +ve skew for CTL &  -ve 
skew for WED 
Skewness: 
CTL .749/.616 = 1.22 
WED -.724/.597 = -1.21 
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WED -.297/ 1.154 = -.26 Kurtosis:  
CTL -.331/1.191 = -.28 
WED .163/1.154 = .14 
LIWC insight session 2 Shapiro-Wilk:  
CTL D(12)=.742, p=.002 
WED D(13)=925, p=.294 
Boxplots: +ve skew (esp. CTL) 
Histograms: +ve skew (esp. CTL) 
Skewness: 
CTL 1.933/.637 = 3.03 
WED .294/.616 = .48  
Kurtosis: 
CTL 3.524/1.232 = 2.86 
WED -1.364/1.191 = -1.15 
LOG + 1 Shapiro-Wilk:  
CTL D(12)=.915, p=.245 
WED D(13)=.953, p=.641 
Boxplots: -ve skew (CTL only) 
Histograms: +ve skew (CTL only) 
Skewness: 
CTL 1.041/.637 = 1.63 
WED .259/.616 = .42 
Kurtosis: 
CTL 2.126/1.232 = 1.73 
WED -.969/1.191 = -.81 
LIWC insight session 3 Shapiro-Wilk:  
CTL D(12)=.894, p=.132 
WED D(12)=.906 , p=.189 
Boxplots: +ve skew (WED) 
Histograms: +ve skew 
Skewness: 
CTL 1.349/.637 = 2.12 
WED 1.087/.637 = 1.71 
Kurtosis: 
CTL 2.712/1.232 = 2.2  
WED 1.058/1.232 = .86 
LOG + 1 Shapiro-Wilk:  
CTL D(12)=.939, p=.487 
WED D(12)=.851, p=.038 
Boxplots: + skew (CTL only) 
Histograms: -ve skew (WED only) 
Skewness: 
CTL .759/.637 = 1.19 
WED -1.576/.637 = -2.47 
Kurtosis: 
CTL -.103/1.232 = -.08 
WED 2.909/1.232 = 2.36 
LIWC cause session 1 Shapiro-Wilk:  
CTL D(13)=.935, p=.392 
WED D(14)=.906, p=.137 
Boxplots: ok 
Histograms: +ve skew (esp. CTL) 
Skewness: 
CTL .177/.616 = .29 
WED .570/.597 = .95 
Kurtosis: 
CTL -1.154/1.191 = -.97 
WED -1.130/1.154 = -.98 
LOG + 1 Shapiro-Wilk:  
CTL D(13)=.937, p=.414 
WED D(14)=.933, p=.334 
Boxplots: ok 
Histograms: ok 
Skewness: 
CTL -.143/.616 = -.23 
WED .316/.597 = .53 
Kurtosis: 
CTL -1.278/1.191 = -1.07 
WED -1.212/1.154 = -1.05 
LIWC cause session 2 Shapiro-Wilk:  
CTL D(12)=.945, p=.564 
WED D(13)=.964, p=.813 
LOG + 1 Shapiro-Wilk:  
CTL D(12)=.945 , p=.566 
WED D(13)=.964, p=.813 
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Boxplots: ok 
Histograms: -ve skew (CTL only) 
Skewness: 
CTL .492/.637 = .77 
WED .325/.616 = .53 
Kurtosis: 
CTL -.125/1.232 = -.10 
WED -.384/1.191 = -.32 
Boxplots: ok 
Histograms: ok 
Skewness: 
CTL -.320/.637 = -.50 
WED -.281/.616 = -.46 
Kurtosis: 
CTL -.210/1.232 = -.17 
WED -.611/1.191 = .51 
LIWC cause session 3 Shapiro-Wilk:  
CTL D(12)=.870, p=.066 
WED D(12)=.932, p=.406 
Boxplots: ok 
Histograms: +ve skew 
Skewness: 
CTL 1.178/.637 = 1.85 
WED .623/.637 = .98 
Kurtosis: 
CTL 2.614/1.232 = 2.12 
WED .064/1.232 = .05 
LOG + 1 Shapiro-Wilk:  
CTL D(12)=.908, p=.201 
WED D(12)=.951, p=.657 
Boxplots: +ve skew (CTL only) 
Histograms: +ve skew (WED only) 
Skewness: 
CTL .077/.637 = .11 
WED -.264/.637 = -.41 
Kurtosis: 
CTL .088/1.232 = .07 
WED .736/1.232 = .60 
Contamination 
LIWC positive emotion 
(average) 
Shapiro-Wilk:  
CTL D(13)=.938, p=.427 
WED D(14)=.898, p=.107 
Boxplots: +ve skew (WED only) 
Histograms: +ve skew (WED only) 
Skewness: 
CTL -.033/.616 = -.05 
WED 1.364/.597 = 2.28 
Kurtosis:  
CTL -1.324/1.191 = -1.11 
WED 2.737/1.154 = 2.37 
LOG Shapiro-Wilk:  
CTL D(13)= .923, p=.272 
WED D(14)=.976, p=.943 
Boxplots: ok 
Histograms: ok 
Skewness: 
CTL -.411/.616 = -.667 
WED .309/.597 = .518 
Kurtosis: 
CTL -1.185/1.191 = -.99 
WED .526/1.154 = .456 
LIWC negative emotion 
(average) 
Shapiro-Wilk:  
CTL D(13)=.911, p=.188 
WED D(14)=.920, p=.218 
Boxplots: -ve skew (WED only) 
Histograms: +ve skew (CTL only) 
Skewness: 
CTL .619/.616 = 1.00 
WED .670/.597 = 1.12 
LOG Shapiro-Wilk:  
CTL D(13)=.949, p=.590 
WED D(14)=.947, p=.522 
Boxplots: ok 
Histograms: ok 
Skewness: 
CTL .164/.616 = .266 
WED -.026/.597 = -.04 
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Kurtosis: 
CTL -.836/1.191 = -.70 
WED .100/1,154 = .09 
Kurtosis: 
CTL -.852/1.191 = -.72 
WED .115/1.154 = .10 
LIWC insight (average) Shapiro-Wilk:  
CTL D(13)=.871, p=.054 
WED D(14)=.922, p=.235 
Boxplots: ok 
Histograms: +ve skew (CLT only) 
Skewness: 
CTL 1.422/.616 = 2.31 
WED .187/.597 = .31 
Kurtosis: 
CTL 1.875/1.191 = 1.57 
WED -1.496/1.154 = -1.30 
LOG Shapiro-Wilk:  
CTL D(13)=.960, p=.760 
WED D(14)=.929, p=.292 
Boxplots:  +ve skew (CTL only) 
Histograms: +ve skew for CTL & -ve 
skew for WED 
Skewness: 
CTL .688/.616 = 1.117 
WED -.149/.597 = -.25 
Kurtosis: 
CTL .200/1.191 = .168 
WED -1.384/1.154 = -1.199 
LIWC cause (average) Shapiro-Wilk:  
CTL D(13)=.925, p=.293 
WED D(14)=.942, p=.440 
Boxplots: -ve skew 
Histograms: -ve skew for WED & +ve skew for CTL 
Skewness: 
CTL -.510/.616 = -.83 
WED -.507/.597 = -.85 
Kurtosis: 
CTL 1.006/1.191 = .84 
WED -.442/1.154 = -.38 
LOG Shapiro-Wilk:  
CTL D(13)=.897, p=.121 
WED D(14)=.914, p=.179 
Boxplots: -ve skew (esp. CTL) 
Histograms: -ve skew (WED only) 
Skewness: 
CTL -.843/.616 = -1.37 
WED -.849/.597= -1.42 
Kurtosis:  
CTL -.409/1.191 = -.34 
WED .051/1.154 = .04 
PANAS negative affect 
(average) 
Shapiro-Wilk:  
CTL D(7)=.608, p=.000 
WED D(10)=.852, p=.061 
Boxplots: +ve skew 
Histograms: +ve skew 
Skewness: 
CTL 2.380/.794 = 3.00 
WED 1.410/.687 = 2.05 
Kurtosis: 
CTL 5.790/1.587 = 3.65 
WED 1.697/1.334 = 1.27 
LOG Shapiro-Wilk:  
CTL D(7)=.629, p=.001 
WED D(10)=.934, p=.492 
Boxplots: +ve skew 
Histograms: +ve skew 
Skewness: 
CTL 2.301/.794 = 2.56 
WED .648/.687 = .94 
Kurtosis: 
CTL 5.416/1.587 = 3.41 
WED -.221/1.334 = -.16 
Exploratory correlations 
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CES-D (change) Shapiro-Wilk:  
WED D(12)=.948, p=.602 
Boxplots: ok 
Histograms: ok 
Skewness: 
WED .837/.637 = 1.31 
Kurtosis: 
WED .564/1.232 = .46 
  
PAID (change) Shapiro-Wilk:  
WED D(11)=.973, p=.915 
Boxplots:  
Histograms: ok 
Skewness: ok 
WED .122/.661 = .18 
Kurtosis: 
WED -.441/1.279 = -.34 
  
EQ-5D utility (change) 
 
Shapiro-Wilk:  
WED D(11)=.644, p=.000 
Boxplots: -ve skew 
Histograms: -ve skew 
Skewness:  
WED -2.544/.661 = -3.84  
Kurtosis: 
WED 6.997/1.279 = 5.47 
  
EQ-5D VAS (change) 
 
Shapiro-Wilk:  
WED D(12)=.686, p=.001 
Boxplots: -ve skew 
Histograms: -ve skew 
Skewness: 
WED -2.427/.637 = -3.81 
Kurtosis: 
WED 7.736/1.232 = 6.28 
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SDSCA general diet (change) 
 
Shapiro-Wilk:  
WED D(12)=.772, p=.005 
Boxplots:  +ve skew 
Histograms: +ve skew 
Skewness: 
WED 2.105/.637 = 3.30 
Kurtosis: 
WED 6.085/1.232 = 4.94 
  
SDSCA specific diet (change) 
 
Shapiro-Wilk:  
WED D(11)=.756, p=.002 
Boxplots: -ve skew 
Histograms: -ve skew 
Skewness: 
WED -1.220/.661 = -1.85 
Kurtosis: 
WED .027/1.279 = .02 
  
SDSCA exercise (change) 
 
Shapiro-Wilk:  
WED D(12)=.820, p=.016 
Boxplots: -ve skew 
Histograms: -ve skew 
Skewness: 
WED -1.854/.637 = -2.91 
Kurtosis: 
WED 5.069/1.232 = 4.11 
  
SDSCA blood glucose testing 
(change) 
 
Shapiro-Wilk:  
WED D(9)=.703, p=.002 
Boxplots: +ve skew 
Histograms: +ve skew 
Skewness:  
WED 1.804/.717 = 2.52 
Kurtosis: 
WED 2.717/1.400 = 1.94 
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SDSCA foot care (change) 
 
Shapiro-Wilk:  
WED D(12)=.920, p=.289 
Boxplots: ok 
Histograms: ok 
Skewness: 
WED.054/.637 = .08 
Kurtosis: 
WED 1.367/1.232 = 1.11 
  
LIWC insight (change) Shapiro-Wilk:  
WED D(12)=.886, p=.106 
Boxplots: +ve skew 
Histograms: +ve skew 
Skewness: 
WED 1.257/.637 = 1.97 
Kurtosis: 
WED 2.782/1.232 = 2.26 
  
LIWC cause (change) Shapiro-Wilk:  
WED D(12)=.905, p=.182 
Boxplots: +ve skew 
Histograms: ok 
Skewness: 
WED .059/.637 = .09 
Kurtosis: 
WED -1.222/1.232 = -.99 
  
LIWC positive emotion  
(change) 
Shapiro-Wilk:  
WED D(12)=.930, p=.383 
Boxplots: ok 
Histograms: ok 
Skewness: 
WED .148/.637 = .23 
Kurtosis: 
WED -1.026/1.232 = .83 
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LIWC negative emotion 
(change) 
Shapiro-Wilk:  
WED D(12)=.911, p=.221 
Boxplots: ok 
Histograms: ok 
Skewness: 
WED -.871/.637 = 1.37 
Kurtosis: 
WED -.087/1.232 = -.07 
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Appendix V: Effect size estimates for effectiveness analyses153  
 
                                                             
153 The adjusted means/SEs relate to analyses with the untransformed data. 
Outcome WED n Control n Untransformed data Transformed data 
૑² 
(small =.01; 
medium=.06;  
large =.14) 
િ² 
(small =.01; 
medium=.06; 
large =.14) 
િܘ
²   
 (small =.01;  
medium=.06; 
large =.14) 
૑² 
(small =.01; 
medium=.06;  
large =.14) 
િ² 
(small =.01; 
medium=.06; 
large =.14) 
િܘ
²   
 (small =.01;  
medium=.06; 
large =.14) Mean SE Mean SE 
ITT analysis             
CES-D 9.90 1.08 23 5.12 1.22 18 .09  M .10  M .19  L .08  M .10  M .19  L 
PAID 35.33 1.41 23 34.37 1.60 18 -.01 X .00  X .01  S -.01  X .00  X .00  X 
EQ-5D: utility .86 .03 23 .87 .03 18 -.01 X .00  X .00  X -.01  X .00  X .00  X 
EQ-5D VAS 77.43 2.75 22 82.09 3.04 18 .01  S .02  S .04  S .01 S .02  S .05  S 
SDSCA: general diet 5.76 .24 23 5.84 .27 18 -.02  X .00  X .00  X  -.01  X .01  S .01  S 
SDSCA: specific diet 4.50 .19 23 5.06 .21 18 .03  S .04 S .10  M  .04  S .05  S .14  L 
SDSCA: exercise 3.46 .28 23 3.96 .31 18 .00  X .01  S .04  S .00  X .01  S .02  S 
SDSCA: blood glucose 
testing 
2.54 .39 22 2.48 .46 16 -.01  X .00  X .00  X  -.01 X .00  X .00  X 
SDSCA: foot care 3.15 .24 23 3.03 .27 18 -.00  X .00  X .00  X .01  S .01  S .04  S 
Complete case analysis            
CES-D 10.63 1.36 18 5.12 1.54 14 .10  M .12  M .21  L .10  M .12  M .20  L 
PAID 33.45 1.82 17 32.80 2.08 13 -.02  X .00  X .00  X -.02  X .00  X .00  X 
EQ-5D: utility .83 .03 17 .84 .04 12 -.02  X .00  X .00  X -.02 X .00  X .00  X 
EQ-5D VAS 74.75 3.46 18 82.22 4.25 12 .02 S .03  S .07  M .02  S .04  S .10  L 
SDSCA: general diet 5.63 .31 18 5.63 .36 13 -.03  X .00  X .00  X -.01  X .01  S .02  S 
SDSCA: specific diet 4.15 .25 17 4.96 .28 13 .07  M .08  M .16  L .08  M .10  M .20  L 
SDSCA: exercise 3.55 .36 18 4.02 .43 13 -.00  X .01  S .03  S -.01  X .00  X .02  S 
SDSCA: blood glucose 
testing 
3.22 .60 13 2.72 .62 12 -.01 X .01  S .02  S -.02  X  .00  X .01  S 
SDSCA: foot care 2.94 .31 18 2.70 .37 13 -.01  X .01  S .01  S .01  S .02  S .06  M 
